<?xml version='1.0' encoding='UTF-8' ?><Trials_downloaded_from_ICTRP>
  <Trial>
    <TrialID>ChiCTR2000029953</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-17</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49217</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>survival group:200;died:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yan Zhao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>doctoryanzhao@whu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13995577963</Contact_Tel>
    <Contact_Affiliation>Emergency Department of Zhongnan Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 2019-nCoV-infected pneumonia diagnosed patients, the diagnostic criteria refer to "guideline of the diagnose and treatment of 2019-nCoV (trial)" published by National Health Committees of Peoples' Republic Country "</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients diagnosed with pneumonia of age &lt;15 years diagnosed according to"guideline of the diagnose and treatment of 2019-nCoV (tested)" published by National Health Committees of Peoples' Republic Country;  Suspected patient with viral nucleic acid-negative 2019-nCoV infection.</Exclusion_Criteria>
    <Condition>2019-nCoV Pneumonia</Condition>
    <Intervention>survival group:none;died:none;</Intervention>
    <Primary_outcome>duration of in hospital;in hospital mortality;the 28s day' mortality after admission;duration of ICU stay;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029935</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)</Public_title>
    <Scientific_title>A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>HwaMei Hospital, University of Chinese Academy of Sciences</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49607</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-06</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ting Cai</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>41 Xibei Street, Ningbo, Zhejiang, China</Contact_Address>
    <Contact_Email>caiting@ucas.ac.cn</Contact_Email>
    <Contact_Tel>+86 13738498188</Contact_Tel>
    <Contact_Affiliation>HwaMei Hospital, University of Chinese Academy of Sciences</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission.&lt;br&gt;Criteria for diagnosis (meet all the following criteria):&lt;br&gt;1. Epidemiologic history.&lt;br&gt;2. Clinical manifestations (meet any 2 of the following): fever, normal or decreased white blood cell count or lymphopenia in the early stage of onset, and Chest radiology in the early stage shows multiple small patchy shadowing and interstitial changes which is especially significant in periphery pulmonary. Furthermore, it develops into bilateral multiple ground-glass opacity and infiltrating shadowing. Pulmonary consolidation occurs in severe cases. Pleural effusion is rare;&lt;br&gt;3. Confirmed case (suspected case obtained one of the following etiologic evidences): a positive result to real-time reverse-transcriptase PCR for respiratory specimen or blood specimen, or Genetic sequencing result of virus in respiratory or blood specimens are highly homologous to SARS-CoV-2.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Female patients during pregnancy; &lt;br&gt;2. Patients with known allergy to chloroquine; &lt;br&gt;3. Patients with haematological diseases; &lt;br&gt;4. Patients with chronic liver or kidney diseases at the end stage; &lt;br&gt;5. Patients with arrhythmia and chronic heart disease; &lt;br&gt;6. Patients with retinal disease, hearing deficiency or hearing loss; &lt;br&gt;7. Patients with psychiatric diseases; &lt;br&gt;8. Patients taking digitalis due to underlying diseases.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Treated with conventional treatment combined with Chloroquine Phosphate;</Intervention>
    <Primary_outcome>Length of hospital stay;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029868</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a multicenter, randomized controlled trial</Public_title>
    <Scientific_title>Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a multicenter, randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49524</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Experimental group:100;Control group:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Guochao Shi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>197 Second Ruijin Road, Huangpu District, Shanghai, China</Contact_Address>
    <Contact_Email>shi_guochao2010@qq.com</Contact_Email>
    <Contact_Tel>+86 13911379001</Contact_Tel>
    <Contact_Affiliation>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 years old and above;&lt;br&gt;2. Meet the novel coronavirus pneumonia (COVID-19) diagnostic criteria. The upper and lower respiratory tract RT-PCR confirmed that 2019-nCoV nucleic acid positive, chest CT imaging examination could be used in conjunction;&lt;br&gt;3. Onset time &lt;=12 days;&lt;br&gt;4. Sign informed consent;&lt;br&gt;5. Do not participate in the clinical study of other study drugs within 28 days.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Severe novel coronavirus pneumonia (COVID-19) patients;&lt;br&gt;2. Other serious medical diseases such as malignant tumor, heart, liver and kidney disease, metabolic disease, etc;&lt;br&gt;3. Not suitable for gastrointestinal administration;&lt;br&gt;4. Pregnant or lactating women;&lt;br&gt;5. Those who are allergic to the ingredients of this product;&lt;br&gt;6. Mental state can not cooperate with the observer or cognitive impairment;&lt;br&gt;7. Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 times ULN);&lt;br&gt;8. Patients with known severe renal impairment (glomerular filtration rate &lt;=30 ml/min/1.73 m2) or continuous renal replacement therapy, hemodialysis, peritoneal dialysis.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:oral hydroxychloroquine sulfate tablets;Control group:Conventional treatment meet the Guideline;</Intervention>
    <Primary_outcome>Viral nucleic acid test;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029850</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Zhejiang University School of Medicine</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49533</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax>99</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>experimental group:10;control group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiaowei Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>xxw69@126.com</Contact_Email>
    <Contact_Tel>+86 13605708066</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Laboratory confirmed diagnosis of COVID19 infection by RT-PCR;&lt;br&gt;2. Aged &gt; 18 years;&lt;br&gt;3. Written informed consent given by the patient or next-of-kin;&lt;br&gt;4. Clinical deterioration despite conventional treatment that required intensive care.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Hypersensitive to immunoglobulin;&lt;br&gt;2. Have immunoglobulin A deficiency.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>experimental group:standardized comprehensive treatment combined with convalescent plasma treatment;control group:standardized comprehensive treatment;</Intervention>
    <Primary_outcome>Fatality rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029814</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Children's Hospital of Fudan University</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49387</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>18</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>control group:15;experimental group:15;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhai Xiaowen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>399 Wanyuan Road, Minhang District, Shanghai</Contact_Address>
    <Contact_Email>zhaixiaowendy@163.com</Contact_Email>
    <Contact_Tel>+86 64931902</Contact_Tel>
    <Contact_Affiliation>Children's Hospital of Fudan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Children diagnosed with novel coronavirus pneumonia through epidemiological history, clinical symptoms, and nucleic acid test results.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No exclusion criteria</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>control group:Western Medicine;experimental group:Integrated Traditional Chinese and Western Medicine;</Intervention>
    <Primary_outcome>Time fo fever reduction;Time of nucleic acid negative;Severe conversion rate;Improvement time of respiratory symptoms;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029805</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Analysis of clinical characteristics of severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Optimization of treatment and diagnosis plan for critically ill patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49188</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wu Wenjuan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Yintan Road, Dongxihu District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>88071718@qq.com</Contact_Email>
    <Contact_Tel>+86 13397192695</Contact_Tel>
    <Contact_Affiliation>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Patients diagnosed with 2019-nCoV pneumonia;&lt;br&gt;(2) Patients admitted to the ICU during the study period.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: N/A</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>case series:N/A;</Intervention>
    <Primary_outcome>28-day mortality and 90-day mortality.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029789</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of He'nan University of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49348</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Experimental group:50;Control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Jiansheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>156 Jinshui Road East, Zhengzhou, He'nan, China</Contact_Address>
    <Contact_Email>li_js8@163.com</Contact_Email>
    <Contact_Tel>+86 371-65676568</Contact_Tel>
    <Contact_Affiliation>He'nan University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. General/severe/critical patients who meet the diagnostic criteria of new coronavirus pneumonia;&lt;br&gt;2. Patients whose viral nucleic acid has turned negative after treatment;&lt;br&gt;3. Patients who are characterized by respiratory symptoms such as cough, shortness of breath, chest tightness or corresponding chest imaging features;&lt;br&gt;4. Patients who meet TCM syndrome; &lt;br&gt;5. Patients who voluntarily participate in the study and sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with cognitive disorder or known mental illness;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. Patients with active tuberculosis, pulmonary abscess or chronic respiratory failure;&lt;br&gt;4. Patients with tumor;&lt;br&gt;5. Patients with severe liver or kidney diseases;&lt;br&gt;6. Patients with severe cardiovascular or cerebrovascular diseases;&lt;br&gt;7. Patients who are participating in clinical trials of other drugs, or known to be allergic to therapeutic drugs.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>Experimental group:TCM based on symptomatic treatment;Control group:Placebo TCM based on symptomatic treatment;</Intervention>
    <Primary_outcome>St. George's Respiratory Questionnaire;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029782</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study for the changes in mental state of medical staff in the department of radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the epidemic of novel coronavirus infection (COVID-19)</Public_title>
    <Scientific_title>Clinical study for the changes in mental state of medical staff in the department of radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the epidemic of novel coronavirus infection (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Zhejiang Provincial People's Hospital</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49445</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-30</Date_enrollement>
    <Target_size>Case series:27;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yongshi Jia</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>158 Shangtang Road, Xiacheng District, Hangzhou, China</Contact_Address>
    <Contact_Email>jiayongshi@medmail.com.cn</Contact_Email>
    <Contact_Tel>+86 13605813177</Contact_Tel>
    <Contact_Affiliation>Zhejiang Provincial People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Medical staff who are currently working during the epidemic of new coronavirus (Covid-19)</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Rest or unattended staff;&lt;br&gt;2. Staff with respiratory symptoms;&lt;br&gt;3. Staff who need the necessary isolation.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19); mental health status</Condition>
    <Intervention>Case series:Not applicable.;</Intervention>
    <Primary_outcome>PSQI;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029764</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a Multicenter Study</Public_title>
    <Scientific_title>Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a Multicenter Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49388</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-16</Date_enrollement>
    <Target_size>case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Bin Song</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>songlab_radiology@163.com</Contact_Email>
    <Contact_Tel>86 28 85423680</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients diagnosed with COVID-19;&lt;br&gt;2. Underwent chest CT scan during the treatment and at least one chest CT scan during follow-up;&lt;br&gt;3. Able to complete the study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. CT image quality does not meet the analysis criteria;&lt;br&gt;2. Pregnant and lactating women.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>case series:N/A;</Intervention>
    <Primary_outcome>imaging feature;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029695</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Exhaled Breath</Public_title>
    <Scientific_title>Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Volatile Organic Compounds in Exhaled Breath                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Shenzhen Third People's Hospital</Primary_sponsor>
    <Date_registration>2020-02-10</Date_registration>
    <Date_registration3>20200210</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49219</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Target condition:300;Difficult condition:300</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Deng Guofang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>29 Bulan Road, Longgang District, Shenzhen, Guangdong, China</Contact_Address>
    <Contact_Email>jxxk1035@yeah.net</Contact_Email>
    <Contact_Tel>+86 13530027001</Contact_Tel>
    <Contact_Affiliation>Pulmonary Diseases Department, Shenzhen Third People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Suspected cases of pneumonitis with the novel coronavirus infection. Suspected case criteria: Any one of the following epidemiological histories meets any two of the clinical manifestations:&lt;br&gt;Comprehensive analysis based on the following epidemiological history and clinical manifestations: &lt;br&gt;1. Epidemiological history:&lt;br&gt;(1) Travel history or residence history of Wuhan and surrounding areas or other communities with case reports within 14 days before the onset of illness; &lt;br&gt;(2) Onset of illness Patients with fever or respiratory symptoms from Wuhan and surrounding areas, or from communities with case reports in the previous 14 days; &lt;br&gt;(3) Aggressive onset; &lt;br&gt;(4) History of contact with new coronavirus infection. People with a new coronavirus infection are those who test positive for nucleic acid. &lt;br&gt;2. Clinical manifestations &lt;br&gt;(1) fever and/or respiratory symptoms; &lt;br&gt;(2) with the imaging mentioned above characteristics of pneumonia; &lt;br&gt;(3) the total number of white blood cells is normal or decreased in the early stage of onset, or the lymphocyte count is decreased.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Severe novel coronavirus pneumonia patients who cannot provide exhaled breath samples.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:RT-PCR of the novel coronavirus;Index test:Exhaled&amp;#32;breath&amp;#32;detection&amp;#32;by&amp;#32;mass&amp;#32;spectrometry;</Intervention>
    <Primary_outcome>Sensitivity of detection of NCP;Specificity of detection of NCP;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029656</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Wuhan Pulmonary Hosptial</Primary_sponsor>
    <Date_registration>2020-02-09</Date_registration>
    <Date_registration3>20200209</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49086</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>control group:50;experimental group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ronghui Du</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>28 Baofeng Road, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>bluesearh006@sina.com</Contact_Email>
    <Contact_Tel>+86 15337110926</Contact_Tel>
    <Contact_Affiliation>Wuhan Pulmonary Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Adults (defined as age &gt;= 18 years); &lt;br&gt;2. Patients with new type of coronavirus infection confirmed by PCR / serum antibodies; &lt;br&gt;3. The time interval between symptom onset and random enrollment is within 10 days.The onset of symptoms is mainly based on fever. If there is no fever, cough or other related symptoms can be used;&lt;br&gt;4. Imaging confirmed pneumonia;&lt;br&gt;5. In the state of no oxygen at rest, the patient's blood oxygen saturation SPO2 &lt;= 94% or shortness of breath (breathing frequency &gt;= 24) or oxygenation index &lt;= 300mmHg.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Known to receive hormone therapy orally or intravenously; &lt;br&gt;2. Hormone therapy is needed due to concomitant disease upon admission; &lt;br&gt;3. Patients with diabetes are receiving oral medication or insulin therapy; &lt;br&gt;4. Known contraindications to dexamethasone or other excipients (such as refractory hypertension; epilepsy or delirium and glaucoma); &lt;br&gt;5. Known active gastrointestinal bleeding in the past 3 months;&lt;br&gt;6. Known difficulties in correcting hypokalemia; &lt;br&gt;7. Known secondary bacterial or fungal infections;&lt;br&gt;8. Known immunosuppressive status (such as chemotherapy / radiotherapy / HIV infection within one month after surgery);&lt;br&gt;9. The clinician thinks that participating in the trial may cause patient damage (such as severe lymphocyte reduction); &lt;br&gt;10. The patient may be transferred to a non-participating hospital within 72 hours.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>control group:Standard treatment;experimental group:Standard treatment and methylprednisolone for injection;</Intervention>
    <Primary_outcome>ECG;Chest imaging;Complications;vital signs;NEWS2 score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029626</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Immune Repertoire (TCR &amp; BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Immune Repertoire (TCR &amp; BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19) Patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Zhejiang University School of Medicine</Primary_sponsor>
    <Date_registration>2020-02-07</Date_registration>
    <Date_registration3>20200207</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49170</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Normal group:10;Severe group:10;</Target_size>
    <Study_type>Basic Science</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fang Xueling</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Hangzhou, China</Contact_Address>
    <Contact_Email>13588867114@163.com</Contact_Email>
    <Contact_Tel>+86 13588867114</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Zhejiang University School of Medicine </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with novel coronavirus infection pneumonia were confirmed by RT-PCR and clinical symptoms. The diagnosic criteria refer to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)";&lt;br&gt;2. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 10 days);&lt;br&gt;3. Patients who voluntarily signed informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Physician judged the patient was not suitable for this clinical trial (for example, patient may be transferred to another hospital during the study period; patient with immune system diseases or cancers etc.)</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Normal group:No;Severe group:No;</Intervention>
    <Primary_outcome>TCR sequencing;BCR sequencing;HLA sequencing;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT00523276</TrialID>
    <Last_Refreshed_on>19 February 2015</Last_Refreshed_on>
    <Public_title>SARS Survivor Evaluations</Public_title>
    <Scientific_title>Immune Responses, Transmission and Nucleotide Polymorphisms in Families With SARS Virus Infections</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</Primary_sponsor>
    <Date_registration>30/08/2007</Date_registration>
    <Date_registration3>20070830</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00523276</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>4 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 1996</Date_enrollement>
    <Target_size>0</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Observational Model: Family-Based, Time Perspective: Cross-Sectional</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        Severe Acute Respiratory Syndrome (SARS) Survivors and Controls:&lt;br&gt;&lt;br&gt;          1. An adult (&gt;= 18 years of age) proven in hospital/laboratory records to have had SARS&lt;br&gt;             as defined by the World Health Organization&lt;br&gt;&lt;br&gt;          2. A control matched for age, gender and health status similar to a SARS survivor and&lt;br&gt;             with a possible SARS exposure (healthcare personnel).&lt;br&gt;&lt;br&gt;          3. Granting informed consent&lt;br&gt;&lt;br&gt;        Family Members of SARS Survivors:&lt;br&gt;&lt;br&gt;          1. Family members currently age 4 or older who were living in a household with the SARS&lt;br&gt;             survivor study case at the time of SARS occurrence.&lt;br&gt;&lt;br&gt;          2. Informed consent granted by subject or parent if child is less than 18 years old.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Severe Acute Respiratory Syndrome (SARS) Survivors and Controls:&lt;br&gt;&lt;br&gt;          1. Presence of an acute illness.&lt;br&gt;&lt;br&gt;          2. Hemoglobin below normal range for gender and age.&lt;br&gt;&lt;br&gt;          3. Current pregnancy or possible pregnancy (by history).&lt;br&gt;&lt;br&gt;        Family Members of SARS Survivors:&lt;br&gt;&lt;br&gt;        1.  Current pregnancy or possible pregnancy (by history).&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus (SARS-CoV)</Condition>
    <Primary_outcome>Positive serology, SARS CoV</Primary_outcome>
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04246242</TrialID>
    <Last_Refreshed_on>3 February 2020</Last_Refreshed_on>
    <Public_title>A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)</Public_title>
    <Scientific_title>A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Xiangya Hospital of Central South University</Primary_sponsor>
    <Date_registration>27/01/2020</Date_registration>
    <Date_registration3>20200127</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04246242</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 25, 2020</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). </Study_design>
    <Phase>Phase 4</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Pinhua Pan, Medical PhD</Contact_Lastname>
    <Contact_Email>pinhuapan668@126.com</Contact_Email>
    <Contact_Tel>+86 13574810968</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        Patients diagnosed with RT-PCR for 2019 Novel Coronavirus (2019-nCoV)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Patients infected with other viruses&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019 Novel Coronavirus</Condition>
    <Intervention>Drug: Conventional treatment group;Drug: arbidol,200mg,tid;Drug: arbidol,400mg,tid</Intervention>
    <Primary_outcome>mortality</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029949</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Emergency Department of Zhongnan hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49181</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-16</Date_enrollement>
    <Target_size>Case series:40;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yan, Zhao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>doctoryanzhao@whu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13995577963</Contact_Tel>
    <Contact_Affiliation>Emergency Department of Zhongnan hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 years; &lt;br&gt;2. Diagnosed of 2019-nCoV infection with "guideline of the diagnose and treatment of 2019-nCoV (tested the fourth edition)" published by National Health Committees of Peoples' Republic Country.&lt;br&gt;3. Failed by conventional treatment needing ECMO support. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Absolutely forbidden criteria for ECMO application</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Extracorporeal Membrane Oxygenation;</Intervention>
    <Primary_outcome>inhospital length;inhospital mortality;ECMO treatment length;28th day mortality after admission;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029624</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia ((COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Shanghai Public Health Clinical Center</Primary_sponsor>
    <Date_registration>2020-02-07</Date_registration>
    <Date_registration3>20200207</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49132</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-08</Date_enrollement>
    <Target_size>Case series:500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lu Hongzhou</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>2901 Caolang Road, Jinshan District, Shanghai, China</Contact_Address>
    <Contact_Email>Luhongzhou@shphc.org.cn</Contact_Email>
    <Contact_Tel>+86 18930810088</Contact_Tel>
    <Contact_Affiliation>Shanghai Public Health Clinical Center</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Suspected case:&lt;br&gt;Patients in observation period of traditional Chinese medicine who are in line with the diagnostic criteria for suspected cases of pneumonia caused by 2019 novel coronavirus infection in the "diagnosis and treatment plan for pneumonia caused by 2019 novel coronavirus infection (trial version IV)", formulated by the National Health Commission, and in accordance with the "diagnosis and treatment plan for pneumonia caused by 2019 nove coronavirus infection in Shanghai (Trial Implementation)",formulated by the office of the leading group for the prevention and control of pneumonia caused by 2019 novel coronavirus infection in Shanghai,.&lt;br&gt;Any one with epidemiological history and any two with clinical manifestations.&lt;br&gt;(1) Epidemiological history&lt;br&gt;1) Within 14 days before the onset of the disease, there was a travel history or residential history in Wuhan or other areas where the local cases continued to spread;&lt;br&gt;2) Within 14 days before the onset of the disease, the patient had been exposed to fever or respiratory symptoms from Wuhan city or other areas where local cases continue to spread;&lt;br&gt;3) There is a clustering disease or an epidemiological association with the new coronavirus infection.&lt;br&gt;(2) Clinical manifestations:&lt;br&gt;1) Fever;&lt;br&gt;2) It has the imaging characteristics of pneumonia: in the early stage, there are multiple small spot shadow and interstitial changes, especially in the extrapulmonary zone. In severe cases, lung consolidation and pleural effusion are rare;&lt;br&gt;3) In the early stage of the disease, the total number of leukocytes was normal or decreased, or the lymphocyte count was decreased.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients who have mental confusion, pregnant or lactating women, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study. </Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Traditional Chinese Medicine;</Intervention>
    <Primary_outcome>Time for body temperature recovery;Chest CT absorption;Time of nucleic acid test turning negative;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029601</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population</Public_title>
    <Scientific_title>Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolated population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Hubei Provincial Hospital of TCM</Primary_sponsor>
    <Date_registration>2020-02-06</Date_registration>
    <Date_registration3>20200206</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48988</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Control group:200;Experimental group:200;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Tong Xiaolin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>856 Luoyu Road, Hongshan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>252417083@qq.com</Contact_Email>
    <Contact_Tel>+86 18908628577</Contact_Tel>
    <Contact_Affiliation>Hubei Provincial Hospital of TCM</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Suspected and confirmed cases of pneumonia in accordance with the above new signs of coronavirus infection and the standard of clinical common diagnosis;&lt;br&gt;2. Aged 18-65 years old;&lt;br&gt;3. Signing the general informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Clear evidences?of bacterial infection;&lt;br&gt;2. Serious primary diseases judged by researchers,such as heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract,?may affect the patients' participation in the trial or the outcome of the study;&lt;br&gt;3. Family history of mental illness or mental illness;&lt;br&gt;4. Allergic constitution or multi drug allergy;&lt;br&gt;5. Pregnant or lactating women.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Health education+Basic treatment of western medicine;Experimental group:Health education+Basic treatment of Western medicine+Dialectical?treatment of traditional Chinese medicine;</Intervention>
    <Primary_outcome>the negative conversion ratio;the proportion of general patients with advanced severe disease;confirmed rate of suspected cases;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029947</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49599</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>experimental group :100;control group :100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>LU Zhenhui</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>725 Wanping Road South, Xuhui District, Shanghai, China</Contact_Address>
    <Contact_Email>tcmdoctorlu@163.com</Contact_Email>
    <Contact_Tel>+86 13817729859</Contact_Tel>
    <Contact_Affiliation>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Meet the diagnostic criteria forconfirmed cases  in the Diagnosis and Treatment of Pneumonia of New Coronavirus Pneumonia (Trial Version 5);&lt;br&gt;2. The acute stage is complicated by sepsis, respiratory failure, ARDS and so on. The patients are with multiple organ damage when improved and tended to recover after organ support and other treatments; &lt;br&gt;3. Meet the TCM diagnostic criteria for the recovery period;&lt;br&gt;4. Aged 18-75 years-old men or women;&lt;br&gt;5. Patients who volunteer to participate in this study and sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with respiratory failure, acute necrotizing encephalopathy, septic shock, multiple organ dysfunction, and other serious clinical conditions requiring monitoring and treatment when enrolled;&lt;br&gt;2. Pregnant, preparing or lactating women;&lt;br&gt;3. Patients with severe heart, cerebrovascular and liver, kidney, hematopoietic system diseases and mental illness;&lt;br&gt;4. Patients with tuberculosis, measles, AIDS and other infectious diseases;&lt;br&gt;5. Patients with known allergies to western medicine or traditional Chinese medicine ingredients used in this research;&lt;br&gt;6. Patients with gastrointestinal bleeding who cannot take Chinese medicine;&lt;br&gt;7. Patients who use oral Chinese medicine within 4 weeks.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment;control group :western medicine symptomatic treatment  ;</Intervention>
    <Primary_outcome>Lung function;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029896</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of Changchun University of traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49432</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-31</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang Tan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1478 Gongnong Road, Changchun, Jilin, China</Contact_Address>
    <Contact_Email>Wangtan215@sina.com</Contact_Email>
    <Contact_Tel>+86 13756858523</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of Changchun University of traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Suspected, mild, normal and severe cases diagnosed in accordance with the diagnosis and treatment scheme for pneumonia of novel coronavirus infection (trial version 5);&lt;br&gt;2. The expert team of consultation in our hospital will participate in the diagnosis and treatment.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Unable to receive traditional Chinese medicine treatment.&lt;br&gt;2. Cases where complete diagnosis and treatment information is not available.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia</Condition>
    <Intervention>Case series:Prescription based on syndrome differentiation of TCM and Routine treatment of Western Medicine;</Intervention>
    <Primary_outcome>Conversion rate of mild and common type patients to severe type;Mortality Rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029569</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial</Public_title>
    <Scientific_title>Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Xiangyang 1st People's Hospital</Primary_sponsor>
    <Date_registration>2020-02-04</Date_registration>
    <Date_registration3>20200204</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49062</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-05</Date_enrollement>
    <Target_size>control group :15;Experimental group :15;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Pei Bin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>15 Jiefang Road, Fancheng District, Xiangyang, Hubei, China </Contact_Address>
    <Contact_Email>xyxzyxzh@163.com</Contact_Email>
    <Contact_Tel>+86 18995678520</Contact_Tel>
    <Contact_Affiliation>Xiangyang 1st People's Hospital </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: On January 27, 2020, the general office of the national health commission and the office of the state administration of traditional Chinese medicine issued the pneumonia diagnosis and treatment plan for new coronavirus infection (trial version 4).&lt;br&gt;1. patients with severe 2019-ncov according to the clinical stage met any of the following criteria: &lt;br&gt;(1) Respiratory distress, RR&gt;=30 times/min; &lt;br&gt;(2) In resting state, oxygen saturation is less than 93%;&lt;br&gt;(3) Partial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) &lt;=300mmHg (1mmHg= 0.133kpa);&lt;br&gt;2. according to the clinical stage of critical 2019-ncov, meet one of the following conditions:&lt;br&gt;(1) Respiratory failure occurs and mechanical ventilation is required;&lt;br&gt;(2) Shock;&lt;br&gt;(3) Combined with other organ failure, intensive care unit is required;&lt;br&gt;3. other inclusion criteria: good compliance, willingness to cooperate with the study, and informed consent signed by the patient.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) diseases need to be differentiated from 2019-ncov, such as influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial pulmonary virus, SARS coronavirus and other known viral pneumonia, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia and non-infectious diseases;&lt;br&gt;(2) suspected case of 2019-ncov with no confirmed patient;&lt;br&gt;(3) the clinical stage was mild: the clinical symptoms were mild, and no pneumonia was observed on imaging;&lt;br&gt;(4) clinical stage: common type: fever, respiratory tract and other symptoms, and imaging findings of pneumonia;&lt;br&gt;(5) have any known disease that seriously affects the immune system, such as a history of infection with the human immunodeficiency virus (HIV), or malignant tumors of the blood system or solid organs, or splenectomy;&lt;br&gt;(6) other circumstances that the researcher considers inappropriate to participate in this study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>control group :Conventional treatment ;Experimental group :conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group;</Intervention>
    <Primary_outcome>PSI;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029542</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Sun Yat sen Memorial Hospital of Sun Yat sen University</Primary_sponsor>
    <Date_registration>2020-02-03</Date_registration>
    <Date_registration3>20200203</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48968</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>Experimental group:10;control group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jiang Shanping</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>102 Yanjiang Road West, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>shanpingjiang@126.com</Contact_Email>
    <Contact_Tel>+86 13922738892</Contact_Tel>
    <Contact_Affiliation>Sun Yat sen Memorial Hospital of Sun Yat sen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 years old; &lt;br&gt;2. Patients has been diagnosed with 2019-nCoV pneumonia according to WHO interim guidance*.&lt;br&gt;* WHO. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. Jan 11, 2020. https://www.who.int/internalpublications-detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed Jan 29, 2020).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. pregnant woman patients;&lt;br&gt;2. Documented allergic history to chloroquine; &lt;br&gt;3. Documented history of hematological system diseases;&lt;br&gt;4. Documented history of chronic liver and kidney diseases; &lt;br&gt;5. Documented history of cardiac arrhythmia or chronic heart diseases; &lt;br&gt;6. Documented history of retina or hearing dysfunction; &lt;br&gt;7. Documented history of mental illnesses; &lt;br&gt;8. Use of digitalis due to the previous disease.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:chloroquine;control group:conventional management;</Intervention>
    <Primary_outcome>viral negative-transforming time;30-day cause-specific mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029830</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A study for the psychological status, social support, and care needs of tumor patients admitted to a general hospital during the novel coronavirus pneumonia (COVID-19) outbreak</Public_title>
    <Scientific_title>A study for the psychological status, social support, and care needs of tumor patients admitted to a general hospital during the novel coronavirus pneumonia (COVID-19) outbreak                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>The Fifth Affiliated Hospital of Sun Yat-Sen University</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49511</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>tumor patients group:200;non tumor patients group:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hongmei Tao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China</Contact_Address>
    <Contact_Email>13926946929@163.com</Contact_Email>
    <Contact_Tel>+86 13926946929</Contact_Tel>
    <Contact_Affiliation>The Fifth Affiliated Hospital of Sun Yat-Sen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients diagnosed as malignant tumor by pathology are admitted to tertiary general hospital, which is a designated hospital for admission to COVID-19;&lt;br&gt;2. Stay in hospital for 3 days or more;&lt;br&gt;3. Aged 18 or above;&lt;br&gt;4. Informed consent and ability to cooperate with research.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Confirmed or suspected novel coronavirus pneumonia infection;&lt;br&gt;2. KPS &gt; 30 points.</Exclusion_Criteria>
    <Condition>malignant tumor</Condition>
    <Intervention>tumor patients group:N/A;non tumor patients group:N/A;</Intervention>
    <Primary_outcome>psychological states;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029811</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Guangzhou reborn health management consultation co., LTD</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49355</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Chao Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>164972769@qq.com</Contact_Email>
    <Contact_Tel>+86 15018720816</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;&lt;br&gt;2. Voluntarily sign written informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional treatment+Anti-aging Active Freeze-dried Powder Granules;Control group:Conventional treatment;</Intervention>
    <Primary_outcome>Time to disease recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029539</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-03</Date_registration>
    <Date_registration3>20200203</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48991</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-04</Date_enrollement>
    <Target_size>experimental group:164;control group:164;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jianping Zhao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei</Contact_Address>
    <Contact_Email>zhaojp@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13507138234</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Adult aged &gt;= 18 years old;&lt;br&gt;2. Patients with unexplained viral pneumonia that have been clinically diagnosed or patients with novel coronavirus serum antibody (IgM or IgG) positive or patients with novel coronavirus infection confirmed by PCR when no rapid diagnostic kit has been developed;&lt;br&gt;3. The interval between the onset of symptoms and randomized is within 7 days. The onset of symptoms is mainly based on fever. If there is no fever, cough or other related symptoms can be used;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Any situation that makes the programme cannot proceed safely; &lt;br&gt;2) patients who have used Kaletra or remdesivir; &lt;br&gt;3) no clinical or chest imaging manifestations; &lt;br&gt;4) In the state of no oxygen at rest, the patient's SPO2 &lt;= 94% or the oxygenation index is less than 300mmHg respiratory rate &gt;= 24/min; &lt;br&gt;5) Patients who need to be admitted to ICU judged by clinicians; &lt;br&gt;6) Known allergy or hypersensitivity reaction to lopinavir / ritonavir; &lt;br&gt;7) Increase in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is more than 3 times the upper limit of normal; &lt;br&gt;8) Drugs that are forbidden to be treated with lopinavir / ritonavir and cannot be replaced or stopped during the study period, such as afzosin, amiodarone, fusidic acid, astemizole, terfenadine, piperazine, dihydroergomethane, ergometrine Alkali, ergotamine, methylergometrine, cisapride, lovastatin, simvastatin, sildenafil, vartanafi, midazolam, triazolam, St. John's wort (Hypericum perforatum extract), etc.; &lt;br&gt;9) Pregnancy: positive pregnancy test for women of childbearing age; &lt;br&gt;10) lactating women did not stop lactation; &lt;br&gt;11) Known HIV infection, because of concerns about the development of resistance to lopinavir/rionavir if used without combination with other anti-HIV drugs; &lt;br&gt;12) Patient likely to be transferred to a non-participating hospital within 72 hours.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:conventional standardized treatment and Lopinavir-Ritonavir;control group:Conventional standardized treatment;</Intervention>
    <Primary_outcome>The incidence of adverse outcome within 14 days after admission: Patients with conscious dyspnea, SpO2 = 94% or respiratory frequency = 24 times / min in the state of resting without oxygen inhalation;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029462</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Study for clinical characteristics and distribution of TCM syndrome of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for clinical characteristics and distribution of TCM syndrome of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of He'nan University of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-02</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48922</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Jiansheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>156 Jinshui East Road, Zhengzhou, He'nan, China</Contact_Address>
    <Contact_Email>li_js8@163.com</Contact_Email>
    <Contact_Tel>+86 371 65676568</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of He'nan University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with pneumonia infected by new coronavirus; &lt;br&gt;2. To sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Serious cognitive or mental disorder.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:NA;</Intervention>
    <Primary_outcome>Clinical characteristics;TCM syndrome;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029810</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19) based on CRISPR-cas protein</Public_title>
    <Scientific_title>Development and application of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19)  based on CRISPR-cas protein                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Shenzhen Second People's Hospital</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49407</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-16</Date_enrollement>
    <Target_size>Target condition:10000;Difficult condition:300</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Weiren Huang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>3002 Sungang Road West, Futian District, Shenzhen</Contact_Address>
    <Contact_Email>pony8980@163.com</Contact_Email>
    <Contact_Tel>+86 13923781386</Contact_Tel>
    <Contact_Affiliation>Shenzhen Second People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Pneumonia cases with suspected SARS-CoV-2have either of the following epidemiological histories consistent with the following two clinical manifestations:&lt;br&gt;A comprehensive analysis was conducted based on the following epidemiological history and clinical manifestations&lt;br&gt;1. Epidemiological history&lt;br&gt;(1) Travel history or residence history of wuhan and surrounding areas or other communities shall provide case reports within 14 days before the onset of the disease;&lt;br&gt;(2) Cases have been reported in the past 14 days in patients with fever or respiratory symptoms in community residents of wuhan and surrounding areas;&lt;br&gt;(3) Aggressive attack;&lt;br&gt;(4) History of exposure to new coronavirus infections people with new coronavirus infections are those who have tested positive for nucleic acid;&lt;br&gt;2. Clinical manifestations&lt;br&gt;(1) Fever and/or respiratory symptoms;&lt;br&gt;(2) Pneumonia with the above imaging features;&lt;br&gt;(3) The total number of white blood cells was normal or decreased or the number of lymphocytes decreased at the initial stage of the disease.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Suspected patients with inability to collect deep sputum, throat swabs, or nose swabs from alveolar lavage.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR&amp;#32;product&amp;#32;of&amp;#32;SARS-CoV-2.;</Intervention>
    <Primary_outcome>SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029779</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging</Public_title>
    <Scientific_title>Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Wuxi People's Hospital</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49378</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>Target condition:0;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiangming Fang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>299 Qingyang Road, Liangxi District, Wuxi, Jiangsu</Contact_Address>
    <Contact_Email>xiangming_fang@njmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13861779030</Contact_Tel>
    <Contact_Affiliation>Wuxi People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients diagnosed by nucleic acid and/or genetic test in Wuxi (later expanded to southern Jiangsu and Jiangsu Province) with novel coronavirus pneumonia, and other types of viral pneumonia confirmed by nucleic acid and/or genetic testing and/or pathological testing, cases of mycoplasma pneumonia, fungal pneumonia, hypersensitivity pneumonia, and mixed pulmonary infections with similar imaging findings that need to be differentiated from novel coronavirus pneumonia.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: N/A</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>Gold Standard:Guidelines for novel coronavirus pneumonia (fifth edition);Index test:Diagnosis&amp;#32;model&amp;#32;based&amp;#32;on&amp;#32;Artificial&amp;#32;Intelligence&amp;#32;(Epidemiological&amp;#32;history,&amp;#32;clinical&amp;#32;information,&amp;#32;laboratory&amp;#32;examination,&amp;#32;hospitalization&amp;#32;profile,&amp;#32;pulmonary&amp;#32;function&amp;#32;examination,&amp;#32;blood&amp;#32;gas&amp;#32;test,&amp;#32;chest&amp;#32;plain&amp;#32;film,&amp;#32;chest&amp;#32;CT,&amp;#32;complications,&amp;#32;final&amp;#32;classification,&amp;#32;disease&amp;#32;stage).;</Intervention>
    <Primary_outcome>Chest CT findings;Epidemiological history;Laboratory examination;Pulmonary function test;SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029438</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Beijing hospital of Traditional Chinese medicine; Hubei integrated traditional Chinese and Western Medicine Hospital</Primary_sponsor>
    <Date_registration>2020-02-01</Date_registration>
    <Date_registration3>20200201</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48911</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-04</Date_enrollement>
    <Target_size>control group:50;Experimental group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>LIU QINGQUAN, MIAO QING, ZHANG BOLI</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>23 Back Street of Art Gallery, Dongcheng District, Beijing, China</Contact_Address>
    <Contact_Email>ZJHTCM@FOXMAIL.COM</Contact_Email>
    <Contact_Tel>+86 13902020873</Contact_Tel>
    <Contact_Affiliation>Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Pneumonia patients diagnosed as new coronavirus infection;&lt;br&gt;2) The type of pneumonia was judged as severe and critical;&lt;br&gt;3) Informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) patients were judged not suitable to participate in the study; &lt;br&gt;2) patients were not suitable to use Chinese patent medicine.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>control group:western medical therapies;Experimental group:Conventional medicine + TCM;</Intervention>
    <Primary_outcome>CURB-65;PSI score;Mechanical ventilation time;Length of stay in hospital;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029436</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>The evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>The First Hospital of He'nan University of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-01</Date_registration>
    <Date_registration3>20200201</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48884</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Group 1:50;Group 2:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Jiansheng, Li Suyun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>19 Renmin Road, Zhengzhou, He'nan, China </Contact_Address>
    <Contact_Email>lisuyun2000@126.com</Contact_Email>
    <Contact_Tel>+86 371 66248624</Contact_Tel>
    <Contact_Affiliation>The First Hospital of He'nan University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. patients with 2019-nCoV pneumonia;&lt;br&gt;2. Sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients complicated with active tuberculosis, malignant arrhythmia, acute myocardial infarction and stroke;&lt;br&gt;2. pregnant and lactating women;&lt;br&gt;3. Patients complicated with severe cognitive and mental disorders;&lt;br&gt;4. Clinical investigators who are participating in other interventions within one month prior to enrollment;&lt;br&gt;5. Those who are known to be allergic to therapeutic drugs.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Group 1:TCM syndrome differentiation treatment+ Western medicine treatment;Group 2:Western medicine treatment;</Intervention>
    <Primary_outcome>Duration of PCR normalization;Clinical symptom score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029778</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Shanghai University of TCM</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49422</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>15</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>TCM Group:150;QFPD decoction group:150;SFJD capsuale group:150;control group:150;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wei Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Pulmonary Department, 5A Ward, 528 Zhanghen Road, Pudong New Area District, Shanghai, China</Contact_Address>
    <Contact_Email>zhangw1190@sina.com</Contact_Email>
    <Contact_Tel>+86 13601733045</Contact_Tel>
    <Contact_Affiliation>Shuguang Hospital Affiliated to Shanghai University of TCM.</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Meet the diagnostic criteria of Novel Coronavirus Pneumonia (COVID-19).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnant or lactating women, allergic to the research drug; &lt;br&gt;2. Combined with cardiovascular, liver, kidney and hematopoietic systems and other serious primary diseases, mental illness;&lt;br&gt;3. Those with observational factors affecting efficacy; &lt;br&gt;4. Those who do not meet the inclusion criteria, do not use the prescribed drugs, can not determine the efficacy or incomplete information and other effects of efficacy or safety judgment.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>TCM Group:herbal medicine and conventional treatment;QFPD decoction group:QFPD decoction and conventional treatment;SFJD capsuale group:SFJD capsuale and conventional treatment;control group:conventional treatment;</Intervention>
    <Primary_outcome>Length of hospital stay;fever clearance time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029777</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy</Public_title>
    <Scientific_title>A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Huangshi Hospital of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49380</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-05</Date_enrollement>
    <Target_size>experimental group:80;control group:80;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Tingrong Huang, Bangjiang Fang, Jun Feng, Jianguo Zuo, Gang Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>6 Guangchang Road, Huangshi, Hubei </Contact_Address>
    <Contact_Email>fangbji@163.com</Contact_Email>
    <Contact_Tel>+86 0714-6224162</Contact_Tel>
    <Contact_Affiliation>Huangshi Hospital of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Hospitalized patients with novel coronavirus pneumonia confirmed by pathogenic detection&lt;br&gt;2. Meet any one of the criteria for severe type:&lt;br&gt;1) Respiratory distress: RP &gt;= 30/min;&lt;br&gt;2) At rest, the oxygen saturation &lt;= 93%;&lt;br&gt;3) Arterial partial pressure of oxygen (PaO2)/Fraction of inspiration (FiO2)(Oxygenation Index, P/F) &lt;= 300mmHg.&lt;br&gt;3. Aged 18 to 75 years;&lt;br&gt;4. Signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregancy or lactating women;&lt;br&gt;2. People with allergies or allergies to components of Truncated Torsion formula; &lt;br&gt;3. Patients with serious basic diseases such as malignant tumor, cirrhosis, chronic renal failure (uremic stage), hematological disease, HIV, etc.;&lt;br&gt;4. Patients with obstructive pneumonia caused by lung tumor, pulmonary fibrosis, alveolar proteinosis and allergic alveolitis;&lt;br&gt;5. Patients with long-term use of hormone, immunosuppressant and other drugs;&lt;br&gt;6. Severe mental illness or inability to cooperate with investigators.</Exclusion_Criteria>
    <Condition>severe novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Truncation and Torsion Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;</Intervention>
    <Primary_outcome>14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT00173563</TrialID>
    <Last_Refreshed_on>19 February 2015</Last_Refreshed_on>
    <Public_title>Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children</Public_title>
    <Scientific_title>Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Taiwan University Hospital</Primary_sponsor>
    <Date_registration>12/09/2005</Date_registration>
    <Date_registration3>20050912</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00173563</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>2 Years</Inclusion_agemin>
    <Inclusion_agemax>50 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>January 2005</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design>Time Perspective: Prospective</Study_design>
    <Phase>N/A</Phase>
    <Countries>Taiwan</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Luan-Yin Chang, MD, PhD;Luan-Yin Chang, MD, PhD</Contact_Lastname>
    <Contact_Email>;Ly7077@tpts6.seed.net.tw</Contact_Email>
    <Contact_Tel>;886-2-23123456</Contact_Tel>
    <Contact_Affiliation>Department of pediatrics, National Taiwan University Hospital</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Healthy adults aged 20 to 50 years old&lt;br&gt;&lt;br&gt;          -  Healthy children aged 2 to 5 years old&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Healthy</Condition>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT01056185</TrialID>
    <Last_Refreshed_on>25 November 2019</Last_Refreshed_on>
    <Public_title>Respiratory Virus Hospitalization Study (FLU 003 Plus)</Public_title>
    <Scientific_title>An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Minnesota</Primary_sponsor>
    <Date_registration>25/01/2010</Date_registration>
    <Date_registration3>20100125</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01056185</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>August 2009</Date_enrollement>
    <Target_size>1000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>Phase 1</Phase>
    <Countries>United States;Argentina;Australia;Belgium;Chile;Denmark;Germany;Greece;Peru;Spain;Thailand;United Kingdom;Argentina;Australia;Belgium;Chile;Denmark;Germany;Greece;Peru;Spain;Thailand;United Kingdom;United States;Austria;China;Norway;Poland;South Africa</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>James Neaton, Professor;James Neaton, Professor</Contact_Lastname>
    <Contact_Email>;neato001@umn.edu</Contact_Email>
    <Contact_Tel>;612-626-9040</Contact_Tel>
    <Contact_Affiliation>University of Minnesota - Dept Biostatistics;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Be = 18 years of age&lt;br&gt;&lt;br&gt;          -  Have been admitted to hospital&lt;br&gt;&lt;br&gt;          -  Have a signed informed consent by participant or surrogate/representative&lt;br&gt;&lt;br&gt;          -  Have a local diagnosis (confirmed or suspected) of influenza, or of a targeted&lt;br&gt;             non-influenza viral respiratory infection*, resulting in (or extending a previous)&lt;br&gt;             hospitalization&lt;br&gt;&lt;br&gt;               -  A list of targeted non-influenza respiratory viruses is maintained on the INSIGHT&lt;br&gt;                  website.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Current imprisonment, or compulsory detention (involuntary incarceration) for treat of&lt;br&gt;             a psychiatric or physical illness.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Influenza;Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV);Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)</Condition>
    <Primary_outcome>Death</Primary_outcome>
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04245631</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV</Public_title>
    <Scientific_title>Development of a Simple, Fast and Portable Recombinase Aided Amplification (RAA) Assay for 2019-nCoV</Scientific_title>
    <Acronym />
    <Primary_sponsor>Beijing Ditan Hospital</Primary_sponsor>
    <Date_registration>26/01/2020</Date_registration>
    <Date_registration3>20200126</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04245631</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1 Year</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 1, 2020</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Yao Xie, Doctor;Yao Xie, Doctor;Yao Xie, Doctor</Contact_Lastname>
    <Contact_Email>;xieyao00120184@sina.com;xieyao00120184@sina.com</Contact_Email>
    <Contact_Tel>;8610-84322200;8610-84322200</Contact_Tel>
    <Contact_Affiliation>Department of Hepatology, Division 2, Beijing Ditan Hospital;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  1. Suspected cases (formerly observed cases)&lt;br&gt;&lt;br&gt;        Meet the following 2 at the same time:&lt;br&gt;&lt;br&gt;        Epidemiological history There was a history of travel or residence in Wuhan within two&lt;br&gt;        weeks before the onset of illness; or patients who had had fever from Wuhan with&lt;br&gt;        respiratory symptoms within 14 days before the onset of illness, or had clustered onset.&lt;br&gt;&lt;br&gt;        Clinical manifestations&lt;br&gt;&lt;br&gt;          1. fever;&lt;br&gt;&lt;br&gt;          2. It has the imaging characteristics of pneumonia mentioned above;&lt;br&gt;&lt;br&gt;          3. The total number of white blood cells is normal or decreased, or the lymphocyte count&lt;br&gt;             is decreased in the early stage of onset.&lt;br&gt;&lt;br&gt;               -  2. confirmed cases On the basis of meeting the criteria for suspected cases,&lt;br&gt;                  sputum, throat swabs, lower respiratory tract secretions, and other specimens&lt;br&gt;                  were tested by real-time fluorescent RT-PCR for positive nucleic acid detection&lt;br&gt;                  of new coronavirus; or viral gene sequencing was highly homologous with known new&lt;br&gt;                  coronaviruses.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  1. Influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus,&lt;br&gt;             rhinovirus, human metapneumovirus, SARS coronavirus, and other known other viral&lt;br&gt;             pneumonia;&lt;br&gt;&lt;br&gt;          -  2. Mycoplasma pneumoniae, chlamydia pneumonia, and bacterial pneumonia; non-infectious&lt;br&gt;             diseases such as vasculitis, dermatomyositis, and organizing pneumonia.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>New Coronavirus</Condition>
    <Intervention>Diagnostic Test: Recombinase aided amplification (RAA) assay</Intervention>
    <Primary_outcome>Detection specificity is greater than 95%;Detection sensitivity is greater than 95%</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04252885</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection</Public_title>
    <Scientific_title>A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection</Scientific_title>
    <Acronym>ELACOI</Acronym>
    <Primary_sponsor>Guangzhou 8th People's Hospital</Primary_sponsor>
    <Date_registration>30/01/2020</Date_registration>
    <Date_registration3>20200130</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04252885</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 28, 2020</Date_enrollement>
    <Target_size>125</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Yueping Li, MD, Master;Linghua Li, MD, PhD</Contact_Lastname>
    <Contact_Email>lipipi007@163.com;</Contact_Email>
    <Contact_Tel>020- 36052117;</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  In sputum, throat swab, lower respiratory tract secretion, blood and other samples,&lt;br&gt;             the nucleic acid of the novel coronavirus was positive, or the sequencing of the virus&lt;br&gt;             gene was highly homologous with the known novel coronavirus&lt;br&gt;&lt;br&gt;          -  Age is between 18-80 years old, the weight is more than 30kg, and there is no limit&lt;br&gt;             for men and women&lt;br&gt;&lt;br&gt;          -  The following conditions were met: creatinine = 110 umol / L, creatinine clearance&lt;br&gt;             rate (EGFR) = 60 ml / min / 1.73m2, AST and ALT = 5  ULN, TBIL = 2  ULN;&lt;br&gt;&lt;br&gt;          -  The subjects should fully understand the purpose, nature, method and possible reaction&lt;br&gt;             of the study, voluntarily participate in the study and sign the informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Have a clear history of lopinavir or ritonavir or arbidol allergy&lt;br&gt;&lt;br&gt;          -  Severe nausea, vomiting, diarrhea and other clinical manifestations affect the oral or&lt;br&gt;             absorption of the drugs&lt;br&gt;&lt;br&gt;          -  At the same time, take drugs that may interact with lopinavir or ritonavir or arbidol&lt;br&gt;&lt;br&gt;          -  Patients with serious underlying diseases, including but not limited to heart disease&lt;br&gt;             (including history of angina pectoris or coronary heart disease or myocardial&lt;br&gt;             infarction, atrioventricular block), lung, kidney, liver malfunction and mental&lt;br&gt;             diseases that cannot be treated together&lt;br&gt;&lt;br&gt;          -  ancreatitis or hemophilia&lt;br&gt;&lt;br&gt;          -  Pregnant and lactating women&lt;br&gt;&lt;br&gt;          -  Suspected or confirmed history of alcohol and drug abuse&lt;br&gt;&lt;br&gt;          -  Participated in other drug trials in the past month&lt;br&gt;&lt;br&gt;          -  The researchers judged that patients were not suitable for the study&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus Infections</Condition>
    <Intervention>Drug: Lopinavir and Ritonavir Tablets;Drug: Arbidol</Intervention>
    <Primary_outcome>The rate of virus inhibition</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029418</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial</Public_title>
    <Scientific_title>Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-01-30</Date_registration>
    <Date_registration3>20200130</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48886</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>Experimental Group:28;Control Group:14;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Tengxiao Liang, Tong Wang, Xuezeng Hao, Jingfeng Zhang, Yaosheng  Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>5 Haiyuncang Lane, Dongcheng District, Beijing</Contact_Address>
    <Contact_Email>shanghongcai@126.com</Contact_Email>
    <Contact_Tel>+86 010 84012510</Contact_Tel>
    <Contact_Affiliation>Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Aged  &gt;= 18 years;&lt;br&gt;2) Meet the diagnostic criteria of severe pneumonia patients with new coronavirus;&lt;br&gt;3) The informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Severe basic diseases that affect survival, including: uncontrolled malignant tumors with multiple metastases that cannot be removed, hematological diseases, cachexia, active bleeding, severe malnutrition, HIV, etc.;&lt;br&gt;2) Obstructive pneumonia caused by lung tumors, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic reaction alveolitis;&lt;br&gt;3) Previous immunosuppressive agents within 6 months before study entry or recipients of a solid-organ or bone marrow transplant;&lt;br&gt;4) Pregnant or lactating women;&lt;br&gt;5) Researchers believe that patients may have other factors affecting the efficacy or safety evaluation of this study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental Group:Combined Treatment of Chinese medicine and western medicine;Control Group:Western medicine treatment;</Intervention>
    <Primary_outcome>Critically ill patients (%);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030173</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration</Public_title>
    <Scientific_title>Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Hunan yuanpin Cell Biotechnology Co., Ltd</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49229</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Experimental group:30;control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xue Zhigang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>102 South Dongwu Road, Changsha Economic and Technological Development Zone, Changsha, Hu'nan, China</Contact_Address>
    <Contact_Email>xuezg@tongji.edu.cn</Contact_Email>
    <Contact_Tel>+86 15000285942</Contact_Tel>
    <Contact_Affiliation>Hu'nan Yuanpin Cell Biotechnology Co., Ltd</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-60 years old;&lt;br&gt;2. Patients with clinical symptoms, signs, auxiliary detection combined with 1 or more nucleic acid test to confirm the diagnosis of new coronavirus pneumonia;&lt;br&gt;3. Voluntarily sign the informed consent to comply with the requirements of the  program.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. History of tumor;&lt;br&gt;2. Vascular embolism and pulmonary hypertension;&lt;br&gt;3. Suspected or established history of alcohol, drug or drug abuse;&lt;br&gt;4. Female patients of child-bearing age who are pregnant, breast-feeding or have a recent family planning;&lt;br&gt;5. Patients who have participated in or are participating in other drug trials within one month;&lt;br&gt;6. Patients considered unfit to participate in this clinical trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:umbilical cord mesenchymal stem cells;control group:convention treatment;</Intervention>
    <Primary_outcome>pulmonary function;Novel coronavirus pneumonic nucleic acid test;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT00533741</TrialID>
    <Last_Refreshed_on>19 February 2015</Last_Refreshed_on>
    <Public_title>SARS Coronavirus Vaccine (SARS-CoV)</Public_title>
    <Scientific_title>Phase I, Double-Blinded, Placebo-Controlled Dosage Escalation Study of the Safety and Immunogenicity of Adjuvanted and Non-Adjuvanted Inactivated SARS Coronavirus (SARS-CoV) Vaccine Administered by the Intramuscular Route</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</Primary_sponsor>
    <Date_registration>20/09/2007</Date_registration>
    <Date_registration3>20070920</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00533741</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>40 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>September 2007</Date_enrollement>
    <Target_size>0</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</Study_design>
    <Phase>Phase 1</Phase>
    <Countries>United States</Countries>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Able to understand and communicate in written and spoken English.&lt;br&gt;&lt;br&gt;          -  Judged to be able to provide informed consent and has signed informed consent form&lt;br&gt;             prior to study participation.&lt;br&gt;&lt;br&gt;          -  Male or female between 18 and 40 years of age.&lt;br&gt;&lt;br&gt;          -  Females of childbearing potential agree to practice adequate contraception for the&lt;br&gt;             entire study period.&lt;br&gt;&lt;br&gt;          -  Good general health as confirmed by medical history, history-directed physical&lt;br&gt;             examination, and laboratory assessments within normal ranges established by Baylor&lt;br&gt;             College of Medicine.&lt;br&gt;&lt;br&gt;          -  Availability for follow-up for six months after the first vaccination.&lt;br&gt;&lt;br&gt;          -  Willing and able to comply with protocol requirements.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Clinically significant medical disorder found by medical history or physical exam.&lt;br&gt;&lt;br&gt;          -  History of anaphylaxis or other significant adverse event following immunization.&lt;br&gt;&lt;br&gt;          -  History of or planned exposure to small mammalian animals that are from Asia, or were&lt;br&gt;             previously housed with Asian counterparts.&lt;br&gt;&lt;br&gt;          -  Pregnant or lactating female.&lt;br&gt;&lt;br&gt;          -  Acute illness (cough, congestion, malaise, diarrhea, feverishness and/or oral&lt;br&gt;             temperature &gt; 99.5 degrees Fahrenheit, etc.) within a week of planned vaccination.&lt;br&gt;&lt;br&gt;          -  Use of an immunosuppressive or immunomodulatory drug such as greater than 5 mg/day of&lt;br&gt;             prednisone orally, or greater than 800 mcg/day of inhaled beclomethasone for 2 or&lt;br&gt;             more consecutive weeks within 3 months prior to the first vaccination.&lt;br&gt;&lt;br&gt;          -  History of or current substance abuse, including alcohol (e.g., greater than or equal&lt;br&gt;             to 4 six-packs of beer or equivalent per week regularly).&lt;br&gt;&lt;br&gt;          -  History of receiving blood or blood products in the previous three months, or&lt;br&gt;             anticipated over the six month study period.&lt;br&gt;&lt;br&gt;          -  Vaccination with a live vaccine within 30 days of study vaccination, or a&lt;br&gt;             non-replicating, inactivated or subunit vaccine within 14 days of study vaccination,&lt;br&gt;             or planned during the study.&lt;br&gt;&lt;br&gt;          -  Positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV),&lt;br&gt;             hepatitis B surface antigen (HbsAg).&lt;br&gt;&lt;br&gt;          -  Positive serology for severe acute respiratory disease (SARS) S protein if testing is&lt;br&gt;             done.&lt;br&gt;&lt;br&gt;          -  Use of any investigational or unregistered drug or vaccine within 30 days before the&lt;br&gt;             first study vaccination, or planned use during the study.&lt;br&gt;&lt;br&gt;          -  Autoimmune disease (e.g., lupus, rheumatoid arthritis), malignancy or tumor.&lt;br&gt;&lt;br&gt;          -  Bleeding disorder by history, or thrombocytopenia.&lt;br&gt;&lt;br&gt;          -  Diagnosis of schizophrenia, bipolar disease or other major psychiatric disorder.&lt;br&gt;&lt;br&gt;          -  Have been hospitalized for psychiatric illness, history of suicide attempt, or&lt;br&gt;             confinement for danger to self or others.&lt;br&gt;&lt;br&gt;          -  Are receiving psychiatric drugs (aripiprazole, clozapine, ziprasidone, haloperidol,&lt;br&gt;             loxapine, thioridazine, molindone, thiothixene, pimozide, fluphenazine, risperidone,&lt;br&gt;             mesoridazine, quetiapine, trifluoperazine, chlorprothixene, chlorpromazine,&lt;br&gt;             perphenazine, trifluopromazine, olanzapine, carbamazepine, divalproex sodium, lithium&lt;br&gt;             carbonate or lithium citrate). Subjects who are receiving a single antidepressant&lt;br&gt;             drug and are stable for at least 3 months prior to enrollment, without&lt;br&gt;             de-compensating symptoms will be allowed to be enrolled in the study.&lt;br&gt;&lt;br&gt;          -  Plans to enroll in another study before study completion (six months).&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus (SARS-CoV)</Condition>
    <Intervention>Drug: Aluminum hydroxide;Drug: Placebo;Biological: SARS-CoV</Intervention>
    <Primary_outcome>Frequency and severity of solicited injection site and systemic signs and symptoms and unsolicited adverse events (AE) / SAEs.;Frequency of significant increases in serum antibody to CoV S protein in Enzyme Linked Immunosorbent Assay (ELISA) and in neutralization tests, and increases in Geometric Mean Titers (GMT)s in sera.;Frequency and description of serious adverse events (SAEs).</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT01376765</TrialID>
    <Last_Refreshed_on>19 February 2015</Last_Refreshed_on>
    <Public_title>Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study</Public_title>
    <Scientific_title>Phase I, Double-Blinded, Placebo-Controlled, Dose- Escalation Study of the Safety and Immunogenicity of Recombinant SARS-CoV deltaTM S Protein Vaccine Formulated With and Without Alhydrogel in Healthy Adults When Administered by the Intramuscular Route</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</Primary_sponsor>
    <Date_registration>16/06/2011</Date_registration>
    <Date_registration3>20110616</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01376765</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>40 Years</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>April 2011</Date_enrollement>
    <Target_size>0</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</Study_design>
    <Phase>Phase 1</Phase>
    <Countries>United States</Countries>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Males or nonpregnant females between the ages of 18 and 40 years, inclusive.&lt;br&gt;&lt;br&gt;          -  Women of childbearing potential (not surgically sterile via tubal ligation, bilateral&lt;br&gt;             oophorectomy or hysterectomy or who have not been postmenopausal for &gt;/=1 year) must&lt;br&gt;             agree to practice adequate contraception for the 30-day period before vaccination&lt;br&gt;             through 90 days after the second vaccination.  Acceptable birth control methods for&lt;br&gt;             the purposes of this study may include, but are not limited to, abstinence,&lt;br&gt;             monogamous relationship with vasectomized partner, barrier methods such as condoms,&lt;br&gt;             diaphragms, spermicides, and intrauterine devices, and licensed hormonal methods.&lt;br&gt;&lt;br&gt;          -  In good health, as judged by the investigator and determined by vital signs&lt;br&gt;             [temperature &lt; 38 degrees C, heart rate &lt;/= 100 bpm and &gt; 50 bpm, systolic blood&lt;br&gt;             pressure &lt;/= 140 mmHg and &gt; 89 mmHg, diastolic blood pressure &lt;/= 90 mmHg and &gt;/= 60&lt;br&gt;             mm Hg, respiratory rate &gt;/= 12 breath per minute and &lt; 17 breaths per minutes (see&lt;br&gt;             toxicity table in Section 9.1.2)], medical history and a targeted physical&lt;br&gt;             examination, as indicated, based on medical history.&lt;br&gt;&lt;br&gt;          -  Screening laboratory values must be within normal limits.  These include blood&lt;br&gt;             hemoglobin, white blood cell (WBC) count, eosinophils, platelets, absolute&lt;br&gt;             eosinophil, neutrophil, and lymphocyte cell counts, creatinine, aspartate&lt;br&gt;             aminotransferase (AST), alanine transaminase (ALT), bilirubin (total), glucose&lt;br&gt;             (random), and urinalysis (proteinuria and hematuria).  See toxicity table in Section&lt;br&gt;             9.1.3.2.  Note: creatinine values lower than the normal are acceptable.&lt;br&gt;&lt;br&gt;          -  Able to understand and comply with planned study procedures.&lt;br&gt;&lt;br&gt;          -  Willing to be available for all study-required procedures, visits and calls for the&lt;br&gt;             duration of the study.&lt;br&gt;&lt;br&gt;          -  Provide written informed consent before initiation of any study procedures and be&lt;br&gt;             available for all study visits.&lt;br&gt;&lt;br&gt;          -  Negative for IgG antibodies to S protein of Severe Acute Respiratory Syndrome&lt;br&gt;             coronavirus (SARS-CoV) measured by ELISA.&lt;br&gt;&lt;br&gt;          -  Negative for antibodies to Human Immunodeficiency Virus (HIV) and hepatitis C virus&lt;br&gt;             and for hepatitis B surface antigen.&lt;br&gt;&lt;br&gt;          -  Negative for IgG antibodies to S protein of Severe Acute Respiratory Syndrome&lt;br&gt;             coronavirus (SARS-CoV) measured by ELISA.&lt;br&gt;&lt;br&gt;          -  Negative for antibodies to Human Immunodeficiency Virus (HIV) and hepatitis C virus&lt;br&gt;             and for hepatitis B surface antigen.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  A known allergy to components of the vaccine.&lt;br&gt;&lt;br&gt;          -  A positive serum or urine pregnancy test within 24 hr prior to vaccination (if female&lt;br&gt;             of childbearing potential as defined in Inclusion Criterion 2), women who are&lt;br&gt;             planning to become pregnant from 30 days prior to entering the study until 90 days&lt;br&gt;             after the final study vaccination, or women who are breastfeeding.&lt;br&gt;&lt;br&gt;          -  Immunosuppression as result of underlying illness or treatment or use of anticancer&lt;br&gt;             chemotherapy or radiation therapy (cytotoxic) within the preceding 36 months.&lt;br&gt;&lt;br&gt;          -  An active neoplastic disease (excluding nonmelanoma skin cancer or prostate cancer&lt;br&gt;             that is stable in the absence of therapy) or a history of any hematologic malignancy.&lt;br&gt;              Nonactive neoplastic disease is defined as no neoplastic disease or treatment for&lt;br&gt;             neoplastic disease within the past 5 years.&lt;br&gt;&lt;br&gt;          -  A history of autoimmune disease (systemic lupus, rheumatoid arthritis, scleroderma,&lt;br&gt;             polyarteritis, thyroiditis, etc).&lt;br&gt;&lt;br&gt;          -  Used an immunosuppressive or immunomodulatory drug such as &gt;0.5 mg/kg/day or &gt;/=20 mg&lt;br&gt;             total dose/day of prednisone orally or &gt;800 mcg of inhaled beclomethasone for 2 or&lt;br&gt;             more consecutive weeks within 6 months prior to the 1st vaccination. (Nasal and&lt;br&gt;             topical steroids are allowed.)&lt;br&gt;&lt;br&gt;          -  A known human immunodeficiency virus (HIV) infection, or active hepatitis B, or&lt;br&gt;             hepatitis C virus infection.&lt;br&gt;&lt;br&gt;          -  A diagnosis of schizophrenia, bipolar disease, or other major psychiatric diagnosis&lt;br&gt;             in the past 3 years.&lt;br&gt;&lt;br&gt;          -  Hospitalized for psychiatric illness, history of suicide attempt, or confinement for&lt;br&gt;             danger to self or others in the past 3 years.&lt;br&gt;&lt;br&gt;          -  Receiving psychiatric drugs listed below*. Subjects who are receiving a single&lt;br&gt;             antidepressant drug and are stable for at least 3 months prior to enrollment, without&lt;br&gt;             decompensating symptoms will be allowed to be enrolled in the study.&lt;br&gt;&lt;br&gt;             *aripiprazole, clozapine, ziprasidone, haloperidol, molindone, loxapine,&lt;br&gt;             thioridazine, thiothixene, pimozide, fluphenazine, risperidone, mesoridazine,&lt;br&gt;             quetiapine, trifluoperazine, trifluopromazine, chlorprothixene, chlorpromazine,&lt;br&gt;             perphenazine, olanzapine, carbamazepine, divalproex sodium, lithium carbonate, or&lt;br&gt;             lithium citrate.&lt;br&gt;&lt;br&gt;          -  A history of receiving immunoglobulin or other blood product within the previous 3&lt;br&gt;             months before vaccination.&lt;br&gt;&lt;br&gt;          -  Received or plan to receive any live licensed vaccines within 4 weeks or inactivated&lt;br&gt;             licensed vaccines within 2 weeks of each vaccination,&lt;br&gt;&lt;br&gt;          -  An acute or chronic medical condition that, in the opinion of the investigator, would&lt;br&gt;             render vaccination unsafe or would interfere with the evaluation of responses or is&lt;br&gt;             not generally seen in healthy, normal subjects. (This includes, but is not limited&lt;br&gt;             to, known cardiac disease, pulmonary disease, liver disease, renal disease, unstable&lt;br&gt;             or progressive neurological disorders, diabetes mellitus, and transplant recipients.)&lt;br&gt;&lt;br&gt;          -  A history of severe reactions following immunization with vaccines.&lt;br&gt;&lt;br&gt;          -  Received an experimental agent (vaccine, drug, biologic, device, blood product, or&lt;br&gt;             medication) within 1 month before vaccination in this study or expect to receive an&lt;br&gt;             experimental agent during the 24-month study period.&lt;br&gt;&lt;br&gt;          -  Any condition that would, in the opinion of the investigator, place them at an&lt;br&gt;             unacceptable risk of injury, render them unable to meet the requirements of the&lt;br&gt;             protocol, or that may interfere with successful completion of the study.&lt;br&gt;&lt;br&gt;          -  A history of alcohol or drug abuse during the previous 1 year; for example, daily&lt;br&gt;             excessive alcohol use or frequent binge drinking as determined by the investigator,&lt;br&gt;             or chronic marijuana abuse or any other illicit drug use.&lt;br&gt;&lt;br&gt;          -  Plans to travel outside North America in the time between the 1st vaccination and 56&lt;br&gt;             days following the first vaccination or have plans to travel to Southeast Asia during&lt;br&gt;             their entire study participation.&lt;br&gt;&lt;br&gt;          -  Body temperature &gt;/=100.4 F (&gt;/=38.0 C) or acute illness within 3 days before&lt;br&gt;             vaccination (subject may be rescheduled).&lt;br&gt;&lt;br&gt;          -  Planned or have had a known exposure to the Himalayan</Inclusion_Criteria>
    <Condition>SARS</Condition>
    <Intervention>Drug: Aluminum hydroxide adjuvant (Alhydrogel);Other: Phosphate buffered saline Placebo;Biological: Recombinant S protein SARS vaccine</Intervention>
    <Primary_outcome>Occurrence of laboratory abnormalities at 8 days after vaccination (Days 8 and 36);Incidence of vaccine-related serious adverse events (SAEs) throughout the duration of the study.;Occurrence of solicited local and systemic adverse events (AE)within 8 days after vaccination (Days 0-7 and Days 28-35)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04251871</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection</Public_title>
    <Scientific_title>Effects of Traditional Chinese Medicines (TCMs) on Patients With 2019-nCoV Infection: A Perspective, Open-labeled, Randomized, Controlled Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>Beijing 302 Hospital</Primary_sponsor>
    <Date_registration>28/01/2020</Date_registration>
    <Date_registration3>20200128</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04251871</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 22, 2020</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Xiao-he Xiao, PD.;Rui-lin Wang, Dr.;Rui-lin Wang, Dr.</Contact_Lastname>
    <Contact_Email>;wrl7905@163.com;wrl7905@163.com</Contact_Email>
    <Contact_Tel>;+86 10 66933436;+86 66933323</Contact_Tel>
    <Contact_Affiliation>302 Military Hospital;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Confirmed 2019-nCoV infection case in term of laboratory evidence;&lt;br&gt;&lt;br&gt;          -  80 years = age = 14years;&lt;br&gt;&lt;br&gt;          -  Within 72 hours after the onset of abnormalities shown by Chest radiology or several&lt;br&gt;             symptoms (fever and cough).&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &lt; 14 years or &gt; 80 years;&lt;br&gt;&lt;br&gt;          -  Pregnant or lactating female;&lt;br&gt;&lt;br&gt;          -  One of the following items occurred at the enrollment: (i) respiratory failure&lt;br&gt;             necessitating mechanical ventilation; (ii) liver failure: total bilirubin = 10mg/dL&lt;br&gt;             and/or severe coagulation disorders; (iii) renal function failure: although adequate&lt;br&gt;             circulating blood and cardiac output, urine = 0.5ml/kgh, Cr or BUN = 1.5 times normal&lt;br&gt;             elevation;&lt;br&gt;&lt;br&gt;          -  Intake of Chinese medicinal herbs during the past 2 weeks;&lt;br&gt;&lt;br&gt;          -  Refused to sign an informed consent form prior to study participation;&lt;br&gt;&lt;br&gt;          -  Unwilling and unable to comply with protocol request.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Pneumonia Caused by Human Coronavirus (Disorder)</Condition>
    <Intervention>Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules;Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)</Intervention>
    <Primary_outcome>Time to complete remission of 2019-nCoV infection-associated symptoms</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04260594</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus</Public_title>
    <Scientific_title>Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).</Scientific_title>
    <Acronym />
    <Primary_sponsor>Jieming QU</Primary_sponsor>
    <Date_registration>06/02/2020</Date_registration>
    <Date_registration3>20200206</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04260594</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 7, 2020</Date_enrollement>
    <Target_size>380</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 4</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Sign the informed consent form;&lt;br&gt;&lt;br&gt;          2. Age =18 years, regardless of gender;&lt;br&gt;&lt;br&gt;          3. Subjects with pneumonia diagnosed as 2019-nCoV infection; A) Detection of 2019-nCoV&lt;br&gt;             nucleic acid positive by RT-PCR in respiratory tract or blood samples.&lt;br&gt;&lt;br&gt;             B) The virus gene sequence of respiratory tract or blood samples is highly homologous&lt;br&gt;             to the known 2019-nCoV.&lt;br&gt;&lt;br&gt;          4. According to the standard of "pneumonia diagnosis and treatment Program of New&lt;br&gt;             Coronavirus infection (trial Fifth Edition)" issued by National Health Commission of&lt;br&gt;             the People's Republic of China, clinical classification: mild, ordinary subjects; A)&lt;br&gt;             Mild type, the clinical symptoms were mild and no pneumonia was found in imaging.&lt;br&gt;&lt;br&gt;        B) Common type, With fever, respiratory tract and other symptoms, the manifestations of&lt;br&gt;        pneumonia can be seen on imaging.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Critical type:&lt;br&gt;&lt;br&gt;             If one of the following conditions is met:&lt;br&gt;&lt;br&gt;             A) Respiratory failure occurs and mechanical ventilation is needed; B) Shock occurred;&lt;br&gt;             C) Patients with other organ failure need ICU monitoring treatment.&lt;br&gt;&lt;br&gt;          2. Severe type:&lt;br&gt;&lt;br&gt;             If one of the following conditions is met:&lt;br&gt;&lt;br&gt;             A) Respiratory distress, RR = 30 beats / min; B) In resting state, finger oxygen&lt;br&gt;             saturation (SaO2) = 93%; C) Partial pressure of arterial oxygen (PaO2) / concentration&lt;br&gt;             of oxygen inhaled (FiO2)=300mmHg)&lt;br&gt;&lt;br&gt;          3. Those who have a history of allergy to this class of drugs and / or severe allergic&lt;br&gt;             constitution;&lt;br&gt;&lt;br&gt;          4. The results of laboratory tests are abnormal:&lt;br&gt;&lt;br&gt;             A) Hematological dysfunction is defined as:&lt;br&gt;&lt;br&gt;             i) Platelet (PLT) count: &lt;100  109 / L; ii) hemoglobin (Hb) level &lt;90g/L.&lt;br&gt;&lt;br&gt;             B) abnormal liver function is defined as:&lt;br&gt;&lt;br&gt;             i) level of total bilirubin(TBil) : &gt;2 times Upper Limits of Normal(ULN); ii) the&lt;br&gt;             levels of aspartate aminotransferase (AST) and Alanine transaminase (ALT):&gt;3 times of&lt;br&gt;             ULN.&lt;br&gt;&lt;br&gt;             C) definition of renal dysfunction:&lt;br&gt;&lt;br&gt;             Serum creatinine&gt;1.5 times of ULN, or calculated creatinine clearance&lt;50ml / min;&lt;br&gt;&lt;br&gt;             D) definition of abnormal blood coagulation:&lt;br&gt;&lt;br&gt;             International normalized ratio(INR) &gt;1.5 times of ULN, and the prothrombin time ((PT))&lt;br&gt;             or activated partial thromboplastin time (aPTT) is 1.5 times of ULN, unless the&lt;br&gt;             subject is receiving anticoagulant therapy.&lt;br&gt;&lt;br&gt;          5. Abidor was used before inclusion(Tablets, capsules, granules).&lt;br&gt;&lt;br&gt;          6. Women who are nursing or pregnant.&lt;br&gt;&lt;br&gt;          7. Serum or urine pregnancy tests were positive for women of child-bearing age.&lt;br&gt;&lt;br&gt;          8. Immunodeficient patient(Patients with malignant tumors, Organ or bone marrow&lt;br&gt;             transplant, HIV patient, those who took immunosuppressive drugs within 3 months before&lt;br&gt;             the screening test ).&lt;br&gt;&lt;br&gt;          9. With the following history of present illness:&lt;br&gt;&lt;br&gt;               1. Neurological and neurodevelopmental disorders, These include diseases of the&lt;br&gt;                  brain, spinal cord, peripheral nerves and muscles(Such as cerebral palsy,&lt;br&gt;                  epilepsy, stroke, mental retardation, moderate to severe developmental delay,&lt;br&gt;                  muscular malnutrition or spinal cord injury ).&lt;br&gt;&lt;br&gt;               2. circulation system disease( congenital heart disease, Congestive heart failure or&lt;br&gt;                  coronary artery disease).&lt;br&gt;&lt;br&gt;               3. Severe heart disease or a history of clinically significant arrhythmias that the&lt;br&gt;                  researchers believe will affect participants' safety (According to the ECG or&lt;br&gt;                  medical history).&lt;br&gt;&lt;br&gt;         10. Other patients considered ineligible for this study were considered ineligible by the&lt;br&gt;             investigators&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV</Condition>
    <Intervention>Drug: Arbidol;Other: basic treatment</Intervention>
    <Primary_outcome>Virus negative conversion rate in the first week</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029776</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>The First Affiliated of Wenzhou Medical University</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49342</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-11</Date_enrollement>
    <Target_size>experimental group:20;control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiaoyin Huang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Nanbaixiang, Ouhai District, Wenzhou, Zhejiang</Contact_Address>
    <Contact_Email>zjwzhxy@126.com</Contact_Email>
    <Contact_Tel>+86 13819711719</Contact_Tel>
    <Contact_Affiliation>The First Affiliated of Wenzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;&lt;br&gt;2. Above 18 years old (inclusive);&lt;br&gt;3. Voluntarily sign written informed consent.  </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Severe pneumonia requires mechanical ventilationcritically severe cases;&lt;br&gt;2. Estimated Time of Death is less than 48 hours;&lt;br&gt;3. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development;&lt;br&gt;4. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory tracts diseases that affecting clinical trial evaluation. Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis;&lt;br&gt;5. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;&lt;br&gt;6. Mental state unable to cooperate, suffering from mental illness, unable to control, unable to express clearly&lt;br&gt;7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug;&lt;br&gt;8. Patients with a history of substance abuse or dependence;&lt;br&gt;9. Pregnant or lactating women;&lt;br&gt;10. Patients who participated in other clinical trials within the last 3 months;&lt;br&gt;11. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>experimental group:Polyinosinic-Polycytidylic Acid Injection and conventional therapy;control group:conventional therapy;</Intervention>
    <Primary_outcome>Time to Clinical recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029742</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-11</Date_registration>
    <Date_registration3>20200211</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49297</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>General patients treated with normal treatment:30;General patients experimental group:30;Severe patients control group 1:10;Severe patients control group 2:10;Severe patients experimental group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qin Ning, Meifang Han</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>31531955@qq.com</Contact_Email>
    <Contact_Tel>+86 27 83662688</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 to 70 years;&lt;br&gt;2. Diagnosed 2019-nCoV infected patients by viral nucleic acid,or although the test was negative and even not be detected, the reseachers judged it to be a novel coronavirus pneumonia;&lt;br&gt;3. Understand and agree to participate in this study and sign informed consent;&lt;br&gt;4. According to the guideline of clinical classification of novel coronavirus pneumonia (2019-nCoV) diagnosis and treatment plan (trial version fifth), the general patients were included in the selection criteria: fever, respiratory tract symptoms, imaging findings of pneumonia; Severe patients were selected according to the following criteria: &lt;br&gt;1) respiratory distress, RR &gt;= 30 times / minute; &lt;br&gt;2) resting state, mean oxygen saturation less than 93%;&lt;br&gt;3) artery. PaO2 / FiO2 &lt;= 300MMHG (1mmhg = 0.133kpa).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnant or lactating women, or pregnant;&lt;br&gt;2. Those who are allergic to the drug ingredients of this program;&lt;br&gt;3. Severe cardiovascular diseases, such as severe center of gravity dysfunction, second or third degree atrioventricular block, etc.;&lt;br&gt;4. Severe hepatic insufficiency: defined as the upper limit of ALT &gt; 2 times normal value or AST &gt; 2 times normal value;&lt;br&gt;5. Severe renal insufficiency: defined as creatinine &gt; 1.5 times the upper limit of normal value;&lt;br&gt;6. Have asthma, COPD serious respiratory disease;&lt;br&gt;7. Serious blood diseases, such as coagulation disorders, systemic bleeding, platelet diseases, etc;&lt;br&gt;8. Serious endocrine system diseases, such as type II diabetes;&lt;br&gt;9. Patients with malignant tumor;&lt;br&gt;10. Patients taking antiedematous drugs for a long time;&lt;br&gt;11. Major operation history;&lt;br&gt;12. Other clinical researchers.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>General patients treated with normal treatment:Normal Treatment;General patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;Severe patients control group 1:Normal treatment plus hormonotherapy;Severe patients control group 2:Normal Treatment;Severe patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;</Intervention>
    <Primary_outcome>Chest imaging (CT);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030168</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A real world study for Compound Houttuyniae Mixture for prevention of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A prospective real world study on Compound Houttuyniae Mixture used in people of the observation period in close contact with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49433</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>??</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-29</Date_enrollement>
    <Target_size>Experimental group:1000;Control group:1000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Dawei Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>100 Shizhi Street, Hongshan Road, Nanjing, Jiangsu, China</Contact_Address>
    <Contact_Email>cleverwdw@126.com</Contact_Email>
    <Contact_Tel>+86 025-52362054</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Those who have close contact with patients with novel coronavirus pneumonia;&lt;br&gt;2) Be over 18 years old (including 18 years old);&lt;br&gt;3) Voluntarily sign written informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) According to the researcher's judgment, the diseases that have been or have suffered may affect the patients to participate in the trial;&lt;br&gt;2) Those who are allergic to the known ingredients of this medicine;&lt;br&gt;3) Pregnant or lactating women;&lt;br&gt;4) Patients who have participated in other clinical trials in the past 3 months;&lt;br&gt;5) The researcher believes that there is anything unsuitable for enrollment.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Increased Compound Houttuynia Mixture in real world situations;Control group:None(People who do not receive Compound Houttuynia Mixture in real world situations);</Intervention>
    <Primary_outcome>Compared with the control group, the positive rate of NCP nucleic acid test on subjects used Compound Houttuynia Mixture.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030166</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>The 5th Medical Center Chinese PLA General Hospital</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49696</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-25</Date_enrollement>
    <Target_size>Control group:10;Investigation group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yanling Zhao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>100 West Fourth Ring Road, Fengtai District, Beijing, China</Contact_Address>
    <Contact_Email>zhaoyl2855@126.com</Contact_Email>
    <Contact_Tel>+86 13681208998</Contact_Tel>
    <Contact_Affiliation>The 5th Medical Center Chinese PLA General Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Inclusion of case criteria (pneumonia diagnosis and treatment protocol for COVID-19 (trial 6th edition))&lt;br&gt;1. Common type patient: with fever, respiratory tract and other symptoms, and imaging findings of pneumonia.&lt;br&gt;2. Severe patients: patients who meet any of the following criteria&lt;br&gt;(1) respiratory distress, RR&gt;=30 times/min;&lt;br&gt;(2) in resting state, oxygen saturation is less than 93%;&lt;br&gt;(3) partial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) =300mmHg (1mmHg = 0.133kpa);&lt;br&gt;3. TCM syndrome differentiation conforms to the clinical diagnostic criteria for patients in the early, middle, severe and convalescent stages of the pneumonia diagnosis and treatment program forCOVID-2019 (trial version 6);&lt;br&gt;4. Signed informed consent voluntarily.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The patient has other immune system, blood system, heart, liver, kidney and other important organs of the disease;&lt;br&gt;2. Accompanied by chronic diseases, such as malignant tumors, chronic obstructive pulmonary disease;&lt;br&gt;3. have a history of mental illness;&lt;br&gt;4. pregnant and nursing women;&lt;br&gt;5. less than 18 years old;&lt;br&gt;6. Studying drug allergies or contraindications;&lt;br&gt;7. Patients participating in other clinical trials;&lt;br&gt;8. The researchers consider other reasons not appropriate for clinical subjects.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Routine treatment (Pure western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection;Investigation group:(Integrated Chinese and western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection(routine treatment)+Qing-Wen Bai-Du-Yin formula granules;</Intervention>
    <Primary_outcome>CT scan of the lungs;Nucleic acid detection of throat secretion;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030118</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Shenzhen national medicine inheritance medical research institute co. LTD</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49594</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Experimental group:60;Control group:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yuan Yongming</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Room 18A 03-2, Anlian Building, 4018 Jintian Road, Fuzhong Community, Lianhua Street, Futian District, Shenzhen, Guangdong, China</Contact_Address>
    <Contact_Email>64699629@qq.com</Contact_Email>
    <Contact_Tel>+86 18664556429</Contact_Tel>
    <Contact_Affiliation>Shenzhen national medicine inheritance medical research institute co. LTD</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) All patients were diagnosed with a new type of coronavirus pneumonia;&lt;br&gt;(2) Clear mind, cooperation and communication; &lt;br&gt;(3) Men and women aged 18 and 80 years; &lt;br&gt;(4) informed consent has been signed and is willing to be assessed.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) with severe liver or kidney failure or other serious underlying diseases; &lt;br&gt;(2) Pregnant and lactating women; &lt;br&gt;(3) Persons who are participating in other clinical trials.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Traditional Chinese medicine soup;Control group:Western antiviral;</Intervention>
    <Primary_outcome>Chest CT scan;Nucleic acid of novel coronavirus;Routine blood test;Routine urine test;Stool routine test;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030116</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Nanchang University</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49901</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Two groups:16;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Dose comparison</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Wei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China</Contact_Address>
    <Contact_Email>zhangweiliuxin@163.com</Contact_Email>
    <Contact_Tel>+86 13707089183</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Nanchang University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients are eligible for admission if they meet all of the following criteria within 5-7 days of their first ICU admission. &lt;br&gt;1) Aged 18-75 years; &lt;br&gt;2) The patient meets the ARDS diagnostic standard (Berlin standard) and needs intubation ventilator-assisted or ECMO-assisted treatment; &lt;br&gt;3) The primary disease caused by 2019-nCoV virus infection; &lt;br&gt;4) Imaging data suggest bilateral lung lesions; &lt;br&gt;5) Voluntarily participate in clinical research; fully understand, know, and sign informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) ARDS caused by other viral infections; &lt;br&gt;2) ARDS caused by other non-viral infections (such as trauma); &lt;br&gt;3) WHO grade III or IV pulmonary hypertension; &lt;br&gt;4) Patients with malignant tumors of the lungs and other systems; &lt;br&gt;5) Positive blood pregnancy test in lactating women or screening women; &lt;br&gt;6) Idiopathic IgA deficiency; &lt;br&gt;7) Cardio-cerebrovascular events in the near future (3 months); &lt;br&gt;8) patients with lung transplantation; &lt;br&gt;9) HIV positive patients; &lt;br&gt;10) Tester excluding from the investigator's judgment a history or current evidence of any disease, treatment, or laboratory abnormality that may confuse the results of the study, interfere with the participant's participation in the study process, or are not in the best interest of the participant to participate in the study. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Two groups:Different stem cell doses;</Intervention>
    <Primary_outcome>Time to leave ventilator on day 28 after receiving MSCs infusion;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029741</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study</Public_title>
    <Scientific_title>Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>The Fifth Affiliated Hospital Sun Yat-Sen University</Primary_sponsor>
    <Date_registration>2020-02-11</Date_registration>
    <Date_registration3>20200211</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49263</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>experimental group:56;control group:56;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xia Jinyu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>52 Meihua Road East, Xiangzhou District, Zhuhai, China</Contact_Address>
    <Contact_Email>xiajinyu@mail.sysu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13823078064</Contact_Tel>
    <Contact_Affiliation>The Fifth Affiliated Hospital Sun Yat-Sen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (All the following criteria are met before being selected):&lt;br&gt;1. Aged &gt;= 18 years;&lt;br&gt;2. Meet all the following criteria (refer to confirmed cases in the 5th edition of the diagnosis and treatment plan):&lt;br&gt;(1) Epidemiological history;&lt;br&gt;(2) Clinical manifestations (according to any of the following 2): fever; normal or decreased white blood cell count or reduced lymphocyte count in the early stages of onset; multiple small patchy shadows and interstitial changes in early chest imaging, which are evident in the extrapulmonary zone. Furthermore, it develops multiple ground glass infiltration and infiltrates in both lungs. In severe cases, pulmonary consolidation and pleural effusion are rare.&lt;br&gt;(3) Confirmed: Suspected cases have one of the following pathogenic evidence: respiratory specimens, blood specimens, or fecal specimens are detected by real-time fluorescent RT-PCR to detect novel coronavirus nucleic acid; the above-mentioned specimens are genetically sequenced and highly homologous to known new coronaviruses .&lt;br&gt;(4) Light or ordinary patients;&lt;br&gt;(5) With or without anti-viral drugs other than chloroquine phosphate, lopinavir/ritonavir.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (Subjects cannot enter the study if they meet any of the following conditions):&lt;br&gt;1. Patients with a history of allergy to chloroquine phosphate, lopinavir, and ritonavir;&lt;br&gt;2. Patients with hematological diseases;&lt;br&gt;3. Patients with chronic liver and kidney disease and reaching the end stage;&lt;br&gt;4. Patients with arrhythmia and chronic heart disease;&lt;br&gt;5. Patients known to have retinal disease, hearing loss or hearing loss;&lt;br&gt;6. Patients with known mental illness;&lt;br&gt;7. Patients who must use digitalis because of the original underlying disease;&lt;br&gt;8. Pancreatitis;&lt;br&gt;9. Hemophilia;&lt;br&gt;10. Broad bean disease;&lt;br&gt;11. Female patients during pregnancy.</Exclusion_Criteria>
    <Condition>2019 Novel Coronavirus Infection (CoVID-19)</Condition>
    <Intervention>experimental group:Chloroquine Phosphate;control group:Lopinavir / Ritonavir;</Intervention>
    <Primary_outcome>Length of stay;Length of severe;oxygenation index during treatment;all-cause mortality in 28 days;Peripheral blood cell count (including white blood cells, lymphocytes, neutrophils, etc.);procalcitonin;C-reactive protein;Inflammatory factors (including IL-6, IL-10, TNF-a, etc.);Lymphocyte subsets and complement;Coagulation indicators (prothrombin time, activated partial prothrombin time, fibrinogen, D-dimer, platelet count);Virus nucleic acid;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029637</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>An observational study for Xin-Guan-1 formula  in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>An observational study for Xin-Guan-1 formula  in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Guangdong Provincial Hospital of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-08</Date_registration>
    <Date_registration3>20200208</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49127</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-07</Date_enrollement>
    <Target_size>Experimental group:50;Control group:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Zhongde</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>doctorzzd99@163.com</Contact_Email>
    <Contact_Tel>+86 13903076359</Contact_Tel>
    <Contact_Affiliation>Guangdong Provincial Hospital of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who meet the diagnostic criteria of Hubei Province pneumonia infected by novel coronavirus(2019-nCoV), and clinical classification of mild, moderate and severe were included.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: ?Allergic constitution, ie, allergic history to 2 or more kinds of medicine or food, or to the medicines of our study.&lt;br&gt;?Patients who do not agree with taking traditional Chinese medicine.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Xinguan-1 formula+Standard treatment;Control group:Standard treatment;</Intervention>
    <Primary_outcome>Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030093</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>The Second Hospital of Shanxi Medical University</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49932</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>1:30;2:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Tian Feng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>382 Wuyi Road, Xinghualing District, Taiyuan, Shanxi, China</Contact_Address>
    <Contact_Email>tflook@163.com</Contact_Email>
    <Contact_Tel>+86 13934570253</Contact_Tel>
    <Contact_Affiliation>The Second Hospital of Shanxi Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Including front-line medical staff for COVID-19 epidemic prevention and control, including front-line medical staff responsible for epidemic prevention and control in Wuhan or other regions, and front-line staff responsible for epidemic prevention and control in communities.&lt;br&gt;Enrollment criteria: &lt;br&gt;1. Voluntarily participated in and sign the informed consent form; &lt;br&gt;2. The generalized anxiety scale (GAD-7) score is greater than 5 points, and the patient health questionnaire-depressive symptoms group scale (PHQ-9) score is greater than 5 points;&lt;br&gt;3. Aged 18-65 years old male or female; &lt;br&gt;4. Education level at or above primary school.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: With other serious physical or mental illnesses.</Exclusion_Criteria>
    <Condition>Mental health; Novel coronavirues pneumonia (COVID-19)</Condition>
    <Intervention>1:Simplify cognitive behavior;2:Supportive psychotherapy;</Intervention>
    <Primary_outcome>State anxiety;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030084</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression</Public_title>
    <Scientific_title>A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>The First Hospital of Shanxi Medical University</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49952</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Psychological Intervention Group:90;Control Group :90;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xu Yong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>85 Jiefang Road South, Yingze District, Taiyuan, Shanxi, China</Contact_Address>
    <Contact_Email>xuyongsmu@vip.163.com</Contact_Email>
    <Contact_Tel>+86 18234016125</Contact_Tel>
    <Contact_Affiliation>The First Hospital of Shanxi Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Age between 18 and 75 years old (including threshold), regardless of gender;&lt;br&gt;2. The patient under isolation observation is diagnosed with mild or common type of 2019-nCoV acute respiratory disease and can cooperate to complete corresponding psychological intervention;&lt;br&gt;3. The total score of Hamilton depression scale (HAMD17) and Hamilton anxiety scale (HAMA14) at baseline is both at least 7;&lt;br&gt;4. The patient has sufficient compliance to complete the experiment according to the protocol;&lt;br&gt;5. The patient and his/her family or guardian sign the informed consent to participate voluntarily in this clinical study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. In the six months before the diagnosis of 2019-nCoV acute respiratory disease, the patient was clearly diagnosed as a psychiatric disorder, including depression, bipolar disorder and so on; &lt;br&gt;2. Patients with psychotic symptoms;&lt;br&gt;3. A history of suicide attempt in the 6 months before the study, or a score of  more than 3 on item 3 (suicide item) of the HAMD17 scale;&lt;br&gt;4. The total score of Hamilton depression scale (HAMD17) is more than 24 or the total score of Hamilton anxiety scale (HAMA14)is more than 21 at baseline;&lt;br&gt;5. The patient is diagnosed with organic mental disorder caused by a systemic disease or a neurological disorder,with a history of severe and unstable physical illness;&lt;br&gt;6. The patient is undergoing psychotherapy or has received psychotherapy 12 weeks prior to screening; &lt;br&gt;7. The patient had alcohol abuse within 30 days prior to screening or alcohol or drug dependence within 6 months prior to screening;&lt;br&gt;8. The patient use antipsychotics, antidepressants, and anti-anxiety drugs within 6 months prior to screening;&lt;br&gt;9. The researchers believe there are other conditions in the patient that are not suitable for this clinical trial.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19) with mild to moderate anxiety and depression</Condition>
    <Intervention>Psychological Intervention Group:"Intelligent Psychosomatic Regulation System" Intervention;Control Group :General Treatment ;</Intervention>
    <Primary_outcome>the score of Hamilton depression scale;the score of Hamilton anxiety scale;the score of Self-Rating Depression Scale;the score of Self-Rating Anxiety Scale;the score of Athens Insomnia Scale;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029636</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial</Public_title>
    <Scientific_title>Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-08</Date_registration>
    <Date_registration3>20200208</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49215</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-09</Date_enrollement>
    <Target_size>Case series:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hu bo, Li wei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>hubo@mail.hust.edu.cn</Contact_Email>
    <Contact_Tel>+86 13707114863</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Aged &gt;=18 years, gender unlimited, inpatient;&lt;br&gt;2) Patients with new coronavirus infection were confirmed: respiratory or blood samples were positive for 2019 ncov nucleic acid by real-time fluorescent RT-PCR, or respiratory or blood samples were highly homologous with known 2019 ncov gene sequencing;&lt;br&gt;3) According to the standard of "diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 5)", the clinical types are common type or severe type;&lt;br&gt;4) The time interval between symptom onset and enrollment was within 7 days. The symptom onset was mainly based on fever. If there was no fever, coughing or other related symptoms could be used, such as fatigue, nasal obstruction, runny nose, chest distress, sore throat, muscle ache, diarrhea, etc;&lt;br&gt;5) Informed consent has been signed.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Known or suspected to be allergic to the components of vMIP.&lt;br&gt;2) Confirmed hepatitis B, C, AIDS and other viral infections.&lt;br&gt;3) Acute respiratory distress syndrome (ARDS) was found.&lt;br&gt;4) According to the judgment of the researchers, there are other conditions that are not suitable for the experiment.&lt;br&gt;5) Pregnant, lactating women or during the trial period and within 6 months after the end of the family planning.&lt;br&gt;6) Have participated in other clinical trials or are using experimental drugs within 12 weeks before administration.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Conventional standardized treatment and vMIP atomized inhalation;</Intervention>
    <Primary_outcome>2019-nCoV nucleic acid turning negative time (from respiratory secretion), or the time to release isolation;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029589</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of ovel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Beijing hospital of Traditional Chinese Medicine; Hubei Integrated Traditional Chinese and Western Medicine Hospital</Primary_sponsor>
    <Date_registration>2020-02-05</Date_registration>
    <Date_registration3>20200205</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49104</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-06</Date_enrollement>
    <Target_size>control group:30;experimental group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>LIU QINGQUAN</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>23 Art Gallery Back Street, Dongcheng District, Beijing, China </Contact_Address>
    <Contact_Email>Liuqingquan2003@126.com</Contact_Email>
    <Contact_Tel>+86 010-52176520</Contact_Tel>
    <Contact_Affiliation>Beijing hospital of Traditional Chinese Medicine; Hubei Integrated Traditional Chinese and Western Medicine Hospital </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Comply with the diagnostic criteria of "Pneumonitis Diagnosis and Treatment Scheme for New Coronavirus Infection (Trial Version 5)";&lt;br&gt;(2) The classification was judged as common type;&lt;br&gt;(3) Body temperature &gt; 37.3 degree C;&lt;br&gt;(4) Subjects are &gt;= 18 years of age.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Patients whose estimated survival time does not exceed 48 hours from the start of screening;&lt;br&gt;(2) Tracheal intubation and mechanical ventilation have been performed during screening;&lt;br&gt;(3) Other problems that doctor's judgment is not suitable for the study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>control group:basic western medical therapies;experimental group:Reduning injection combined with basic western medical therapies;</Intervention>
    <Primary_outcome>Antipyretic time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030043</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial</Public_title>
    <Scientific_title>Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Peking University Third Hospital</Primary_sponsor>
    <Date_registration>2020-02-21</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49866</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-21</Date_enrollement>
    <Target_size>Experimental:150;control:150;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ma Penglin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>49 North Huayuan Road, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>mapenglin1@163.com</Contact_Email>
    <Contact_Tel>+86 13810339898</Contact_Tel>
    <Contact_Affiliation>Peking University Third Hospital </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Confirmed and suspected cases of pneumonia from novel coronavirus infection;&lt;br&gt;2. Meet the diagnostic criteria for community - acquired pneumonia;&lt;br&gt;3. Clinical classification is "heavy" or "critical";&lt;br&gt;4. Aged 18 to 75 years;&lt;br&gt;5. Obtain informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnancy or lactating women;&lt;br&gt;2. People with allergies or allergies to Shenfu injection and its components;&lt;br&gt;3. Severe basic diseases that affect survival, including: uncontrolled malignant tumors with multiple metastases that cannot be removed, hematological diseases, cachexia, active bleeding, severe malnutrition, HIV, etc.;&lt;br&gt;4. Obstructive pneumonia caused by lung tumors, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic reaction alveolitis;&lt;br&gt;5. Previous immunosuppressive agents within 6 months before study entry or recipients of a solid-organ or bone marrow transplant;&lt;br&gt;6. Extracorporeal life support (ECMO, ECCO2R, RRT);&lt;br&gt;7. Expected to die within 48 hours;&lt;br&gt;8. Patients who are considered by the investigator to be unsuitable subjects for this study. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental:Conventional treatment and Shenfu injection;control:Conventional treatment;</Intervention>
    <Primary_outcome>pneumonia severity index (PSI);Incidence of new organ dysfunction;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030041</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-21</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49891</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-25</Date_enrollement>
    <Target_size>Case series:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Cheng Zhenshun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>chzs1990@163.com</Contact_Email>
    <Contact_Tel>+86 02767812787</Contact_Tel>
    <Contact_Affiliation>Zhongnan Hospital of Wuhan University </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Aged &gt;=18 years old inpatient;&lt;br&gt;(2) novel coronavirus nucleic acid positive was detected by real-time fluorescent RT-PCR in throat swabs;&lt;br&gt;(3) The clinical types were common type or severe type;&lt;br&gt;(4) Informed consent has been signed.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) It is known or suspected that it is allergic to the components of azvudine tablets;&lt;br&gt;(2) Light or severe patients;&lt;br&gt;(3) Patients with dysabsorption syndrome, or any other condition that affects gastrointestinal absorption, or who are unable to take drugs orally;&lt;br&gt;(4) Severe liver diseases (such as child Pugh score&gt;=C, TBIL&gt;=2 times the upper limit of normal value, ALT/AST&gt;=5 ULN, or HBsAg positive;&lt;br&gt;(5) Patients with severe renal insufficiency (eGFR&lt;=30ml/min/1.73m2) or undergoing continuous renal replacement therapy, hemodialysis and peritoneal dialysis;&lt;br&gt;(6) Women during pregnancy and lactation or having family planning during the trial period / within 6 months of the end of the trial;&lt;br&gt;(7) Other factors that are not suitable for entering the trial (According to the judgment of the researcher).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:FNC;</Intervention>
    <Primary_outcome>The novel coronavirus nucleic acid negative rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04255940</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>2019-nCoV Outbreak and Cardiovascular Diseases</Public_title>
    <Scientific_title>Impact of a Novel Coronavirus (2019-nCoV) Outbreak on Public Anxiety and Cardiovascular Disease Risk in China</Scientific_title>
    <Acronym />
    <Primary_sponsor>Qilu Hospital of Shandong University</Primary_sponsor>
    <Date_registration>03/02/2020</Date_registration>
    <Date_registration3>20200203</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04255940</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 20, 2020</Date_enrollement>
    <Target_size>12000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>Phase 4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Panpan Hao, MD</Contact_Lastname>
    <Contact_Email>panda.how@sdu.edu.cn</Contact_Email>
    <Contact_Tel>86-18560086593</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients visiting emergency department.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        -&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Cardiovascular Death; Major Adverse Cardiovascular Events</Condition>
    <Primary_outcome>Cardiovascular Death</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04260308</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia</Public_title>
    <Scientific_title>A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia in Wuhan, China</Scientific_title>
    <Acronym />
    <Primary_sponsor>Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>03/02/2020</Date_registration>
    <Date_registration3>20200203</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04260308</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 3, 2020</Date_enrollement>
    <Target_size>30000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Yuhong Dai;Yuhong Dai</Contact_Lastname>
    <Contact_Email>eier_dai@163.com;eier_dai@163.com</Contact_Email>
    <Contact_Tel>+86 13476229575;+86 13476229575</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  can use mobil phone or computer&lt;br&gt;&lt;br&gt;          -  volunteer to take part in the investigation&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  can not use phone or computer&lt;br&gt;&lt;br&gt;          -  unwilling to take part in the investigation&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Virus; Pneumonia</Condition>
    <Primary_outcome>GHQ-12(general health questionnaire-12)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029883</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR</Public_title>
    <Scientific_title>A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49549</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Target condition:200;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xu Shuyun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>sxu@hust.edu.cn</Contact_Email>
    <Contact_Tel>+86 13517248539</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Confirmed or suspected case of COVID-19 in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.&lt;br&gt;1. Aged &lt;= 75 years;&lt;br&gt;2. Patients with newly diagnosed and suspected coronavirus pneumonia;&lt;br&gt;3. Willing and able to sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients without any clinical or chest imaging manifestations;&lt;br&gt;2. Those with severe nasal diseases affecting the sampling;&lt;br&gt;3. Inability to understand or follow research protocols for severe mental illness;&lt;br&gt;4. Invasive ventilation with endotracheal intubation.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: &lt;br&gt;1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-CoV-2; &lt;br&gt;2. Gene sequencing of respiratory or blood samples is highly homologous with SARS-CoV-2.;Index test:SARS-CoV-2&amp;#32;nucleic&amp;#32;acid&amp;#32;test:&amp;#32;1.&amp;#32;nasopharyngeal&amp;#32;samples;&amp;#32;2.&amp;#32;oropharyngeal&amp;#32;samples;</Intervention>
    <Primary_outcome>detection of SARS-CoV-2 nucleic acid;SEN;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04261426</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia</Public_title>
    <Scientific_title>A Randomized, Open-label, Controlled, Single-center Study to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Patients With Severe 2019- nCoV Pneumonia</Scientific_title>
    <Acronym />
    <Primary_sponsor>Peking Union Medical College Hospital</Primary_sponsor>
    <Date_registration>06/02/2020</Date_registration>
    <Date_registration3>20200206</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04261426</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 10, 2020</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Taisheng Li</Contact_Lastname>
    <Contact_Email>litsh@263.net</Contact_Email>
    <Contact_Tel>010-69155086</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adult aged &gt;=18years old;&lt;br&gt;&lt;br&gt;          -  Laboratory (RT-PCR) confirmed 2019-nCoV infection in throat swab and/or sputum and/or&lt;br&gt;             lower respiratory tract samples;&lt;br&gt;&lt;br&gt;          -  The interval between the onset of symptoms and randomized is within 7 days. The onset&lt;br&gt;             of symptoms is mainly based on fever. If there is no fever, cough or other related&lt;br&gt;             symptoms can be used;&lt;br&gt;&lt;br&gt;          -  Meet any of the following criteria for severe or critical ill conditions:&lt;br&gt;&lt;br&gt;               1. Respiratory rate &gt;=30/min; or&lt;br&gt;&lt;br&gt;               2. Rest SPO2&lt;=90%; or&lt;br&gt;&lt;br&gt;               3. PaO2/FiO2&lt;=300mmHg; or&lt;br&gt;&lt;br&gt;               4. Respiratory failure and needs mechanical ventilation; or&lt;br&gt;&lt;br&gt;               5. Shock occurs; or&lt;br&gt;&lt;br&gt;               6. Multiple organ failure and needs ICU monitoring;&lt;br&gt;&lt;br&gt;          -  Sign the Informed Consent Form on a voluntary basis.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Exist of other evidences that can explain pneumonia including but not limited to:&lt;br&gt;&lt;br&gt;        influenza A virus, influenza B virus, bacterial pneumonia, fungal pneumonia, noninfectious&lt;br&gt;        causes, etc.;&lt;br&gt;&lt;br&gt;          -  Allergy to Intravenous Immunoglobulin or its preparation components;&lt;br&gt;&lt;br&gt;          -  Patients with selective IgA deficiency&lt;br&gt;&lt;br&gt;          -  Women who are pregnant or breast-feeding;&lt;br&gt;&lt;br&gt;          -  Researchers consider unsuitable.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV</Condition>
    <Intervention>Drug: Intravenous Immunoglobulin;Other: Standard care</Intervention>
    <Primary_outcome>Lower Murray lung injury score;Lower Murray lung injury score;Clinical improvement based on the 7-point scale</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04261907</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection</Public_title>
    <Scientific_title>A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection</Scientific_title>
    <Acronym />
    <Primary_sponsor>First Affiliated Hospital of Zhejiang University</Primary_sponsor>
    <Date_registration>06/02/2020</Date_registration>
    <Date_registration3>20200206</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04261907</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 7, 2020</Date_enrollement>
    <Target_size>160</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Yunqing Qiu, Master;Xiaowei Xu, Master</Contact_Lastname>
    <Contact_Email>;xxw69@126.com</Contact_Email>
    <Contact_Tel>;+86 13605708066</Contact_Tel>
    <Contact_Affiliation>First Affiliated Hospital of Zhejiang University;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  1. Aged between 18 and 75 years, extremes included, male or female&lt;br&gt;&lt;br&gt;          -  2. Laboratory (RT-PCR) and clinical symptoms confirmed case of 2019-nCoV pneumonia,&lt;br&gt;             according to the official guideline "Pneumonia Diagnosis and Treatment Scheme for&lt;br&gt;             Novel Coronavirus Infection (Trial Version 5)"&lt;br&gt;&lt;br&gt;          -  3. Hospitalised with a new onset respiratory illness (=7 days since illness onset)&lt;br&gt;&lt;br&gt;          -  4. No family planning within six months, and agree to take effective contraceptive&lt;br&gt;             measures throughout the study and for at least 30 days after the final study drug dose&lt;br&gt;&lt;br&gt;          -  5. Must agree not to enroll in another study of an investigational agent prior to&lt;br&gt;             completion of Day 30 of study&lt;br&gt;&lt;br&gt;          -  6. Informed Consent Form (ICF) signed voluntarily&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  1. Severe 2019-nCoV pneumonia met one of the following criteria: respiratory distress,&lt;br&gt;             RR = 30 times / min, or SaO2 / SpO2 = 93% in resting state, or arterial partial&lt;br&gt;             pressure of oxygen (PaO2) /concentration of oxygen (FiO2) = 300mmHg (1mmHg = 0.133kpa)&lt;br&gt;&lt;br&gt;          -  2. Critical severe 2019-nCoV pneumonia met one of the following criteria: respiratory&lt;br&gt;             failure and mechanical ventilation required, or shock, or combined with other organ&lt;br&gt;             failure required ICU monitoring treatment&lt;br&gt;&lt;br&gt;          -  3. Severe liver disease (e.g. Child Pugh score = C, AST &gt; 5 times upper limit)&lt;br&gt;&lt;br&gt;          -  4. Known allergic reaction to any of components of ASC09 / ritonavir compound tablets&lt;br&gt;&lt;br&gt;          -  5. Patients with definite contraindications in the label of ritonavir&lt;br&gt;&lt;br&gt;          -  6. Positive serum pregnancy test result for women with childbearing potential at&lt;br&gt;             screening&lt;br&gt;&lt;br&gt;          -  7. Using HIV protease inhibitor drugs&lt;br&gt;&lt;br&gt;          -  8. Not suitable for the study, in the opinion of the Investigator (e.g. patient may be&lt;br&gt;             transferred to another hospital during the study period, patient with multiple basic&lt;br&gt;             diseases, etc.)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV</Condition>
    <Intervention>Drug: ASC09/ritonavir group;Drug: lopinavir/ritonavir group</Intervention>
    <Primary_outcome>The incidence of composite adverse outcome</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029941</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49596</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>experimental group :100;control group:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>LU Zhenhui</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>725 Wanping Road South, Xuhui District, Shanghai, China</Contact_Address>
    <Contact_Email>tcmdoctorlu@163.com</Contact_Email>
    <Contact_Tel>+86 13817729859</Contact_Tel>
    <Contact_Affiliation>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Meet the diagnostic criteria for suspected and confirmed cases (including mild, general, and severe) in the Diagnosis and Treatment of Pneumonia of New Coronavirus Pneumonia (Trial Version 5);&lt;br&gt;2. Meet the TCM diagnostic criteria for each stage of the novel coronavirus pneumonia;&lt;br&gt;3. Aged 18-75 years-old men or women;&lt;br&gt;4. Patients who volunteer to participate in this study and sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with respiratory failure, acute necrotizing encephalopathy, septic shock, multiple organ dysfunction, and other serious clinical conditions requiring monitoring and treatment when enrolled;&lt;br&gt;2. Pregnant, preparing or lactating women;&lt;br&gt;4. Patients with severe heart, cerebrovascular and liver, kidney, hematopoietic system diseases and mental illness;&lt;br&gt;3. Patients with tuberculosis, measles, AIDS and other infectious diseases;&lt;br&gt;5. Patients with known allergies to western medicine or traditional Chinese medicine ingredients used in this research;&lt;br&gt;6. Patients with gastrointestinal bleeding who cannot take Chinese medicine;&lt;br&gt;7. Patients who use oral Chinese medicine within 4 weeks.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment ;control group:western medicine symptomatic treatment ;</Intervention>
    <Primary_outcome> Number of worsening events;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029578</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, sing-arm trial</Public_title>
    <Scientific_title>Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Zhejiang Chinese Medical University</Primary_sponsor>
    <Date_registration>2020-02-05</Date_registration>
    <Date_registration3>20200205</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49080</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-06</Date_enrollement>
    <Target_size>Treatment group:1000;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chengping Wen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>548 Binwen Road, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>wengcp@163.com</Contact_Email>
    <Contact_Tel>+86 571 86613587</Contact_Tel>
    <Contact_Affiliation>Zhejiang Chinese Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who meet the diagnostic criteria of the fifth edition of pneumonia diagnosis and treatment plan for new coronavirus infection issued by the national health and health commission (annex 1) for the confirmed cases of light (medical observation period), common (early stage of TCM clinical treatment) or heavy (middle stage of TCM clinical treatment);&lt;br&gt;2. Prospective study patients informed and consented to participate in this study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with other serious organ diseases or mental illness.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Treatment group:Integrated Traditional Chinese and Western Medicine;</Intervention>
    <Primary_outcome>Cure rate;The cure time;The rate and time at which the normal type progresses to the heavy type;Rate and time of progression from heavy to critical type and even death;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029518</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial</Public_title>
    <Scientific_title>A prospective randomized double-blind placebo-controlled study of traditional Chinese medicine staging regimen in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Zhejiang Chinese Medical University</Primary_sponsor>
    <Date_registration>2020-02-03</Date_registration>
    <Date_registration3>20200203</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48860</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-04</Date_enrollement>
    <Target_size>(ordinary) Western medicine group:40;(ordinary) Chinese and Western Medicine Group:40;(severe) Western medicine group:30;(severe) Chinese and Western Medicine Group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wen Chengping</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>548 Binwen Road, Binjiang District, Hangzhou, Zhejiang</Contact_Address>
    <Contact_Email>wengcp@163.com</Contact_Email>
    <Contact_Tel>+86 13906514781</Contact_Tel>
    <Contact_Affiliation>Zhejiang Chinese Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Patients who meet the diagnostic criteria of the common type of confirmed cases (the initial stage of clinical treatment of traditional Chinese medicine) or the severe cases of confirmed cases (the middle stage of clinical treatment of traditional Chinese medicine);&lt;br&gt;(2) The cases of common type (the initial stage of clinical treatment of traditional Chinese medicine) belong to the type of cold-dampness stagnant lung;&lt;br&gt;(3) The confirmed cases were severe (in the middle stage of clinical treatment of traditional Chinese medicine).&lt;br&gt;(4) The patients knew and agreed to participate in this study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) The critically ill patients in the diagnosis and treatment program of pneumonia with new coronavirus infection issued by the National Health Commission;&lt;br&gt;(2) It is not suitable for patients who take traditional Chinese medicine decoction;&lt;br&gt;(3) Those with other serious organ diseases or mental diseases;&lt;br&gt;(4) Those who are allergic to or have contraindications to the drugs involved in the study scheme.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>(ordinary) Western medicine group:Use the (ordinary)  western medicine treatment plan in "the diagnosis and treatment plan of new coronavirus infection pneumonia" issued by the National Health Commission of the fourth edition.;(ordinary) Chinese and Western Medicine Group:Use the (ordinary)   TCM clinical prescription combined with the western medicine  treatment plan in "the diagnosis and treatment plan of new coronavirus infection pneumonia" issued by the National Health Commission of the fourth edition.;(severe) Western medicine group:Use the (severe) TCM clinical prescription combined with the western medicine treatment plan in "the diagnosis and treatment plan of new coronavirus infection pneumonia" issued by the National Health Commission of the fourth edition.;(severe) Chinese and Western Medicine Group:Use the(severe)TCM clinical prescription combined with the western medicine treatment plan in "the diagnosis and treatment plan of new coronavirus infection pneumonia" issued by the National Health Commission of the fourth edition.;</Intervention>
    <Primary_outcome>Recovery time;Ratio and time for the general type to progress to heavy;Ratio and time of severe progression to critical or even death;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030034</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial</Public_title>
    <Scientific_title>Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Tongde Hospital of Zhejiang Province</Primary_sponsor>
    <Date_registration>2020-02-21</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49647</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-07</Date_enrollement>
    <Target_size>Experimental group:88;Control group:44;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Kequn Chai</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>234 Gucui Road, Xihu District, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>ckqmzygzs@163.com</Contact_Email>
    <Contact_Tel>+86 13906503739</Contact_Tel>
    <Contact_Affiliation>Tongde Hospital of Zhejiang Province</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Patients in accordance with the diagnostic criteria of "Quick reference guide for diagnosis and treatment of novel coronavirus pneumonia(2019-nCoV)(Standard Edition)" and "Diagnostic and treatment protocols of novel coronavirus pneumonia(Trial version 5)" issued by National Health Commission;&lt;br&gt;(2) Patients in accordance with the TCM syndrome differentiation standard;&lt;br&gt;(3) Aged 18 to 85 years;&lt;br&gt;(4) Before the trial begins, patients or their legal representatives voluntarily agree to participate by giving written informed consent approved by ethic committee. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Diagnosed with other known viral pneumonia,like influenza virus, parainfluenza virus, adenovirus, respiratory syncytical virus, rhinovirus, human metapneumovirus and SARS coronavirus, etc.;&lt;br&gt;(2) Diagnosed with mycoplasma pneumonia, chlamydial pneumonia and bacterial pneumonia;&lt;br&gt;(3) Diagnosed with vasculitis, dermatomyositis, organizing pneumonia and other noninfectious diseases;&lt;br&gt;(4) pregnant or breastfeeding woman;&lt;br&gt;(5) Known to be allergic to this medicine ingredient;&lt;br&gt;(6) Patients with serious underlying disease, and researchers considered inappropriate to participate.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:TCM+Routine treatment of Western Medicine;Control group:Routine treatment of Western Medicine;</Intervention>
    <Primary_outcome>Body temperature;TCM syndrome integral;Murray lung injury score;The transition time of novel coronavirus nucleic acid;MuLBSTA score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030032</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Study on ultrasonographic manifestations of new type of novel coronavirus pneumonia (covid-19) in non-critical stage of pulmonary lesions</Public_title>
    <Scientific_title>Study on ultrasonographic manifestations of new type of novel coronavirus pneumonia (covid-19) in non-critical stage of pulmonary lesions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Xi'an Chest Hospital</Primary_sponsor>
    <Date_registration>2020-02-21</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49816</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Case series:20;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Huang Yi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Xi'an Chest Hospital, East Section of Hangtian Avenue, Chang'an District, Xi'an, Shaanxi, China</Contact_Address>
    <Contact_Email>huang-yi-1980@163.com</Contact_Email>
    <Contact_Tel>+86 13319184133</Contact_Tel>
    <Contact_Affiliation>Xi'an Chest Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. novel coronavirus: &lt;br&gt;(1) 1 days before onset, 14 had travel history or residence history in Wuhan or other areas with local cases;&lt;br&gt;(2) during the 14 days before onset, patients with fever or respiratory symptoms from Wuhan or other areas with persistent local cases were exposed;&lt;br&gt;(3) there was an epidemiological association between clustering onset or new coronavirus infection;&lt;br&gt;2. Clinical manifestations: &lt;br&gt;(1) fever; &lt;br&gt;(2) radiographically characteristic of ground glass or patchy consolidation pneumonia in the lung; &lt;br&gt;(3) normal or reduced leukocyte count or lymphocyte count in the early stage of the disease.&lt;br&gt;3. novel coronavirus nucleic acid positive novel coronavirus was detected by real-time fluorescence RT-PCR based on the standard of suspected cases: &lt;br&gt;(1) positive result of nCoV nucleic acid test;&lt;br&gt;(2) sequencing of the virus gene was highly homologous to the known new coronavirus. Patients included in the study need to meet the above three criteria and be clinically diagnosed as non critical patients.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Exclude participants who disagree;&lt;br&gt;2. Exclude those who cannot cooperate.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Distribution of 'B' line around lungs of both lungs;Whether there is peripulmonary focus;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029939</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)</Public_title>
    <Scientific_title>A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>HwaMei Hospital, University of Chinese Academy of Sciences</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49612</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Conventional treatment group:50;Experimental group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ting Cai</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>41 Xibei Street, Ningbo, Zhejiang, China</Contact_Address>
    <Contact_Email>caiting@ucas.ac.cn</Contact_Email>
    <Contact_Tel>+86 13738498188</Contact_Tel>
    <Contact_Affiliation>HwaMei Hospital, University of Chinese Academy of Sciences</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission.&lt;br&gt;Criteria for diagnosis (meet all the following criteria):&lt;br&gt;1. With epidemiological history;&lt;br&gt;2. Clinical manifestations (meet any 2 of the following): fever, normal or decreased white blood cell count or lymphopenia in the early stage of onset, and Chest radiology in the early stage shows multiple small patchy shadowing and interstitial changes which is especially significant in periphery pulmonary. Furthermore, it develops into bilateral multiple ground-glass opacity and infiltrating shadowing. Pulmonary consolidation occurs in severe cases. Pleural effusion is rare;&lt;br&gt;3. Confirmed case (suspected case obtained one of the following etiologic evidences): a positive result to real-time reverse-transcriptase PCR for respiratory specimen or blood specimen, or Genetic sequencing result of virus in respiratory or blood specimens are highly homologous to SARS-CoV-2.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Female patients during pregnancy; &lt;br&gt;2. Patients with known allergy to chloroquine; &lt;br&gt;3. Patients with haematological diseases; &lt;br&gt;4. Patients with chronic liver or kidney diseases at the end stage; &lt;br&gt;5. Patients with arrhythmia and chronic heart disease; &lt;br&gt;6. Patients with retinal disease, hearing deficiency or hearing loss; &lt;br&gt;7. Patients with psychiatric diseases; &lt;br&gt;8. Patients taking digitalis due to underlying diseases.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Conventional treatment group:The conventional treatment group will be treated according to the guidance of the Diagnosis and Treatment Scheme of COVID-19 published by the National Health Commission.;Experimental group:conventional treatment combined with Chloroquine Phosphate.;</Intervention>
    <Primary_outcome>Length of hospital stay;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029907</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients</Public_title>
    <Scientific_title>Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49587</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-16</Date_enrollement>
    <Target_size>Case series:1000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yao, Rong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>1037070596@qq.com</Contact_Email>
    <Contact_Tel>+86 18980601415</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who meet the suspected or confirmed diagnostic criteria of COVID-19.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: N/A</Exclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>clinical features and risk factors;validity and reliability of the model;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029869</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy</Public_title>
    <Scientific_title>A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Huangshi Hospital of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49486</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>experimental group:150;control group:150;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Tingrong Huang, Bangjiang Fang, Jun Feng, Jianguo Zuo, Gang Wang </Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>6 Guangchang Road, Huangshi, Hubei, China</Contact_Address>
    <Contact_Email>fangbji@163.com</Contact_Email>
    <Contact_Tel>+86 0714-6224162</Contact_Tel>
    <Contact_Affiliation>Huangshi Hospital of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. patients with novel coronavirus pneumonia confirmed by pathogenic detection;&lt;br&gt;2. Fever, respiratory tract and other symptoms, the change of pneumonia can be seen in imaging;&lt;br&gt;3. Aged 18 to 80 years;&lt;br&gt;4. Signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregancy or lactating women;&lt;br&gt;2. People with allergies or allergies to traditional Chinese medicine  &lt;br&gt;3. Severe Primary disease such as uncontrolled and metastasis malignancy, hematopathy, HIV;&lt;br&gt;4. Obstructive pneumonia caused by lung tumors, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic reaction alveolitis;&lt;br&gt;5. Previous immunodepressant within 6 months before study entry or Receipt of a solid-organ or bone marrow transplant;&lt;br&gt;6. Severe mental illness or inability to cooperate with investigators.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Truncated Torsion' Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;</Intervention>
    <Primary_outcome>14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029867</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial</Public_title>
    <Scientific_title>The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Beijing You'an Hospital, Capital Medical University</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49514</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Experimental group:260;Control group:260;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ronghua Jin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>8 Xitoutou, You'anmen, Fengtai District, Beijing</Contact_Address>
    <Contact_Email>dinghuiguo@medmail.com.cn</Contact_Email>
    <Contact_Tel>+86 13811611118</Contact_Tel>
    <Contact_Affiliation>Beijing You'an Hospital, Capital Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Subjects have signed informed consent; agree not to participate in other clinical studies within 30 days from the first administration of the research drug to the last administration.&lt;br&gt;2. Aged &gt;= 18 and &lt;= 75 years.&lt;br&gt;3. Met the diagnostic criteria for COVID-19 (fifth edition, China).&lt;br&gt;4. SOFA score: 2 to 13 points.&lt;br&gt;COVID-19 clinical stratifications:&lt;br&gt;1. Mild (n = 200): The clinical symptoms are mild or asymptomatic, and no pneumonia is seen on imaging, but the throat swab or mouthwash 2019-nCOV is positive.&lt;br&gt;2. General type (n = 160): with fever, respiratory tract symptoms, etc. Imaging shows pneumonia.&lt;br&gt;3. Severe type (n = 80): Meet any of the following criteria.&lt;br&gt;(1) Respiratory distress, RR &gt;= 30 times / minute.&lt;br&gt;(2) In the resting state, the oxygen saturation is &lt;= 93%.&lt;br&gt;(3) Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) &lt;= 300mmHg (1mmHg = 0.133kPa).&lt;br&gt;4. Critical type (n = 80): One of the following criteria:&lt;br&gt;(1) Respiratory failure (ARDS) occurs and requires mechanical ventilation.&lt;br&gt;(2) Shock.&lt;br&gt;(3) Combined failure of other organs requires ICU monitoring and treatment.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who have received immunotherapy (such as PD-1 / L1, CTLA4, etc.) and inflammatory factor modulators (such as Ulinastatin) within one month.&lt;br&gt;2. Patients who have used antibacterial drugs such as macrolides within one week.&lt;br&gt;3. Patients who have received other anti-2019-nCOV potentially effective drugs such as Lopinavir and Ritonavir within one week.&lt;br&gt;4. Those who have undergone organ transplantation or surgery planning within 6 months.&lt;br&gt;5. Patients with coma or intestinal obstruction can not eat or take medicine.&lt;br&gt;6. With severe illness affected survival, including uncontrolled malignant tumors that have been metastatic and can not be removed, blood diseases, cachexia, active bleeding, severe malnutrition, HIV, etc..&lt;br&gt;7. Pregnant and lactating women, subjects (including male subjects) have a pregnancy plan (including sperm donation, egg donation plan) within the next 6 months or are unable to take effective contraceptive measures.&lt;br&gt;8. Patients with allergies or allergies to macrolide drugs, lopinavir / ritonavir tablets.&lt;br&gt;9. Patients with contraindications to using lopinavir / ritonavir tablets who plan or are using drugs that interact with the drug (including: highly dependent on CYP3A clearance and increased plasma concentrations can be severe and / or Life-threatening events [narrow therapeutic index] drugs, CYP3A inducers [see the instructions for details]), and can not be stopped or switched to other drugs.&lt;br&gt;10. Elevated alanine aminotransferase (ALT) / glutaminase (AST) is more than five times the upper limit of normal, total bilirubin is three times the upper limit of normal, or child-Pugh grade C cirrhosis.&lt;br&gt;11. Extracorporeal life support (ECMO, ECCO2R, RRT).&lt;br&gt;12. Critical patients with an estimated survival time of &lt; 48 h.&lt;br&gt;13. Participants in other clinical research in the past  month.&lt;br&gt;14. At the investigator's discretion, patients were deemed unsuitable for inclusion.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>Experimental group:Carrimycin;Control group:Lopinavir and Ritonavir Tablets;</Intervention>
    <Primary_outcome>Body temperature returns to normal time;Pulmonary inflammation resolution time (HRCT);Mouthwash (pharyngeal swab) at the end of treatment COVID-19 RNA negative rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029517</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Chinese medicine prevention and treatment program for suspected novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial</Public_title>
    <Scientific_title>Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Zhejiang Chinese Medical University</Primary_sponsor>
    <Date_registration>2020-02-03</Date_registration>
    <Date_registration3>20200203</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48861</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-04</Date_enrollement>
    <Target_size>treament group:50;placebo group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chengping Wen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>548 Binwen Road, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>wengcp@163.com</Contact_Email>
    <Contact_Tel>+86 13601331063</Contact_Tel>
    <Contact_Affiliation>Zhejiang Chinese Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Conforming to the diagnostic criteria of suspected cases (Chiese medicine observation period) in the fourth edition of pneumonia diagnosis and treatment program for new coronavirus infection issued by the national health and health commission;&lt;br&gt;(2) Age between 14 and 80 years old;&lt;br&gt;(3) Patients informed and agreed to participate in the study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Patients are not suitable to take Chinese medicine decoction.&lt;br&gt;(2) Patients have other serious organ disease or mental illness;&lt;br&gt;(3) Patients allergy or have contraindications to the drugs involved in the research program.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>treament group:Chinese medicine decoction;placebo group:placebo;</Intervention>
    <Primary_outcome>Relief of clinical symptoms and duration;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029495</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period</Public_title>
    <Scientific_title>Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>1. Xinhua Affiliated Hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine</Primary_sponsor>
    <Date_registration>2020-02-02</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48971</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>experimental group:30;	 Control group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Min Huang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>1025823309@qq.com</Contact_Email>
    <Contact_Tel>+86 13307161995</Contact_Tel>
    <Contact_Affiliation>1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV); &lt;br&gt;2. virus turned negative after treatment; &lt;br&gt;3. aged 18-70 years old; &lt;br&gt;4. patients with clear consciousness &lt;br&gt;5. Signing the informed consent form.  </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; &lt;br&gt;2. Pregnant or lactating women; &lt;br&gt;3. Patients who have mental confusion, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study. </Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Traditional Chinese Medicine+psychological intervention;	 Control group:Traditional Chinese Medicine;Control group:psychological intervention;</Intervention>
    <Primary_outcome>Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;ocial support rate scale, SSRS;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030016</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Basic and clinical study of inhalation of inactivated mycobacterium vaccine in the treatment of Novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Guangxi medical uniwresity</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49799</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-04</Date_enrollement>
    <Target_size>1:30;2:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chaoqian Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, China</Contact_Address>
    <Contact_Email>2534776680@qq.com</Contact_Email>
    <Contact_Tel>+86 13807887867</Contact_Tel>
    <Contact_Affiliation>Department of respiratory medicine, the First Affiliated Hospital of Guangxi Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients aged &gt;=18 years with novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnant women;&lt;br&gt;2. Patients with a history of angina pectoris, myocardial infarction and other serious cardiovascular diseases;&lt;br&gt;3. The researchers judged that this study was not in the interests of patients.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>1:inhalate the mycobacterium vaccae for injection;2:inhalate  Physiological saline;</Intervention>
    <Primary_outcome>viral negative-transforming time;30-day cause-specific mortality;30-day cause-adverse events;30-day all-cause mortality;co-infections;Time from severe and critical patients to clinical improvement;Others (liver function, kidney function, myocardial enzyme);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030007</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Guangzhou Medical University</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49619</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>15</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>Experimental group:100;Control group:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Nanshan Zhong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>151 Yanjiang Road, Yuexiu District, Guangzhou</Contact_Address>
    <Contact_Email>linling@gird.cn</Contact_Email>
    <Contact_Tel>+86 13902233092</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Guangzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients aged  15-80 years,diagnosed with mild, common, and severe novel coronavirus pneumonia in accordance with the diagnostic criteria for the diagnosis and treatment of novel coronavirus pneumonia issued by the National Health Commission (trial version 5);&lt;br&gt;2. White blood cell Count &lt; 15.0 x 10^9/L and Lymphocyte Count &lt; 0.8 x10^9/L.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Combining basic diseases such as hypertension, diabetes, and coronary heart disease;&lt;br&gt;2. Malignant tumor or with a history of malignant tumor;&lt;br&gt;3. pregnant or lactating women;&lt;br&gt;4. suffer from severe mental illness;&lt;br&gt;5. History of unstable angina pectoris or myocardial infarction within 6 months; coronary angiography suggested severe stenosis of the main branches of the coronary arteries;&lt;br&gt;6. History of cerebral infarction or cerebral hemorrhage within 6 months;&lt;br&gt;7. People who are intolerant or allergic to rhG-CSF;&lt;br&gt;8. Patients were judged unsuitable for inclusion in the trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:rhG-CSF, 5ug/kg, combinated with standard treatment;Control group:standard treatment;</Intervention>
    <Primary_outcome>Clinical symptoms;Blood routine;the viral load of 2019-nCOV of throat swab;TBNK cell subsets;TH1/TH2 Cytokine;Chest CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029905</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A medical records based study of novel coronavirus pneumonia (COVID-19) and influenza virus co-infection</Public_title>
    <Scientific_title>Co-infection of novel coronavirus pneumonia (COVID-19) and influenza virus: a single-center, two-phase, observational study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49595</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Case series:271;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhao Yan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>doctoryanzhao@whu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13995577963</Contact_Tel>
    <Contact_Affiliation>Zhongnan Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Influenza patients diagnosed in our center from December 1 to February 28 in the past 5 years (positive throat swab antigens of influenza A, B and H7 subtypes);&lt;br&gt;2. From December 1, 2019 to February 13, 2020, patients with positive detection of SARS-COV-2 (throat swab) in our center;&lt;br&gt;3. novel coronavirus (COVID-19) (throat swab) positive patients admitted to our hospital after February 13, 2020&lt;br&gt;4. Influenza virus antigen/nucleic acid positive patients admitted to our hospital after February 13, 2020</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who refuse to sign informed consent;&lt;br&gt;2. Clinical data is seriously missing or unable to ensure the authenticity of data.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Incidence of co-infection;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029870</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Jiangsu Institute of Parasitic Diseases</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49563</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Target condition:500;Difficult condition:100</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Cao Jun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>117 Meiyuan Yangxiang, Wuxi, Jiangsu, China</Contact_Address>
    <Contact_Email>caojuncn@hotmail.com</Contact_Email>
    <Contact_Tel>+86 0510-68781007</Contact_Tel>
    <Contact_Affiliation>Jiangsu Institute of Parasitic Diseases</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Confirmed and suspected cases of novel Coronavirus pneumonia </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: None</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Nucleic acid detection method of novel Coronavirus pneumonia ;Index test:IgM/IgG;</Intervention>
    <Primary_outcome>Positive/Negtive;SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029849</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Zhengzhou University</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49530</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Huaqi Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Jianshe Road East, Zhengzhou, He'nan, China</Contact_Address>
    <Contact_Email>wanghuaqi2004@126.com</Contact_Email>
    <Contact_Tel>+86 15890689220</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Zhengzhou University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Participants with 18 to 75 years of age who have been diagnosed with NCP by nucleic acid testing and meet the clinical classification of severe NCP referring to the clinical classification standard in the General Office of the National Health and Health Commission-Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 4).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Participants who have used fluoroquinolone antibiotics within 1 week</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Regulating intestinal flora + conventional treatment;Control group:conventional treatment;</Intervention>
    <Primary_outcome>Length of admission;mortality rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029822</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection</Public_title>
    <Scientific_title>A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Nanjing Second Hospital</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49502</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-07</Date_enrollement>
    <Target_size>Experimental group:70;Control group:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Yongxiang Yi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Kangfu Road, Tangshan Street, Jiangning District, Nanjing, China</Contact_Address>
    <Contact_Email>ian0126@126.com</Contact_Email>
    <Contact_Tel>+86 13338628626</Contact_Tel>
    <Contact_Affiliation>Nanjing Second Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Age is not limited;&lt;br&gt;2. Clinical diagnosis is in accordance with the "Notice on issuing a new type of coronavirus pneumonia diagnosis and treatment program (Fifth edition)" on the diagnosis of a new type of coronavirus infection;&lt;br&gt;3. potable decoction;&lt;br&gt;4. no honeysuckle allergy;&lt;br&gt;5. child-bearing age female subjects pregnancy test negative person;&lt;br&gt;6. child-bearing age female subjects pregnancy test positive person needs targeted communication, the patient's consent can be included;&lt;br&gt;7. pregnancy or breast-feeding subjects need targeted communication, the patient's consent can be included in the voluntary informed consent signed by the person under the age of 16.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Those who cannot take Chinese traditional medicine decoction;&lt;br&gt;(2) mentally ill subjects who are not easy to control;&lt;br&gt;(3) those who are pregnant or breast-feeding;&lt;br&gt;(4) those who use other Chinese medicines;&lt;br&gt;(5) those who are not considered suitable to participate in this trial by researchers.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:honeysuckle decoction;Control group:placebo;</Intervention>
    <Primary_outcome>rate of cure;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030000</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)</Public_title>
    <Scientific_title>An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Nanchang Ninth Hospital</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49748</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-16</Date_enrollement>
    <Target_size>Ganovo / ritonavir group:10;Pegasys group:10;Novaferon group:10;Coriolus group:10;Comparator:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hongyi Chen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>167 Hongdu Middle Avenue, Qingshanhu District, Nanchang, Jiangxi, China</Contact_Address>
    <Contact_Email>Chenhongyi8660@163.com</Contact_Email>
    <Contact_Tel>+86 13807088660</Contact_Tel>
    <Contact_Affiliation>Nanchang Ninth Hospital </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-75 years old;&lt;br&gt;2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 4);&lt;br&gt;3. patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days);&lt;br&gt;4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;&lt;br&gt;5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration.&lt;br&gt;6.Patients who voluntarily sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR 30 times / min; or SaO2 / SpO2 &lt;93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt;300MMHG (1mmhg = 0.133kpa);&lt;br&gt;2. Pneumonia patients with severe new coronavirus infection meet one of the following conditions: respiratory failure and need mechanical ventilation; or shock; or other organ failure combined with ICU monitoring treatment;&lt;br&gt;3. Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 times upper limit);&lt;br&gt;4. Patients with contraindications specified in the instructions of ritonavir tablets;&lt;br&gt;5. The pregnancy test of female subjects in the screening period was positive;&lt;br&gt;6. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).</Exclusion_Criteria>
    <Condition>Pneumonia caused by new coronavirus</Condition>
    <Intervention>Ganovo / ritonavir group:Ganovo/ ritonavir oral;Pegasys group:Pegasys injection;Novaferon group:Novaferon  intramuscular injection+Spray inhalation;Coriolus group:Coriolus  oral;Comparator:TCM+Spray inhalation;</Intervention>
    <Primary_outcome>Rate of composite advers outcomes:SpO2,PaO2/FiO2, respiratory rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029956</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)</Public_title>
    <Scientific_title>Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Hospital of Chengdu University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-17</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49618</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-18</Date_enrollement>
    <Target_size>Experimental group:60;Control group:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Tang Jianyuan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>tangjianyuan163@163.com</Contact_Email>
    <Contact_Tel>+86 13910768464</Contact_Tel>
    <Contact_Affiliation>Hospital of Chengdu University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: cured patients of 2019 novel coronavirus.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Health Guidance + Guixi Regulating Lung Gong Method + Shenling Baizhu Powder + Moxibustion Treatment;Control group:Health Guidance + Guixi Regulating Lung Gong Method ;</Intervention>
    <Primary_outcome>Quality of life;Anxiety assessment;Depression assessment;Major symptoms improved;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029855</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Medical College of Zhejiang University</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49543</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Chinese traditional medicine group 1:60;Chinese traditional medicine group 2:60;Control group:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wu Guolin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>wuguolin28@163.com</Contact_Email>
    <Contact_Tel>+86 13136150848</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Medical College of Zhejiang University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) common type pneumonia patients with confirmed new coronavirus infection;&lt;br&gt;2) aged 18 to 75 years old;&lt;br&gt;3) voluntary signing of written informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) pneumonia patients with severe or critical new coronavirus infection;&lt;br&gt;2) daily treatment of asthma, any other chronic respiratory disease;&lt;br&gt;3) patients with confirmed history of diabetes and HbA1C &gt;=8.0%;&lt;br&gt;4) those allergic to the known ingredients of the drug;&lt;br&gt;5) pregnant or nursing women;&lt;br&gt;6) patients with severe mental illness;&lt;br&gt;7) patients who have participated in other clinical trials within the past 1 month.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Chinese traditional medicine group 1:Traditional Chinese medicine qingfei prescription treatment;Chinese traditional medicine group 2:Traditional Chinese medicine clear lung prescription and compound houttuynia mixture treatment;Control group:Conventional treatment;</Intervention>
    <Primary_outcome>TCM symptom score;Antifebrile time;The time and rate of transition of new coronavirus to Yin;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029853</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>People's Hospital of Guangshan County</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49532</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-16</Date_enrollement>
    <Target_size>Experimental group:10;Control group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Pei Guangzhong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>222 Zhengda Street, Guangshan County, He'nan, China</Contact_Address>
    <Contact_Email>503818505@qq.com</Contact_Email>
    <Contact_Tel>+86 13839708181</Contact_Tel>
    <Contact_Affiliation>People's Hospital of Guangshan County</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) aged &gt;=18 years old;&lt;br&gt;(2) real-time fluorescence rt-pcr of respiratory or blood samples presents the positive nucleic acid of COVID-19, or the viral gene sequencing of respiratory or blood samples was highly homologous with the known COVID-19.&lt;br&gt;(3) patients diagnosed with novel coronavirus meet the diagnostic criteria of the latest clinical guidelines for novel coronavirus issued by the world health organization (WHO) on January 28, 2020 and the diagnostic criteria of the pneumonia diagnosis and treatment program for novel coronavirus infection (trial version 5) issued by National Health commission of the People's Republic of China.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) known or suspected allergy to the components of Azivudine tablets;&lt;br&gt;(2) patients with malabsorption syndrome or any other condition that affects gastrointestinal absorption and requires intravenous nutrition or unable to take oral medication;&lt;br&gt;(3) patients who is currently receiving anti-hiv treatment;&lt;br&gt;(4) patients with one of the following conditions: respiratory failure and mechanical ventilation;Shock;Combined with other organ failure, intensive care unit(ICU) was needed.&lt;br&gt;(5) women who are pregnant or breast-feeding or have a family planning plan during the trial period and within 6 months after the end of the trial;&lt;br&gt;(6) participating in another clinical trials or using experimental drugs within 12 weeks prior to administration;&lt;br&gt;(7)  there are other conditions that are not suitable for participating in this experiment evaluated by the investigator.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Oral administration of 5 tablets of 1mg Azvudine tablets daily;Control group:According to the "Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Version 5)" issued by National Health Commission of People's Republic of China, the subjects were given corresponding treatment.;</Intervention>
    <Primary_outcome>time and rate of temperature return to normal;;time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.);time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms;time and rate of pulmonary imaging improvement;time and rate of change to negative COVID-19 nucleic acid test;time and rate of improvement of oxygenation measurement;improvement time and rate of CD4 count;rate of mild/modorate type to severe type, rate of severe type to critical type;length of hospitalization;mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029493</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial</Public_title>
    <Scientific_title>Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine</Primary_sponsor>
    <Date_registration>2020-02-02</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48931</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>experimental group 	:50;control group :50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jixian Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>jxzhang1607@163.com</Contact_Email>
    <Contact_Tel>+86 13377897297</Contact_Tel>
    <Contact_Affiliation>1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);&lt;br&gt;2. virus turned negative after treatment;&lt;br&gt;3. Patients diagnosed with pulmonary fibrosis; &lt;br&gt;4. aged 18-70 years old;&lt;br&gt;5. patients with clear consciousness;&lt;br&gt;6. Signing the informed consent form.  </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; &lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. Patients who have mental confusion, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months, or who have other conditions not suitable for clinical study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group 	:TCM decoctions+basic western medical therapies ;control group :basic western medical therapies ;</Intervention>
    <Primary_outcome>pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029432</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A Real World Study For the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>The First Afflicated Hospital of Guangzhou University of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-01</Date_registration>
    <Date_registration3>20200201</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48881</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:72;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhongqi Yang, Minyong Wen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>yang_zhongqi@163.com</Contact_Email>
    <Contact_Tel>+86 13688867618</Contact_Tel>
    <Contact_Affiliation>The First Afflicated Hospital of Guangzhou University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Confirmed or suspected cases who are comply with the diagnostic criteria for pneumonia caused by novel coronavirus infection in the "Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 4)";&lt;br&gt;2. Inpatients aged 18-75 years;&lt;br&gt;3. Obtain the informed consent form. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with severe novel coronavirus pneumonia;&lt;br&gt;2. Patients with severe basic diseases;&lt;br&gt;3. Patients who have mental confusion, pregnant or lactating women, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Add 500ml of 5% glucose injection or 0.9% sodium chloride injection into Tanreqing injection, intravenous drip, control the number of drops no more than 60 drops per minute, 1-2 times a day; the dosage is determined by the doctor,but no more than 80ml / day, 40ml / day is recommended.;</Intervention>
    <Primary_outcome>Time for body temperature recovery;Chest X-ray absorption;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029815</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Psychological survey of frontline medical staff in various regions of China during the epidemic of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Psychological survey of frontline medical staff in various regions of China during the epidemic of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Guangdong Provincial Hospital of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49346</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:800;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhan Jie</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>zhanjie34@126.com</Contact_Email>
    <Contact_Tel>+86 15818136908</Contact_Tel>
    <Contact_Affiliation>Guangdong Provincial Hospital of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged&gt; 18 years old;&lt;br&gt;2. Working time in the front line of novel coronavirus pneumonia prevention and control =1 week;&lt;br&gt;3. The working department is the hot spot for the sample hospital, the ward for the suspected cases, and the ward for the confirmed cases;&lt;br&gt;4. No previous history of mental illness or mental illness;&lt;br&gt;5. Voluntarily participate in this research.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Staff and pharmacists in the administrative, logistics and medical technology departments;&lt;br&gt;2. Regulatory students, interns, re-employment, external employment and labor dispatch personnel;&lt;br&gt;3. Those who refused to participate in this survey.</Exclusion_Criteria>
    <Condition>Emotional  disorder</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029813</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Shanghai Public Health Clinical Center</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49425</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>Experimental group:36;Control Group:36;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hongzhou Lu, Xiaorong Chen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>2901 Caolang Road, Jinshan District, Shanghai</Contact_Address>
    <Contact_Email>luhongzhou@fudan.edu.cn</Contact_Email>
    <Contact_Tel>+86 18930810088</Contact_Tel>
    <Contact_Affiliation>Shanghai Public Health Clinical Center</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Those who meet the diagnosis of new coronavirus pneumonia and have clinical classification of low and medium;&lt;br&gt;(2) Those who have been diagnosed with TCM as epidemic-closed lungs;&lt;br&gt;(3) Inpatients aged 18 to 75 years, regardless of gender;&lt;br&gt;(4) Voluntarily receive treatment with the drug and sign informed consent. The informed consent process complies with relevant GCP regulations.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Immunodeficiency disease, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months;&lt;br&gt;(2) Preparing pregnant, pregnant and lactating women;&lt;br&gt;(3) Patients with allergies (referring to allergies to two or more medicines, foods or known ingredients in this study);&lt;br&gt;(4) Patients with mental illness, or have no cognitive ability;&lt;br&gt;(5) Patients with an estimated survival time of less than 48 hours from the start of screening;&lt;br&gt;(6) Those who have been intubated or mechanically ventilated at the time of screening;&lt;br&gt;(7) Obvious symptoms of heart, liver, kidney or various other systems, ALT, AST exceed 1.5 times the upper limit of normal value;&lt;br&gt;(8) Believed to be not suitable to participate in clinical trials by investigator.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional Treatment &amp; Tanreqing Capsules (oral, 3 capsules at a time, 3 times a day);Control Group:Conventional Treatment;</Intervention>
    <Primary_outcome>Time of viral nucleic acid turns negative;Antipyretic time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029839</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>An observational study on the clinical characteristics, treatment and outcome of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>An observational study on the clinical characteristics, treatment and outcome of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Ningbo First Hospital</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49439</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chao Cao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>59 Liuting Road, Ningbo, Zhejiang, China</Contact_Address>
    <Contact_Email>caocdoctor@163.com</Contact_Email>
    <Contact_Tel>+86 574-87089878</Contact_Tel>
    <Contact_Affiliation>Ningbo First Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;= 18 years; &lt;br&gt;2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV;&lt;br&gt;3. Pneumonia confirmed with chest CT;&lt;br&gt;4. &lt;= 8 days since illness onset and hospitalization with feverat, cough, or dyspnea; &lt;br&gt;5. Willing to participant in this study and sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnant and nursing women;&lt;br&gt;2. Patients with severe liver disease and severe renal dysfunction.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:variety treatments;</Intervention>
    <Primary_outcome>Time to clinical recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029821</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation</Public_title>
    <Scientific_title>Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Deyang Integrated Traditional Chinese and Western Medicine Hospital</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49306</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>3</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>Observation  group:300;Health  education unit:100;</Target_size>
    <Study_type>Prevention</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qiu Jun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>159 Tianshan Road South, Jingyang District, Deyang, Sichuan, China</Contact_Address>
    <Contact_Email>973007530@qq.com</Contact_Email>
    <Contact_Tel>+86 13881070630</Contact_Tel>
    <Contact_Affiliation>Deyang integrative medicine hospital </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Non suspected cases and non confirmed cases;&lt;br&gt;2. Participate in novel coronavirus front-line prevention and control of medical staff, street community office staff;&lt;br&gt;3. Novel coronavirus pneumonia is recommended by people who voluntarily accept TCM technology.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Suspected cases and confirmed cases;&lt;br&gt;2. Patients with severe heart, brain, liver, kidney and other visceral diseases or other serious metabolic disorders and tumors;&lt;br&gt;3. People who could not complete the study for other reasons;&lt;br&gt;4. Pregnant or lactating women.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Observation  group:TCM prevention;Health  education unit:Health  education;</Intervention>
    <Primary_outcome>CD4+;CD3+;HAMA;HAMD;STAI;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029781</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49138</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>experimental group:80;control group:80;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xin Zheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Wuhan, Hubei</Contact_Address>
    <Contact_Email>Xin11@hotmail.com</Contact_Email>
    <Contact_Tel>+86 18602724981</Contact_Tel>
    <Contact_Affiliation>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Aged &gt;= 18 years;            &lt;br&gt;2) In line with the diagnostic criteria of "new coronavirus pneumonia diagnosis program", the patient was diagnosed as pneumonia infected by the new coronavirus;&lt;br&gt;3) Severe pneumonia index (PSI) class for I ~ II;            &lt;br&gt;4) Hospitalized for:            &lt;br&gt;Fever: axillary temperature &gt;= 36.7 degree C, oral temperature &gt;= 38.0 degree C, Anal temperature &gt;= 38.6 degree C;            &lt;br&gt;respiratory rate &gt; 24 times / min or cough (at least one of them);            &lt;br&gt;5) The course of symptoms should be less than or equal to 8 days;            &lt;br&gt;6) Volunteers and comply with the hospital regulations, can cooperate with the completion of the prescribed inspection;           &lt;br&gt;7) Voluntary informed consent was signed prior to the trial.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1)One of the following conditions:&lt;br&gt;Respiratory distress, RR &gt;= 30 times/min;&lt;br&gt;At rest, oxygen saturation is less than 93%;&lt;br&gt;Atrial  arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) &lt;= 300mmHg (1mmHg=0.133kPa);&lt;br&gt;Respiratory failure is present and mechanical ventilation is required;&lt;br&gt;Shock;&lt;br&gt;Combined with other organ failure requires intensive care unit.&lt;br&gt;2)Severe influenza and influenza patients with complications (such as secondary bacterial pneumonia, pneumonia caused by other pathogens and other viral pneumonia);Or the patient is hospitalized with severe influenza;&lt;br&gt;3)Patients with other upper respiratory tract infections: asthma requiring daily treatment, any other chronic respiratory diseases, respiratory bacterial infections such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media and other respiratory diseases affecting clinical trial evaluation. Imaging  confirmed the existence of severe pulmonary interstitial lesions, bronchiectasis and other basic pulmonary diseases;&lt;br&gt;4)It is expected to be transferred to a non-study hospital within 72 hours;&lt;br&gt;5)Past or present diseases may affect the outcome of the study, such as unresectable malignant tumors, hematological diseases, active bleeding, malignant fluid, liver and kidney diseases, nervous system diseases, endocrine system diseases, etc Suffering from diseases that seriously affect the immune system, such as HIV infection, splenectomy, organ transplantation, etc.;&lt;br&gt;6)A woman who is pregnant or breastfeeding;&lt;br&gt;7)Test drug components allergy, or allergic constitution;&lt;br&gt;8)Patients with a history of substance abuse;&lt;br&gt;9)Participants in other clinical trials in the last 3 months;&lt;br&gt;10)The investigator considers it inappropriate to participate in this clinical trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>experimental group:routine treatment and Kangbingdu granules;control group:routine treatment ;</Intervention>
    <Primary_outcome>Disappearance rate of fever symptoms;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029740</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)</Public_title>
    <Scientific_title>Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>The First Hospital of Peking University</Primary_sponsor>
    <Date_registration>2020-02-11</Date_registration>
    <Date_registration3>20200211</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49317</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax>99</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-11</Date_enrollement>
    <Target_size>hydroxychloroquine group:54;control group:24;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhuoli Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>8 Xishiku Street, Beijing, China</Contact_Address>
    <Contact_Email>zhuoli.zhang@126.com</Contact_Email>
    <Contact_Tel>+86 13901094780</Contact_Tel>
    <Contact_Affiliation>The First hospital of Peking University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with novel coronavirus infection who agreed to participate in this trial and signed the informed consent form. The diagnose criteria was according to Diagnostic and treatment protocol of COVID-19 pneumonia published by Chinese General Office of National Health Committee(6th and further edition).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients who is enrolled in other clinical trial&lt;br&gt;who had diagnosed as macular degeneration of retinawere or defects of visual field;&lt;br&gt;who was allergic to 4-aminoquinoline compounds or is prescribed any drug had interactions with hydrocholoroquine&lt;br&gt;emergency or critically ill patients who can not received oral drugs&lt;br&gt;pregnancy or lactation&lt;br&gt;severe heart disease, digestive disease,neurological or ocular disease,or porphyrin;&lt;br&gt;WBC less than 2.0*10^9/L,hemoglobin 60g/L,liver enzyme or creatine higher than 3 times of ULT,or heart marker elevated,&lt;br&gt;unsuitable to participate this trial by investigator or in other special circumstances. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>hydroxychloroquine group:oral intake hydroxycholoroquine 0.2 twice a day;control group:conventional therapy;</Intervention>
    <Primary_outcome>oxygen index;max respiratory rate;lung radiography;count of lymphocyte;temperature;other infection;time when the nuleic acid of the novel coronavirus turns negative;prognosis;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029806</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Optimization of treatment and diagnosis plan for critically ill patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49161</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>Thymosin treatment group:40;PD-1 treatment group:40;Conventional treatment group:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xia Jiaan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Yintan Road, Dongxihu District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>3131862959@qq.com</Contact_Email>
    <Contact_Tel>+86 13871120171</Contact_Tel>
    <Contact_Affiliation>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. 2019 adult patients with new-type coronavirus pneumonia diagnosed with 2019-nCoV infection by PCR according to the "Pneumonitis Diagnosis and Treatment Protocol for New-type Coronavirus Infection (Trial Version 5)"&lt;br&gt;2. The absolute value of lymphocytes &lt;0.6x10^9/L;&lt;br&gt;3. Severe respiratory failure does not exceed 48 hours and requires ICU treatment. Among them, severe respiratory failure is defined as PaO2 / FiO2 &lt;200 mmHg and requires positive pressure mechanical ventilation (including non-invasive and invasive mechanical ventilation, PEEP &gt;=5 cmH2O);&lt;br&gt;4. Sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Aged &lt;18 years;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. Allergic to the test drug;&lt;br&gt;4. The underlying disease is very serious, and the expected survival time is less than 6 months (such as advanced malignant tumors);&lt;br&gt;5. COPD or end-stage lung disease requires home oxygen therapy;&lt;br&gt;6. Expected survival time does not exceed 48 hours;&lt;br&gt;7. Participated in other clinical intervention trials in the past 3 months;&lt;br&gt;8. Suffering from autoimmune diseases;&lt;br&gt;9. History of organ, bone marrow or hematopoietic stem cell transplant Received radiotherapy and chemotherapy for malignant tumors within 10.6 months;&lt;br&gt;11. HIV-infected patients or acquired immune deficiency diagnosed within the past year (CD4 T cells &lt;= 200 / mm3);&lt;br&gt;12. Patients receiving anti-HCV treatment;&lt;br&gt;13. 90 days with retinal detachment or eye surgery;&lt;br&gt;14. Permanent blindness in one eye;&lt;br&gt;15. History of iritis, endophthalmitis, scleritis, or retinitis;&lt;br&gt;16. The doctor in charge considers it inappropriate to participate in this study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Thymosin treatment group:Thymosin for injection 1.6 mg sc qd for 5 days;PD-1 treatment group:Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion;Conventional treatment group:Conventional treatment;</Intervention>
    <Primary_outcome>Proportion of patients with a lung injury score reduction of 1-point or more 7 days after randomization;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029790</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Shanghai Pulmonary Hospital</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49453</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Control group:60;Experimental group:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lixin Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>507 Zhengmin Road, Yangpu District, Shanghai, China </Contact_Address>
    <Contact_Email>wlx1126@hotmail.com</Contact_Email>
    <Contact_Tel>+86 18917962300</Contact_Tel>
    <Contact_Affiliation>Shanghai Pulmonary Hospital </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Comply with the standards of diagnosis and classification of western medicine, and the standards of syndromes of traditional Chinese medicine.&lt;br&gt;(2) Aged 18-80 years.&lt;br&gt;(3) Those who voluntarily participated in this research and signed written informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Impaired consciousness or mental illness cannot cooperate with treating the observer.&lt;br&gt;(2) Those with severe organ dysfunction.&lt;br&gt;(3) Pregnant women.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Western medicine basic treatment;Experimental group:Western medicine basic treatment combined with traditional Chinese medicine;</Intervention>
    <Primary_outcome>TCM symptoms efficacy;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029819</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Ba-Bao-Dan in the adjuvant therapy of novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>Study for the pharmacodynamics and mechanism of traditional Chinese medicine in the treatment of novel coronavirus infection (COVID-19) based on inflammatory factor network                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49490</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-11</Date_enrollement>
    <Target_size>Experimental group:40;Control group:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ying Kejing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>3 Qingchun Road East, Jianggan District, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>yingsrrsh@163.com</Contact_Email>
    <Contact_Tel>+86 13588706900</Contact_Tel>
    <Contact_Affiliation>Sir Run Run Show Hospital, School of Medicine, Zhejiang University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 years, unlimited for men and women;&lt;br&gt;2. A novel coronavirus infection confirmed by pathogenic detection;&lt;br&gt;3. According to novel coronavirus infection pneumonia treatment plan (trial version fifth), severe patients should comply with any of the following: respiratory distress (RR&gt;30 times / points); resting state, refers to oxygen saturation less than 93%; arterial oxygen partial pressure (PaO2) / oxygen inhalation concentration (FiO2) is less than 300 mmHg;&lt;br&gt;4. Sign the informed consent voluntarily.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnant or lactating women;&lt;br&gt;2. The patients had mental disorder, drug abuse or dependence history, allergy to research drugs, and participated in other clinical studies within 3 months;&lt;br&gt;3. Potential violation of test compliance or any other situation affecting safety and effectiveness evaluation.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional treatment + take Ba-Bao-Dan;Control group:Conventional treatment;</Intervention>
    <Primary_outcome>Clinical and laboratory indicators;Viral load;chest CT;serum cell factor;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029804</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Application of ECMO in the Treatment of Patients with Very Serious Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Optimization of treatment and diagnosis plan for critically ill patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49178</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Prognosis study</Study_type>
    <Study_design>Cohort study</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wu Wenjuan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Yintan Road, Dongxihu District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>1346801465@qq.com</Contact_Email>
    <Contact_Tel>+86 13397192695</Contact_Tel>
    <Contact_Affiliation>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who meet the requirements of the "New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (Trial Version 4)" which issued by the General Office of the National Health Commission.&lt;br&gt;2. ECMO-treated patients with severe hypoxic respiratory failure.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Age&gt; 75 years.&lt;br&gt;2. After CPR.&lt;br&gt;3. Accompanied by other serious organ dysfunction (including severe liver and kidney dysfunction, upper gastrointestinal bleeding, DIC, etc.).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:NA;</Intervention>
    <Primary_outcome>Inpatient mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029431</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study of type I macrophages therapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Affiliated Zhongshan Hospital of Dalian University</Primary_sponsor>
    <Date_registration>2020-02-01</Date_registration>
    <Date_registration3>20200201</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48907</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-29</Date_enrollement>
    <Target_size>A:15;B:15;C:15;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Dewei Zhao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>6 Jiefang Street, Dalian, Liaoning, China </Contact_Address>
    <Contact_Email>zhaodewei2016@163.com</Contact_Email>
    <Contact_Tel>+86 0411-62893509</Contact_Tel>
    <Contact_Affiliation>Affiliated Zhongshan Hospital of Dalian University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. 2019-nCoV infected patients treated at Affiliated Zhongshan Hospital of Dalian University and Zhongnan Hospital of Wuhan University from January 2020 to December 2020&lt;br&gt;2. nCoV nucleic acid positive;&lt;br&gt;3. Aged &gt;=18 years;&lt;br&gt;4. Patients understand the purpose of the trial, voluntarily sign informed consent, and agree to complete the rectification research process.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Those with allergies;&lt;br&gt;2. Patients with a history of severe cardio-cerebral vascular disease, diabetes, mental and neurological diseases, severe liver and renal insufficiency;&lt;br&gt;3. History of hip or knee trauma or surgery;&lt;br&gt;4. Patients who abuse drugs;&lt;br&gt;5. Those who are in the acute phase of chronic diseases;&lt;br&gt;6. Patients with other malignant diseases and a survival time of less than 12 months;&lt;br&gt;7. pregnancy,lactating women;&lt;br&gt;8. Poor compliance and unable to follow up on time;&lt;br&gt;9. Participants in clinical trials of other drugs or devices within the past 3 months.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>A:Critical Treatment in Critical Period + Ankylosaurus;B:Critical Treatment in Critical Period + Ankylosaurus+M1 suppression therapy;C:Critical Treatment in Critical Period;</Intervention>
    <Primary_outcome>CT of lung;CT and MRI of hip;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04251767</TrialID>
    <Last_Refreshed_on>24 February 2020</Last_Refreshed_on>
    <Public_title>Washed Microbiota Transplantation for Patients With 2019-nCoV Infection</Public_title>
    <Scientific_title>Washed Microbiota Transplantation in Patients With 2019-novel Coronavirus Infection</Scientific_title>
    <Acronym />
    <Primary_sponsor>The Second Hospital of Nanjing Medical University</Primary_sponsor>
    <Date_registration>30/01/2020</Date_registration>
    <Date_registration3>20200130</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04251767</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 2, 2020</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). </Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Faming Zhang, MD; PHD</Contact_Lastname>
    <Contact_Email />
    <Contact_Tel />
    <Contact_Affiliation>The Second Hospital of Nanjing Medical University</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. 14-70 years old&lt;br&gt;&lt;br&gt;          2. 2019 novel coronavirus pneumonia (severe type)&lt;br&gt;&lt;br&gt;          3. Subjects voluntarily participate in the clinical trial and sign the informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Disturbance of consciousness&lt;br&gt;&lt;br&gt;          2. Difficulty swallowing and frequent vomiting&lt;br&gt;&lt;br&gt;          3. Patients requiring blood transfusion&lt;br&gt;&lt;br&gt;          4. Pulmonary abscess, hepatitis, cirrhosis, tuberculosis, emphysema and pulmonary&lt;br&gt;             infarction&lt;br&gt;&lt;br&gt;          5. Fungal and other identified pathogens infection&lt;br&gt;&lt;br&gt;          6. Heart failure existed before diagnosis of novel coronavirus infection&lt;br&gt;&lt;br&gt;          7. Liver function: alanine aminotransferase &gt; 500 U/L&lt;br&gt;&lt;br&gt;          8. Patients requiring hemodialysis&lt;br&gt;&lt;br&gt;          9. Taking anticoagulant drugs due to cardiovascular and cerebrovascular diseases&lt;br&gt;&lt;br&gt;         10. Other conditions that the investigator considers ineligible for clinical trial&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV</Condition>
    <Intervention>Other: washed microbiota transplantation;Other: placebo</Intervention>
    <Primary_outcome>Number of participants with improvement from severe type to common type</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029769</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Enze Hospital of Taizhou Enze Medical Center (Group)</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49415</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Experimental group:20;Control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lv Dongqing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Tongyang Road East, Luqiao District, Taizhou, Zhejiang, China</Contact_Address>
    <Contact_Email>lvdq@enzemed.com</Contact_Email>
    <Contact_Tel>+86 13867622009</Contact_Tel>
    <Contact_Affiliation>Enze Hospital of Taizhou Enze Medical Center (Group)</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Severe patients (according to any of the following): respiratory distress (RR&gt; 30 beats / min); at rest, means oxygen saturation &lt;= 93%; arterial oxygen pressure (PaO2) / oxygen concentration (FiO2) &lt; = 300 mmHg</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Children, pregnant women</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Routine treatment + Babaodan 6 capsules, bid orally;Control group:Conventional treatment;</Intervention>
    <Primary_outcome>28-day survival;Inflammatory factor levels;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029768</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency</Public_title>
    <Scientific_title>A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49131</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>experimental group:30;control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jun Lin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuchang District, Wuhan, Hubei </Contact_Address>
    <Contact_Email>wdznyy@126.com</Contact_Email>
    <Contact_Tel>+86 13971156723</Contact_Tel>
    <Contact_Affiliation>Zhongnan Hospital of Wuhan University </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-75 years male or female;&lt;br&gt;2. Body weight 40-100 kg and BMI &gt;= 18kg/m2;&lt;br&gt;3. Been Confirmed with commom 2019-nCoV pneumonia inpatient;&lt;br&gt;4. With fever, respiratory tract and other symptoms, imaging shows pneumonia;&lt;br&gt;5. 2019-nCoV nucleic acid test was positive by pathogenic detection within 72 hours;&lt;br&gt;6. Have undergone surgical sterilization or take effective contraception during the trial;&lt;br&gt;7. Written the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Infected with other viruses such as HCV, HIV, and syphilis;&lt;br&gt;2. Used non-steroidal anti-inflammatory drugs within 3 days before enrollment;&lt;br&gt;3. Have severe liver disease;&lt;br&gt;4. Those who are known to be allergic to the test drug and its ingredients;&lt;br&gt;5. Any of the following risk factors: &lt;br&gt;1) Chronic respiratory diseases such as chronic dual lung disease, acute bronchial respiratory disease; &lt;br&gt;2) Severe cardiovascular diseases such as congenital hypertension, congestive heart failure, coronary artery disease, except hypertension; &lt;br&gt;3) Nervous system and neuromuscular diseases, such as cerebral palsy, epilepsy, stroke,Intellectual Disability, muscular dystrophy or spinal cord injury, etc .; &lt;br&gt;4) Severe blood system diseases such as sickle cell disease; &lt;br&gt;5) Malignant tumor.&lt;br&gt;6. Pregnancy or breastfeeding,or positive pregnancy test in a predose examination;&lt;br&gt;7. Patients who participated in other clinical trials within the last 3 months;&lt;br&gt;8. Patients who are pregnant or in lactation period.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150mg, Tid), Vitamin C tablets (oral, 0.5g, QD) and clinical standard antiviral treatment;control group:clinical standard antiviral treatment;</Intervention>
    <Primary_outcome>Time to Clinical recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029788</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial</Public_title>
    <Scientific_title>Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49452</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Control group :30;Intervention group :30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> Yaosheng Zhang, Jianwei Shang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>5 Hai-Yun-Cang Lane, Dongcheng District, Beijing, China</Contact_Address>
    <Contact_Email>zysjsgzs@163.com</Contact_Email>
    <Contact_Tel>+86 18134048843</Contact_Tel>
    <Contact_Affiliation>Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Meet the diagnostic criteria of the "New Coronavirus Pneumonia Diagnosis and Treatment Scheme", patients with pneumonia confirmed by new coronavirus infection; &lt;br&gt;2. Pneumonia Severity Index (PSI) grade is I ~ II; &lt;br&gt;3. Aged 18-80 years; &lt;br&gt;4. Those who have signed the informed consent voluntarily.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. People with allergies and allergies to experimental drugs; &lt;br&gt;2. Combined with other malignant tumors; &lt;br&gt;3. Patients with hematological diseases, coagulopathy and autoimmune diseases; &lt;br&gt;4. Combined with severe cardiovascular diseases, Patients with vascular disease, hematopoietic system disease, and neuropathy; &lt;br&gt;5. Participated in other clinical researchers 3 months before the trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group :Western medicine routine treatment plan;Intervention group :Western medicine routine treatment plan plus TCM syndrome differentiation treatment;</Intervention>
    <Primary_outcome>Antipyretic time;Pharyngeal swab nucleic acid negative time;Blood gas analysis;Traditional Chinese medicine syndrome score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029765</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49409</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>control group:94;Experience group:94;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiaoling Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>17 Lujiang Road, Luyang District, Hefei, Anhui, China</Contact_Address>
    <Contact_Email>xxlahh08@163.com</Contact_Email>
    <Contact_Tel>+86 18963789002</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. The patients who were diagnosed with the common type of NCP (including   severe risk factors) and severe cases of new coronavirus pneumonia;&lt;br&gt;2. Aged 18 to 85 years;&lt;br&gt;3. IL-6 elevated (using Elisa method, using the same company kit);&lt;br&gt;4. Patients or authorized family members volunteered to participate in this study and signed informed consent.&lt;br&gt;Definition of Novel Coronavirus Pneumonia (NCP) clinical cases:&lt;br&gt;1. Regular patients with NCP (including severe risk factors): patients with dual pulmonary lesions based on common NCP clinical symptoms accompanied by fever or no fever;&lt;br&gt;2. Critical NCP patient: Refer to the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Fifth Edition)" formulated by the National Health Commission.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who are participating in other drug clinical trials;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. ALT / AST&gt; 5 ULN, neutrophils &lt;0.5, platelets less than 50;&lt;br&gt;4. Definite diagnosis of rheumatic immune-related diseases;&lt;br&gt;5. Long-term oral anti-rejection or immunomodulatory drugs;&lt;br&gt;6. Hypersensitivity to tocilizumab or any excipients;&lt;br&gt;7. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.</Exclusion_Criteria>
    <Condition>new coronavirus pneumonia</Condition>
    <Intervention>control group:conventional therapy;Experience group:conventional  therapy+tocilizumab;</Intervention>
    <Primary_outcome>cure rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029754</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Study for the Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People</Public_title>
    <Scientific_title>Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-12</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49370</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Epilepsy group:500;Health Control group:1000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chen Lei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxuexiang, Wuhou District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>leilei_25@126.com</Contact_Email>
    <Contact_Tel>+86 18980605819</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Long-term follow-up of patients with epilepsy and healthy subjects in the natural population cohort study of west China hospital, sichuan university.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who are unable to complete the questionnaire;&lt;br&gt;2. Patients and healthy people who are not willing to participate in the survey.</Exclusion_Criteria>
    <Condition>Epilepsy, Chronic diseases, Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Epilepsy group:N/A;Health Control group:N/A;</Intervention>
    <Primary_outcome>Physical and mental health;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029751</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-12</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49354</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Suspected patient control group:100;Suspected patient Treatment group:100;Common NCP patient control group:50;Common NCP patient Treatment group:50;Severe NCP patient:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Mao Wei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>54 Youdian Road, Shangcheng District, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>maoweilw@163.com</Contact_Email>
    <Contact_Tel>+86 0571-87068001</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients diagnosed with suspected or confirmed NCP (divided into ordinary type and severe type according to their clinical classification);&lt;br&gt;2. Be between 18-85 years of age;&lt;br&gt;3. Informed consent and signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with severe primary diseases such as heart, lung, liver, kidney, brain, and hematopoietic system;&lt;br&gt;2. pregnant or lactating women;&lt;br&gt;3. Patients with mental illness;&lt;br&gt;4. Those who are participating in other clinical trials or taking other Chinese herbal medicines.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Suspected patient control group:Routine respiratory disease treatment;Suspected patient Treatment group:Oral Chinese medicine treatment based on control group;Common NCP patient control group:treatment according to the guideline;Common NCP patient Treatment group:Oral Chinese medicine treatment based on control group;Severe NCP patient:Oral Chinese medicine treatment and treatment according to the guideline;</Intervention>
    <Primary_outcome>blood routine examination;CRP;PCT;Chest CT;Liver and kidney function;Etiology test;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029763</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trial</Public_title>
    <Scientific_title>Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>China Academy of Chinese Medical Sciences; Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-12</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49408</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-13</Date_enrollement>
    <Target_size>experimental group:204;control group:204;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Huang Luqi; Li Zhiqiang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China</Contact_Address>
    <Contact_Email>huangluqi01@126.com</Contact_Email>
    <Contact_Tel>+86 010-64089801</Contact_Tel>
    <Contact_Affiliation>China Academy of Chinese Medical Sciences</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Comply with the diagnostic criteria for general type COVID-19 in the "Diagnosis and Treatment Program for COVID-19"(trial version 5th).&lt;br&gt;(2) Agree to participate in the study and the patient or legal guardian signs the informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Patients who can not guarantee compliance of using TCM during the treatment period, or patients who are difficult to take medicine by oral or nasal route.&lt;br&gt;(2) Patients who have been more than 7 days since definite diagnosis.&lt;br&gt;(3) Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID-19.&lt;br&gt;(4) Maternal, or patients with a positive urine pregnancy test.&lt;br&gt;(5) Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, etc., which the researchers consider unsuitable for participation in the study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:TCM and general treatment;control group:general treatment;</Intervention>
    <Primary_outcome>Rate of conversion to severe or critical illness;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029758</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients</Public_title>
    <Scientific_title>Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Department of Critical Care Medicine, West China Hospital of Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-12</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49295</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Kang Yan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>Kangyan@scu.edu.cn</Contact_Email>
    <Contact_Tel>+86 18980601566</Contact_Tel>
    <Contact_Affiliation>Department of Critical Care Medicine, West China Hospital of Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who meet the diagnostic criteria of pneumonia caused by novel coronavirus.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: N/A</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia  (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>length of stay;length of stay in ICU;Antibiotic use;Hospital costs;Organ function support measures;Organ function;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04270383</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children</Public_title>
    <Scientific_title>A Multicenter Observational Study About the Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children</Scientific_title>
    <Acronym />
    <Primary_sponsor>Beijing Children's Hospital</Primary_sponsor>
    <Date_registration>11/02/2020</Date_registration>
    <Date_registration3>20200211</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04270383</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>18 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 15, 2020</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>Phase 1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; ; ; </Contact_Firstname>
    <Contact_Lastname>Kunling Shen, MD,PhD;Tianyou Wang, MD,PhD;Baoping Xu, MD,PhD;Baoping Xu, MD,PhD;Lina Wang</Contact_Lastname>
    <Contact_Email>;;;xubaopingbch@163.com;</Contact_Email>
    <Contact_Tel>;;;861059616308;</Contact_Tel>
    <Contact_Affiliation>Beijing Children's Hospital of Capital Medical University, China;Beijing Children's Hospital of Capital Medical University, China;Beijing Children's Hospital of Capital Medical University, China;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        1. For the 2019-nCoV infection group&lt;br&gt;&lt;br&gt;             Inclusion Criteria:&lt;br&gt;&lt;br&gt;             Diagnosed with 2019-nCoV infection (with direct laboratory evidence).&lt;br&gt;&lt;br&gt;               1. Respiratory or blood samples tested positive for novel coronavirus nucleic acid&lt;br&gt;                  with RT-PCR.&lt;br&gt;&lt;br&gt;               2. Gene sequencing of respiratory or blood samples show highly homologous with known&lt;br&gt;                  novel coronaviruses.&lt;br&gt;&lt;br&gt;             Exclusion Criteria:&lt;br&gt;&lt;br&gt;             Subjects will be excluded if the children or their parents disagree to conduct this&lt;br&gt;             study.&lt;br&gt;&lt;br&gt;          2. For the control group&lt;br&gt;&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Diagnosed with pneumonia, and excepted of novel coronavirus infection.&lt;br&gt;&lt;br&gt;          2. The hospitalization time is the same as that of novel coronavirus pneumonia.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        Subject will be excluded if she or he has one of the following:&lt;br&gt;&lt;br&gt;          1. First diagnosis is not pneumonia.&lt;br&gt;&lt;br&gt;          2. Any one of the novel coronavirus laboratory test results show positive.&lt;br&gt;&lt;br&gt;          3. Children or their parents disagree to conduct this study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV</Condition>
    <Primary_outcome>The cure rate of 2019-nCoV.;The improvement rate of 2019-nCoV.;The incidence of long-term adverse outcomes.</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04273646</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia</Public_title>
    <Scientific_title>Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia</Scientific_title>
    <Acronym />
    <Primary_sponsor>Wuhan Union Hospital, China</Primary_sponsor>
    <Date_registration>14/02/2020</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04273646</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 16, 2020</Date_enrollement>
    <Target_size>48</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Yang Jin, MD</Contact_Lastname>
    <Contact_Email>whuhjy@sina.com</Contact_Email>
    <Contact_Tel>+8613554361146</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. CT image is characteristic of viral pneumonia;&lt;br&gt;&lt;br&gt;          2. 2019-ncov infection (positive nucleic acid test) is confirmed by pathogenic test;&lt;br&gt;&lt;br&gt;          3. In compliance with the 2019-nCoV infection severe pneumonia diagnosis standard&lt;br&gt;             (according to the novel coronavirus infection pneumonia diagnosis and treatment&lt;br&gt;             program (Trial Implementation Version 5) issued by the National Health and Medical&lt;br&gt;             Commission, and WHO 2019 new coronavirus guidelines standards). It is severe if it&lt;br&gt;             meets any of the following: (A) Increased breathing rate (=30 beats / min), difficulty&lt;br&gt;             breathing, cyanosis of the lips; (B) When inhaling, means oxygen saturation =93%; (C)&lt;br&gt;             Partial pressure of arterial oxygen (PaO2) / Fraction of inspired oxygen (FiO2) =300&lt;br&gt;             mmHg (1mmHg = 0.133kPa);&lt;br&gt;&lt;br&gt;          4. 18 years old = age = 65 years old, regardless of gender;&lt;br&gt;&lt;br&gt;          5. The patient or legal donor agrees to participate in the study and signs the informed&lt;br&gt;             consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients with severe allergies or allergies to stem cell preparations and their&lt;br&gt;             components;&lt;br&gt;&lt;br&gt;          2. Patients with serious basic diseases that affect survival, including: blood diseases,&lt;br&gt;             cachexia, active bleeding, severe malnutrition, etc .;&lt;br&gt;&lt;br&gt;          3. Patients with pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis,&lt;br&gt;             alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or&lt;br&gt;             bacterial pneumonia;&lt;br&gt;&lt;br&gt;          4. Continuous use of immunosuppressive agents or organ transplants in the past 6 months;&lt;br&gt;&lt;br&gt;          5. In vitro life support (ECMO, ECCO2R, RRT);&lt;br&gt;&lt;br&gt;          6. Expected deaths within 48 hours, uncontrolled infections;&lt;br&gt;&lt;br&gt;          7. Patients with malignant blood-borne diseases such as HIV or syphilis;&lt;br&gt;&lt;br&gt;          8. Patient with pregnancy, are planning to become pregnant or breastfeeding;&lt;br&gt;&lt;br&gt;          9. Patients with poor compliance and unable to complete the full study;&lt;br&gt;&lt;br&gt;         10. The investigator determines that there may be increased risk of the subject or other&lt;br&gt;             conditions that interfere with the clinical trial and the judgment of the results&lt;br&gt;             (such as excessive stress, sensitivity or cognitive impairment, etc.);&lt;br&gt;&lt;br&gt;         11. There are other situations that the researchers think are not suitable to participate&lt;br&gt;             in this clinical study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019 Novel Coronavirus Pneumonia;COVID-19</Condition>
    <Intervention>Biological: UC-MSCs;Drug: Placebo</Intervention>
    <Primary_outcome>Pneumonia severity index;Oxygenation index (PaO2/FiO2)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04275947</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>The COVID-19 Mobile Health Study (CMHS)</Public_title>
    <Scientific_title>The COVID-19 Mobile Health Study, a Large-scale Clinical Observational Study Using nCapp</Scientific_title>
    <Acronym>CMHS</Acronym>
    <Primary_sponsor>Chinese Alliance Against Lung Cancer</Primary_sponsor>
    <Date_registration>17/02/2020</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04275947</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 14, 2020</Date_enrollement>
    <Target_size>450</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Chunxue Bai;Chunxue Bai;Chunxue Bai</Contact_Lastname>
    <Contact_Email>;bai.chunxue@zs-hospital.sh.cn;</Contact_Email>
    <Contact_Tel>;+8618621170011?;</Contact_Tel>
    <Contact_Affiliation>Shanghai Respiratory Research Institution;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  High risk of COVID-19&lt;br&gt;&lt;br&gt;          -  RT-PCR test result of SAR2-CoV-19&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Not available for RT-PCR test result of SAR2-CoV-19&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Other: nCapp, a cell phone-based auto-diagnosis system</Intervention>
    <Primary_outcome>Accuracy of nCapp COVID-19 risk diagnostic model</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030420</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform</Public_title>
    <Scientific_title>A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Institute of Integrative Medicine of Dalian Medical University, Dalian, China.</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50286</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Control group:30;Experimental group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Dong Shang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>9 West Section, Lushun Road South, Lushunkou District, Dalian, Liaoning, China</Contact_Address>
    <Contact_Email>shangdongdalian@163.com</Contact_Email>
    <Contact_Tel>+86 18098875933</Contact_Tel>
    <Contact_Affiliation>Institute of Integrative Medicine of Dalian Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) confirmed or suspected cases of new coronavirus pneumonia;&lt;br&gt;2) be able to understand the content of this study, and have the ability of normal communication and understanding;&lt;br&gt;3) voluntarily participate in this study and obtain written informed consent from the guardian or the patient.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) patients in coma, unable to carry out voluntary activities and social activities;&lt;br&gt;2) patients with mental illness or adverse reactions caused by drugs;&lt;br&gt;3) patients with serious diseases such as cardiovascular, cerebrovascular, liver and kidney damage.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Conventional integrated traditional Chinese and western medicine treatment and western medicine psychological intervention treatment;Experimental group:Conventional integrated traditional Chinese and western medicine treatment, western medicine psychological intervention therapy and traditional chinese medicine psychological intervention therapy;</Intervention>
    <Primary_outcome>Psychological status;Treatment compliance;To evaluate the difference in isolation and rehabilitation of patients after discharge;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029735</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-10</Date_registration>
    <Date_registration3>20200210</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49279</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-26</Date_enrollement>
    <Target_size>non-severe group and severe gorup:500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Min Xie</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>xie_m@126.com</Contact_Email>
    <Contact_Tel>+86 18602724678</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: SARI&lt;br&gt;1. An ARI with history of fever or measured temperature &gt;= 38 degree C and cough; onset within the last ~10 days; and requiring hospitalization. However, the absence of fever does NOT exclude viral infection.&lt;br&gt;2. Surveillance case definitions for 2019-nCoV:&lt;br&gt;(1) Patients with severe acute respiratory infection (fever, cough, and requiring admission to hospital), AND with no other etiology that fully explains the clinical presentation1 AND at least one of the following:&lt;br&gt;A. a history of travel to or residence in the city of Wuhan, Hubei Province, China in the 14 days prior to symptom onset, or&lt;br&gt;B. patient is a health care worker who has been working in an environment where severe acute respiratory infections of unknown etiology are being cared for.&lt;br&gt;(2) Patients with any acute respiratory illness AND at least one of the following:&lt;br&gt;A. close contact2 with a confirmed or probable case of 2019-nCoV in the 14 days prior to illness onset, or&lt;br&gt;B. visiting or working in a live animal market in Wuhan, Hubei Province, China in the 14 days prior to symptom onset, or&lt;br&gt;C. worked or attended a health care facility in the 14 days prior to onset of symptoms where patients with hospital-associated 2019-nCov infections have been reported.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Researchers believe that patients are not suitable for any other situation in this study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>non-severe group and severe gorup:N/A;</Intervention>
    <Primary_outcome>incidence;mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029734</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>The First People's Hospital of Huaihua</Primary_sponsor>
    <Date_registration>2020-02-10</Date_registration>
    <Date_registration3>20200210</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48868</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-08</Date_enrollement>
    <Target_size>Case series:40;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chengfeng Qiu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>144 Jinxi Road South, Hecheng District, Huaihua, Hu'nan, China</Contact_Address>
    <Contact_Email>qiuchengfeng0721@163.com</Contact_Email>
    <Contact_Tel>+86 14786531725</Contact_Tel>
    <Contact_Affiliation>The First People's Hospital of Huaihua</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who are positive for novel coronary virus detected by RC-PCR and  second-generation sequencing.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:N/A;</Intervention>
    <Primary_outcome>Epidemiological history;haematological;First symptom;blood glucose;blood glucose;prognosis;Blood gas analysis;complication;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029756</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Renmin Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-12</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49222</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>60</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>experimental group:119;control group:119;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhan Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>doctorzhang2003@163.com</Contact_Email>
    <Contact_Tel>+86 18062567610</Contact_Tel>
    <Contact_Affiliation>Renmin Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. 18 years old &lt;= age &lt;= 60 years old at the time of screening;&lt;br&gt;2. Pharyngeal swabs, alveolar lavage fluid, or sputum specimens during screening showed that 2019-nCoV virus nucleic acid test results were positive for at least two of nCov-EP, nCov-NP, and nCovORF1ab, in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment plan (trial version 5);&lt;br&gt;3. The investigator determined that aerosolized inhalation treatment was appropriate, and volunteered to participate in the study and signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Chronic lung diseases requiring long-term oxygen therapy;&lt;br&gt;2. Long-term application of glucocorticoids due to underlying diseases;&lt;br&gt;3. Based on the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;&lt;br&gt; Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory diseases affecting clinical trial evaluation, Chest CT confirmed that patients with severe pulmonary interstitial lesions, bronchiectasis and other underlying lung diseases;&lt;br&gt;4. Breastfeeding or pregnancy test result is positive during screening or test;&lt;br&gt;5. Allergic constitution (persons who are allergic to more than 2 types of substances), persons who are allergic to similar drugs in the past or those who are known to be allergic to the ingredients and auxiliary materials in the test drugs;&lt;br&gt;6. The investigator decides that it is not in the best interest of the subject to participate in the study, or that the subject has any situation in which the protocol cannot be fully followed.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Xiyanping injection;control group:alpha-interferon;</Intervention>
    <Primary_outcome>vital signs (Body temperature, blood pressure, heart rate, breathing rate);Respiratory symptoms and signs (Lung sounds, cough, sputum);Etiology and laboratory testing;PaO2/SPO2;Liquid balance;Ventilator condition;Imaging changes;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029747</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-11</Date_registration>
    <Date_registration3>20200211</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49287</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>12</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-11</Date_enrollement>
    <Target_size>Experimental group:100;control group:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Nianzhi Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>117 Meishan Road, Hefei, Anhui, China</Contact_Address>
    <Contact_Email>13505615645@163.com</Contact_Email>
    <Contact_Tel>+86 13505615645</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Conforming to the diagnostic standard of COVID-19; Participants in the first and second trials need to meet the diagnostic criteria of traditional Chinese medicine for epidemic diseases; Participants in the third trial need to meet the diagnostic criteria of deficiency of qi in lung and spleen of epidemic diseases.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients over 80 years of age or less than 12 years of age (trial 3 and less than 18 years old); patients with contraindications to study drugs; cancer patients, life expectancy &lt;6 months; participants in other clinical trials in the past three months; pregnant women, breastfeeding Women.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Traditional Chinese Medicine;control group:Basic treatment of modern medicine;</Intervention>
    <Primary_outcome>Chest CT;Routine blood test;liver and renal function;TCM syndrome;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030390</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology</Public_title>
    <Scientific_title>Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50224</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-01</Date_enrollement>
    <Target_size>Target condition:3000;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Kunlun He</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>28 Fuxing Road, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>hekl301@aliyun.com</Contact_Email>
    <Contact_Tel>+86 010 66939107</Contact_Tel>
    <Contact_Affiliation>Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. confirmed clinical records in the database of the hospital;&lt;br&gt;2. inpatients have confirmed clinical diagnosis and relevant laboratory tests;&lt;br&gt;3. the CT images are complete, the image quality meets the diagnostic and measurement requirements;&lt;br&gt;4. the format of image storage and transmission is DICOM file. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The cases of artifacts caused by poor breath-holding coordination or operator factors are excluded </Exclusion_Criteria>
    <Condition>Novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Postive result of SARS-CoV-2 nucleic acid examination;Index test:Diagnostic&amp;#32;Assistance&amp;#32;Decision&amp;#32;Support&amp;#32;System;</Intervention>
    <Primary_outcome>CT;SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030363</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome</Public_title>
    <Scientific_title>Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of science and technology</Primary_sponsor>
    <Date_registration>2020-02-29</Date_registration>
    <Date_registration3>20200229</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49984</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>18</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-23</Date_enrollement>
    <Target_size>Monitor cases, suspected cases and diagnosed cases:120;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yan Hao; Xiaoping Luo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>haoyaner@163.com</Contact_Email>
    <Contact_Tel>+86 13971679960</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: This study intends to select surveillance cases, suspected cases, and diagnosed cases of COVID-19 for children aged 0-18 who were admitted to the Department of Pediatrics, Tongji Hospital from December 2019 to June 2020.&lt;br&gt;1. Epidemiological classification: All Participants divided into three levels: high, medium and low risk according to the epidemiological history:&lt;br&gt;(1) high risk: the participants are close to suspected or confirmed cases of COVID-19 within 14 days before the onset of illness;&lt;br&gt;(2) medium risk: cluster cases of COVID-19 in the residence or community;&lt;br&gt;(3) low risk: the residence or community has no cluster cases or not from epidemic place;&lt;br&gt;2. Monitoring cases: high-risk children with no symptom and medium-risk or low-risk children with the following symptoms:&lt;br&gt;(1) Fever;&lt;br&gt;(2) respiratory symptoms or weakness, nausea, vomiting, abdominal discomfort and diarrhea;&lt;br&gt;3. Suspected cases: If the high-risk children meet any 2 of the following 3 conditions, they are suspected cases. Any 2 of the following 3 surveillance cases in medium and low risk were suspected cases after elimination of influenza (no effect of oseltamivir phosphate for 2 days) and other common respiratory pathogenic infections:&lt;br&gt;(1) Persistent fever, obvious respiratory symptoms, shortness of breath, pulse oxygen saturation decreased, or gastrointestinal symptoms such as nausea, vomiting, abdominal discomfort and diarrhea;&lt;br&gt;(2) laboratory tests: white blood cells level normal or decreased , lymphocyte count decreased, CRP normal or slightly elevated;&lt;br&gt;(3) chest radiology shows signs of COVID-19;&lt;br&gt;4. Diagnosed cases: all suspected cases who respiratory swabs or secretions, blood, feces and urine SARS-CoV-2 nucleic acid test is positive; viral gene sequencing is highly homologous with SARS-CoV -2.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Exclude influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus,rhinovirus, human metapneumovirus, boca virus, and other known viral respiratory infections;&lt;br&gt;(2) Exclude pneumonia caused by atypical microorganisms such as mycoplasma pneumoniae and legionella,bacterial pneumonia, fungal pneumonia, and tuberculosis;&lt;br&gt;(3) Exclude children with basic diseases who have invasive fungal infections;&lt;br&gt;(4) Exclude children with no clear infectious etiology, who have non-infectious diseases such as vasculitis, dermatomyositis, idiopathic interstitial lung disease, and organizing pneumonia;&lt;br&gt;(5) The guardian does not agree to sign the informed consent or collect information.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Monitor cases, suspected cases and diagnosed cases:No;</Intervention>
    <Primary_outcome>Epidemiological characteristics;clinical features;Treatment outcome;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029621</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Multicenter, randomized, open-label, controlled trial for the efficacy and safety of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</Primary_sponsor>
    <Date_registration>2020-02-07</Date_registration>
    <Date_registration3>20200207</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49165</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-07</Date_enrollement>
    <Target_size>Experimental group:190;Control group:190;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qu Jieming</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>197 Second Ruijin Road, Huangpu District, Shanghai, China</Contact_Address>
    <Contact_Email>jmqu0906@163.com</Contact_Email>
    <Contact_Tel>+86 21 64370045</Contact_Tel>
    <Contact_Affiliation>Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Sign the informed consent form;&lt;br&gt;2. Aged &gt;=18 years;&lt;br&gt;3. Subjects diagnosed as 2019-nCoV pneumonia;&lt;br&gt;(1) Detection of 2019-nCoV nucleic acid positive by RT-PCR in respiratory tract or blood samples;&lt;br&gt;(2) The virus gene sequence of respiratory tract or blood samples is highly homologous to the known 2019-nCoV;&lt;br&gt;4. According to the standard of "2019-nCoV pneumonia diagnosis and treatment Program of New Coronavirus infection (trial Fifth Edition)" issued by National Health Commission of China, clinical classification: mild, ordinary subjects;&lt;br&gt;(1) Mild type, the clinical symptoms were mild and no pneumonia was found in imaging;&lt;br&gt;(2) Common type, With fever, respiratory tract and other symptoms, the manifestations of pneumonia can be seen on imaging.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Critical type: If one of the following conditions is met&lt;br&gt;(1) Respiratory failure occurs and mechanical ventilation is needed;&lt;br&gt;(2) Shock occurred;&lt;br&gt;(3) Patients with other organ failure need ICU monitoring treatment;&lt;br&gt;2. Severe type: If one of the following conditions is met&lt;br&gt;(1) Respiratory distress, RR &gt;= 30 beats / min;&lt;br&gt;(2) In resting state, finger oxygen saturation (SaO2) &lt;= 93%;&lt;br&gt;(3) Partial pressure of arterial oxygen (PaO2) / concentration of oxygen inhaled (FiO2)&lt;= 300mmHg;&lt;br&gt;3. Those who have a history of allergy to this class of drugs and / or severe allergic constitution;&lt;br&gt;4. The results of laboratory tests are abnormal:&lt;br&gt;(1) Hematological dysfunction is defined as:&lt;br&gt;1) Platelet (PLT) count &lt;100x10^9/L;&lt;br&gt;2) Hemoglobin (Hb) level &lt;90g/L;&lt;br&gt;(2) Abnormal liver function is defined as:&lt;br&gt;1) Level of total bilirubin(TBil) &gt;2 ULN;&lt;br&gt;2) The levels of aspartate aminotransferase (AST) and Alanine transaminase (ALT)&gt;3 ULN;&lt;br&gt;3) Definition of renal dysfunction:&lt;br&gt;Serum creatinine&gt;1.5 ULN, or calculated creatinine clearance&lt;50ml/min;&lt;br&gt;4) Definition of abnormal blood coagulation:&lt;br&gt;International normalized ratio(INR) &gt;1.5 ULN, and the prothrombin time ((PT)) or activated partial thromboplastin time (aPTT) 1.5 ULN, unless the subject is receiving anticoagulant therapy;&lt;br&gt;5. Abidor was used before inclusion(Tablets, capsules, granules);&lt;br&gt;6. Women who are nursing or pregnant;&lt;br&gt;7. Serum or urine pregnancy tests were positive for women of child-bearing age;&lt;br&gt;8. Immunodeficient patient(Patients with malignant tumors, Organ or bone marrow transplant, HIV patient, those who took immunosuppressive drugs within 3 months before the screening test );&lt;br&gt;9. With the following history of present illness:&lt;br&gt;(1) Neurological and neurodevelopmental disorders, These include diseases of the brain, spinal cord, peripheral nerves and muscles(Such as cerebral palsy, epilepsy, stroke, mental retardation, moderate to severe developmental delay, muscular malnutrition or spinal cord injury );&lt;br&gt;(2) Circulation system disease( congenital heart disease, Congestive heart failure or coronary artery disease);&lt;br&gt;(3) Severe heart disease or a history of clinically significant arrhythmias that the researchers believe will affect participants' safety (According to the ECG or medical history);&lt;br&gt;10. Other patients considered ineligible for this study were considered ineligible by the investigators.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Arbidol tablets + basic treatment;Control group:Basic treatment;</Intervention>
    <Primary_outcome>Virus negative conversion rate in the first week;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029609</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>The Fifth Affiliated Hospital of Sun Yat-Sen University</Primary_sponsor>
    <Date_registration>2020-02-06</Date_registration>
    <Date_registration3>20200206</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49145</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>mild-moderate chloroquine group:59;mild-moderate Lopinavir/ritonavir group:59;mild-moderate combination group:59;severe-chloroquine group :14;severe- Lopinavir/ritonavir group:14;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hong Shan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>52 Meihua Road East, Zhuhai, Guangdong, China</Contact_Address>
    <Contact_Email>shanhong@mail.sysu.edu.cn</Contact_Email>
    <Contact_Tel>+86 0756 2528573</Contact_Tel>
    <Contact_Affiliation>The Fifth Affiliated Hospital of Sun Yat-Sen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 years old; &lt;br&gt;2. Patients has been diagnosed with 2019-nCoV pneumonia according to the fifth version of 2019-nCoV pneumonia management guideline made by the national health commission of the People's Repulic of China.&lt;br&gt;More details see: http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnant woman patients;&lt;br&gt;2. Documented allergic history to any of chloroquine phosphate, ritonavir and lopinavir;&lt;br&gt;3. Documented history of hematological system diseases;&lt;br&gt;4. Documented history of chronic liver and kidney diseases;&lt;br&gt;5. Documented history of cardiac arrhythmia or chronic heart diseases;&lt;br&gt;6. Documented history of retina or hearing dysfunction;&lt;br&gt;7. Documented history of mental illnesses;&lt;br&gt;8. Use of digitalis due to the previous disease;&lt;br&gt;9. Onging pancreatitis;&lt;br&gt;10. Documented history of hemophilia;&lt;br&gt;11. Documented history of glucose-6 phosphate dehydrogenase (G-6-PD) deficiency.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>mild-moderate chloroquine group:oral chloroquine phosphate;mild-moderate Lopinavir/ritonavir group:oral Lopinavir/ritonavir;mild-moderate combination group:chloroquine phosphate plus Lopinavir/ritonavir;severe-chloroquine group :oral chloroquine phosphate  ;severe- Lopinavir/ritonavir group:oral Lopinavir/ritonavir;</Intervention>
    <Primary_outcome>virus nucleic acid negative-transforming time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029739</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Guangzhou Medical University</Primary_sponsor>
    <Date_registration>2020-02-11</Date_registration>
    <Date_registration3>20200211</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49283</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>Experimental group:220;Control group:220;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Nanshan Zhong, Zeguang Zheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>151 Yanjing Road, Yuexiu District, Guangzhou, China</Contact_Address>
    <Contact_Email>zheng862080@139.com</Contact_Email>
    <Contact_Tel>+86 18928868242</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Guangzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Subjects participating in this clinical study must meet all of the following criteria:&lt;br&gt;1. General- severe hospitalized patients who meet the diagnostic criteria of the "New Coronavirus Infected Pneumonia Diagnosis and Treatment Plan (Trial Version 5)". That is, one of the following three conditions is met on the premise that the general diagnostic criteria are met:&lt;br&gt;1) Respiratory frequency (RR): 20-30 times / minute;&lt;br&gt;2) Peripheral oxygen saturation: 93-95%;&lt;br&gt;3) Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2): 300-400mmHg (1mmHg = 0.133kPa).&lt;br&gt;2. Patients aged &gt;= 18 and &lt;= 85 years, with normal autonomous judgment ability, regardless of gender and region;&lt;br&gt;3. Patients who voluntarily participated in the study and signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with a significant disease or condition other than the new coronavirus pneumonia, that is, a disease that, according to the investigator's judgment, may cause the subject to be at risk due to participation in the study, or affect the results of the study and the ability of the subject to participate in the study.&lt;br&gt;2. Women who are pregnant or nursing or plan to become pregnant during the study.&lt;br&gt;3. Have one of the following respiratory diseases:&lt;br&gt;1) Asthma: Based on the investigator's judgment, the subject is currently diagnosed with asthma.&lt;br&gt;2) Subjects with a previous history of COPD or long-term medication or imaging that showed significant lung structural damage (eg, giant pulmonary bullae).&lt;br&gt;3) Other respiratory diseases: subjects with other active lung diseases, such as active tuberculosis, lung cancer, wet bronchiectasis (high-resolution CT shows bronchiectasis, yellow sputum every day), sarcoidosis, idiopathic Interstitial Pulmonary Fibrosis (IPF), Primary Pulmonary Arterial Hypertension, Uncontrolled Sleep Apnea (ie, the severity of the disease will affect the implementation of the study at the investigator's discretion), combined with pneumothorax, pleural effusion and pulmonary embolism , Bronchial asthma, tumors, fever of unknown origin, etc.&lt;br&gt;4) Lung volume reduction: Lung volume reduction, lobectomy, or bronchoscopic lung volume reduction within 6 months (bronchial obstruction, airway bypass, bronchial valve, steam thermal ablation, biological sealant, Implants).&lt;br&gt;5) Patients who are critically ill or unstable. Definition of Severe Pneumonia: &lt;br&gt;A. Increased breathing rate ( &gt;= 30 beats / min), difficulty breathing; &lt;br&gt;B. Peripheral blood oxygen saturation &lt;= 93% when inhaling air, or arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) &lt;= 300mmHg; &lt;br&gt;C. Lung imaging showed multi-leaf disease or lesion progression&gt; 50% within 48 hours; &lt;br&gt;D. Combined with pneumothorax.&lt;br&gt;6) Pneumonia risk factors: immunosuppression (HIV), severe neurological disease affecting upper respiratory tract control, or other risk factors that the investigator believes may put the subject at a significant risk of pneumonia.&lt;br&gt;4. Complicate serious primary diseases such as heart, liver, kidney, and hematopoietic system.&lt;br&gt;5. People with mental disorders and cognitive impairment.&lt;br&gt;6. Non-compliance: Subjects who did not comply with the study procedures, including non-compliance completion logs.&lt;br&gt;7. Questions about the effectiveness of informed consent: subjects with a history of psychosis, mental retardation, poor motivation, substance abuse (including drugs and alcohol), or other medical conditions that limit the effectiveness of informed consent in this study.&lt;br&gt;8. Those who use non-expectorant antioxidant drugs, including large doses of vitamin C and vitamin E.&lt;br&gt;9. Researchers consider it inappropriate to participate in this research.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Hydrogen-Oxygen Nebulizer;Control group:Oxygen concentrator;</Intervention>
    <Primary_outcome>the condition worsens and develops into severe or critical condition;the condition improves significantly and reaches the discharge standard;The overall treatment time is no longer than 14 days;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029732</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Impact of vitamin D deficiency on prognosis of patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Impact of vitamin D deficiency on prognosis of patients novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-10</Date_registration>
    <Date_registration3>20200210</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49302</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Vitamin D deficiency group:104;Vitamin D normal group:52;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jun Guo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China  </Contact_Address>
    <Contact_Email>guojun@wchscu.cn</Contact_Email>
    <Contact_Tel>+86 15388178461</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;= 18 years.&lt;br&gt;2. Patients who meet the diagnostic criteria of suspected cases of pneumonia caused by novel coronavirus infection. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients without any clinical and chest imaging findings;&lt;br&gt;2. Supplementation with vitamin D or calcium within one week before admission&lt;br&gt;3. Patients with severe failure with chronic organ dysfunction;&lt;br&gt;4. Malignant tumors; diseases of the immune system; radiation and chemotherapy.&lt;br&gt;5. Pregnancy: The pregnancy test is positive for women of childbearing age; the breastfeeding women have not stopped breastfeeding.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Vitamin D deficiency group:N/A;Vitamin D normal group:N/A;</Intervention>
    <Primary_outcome>ROX index;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030331</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui</Public_title>
    <Scientific_title>Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>the First Affiliated Hospital Division of Life Sciences and Medicine University of Science and Technology of China</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50271</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>120</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:498;</Target_size>
    <Study_type>Epidemilogical research</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Weng Jianping</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>17 Lujiang Road, Luyang District, Hefei, Anhui, China</Contact_Address>
    <Contact_Email>wengjp@ustc.edu.cn</Contact_Email>
    <Contact_Tel>+86 0551-62286223</Contact_Tel>
    <Contact_Affiliation>the First Affiliated Hospital Division of Life Sciences and Medicine University of Science and Technology of China</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients confirmed to be infected with SARS-CoV-2.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who refused to participate in the project; &lt;br&gt;2. Patients developed symptoms caused by other pathogens rather than the SARS-CoV-2, and there was no evidence show that patients were infected with SARS-CoV-2.</Exclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Case series:NA;</Intervention>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030322</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients</Public_title>
    <Scientific_title>Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Xinyang Central Hospital</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50240</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Light and common type group:80;Severe group:40;Western medicine treatment group:30;Chinese and western medicine combined treatment group:30;Non-invasive mechanical ventilation group:15;Nasal high flow oxygen therapy group:15;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lu Yibin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Siyi Road, Shihe District, Xinyang, He'nan, China</Contact_Address>
    <Contact_Email>luyb6810@163.com</Contact_Email>
    <Contact_Tel>+86 13937642780</Contact_Tel>
    <Contact_Affiliation>Xinyang Central Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: According to the "Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (Trial Version 6)" issued by the General Office of the State Health Committee of the People's Republic of China, newly diagnosed patients with pneumonia have been diagnosed.  Clinical classification: &lt;br&gt;(1) mild: clinical symptoms are mild, and no pneumonia is found on imaging;&lt;br&gt;(2) Common type: with fever, respiratory tract and other symptoms, pneumonia can be seen on imaging;&lt;br&gt;(3) Heavy duty.  &lt;br&gt;Comply with any of the following: &lt;br&gt;1. shortness of breath, RR&gt;=30 times/min;&lt;br&gt;2. In the resting state, oxygen saturation &lt;=93%;&lt;br&gt;3. arterial partial pressure of oxygen (PaO2)/ oxygen concentration (FiO2)&lt;=300mmHg(1mmHg=0.133kPa). In areas with high altitude (over 1,000 meters above sea level), PaO2/FiO2 shall be corrected according to the following formula: PaO2/FiO2*[ atmospheric pressure (mmHg)/760];  Pulmonary imaging showed that patients with obvious lesion progress &gt; 50% within 24-48 hours should be managed according to heavy duty;&lt;br&gt;4. Critical type: one of the following conditions is met: &lt;br&gt;(1) Respiratory failure occurs and mechanical ventilation is required;&lt;br&gt;(2) Shock;&lt;br&gt;(3) ICU monitoring and treatment are required for patients with other organ failure.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with serious heart and lung, liver and kidney functions and central nervous system diseases;&lt;br&gt;2. Pregnant or lactating patients.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19);U07.100x001</Condition>
    <Intervention>Light and common type group:Conventional treatment;Severe group:Conventional treatment;Western medicine treatment group:Give routine western medicine treatment;Chinese and western medicine combined treatment group:Traditional Chinese medicine is combined with conventional western medicine treatment.;Non-invasive mechanical ventilation group:Give noninvasive mechanical ventilation and respiratory support;Nasal high flow oxygen therapy group:Give nasal high flow oxygen therapy respiratory support;</Intervention>
    <Primary_outcome>Epidemiological and clinical characteristics;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029658</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19): a randomized clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Guangzhou University of TCM</Primary_sponsor>
    <Date_registration>2020-02-09</Date_registration>
    <Date_registration3>20200209</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49074</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>experimental group:30;control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wu Caineng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>16 Jichang Road, Guangzhou, Guangdong, China  </Contact_Address>
    <Contact_Email>wucaineng861010@163.com</Contact_Email>
    <Contact_Tel>+86 13580315308</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Guangzhou University of TCM</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Eligible patients were adults ((aged 18-80 years);&lt;br&gt;2. Were identified as laboratory-confirmed 2019-nCoV infection;&lt;br&gt;3. Those who need intubation in ICU, and with no severe hypoxemia.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Intubation required immidiately in case of cardiac arrest or asphyxia;&lt;br&gt;2. Pregnancy, severe chronic respiratory, uncontrolled gastric reflux disease and any nasopharyngeal anatomical obstacle;&lt;br&gt;3. Those patients has intubated in ICU.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:high-fow therapy by nasal cannulae (HFNC);control group:bag- valve mask oxygenation (SMO);</Intervention>
    <Primary_outcome>the lowest SpO2 during intubation;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029639</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Study for Mental health and psychological status of doctors, nurses and patients in novel coronavirus pneumonia (COVID-19) designated hospital and effect of interventions</Public_title>
    <Scientific_title>Mental health and psychological interventions on doctors, nurses and patients at the novel coronavirus pneumonia (COVID-19) designated hospitals: a prospective, open, single-center clinical study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>The Fifth Affiliated Hospital Sun Yat-Sen University</Primary_sponsor>
    <Date_registration>2020-02-08</Date_registration>
    <Date_registration3>20200208</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49187</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>??</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>doctors group:48;nurses group:48;suspected cases group:48;cases group:48;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wen Shenglin, Xia Jinyu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>52 Meihua Road East, Zhuhai, Guangdong, China</Contact_Address>
    <Contact_Email>wenshl@mail.sysu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13312883618</Contact_Tel>
    <Contact_Affiliation>Department of Psychology, the Fifth Affiliated Hospital Sun Yat-Sen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Medical staff involved in the diagnosis and treatment of new coronavirus pneumonia;&lt;br&gt;2) 2019-nCoV infection suspected or confirmed cases;&lt;br&gt;3) Voluntarily participate in this research project and sign informed consent;&lt;br&gt;4) Able to cooperate with the scale assessor.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: no exclusion criteria.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (NCP)</Condition>
    <Intervention>doctors group:Psychological intervention;nurses group:Psychological intervention;suspected cases group:Psychological intervention or drug intervention;cases group:Psychological intervention or drug intervention;</Intervention>
    <Primary_outcome>Physical examination;Nucleic acid;Oxygenation index;GAD-7;PHQ-9;SASRQ;PSQI;Lymphocyte subsets;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030314</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50248</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1</Inclusion_agemin>
    <Inclusion_agemax>15</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-28</Date_enrollement>
    <Target_size>Case series:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Rui Pan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>136 Jingzhou Street, Xiangcheng, Xiangyang, Hubei, China</Contact_Address>
    <Contact_Email>55815147@qq.com</Contact_Email>
    <Contact_Tel>+86 13986394739</Contact_Tel>
    <Contact_Affiliation>Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Confirmed or clinically diagnosed cases;&lt;br&gt;2. Aged &gt; 1 year;&lt;br&gt;3. Volunteers.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.With vomiting, diarrhea or other contraindications;&lt;br&gt;2.refuse to traditional Chinese medicine.</Exclusion_Criteria>
    <Condition>pediatric COVID19</Condition>
    <Intervention>Case series:Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San;</Intervention>
    <Primary_outcome>temperature;respiratory symptoms;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030305</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Li Caixia</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50223</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-09</Date_enrollement>
    <Target_size>Case series:20;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Caixia</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>N1 Shangcheng Road, Yiwu, Zhejiang, China</Contact_Address>
    <Contact_Email>li_caixia@zju.edu.cn</Contact_Email>
    <Contact_Tel>+86 15268118258</Contact_Tel>
    <Contact_Affiliation>The Fourth Affiliated Hospital of Zhejiang University School of Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Adult patients with confirmed 2019-nCoV</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Severe liver and kidney damage, pulmonary tuberculosis, congenital heart disease, autoimmune disease, interstitial pneumonia, bacterial pneumonia, malignant tumor, history of psychiatric disease</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:traditional Chinese medicine;</Intervention>
    <Primary_outcome>blood RNA;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029628</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A clinical observational study for Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Observational study of Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Guangdong Provincial Hospital of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-07</Date_registration>
    <Date_registration3>20200207</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49155</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-07</Date_enrollement>
    <Target_size>Experimental group:50;Control group:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Zhongde</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>doctorzzd99@163.com</Contact_Email>
    <Contact_Tel>+86 13903076359</Contact_Tel>
    <Contact_Affiliation>Guangdong Provincial Hospital of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who meet the diagnostic criteria of suspected cases of pneumonia caused by novel coronavirus infection.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients in Xin-Guan-2 formula.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Xinguan-2 formula+Standard treatment;Control group:Standard treatment;</Intervention>
    <Primary_outcome>Time to completely antipyretic time:completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Main symptom relief/disappearance time: defined as the days when the three main symptoms of fever, cough and shortness of breath all remission/disappear.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029625</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Zhejiang University School of Medicine</Primary_sponsor>
    <Date_registration>2020-02-07</Date_registration>
    <Date_registration3>20200207</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49177</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Target condition:80;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Cai Hongliu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>caiicu@163.com</Contact_Email>
    <Contact_Tel>+86 13505811696</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Zhejiang University School of Medicine </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with novel coronavirus infection pneumonia were confirmed by RT-PCR and clinical symptoms. The diagnosic criteria refer to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)";&lt;br&gt;2. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 10 days);&lt;br&gt;3. Patients who voluntarily signed informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Physician judged the patient was not suitable for this clinical trial (for example, patient may be transferred to another hospital during the study period; patient with immune system diseases or cancers etc.)</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Clinical outcome;Index test:early&amp;#32;warning&amp;#32;and&amp;#32;prediction&amp;#32;system;</Intervention>
    <Primary_outcome>Lymphocyte subpopulation analysis;Cytokine detection;Single cell sequencing of bronchial lavage fluid cells;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030262</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Shanghai Public Health Clinical Center</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50136</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Group 2:10;Group 3:10;Group 1:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jianqing Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>2901 Caolang Road, Jinshan District, Shanghai, China</Contact_Address>
    <Contact_Email>xujianqing@shphc.org.cn</Contact_Email>
    <Contact_Tel>+86 18964630206</Contact_Tel>
    <Contact_Affiliation>Shanghai Public Health Clinical Center </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged from 18 to 70 years old;&lt;br&gt;2. According with the clinical diagnosis of viral pneumonia symptoms,including fever, Low white blood cells or platelets infiltration shadow in CT;&lt;br&gt;3. Positive result for  nucleic acid of 2019-nCov;&lt;br&gt;4. Patients can receive aerosol inhalation&lt;br&gt;5. Consent to sign a written informed statement prior to the beginning of the study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pneumonia caused by other viruses, except for 2019-nCov;&lt;br&gt;2. Clear bacterial infection;&lt;br&gt;3. Subjects who have used antiviral drugs and may need another antiviral treatment during the study;&lt;br&gt;4. There are serious non-infectious pulmonary diseases, including tuberculosis, pulmonary edema and pulmonary embolism;&lt;br&gt;5. Severe liver and kidney dysfunction;&lt;br&gt;6. Participating in other clinical studies within 30 days before administration;&lt;br&gt;7. Allergic to type 1 interferon;&lt;br&gt;8. Pregnant or lactating women;&lt;br&gt;9.In any other case, if the investigator thinks it is not suitable for the trial, or it may increase the risk of the subject or interfere with the clinical trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 2:Once for two days;Group 3:Once for one day;Group 1:Control Group;</Intervention>
    <Primary_outcome>Viral load;Clinical features;Inflammation;Pulmonary imaging;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030260</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical study for individualized nutritional assessment and supportive treatment of novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau</Public_title>
    <Scientific_title>Clinical study on novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau promoted by individualized nutritional assessment and supportive treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Ganzi Hospital of West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50130</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-27</Date_enrollement>
    <Target_size>Experimental group:10;Control group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lijia Deng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>94 West Street, Kangding City, Ganzi Prefecture, Sichuan, China</Contact_Address>
    <Contact_Email>27216302@qq.com</Contact_Email>
    <Contact_Tel>+86 17723451376</Contact_Tel>
    <Contact_Affiliation>Ganzi Hospital of West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. novel coronavirus pneumonia patients with nutritional malnutrition diagnosed by nutritional assessment;&lt;br&gt;2. enteral nutrition support treatment for at least 5 days;&lt;br&gt;3. No use of Fat emulsion taboo;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. No malnutrition;&lt;br&gt;2. Patients who had received antiviral drugs, immunosuppressive drugs and cytotoxic drugs 2 weeks before diagnosis;&lt;br&gt;3. patients with hypertriglyceridemia (TG): Serum TG &gt; 3.0mmol/l;&lt;br&gt;4. patients with severe liver and kidney dysfunction;&lt;br&gt;5. pregnant women; 6.tumor patients.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:enteral nutrition emulsion, tpf-t 200ml Bid;Control group:No intervention;</Intervention>
    <Primary_outcome>NRS 2002 score;BMI;triceps skinfold thickness (TSF);prealbumin;total albumin;leucocyte count;CRP;lymphocyte percentage;TNF- alpha;IL-6;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029602</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population</Public_title>
    <Scientific_title>Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Hubei Provincial Hospital of TCM</Primary_sponsor>
    <Date_registration>2020-02-06</Date_registration>
    <Date_registration3>20200206</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48985</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Experimental group:300;Control group:300;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiaolin Tong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>856 Luoyu Road, Hongshan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>Xiaolintong66@sina.com</Contact_Email>
    <Contact_Tel>+86 13910662116</Contact_Tel>
    <Contact_Affiliation>Hubei Provincial Hospital of TCM</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Conforming to the diagnostic criteria for the above close contacts;&lt;br&gt;2. Aged between 18 and 65 years old;&lt;br&gt;3. Signing the generalized informed consent form.  (The intervention objects is incorporated in the clinical study as desired).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Severe or critically severe patients;&lt;br&gt;2. Clear evidence of bacterial infection; &lt;br&gt;3. Patients with severe primary diseases such as heart, kidney, lung, endocrine, blood, metabolism, and gastrointestinal tract, etc., may affect participation in the trial or may affect the outcome of the study by the judgment of the researcher;&lt;br&gt;4. Patients who have a family history of mental illness or have had a mental illness; &lt;br&gt;5. Patients who are allergic constitution or allergy to multiple drug; &lt;br&gt;6. pregnant or lactating women.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:health education, follow-up condition management by team of family doctors, Chinese medicine treatment;Control group:health education, follow-up condition management by team of family doctors;</Intervention>
    <Primary_outcome>Incidence of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;days of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029600</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>The Third People's Hospital of Shenzhen</Primary_sponsor>
    <Date_registration>2020-02-06</Date_registration>
    <Date_registration3>20200206</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49042</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-30</Date_enrollement>
    <Target_size>Group A:30;Group B:30;Group C:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Liu Yingxia</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>29 Bulan Road, Longgang District, Shenzhen, Guangdong, China</Contact_Address>
    <Contact_Email>yingxialiu@hotmail.com</Contact_Email>
    <Contact_Tel>+86 755 61238922</Contact_Tel>
    <Contact_Affiliation>The Third People's Hospital of Shenzhen</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. 16 to 75 years of age, male or female;&lt;br&gt;2. Respiratory or blood samples tested positive for novel coronavirus;&lt;br&gt;3. Within 7 days of onset: Onset is defined as body temperature exceeding 38 degree C (armpit temperature) or at least one 2019-nCoV pneumonia related systemic or respiratory symptom;&lt;br&gt;4. Willing to take contraception during the study and within 7 days after treatment;&lt;br&gt;5. No difficulty in swallowing the Pills;&lt;br&gt;6. Willing to sign informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Any situation which the protocol cannot be carried out safely;&lt;br&gt;2. Patient refuses to receive invasive tracheal support (if needed);&lt;br&gt;3. Pregnant or lactating women:childbearing age women with positive pregnancy test, breastfeeding, miscarriage or within 2 weeks after delivery.Postmenopausal and hysterectomy women do not need a pregnancy test;&lt;br&gt;4. Patients with chronic liver and kidney disease and reaching end-stage;&lt;br&gt;5. Previous history of allergic reactions to Fapiravir or Lopinavir and Ritonavir;&lt;br&gt;6. Currently or in the past 28 days, participated in another clinical trial against novel coronavirus treatment;&lt;br&gt;7. After the investigator's judgment, the subjects could not participate the study protocol, follow-up or self-evaluation after enrollment.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Group A:alpha-Interferon atomization;Group B:Lopinavir and Ritonavir + alpha-Interferon atomization;Group C:Favipiravir + alpha-Interferon atomization;</Intervention>
    <Primary_outcome>Declining speed of Novel Coronavirus by PCR;Negative Time of Novel Coronavirus by PCR;Incidentce rate of chest imaging;Incidence rate of liver enzymes;Incidence rate of kidney damage;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029606</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital, College of Medicine, Zhejiang University</Primary_sponsor>
    <Date_registration>2020-02-07</Date_registration>
    <Date_registration3>20200207</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49146</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1</Inclusion_agemin>
    <Inclusion_agemax>99</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-25</Date_enrollement>
    <Target_size>experimental group A:18;control gorup A:15;Experimental Group B1:10;Experimental Group B2:10;Control Gorup A:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lanjuan Li /Xiaowei Xu/Charile Xiang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>ljli@zju.edu.cn</Contact_Email>
    <Contact_Tel>+86 0571-87236426</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital, College of Medicine, Zhejiang University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Diagnosed as novel coronavirus pneumonia (NCP) Patient:&lt;br&gt;1) Basis of diagnostic criteria: "Notice on Printing and Distributing Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Implementation Fourth Edition)" (National Health Office Medical Letter C2020377)&lt;br&gt;2019-nCoV diagnosis of pneumonia: &lt;br&gt;(1) Epidemiological history: A. Travel history or residence history in Wuhan area or other areas with continuous local case transmission within 14 days before onset; B. Contact history within 14 days before onset Patients with fever or respiratory symptoms from Wuhan City or other areas where local case transmission is ongoing; C. Aggregative onset or epidemiological association with new coronavirus infection. &lt;br&gt;(2) Clinical manifestations: A. fever; B. imaging characteristics of pneumonia: multiple small patchy shadows and interstitial changes in the early stage, which are obvious in the extrapulmonary zone, and then develop into multiple ground glass infiltrates and infiltrates, which are severe Patients may have pulmonary consolidation, and pleural effusion is rare; C. The total number of white blood cells is normal or reduced in the early stage of onset, or the lymphocyte count is reduced. &lt;br&gt;(3) Any one of the epidemiological history meets any two of the clinical manifestations as suspected cases, and those who have one of the following pathogenic evidence are confirmed cases: A. A new type of real-time fluorescence RT-PCR test for respiratory specimens or blood specimen Coronavirus-positive nucleic acid; B. Sequencing of viral genes in respiratory specimens or blood specimens, highly homologous to known new coronaviruses. &lt;br&gt;(4) It is severe if it meets any of the following: A. Respiratory distress, RR &gt; 30 beats / min; B. In resting state, means oxygen saturation &lt; 93%; C. Arterial partial pressure of oxygen (PaO2) / oxygen Concentration (FiO2) &lt;= 300mmHg (lmmHg = 0.133kPa).&lt;br&gt;(5) It is critical if it meets any of the following: 1) respiratory failure occurs and requires mechanical ventilation; 2) shock occurs; 3) combined organ failure requires ICU monitoring and treatment&lt;br&gt;2. The patient or legal donor agrees to participate in the study and signs an informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnant or lactating women;&lt;br&gt;2. There are comorbidities that affect the judgment of the efficacy, such as those with malignant tumors or long-term immunosuppressants;&lt;br&gt;3. The investigator believes that the patient has other conditions that are not suitable for enrollment;&lt;br&gt;4. Allergic to dimethyl sulfoxide (DMSO), dextran 40 or human albumin;&lt;br&gt;5. Contraindicated signs of artificial liver therapy</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group A:Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations;control gorup A:Conventional treatment;Experimental Group B1:Artificial liver therapy+conventional treatment;Experimental Group B2:Artificial liver therapy followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations+conventional treatment;Control Gorup A:Conventional treatment;</Intervention>
    <Primary_outcome>Mortality in patients;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029605</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of ovel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-07</Date_registration>
    <Date_registration3>20200207</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49051</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-06</Date_enrollement>
    <Target_size>Low dose group:100;Medium dose of group:100;High dose of group:100;Control group:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>Wuhan</Countries>
    <Contact_Firstname>Wang Daowen, Zhao Jianping</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>dwwang@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13971301060</Contact_Tel>
    <Contact_Affiliation>Department of Cardiovascular Medicine, Tongji Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;&lt;br&gt;2. Above 18 years old (inclusive);&lt;br&gt;3. Voluntarily sign written informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Severe pneumonia requires mechanical ventilationcritically severe cases;&lt;br&gt;2. Estimated Time of Death is less than 48 hours;&lt;br&gt;3. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development;&lt;br&gt;4. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory tracts diseases that affecting clinical trial evaluation . Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis;&lt;br&gt;5. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;&lt;br&gt;6. Mental state unable to cooperate, suffering from mental illness, unable to control, unable to express clearly&lt;br&gt;7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug;&lt;br&gt;8. Patients with a history of substance abuse or dependence;&lt;br&gt;9. Pregnant or lactating women;&lt;br&gt;10. Patients who participated in other clinical trials within the last 3 months;&lt;br&gt;11. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (NCP)</Condition>
    <Intervention>Low dose group:Shuanghuanglian 2 bottles/time, 3 times a day; Routine treatment.;Medium dose of group:Shuanghuanglian 4 bottles/time, 3 times a day; routine treatment.;High dose of group:Shuanghuanglian 6 bottles/time, 3 times a day; routine treatment.;Control group:Routine treatment;</Intervention>
    <Primary_outcome>Time to disease recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030255</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome</Public_title>
    <Scientific_title>Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Shanghai University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50089</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Routine treatment +  Jing-Yin Granule:200;Routine treatment :100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Liu Hua/Wang Qian</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1200 Cailun Road, Zhangjiang Hi-TechPark, Pudong New Area, Shanghai, China</Contact_Address>
    <Contact_Email>yyliuhua@126.com</Contact_Email>
    <Contact_Tel>+86 18930568010</Contact_Tel>
    <Contact_Affiliation>Shanghai University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia, clinical classification is ordinary or heavy;&lt;br&gt;2. TCM syndrome differentiation is wind-heat syndrome;&lt;br&gt;3. Aged between 18-75 years old, regardless of gender;&lt;br&gt;4. Voluntarily sign written informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development;&lt;br&gt;2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory tracts diseases that affecting clinical trial evaluation . Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis;&lt;br&gt;3. Severe pneumonia requires mechanical ventilation;&lt;br&gt;4. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;&lt;br&gt;5. Pregnant or lactating women;&lt;br&gt;6. Patients who participated in other clinical trials within the last 3 months;&lt;br&gt;7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug;&lt;br&gt;8. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Routine treatment +  Jing-Yin Granule:Jing-Yin Granule 2 bags / time, 3 times a day 	;Routine treatment :Treat as prescribed in the sixth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;</Intervention>
    <Primary_outcome>Clearance rate and time of main symptoms (fever, fatigue, cough);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030253</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid</Public_title>
    <Scientific_title>Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Ganzi Hospital of West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50143</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-27</Date_enrollement>
    <Target_size>Target condition:30;Difficult condition:30</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Cross-sectional</Study_design>
    <Phase>1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lijia Deng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>94 West Street, Kangding City, Ganzi Prefecture, Sichuan, China</Contact_Address>
    <Contact_Email>27216302@qq.com</Contact_Email>
    <Contact_Tel>+86 17723451376</Contact_Tel>
    <Contact_Affiliation>Ganzi Hospital of West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: suspected infection and Confirmed novel coronavirus patients</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Non Novel coronavirus suspected infection and Confirmed patients</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Detection of novel coronavirus by fluorescence RT-PCR;Index test:Detection&amp;#32;of&amp;#32;viral&amp;#32;nucleic&amp;#32;acids&amp;#32;in&amp;#32;eye&amp;#32;swabs,&amp;#32;throat&amp;#32;swabs,&amp;#32;oral&amp;#32;saliva,&amp;#32;feces,&amp;#32;urine&amp;#32;and&amp;#32;plasma;</Intervention>
    <Primary_outcome>SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029572</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial</Public_title>
    <Scientific_title>Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Xiangyang First People's Hospital</Primary_sponsor>
    <Date_registration>2020-02-05</Date_registration>
    <Date_registration3>20200205</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=41760</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-05</Date_enrollement>
    <Target_size>control group:15;experimental group:15;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Pei Bei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>15 Jiefang Road, Fancheng District, Xiangyang, Hubei, China </Contact_Address>
    <Contact_Email>xyxzyxzh@163.com</Contact_Email>
    <Contact_Tel>+86 18995678520</Contact_Tel>
    <Contact_Affiliation>Xiangyang First People's Hospital </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: On January 27, 2020, the general office of the national health commission and the office of the state administration of traditional Chinese medicine issued the pneumonia diagnosis and treatment plan for new coronavirus infection (trial version 4).&lt;br&gt;Only patients with severe and critical 2019-ncov were included in this study. &lt;br&gt;1. Patients with severe 2019-ncov according to the clinical stage met any of the following criteria: &lt;br&gt;(1) Respiratory distress, RR &gt;= 30 times/min; &lt;br&gt;(2) In resting state, oxygen saturation is less than 93%;&lt;br&gt;(3) Partial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) &lt;= 300mmHg (1mmHg= 0.133kpa);&lt;br&gt;2. According to the clinical stage of critical 2019-ncov, one of the following conditions is met: &lt;br&gt;(1) Respiratory failure occurs and mechanical ventilation is required; &lt;br&gt;(2) Shock;&lt;br&gt;(3) Combined with other organ failure, intensive care unit is required.&lt;br&gt;3. Other inclusion criteria: good compliance, willingness to cooperate with the study, and informed consent signed by the patient.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Have any known disease that seriously affects the immune system, such as a history of infection with the human immunodeficiency virus (HIV), or malignant tumors of the blood system or solid organs, or splenectomy;&lt;br&gt;2. Other circumstances that the researcher considers inappropriate to participate in this study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>control group:Conventional treatment;experimental group:conventional treatment combined with umbilical cord blood mononuclear cells group;</Intervention>
    <Primary_outcome>PSI;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029559</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Renmin Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-04</Date_registration>
    <Date_registration3>20200204</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48880</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>30</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-31</Date_enrollement>
    <Target_size>experimental group 1:100;experimental group 2:100;Placebo control group:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Zhan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>238 Jiefang Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>doctorzhang2003@163.com</Contact_Email>
    <Contact_Tel>+86 18962567610</Contact_Tel>
    <Contact_Affiliation>Renmin Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The investigator considers that the subject has other conditions that make him/her unsuitable to participate in the clinical trial or other special circumstances.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group 1:Hydroxychloroquine 0.1 oral 2/ day;experimental group 2:Hydroxychloroquine 0.2 oral 2/ day;Placebo control group:Starch pill oral 2/ day;</Intervention>
    <Primary_outcome>The time when the nucleic acid of the novel coronavirus turns negative;T cell recovery time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029603</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Zhejiang University School of Medicine</Primary_sponsor>
    <Date_registration>2020-02-06</Date_registration>
    <Date_registration3>20200206</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49075</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-06</Date_enrollement>
    <Target_size>Experimental group:80;Control group:80;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qiu Yunqing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>qiuyq@zju.edu.cn</Contact_Email>
    <Contact_Tel>+86 13588189339</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Zhejiang University School of Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-75 years old;&lt;br&gt;2. Patients with novel coronavirus infection pneumonia were confirmed by RT-PCR and clinical symptoms. The diagnostic criteria refer to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)";&lt;br&gt;3. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days);&lt;br&gt;4. Women and partners who have no planned pregnancy within the past six months, and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;&lt;br&gt;5. Agree not to participate in other clinical studies within 30 days from the first administration of the study drug to the last administration;&lt;br&gt;6. Patients who voluntarily signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with severe 2019-nCoV pneumonia met one of the following conditions: respiratory distress, RR &gt;= 30 times / min; or SaO2 / SpO2 &lt;= 93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt;= 300MMHG (1mmhg = 0.133kpa);&lt;br&gt;2. Patients with critical 2019-nCoV pneumonia met one of the following conditions: respiratory failure and mechanical ventilation required; or shock; or combined with other organ failure required ICU monitoring treatment;&lt;br&gt;3. Severe liver disease (such as child Pugh score &gt;= C, AST &gt; 5 times upper limit);&lt;br&gt;4. Patients were allergic to the components of ASC09 / ritonavir compound tablets;&lt;br&gt;5. Patients with definite contraindications in the label of ritonavir tablets;&lt;br&gt;6. Female subjects pregnancy test was positive during the screening period;&lt;br&gt;7. Patients who are taking HIV protease inhibitor drugs;&lt;br&gt;8. Physician judged the patient was not suitable for this clinical trial (for example, patient may be transferred to another hospital during the study period; patient with multiple basic diseases, etc.).</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional standardized treatment and ASC09/Ritonavir;Control group:Conventional standardized treatment and Lopinavir/Ritonavir;</Intervention>
    <Primary_outcome>The incidence of composite adverse outcome within 14 days after admission: Defined as (one of them) SPO2&lt;= 93% without oxygen supplementation, PaO2/FiO2 &lt;= 300mmHg or RR &lt;=30 breaths per minute.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029558</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province</Public_title>
    <Scientific_title>Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Hospital of Chengdu University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-04</Date_registration>
    <Date_registration3>20200204</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48792</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-29</Date_enrollement>
    <Target_size>single arm:200;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xie Chunguang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>xcg718@aliyun.com</Contact_Email>
    <Contact_Tel>+86 18980880132</Contact_Tel>
    <Contact_Affiliation>Hospital of Chengdu University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who meet the suspected and confirmed diagnostic criteria for the 2019-nCoV pneumonia version 4.0 of the National Health and Medical Commission (released 2020.01.27).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No exclusion criteria.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>single arm:Chinese medicine treatment combined with western medicine treatment;</Intervention>
    <Primary_outcome>blood routine;urine routines;CRP;PCT;ESR;creatase;troponin;myoglobin;D-Dimer;arterial blood gas analysis;Nucleic acid test for 2019-nCoV ;chest CT;Biochemical complete set;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030219</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-25</Date_registration>
    <Date_registration3>20200225</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50110</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>8</Inclusion_agemin>
    <Inclusion_agemax>91</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-21</Date_enrollement>
    <Target_size>Case series:120;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>New Treatment Measure Clinical Study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Bi Ying-fei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>88 Changling Road, Xiqing District, Tianjin, China</Contact_Address>
    <Contact_Email>yingfei1981@163.com</Contact_Email>
    <Contact_Tel>+86 13920648942</Contact_Tel>
    <Contact_Affiliation>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Any age;&lt;br&gt;2) Meet the diagnostic standard of COVID-19;&lt;br&gt;3) Voluntarily accept TCM syndrome differentiation treatment;&lt;br&gt;4) Agree to sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Liver and kidney dysfunction (alt, AST &gt; 2 times the upper limit of normal reference value or / and serum creatinine &gt; 2 times the upper limit of normal reference value);&lt;br&gt;2) Psychosis, or cognitive impairment;&lt;br&gt;3) Those who are unwilling to cooperate with information collection.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Integration of traditional Chinese and Western Medicine;</Intervention>
    <Primary_outcome>Clinical symptoms;TCM syndrome;Lung imaging;Time of nucleic acid turning negative;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030091</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)</Public_title>
    <Scientific_title>A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49914</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>15</Inclusion_agemin>
    <Inclusion_agemax>35</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-22</Date_enrollement>
    <Target_size>Experimental group:100;Control group:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>XIONG YAN</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>363 Furong Avenue, Wenjing District, Chengdu, Sichuan </Contact_Address>
    <Contact_Email>luyibingli@163.com</Contact_Email>
    <Contact_Tel>+86 18328737998</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Nursing student will be invited to participate in this research. Students will voluntarily participate in the study and ask for an informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: NONE</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Exercise prescription;Control group:none;</Intervention>
    <Primary_outcome>Mood index;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029544</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy</Public_title>
    <Scientific_title>A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>The First Hospital Affiliated to Zhejiang University's Medical School</Primary_sponsor>
    <Date_registration>2020-02-03</Date_registration>
    <Date_registration3>20200203</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49013</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-04</Date_enrollement>
    <Target_size>Experimental group 1:10;Experimental group 2:10;Control group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qiu Yunqing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>qiuyq@zju.edu.cn</Contact_Email>
    <Contact_Tel>+86 13588189339</Contact_Tel>
    <Contact_Affiliation>The First Hospital Affiliated to Zhejiang University's Medical School</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. 18 to 75 years of age, male or female, willing to sign informed consent;&lt;br&gt;2. Tested positive for novel coronavirus infection after the onset of symptoms using a real time polymerase chain reaction (RT-PCR)-based diagnostic assay;&lt;br&gt;3. At least 2 viral nucleic acid tests are still positive under current antiviral therapy;&lt;br&gt;4. No difficulty in swallowing the pills;&lt;br&gt;5. Willing to abide by the protocol.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Allergic constitution, known to be allergic to balosavir or farpiravir or pharmaceutical excipients;&lt;br&gt;2. Body weight &lt;40 kg;&lt;br&gt;3. Considered as severe disease: has an ongoing respiratory deficiency and subjected to invasive mechanical ventilation; or presence of shock; or admitted to the ICU due to complications;&lt;br&gt;4. Has known kidney dysfunction determined as CLcr&lt;60 mL/min;&lt;br&gt;5. Increase in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is more than 5 times the upper limit of normal; or increase in ALT or AST is more than 3 ULN and increase in total bilirubin more than 2 ULN;&lt;br&gt;6. In the investigator's judgment, there are other factors that may cause the subject to be forced to terminate the study, such as other serious illnesses, serious laboratory abnormalities, and other factors that may affect the safety of the subject or the collection of test data and blood samples.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group 1:current antiviral treatment+Baloxavir Marboxil  tablets;Experimental group 2:current antiviral treatment+fabiravir tablets;Control group:current antiviral treatment;</Intervention>
    <Primary_outcome>Time to viral negativity by RT-PCR;Time to clinical improvement;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029541</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-03</Date_registration>
    <Date_registration3>20200203</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48992</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>DRV/c group:40;LPV/r group:40;other group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang Xinghuan/Ke Hengning </Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>wangxinghuan@whu.edu.cn</Contact_Email>
    <Contact_Tel>+86 18971387168/+86 15729577635</Contact_Tel>
    <Contact_Affiliation>Zhongnan Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-65 years;&lt;br&gt;2. been Confirmed with 2019-nCoV pneumonia, hospitalized or will be hospitalized;&lt;br&gt;3. Sign the ICF;&lt;br&gt;4. no more than 10 days from the occurrence of relevant clinical symptoms to the diagnosis been confirmed.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Allergic history to study medicines;&lt;br&gt;2. ALT/AST &gt;5 UNL or Child-Pugh Class C;&lt;br&gt;3. Severely ill patients with life expectance &lt;48 hours;&lt;br&gt;4. Contraindication of DRV or thymosin;&lt;br&gt;5. Pregnancy testing positive for child-bearing woman;&lt;br&gt;6. Known HIV infection;&lt;br&gt;7. not adequate to be enrolled.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>DRV/c group:DRV/c (800mg/150mg QD) + Conventional treatment containing thymosin (1.6 mg SC QOD) ;LPV/r group:LPV/r (400mg/100mg bid) + Conventional treatment containing thymosin (1.6 mg SC QOD);other group:Conventional treatment containing thymosin (1.6 mg SC QOD) ;</Intervention>
    <Primary_outcome>Time to conversion of 2019-nCoV RNA result from RI sample;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029548</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital, Zhejiang University School of Medicine</Primary_sponsor>
    <Date_registration>2020-02-04</Date_registration>
    <Date_registration3>20200204</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49015</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-04</Date_enrollement>
    <Target_size>A:10;B:10;C:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yunqing Qiu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>qiuyq@zju.edu.cn</Contact_Email>
    <Contact_Tel>+86 13588189339</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital, Zhejiang University School of Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 75 years male or female, willing to sign the informed consent;&lt;br&gt;2. Tested positive for novel coronavirus infection after the onset of symptoms using a real time polymerase chain&lt;br&gt;reaction (RT-PCR)-based diagnostic assay;&lt;br&gt;3. Enrollment and initiation of study drug treatment &lt;=96 hours after onset of symptoms;&lt;br&gt;4. No difficulty in swallowing the pills;	&lt;br&gt;5. Willing to abide by the protocol.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Hypersensitive to study drug;&lt;br&gt;2. Body weight &lt;40 kg;&lt;br&gt;3. Considered as severe disease: has an ongoing respiratory deficiency and subjected to invasive mechanical ventilation; or presence of shock; or admitted to the ICU due to complications;&lt;br&gt;4. Has known kidney dysfunction determined as CLcr&lt;60 mL/min;&lt;br&gt;5. Increase in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is more than 5 times the upper limit of normal; or increase in ALT or AST is more than 3 ULN and increase in total bilirubin more than 2 ULN;&lt;br&gt;6. Pregnancy or breastfeeding,or positive pregnancy test in a predose examination, or have a plan to be pregnant within 3 months after the study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>A:BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.;B:Favipiravir: 600 mg tid with 1600mg first loading dosage for no more than 14 days.;C:Lopinavir-Ritonavir: 2# (200mg/50 mg), twice daily, for 14days.;</Intervention>
    <Primary_outcome>Time to viral negativityby RT-PCR;Time to clinical improvement: Time from start of study drug to hospital discharge or to NEWS2&lt;2 for 24 hours.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029461</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine</Primary_sponsor>
    <Date_registration>2020-02-02</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48927</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>experimental group:50;Control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wenguang Xia</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>docxwg@163.com</Contact_Email>
    <Contact_Tel>+86 13377897278</Contact_Tel>
    <Contact_Affiliation>1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);The classification was judged as common type;&lt;br&gt;2. aged 18-70 years old;&lt;br&gt;3. patients with clear consciousness;&lt;br&gt;4. Signing the informed consent form.  </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; &lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. Patients who have mental confusion, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:TCM decoctions+basic conventional therapy;Control group:basic conventional therapies;</Intervention>
    <Primary_outcome>pulmonary function;Antipyretic time;Time of virus turning negative;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030042</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled due to lack of patient                                                                A Medical Records Based Study for Construction and Analysis of Diagnosis Predictive&amp;</Public_title>
    <Scientific_title>A Medical Records Based Study for Construction and Analysis of Diagnosis Predictive Model of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Chongqing Liangjiang New Area first people's Hospital</Primary_sponsor>
    <Date_registration>2020-02-21</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49899</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>99</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-21</Date_enrollement>
    <Target_size>Case series:240;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chen Hao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>116 North Street, Guixi Street, Dianjiang, Chongqing, China</Contact_Address>
    <Contact_Email>1041863309@qq.com</Contact_Email>
    <Contact_Tel>+86 023 61103649</Contact_Tel>
    <Contact_Affiliation>Chongqing Dianjiang County People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Novel coronavirus pneumonia real-time fluorescence RT-PCR virus nucleic acid detection cases were detected in all centers.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Children (less than 14 years old);&lt;br&gt;2) lack of important case information (such as blood routine, C-reactive protein, epidemic history, chest CT, etc.).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>ROC;calibration curve;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029975</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>The First Hospital of Jilin University</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49592</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Experimental group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hua Shucheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>71 Xinmin Street, Changchun, Jilin, China</Contact_Address>
    <Contact_Email>shuchenghua@126.com</Contact_Email>
    <Contact_Tel>+86 13756661209</Contact_Tel>
    <Contact_Affiliation>The First Hospital of Jilin University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: A novel coronavirus pneumonia patient who was more than 18 years old and agreed to participate in the trial and signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Known to be allergic to hydroxychloroquine or 4-aminoquinoline;&lt;br&gt;2. Patients with severe renal insufficiency (EGFR &lt; = 30 ml / min / 1.73 m2) and RRT;&lt;br&gt;3. Severe liver disease (child Pugh score &gt; =C,Ast &gt; 5 times of the upper limit);&lt;br&gt;4. Suffering from retinopathy;&lt;br&gt;5. History of epilepsy;&lt;br&gt;6.G6PD deficiency;&lt;br&gt;7. Pregnancy or lactation;&lt;br&gt;8. Patients taking tamoxifen;&lt;br&gt;9. Doctors judged that this study was not in the interests of patients;&lt;br&gt;10. Transfer to another hospital which is not the study site within 72 hours;&lt;br&gt;11. Receive any trial treatment drug (off label, compassionate use or trial related) for 2019-ncov within 30 days prior to screening evaluation.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Chloroquine phosphate;</Intervention>
    <Primary_outcome>viral negative-transforming time;30-day cause-specific mortality;co-infections;Time from severe and critical patients to clinical improvement;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04259892</TrialID>
    <Last_Refreshed_on>24 February 2020</Last_Refreshed_on>
    <Public_title>Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection</Public_title>
    <Scientific_title>Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection</Scientific_title>
    <Acronym>Cov-CONTACT</Acronym>
    <Primary_sponsor>Institut National de la Sant Et de la Recherche Mdicale, France</Primary_sponsor>
    <Date_registration>05/02/2020</Date_registration>
    <Date_registration3>20200205</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04259892</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 4, 2020</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>France</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Xavier Duval, MD;Xavier Duval, MD;Xavier Duval, MD</Contact_Lastname>
    <Contact_Email>;xavier.duval@aphp.fr;xavier.duval@aphp.fr</Contact_Email>
    <Contact_Tel>;01 40 25 71 48;01 40 25 71 48</Contact_Tel>
    <Contact_Affiliation>Institut National de la Sant Et de la Recherche Mdicale, France;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  High/moderate risk contact with a laboratory-confirmed 2019-nCoV case&lt;br&gt;&lt;br&gt;          -  Undergoing standard sanitary surveillance by Sant Publique France&lt;br&gt;&lt;br&gt;          -  Written informed consent for patients = 18 years&lt;br&gt;&lt;br&gt;          -  Written informed consent of both parents for patients &lt; 18 years&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subject deprived of freedom&lt;br&gt;&lt;br&gt;          -  Subject under a legal protective measure&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus</Condition>
    <Intervention>Biological: 2019-nCoV PCR</Intervention>
    <Primary_outcome>Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04264858</TrialID>
    <Last_Refreshed_on>24 February 2020</Last_Refreshed_on>
    <Public_title>Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients</Public_title>
    <Scientific_title>An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Wuhan Union Hospital, China</Primary_sponsor>
    <Date_registration>08/02/2020</Date_registration>
    <Date_registration3>20200208</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04264858</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 17, 2020</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Volunteers who have understood and signed the informed consent;&lt;br&gt;&lt;br&gt;          2. Age =18 years, gender unlimited;&lt;br&gt;&lt;br&gt;          3. Patients diagnosed with acute severe 2019-nCoV pneumonia:&lt;br&gt;&lt;br&gt;               1. Laboratory (RT-PCR) confirmed infection with 2019-nCoV.&lt;br&gt;&lt;br&gt;               2. Lung involvement confirmed with pulmonary CT scan.&lt;br&gt;&lt;br&gt;               3. At least one of the following conditions should be met: respiratory distress, RR&lt;br&gt;                  = 30 times/min; oxygen saturation = 93% in resting state; PaO2/FiO2 = 300mmHg;&lt;br&gt;                  respiratory failure and mechanical ventilation are required; shock occurs; ICU&lt;br&gt;                  monitoring and treatment is required in combination with other organ failure.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Viral pneumonia with other viruses besides 2019-nCoV.&lt;br&gt;&lt;br&gt;          2. Patients are not suitable for immunoglobulin therapy.&lt;br&gt;&lt;br&gt;          3. Participation in other studies.&lt;br&gt;&lt;br&gt;          4. Other circumstances in which the investigator determined that the patient is not&lt;br&gt;             suitable for the clinical trial.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV;Immunoglobulin of Cured Patients</Condition>
    <Intervention>Drug: Immunoglobulin of cured patients;Drug: ?-Globulin</Intervention>
    <Primary_outcome>Time to Clinical Improvement (TTCI)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04268537</TrialID>
    <Last_Refreshed_on>24 February 2020</Last_Refreshed_on>
    <Public_title>Immunoregulatory Therapy for 2019-nCoV</Public_title>
    <Scientific_title>Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Southeast University, China</Primary_sponsor>
    <Date_registration>08/02/2020</Date_registration>
    <Date_registration3>20200208</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04268537</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 10, 2020</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). </Study_design>
    <Phase>Phase 2</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Adult SARI patients with 2019-ncov infection confirmed by PCR;&lt;br&gt;&lt;br&gt;          2. Absolute value of lymphocytes &lt; 0. 6x 109/L;&lt;br&gt;&lt;br&gt;          3. Severe respiratory failure within 48 hours and requires admission to ICU. (severe&lt;br&gt;             respiratory failure was defined as PaO2/FiO2 &lt; 200 mmHg and was supported by positive&lt;br&gt;             pressure mechanical ventilation (including non-invasive and invasive mechanical&lt;br&gt;             ventilation, PEEP&gt;=5cmH2O))&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age &lt; 18&lt;br&gt;&lt;br&gt;          2. Pregnant&lt;br&gt;&lt;br&gt;          3. Allergic to experimental drugs&lt;br&gt;&lt;br&gt;          4. The underlying disease is very serious and the expected survival time is less than 6&lt;br&gt;             months (such as advanced malignant tumor);&lt;br&gt;&lt;br&gt;          5. COPD or end-stage lung disease requires home oxygen therapy&lt;br&gt;&lt;br&gt;          6. Expected survival time not exceeding 48 hours&lt;br&gt;&lt;br&gt;          7. Participated in other clinical intervention trials within the last 3 months&lt;br&gt;&lt;br&gt;          8. Autoimmune diseases&lt;br&gt;&lt;br&gt;          9. A history of organ, bone marrow or hematopoietic stem cell transplantation 10.&lt;br&gt;             Received radiotherapy and chemotherapy for malignant tumor within 6 months&lt;br&gt;&lt;br&gt;        11.HIV infected patients or diagnosed with acquired immunodeficiency within the past year&lt;br&gt;        (CD4 T cells &lt;=200/mm3) 12. Patients receiving anti-hcv treatment 13.90 days of retinal&lt;br&gt;        detachment or eye surgery 14. Permanent blindness in one eye 15. History of iritis,&lt;br&gt;        endophthalmitis, scleral inflammation or retinitis 16. The competent physician considered&lt;br&gt;        it inappropriate to participate in the study&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019 nCoV, PD-1</Condition>
    <Intervention>Drug: PD-1 blocking antibody+standard treatment;Drug: Thymosin+standard treatment;Other: standard treatment</Intervention>
    <Primary_outcome>lung injury score</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030179</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Nanchang University</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50059</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Experimental group:50;Control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>New Treatment Measure Clinical Study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Le Aiping</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>17 Yongwai Main Street, Nanchang, Jiangxi, China</Contact_Address>
    <Contact_Email>leaiping@126.com</Contact_Email>
    <Contact_Tel>+86 13707089009</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Nanchang University </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) The confirmed patient (or legal guardian) agrees to participate in the study and signs the informed consent form;&lt;br&gt;2) aged 18 to 65 years;&lt;br&gt;3) Real-time fluorescent RT-PCR of respiratory specimens or blood specimens to detect patients with new type of coronavirus positive;&lt;br&gt;4) Patients diagnosed as severe and critically ill and with rapid disease progression according to the "Diagnosis and Treatment Program for Pneumonia of New Coronavirus Infection (Trial Version 6)".</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Any situation where the solution cannot be carried out safely;&lt;br&gt;2) Allergic constitution, allergic to plasma or drugs;&lt;br&gt;3) Being too old with severe underlying diseases that affect survival, including uncontrolled clinically significant heart, lung, kidney, digestive, hematological, neuropsychiatric, immune, metabolic, or malignant tumors, Severe malnutrition, etc.;&lt;br&gt;4) Patients with severe respiratory failure, heart failure, and multiple organ failure;&lt;br&gt;5) Participants in other clinical trials.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Routine treatment + plasma treatment;Control group:Routine treatment;</Intervention>
    <Primary_outcome>Cure rate;Mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029487</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children</Public_title>
    <Scientific_title>Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Wuhan Hospital of Integrated Traditional Chinese and Western Medicine</Primary_sponsor>
    <Date_registration>2020-02-02</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48965</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Experimental group:100;Control group:100;</Target_size>
    <Study_type>Prevention</Study_type>
    <Study_design>Case-Control study</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Su Wen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>784404524@qq.com</Contact_Email>
    <Contact_Tel>+86 13659897175</Contact_Tel>
    <Contact_Affiliation>Wuhan Hospital of Integrated Traditional Chinese and Western Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Healthy children between the ages of 1 and 18 who meet the TCM constitutional doctrine:&lt;br&gt;(1) Main features: moderate body shape, ruddy complexion, energetic, etc .;&lt;br&gt;(2) Common manifestations: Symmetric body shape, complexion, moisturized complexion, thick and shiny hair, bright eyes, clear nose, moist olfactory, rosy lips, not easy to fatigue, energetic, cold and heat tolerance, good sleep, stomach Najia, the second stool is normal, the tongue is reddish, the moss is thin and white, the veins are gentle and strong, and the fingerprint is faint purple. Lively and cheerful character. Usual disease is less common.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Clinical suspected or confirmed cases [Refer to the recommendations for diagnosis and treatment of 2019-nCoV infection in children in Hubei Province (trial version 1)]&lt;br&gt;2. Those who have received other traditional Chinese medicine, proprietary Chinese medicines or immunomodulators to prevent new coronavirus pneumonia;&lt;br&gt;3. Participants in clinical trials of other drugs in the past 12 weeks;&lt;br&gt;4. People with other serious primary diseases such as cardiovascular and cerebrovascular diseases, liver and kidney or hematopoietic diseases, genetic metabolic diseases;&lt;br&gt;5. Those who are known to be allergic to the test drug and its ingredients;&lt;br&gt;6. Other constitutions in TCM constitution theory.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19) in children</Condition>
    <Intervention>Experimental group:Isolation and oral  Gubiao Jiedu Ling Chinese medicine;Control group:Isolated observation;</Intervention>
    <Primary_outcome>body temperature;Whole blood count and five classifications;C-reactive protein;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029468</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A real-world  study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>The early use of lopinavir/litonavir (LPV/r) and emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19): a real-world study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Institute of Emergency Medicine and Disaster Medicine Sichuan People's Hospital, Sichuan Academy of Medical Sciences</Primary_sponsor>
    <Date_registration>2020-02-02</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48919</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>experimental group:60;Historical Control:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jiang Hua</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>32 Second Section, First Ring Road West, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>cdjianghua@qq.com</Contact_Email>
    <Contact_Tel>+86 028 87393881</Contact_Tel>
    <Contact_Affiliation>Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. diagnosis of 2019-new coronavirus (2019-nCoV) pneumonia;&lt;br&gt;2. adult patients aged 18-80 years old.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. ARDS was developed after infection without antiviral treatment;&lt;br&gt;2. suffering from HBV, HIV, pancreatitis, intrahepatic bile duct stones or having the previous history mentioned above ;&lt;br&gt;3. severe heart, liver, kidney and respiratory diseases before infection;&lt;br&gt;4. history of metabolic and endocrine diseases such as osteoporosis;&lt;br&gt;5. pregnant or nursing women;&lt;br&gt;6. those who are unable to cooperate in mental state, suffer from mental disease, have no self-control and cannot express clearly;&lt;br&gt;7. participating in other clinical trials.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Lopinavir/litonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination;Historical Control:LPV/r;</Intervention>
    <Primary_outcome>Patient survival rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029460</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period</Public_title>
    <Scientific_title>The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine</Primary_sponsor>
    <Date_registration>2020-02-02</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48930</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-02</Date_enrollement>
    <Target_size>experimental group:50;Control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chanjuan Zheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>chanjuanzheng@163.com</Contact_Email>
    <Contact_Tel>+86 18971317115</Contact_Tel>
    <Contact_Affiliation>1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);&lt;br&gt;2. virus turned negative after treatment;&lt;br&gt;3. aged 18-70 years old;&lt;br&gt;4. patients with clear consciousness&lt;br&gt;5. Signing the informed consent form.  </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; &lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. Patients who have mental confusion, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:shadowboxing +conventional treatment;Control group:conventional treatments;</Intervention>
    <Primary_outcome>pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;Incidence of adverse events;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029459</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>The effect of pulmonary rehabilitation for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period</Public_title>
    <Scientific_title>Pulmonary rehabilitation to improve pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>1.Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine</Primary_sponsor>
    <Date_registration>2020-02-02</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48929</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>experimental group:50;control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wenguang Xia</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>docxwg@163.com</Contact_Email>
    <Contact_Tel>+86 13377897278</Contact_Tel>
    <Contact_Affiliation>1.Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);&lt;br&gt;2. virus turned negative after treatment;&lt;br&gt;3. aged 18-70 years old;&lt;br&gt;4. patients with clear consciousness;&lt;br&gt;5. Signing the informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; &lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. Patients with mental confusion, with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.</Exclusion_Criteria>
    <Condition>new coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Pulmonary rehabilitation+Conventional treatment;control group:Conventional treatment;</Intervention>
    <Primary_outcome>pulmonary function;St Georges respiratory questionnaire, SGRQ;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029762</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled due to lack of patient                                                                              Clinical study for the effect and</Public_title>
    <Scientific_title>A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Chongqing Medical University</Primary_sponsor>
    <Date_registration>2020-02-12</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49404</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wenxiang Huang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, China</Contact_Address>
    <Contact_Email>wenxiang_huang@163.com</Contact_Email>
    <Contact_Tel>+86 13883533808</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Chongqing Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Subjects who meet the following conditions can become subjects of this study:&lt;br&gt;1. Sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian;&lt;br&gt;2. Chinese aged &gt;=18 years;&lt;br&gt;3. It complies with the NCP Critical and Critical Diagnostic Standards, namely "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5). Combined with the following epidemiological history, clinical manifestations, and pathogenic examinations to make a comprehensive judgment.&lt;br&gt;4. The course of disease is within 14 days after the onset of illness;&lt;br&gt;5. Will take nasopharyngeal or oropharyngeal swabs before administration.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with any of the following were excluded from the study:&lt;br&gt;1. Patients with previous allergy to 4-aminoquinoline compounds;&lt;br&gt;2. Patients with previous severe retinal or visual field related diseases;&lt;br&gt;3. Patients with severe liver damage;&lt;br&gt;4. Patients with impaired renal function (creatinine clearance &lt;=50 mL / min);&lt;br&gt;5. Patients weighing &lt;35kg;&lt;br&gt;6. Patients exposed to other study drugs within 30 days before administration;&lt;br&gt;7. Being pregnant or breastfeeding. Or have a pregnancy plan (including partner) within one month.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional treatent and hydroxychloroquine;Control group:Conventional treatment;</Intervention>
    <Primary_outcome>Negative conversion rate of COVID-19 nucleic acid;Lung inflammation absorption ratio;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029760</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled due to lack of patient                              A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases</Public_title>
    <Scientific_title>A randomized controlled study to evaluate the efficacy and safety of hydroxychloroquine for mild and moderate COVID-19 Infectious diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The Second Affiliated Hospital of Chongqing Medical University</Primary_sponsor>
    <Date_registration>2020-02-12</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49369</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>Experimental group:120;Control group:120;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Huawei Mao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>136 Second Zhongshan Road, Yuzhong District, Chongqing, China</Contact_Address>
    <Contact_Email>maohwei@qq.com</Contact_Email>
    <Contact_Tel>+86 13928459556</Contact_Tel>
    <Contact_Affiliation>Chongqing Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Informed consent offered;&lt;br&gt;2. Confirmed infection with 2019-nCoV by RT-PCR;&lt;br&gt;3. Compliance with the intervention of study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Known allergic to hydroxychloroquine or 4-aminoquinoline;&lt;br&gt;2. Severe renal impairment (eGFR &lt;= 30 mL/min/1.73 m2), and those with RRT;&lt;br&gt;3. Severe liver disease (Child Pugh score &gt;= C, AST&gt;5 times upper limit);&lt;br&gt;4. Pre-existing retinopathy of the eye;&lt;br&gt;5. History of epilepsy;&lt;br&gt;6. G6PD deficiency;&lt;br&gt;7. Pregnant or breastfeeding; &lt;br&gt;8. Patients taking tamoxifen;&lt;br&gt;9. The study not in patients' best interests judged by the physician. </Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Hydroxychloroquin;Control group:Lopinavir /Ritonavir;</Intervention>
    <Primary_outcome>Time to clinical recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030164</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU</Public_title>
    <Scientific_title>A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Wuhan Jin Yin-tan hospital</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49983</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Case series:10;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>You Shang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>you_shang@126.com</Contact_Email>
    <Contact_Tel>+86 15972127819</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All patients with SARS-CoV-2 pneumonia in the ICU</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: none</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:N/A;</Intervention>
    <Primary_outcome>the daily treatment intensity;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030113</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir</Public_title>
    <Scientific_title>Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>The Third People's Hospital of Shenzhen</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49988</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-22</Date_enrollement>
    <Target_size>Control group:15;Experimental group:15;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Liu Yingxia</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>29 Bulan Road, Logngang District, Shenzhen, Guangdong, China</Contact_Address>
    <Contact_Email>yingxialiu@hotmail.com</Contact_Email>
    <Contact_Tel>+86 755 61238922</Contact_Tel>
    <Contact_Affiliation>Shenzhen the 3rd People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. 16 to 75 years of age, male or female;&lt;br&gt;2. Respiratory or blood samples tested positive for novel coronavirus;&lt;br&gt;3. A novel coronavirus nucleic acid was detected in respiratory or anal swabs after 10 days of standard treatment with roranavir / ritonavir;&lt;br&gt;4. Willing to take contraception during the study and within 7 days after treatment;&lt;br&gt;5. No difficulty in swallowing the Pills;&lt;br&gt;6. Willing to sign informed consent form. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Any situation which the protocol cannot be carried out safely;&lt;br&gt;2. Patient refuses to receive invasive tracheal support (if needed);&lt;br&gt;3. Pregnant or lactating women:childbearing age women with positive pregnancy test, breastfeeding, miscarriage or within 2 weeks after delivery.Postmenopausal and hysterectomy women do not need a pregnancy test;&lt;br&gt;4. Patients with chronic liver and kidney disease and reaching end-stage;&lt;br&gt;5. Previous history of allergic reactions to Fapiravir or Lopinavir and Ritonavir;&lt;br&gt;6. After the investigator's judgment, the subjects could not participate the study protocol, follow-up or self-evaluation after enrollment. </Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Keep ritonavir/ritonavir treatment;Experimental group:Favipiravir;</Intervention>
    <Primary_outcome>Blood routine tests, Liver function examination, Renal function examination, Blood gas analysis, Chest CT examination;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029437</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Hubei Provincial Integrated Hospital of traditional Chinese and Western Medicine</Primary_sponsor>
    <Date_registration>2020-02-01</Date_registration>
    <Date_registration3>20200201</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48913</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>Case series:300;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xia Wenguang, An Changqing, Zhang Boli</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>DOCXWG@16.COM</Contact_Email>
    <Contact_Tel>+86 13902020873</Contact_Tel>
    <Contact_Affiliation>Hubei integrated hospital of traditional Chinese and Western Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Inpatient patients diagnosed as neumonia caused by new coronavirus infection.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Doctor's judgment is not suitable for the study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:according to guidelines;</Intervention>
    <Primary_outcome>all available outcome;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029435</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population</Public_title>
    <Scientific_title>Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Wuhan 1st Hospital</Primary_sponsor>
    <Date_registration>2020-02-01</Date_registration>
    <Date_registration3>20200201</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48827</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>60</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Community exposure TCM intervention group:20;Community exposure control group:20;Hospital exposure TCM intervention group:20;Hospital exposure control group:20;Community suspected TCM intervention group:20;Community suspected control group:20;Hospital su</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wei Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>whsdyyykjc@126.com</Contact_Email>
    <Contact_Tel>+86 13163283819</Contact_Tel>
    <Contact_Affiliation>Wuhan 1st Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. aged 18 to 60 years&lt;br&gt;2. to be confirmed with a exposure history of diagnosed population within last 14 days;&lt;br&gt;3. with fever, positive results of blood routine examination and positive findings in CT examination, any two in three items met.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnancy or lactation;&lt;br&gt;2. Previous serious chronic basic diseases;&lt;br&gt;3. Previous allergy to traditional Chinese medicine;&lt;br&gt;4. Newly diagnosed 2019-nCOV pneumonia.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Community exposure TCM intervention group:TCM intervention;Community exposure control group:Placebo;Hospital exposure TCM intervention group:TCM intervention;Hospital exposure control group:Placebo;Community suspected TCM intervention group:TCM intervention;Community suspected control group:Placebo;Hospital suspected TCM intervention group:TCM intervention;Hospital suspected control group:Placebo;</Intervention>
    <Primary_outcome>Viral nucleic acid detection;CT Scan of the Lungs;Blood routine examination;Temperature;Height;Weight;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029439</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Combination of traditional Chinese medicine and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Combination of traditional chinese medicne and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese MedHubei integrated traditional Chinese and Western Medicine Hospital</Primary_sponsor>
    <Date_registration>2020-02-01</Date_registration>
    <Date_registration3>20200201</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48904</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-02</Date_enrollement>
    <Target_size>control group:60;experimental group:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>WANG YUGUANG, LI XUCHENG, ZHANG BOLI</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>23 Back Street of Art Gallery, Dongcheng District, Beijing/11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>ZJHTCM@FOXMAIL.COM</Contact_Email>
    <Contact_Tel>+86 13902020873</Contact_Tel>
    <Contact_Affiliation>Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);&lt;br&gt;2) The classification was judged as common type;&lt;br&gt;3) Informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Pregnant or lactating women;&lt;br&gt;2) Severe basic diseases that affect survival;&lt;br&gt;3) Other problems thant doctor's judgment is not suitable for the study;&lt;br&gt;4) Patients have difficulty in taking TCM standard decoctions.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>control group:basic western medical therapies;experimental group:TCM standard decoctions+basic western medical therapies;</Intervention>
    <Primary_outcome>Antipyretic time;Time of virus turning negative;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029381</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Guangzhou Medical University</Primary_sponsor>
    <Date_registration>2020-01-27</Date_registration>
    <Date_registration3>20200127</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48768</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-24</Date_enrollement>
    <Target_size>Group 1:200;Group 2:200;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhong Nanshan / Song Yuanlin/Qiu Haibo/Li Yimin/Liu Xiaoqinqing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>ylsong70@163.com</Contact_Email>
    <Contact_Tel>+86 020 34294311</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Guangzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. New coronavirus-infected pneumonia confirmed by pathogenic detection;&lt;br&gt;2. Meet the diagnostic criteria for community-acquired pneumonia (based on 2019 ATS/IDSA diagnostic criteria);&lt;br&gt;3. Pneumonia Severity Index (PSI) III-V or Oxygenation Index (P/F)&lt;=300 mmHg;&lt;br&gt;4. Aged 18 to 75 years;&lt;br&gt;5. Obtain informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnancy or lactating women;&lt;br&gt;2. People with allergies or allergies to Xuebijing injection and its components;&lt;br&gt;3. Severe basic diseases that affect survival, including: uncontrolled malignant tumors with multiple metastases that cannot be removed, hematological diseases, cachexia, active bleeding, severe malnutrition, HIV, etc.;&lt;br&gt;4. Obstructive pneumonia caused by lung tumors, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic reaction alveolitis;&lt;br&gt;5. Previous immunosuppressive agents within 6 months before study entry or recipients of a solid-organ or bone marrow transplant;&lt;br&gt;6. Extracorporeal life support (ECMO, ECCO2R, RRT);&lt;br&gt;7. Expected to die within 48 hours.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 1:Xuebijing Injiection;Group 2:Conventional treatment;</Intervention>
    <Primary_outcome>pneumonia severity index (PSI);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04286503</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>The Clinical Study of Carrimycin on Treatment Patients With COVID-19</Public_title>
    <Scientific_title>The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Beijing YouAn Hospital</Primary_sponsor>
    <Date_registration>25/02/2020</Date_registration>
    <Date_registration3>20200225</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04286503</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 23, 2020</Date_enrollement>
    <Target_size>520</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 4</Phase>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Ronghua Jin;Huiguo Ding</Contact_Lastname>
    <Contact_Email>;dinghuiguo@medmail.com.cn</Contact_Email>
    <Contact_Tel>;+86-13911683832</Contact_Tel>
    <Contact_Affiliation>Beijing YouAn Hospital;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Subjects or their legal representatives have signed the informed consent form(ICF);&lt;br&gt;             agree not to participate in other clinical studies within 30 days after the last&lt;br&gt;             administration from the first administration of the study drug.&lt;br&gt;&lt;br&gt;          2. Subjects are aged = 18 and = 75;&lt;br&gt;&lt;br&gt;          3. Meet the diagnostic criteria for 2019-nCoV pneumonia (V5.0);&lt;br&gt;&lt;br&gt;          4. SOFA score: 1 ~ 13 points.&lt;br&gt;&lt;br&gt;          5. A retreated patient or the relapsed patient meets any of the following criteria:&lt;br&gt;&lt;br&gt;               -  Have fever again or aggravated clinical symptoms; ? 2019nCOVRNA in the throat&lt;br&gt;                  swabs converts from negative to positive; ? The clinical symptoms don't improve&lt;br&gt;                  or 2019nCOVRNA continues to be positive; ? The chest CT shows pneumonia or&lt;br&gt;                  fibrosis progression.&lt;br&gt;&lt;br&gt;        Clinical stratification:&lt;br&gt;&lt;br&gt;          1. Mild type: clinical symptoms mild or asymptomatic, no pneumonia performance in CT, but&lt;br&gt;             positive 2019-nCoV in throat swabs or gargle.&lt;br&gt;&lt;br&gt;          2. Ordinary type: fever, respiratory symptoms, etc., pneumonia performance visible in CT.&lt;br&gt;&lt;br&gt;          3. Severe type: meeting any of the following criteria:&lt;br&gt;&lt;br&gt;        (1) Respiratory distress, RR=30 times/min; (2) Finger oxygen saturation =93% in rest state;&lt;br&gt;        (3) Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation&lt;br&gt;        (FiO2)=300mmHg (1mmHg=0.133kPa).&lt;br&gt;&lt;br&gt;        4. Critical type: meeting any of the following criteria:(1)Respiratory failure occurs and&lt;br&gt;        mechanical ventilation is required;(2)Patients go into shock;(3)ICU is needed for other&lt;br&gt;        organ failure.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Other viral pneumonia&lt;br&gt;&lt;br&gt;          2. Patients who have received tumor immunotherapy (such as PD-1/L1, CTLA4, etc.) in the&lt;br&gt;             past 1 month, and inflammatory factor modulators such as Ulinastatin;&lt;br&gt;&lt;br&gt;          3. Patients who have taken anti-bacterial drugs such as macrolide in the past 1 week;&lt;br&gt;&lt;br&gt;          4. Patients who have received organ transplantation or surgery planning in the past 6&lt;br&gt;             months;&lt;br&gt;&lt;br&gt;          5. Patients who can't take food or drugs due to coma or intestinal obstruction;&lt;br&gt;&lt;br&gt;          6. Patients who have severe underlying diseases that affects survival, including&lt;br&gt;             uncontrolled malignant tumor with multiple metastases that cannot be resected, blood&lt;br&gt;             diseases, dyscrasia, active bleeding, severe malnutrition, etc.&lt;br&gt;&lt;br&gt;          7. Women subjects that are pregnant or lactating, or subjects (including male subjects)&lt;br&gt;             having a pregnancy plan (including plans for sperm donation or egg donation), or&lt;br&gt;             subjects that may fail to take effective contraceptive measures within the next 6&lt;br&gt;             months;&lt;br&gt;&lt;br&gt;          8. Patients with allergic constitution, or patients allergic to macrolides and&lt;br&gt;             lopinavir/ritonavir tablets;&lt;br&gt;&lt;br&gt;          9. Patients with contraindications to lopinavir/ritonavir tablets who plan or are using&lt;br&gt;             drugs that interact with the drug (including: drugs that are highly dependent on CYP3A&lt;br&gt;             clearance and whose elevated plasma concentrations can be associated with severe&lt;br&gt;             and/or life-threatening events [with a narrow therapeutic index], CYP3A inducer [see&lt;br&gt;             instruction for details]) and cannot stop using or use other drugs instead;&lt;br&gt;&lt;br&gt;         10. Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total&lt;br&gt;             bilirubin is 3 times higher than the upper limit of normal, or patients with&lt;br&gt;             child-Pugh grade C cirrhosis.&lt;br&gt;&lt;br&gt;         11. ECLS (ECMO, ECCO2R, RRT)&lt;br&gt;&lt;br&gt;         12. Critical patients with expected life&lt;48 hours&lt;br&gt;&lt;br&gt;         13. Patients who have participated in any other clinical study within 1 month;&lt;br&gt;&lt;br&gt;         14. The investigators conclude that the patients not suitable for the study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Novel Coronavirus Infectious Disease (COVID-19)</Condition>
    <Intervention>Drug: Carrimycin;Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate;Drug: basic treatment</Intervention>
    <Primary_outcome>Fever to normal time (day);Pulmonary inflammation resolution time (HRCT) (day);Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030581</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>The immediate psychological impact of novel coronavirus pneumonia (COVID-19) outbreak on medical students in anesthesiology and how the cope</Public_title>
    <Scientific_title>The immediate psychological impact of novel coronavirus pneumonia (COVID-19) outbreak on medical students in anesthesiology and how the cope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-03-08</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50394</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>35</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-02</Date_enrollement>
    <Target_size>Case series:192;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yunxia Zuo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>zuoyunxiahxa@qq.com</Contact_Email>
    <Contact_Tel>+86 18980601541</Contact_Tel>
    <Contact_Affiliation>Department of Anesthesiology, West China School of Medicine, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: medical students in anesthesiology department</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:observation;</Intervention>
    <Primary_outcome>intrusion;avoidance;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029430</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Study for the TCM syndrome characteristics of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>An epidemiology study for TCM syndrome  of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Hubei Integrated Hospital of Traditional Chinese and Western Medicine</Primary_sponsor>
    <Date_registration>2020-02-01</Date_registration>
    <Date_registration3>20200201</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48902</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>Case series:600;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>ZHANG ZHONGDE, ZHANG BOLI</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>10 Poyang Lake Road, Jinghai District, Tianjin, China</Contact_Address>
    <Contact_Email>ZJHTCM@FOXMAIL.COM</Contact_Email>
    <Contact_Tel>+86 13902020873</Contact_Tel>
    <Contact_Affiliation>Tianjin University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with Confirmed 2019-nCoV infected pneumonia</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: NA</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>TCM syndroms;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029400</TrialID>
    <Last_Refreshed_on>17 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>China Academy of Chinese Medical Sciences</Primary_sponsor>
    <Date_registration>2020-01-29</Date_registration>
    <Date_registration3>20200129</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48824</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-29</Date_enrollement>
    <Target_size>Group A:20;Group B:20;Group C:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Huang Luqi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China</Contact_Address>
    <Contact_Email>huangluqi01@126.com</Contact_Email>
    <Contact_Tel>+86 010-64089801</Contact_Tel>
    <Contact_Affiliation>China Academy of Chinese Medical Sciences</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Comply with the diagnostic criteria for pneumonia caused by novel coronavirus infection in the "Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 4)";&lt;br&gt;2) Agree to participate in the study and the patient or legal guardian signs the informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Patients with particularly severe pneumonia caused by novel coronavirus infection.&lt;br&gt;2) Patients whose initial onset time exceeds 5 days.&lt;br&gt;3) Patients with severe primary respiratory disease.&lt;br&gt;4) It is difficult to administer to patients by oral or nasal feeding.&lt;br&gt;5) Pregnant women, as well as patients with other malignancies such as malignant tumors, mental illnesses, and patients who are not considered suitable for study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Group A:traditional Chinese medicine treatment;Group B:Lopinavir / Ritonavir;Group C:traditional Chinese medicine treatment and Lopinavir / Ritonavir;</Intervention>
    <Primary_outcome>the rate of remission;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030096</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Study for establishment of correlation between virological dynamics and clinical features in noveal coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for establishment of correlation between virological dynamics and clinical features in noveal coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Peking University First Hospital</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49794</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Case series:120;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hong Zhao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>8 Xi-Shi-Ku Street, Xicheng District, Beijing, China</Contact_Address>
    <Contact_Email>zhaohong_pufh@bjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13810765943</Contact_Tel>
    <Contact_Affiliation>Peking University First Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. COVID-19 diagnosed based on the interim guidelines of the World Health Organization;&lt;br&gt;2. Excess specimens for clinical testing (sputum, nasopharyngeal swabs, blood specimens, urine, anal swabs).&lt;br&gt;3. Sign the informed consent form (WeChat or electronic signature record).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The doctor believes that the subject is not suitable to continue the clinical study;</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>SARS-CoV2 Nucleic Acid Quantification;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030095</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia</Public_title>
    <Scientific_title>Optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Nanchang University</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49845</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-23</Date_enrollement>
    <Target_size>Case series:94;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wei Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China</Contact_Address>
    <Contact_Email>zhangweiliuxin@163.com</Contact_Email>
    <Contact_Tel>+86 13707089183</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Nanchang University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Viral nucleic acid test positive</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Viral nucleic acid test negative</Exclusion_Criteria>
    <Condition>2019 - nCoV pneumonia</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>detection of virus nucleic acid;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030574</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Research on peripheral immunity function monitoring and its clinical application in patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Research on peripheral immunity function monitoring and its clinical application in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-07</Date_registration>
    <Date_registration3>20200307</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49953</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-08</Date_enrollement>
    <Target_size>case series:500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Mei Heng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei</Contact_Address>
    <Contact_Email>hmei@hust.edu.cn</Contact_Email>
    <Contact_Tel>+86 13886160811</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Diagnosed Novel coronavirus pneumonia patients or clinically diagnosed NCP patients;&lt;br&gt;2. Aged 18 to 90 years;&lt;br&gt;3. Sign the written informed consent before the study.  </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnant and lactating women; &lt;br&gt;2. Patients with mental illness.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>case series:N/A;</Intervention>
    <Primary_outcome>Immunity function;cytokines;viral load;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030556</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Anhui Cancer Hospital</Primary_sponsor>
    <Date_registration>2020-03-07</Date_registration>
    <Date_registration3>20200307</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50672</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>-</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-15</Date_enrollement>
    <Target_size>Target condition:200;Difficult condition:200</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hu Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>107 Huanhu Road East, Hefei, Anhui, China </Contact_Address>
    <Contact_Email>drliuhu@gmail.com</Contact_Email>
    <Contact_Tel>+86 13866175691</Contact_Tel>
    <Contact_Affiliation> Anhui Cancer Hospital </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: COVID-19 group: &lt;br&gt;1. Age&gt; = 18 years old, no gender restriction; &lt;br&gt;2. Patients with covid-19 determined by gold standard; &lt;br&gt;3. Total bilirubin &lt;=1.5 UNL, aspartate aminotransferase AST (SGOT) and alanine aminotransferase ALT (SGPT) &lt;=2.5 UNL; &lt;br&gt;4. The patients had no smoking or drinking in the past week;&lt;br&gt;5. All patients should be informed.&lt;br&gt;Similar symptoms group: &lt;br&gt;1. Age&gt; = 18 years old;&lt;br&gt;2. Patients with negative nucleic acid test;&lt;br&gt;3. Blood biochemical urea nitrogen &lt;=1.25 UNL, creatinine &lt;=1.25 UNL; Total bilirubin &lt;=1.5 UNL, aspartate aminotransferase AST (SGOT) and alanine aminotransferase ALT (SGPT) &lt;=2.5 UNL;&lt;br&gt;4. With Symptoms of fever and cough; &lt;br&gt;5. No smoking or drinking in the past week;&lt;br&gt;6. All patients should be informed.&lt;br&gt;Healthy control group:&lt;br&gt;1. Healthy patients who were screened by the physical examination center;&lt;br&gt;2. Had no history of acute disease in the past two weeks;&lt;br&gt;3. No smoking and drinking history in the past week;&lt;br&gt;4. Patients with informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: COVID-19 group: &lt;br&gt;1. Patients without self-awareness; &lt;br&gt;2. Patients who used drugs that can affect metabolism in the past 2 weeks, such as antibiotics (penicillins, erythromycin), hormones (deoxycortisol, dexamethasone), non-steroidal anti-inflammatory drugs (aspirin, sanitin), etc. &lt;br&gt;3. Patients with significant abnormalities in lung ventilation;&lt;br&gt;4. Pregnant or lactating women;&lt;br&gt;5. Patients with other metabolic disorders and any acute disease symptoms in the past 2 weeks.&lt;br&gt;Similar symptoms group &lt;br&gt;1. Patients without knowledge;&lt;br&gt;2. With previous medical history of COVID-19.&lt;br&gt;3. Patients with other metabolic disorders and any acute disease symptoms in the past 2 weeks;&lt;br&gt;4. Patients with significant abnormalities in lung ventilation.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Nucleic acid test;Index test:Nano-nasal&amp;#32;COVID-19&amp;#32;diagnostic&amp;#32;screening&amp;#32;model;</Intervention>
    <Primary_outcome>Volatile organic compounds, VOCs;SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04244591</TrialID>
    <Last_Refreshed_on>24 February 2020</Last_Refreshed_on>
    <Public_title>Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure</Public_title>
    <Scientific_title>Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by Noval Coronovirus 2019-nCoV: a Prospective, Randomized Controlled Trial</Scientific_title>
    <Acronym>Steroids-SARI</Acronym>
    <Primary_sponsor>Peking Union Medical College Hospital</Primary_sponsor>
    <Date_registration>23/01/2020</Date_registration>
    <Date_registration3>20200123</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04244591</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 26, 2020</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Bin Du, MD</Contact_Lastname>
    <Contact_Email>dubin98@gmail.com</Contact_Email>
    <Contact_Tel>8610-6915-5036</Contact_Tel>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adult&lt;br&gt;&lt;br&gt;          -  PCR confirmed noval coronavirus infection&lt;br&gt;&lt;br&gt;          -  Symptoms developed more than 7 days&lt;br&gt;&lt;br&gt;          -  PaO2/FiO2 &lt; 200 mmHg&lt;br&gt;&lt;br&gt;          -  Positive pressure ventilation (non-invasive or invasive) or high flow nasal cannula&lt;br&gt;             (HFNC) higher than 45 L/min for less than 48 hours&lt;br&gt;&lt;br&gt;          -  Requiring ICU admission&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  pregnancy;&lt;br&gt;&lt;br&gt;          -  patients currently taking corticosteroids (cumulative 400 mg prednisone or&lt;br&gt;             equivalent);&lt;br&gt;&lt;br&gt;          -  Severe underlying disease, i.e. end stage of malignancy disease or end stage of&lt;br&gt;             pulmonary disease;&lt;br&gt;&lt;br&gt;          -  Severe adverse events before ICU admission, i.e. cardiac arrest;&lt;br&gt;&lt;br&gt;          -  Underlying disease requiring corticosteroids;&lt;br&gt;&lt;br&gt;          -  Contraindication for corticosteroids;&lt;br&gt;&lt;br&gt;          -  Recruited in other clinical intervention trial&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus Infections;Respiratory Infection Virus</Condition>
    <Intervention>Drug: methylprednisolone therapy;Other: Standard care</Intervention>
    <Primary_outcome>Lower Murray lung injury score;Lower Murray lung injury score</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030185</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>West China Hospital of Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50058</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Target condition:40;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wanhong Yin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>doctorwhy@126.com</Contact_Email>
    <Contact_Tel>+86 13518106758</Contact_Tel>
    <Contact_Affiliation>Department of Critical Care Medicine, West China Hospital of Sichuan University </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who meet the diagnostic criteria of pneumonia caused by novel coronavirus. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: none</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Clinical outcome and Viral nucleic acid detection;Index test:critical&amp;#32;care&amp;#32;ultrasound&amp;#32;examination;</Intervention>
    <Primary_outcome>28day mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030094</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body construction and psychological state for female at different ages</Public_title>
    <Scientific_title>Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body construction and psychological state for female at different ages                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Chengdu University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49970</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax>50</Inclusion_agemax>
    <Inclusion_gender>Female</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Adolescent group:50;Childbearing group:100;Climacterium group:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hua Lu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China </Contact_Address>
    <Contact_Email>1924238034@qq.com</Contact_Email>
    <Contact_Tel>+86 18980880525</Contact_Tel>
    <Contact_Affiliation>Chengdu University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. aged between 16 and 50 years;&lt;br&gt;2. no history of gynecological diseases before;&lt;br&gt;3. willing to join this research and sign an informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. pregnancy or lactation;&lt;br&gt;2. history of psychiatric disorders(serious anxiety and depression,schizophrenia);&lt;br&gt;3. take sedatives in the past week.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Adolescent group:NA;Childbearing group:NA;Climacterium group:NA;</Intervention>
    <Primary_outcome>menstruation changes;TCM body constitution score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030046</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)</Public_title>
    <Scientific_title>A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital)</Primary_sponsor>
    <Date_registration>2020-02-21</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49861</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-07</Date_enrollement>
    <Target_size>Case series:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Bende Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Culture Avenue, Jiangxia District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>liubende99@outlook.com</Contact_Email>
    <Contact_Tel>+86 13907191851</Contact_Tel>
    <Contact_Affiliation>First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital)</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Inpatients aged 18 to 80 years old, male or female;&lt;br&gt;2. Confirmed patient diagnosed according to the guideline for Diagnosis and Treatment for COVID-19 (5th version), whose clinical classification is common or severe case;&lt;br&gt;Clinically diagnosed cases (suspected cases with radiological characteristics of pneumonia) or suspected cases have one of the following pathogenic evidences:&lt;br&gt;1) positive sputum or blood SARS-CoV-2 real-time RT-PCR assay;&lt;br&gt;2) Virus gene sequence from respiratory tract samples or blood samples, is highly homologous with SARS-CoV-2;&lt;br&gt;3. All subjects with childbearing ages must take effective contraceptive measures within 3 months after enrolling the screening period and after this clinical trial;&lt;br&gt;4. Full evaluation of the patient's condition, and confirmation that the patient can be transfused into convalescent plasma by doctors;&lt;br&gt;5. Volunteer to transfuse convalescent plasma, and sign the informed transfusion form and sign the notice of infusion (when neither the subject nor the legal guardian can read and understand the agreed contents of the notice of infusion, they need to sign it together with a third-party witness or/and his legal guardian or his legal representative to sign it together).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Previous or current allergic history to human plasma protein products or excipients (sodium citrate) contained in this product;&lt;br&gt;2. Patients diagnosed as severe COVID-19;&lt;br&gt;3. Patients diagnosed as infection of influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, SARS virus and other known viral pneumonia; Patients diagnosed as mycoplasma pneumonia, chlamydia pneumonia and bacterial pneumonia;&lt;br&gt;4. Subjects who had suffered or suffered from deep vein thrombosis, pulmonary embolism or arterial embolism within 1 year before signing the informed transfusion form or currently;&lt;br&gt;5. Patients with severe heart disease, including myocardial infarction and chronic cardiac insufficiency (NYHA grades III and IV);&lt;br&gt;6. Researchers judge that patients with severe liver and kidney diseases who are not suitable for clinical trial;&lt;br&gt;7. Patients with positive HBsAg antigen (or nucleic acid test) or HCV antibody (or nucleic acid test) or HIV antibody (or nucleic acid test) or Treponema pallidum antibody;&lt;br&gt;8. Pregnant women or breast-feeding women or women of childbearing age or male subjects in childbearing age are unwilling to take contraceptive measures during the study period;&lt;br&gt;9. Participated in clinical trials for other drugs or medical devices within 1 month before signing the informed transfusion form;&lt;br&gt;10. Suffering from mental illness, obvious mental disorder or epilepsy; Patients with acute diseases; Patients with current or previous malignant tumor diseases; Incapable of behavior or cognition;&lt;br&gt;11. Alcoholics, drug addicts, drug abusers and addicts;&lt;br&gt;12. Poor compliance or any circumstances that other researchers believe are not suitable for inclusion (e.g. Expected survival time is less than 3 months).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia</Condition>
    <Intervention>Case series:Anti-2019-nCoV virus inactivated plasma;</Intervention>
    <Primary_outcome>The changes of clinical symptom, laboratory and radiological data ;Oxyhemoglobin saturation.;dyspnea;Body temperature;Radiological characteristic sign;Blood routine;C-reaction protein;lymphocyte count;Liver function: TBIL(total bilirubin), AST(alanine aminotransferase) and ALT(aspartate aminotransferase);Neutralization antibody level;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030542</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A clinical study about the diagnosis and prognosis evaluation of novel coronacirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes.</Public_title>
    <Scientific_title>A clinical study about the diagnosis and prognosis of novel coronacirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>West China Hospital of Sichuan University</Primary_sponsor>
    <Date_registration>2020-03-06</Date_registration>
    <Date_registration3>20200306</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50608</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-09</Date_enrollement>
    <Target_size>Patients with COVID-19 VS Healthy controls; Severe group VS Mild group:600;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ying binwu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>binwuying@126.com</Contact_Email>
    <Contact_Tel>+86 18980601655</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients diagnosed with COVID-19&lt;br&gt;Mild group&lt;br&gt;Diagnosed patients classified as mild and ordinary types according to the National Health Commission of the Peoples Republic of China. Report of Novel Coronavirus-Infected Pneumonia in China by January 18, 2020. &lt;br&gt;Severe group&lt;br&gt;Diagnosed patients classified as severe type according to the National Health Commission of the Peoples Republic of China. Report of Novel Coronavirus-Infected Pneumonia in China by January 18, 2020.&lt;br&gt;Healthy control&lt;br&gt;RT-PCR test of novel coronavirus nucleic acid was negative. A healthy person is confirmed by a comprehensive physical examination.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Participants who are not suitable to be included in the project evaluated by the researchers.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Patients with COVID-19 VS Healthy controls; Severe group VS Mild group:None;</Intervention>
    <Primary_outcome>Pulmonary image findings;Relevant clinical manifestations of COVID-19;Oxygen saturation in resting state;Arterial partial pressure of oxygen/ Oxygen absorption concentration;Length of hospital stay;Viral genome information;Host genome information;Expression level of host cytokines;Conventional laboratory testing index;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030540</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy</Public_title>
    <Scientific_title>Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology</Primary_sponsor>
    <Date_registration>2020-03-06</Date_registration>
    <Date_registration3>20200306</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50658</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-08</Date_enrollement>
    <Target_size>CRRT group:76;Control group:76;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Shusheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>shushengli16@sina.com</Contact_Email>
    <Contact_Tel>+86 13971086498</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Adult patients confirmed by 2019-nCov throat swab or other samples of nucleic acid positive; &lt;br&gt;2. Patients with clear manifestations of pulmonary exudation on chest imaging; &lt;br&gt;3. Patients requiring oxygen therapy or mechanical ventilation,  ARDS (oxygenation index &lt; 200mmHg) was diagnosed according to the Berlin standard in 2012.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with cardiopulmonary resuscitation at the end of the disease; &lt;br&gt;2. Pregnant women.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>CRRT group:CRRT;Control group:Routine treatment, CRRT only when there are emergency indications;</Intervention>
    <Primary_outcome>Chest imaging;Oxygenation index;Extravascular pulmonary water;pulmonary vascular permeability index, PVPI;Inflammatory factors;Tissue kallikrein;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04269525</TrialID>
    <Last_Refreshed_on>24 February 2020</Last_Refreshed_on>
    <Public_title>Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia</Public_title>
    <Scientific_title>Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection</Scientific_title>
    <Acronym />
    <Primary_sponsor>ZhiYong Peng</Primary_sponsor>
    <Date_registration>07/02/2020</Date_registration>
    <Date_registration3>20200207</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04269525</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 6, 2020</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). </Study_design>
    <Phase>Phase 2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>XingHuan Wang, professor;XingHuan Wang, professor;XingHuan Wang, professor</Contact_Lastname>
    <Contact_Email>;znyylcsy@126.com;</Contact_Email>
    <Contact_Tel>;18971387168;</Contact_Tel>
    <Contact_Affiliation>Wuhan University;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  18-75 years old ,no gender restriction&lt;br&gt;&lt;br&gt;          -  According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV&lt;br&gt;             infection(Trial Version 4), patients are diagnosed with severe or critical 2019-nCoV&lt;br&gt;             pneumonia with stay in the ICU of less than 48 hours&lt;br&gt;&lt;br&gt;          -  Women of childbearing age should have a negative blood pregnancy test before the start&lt;br&gt;             of dosing and agree to take effective contraceptive measures during the trial until&lt;br&gt;             the last follow-up (28 days)&lt;br&gt;&lt;br&gt;          -  Sequential Organ Failure Assessment(SOFA) score between 2-13 point&lt;br&gt;&lt;br&gt;          -  Voluntarily participate in this clinical study and sign a written informed consent. If&lt;br&gt;             the patient cannot obtain informed consent, he can authorize his legal representative.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Liver or kidney SOFA score of more than 3 points;&lt;br&gt;&lt;br&gt;          -  HIV positive&lt;br&gt;&lt;br&gt;          -  Highly allergic constitution or history of severe allergies;&lt;br&gt;&lt;br&gt;          -  Pregnant and lactating women;&lt;br&gt;&lt;br&gt;          -  Patients with malignant tumors;&lt;br&gt;&lt;br&gt;          -  Patients with previous history of pulmonary embolism;&lt;br&gt;&lt;br&gt;          -  Participating in clinical trials of other drugs within 3 months before enrollment.&lt;br&gt;&lt;br&gt;          -  be thought by researchers to be inappropriate to participate in this clinical study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Pneumonia, Viral;Pneumonia, Ventilator-Associated</Condition>
    <Intervention>Biological: UC-MSCs</Intervention>
    <Primary_outcome>Oxygenation index</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030188</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Guangdong Provincial Hospital of Chinese Medicine - Zhuhai Hospital</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50025</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Experimental group:80;Control group:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Donghui Huang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>53 Jidajingle Road, Zhuhai, Guangdong, China</Contact_Address>
    <Contact_Email>13600001163@139.com</Contact_Email>
    <Contact_Tel>+86 0756-3325892</Contact_Tel>
    <Contact_Affiliation>Guangdong Provincial Hospital of Chinese Medicine - Zhuhai Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Comply with the diagnostic criteria for COVID-19 in the "Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 5)", meet the the criteria of severe and critical type;&lt;br&gt;(2) Agree to participate in the study and the patient or legal guardian signs the informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) It is difficult to administer to patients by oral or nasal feeding;&lt;br&gt;(2) Pregnant women, as well as patients with other malignancies such as malignant tumors, mental illnesses, and patients who are not considered suitable for study. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Syndrome differential treatment of Chinese Medicine + Western medicine basic treatment;Control group:Western medicine basic treatment;</Intervention>
    <Primary_outcome>TCM symptom score;Becomes negative time of COVID-19;Cure / mortality rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030167</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Renmin Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49567</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-02</Date_enrollement>
    <Target_size>Experimental Group:40;Control Group:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qianxue Chen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>99 Jiefang Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>chenqx666@whu.edu.cn</Contact_Email>
    <Contact_Tel>+86 027-88041911-82237</Contact_Tel>
    <Contact_Affiliation>Renmin Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Those who meet the diagnosis of new coronavirus pneumonia and have clinical classification of low and medium;&lt;br&gt;(2) Inpatients aged 18 to 75 years;&lt;br&gt;(3) Voluntarily receive treatment with the drug and sign informed consent. The informed consent process complies with relevant GCP regulations. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Immunodeficiency disease, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months;&lt;br&gt;(2) Preparing pregnant, pregnant and lactating women;&lt;br&gt;(3) Patients with allergies (referring to allergies to two or more medicines, foods or known ingredients in this study);&lt;br&gt;(4) Patients with mental illness, or have no cognitive ability;&lt;br&gt;(5) Patients with an estimated survival time of less than 48 hours from the start of screening;&lt;br&gt;(6) Those who have been intubated or mechanically ventilated at the time of screening;&lt;br&gt;(7) Obvious symptoms of heart, liver, kidney or various other systems, ALT, AST exceed 1.5 times the upper limit of normal value;&lt;br&gt;(8) Believed to be not suitable to participate in clinical trials by investigator. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental Group:Conventional Treatment &amp; Low Dose  Recombinant Human Interleukin-2, i.m.(1 million IU per time, once another day, 3 times per week, 2 weeks);Control Group:Conventional Treatment+Placebo  i.m.(once another day, 3 times per week, 2 weeks);</Intervention>
    <Primary_outcome>CD8+ T cells numbers;CD4+ T cell numbers;NK cell numbers;Fatality rate;Clinical recovery time;Critical (severe or critical) conversion rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030165</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Tianjin University</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49947</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>control group:30;mild ill patients:15;severe/critical ill patients:15;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yu Hongzhi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>890 Jin'gu Road, Jinnan District, Tianjin, China</Contact_Address>
    <Contact_Email>ykb@tju.edu.cn</Contact_Email>
    <Contact_Tel>+86 22 58830026</Contact_Tel>
    <Contact_Affiliation>Haihe hospital, Tianjin University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Confirmed patients (or legal guardian) sign a written informed consent form;&lt;br&gt;(2) Aged from 18 to 80 years, male or female;&lt;br&gt;(3) Patients with positive detection of 2019 Novel Coronavirus Pneumonia fluorescence RT-PCR in respiratory specimens or blood samples;&lt;br&gt;(4) Mild ill, severe ill and critical ill patients are grouped based on the fifth edition of the treatment and diagnosis plan published by the National Health Commission of the Peoples Republic of China.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Patients who may be transferred to other hospitals that are not included in the trial within 72 hours; &lt;br&gt;2) G-6PD defect (Favism); &lt;br&gt;3) Pregnancy, especially early pregnancy; &lt;br&gt;4) Patients who continually use immunosuppressant, or are organ transplant recipients within 6 months; &lt;br&gt;5) Hyperthyroidism; &lt;br&gt;6) Patients with medical ozone allergy; &lt;br&gt;7) Patients who are receiving other clinical trials.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>control group:conventional treatment;mild ill patients:conventional treatment and ozonated autohemotherapy;severe/critical ill patients:conventional treatment and ozonated autohemotherapy;</Intervention>
    <Primary_outcome>Chest CT;Whole blood cell analysis;Recovery rate;Oxygenation index;Inflammatory response index;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030030</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for acute kidney injury in novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>The risk factor and prognosis of acute kidney injury in novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-20</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49841</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Case series:2000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Gang Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>xugang@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13507181312</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: COVID-19 patients admitted to Tongji Hospital ,Tongji Medical College, Huazhong University of Science and Technology</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: age&lt;18 year; missing baseline and follow-up data</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Acute kidney injury;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030029</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Zhejiang University School of Medicine</Primary_sponsor>
    <Date_registration>2020-02-21</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49824</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Case series:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Shentu Jianzhong?Wu Lihua</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Hangzhou, Zhejiang, China </Contact_Address>
    <Contact_Email>stjz@zju.edu.cn</Contact_Email>
    <Contact_Tel>13957111817</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Zhejiang University School of Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 75 years male or female, willing to sign the informed consent; &lt;br&gt;2. Patients with novel coronavirus infection pneumonia were confirmed by epidemiology and clinical symptoms. The diagnostic criteria refer to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 6)";&lt;br&gt;3.Tested positive for novel coronavirus infection using a real time polymerase chain reaction (RT-PCR)-based diagnostic assay; or highly homologous to COVID-19 according to Virus gene sequencing;&lt;br&gt;4. Patients with pneumonia were confirmed by Chest imaging;&lt;br&gt;5. Enrollment and initiation of study drug treatment &lt;=10 days after onset of symptoms; Symptom are mainly fever, or cough on patients without fever;&lt;br&gt;6. Willing to abide by the protocol according investigators.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Hypersensitive to suramin or 2 or more drugs or food; &lt;br&gt;2. Body weight &lt;40 kg; &lt;br&gt;3. Considered as severe disease: has an ongoing respiratory deficiency and subjected to invasive mechanical ventilation; or presence of shock; or admitted to the ICU due to complications; &lt;br&gt;4. Has known kidney dysfunction determined as CLcr&lt;60 mL/min; &lt;br&gt;5. Increase in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is more than 5 times the upper limit of normal; or increase in ALT or AST is more than 3 ULN and increase in total bilirubin more than 2 ULN; &lt;br&gt;6. Pregnancy or breastfeeding, or positive pregnancy test in a predose examination, or have a plan to be pregnant within 3 months after the study;&lt;br&gt;7. Physician judged the patient was not suitable for this clinical trial (for example, patient with severe abnormality laboratory indexes; patient with multiple basic diseases, etc.). </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Suramin( IV.);</Intervention>
    <Primary_outcome>clinical cure rate;Incidence of mechanical ventilation by day28;All-cause mortality by day28;Incidence of ICU admission by day28;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030170</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Shanghai Public Health Clinical Center</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50017</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>50</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>severe NCP group:8;Acute exacerbation NCP group:8;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lu Hongzhou</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>2901 Caolang Road, Jinshan District, Shanghai, China</Contact_Address>
    <Contact_Email>luhongzhou@shphc.org.cn</Contact_Email>
    <Contact_Tel>+86 18930810088</Contact_Tel>
    <Contact_Affiliation>Shanghai Public Health Clinical Center</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Inpatients aged 50 and over, regardless of gender, voluntarily signed informed consent;&lt;br&gt;(2) Persons diagnosed with 2019-nCoV infection: respiratory specimens or blood specimens are tested positive for 2019-nCoV nucleic acid by real-time fluorescent RT-PCR; or respiratory specimens or blood specimens are sequenced for viral genes, which are highly homologous with known 2019-nCoV;&lt;br&gt;(3) Severe NCP group: meets ("New Coronavirus Infected Pneumonia Diagnosis and Treatment Plan (Trial Fifth Edition)") diagnostic criteria for heavy NCP.&lt;br&gt;(4) NCP group in acute exacerbation period: NCP patients with acute exacerbation period in general to severe and critically severe (for definition of severe and critically severe, see "Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Fifth Edition)");&lt;br&gt;Remarks: "Judgment Criteria for NCP Patients with Acute Exacerbation in General to Severe and Critical Severity"&lt;br&gt;1) Aged 50 years or older;&lt;br&gt;2) Dyspnea (those who inhale oxygen in a mask);&lt;br&gt;3) Combined with basic diseases, such as COPD, diabetes, hypertension, coronary heart disease;&lt;br&gt;4) White blood cell count is less than 4  109 / L or has a tendency to decrease continuously;&lt;br&gt;5) Lymphocyte count &lt;1.5x10^9 / L or a trend of continuous decrease;&lt;br&gt;6) Platelet count is less than 150x10^9/L or has a tendency to decrease continuously;&lt;br&gt;7) Hemoglobin has continued to decrease;&lt;br&gt;8) C-reactive protein &gt;=10 mg / L or a trend of continuous increase;&lt;br&gt;9) Procalcitonin &gt;=0.5 ng / mL or a tendency of continuous increase;&lt;br&gt;10) Lactate dehydrogenase &gt;=250 U/L or a trend of continuous increase;&lt;br&gt;11) Aspartate aminotransferase and alanine aminotransferase have a tendency to increase continuously;&lt;br&gt;12) Creatinine &gt;=133 umol/L or a tendency of continuous increase;&lt;br&gt;13) D-dimer &gt;=0.5 mg/L or a trend of continuous increase;&lt;br&gt;14) There is a continuous decrease in serum potassium;&lt;br&gt;15) IL-6 has a tendency to increase continuously;&lt;br&gt;16) Any of IL-2, IL-4, IL-10, TNF, IFN-r, and IL-17A has a tendency to increase continuously;&lt;br&gt;17) Imaging findings consistent with NCP progression.&lt;br&gt;Remarks: (1) If 9 or more of the above 17 items are met, they are judged to be "normal-to-severe, severely severe NCP patients with acute exacerbation period"; (2) continuous increase or decrease trend: at least 3 consecutive measurements, specific trends Determined by the research doctor; (3) In view of the special circumstances of the NCP, during the trial implementation, the selection criteria of the protocol can be appropriately updated and adjusted according to the clinical progress.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclusion criteria for the severe NCP group were the same as those for the acutely exacerbated NCP group:&lt;br&gt;1. Have a history of drug dependence or substance abuse;&lt;br&gt;2. female patients who are pregnant or lactating;&lt;br&gt;3. People with allergies or known allergies to research drugs and excipients;&lt;br&gt;4. In patients with impaired liver function, alanine aminotransferase (ALT) / aspartate aminotransferase (AST) increases more than five times the upper limit of normal;&lt;br&gt;5. Patients with renal impairment (dialysis treatment patients or eGFR &lt;60mL / min);&lt;br&gt;6. Those who meet the diagnostic criteria of ARDS:&lt;br&gt;(1) acute onset;&lt;br&gt;(2) oxygenation index (PaO2 / FiO2) &lt;=200mmHg [1mmHg = 0.133kPa, regardless of the positive end-expiratory pressure (PEEP) level];&lt;br&gt;(3) positive X A chest radiograph showed patchy shadows in both lungs;&lt;br&gt;(4) pulmonary artery incarceration pressure &lt;=18mmHg, or no clinical evidence of increased left atrial pressure.&lt;br&gt;7. Patients with significantly impaired cardiac function: those with A and NYHA heart failure classification = Grade II or LVEF &lt;=lower limit of normal value; those with ECG in leads B and 12 suggesting conduction block or acute myocardial infarction requiring urgent treatment;&lt;br&gt;8. Combining other serious diseases that affect patient survival, such as malignant tumors;&lt;br&gt;9. the use of immunosuppressants or diseases that seriously affect the immune system, such as human immunodeficiency virus infection;&lt;br&gt;10. Combining other infections that are severe and uncontrollable (bacteria, chlamydia, deep fungi, etc.);&lt;br&gt;11. Those with diarrhea&gt; 4 times / day;&lt;br&gt;12. People who have difficulty swallowing oral drugs;&lt;br&gt;13. Situations in which other researchers find it inappropriate to participate in research.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;Acute exacerbation NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;</Intervention>
    <Primary_outcome>Severe NCP group: Time to clinical improvement (TTCI) [time window: 28 days];Acute exacerbation NCP group: Time to clinical recovery [time window: 28 days] and the ratio of common to severe and critically severe.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030138</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Chinese PLA General Hospital</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50004</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jian Bo and Chuanzhu Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>28 Fuxing Road, Haidian Distract, Beijing, China</Contact_Address>
    <Contact_Email>boj301@sina.com</Contact_Email>
    <Contact_Tel>+86 13801257802</Contact_Tel>
    <Contact_Affiliation>Chinese PLA General Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Subjects who met all of the following conditions entered the trial:&lt;br&gt;1. Male or female patients aged 16 to 75 years;&lt;br&gt;2. willing to sign informed consent;&lt;br&gt;3. Based on the criteria for suspected cases of COVID-19 infection, sputum, throat swabs, lower respiratory tract secretions and other specimens were tested for positive COVID-19 nucleic acid by real-time fluorescent RT-PCR; or viral gene sequencing was performed with known COVID- 19 highly homologous;&lt;br&gt;4. The imaging findings are consistent with pneumonia.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Subjects who meet one of the following conditions will not be eligible for the trial:&lt;br&gt;1. pregnant or lactating women;&lt;br&gt;2. Malignant tumors, patients with other severe systemic diseases and mental illness;&lt;br&gt;3. Those who have recently participated in other clinical trials;&lt;br&gt;4. There is evidence of drug addiction within one year before joining the trial;&lt;br&gt;5. Unable or unwilling to provide informed consent or comply with test requirements;&lt;br&gt;6. Combined with HIV, tuberculosis, influenza virus, adenovirus and other respiratory infections.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC);Control group:Routine treatment + placebo;</Intervention>
    <Primary_outcome>Clinical index;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030117</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Shanghai Public Health Clinical Center</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49762</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Combination therapy group:232;Conventional treatment group:116;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hongzhou Lu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>9th Floor, Block 3, Lufthansa Center, 16 Xinyuanli Street, Chaoyang District, Beijing, China</Contact_Address>
    <Contact_Email>luhongzhou@shphc.org.cn</Contact_Email>
    <Contact_Tel>+86 21-37990333</Contact_Tel>
    <Contact_Affiliation>Jiangxi Qingfeng Pharmaceutical Co., Ltd.</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-70 years old;&lt;br&gt;2. Meet the diagnostic criteria for confirmed cases in the diagnosis and treatment plan of new coronavirus-infected pneumonia (trial version 5); and the clinical symptoms before admission or screening must meet the following conditions:&lt;br&gt;Fever (armpit temperature &gt;=37.3 degree C, or mouth temperature &gt;=38.0 degree C, or anal or ear temperature &gt;=38.6 degree C) &lt;=7 days; and breathing rate&gt; 24 beats / min or cough (at least one of the two);&lt;br&gt;3. Confirmed 2019-nCoV infection by Laboratory inspection (RT-PCR);&lt;br&gt;4. Have not previously received treatment or experimental treatment for COVID-19. Patients who have been treated with proprietary Chinese medicine or lopinavir / ritonavir tablets for less than 3 days can be enrolled;&lt;br&gt;5. Subjects volunteerly participate in this study and agree to sign informed consent;&lt;br&gt;6. According to the researcher's judgment, the subject / legal guardian is considered reliable and able to comply with this plan, visit plan and medication arrangement.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Allergic constitution (persons who are allergic to more than 2 kinds of substances), people who are allergic to similar drugs in the past or those who are known to be allergic to the ingredients and auxiliary materials in the test drugs;&lt;br&gt;2. Patients who have participated in other clinical trials in the past 3 months;&lt;br&gt;3. Patients not suitable for the clinical trials judged by researchers.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Combination therapy group:Xiyanping injection+ conventional treatment;Conventional treatment group:Lopinavir / Ritonavir tablets, alpha-interferon;</Intervention>
    <Primary_outcome>Clinical recovery time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030115</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49964</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-27</Date_enrollement>
    <Target_size>Case series:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang Shaogang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>lingqing1985@163.com</Contact_Email>
    <Contact_Tel>+86 15827257012</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 years;&lt;br&gt;2. Severed COVID-19 patients, matched the requirements of &lt;COVID-19 diagnosis and treatment programme (trial sixth edition)&gt; launched by NHC, which is meeting any of the following:&lt;br&gt;RR&gt;=30 times/min;&lt;br&gt;Rest SaO2&lt;=93%;&lt;br&gt;PaO2/FiO2&lt;=300mmHg;&lt;br&gt;Lung lesion area increasing &gt;50% with 24-28h via imaging examination;&lt;br&gt;3. Be able to work with researchers and be willing to comply with the entire research requirements.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who have been treated with glucocorticoids;&lt;br&gt;2. Patients who have received invasive ventilator-assisted ventilation treatment;&lt;br&gt;3. Patients with shock;&lt;br&gt;4. Patients combined with organ failure and needed ICU monitoring;&lt;br&gt;5. Other situations that researchers think not-suitable for enrollment.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Basic symptomatic therapy combined with glucocorticoid therapy;</Intervention>
    <Primary_outcome>Cortisol;ACTH;Form of Adrenal tissue;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030492</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Retrospective study for integrate Chinese and conventional medicine  treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province</Public_title>
    <Scientific_title>Retrospective studyfor integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-04</Date_registration>
    <Date_registration3>20200304</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50549</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-04</Date_enrollement>
    <Target_size>Control group:30;Experimental group:170;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>CHEN Xinyu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>95 Shaoshan Middle Road, Yuhua District, Changsha, Hu'nan, China</Contact_Address>
    <Contact_Email>chenxinyuchen@163.com</Contact_Email>
    <Contact_Tel>+86 13807312410</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The diagnostic criteria of novel coronavirus infection pneumonia can be observed and agreed by the patients themselves.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: pregnant or lactating women</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Western medicine treatment;Experimental group:integrate Chinese and conventional medicine  treatment;</Intervention>
    <Primary_outcome>TCM syndrome;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030490</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Huo-Shen-Shan Hospital</Primary_sponsor>
    <Date_registration>2020-03-04</Date_registration>
    <Date_registration3>20200304</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50487</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Wang Hao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Zhiyin Aveneu, Caidian District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>wanghaohh@vip.126.com</Contact_Email>
    <Contact_Tel>+86 13901883868</Contact_Tel>
    <Contact_Affiliation>Huo-Shen-Shan Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Must meet all of the following criteria&lt;br&gt;1. aged 18 to 75 years male or female;&lt;br&gt;2. Body Weight 40-100kg, and BMI &gt;=18kg/M2;&lt;br&gt;3. to meet the diagnostic criteria in the fourth edition of the diagnostic protocol for pneumonia caused by 2019-ncov infection issued by the National Health Commission, and to identify patients with pneumonia caused by common type of 2019-ncov infection.&lt;br&gt;Note: suspected patient with one of the following etiological evidence:&lt;br&gt;(1) Respiratory Specimens or blood samples were positive for 2019-ncov acid by real-time fluorescent RT-PCR;&lt;br&gt;(2) Respiratory Specimens or blood samples were genetically sequenced and highly homologous to known 2019-ncov.&lt;br&gt;4. has fever, respiratory symptoms, imaging can see the performance of pneumonia.&lt;br&gt;5. the positive test result of etiological evidence within 72 hours;&lt;br&gt;6. A woman must:&lt;br&gt;(1) Surgical sterilization has been performed. &lt;br&gt;(2) Menopause, menopause at least 1 year; &lt;br&gt;(3) The following conditions must be met for the child to be fertile;&lt;br&gt;The pre-trial Serum / urine pregnancy test was negative in the study group, and during the study period (interview 1-5), consenting to an approved method of contraception (E. G. Oral, injectable or implantable, barrier-forming, spermicide and condom, or intrauterine device) , contraceptive methods remained the same throughout the study period.&lt;br&gt;Men must meet one of the following requirements:&lt;br&gt;(1) Surgical sterilization has been performed; &lt;br&gt;(2) An approved method of contraception must be used throughout the study period and the method remains the same throughout the study period;&lt;br&gt;7. those who agree to take part in the test and sign the informed consent form voluntarily.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. according to the clinical classification of severe and critical cases in the sixth edition of Diagnosis and treatment of pneumonia with 2019-ncov infection issued by the National Health Commission.&lt;br&gt;Note: those who comply with any of the following provisions shall not be included:&lt;br&gt;Heavy duty:&lt;br&gt;(1) Respiratory Distress, Rr &gt;=3/Min; &lt;br&gt;(2) At rest, oxygen saturation &lt;=93% ; &lt;br&gt;(3) Arterial Partial Oxygen Pressure (PAO2) / oxygen uptake concentration (FIO2)&lt;=300 MMHG 10.133 KPA&lt;br&gt;Critical type: &lt;br&gt;(1) Respiratory Failure with Mechanical Ventilation; &lt;br&gt;(2) Go into shock;. &lt;br&gt;(3) Patients with other organ failure need intensive care in ICU.&lt;br&gt;2. merger other virus like HCV, HIV, syphilis and so on infection person;&lt;br&gt;3. Chest radiography or CT confirmed interstitial lesions and other diseases;&lt;br&gt;4. combined with severe liver and kidney damage, ALT, AST, Tbil or any of the above items; 1.5 times the upper limit of normal value, or CR &amp; GT;&lt;br&gt;5. those diagnosed as immunodeficient or who have taken immunosuppressive drugs or glucocorticoid within 3 months;&lt;br&gt;6. Known history of allergy to experimental drugs or their excipients&lt;br&gt;7. The risk factors are as follows:&lt;br&gt;(1) chronic obstructive pulmonary disease, chronic respiratory disease such as asthma;&lt;br&gt;(2) serious cardiovascular diseases such as congenital heart defect, heart failure and coronary artery disease, except hypertension;&lt;br&gt;(3) neurological and neuromuscular diseases such as cerebral palsy, epilepsy, stroke, mental retardation, muscular dystrophy or spinal cord injury;&lt;br&gt;(4) serious hematological diseases such as sickle cell disease;&lt;br&gt;(5) malignant tumors;&lt;br&gt;8. Female subjects who were pregnant, lactating or positive in pregnancy during the screening period or during the trial; male and female patients with reproductive potential who were unwilling to use an effective, protocol-prescribed method of contraception during the study period;&lt;br&gt;9. persons with Infectious Disease and mental illness;&lt;br&gt;10. Who have been in clinical trials for other drugs in the last 3 months;&lt;br&gt;11. The researchers did not consider it appropriate to participate in this clinical trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:diammonium glycyrrhizinate enteric-coated capsule combined with hydrogen-rich water;</Intervention>
    <Primary_outcome>Cure rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030028</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>West China Hospital</Primary_sponsor>
    <Date_registration>2020-02-20</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49840</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Experimental group:20;Control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yan Kang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>kangyan_hx@163.com</Contact_Email>
    <Contact_Tel>+86 18980601556</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) RT-PCR detection of the respiratory or blood samples shows positive nucleic acid of the novel coronavirus;&lt;br&gt;(2) Gene sequence of the virus in respiratory or blood samples are highly homologous to the known coronaviruses;&lt;br&gt;(3) The CT images of chest shows radiographic features of pneumonia;&lt;br&gt;(4) Patients with severe or critical conditions;&lt;br&gt;(5) Aged &gt;=18, male or female;&lt;br&gt;(6) The subjects should volunteer to join the study, sign the informed consent, have good compliance and cooperate with the follow-up.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Subjects who have any active autoimmune disease or history of autoimmune disease;&lt;br&gt;(2) Subjects who received immunosuppressive therapy by using immunosuppressant, or systemic or absorbable topic hormone therapy (temprednisone or other therapeutic hormones with a dosage &gt;10 mg/day) within 14 days prior to the administration of the studied drug;&lt;br&gt;(3) Severe allergic reaction to other monoclonal antibodies;&lt;br&gt;(4) Women in pregnancy or lactation;&lt;br&gt;(5) Human immunodeficiency virus (HIV) infection;&lt;br&gt;(6) Subjects with abnormal coagulation, bleeding tendency or undergoing thrombolysis or anticoagulation;&lt;br&gt;(7) Subjects with any known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs, coagulation disorders or thrombocytopenia);&lt;br&gt;(8) Subjects who have previously received other PD-1 antibody therapy or other immunotherapy for PD-1/PD-L.</Exclusion_Criteria>
    <Condition>novel coronavirus disease (COVID-19)</Condition>
    <Intervention>Experimental group:PD-1 mAb + Standard treatment;Control group:Standard treatment;</Intervention>
    <Primary_outcome>Neutrophil count;Lymphocyte count;Monocyte / macrophage count;Monocyte / macrophage function test;NK cell count;DC cell count;PD-1( immunosuppressive biomarker );PD-L1(immunosuppressive biomarker );CTLA4 (immunosuppressive biomarker );CD79;Blnk;Il7r;T lymphocyte count;CD4+ T lymphocyte count;CD8+ T lymphocyte count;B lymphocyte count;NK cell count;Proportion of navie CD4+ T lymphocytes to CD4+ T lymphocytes;Proportion of memory CD4+ T lymphocyte to CD4+ T lymphocytes;Proportion of CD4+ T lymphocyte subsets to CD4+ T lymphocytes;Proportion of CD8+ CD28+ subsets to CD8 + T lymphocytes;Activation ratio of CD8+ T lymphocytes;Ratio of CD4+ T lymphocytes to CD8+ T lymphocytes;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030027</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial</Public_title>
    <Scientific_title>Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-20</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49852</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Case series:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yao-sheng Zhang/Ting-rong Huang/Chun-yan Ji/Jian-wei Shang  </Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>5 Hai-Yun-Cang Lane, Dongcheng District, Beijing, China</Contact_Address>
    <Contact_Email>ysz3129@163.com</Contact_Email>
    <Contact_Tel>+86 18610329658</Contact_Tel>
    <Contact_Affiliation>Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing China</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Meet the diagnostic criteria of the "New Coronavirus Pneumonia Diagnosis and Treatment Scheme" and patients diagnosed with new coronavirus infection; &lt;br&gt;2. Meet the diagnostic criteria for severe cases in the "Plan", namely: respiratory distress, RR &gt;=30 times / min; Below, refers to oxygen saturation &lt;=93%; arterial blood oxygen partial pressure (PaO2 / oxygen concentration (FiO2) &lt;=300mmHg;&lt;br&gt;3. aged &gt;=18 years old;&lt;br&gt;4. those who have voluntarily signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria:  People with allergies and allergies to experimental drugs; </Exclusion_Criteria>
    <Condition>Novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Western medicine routine treatment plan plus TCM syndrome differentiation treatment;</Intervention>
    <Primary_outcome>Release rate of discharge standards for isolation;Change in Critical Illness;Traditional Chinese medicine syndrome score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030137</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Humanistic Care in Healthcare Workers in Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>The Effect of Humanistic Care in Healthcare Workers Participated in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>The Second Affiliated Hospital of Xi'an Jiaotong University</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50007</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>15</Inclusion_agemin>
    <Inclusion_agemax>60</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Case series:130;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Gong Shouping</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>157 West 5th Road, Xi'an, Shaanxi, China</Contact_Address>
    <Contact_Email>shpingg@126.com</Contact_Email>
    <Contact_Tel>+86 13709206398</Contact_Tel>
    <Contact_Affiliation>The Second Affiliated Hospital of Xi'an Jiaotong University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Healthcare-personnel who are working for treating COVID-19</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: disagree to consent or infected with COVID-19</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Humanistic care;</Intervention>
    <Primary_outcome>Self-rating depression scale;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030136</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With  Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>the Second Affiliated hospital of Xi'an Jiaotong University</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50005</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Humanistic care:100;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Gong Shouping</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>157 West 5th Road, Xi'an, Shaanxi, China</Contact_Address>
    <Contact_Email>shpingg@126.com</Contact_Email>
    <Contact_Tel>+86 13709206398</Contact_Tel>
    <Contact_Affiliation>the Second Affiliated hospital of Xi'an Jiaotong University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Inpatients with 2019 Novel Coronavirus infection in the severe case section running by national medical team from the Second Affiliated hospital of Xian Jiaotong University</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients can not follow-up;&lt;br&gt;Investigator considering inappropriate</Exclusion_Criteria>
    <Condition>Coronavirus Disease 2019</Condition>
    <Intervention>Humanistic care:Humanistic care+routine regimen;Control group:routine regimen;</Intervention>
    <Primary_outcome>recovery time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030092</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Assessment of cardiac function in patients with Novel Coronavirus Pneumonia (COVID-19) by echocardiography and its new techniques</Public_title>
    <Scientific_title>Assessment of cardiac function in patients with Novel Coronavirus Pneumonia (COVID-19) by echocardiography and its new techniques                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Department of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49880</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>Severe group:200;Critical group:200;Light group:200;Common group:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Mingxing Xie</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>xiemx@hust.edu.cn</Contact_Email>
    <Contact_Tel>+86 13607108938</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Diagnosis confirmed Novel Coronavirus Pneumonia (COVID-19) </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Diagnosis confirmed not coronavirus disease-19.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Severe group:None;Critical group:none;Light group:None;Common group:None;</Intervention>
    <Primary_outcome>M mode echocardiography;two-dimensional echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030090</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students</Public_title>
    <Scientific_title>A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49910</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>15</Inclusion_agemin>
    <Inclusion_agemax>35</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-22</Date_enrollement>
    <Target_size>Exercise prescription group:200;Control group:200;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>XIONG YAN</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>363 Furong Avenue, Wenjing District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>luyibingli@163.com</Contact_Email>
    <Contact_Tel>+86 18328737998</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All students from China University will be invited to participate in this research. Students will voluntarily participate in the study and ask for an informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: None</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Exercise prescription group:Exercise prescription;Control group:None;</Intervention>
    <Primary_outcome>Mood index;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030481</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial</Public_title>
    <Scientific_title>The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50453</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Early corticosteroid intervention group:75;Middle-late corticosteroid intervention group:75;Control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chen Zhenshun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>chzs1990@163.com</Contact_Email>
    <Contact_Tel>+86 13627288300</Contact_Tel>
    <Contact_Affiliation>Zhongnan Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who are more than 18 years are definitely diagnosed with COVID-19. [That is, the diagnosis of 2019-nCoV-infected pneumonia patients was diagnosed according to the diagnostic criteria for novel coronavirus pneumonia diagnosis and treatment program (trial version 5) issued by the National Health and Health Commission on February 5, 2020. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who are allergic to corticosteroid;&lt;br&gt;2. Patients who are diagnosed with adrenal insufficiency;&lt;br&gt;3. Severe immunosuppression, one of the following: infection with human immunodeficiency virus and CD4 cell count below 350 cells per microliter, immunosuppressive therapy after solid organ transplantation, neutropenia (less than 500 cells Per microliter) and so on;&lt;br&gt;4. Patients with cystic fibrosis or active tuberculosis;&lt;br&gt;5. Patients with gastrointestinal bleeding in the past three months;&lt;br&gt;6. Incomplete clinical data;&lt;br&gt;7. Participated in other clinical research;&lt;br&gt;8. Patients who cannot understand and execute the survey plan;&lt;br&gt;9. Patients who abandoned treatment.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Early corticosteroid intervention group:Early corticosteroid intervention;Middle-late corticosteroid intervention group:Middle-late corticosteroid intervention;Control group:No corticosteroid;</Intervention>
    <Primary_outcome>The time of duration of COVID-19 nucleic acid RT-PCR test results of respiratory specimens (such as throat swabs) or blood specimens change to negative.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030467</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform</Public_title>
    <Scientific_title>A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Dalian Medical University, Dalian, China.</Primary_sponsor>
    <Date_registration>2020-03-02</Date_registration>
    <Date_registration3>20200302</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50378</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Control group:30;Experimental group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wei Yao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>9 West Section, Lushun Road South, Lushunkou District, Dalian, Liaoning, China</Contact_Address>
    <Contact_Email>411484335@qq.com</Contact_Email>
    <Contact_Tel>+86 17709877386</Contact_Tel>
    <Contact_Affiliation>Dalian Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) confirmed or suspected cases of new coronavirus pneumonia;&lt;br&gt;2) be able to understand the content of this study, and have the ability of normal communication and understanding;&lt;br&gt;3) voluntarily participate in this study and obtain written informed consent from the guardian or the patient. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) patients in coma, unable to carry out voluntary activities and social activities; &lt;br&gt;2) patients with mental illness or adverse reactions caused by drugs; &lt;br&gt;3) patients with serious diseases such as cardiovascular, cerebrovascular, liver and kidney damage. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:TCM + Conventional medicine treatment + conventional medicine's psychological intervention;Experimental group:Integrated Chinese and Conventional medicine treatment + conventional medicine's psychological intervention + TCM psychological intervention;</Intervention>
    <Primary_outcome>Psychological status;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030012</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Development of anti-2019-nCoV therapeutic antibody from the recovered novel coronavirus pneumonia patients (COVID-19)</Public_title>
    <Scientific_title>Development of 2019-nCoV  therapeutic antibody                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>The First People's Hospital of Chenzhou, Institute of Translational Medicine,University of South China</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49718</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>60</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-19</Date_enrollement>
    <Target_size>Case series:20;</Target_size>
    <Study_type>Treatment study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>XiaoWang Qu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>102 Luo-Jia-Jing, Beihu District, Chenzhou, Hu'nan, China</Contact_Address>
    <Contact_Email>quxiaowang@163.com</Contact_Email>
    <Contact_Tel>+86 15526272595</Contact_Tel>
    <Contact_Affiliation>The First People's Hospital of Chenzhou, Institute of Translational Medicine,University of South China</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1)2019-nCoV-cured patients that over 18 years of age&lt;br&gt;2)Sign informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: NA</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:NA;</Intervention>
    <Primary_outcome>NA;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030010</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)</Public_title>
    <Scientific_title>A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49777</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-19</Date_enrollement>
    <Target_size>Experimental group:50;Control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Dingyu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Yintan Road, Dongxihu District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>1813886398@qq.com</Contact_Email>
    <Contact_Tel>+86 13507117929</Contact_Tel>
    <Contact_Affiliation>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 70 years old, inpatients, male or female;&lt;br&gt;2. Patients with severe novel coronavirus infection: According to the "Pneumonitis Diagnosis and Treatment Guideline for the Novel Coronavirus Infection (Trial Version 5)", clinically diagnosed cases (suspected cases with pneumonia imaging features) or suspected cases.&lt;br&gt;Severe patients must also meet any of the following:&lt;br&gt;1) Respiratory distress, RR&gt;=30 times / minute&lt;br&gt;2) In the resting state, the oxygen saturation is &lt;=93%;&lt;br&gt;3) Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) &lt;=300 mmHg (1mm Hg = 0.133 kPa).&lt;br&gt;3. Subjects and / or legal guardians of the subjects volunteered to participate in the study and voluntarily signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The clinical classification of patients with severe novel coronavirus infection is to meet any of the following:&lt;br&gt;1) Respiratory failure occurs and requires mechanical ventilation;&lt;br&gt;2) Shock occurs;&lt;br&gt;3) Combined failure of other organs requires ICU monitoring and treatment;&lt;br&gt;2. Those who are allergic to blood products or plasma components and auxiliary materials (sodium citrate);&lt;br&gt;3. There is multiple organ failure, and the estimated survival time is less than 3 days;&lt;br&gt;4. Those who tested positive for HIV antibodies before enrollment;&lt;br&gt;5. Women who are pregnant or breastfeeding or have a birth plan within the past year;&lt;br&gt;6. Participants in other clinical trials within 3 months before screening;&lt;br&gt;Poor adherence or other conditions that the investigator believes are not suitable for inclusion (such as poor physical condition).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;</Intervention>
    <Primary_outcome>Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030102</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Tianjin Huanhu Hospital</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49747</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>control group with common NCP:30;experimental group with common NCP:30;experimental group with severe NCP:30;control group with severe NCP:30;experimental group with critical NCP:30;control group with critical NCP:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiaoguang Tong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>6 Jizhao Road, Jinnan District, Tianjin</Contact_Address>
    <Contact_Email>Tongxg@yahoo.com</Contact_Email>
    <Contact_Tel>+86 13820088121</Contact_Tel>
    <Contact_Affiliation>Tianjin Huanhu Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-80 years;&lt;br&gt;2. Within 1 week of onset;&lt;br&gt;3. Meet the diagnostic criteria of common, severe and critical NCP, according to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Pneumonia (Trial Version 6)".&lt;br&gt;4. Sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Any situation that does not allow the program to proceed safely; &lt;br&gt;2. The patient may be transferred to a non-participating hospital within 72 hours; &lt;br&gt;3. Those who have continued to use immunosuppressive agents or organ transplants for the past 6 months; &lt;br&gt;4. Glucose-6-phosphate dehydrogenation Enzyme deficiency (faba bean disease) 5; &lt;br&gt;5. Patients treated with any of the antiviral drugs listed in the protocol during hospitalization before enrollment; &lt;br&gt;6. Those participating in other clinical trials. &lt;br&gt;7. Those who are allergic to ozone or hypersensitive.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>control group with common NCP:conventional treatment;experimental group with common NCP:conventional treatment combined with ozone therapy;experimental group with severe NCP:conventional treatment combined with ozone therapy;control group with severe NCP:conventional treatment;experimental group with critical NCP:conventional treatment combined with ozone therapy;control group with critical NCP:conventional treatment;</Intervention>
    <Primary_outcome>Chest imaging;RNA test of COVID-19;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Blood oxygen saturation;Time to 2019-nCoV RT-PCR negativity: defined as the last test time for two consecutive negative respiratory viral nucleic acid tests (sampling interval of at least 1 day);Liver, renal  and heart  function;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030089</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label, controlled trial for the efficacy and safety of  Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Shanghai Changzheng Hospital</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49889</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-28</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Huji Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>415 Fengyang Road, Huangpu District, Shanghai, China</Contact_Address>
    <Contact_Email>xuhuji@smmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13671609764</Contact_Tel>
    <Contact_Affiliation>Shanghai Changzheng Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Subjects who meet the following conditions can become subjects of this study:&lt;br&gt;1. Will sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian;&lt;br&gt;2. Chinese aged &gt;=18 years;&lt;br&gt;3. In accordance with NCP criteria for severe and critical illness, namely "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 6)". Combined with the following epidemiological history, clinical manifestations, and pathogenic examinations to make a comprehensive judgment.&lt;br&gt;4. The course of disease is within 14 days after the onset of illness;&lt;br&gt;5. Will take nasopharyngeal or oropharyngeal swabs before administration.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who are participating in other drug clinical trials;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. ALT / AST&gt; 5 ULN, neutrophils &lt;0.5, platelets less than 50;&lt;br&gt;4. Expected survival is less than 1 week;&lt;br&gt;5. Patients diagnosed with rheumatic immune related diseases;&lt;br&gt;6. Take orally anti rejection drugs or immunomodulatory drugs for a long time;&lt;br&gt;7. Hypersensitive to adalimumab or any excipients;&lt;br&gt;8. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia(COVID-19)</Condition>
    <Intervention>Experimental group:Conventional treatent and adalimumab;Control group:conventional treatment ;</Intervention>
    <Primary_outcome>TTCI (Time to Clinical Improvement);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029996</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Beijing Chaoyang Hospital, Capital Medical University</Primary_sponsor>
    <Date_registration>2020-02-20</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49510</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Low-dose group:20;Middle-dose group:20;High-dose group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhaohui Tong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>8 Workers Stadium Road South, Chaoyang District, Beijing</Contact_Address>
    <Contact_Email>13910930309@163.com</Contact_Email>
    <Contact_Tel>+86 13910930309</Contact_Tel>
    <Contact_Affiliation>Beijing Chaoyang Hospital, Capital Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Voluntarily sign the Consent Form;&lt;br&gt;2. Male or female aged 18 and over;&lt;br&gt;3. According to the "Diagnosis and Treatment Scheme for Pneumonia of Novel coronavirus pneumonia Infection-Trial Fifth Edition", inpatient diagnosed with Novel coronavirus pneumonia diagnosed and clinical classification of ordinary type: Inpatients with fever (underarm temperature &gt;= 37.0 degree C), respiratory tract, etc. Imaging shows pneumonia.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Females who are pregnant or likely to be pregnant, or who are lactating and unable to stop breastfeeding, or who have positive pregnancy tests during screening;&lt;br&gt;2. Males or females who have a birth plan or are unwilling to take reliable contraceptive measures for contraception within 90 days from signing the informed consent to the last dose;&lt;br&gt;3. Other circumstances that the researchers consider inappropriate for participation in this study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>Low-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 1600 mg per time on first day; the duration of treatment will be 10 d.;Middle-dose group:Tablets; 200mg; orally; twice a day;The adult dose is 1800 mg per time on first day; the duration of treatment will be 10 d.;High-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 2400 mg per time on first day; the duration of treatment will be 10 d.;</Intervention>
    <Primary_outcome>Time to Clinical Recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029995</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Study on anxiety of different populations under novel coronavirus (COVID-19) infection</Public_title>
    <Scientific_title>Study on anxiety of different populations under novel coronavirus (COVID-19) infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Shanghai General Hospital of Shanghai Jiaotong University</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49418</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>pneumonia patients group:100;medical staff group:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jiang Hong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>650 Xinsongjiang Road, Songjiang District, Shanghai, China</Contact_Address>
    <Contact_Email>jhong.pku@163.com</Contact_Email>
    <Contact_Tel>+86 15301655562</Contact_Tel>
    <Contact_Affiliation>Shanghai General hospital of Shanghai Jiaotong University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. First-line medical staff: doctors and nurses who enter the fixed-point pneumonia treatment hospital in Hubei Province for first-line clinical work, or clinical doctors and nurses who have treated COVID19 pneumonia cases in local designated pneumonia treatment hospitals, and clinical first-line medical staff who are exposed to/receive suspected cases of fever and confirmed cases of COVIP19 in hospital fever clinics&lt;br&gt;2. Confirmed and suspected cases: In the time of this investigation, in accordance with the latest version of the country's "new coronavirus pneumonia diagnosis and treatment program" confirmed and clinically confirmed patients. Suspected cases: In the time of this investigation, in accordance with the latest version of the country's "new coronavirus pneumonia treatment program" of suspected patients, but has not yet reached the diagnosis of patients. If the patient is eventually diagnosed but is suspected in the investigation, it is still classified as a suspected case.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who have been admitted to the hospital for reasons other than pneumonia&lt;br&gt;2. Patients with mental illness have been identified or have been clearly diagnosed with emotional disorders&lt;br&gt;3. Minors</Exclusion_Criteria>
    <Condition>Anxiety; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>pneumonia patients group:N/A;medical staff group:N/A;</Intervention>
    <Primary_outcome>Self-Rating Anxiety Scale;Self-Rating Depression Scale;Posttraumatic stress disorder checklist,;Questionnaire for Simple Responses;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030465</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                        Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Guangzhou University of TCM</Primary_sponsor>
    <Date_registration>2020-03-02</Date_registration>
    <Date_registration3>20200302</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50388</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-02</Date_enrollement>
    <Target_size>Group 2:35;Group 1:35;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wu Caineng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>16 Jichang Road, Guangzhou, Guangdong, China  </Contact_Address>
    <Contact_Email>wucaineng861010@163.com</Contact_Email>
    <Contact_Tel>+86 13580315308</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Guangzhou University of TCM </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Eligible patients were adults ((aged 18-80 years); &lt;br&gt;2. Were identified as laboratory-confirmed COVID-19 infection; &lt;br&gt;3. Those who need intubation in ICU, and with no severe hypoxemia.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Intubation required immidiately in case of cardiac arrest or asphyxia; 2. Pregnancy, severe chronic respiratory, uncontrolled gastric reflux disease and any nasopharyngeal anatomical obstacle; 3. Those patients has intubated in ICU. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 2:SMO Assisted tracheal intubation;Group 1:Assisted tracheal intubation via nasal high-flow oxygen inhalation;</Intervention>
    <Primary_outcome>SpO2 during intubation;the total time of intubation;Mask ventilation for SpO2 &lt; 90%;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030014</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled due to lack of patient                               Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Wuhan Fourth Hospital</Primary_sponsor>
    <Date_registration>2020-02-20</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49802</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-19</Date_enrollement>
    <Target_size>Experimental group:150;control group:150;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>CAI YU</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>473 Hanzheng Street, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>caiy_kf@163.com</Contact_Email>
    <Contact_Tel>+86 18702745799</Contact_Tel>
    <Contact_Affiliation>Wuhan Fourth Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: pneumoniaits were diagnosed by chest CT findings and positive nucleic acid tests</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclude patients with influenza, adenovirus and other upper respiratory tract infections</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:pulmonary training;control group:Conventional medication;</Intervention>
    <Primary_outcome>MRC breathlessness scale;6MWD;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030088</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>The Sixth Medical Center of PLA General Hospital</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49902</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Experimental group:20;Control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lianru Gao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>6 Fucheng Road, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>lianru666@163.com</Contact_Email>
    <Contact_Tel>+86 18600310121</Contact_Tel>
    <Contact_Affiliation>The Sixth Medical Center of PLA General Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) age 18-80 years old, regardless of gender: 2) the diagnosis criteria of severe nCoV pneumonia in line with the 6th edition of China's new coronavirus pneumonia diagnosis scheme: a.B. Real-time fluorescence rt-pcr of respiratory tract specimens or blood samples was used to detect positive nCoV nucleic acid;3) critical cases of nCoV pneumonia: meet one of the following criteria: a. respiratory failure and mechanical ventilation required;B. shock;C. Combined with other organ failure, intensive care unit is required;4) patients with poor treatment response: that is, the above critically ill patients have undergone active modern medicine to fight against shock, correct acidosis, improve multi-organ function rescue and ECMO assisted breathing, and have not been improved by circulation assisted treatment and hormone application;5) those who signed the informed consent and agreed to participate in the initial clinical trial were selected.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Iv injection of Wharton's Jelly mesenchymal stem cells (110^6/kg), cell suspension volume: 40ml;Control group:Iv 40ml saline;</Intervention>
    <Primary_outcome>The nucleic acid of the novel coronavirus is negative;CT scan of ground glass shadow disappeared;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030087</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49919</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>Light group:200;Common group:200;Severe group:200;Critical group:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Mingxing Xie</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>xiemx@hust.edu.cn</Contact_Email>
    <Contact_Tel>+86 13607108938</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The COVID-19 patients are confirmed according to the novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) issued by the National Health Protection Commission and the Chinese medicine administration.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Previous cheset trauma and surgery;&lt;br&gt;2. Previous severe emphysema and chronic obstructive pulmonary disease.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Light group:N/A;Common group:N/A;Severe group:N/A;Critical group:N/A;</Intervention>
    <Primary_outcome>Three-dimensional ultrasound;Two-dimensional ultrasound;Respiration related parameters;Doppler ultrasound;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030058</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Renmin Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49831</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-10</Date_enrollement>
    <Target_size>Experimental group :100;Control group:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ke Hu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>hukejx@163.com</Contact_Email>
    <Contact_Tel>+86 18971035988</Contact_Tel>
    <Contact_Affiliation>Renmin Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. aged 18-70 years male or female;&lt;br&gt;2. 2019 new coronavirus nucleic acid test positive;&lt;br&gt;3. meet the national diagnosis criteria;&lt;br&gt;4. subjects onset within 8 days (severe cases can be delayed to 14 days);&lt;br&gt;5. subjects or agency personnel agree to sign the informed consent;&lt;br&gt;6. subjects who can take oral medication or who receive oral medication;&lt;br&gt;7. subjects agree to collect clinical samples;&lt;br&gt;8. female subjects of child-bearing age are not pregnant and agree to take effective contraceptive measures within 7 days of the last oral medication to ensure that they will not pregnant;&lt;br&gt;9. men agree not to have sex with women for seven days after taking their last oral medication.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. severe vomiting and difficulty in taking oral medication or absorbing in oral medication;&lt;br&gt;2. pregnant and nursing women;&lt;br&gt;3. subjects received lopinavir/ridonavir, ribavirin, monoclonal antibodies and other specific antiviral drugs in the week prior to admission;&lt;br&gt;4. subjects exist respiratory failure requiring mechanical ventilation;&lt;br&gt;5. subjects of shock;&lt;br&gt;6. subjects combined with other organ failure requires intensive care unit;&lt;br&gt;7. subjects with no clinical expectation of survival and only give end-of-life care, or those in a deep coma who did not respond to supportive treatment within three hours of admission.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group :Oral leflunomide;Control group:Oral placebo;</Intervention>
    <Primary_outcome>The days from positive to negative for viral nucleic acid testing;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030056</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49904</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-23</Date_enrollement>
    <Target_size>case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qingping Wu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>wqp1968@163.com</Contact_Email>
    <Contact_Tel>+86 13971605283</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. In line with the diagnosis and treatment plan of pneumonia infected by novel coronavirus of the National Health Commission (Fifth Edition) Hubei Province Diagnostic criteria: including clinical diagnosis and etiological diagnosis;&lt;br&gt;2. Obtain the informed consent signed by the patient or the legally authorized agent of the patient.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients who refuse to sign informed consent form</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>case series:none;</Intervention>
    <Primary_outcome>ICU hospitalization days;Death rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029994</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial</Public_title>
    <Scientific_title>Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Shanghai University of TCM</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49309</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-19</Date_enrollement>
    <Target_size>Control group:100;Experimental group:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fang Lei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1200 Cailun Road, Pudong New District, Shanghai, China</Contact_Address>
    <Contact_Email>fanglei586@126.com</Contact_Email>
    <Contact_Tel>+86 021-51323092</Contact_Tel>
    <Contact_Affiliation>Faculty of Rehabilitation Medicine, Shanghai University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Meet NCP critical diagnosis criteria;&lt;br&gt;(2) Volunteer to participate in this study, cooperate with examination and treatment;&lt;br&gt;(3) The selected patients were basically stable, conscious and cooperative;&lt;br&gt;(4) No serious mental disorder;&lt;br&gt;(6) Aged between 20-80 years.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with other serious diseases such as lung diseases, cardiovascular and cerebrovascular diseases, hematopoietic diseases, autoimmune diseases, digestive system, or mental illness;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. Participate in other forms of exercise during the trial </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Conventional treatment;Experimental group:Conventional treatment +acupressure+Liuzijue qigong;</Intervention>
    <Primary_outcome>lung function;ADL;6min walk;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029978</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine,</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49702</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>60</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-21</Date_enrollement>
    <Target_size>Control group:93;Experimental group:93;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fang Min</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>110 Ganhe Road, Hongkou District, Shanghai, China</Contact_Address>
    <Contact_Email>fangmin19650510@163.com</Contact_Email>
    <Contact_Tel>+86 18930568005</Contact_Tel>
    <Contact_Affiliation>Tuina Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 60 years old;&lt;br&gt;2. Inpatients who meet the diagnostic criteria for mild, general and neonatal pneumonia in western medicine, and early and recovery stages of traditional Chinese medicine;&lt;br&gt;3. Understand and agree to participate in this study and sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with other serious diseases such as lung diseases, cardiovascular and cerebrovascular diseases, hematopoietic diseases, autoimmune diseases, digestive system, or mental illness;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. Participate in other forms of exercise during the trial</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Conventional treatment;Experimental group:Conventional treatment pius Dao Yin;</Intervention>
    <Primary_outcome>Length of hospital stay;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029982</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Study for using multiomics in the diagnosis and treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) by using multiomics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49724</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-18</Date_enrollement>
    <Target_size>Mild COVID-19 group:200;Moderate COVID-19 group:200;Severe COVID-19:200;Influenza group:500;Bacterial infection group:500;Fungus infection group:500;Healthy people:500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jin Yang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>whuhjy@sina.com</Contact_Email>
    <Contact_Tel>+86 13554361146</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)";&lt;br&gt;2. Those without broad-spectrum antibacterial, antifungal, and antiviral treatment;&lt;br&gt;3. Imaging revealed pneumonia in patients with a diagnosis of pathogen: influenza, CAP / HAP bacterial infection, and fungal infection.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. A coma, MODS or death occurred on admission;&lt;br&gt;2. The estimated survival time is &lt;7 days;&lt;br&gt;3. The patient's medical history is not detailed and relatives cannot be contacted.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Mild COVID-19 group:NA;Moderate COVID-19 group:NA;Severe COVID-19:NA;Influenza group:NA;Bacterial infection group:NA;Fungus infection group:NA;Healthy people:NA;</Intervention>
    <Primary_outcome>Patients' general information: epidemiological indicators such as age, gender, address, telephone, past medical history, and BMI;Division of disease;Genomics;Transcriptomics;Metabolomics;Proteomics;Laboratory inspection;Imaging examination;Etiological examination;The remaining observation indicators are supplemented according to clinical needs.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029580</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial</Public_title>
    <Scientific_title>Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-05</Date_registration>
    <Date_registration3>20200205</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49088</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-31</Date_enrollement>
    <Target_size>Experimental group:35;control group:35;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jianfeng Zhou</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>zhougene@medmail.com.cn</Contact_Email>
    <Contact_Tel>+86 027 83665506</Contact_Tel>
    <Contact_Affiliation>Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;= 18 years and &lt;= 75 years;&lt;br&gt;2. Patients clinically diagnosed as novel coronavirus infection; or with positive serum antibodies (IgM or IgG); or with novel coronavirus infection confirmed by PCR; &lt;br&gt;3. Severe/critical patients.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with other malignant tumors requiring treatment;&lt;br&gt;2. Severe cardiovascular and metabolic diseases beyond the control of combination with other drugs &lt;br&gt;3. Patients with clinical symptoms of brain dysfunction or serious mental illness who cannot understand or follow the study protocol;&lt;br&gt;4. Endotracheal intubation with invasive ventilation;&lt;br&gt;5. Patients who cannot guarantee completion of necessary treatment plan and follow-up observation;&lt;br&gt;6. Women of child-bearing age who are positive in pregnancy test or do not stop breastfeeding in lactation period;&lt;br&gt;7. Patients with other infections at the time of enrollment;&lt;br&gt;8. Other circumstances that prevent the protocol from proceeding safely.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Ruxolitinib combined with mesenchymal stem cell;control group:  Routine treatment;</Intervention>
    <Primary_outcome>Safety;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030033</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Guangzhou Medical University</Primary_sponsor>
    <Date_registration>2020-02-21</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49703</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Intervention group 1:276;Intervention group 2:276;Control group:276;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>New Treatment Measure Clinical Study</Phase>
    <Countries>Chinese</Countries>
    <Contact_Firstname>Feng WANG</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>151 Yanjiang Road, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>412475734@qq.com</Contact_Email>
    <Contact_Tel>+86 13710801606</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Guangzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 80 years (inclusive);&lt;br&gt;2. People who had ineffective protection, i.e.:&lt;br&gt;1) living, studying, working together with, or having close contacts with confirmed cases and positive testers, such as working at close distances or sharing the same classroom or living in the same house;&lt;br&gt;2) had close contacts with medical personnel, family members or people who have similar close contact during the diagnosis, treatment, and visits, such as visiting or staying in a closed environment with other patients in the ward and their accompanying staff personnel;&lt;br&gt;3) people who took the same transportation and have close contact with the cases, including carers on the transportation vehicle;&lt;br&gt;4) people traveled together (e.g., family, colleagues, friends, etc.);&lt;br&gt;5) Other passengers or flight attendants who possibly had close contact with confirmed cases and positive testers after investigation and evaluation;&lt;br&gt;3. People who were considered as having close contacts with cases after an assessment by onsite investigators.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The physician decides that participating in this study is not in the best interest of the subject or that there exist a circumstance in which the agreed protocol cannot be safely followed;&lt;br&gt;2. People who have allergic reactions or allergies to antiviral oral solution or Wuzhifangguanfang decoction;&lt;br&gt;3. Those who do not meet the national diagnostic criteria for close contacts of new coronary pneumonia;&lt;br&gt;4. Confirmed cases of new coronavirus pneumonia;&lt;br&gt;5. People with mental disorders who cannot communicate normally;&lt;br&gt;6. Pregnant woman;&lt;br&gt;7. People who do not agree to participate;</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Intervention group 1:Oral antiviral oral solution (Xiangxue Pharmaceutical);Intervention group 2:Oral "Wu-Zhi-Fang-Guan-Fang" decoction;Control group:Routine quarantine measures;</Intervention>
    <Primary_outcome>Proportion of COVID-19 close contacts who have developed as confirmed cases;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030017</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Department of Ultrasound Imaging, Renmin Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-20</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49798</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Severe group:100;Non-severe group:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qing Zhou</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>238 Jiefang Road, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>qingzhou.wh.edu@hotmail.com</Contact_Email>
    <Contact_Tel>+86 13971358226</Contact_Tel>
    <Contact_Affiliation>Renmin Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Diagnosis confirmed Novel Coronavirus Pneumonia (COVID-19)</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Diagnosis confirmed not coronavirus disease-19.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Severe group:None;Non-severe group:None;</Intervention>
    <Primary_outcome>Death;Recovered;Discharged;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030086</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae</Public_title>
    <Scientific_title>Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49934</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>general anesthesia group vs. intraspinal anesthesia group:30;Health care goup:180;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Haifa Xia, Xiangdong Chen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>xiangdongchen2013@163.com</Contact_Email>
    <Contact_Tel>+86 15071096621</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) The NCP puerperae undergoing cesarean section (The diagnosis and treatment plan of pneumonia infected by novel coronavirus of the National Health Commission (Fifth Edition) Hubei Province Diagnostic criteria: including clinical diagnosis and etiological diagnosis);&lt;br&gt;2) Contact medical staff related to cesarean section of NCP puerperae;&lt;br&gt;3) Voluntary participation in the test and signing of informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Medical staff with contact history outside the operating room.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>general anesthesia group vs. intraspinal anesthesia group:N/A;Health care goup:N/A;</Intervention>
    <Primary_outcome>CT image of lung of close contact medical staff;Human body temperature of close contact medical staff;Anxiety Scale of of close contact medical staff;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030054</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19)</Public_title>
    <Scientific_title>An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Zhongshan Hospital Affiliated to Xiamen University</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49869</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-22</Date_enrollement>
    <Target_size>Hydroxychloroquine sulfate gloup:40;Chloroquine phosphate gloup:40;Control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yin Zhenyu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Room 507, Xianyue Haijing Building, 195 Xianyue Road, Siming Square, Xiamen, Fujian, China</Contact_Address>
    <Contact_Email>Yinzy@xmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13950120518</Contact_Tel>
    <Contact_Affiliation>Zhongshan Hospital Affiliated to Xiamen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-75 years old;&lt;br&gt;2. RT-PCR positive for 2019-nCoV or Confirmed lung involvement with chest imaging;&lt;br&gt;3. The clinical symptoms are slight, and there is no obvious manifestation of pneumonia (mild disease) or clinical symptoms such as fever and respiratory tract in imaging. The manifestation of pneumonia (common type) can be seen in imaging;&lt;br&gt;4. &lt;=7 days since onset of the disease;&lt;br&gt;5. Willingness of study participant to accept randomization to any assigned treatment arm;&lt;br&gt;6. Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Investigator makes a decision that trial participation is not in patients' best interest, or any condition that does not allow the protocol to be followed safely;&lt;br&gt;2. As judged by investigator historic or current diseases that may have impact on the subjects participation of the study or the study outcome. These diseases include but not limited to cadiac diease and arrhythmia and QT prolongation), neurological disease psychiatric disease,active bleeding, serious malnutrition and endocrine disease; currently complicated with serious respiratory disease or that seriously affect immune system, such as flu, COPD, asthma, HIV infection, blood system disease, or splenectomy, organ transplantation etc.;&lt;br&gt;3. Severe liver disease (AST&gt;3 ULN);&lt;br&gt;4. Patients with known severe renal impairment (estimated glomerular filtration rate &lt;=60 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis;&lt;br&gt;5. QT elongation;&lt;br&gt;6. Allergic to chloroquine or hydroxychloroquine;&lt;br&gt;7. Pregnant or breastfeeding, or positive pregnancy test in a predose examination;&lt;br&gt;8. Will be transferred to another hospital within 72 hours;&lt;br&gt;9. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or trial related) within the 14 days prior to the time of the screening evaluation.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days a day ;Chloroquine phosphate gloup:The first dose of chloroquine phosphate was 1gx2 days, and the third day was 0.5gx12 days ;Control group:Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan ;</Intervention>
    <Primary_outcome>Clinical recovery time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029960</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province</Public_title>
    <Scientific_title>Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-17</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49639</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-28</Date_enrollement>
    <Target_size>Control group:30;Experimental group:70;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>CHEN Xinyu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>95 Shaoshan Middle Road, Yuhua District, Changsha, Hu'nan, China</Contact_Address>
    <Contact_Email>chenxinyuchen@163.com</Contact_Email>
    <Contact_Tel>+86 13807312410</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The diagnostic criteria of novel coronavirus infection pneumonia can be observed and agreed by the patients themselves.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: pregnant or lactating women</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Conventional medicine;Experimental group:integrated Chinese and conventional medicine;</Intervention>
    <Primary_outcome>TCM syndrome;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029959</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Clinical observation and research of  Severe acute respiratory syndrome coronavirus 2(COVID-19) infection in perinatal newborns</Public_title>
    <Scientific_title>Clinical observation of the novel coronavirus pneumonia (COVID-19) in neonatal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>West China Second Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-17</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49636</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>1</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-25</Date_enrollement>
    <Target_size>COVID-19 pregnant women and normal pregnant women and infants born to them:30;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jun Tang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>20 Third Section, Renmin Road South, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>tj1234753@sina.com</Contact_Email>
    <Contact_Tel>+86 18180609287</Contact_Tel>
    <Contact_Affiliation>West China Second Hospital, Sichuan University, Chengdu, China</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. The neonates delivered by the mother who were suspected or confirmed infection of COVID-19;&lt;br&gt;2. The newborn,whose mother had no diagnosis of COVID-19 before delivery, had a history of epidemiological exposure (including diagnosis of COVID-19 of their mother after delivery or other people who had a close contacts with neonates), and the newborn tested positive for SARS-Cov-2 nucleic acid after birth, whether they had clinical symptom or not.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>COVID-19 pregnant women and normal pregnant women and infants born to them:None;</Intervention>
    <Primary_outcome>CoVID-19 Perinatal Outcomes;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030015</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women</Public_title>
    <Scientific_title>Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-20</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49800</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Female</Inclusion_gender>
    <Date_enrollement>2020-02-19</Date_enrollement>
    <Target_size>Case series:300;</Target_size>
    <Study_type>Basic Science</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Shixuan Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>sxwang@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 027-83663078</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Female of after menarche;&lt;br&gt;2. Meet the pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic criteria of hubei province: including clinical diagnosis and etiological diagnosis;&lt;br&gt;4. Patients who signed the informed consent</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients who the researchers determined not suitable for this study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>menstruation changes;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030008</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak</Public_title>
    <Scientific_title>Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>The Fifth Affiliated Hospital of Sun Yat-Sen University</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49426</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jing Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China.</Contact_Address>
    <Contact_Email>liujing25@mail.sysu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13844021812</Contact_Tel>
    <Contact_Affiliation>The Fifth Affiliated Hospital of Sun Yat-Sen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Volunteer to participate in the study and sign informed consent;&lt;br&gt;2. Aged 18-65 years, male or female;&lt;br&gt;3. Weight &gt;= 40kg and &lt;=100kg, and BMI &gt;= 18kg/m2;&lt;br&gt;4. Medical staff during the novel coronavirus (COVID-19) outbreak.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Plan for pregnant,breast-feeding or pregnant;&lt;br&gt;2. Hospitalized for other reasons within 14 days before the election;&lt;br&gt;5. Combined with serious diseases of heart, lung, brain, liver, kidney, blood system;&lt;br&gt;6. Has fever, runny nose, diarrhea and other respiratory and digestive symptoms.</Exclusion_Criteria>
    <Condition>anxiety and depression; novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>psychological scale;Intestinal flora abundance, etc;Upper respiratory flora abundance, etc;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030039</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of Xuzhou Medical University</Primary_sponsor>
    <Date_registration>2020-02-21</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49544</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>60</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-05-31</Date_enrollement>
    <Target_size>Experimental group:30;control group:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xuebing Yan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>9 Kunpeng Road, Gulou District, Xuzhou, Jiangsu, China</Contact_Address>
    <Contact_Email>yxbxuzhou@126.com</Contact_Email>
    <Contact_Tel>+86 15205215685</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of Xuzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. The diagnosis conforms to the diagnostic criteria of "pneumonia diagnosis and treatment program for new coronavirus infection (trial version 5)";&lt;br&gt;2. Clinical classification is normal,severe or critical;&lt;br&gt;3. Subject aged &gt;=18 years old;&lt;br&gt;4. The patient or his/her legal guardian will participate voluntarily and sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Highly allergic constitution or history of severe allergy, especially plasma allergy;&lt;br&gt;2. The doctor believes that there are other reasons not to include the healer.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:conventional therapy with Infusion of convalescent plasma: 200-500ml, two infusions are recommended;control group:conventional therapy;</Intervention>
    <Primary_outcome>SARS-CoV-2 DNA;SARS-CoV-2  antibody levels;thoracic spiral CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030021</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A medical records based analysis for the clinical characteristics of novel coronavirus pneumonia (COVID-19) in immunocompromised patients</Public_title>
    <Scientific_title>A medical records based analysis for the clinical characteristics of novel coronavirus pneumonia (COVID-19) in immunocompromised patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Department of respiratory and critical care medicine, Tongji Hospital, Tongji Medical College, Huazhong University of science and technology</Primary_sponsor>
    <Date_registration>2020-02-20</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49690</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Case series:10;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhou Min</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>minzhou@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 15002749377</Contact_Tel>
    <Contact_Affiliation>Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Diagnostic criteria refers to the WHO standards, including clinically diagnosed cases and laboratory confirmed cases</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Pneumonia caused by other pathogens</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Clinical characteristics;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029866</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics</Public_title>
    <Scientific_title>Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Enze Hospital of Taizhou Enze Medical Center (Group)</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49519</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Target condition:120;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lyu Dongqing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Tongyang Road East, Luqiao District, Taizhou, Zhejiang </Contact_Address>
    <Contact_Email>lvdq@enzemed.com</Contact_Email>
    <Contact_Tel>+86 13867622009</Contact_Tel>
    <Contact_Affiliation>Enze Hospital of Taizhou Enze Medical Center (Group) </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;18 years; &lt;br&gt;2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV; &lt;br&gt;3. Lung involvement confirmed with chest imaging.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Pregnant women.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Diagnostic criteria for severe novel coronavirus pneumonia.;Index test:early&amp;#32;warning&amp;#32;and&amp;#32;prediction&amp;#32;system.;</Intervention>
    <Primary_outcome>Cytokine detection;Lymphocyte subpopulation analysis ;SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029865</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Descriptive study on the clinical characteristics and outcomes of novel coronavirus pneumonia (COVID-19) in cardiovascular patients</Public_title>
    <Scientific_title>Clinical characteristics and outcomes of cardiovascular disease patients infected by COVID-19 in Wuhan, China: a descriptive study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49545</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>common group:400;severe group:400;critical group:400;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Peng Yudong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>am-penicillin@163.com</Contact_Email>
    <Contact_Tel>+86 13886157176</Contact_Tel>
    <Contact_Affiliation>Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All patients who were diagnosed as COVID-19 according to the interim guidance of China National Health Commission (NHC)  were screened in this study. CVD included hypertension, coronary heart disease or/and heart failure confirmedly diagnosed in the past.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Aged &lt;18 years;&lt;br&gt;2. Patients with systemic disease and severe liver and kidney dysfunction were excluded. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>common group:N/A;severe group:N/A;critical group:N/A;</Intervention>
    <Primary_outcome>blood cell count;C-reactive protein (CRP);arterial blood-gas analysis;markers of myocardial injury;coagulation profile;serum biochemical test;brain natriuretic peptide(BNP);blood lipid;fibrinogen(FIB), D-Dimer.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030006</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49737</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-19</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chen Xiangdong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>xiangdongchen2013@163.com</Contact_Email>
    <Contact_Tel>+86 15071096621</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) In line with ethics, sign a written informed consent form;&lt;br&gt;(2) Patients with positive detection of new coronavirus nucleic acid;&lt;br&gt;(3) Chest CT confirmed pulmonary lesions;&lt;br&gt;(4) Hospitalized patients with fever or respiratory symptoms;&lt;br&gt;(5) Patients who did not participate in other clinical studies within three months.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Hyperthyroidism; &lt;br&gt;(2) Favism; &lt;br&gt;(3) Pregnancy; &lt;br&gt;(4) Abnormal coagulation, thrombocytopenia, active bleeding;&lt;br&gt;(5) People with medical ozone allergy or hypersensitivity; &lt;br&gt;(6) Severe anemia; &lt;br&gt;(7) Hypocalcemia; &lt;br&gt;(8) Unstable period of severe cardiovascular disease; &lt;br&gt;(9) Uncontrolled diabetes.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:ozonated autohemotherapy;Control group:Standard medical treatment;</Intervention>
    <Primary_outcome>Recovery rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030001</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial</Public_title>
    <Scientific_title>The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Health commission of Heilongjiang province</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49723</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Experimental group:120;Control group:120;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Baofeng Yang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>194 Xuefu Road, Nangang District, Harbin, Heilongjiang, China</Contact_Address>
    <Contact_Email>yangbf@ems.hrbmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 133 0451 2381</Contact_Tel>
    <Contact_Affiliation>Heilongjiang Province hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Adult aged &gt;=18 years and agrees to sign the informed consent;&lt;br&gt;(2) Laboratory-confirmed 2019-nCoV infection by real-time RT-PCR;&lt;br&gt;(3) Chest imaging (CT) confirmed lung damage: multiple small plaques and stromal changes in the lungs, which were obvious in the outer lung, or multiple ground-glass shadows and infiltration shadows in both lungs, the changes may not be present in mild patients;&lt;br&gt;(4) Hospitalized patients with fever (axillary temperature &gt;=37.0 degree C) or respiratory symptoms;&lt;br&gt;(5) The interval between symptom onset and randomization was within 12 days;&lt;br&gt;(6) Did not participate in other clinical researches within 3 months;&lt;br&gt;(7) Do not participate other antiviral studies within 28 days of follow-up.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) The PI considers that the patient is not suitable to participate the study or  the patient may be unsafe if he participate the study;&lt;br&gt;(2) Patients with serious liver disease, grade C according to child-pugh;&lt;br&gt;(3) Patients with severe renal impairment (glomerular filtration rate &lt;=30mL/min/1.73m2) or who have received continuous renal replacement therapy, hemodialysis or peritoneal dialysis;&lt;br&gt;(4) Patients with severe anemia, Hgb &lt; 60g/L.&lt;br&gt;(5) Pregnant women or women with pregnancy test positive or breastfeeding women;&lt;br&gt;(6) Patients with allergy history of Triazavirin or its components;&lt;br&gt;(7) Confused to sign the informed consent;&lt;br&gt;(8) Patients may be transferred to another hospital within 72h;&lt;br&gt;(9) Received any experimental treatment for novel coronavirus infection within 30 days prior to screening.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Basic treatment combined Triazavirin;Control group:Basic treatment combined Triazavirin placebo;</Intervention>
    <Primary_outcome>Time to Clinical recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030020</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Second Hospital of University of South China, Hengyang</Primary_sponsor>
    <Date_registration>2020-02-20</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49812</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-06</Date_enrollement>
    <Target_size>Case series:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Luo Zhigang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>35 Jiefang Avenue, Zhengxiang District, Hengyang, Hu'nan, China</Contact_Address>
    <Contact_Email>706885399@qq.com</Contact_Email>
    <Contact_Tel>+86 13907342350</Contact_Tel>
    <Contact_Affiliation>Second Hospital of University of South China, Hengyang</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Age 18-70 years&lt;br&gt;(2) Clinical symptoms, signs, and lung CT suggest changes in lung inflammation. Patients diagnosed with new type of coronavirus pneumonia combined with more than one nucleic acid test&lt;br&gt;(3) Clinical symptoms, signs, and lung CT suggest lung inflammation changes. Combined with more than one respiratory or blood specimen virus gene sequencing, it is highly homologous to known new coronaviruses.&lt;br&gt;(4) Negative nucleic acid or viral gene test, but New Crown Pneumonia expert group discusses cases with high suspicion of New Crown Pneumonia&lt;br&gt;(5) Voluntarily sign the informed consent and agree to comply with the requirements of the test protocol&lt;br&gt;(6) Patients can communicate in words or words. Sign informed consent&lt;br&gt;(7) The patient agrees and has the ability to complete auxiliary tests related to the trial</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Subject has a history of tumor&lt;br&gt;(2) Female patients of childbearing age during pregnancy, lactation or recent birth planning&lt;br&gt;(3) Highly allergic constitution or history of severe allergies&lt;br&gt;(4) Coagulation disorders such as hemophilia&lt;br&gt;(5) Those with positive serological tests such as AIDS, syphilis, etc.&lt;br&gt;(6) Patients who have participated in or are participating in other drug trials within one month&lt;br&gt;(7) Patients who the investigator refused to participate in this clinical trial&lt;br&gt;(8) There is a large area of pulmonary vascular embolism and severe pulmonary hypertension</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:mesenchymal stem cells therapy;</Intervention>
    <Primary_outcome>Coronavirus nucleic acid markers negative rate;Symptoms improved after 4 treatments;Inflammation (CT of the chest);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030019</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational registration study using nCapp</Public_title>
    <Scientific_title>The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational registration study using nCapp                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Zhongshan Hospital Fudan University</Primary_sponsor>
    <Date_registration>2020-02-20</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49768</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-28</Date_enrollement>
    <Target_size>Training:150;Vaidation:450;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chunxue Bai</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>180 Fenglin Road, Xuhui District, Shanghai, China</Contact_Address>
    <Contact_Email>bai.chunxue@zs-hospital.sh.cn</Contact_Email>
    <Contact_Tel>+86 18621170011</Contact_Tel>
    <Contact_Affiliation>Zhongshan Hospital Fudan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-90 years;&lt;br&gt;2. With risk factor of COVID-19;&lt;br&gt;3. Access to nCapp platform;&lt;br&gt;4. to be able to complete a 1 year follow up.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Unable to access the nCapp platform</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Training:None;Vaidation:None;</Intervention>
    <Primary_outcome>Accuracy;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029851</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Zhongshan Hospital, Fudan University</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49534</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>35</Inclusion_agemin>
    <Inclusion_agemax>74</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-19</Date_enrollement>
    <Target_size>control group:34;Experience group:34;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Junbo Ge</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>180 Fenglin Road, Xuhui District, Shanghai, China</Contact_Address>
    <Contact_Email>jbge@zs-hospital.sh.cn</Contact_Email>
    <Contact_Tel>+86-21-64041990</Contact_Tel>
    <Contact_Affiliation>Zhongshan Hospital, Fudan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Severe patients diagnosed with novel coronavirus pneumonia (COVID-19);&lt;br&gt;2. Aged 35 years old to 74 years old;&lt;br&gt;3. Patients or authorized family members volunteered to participate in this study and signed informed consent.&lt;br&gt;Note: Case definition: Severe NCP: Refer to the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Fifth Edition)" formulated by the National Health Commission.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Involving in other drug clinical trial;&lt;br&gt;2. Pregnant or breastfeeding;&lt;br&gt;3. Presence of other serious diseases that may be life threatening, such as cancer;&lt;br&gt;4. Expected life is less than 24 hours;&lt;br&gt;5. Allergy to ALA or drugs of similar chemical classes (Vitamin B),previous history of intolerance to recommended target doses of alpha-LA;&lt;br&gt;6. diagnosed with diseases of immune system.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>control group:conventional therapy and placebo;Experience group:conventional therapy and ALA;</Intervention>
    <Primary_outcome>SOFA;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04252664</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Mild/Moderate 2019-nCoV Remdesivir RCT</Public_title>
    <Scientific_title>A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate 2019-nCoV Respiratory Disease.</Scientific_title>
    <Acronym />
    <Primary_sponsor>Capital Medical University</Primary_sponsor>
    <Date_registration>31/01/2020</Date_registration>
    <Date_registration3>20200131</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04252664</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 12, 2020</Date_enrollement>
    <Target_size>308</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). </Study_design>
    <Phase>Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Bin Cao, Professor;Ying Liu</Contact_Lastname>
    <Contact_Email>caobin@zryhyy.com.cn;</Contact_Email>
    <Contact_Tel>+01084206264;</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age =18 years at time of signing Informed Consent Form&lt;br&gt;&lt;br&gt;          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV.&lt;br&gt;&lt;br&gt;          3. Lung involvement confirmed with chest imaging&lt;br&gt;&lt;br&gt;          4. Hospitalised with:&lt;br&gt;&lt;br&gt;               -  Fever - =36.7? -axilla or Oral temperature = 38.0 ? or =38.6C tympanic or rectal&lt;br&gt;                  or&lt;br&gt;&lt;br&gt;               -  And at least one of Respiratory rate &gt;24/min Or Cough&lt;br&gt;&lt;br&gt;          5. =8 days since illness onset&lt;br&gt;&lt;br&gt;          6. Willingness of study participant to accept randomization to any assigned treatment&lt;br&gt;             arm.&lt;br&gt;&lt;br&gt;          7. Must agree not to enroll in another study of an investigational agent prior to&lt;br&gt;             completion of Day 28 of study.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Physician makes a decision that trial involvement is not in patients' best interest,&lt;br&gt;             or any condition that does not allow the protocol to be followed safely.&lt;br&gt;&lt;br&gt;          2. Severe liver disease (e.g. Child Pugh score = C, AST&gt;5 times upper limit)&lt;br&gt;&lt;br&gt;          3. SaO2/SPO2=94% in room air condition, or the Pa02/Fi02 ratio &lt;300mgHg&lt;br&gt;&lt;br&gt;          4. Known allergic reaction to remdesivir&lt;br&gt;&lt;br&gt;          5. Patients with known severe renal impairment (estimated glomerular filtration rate =30&lt;br&gt;             mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis,&lt;br&gt;             peritoneal dialysis&lt;br&gt;&lt;br&gt;          6. Pregnant or breastfeeding, or positive pregnancy test in a predose examination&lt;br&gt;&lt;br&gt;          7. Will be transferred to another hospital which is not the study site within 72 hours.&lt;br&gt;&lt;br&gt;          8. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or&lt;br&gt;             trial related) within the 30 days prior to the time of the screening evaluation.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV</Condition>
    <Intervention>Drug: Remdesivir;Drug: Remdesivir placebo</Intervention>
    <Primary_outcome>Time to Clinical recoveryTime to Clinical Recovery (TTCR)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029434</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Hebei Yiling Hospital, Renmin Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-01</Date_registration>
    <Date_registration3>20200201</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48889</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Routine treatment + Lianhua Qingwen Capsules/granules:120;Conventional treatment:120;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhong Nanshan/Zhang Boli/Li Lanjuan/Duan Zhongping/Li Xingwang/Liu Qingquan/Song Yuanlin/Jia Zhenhua</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>385 Xinshi Road North, Qiaoxi District, Shijiazhuang, Hebei, China</Contact_Address>
    <Contact_Email>jiactm@163.com</Contact_Email>
    <Contact_Tel>+86 0311 83855881</Contact_Tel>
    <Contact_Affiliation>Hebei Yiling Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;&lt;br&gt;2. Above 18 years old (inclusive);&lt;br&gt;3. At the time of enrollment, the patient had any of the main symptoms (fever, cough, fatigue);&lt;br&gt;4. Voluntarily sign written informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development;&lt;br&gt;2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory tracts diseases that affecting clinical trial evaluation . Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis;&lt;br&gt;3. Severe pneumonia requires mechanical ventilation;&lt;br&gt;4. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;&lt;br&gt;5. Pregnant or lactating women;&lt;br&gt;6. Patients who participated in other clinical trials within the last 3 months;&lt;br&gt;7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug;&lt;br&gt;8. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;</Intervention>
    <Primary_outcome>Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04255017</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia</Public_title>
    <Scientific_title>An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tongji Hospital</Primary_sponsor>
    <Date_registration>02/02/2020</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04255017</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 1, 2020</Date_enrollement>
    <Target_size>400</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). </Study_design>
    <Phase>Phase 4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Qing Ning, Professor;Qin Ning, professor</Contact_Lastname>
    <Contact_Email>qning@vip.sina.com;qning@vip.sina.com</Contact_Email>
    <Contact_Tel>+8613971521450;</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. 2019-nCoV nucleic acid test was positive.&lt;br&gt;&lt;br&gt;          2. CT of the lung conformed to the manifestation of viral pneumonia.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients who meet any of the contraindications in the experimental drug labeling&lt;br&gt;&lt;br&gt;          2. Patients who do not want to participate in this clinical study&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV</Condition>
    <Intervention>Drug: Abidol hydrochloride;Drug: Oseltamivir;Drug: Lopinavir/ritonavir</Intervention>
    <Primary_outcome>Rate of disease remission;Time for lung recovery</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029999</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Shanghai 10th people's hospital</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49717</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Mild Group:30;Severe Group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Peng Hu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>301 Yanchang Middle Road, Shanghai, China</Contact_Address>
    <Contact_Email>18917683122@189.cn</Contact_Email>
    <Contact_Tel>+86 18917683122</Contact_Tel>
    <Contact_Affiliation>Shanghai 10th People's Hospital, Tongji University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. aged &gt;=18 years;&lt;br&gt;2. Gender limitation;&lt;br&gt;3. Patients must be able to sign informed consent and understand the possible risks of microecological intervention;&lt;br&gt;4. Be willing to provide stool and blood samples on time.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. patients with dysphagia or gastrointestinal obstruction;&lt;br&gt;2. Patients with autoimmune diseases, or with extremely low immunity, or with other diseases requiring systemic use of immunosuppressive drugs or hormone therapy;&lt;br&gt;3. Human immunodeficiency virus (HIV) positive or active hepatitis b or c infection;&lt;br&gt;4. Pregnant or nursing women;&lt;br&gt;5. After evaluation, the researcher believes that the study is not conducive to patients and is not suitable for other conditions of study participation.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia</Condition>
    <Intervention>Mild Group:probiotics;Severe Group:probiotics;</Intervention>
    <Primary_outcome>gut microbiome;Fecal metabolomics;Blood routine;albumin;serum potassium;CRP;ALT;AST;urea;Cr;urea nitrogen;D-Dimer;ESR;IgG;IgM;IgA;hepatitis B surface antigen;2-microglobulin;IFN-gama;IL-6;TNF-beta;IL-10;IL-2;IL-4;IL-13;IL-12;chest CT;abdominal CT;ECG;Weight;height;body temperature;respiratory rate;Heart Rate;Blood Pressure;Defecate frequency;Bristol grading;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029992</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Zhongshan Hospital Affiliated to Xiamen University</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49574</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Chloroquine phosphate gloup:40; Hydroxychloroquine sulfate gloup:40;Routine treatment group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yin Zhenyu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>201-209 Hubin Road South, Siming District, Xiamen, Fujian</Contact_Address>
    <Contact_Email>Yinzy@xmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13950120518</Contact_Tel>
    <Contact_Affiliation>Zhongshan Hospital Affiliated to Xiamen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. The age at the time of signing the informed consent is &gt;= 18 years old and &lt;= 75 years old, both male and female; &lt;br&gt;2. The change of typical viral pneumonia in lung was detected by RT-PCR test of novel coronavirus nucleic acids or lung CT; &lt;br&gt;3. SaO2 / SpO2 &lt;= 94% or pa02 / fi02 ratio &lt; 300mghg at room temperature at admission; &lt;br&gt;4. Onset &lt;=12 days; &lt;br&gt;5. Willing to participate in the trial and randomly assigned to any treatment group; &lt;br&gt;6. Cannot participate in another experiment during the study period.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. In the opinion of the researchers, the participation of the trial is not in the best interests of the patients, or any situation is not in line with the situation that the trial scheme is allowed to be followed safely;&lt;br&gt;2. According to the judgment of the investigator, the diseases previously or now may affect the patients' participation in the trial or the outcome of the study, including but not limited to: malignant tumors, autoimmune diseases, liver and kidney diseases, cardiovascular system diseases (including but not limited to having a clear history of heart disease, cardiac arrhythmia and ECG QT Patients with prolonged interval), nervous system diseases, mental system diseases, active bleeding, severe malnutrition and endocrine diseases; patients with severe respiratory system diseases or diseases seriously affecting the immune system, such as: influenza, COPD, asthma, human immunodeficiency virus (HIV) infection, or blood system diseases, or splenectomy, organ transplantation, etc.;&lt;br&gt;3. Severe liver disease (AST &gt; 3 times of upper limit);&lt;br&gt;4. Patients with known renal insufficiency (estimated glomerular filtration rate &lt;= 60ml / min / 1.73 m2 or continuous renal replacement therapy, hemodialysis, peritoneal dialysis;&lt;br&gt;5. Extended QT interval in ECG;&lt;br&gt;6. Allergic to chloroquine or hydroxychloroquine;&lt;br&gt;7. Pregnant or lactating or positive pregnancy test during pre medication examination;&lt;br&gt;8. Transfer to another hospital within 72 hours;&lt;br&gt;9. Receive any trial treatment drug for 2019-ncov within 14 days prior to screening evaluation (off label, compassionate use or trial related).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Chloroquine phosphate gloup:Chloroquine phosphate1.0gx2 days for the first dose, 0.5gx12 day from the third day   ; Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days;Routine treatment group:Recommended treatment plan for novel coronavirus pneumonia severe and critical cases;</Intervention>
    <Primary_outcome>Clinical recovery time;Clinical recovery time;Changes in viral load of upper and lower respiratory tract samples compared with the baseline;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030004</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Effect of Novel Coronavirus Pneumonia (COVID-19) on the Mental Health of College Students</Public_title>
    <Scientific_title>Effect of New Coronavirus Pneumonia (COVID-19) on the Mental Health of College Students                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49783</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax>30</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>college students:150000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Tao Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>28 South Dianxin Street, Wuhou District, Chengdu, Sichuan, China </Contact_Address>
    <Contact_Email>xuntao26@hotmail.com</Contact_Email>
    <Contact_Tel>+86 18980601817</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All students from Sichuan University will be invited to participate in this research. Students will voluntarily participate in the study and ask for an informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: None</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia</Condition>
    <Intervention>college students:none;</Intervention>
    <Primary_outcome>Mental health status;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030003</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Optimization Protocal of Integrated Traditional Chinese and Western Medicine in the Treatment for Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Optimization Protocal of Integrated Traditional Chinese and Western Medicine Treatment for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Hospital of Chengdu University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49770</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-19</Date_enrollement>
    <Target_size>Group 1:120;Group 2:240;Group 3:120;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Tang Jianyuan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>tangjianyuan163@163.com</Contact_Email>
    <Contact_Tel>+86 13910768464</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of Chengdu University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Patients with mild who are in compliance with the "Pneumonitis Diagnosis and Treatment Program for COVID-19(Trial Fifth Edition)" (released on 2020.2.4);&lt;br&gt;(2) Aged more than 18 years old;&lt;br&gt;(3) Informed consent of the patient.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 1:Traditional Chinese Medicine prescription No. 1 and 2;Group 2:Gankeshuangqing capsule;Group 3:Shuanghuanglian oral liquid;</Intervention>
    <Primary_outcome>hospital stay;Discharge rate;Site-specific hospital metastasis rate or severe conversion rate;Body temperature normalization time;Clinical symptoms disappearance rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04256395</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19</Public_title>
    <Scientific_title>Registry Study on the Efficacy of a Self-test and Self-alert Applet in Detecting Susceptible Infection of COVID-19 a Population Based Mobile Internet Survey</Scientific_title>
    <Acronym>COVID-19</Acronym>
    <Primary_sponsor>Beijing Tsinghua Chang Gung Hospital</Primary_sponsor>
    <Date_registration>01/02/2020</Date_registration>
    <Date_registration3>20200201</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04256395</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 1, 2020</Date_enrollement>
    <Target_size>300000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Jiahong Dong, M.D;Xiaobin Feng, M.D;Xiaobin Feng, M.D</Contact_Lastname>
    <Contact_Email>;fengxiaobin200708@aliyun.com;</Contact_Email>
    <Contact_Tel>;+86 13228683243;</Contact_Tel>
    <Contact_Affiliation>Beijing Tsinghua Changgung Hospital;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  people who lived in or out of China at present and threatened by the infection and&lt;br&gt;             spread of COVID-19&lt;br&gt;&lt;br&gt;               -  without gender and age restriction&lt;br&gt;&lt;br&gt;               -  people who have concerns of his health&lt;br&gt;&lt;br&gt;               -  voluntary completion of the self-test and evaluation.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  people who are not internet accessible or can not use this Mobile Applet.&lt;br&gt;&lt;br&gt;          -  people who can not recognize the questionnaire.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Susceptibility to Viral and Mycobacterial Infection</Condition>
    <Intervention>Other: mobile internet survey on self-test</Intervention>
    <Primary_outcome>positive number diagnosed by national guideline in the evaluated population</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04273321</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Corticosteroids in COVID-19</Public_title>
    <Scientific_title>Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails</Scientific_title>
    <Acronym />
    <Primary_sponsor>Beijing Chao Yang Hospital</Primary_sponsor>
    <Date_registration>15/02/2020</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04273321</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 14, 2020</Date_enrollement>
    <Target_size>400</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Bing Sun, MD</Contact_Lastname>
    <Contact_Email>ricusunbing@126.com</Contact_Email>
    <Contact_Tel>86013911151075</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  age more than 18 years old&lt;br&gt;&lt;br&gt;          -  accord with the clinical diagnosis and/ or etiological diagnosis diagnostic criteria&lt;br&gt;             of Novel coronavirus pneumonia (COVID-19).&lt;br&gt;&lt;br&gt;          -  admitted in the general wards&lt;br&gt;&lt;br&gt;          -  be able to sign informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  severe immunosuppression (HIV infection, long-term use of immunosuppressive agents&lt;br&gt;&lt;br&gt;          -  pregnant or lactation period women&lt;br&gt;&lt;br&gt;          -  glucocorticoids are needed for other diseases&lt;br&gt;&lt;br&gt;          -  unwilling or unable to participate or complete the study&lt;br&gt;&lt;br&gt;          -  participate in other study&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19;Novel Coronavirus Pneumonia</Condition>
    <Intervention>Drug: Methylprednisolone</Intervention>
    <Primary_outcome>the incidence of treatment failure in 14 days</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04273529</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia</Public_title>
    <Scientific_title>The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>First Affiliated Hospital of Wenzhou Medical University</Primary_sponsor>
    <Date_registration>14/02/2020</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04273529</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 20, 2020</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). </Study_design>
    <Phase>Phase 2</Phase>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Jinglin Xia, MD;Jinglin Xia, MD</Contact_Lastname>
    <Contact_Email>;xiajinglin@fudan.edu.cn</Contact_Email>
    <Contact_Tel>;0577-55578166</Contact_Tel>
    <Contact_Affiliation>First Affiliated Hospital of Wenzhou Medical University;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age =18 years;&lt;br&gt;&lt;br&gt;          2. Laboratory (RT-PCR) diagnosis of common patients infected with COVID-19 (refer to the&lt;br&gt;             fifth edition of the Chinese Guidelines for Diagnosis and Treatment);&lt;br&gt;&lt;br&gt;          3. chest imaging confirmed lung damage;&lt;br&gt;&lt;br&gt;          4. The diagnosis is less than or equal to 8 days;&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Severe liver disease (such as Child Pugh score = C, AST&gt; 5 times the upper limit);&lt;br&gt;             severe renal dysfunction (the glomerulus is 30ml / min / 1.73m2 or less)&lt;br&gt;&lt;br&gt;          2. Positive pregnancy or breastfeeding or pregnancy test;&lt;br&gt;&lt;br&gt;          3. In the 30 days before the screening assessment, have taken any experimental treatment&lt;br&gt;             drugs for COVID-19 (including off-label, informed consent use or trial-related);&lt;br&gt;&lt;br&gt;          4. Those with a history of thromboembolism, except for those caused by PICC.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19 Thalidomide</Condition>
    <Intervention>Drug: thalidomide;Drug: placebo</Intervention>
    <Primary_outcome>Time to Clinical recoveryTime to Clinical Recovery (TTCR)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030002</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49738</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>control group:30;Experience group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hongliang He</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>17 Lujiang Road, Luyang District, Hefei, Anhui, China</Contact_Address>
    <Contact_Email>44271370@qq.com</Contact_Email>
    <Contact_Tel>+86 15956927046</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital) </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. The patients who were diagnosed with the common type of NCP (including severe risk factors) and severe cases of new coronavirus pneumonia;&lt;br&gt;2. Aged 18 to 85 years;&lt;br&gt;3. IL-1 elevated (using Elisa method, using the same company kit);&lt;br&gt;4. Patients or authorized family members volunteered to participate in this study and signed informed consent;&lt;br&gt;Definition of Novel Coronavirus Pneumonia (NCP) clinical cases:&lt;br&gt;1. Regular patients with NCP (including severe risk factors): patients with dual pulmonary lesions based on common NCP clinical symptoms accompanied by fever or no fever;&lt;br&gt;2. Critical NCP patient: Refer to the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Fifth Edition)" formulated by the National Health Commission. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who are participating in other drug clinical trials;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. ALT / AST&gt; 5 ULN, neutrophils &lt;0.5, platelets less than 50;&lt;br&gt;4. Expected life&lt;1 week;&lt;br&gt;5. Definite diagnosis of asthma-related diseases;&lt;br&gt;6. Long-term oral anti-rejection or immunomodulatory drugs;&lt;br&gt;7. Hypersensitivity to tocilizumab or any excipients;&lt;br&gt;8. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>control group:conventional therapy;Experience group:conventional therapy and Tranilast;</Intervention>
    <Primary_outcome>cure rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029989</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Chinese PLA General Hospital</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49720</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>60</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>experimental group.:150;Control group:150;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Feng Cao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>28 Fuxing Road, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>fengcao8828@163.com</Contact_Email>
    <Contact_Tel>+86 13911798280</Contact_Tel>
    <Contact_Affiliation>Chinese PLA General Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=60 years;&lt;br&gt;2. Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)";&lt;br&gt;3. Those without broad-spectrum antibacterial, antifungal, and antiviral treatment;&lt;br&gt;4. Imaging revealed pneumonia in patients with a diagnosis of pathogen: influenza, CAP/HAP bacterial infection, and fungal infection;&lt;br&gt;5. Participants signed informed consent before the study;&lt;br&gt;6. It must be agreed not to participate in other clinical studies until the 28th day of completion.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. critically ill patients based on the New Protocol for Diagnosis and Treatment of NCP;&lt;br&gt;2. Patients with eye diseases (such as cataract, conjunctivitis, glaucoma)&lt;br&gt;3. Severe liver disease (such as  AST &gt; 3 ULN);&lt;br&gt;4. Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;=30ml/min/1.73m2) or continuous renal replacement therapy, hemodialysis or peritoneal dialysis;&lt;br&gt;5. Pregnant or breast-feeding women;&lt;br&gt;6. Patients may be transferred to non-designated hospitals within 72 hours;&lt;br&gt;7. Patients who have participated in other clinical trials in the past 7 days;&lt;br&gt;8. Allergic constitution, such as those who are allergic to two or over twodrugs ,with history of food allergies, or known to be allergic to the ingredients of this drug;&lt;br&gt;9. In the opinion of the investigator, subjects who are not suitable for enrollment or with any factors that affect the outcome of the trial. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group.:Recombinant Human Interferon a1b Eye Drops ;Control group:placebo drop;</Intervention>
    <Primary_outcome>Arterial Blood Oxygen Saturation;TTCR,Time to Clinical recovery;temperature;respiratory rate;Lung CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029990</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49674</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-30</Date_enrollement>
    <Target_size>experimental group:60;control group:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>1-2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Robert Chunhua Zhao/Ronghua Jin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>5 Shantiao Street, Dongdan, Dongcheng District, Beijing, China</Contact_Address>
    <Contact_Email>zhaochunhua@vip.163.com</Contact_Email>
    <Contact_Tel>+86 010-65125311</Contact_Tel>
    <Contact_Affiliation>institute of basic medicine, Chinese Academy of medical sciences</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Male or female, 18-95 years old;&lt;br&gt;2. 2019 new coronavirus nucleic acid test positive;&lt;br&gt;3. Diagnosed as moderate to severe cases of new coronavirus pneumonia in 2019, which meets the following clinical manifestations:&lt;br&gt;4. With fever and respiratory symptoms, imaging shows pneumonia;&lt;br&gt;5. A severe case diagnosed with 2019 new coronavirus pneumonia, that is, any of the following:&lt;br&gt;(1) Increased breathing rate (&gt;=30 beats / min), difficulty breathing, cyanosis of lips;&lt;br&gt;(2) In the resting state, it means that oxygen saturation &lt;=93%; or blood oxygen drops rapidly;&lt;br&gt;(3) Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) &lt;=300mmHg (1mmHg = 0.133kPa);&lt;br&gt;6. I or the authorized agent signed the informed consent form;&lt;br&gt;7. Agree to collect clinical samples.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Malignant disease in the past five years;&lt;br&gt;2. The clinical prediction is that there is no hope for survival, only cases of hospice care, or cases of deep coma that do not respond to supportive treatment measures within three hours of admission;&lt;br&gt;3. Subjects who are participating in other clinical trials or within 3 months;&lt;br&gt;4. Cases of very severe shock and respiratory failure.</Exclusion_Criteria>
    <Condition>pneumonitis caused by novel coronavirus</Condition>
    <Intervention>experimental group:mesenchymal stem cells;control group:saline;</Intervention>
    <Primary_outcome>Improved respiratory system function (blood oxygen saturation) recovery time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029981</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions</Public_title>
    <Scientific_title>Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49692</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Female</Inclusion_gender>
    <Date_enrollement>2020-02-18</Date_enrollement>
    <Target_size>Target condition:60;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Shixuan Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>sxwang@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 02783663078</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 years old female;&lt;br&gt;2. A history of fertility or sexual activity&lt;br&gt;3. Meet the pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic criteria of Hubei province: including clinical diagnosis and etiological diagnosis;&lt;br&gt;4. Sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients that the researchers determined not suitable for this study</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic criteria of Hubei province: including clinical diagnosis and Pathogenic nucleic acid test of pharynx swab.;Index test:expression&amp;#32;of&amp;#32;sars-cov-2&amp;#32;nucleic&amp;#32;acid&amp;#32;in&amp;#32;vaginal&amp;#32;secretions;</Intervention>
    <Primary_outcome>SARS-COV-2 nucleic acid;SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04273581</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19</Public_title>
    <Scientific_title>The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>First Affiliated Hospital of Wenzhou Medical University</Primary_sponsor>
    <Date_registration>14/02/2020</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04273581</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 18, 2020</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). </Study_design>
    <Phase>Phase 2</Phase>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Jinglin Xia, MD;Jinglin Xia, MD</Contact_Lastname>
    <Contact_Email>;xiajinglin@fudan.edu.cn</Contact_Email>
    <Contact_Tel>;0577-55578166</Contact_Tel>
    <Contact_Affiliation>First Affiliated Hospital of Wenzhou Medical University;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age =18 years;&lt;br&gt;&lt;br&gt;          2. The laboratory (RT-PCR) confirmed the diagnosis of severe patients infected with&lt;br&gt;             CoVID-19 (refer to the fifth edition of the Chinese diagnosis and treatment guideline&lt;br&gt;             for trial); the diagnosis of new coronavirus pneumonia was confirmed, and any of the&lt;br&gt;             following: 1) Respiratory distress, breathing =30 beats / min; 2) In the resting&lt;br&gt;             state, the oxygen saturation is =93%; 3) Arterial blood oxygen partial pressure /&lt;br&gt;             oxygen concentration =300mmHg&lt;br&gt;&lt;br&gt;          3. The diagnosis is less than or equal to 12 days;&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Severe liver disease (such as Child Pugh score = C, AST&gt; 5 times the upper limit);&lt;br&gt;             severe renal dysfunction (the glomerulus is 30ml / min / 1.73m2 or less)&lt;br&gt;&lt;br&gt;          2. Pregnancy or breastfeeding or positive pregnancy test;&lt;br&gt;&lt;br&gt;          3. In the 30 days before the screening assessment, have taken any experimental treatment&lt;br&gt;             drugs for CoVID-19 (including off-label, informed consent use or trial-related);&lt;br&gt;&lt;br&gt;          4. Those with a history of thromboembolism, except for those caused by PICC.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19 Thalidomide</Condition>
    <Intervention>Drug: placebo;Drug: Thalidomide</Intervention>
    <Primary_outcome>Time to Clinical Improvement (TTCI)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04274322</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool</Public_title>
    <Scientific_title>Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool (COV_NUTRIC)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Peking University Third Hospital</Primary_sponsor>
    <Date_registration>16/02/2020</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04274322</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 2020</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Qinggang Ge, M.D.</Contact_Lastname>
    <Contact_Email>qingganggelin@126.com</Contact_Email>
    <Contact_Tel>86-10-82266699</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Admitted to intensive care unit (ICU), Peking University Third Hospital since Feb 2020&lt;br&gt;&lt;br&gt;          -  Adult (aged over 18 years)&lt;br&gt;&lt;br&gt;          -  Anticipate a length of ICU stay (LOS) of more than 48 hours&lt;br&gt;&lt;br&gt;          -  Diagnosed as 2019 coronavirus disease (COVID-19)&lt;br&gt;&lt;br&gt;          -  With food intake difficulties (can't intake food by oneself)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  aged under 18 years&lt;br&gt;&lt;br&gt;          -  Actual ICU LOS of less than 48 hours&lt;br&gt;&lt;br&gt;          -  Using medications of IL-6 or IL-6R&lt;br&gt;&lt;br&gt;          -  Overdose&lt;br&gt;&lt;br&gt;          -  Written informed consent not obtained in the prospective cohort&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Critically Ill;Coronavirus Infections</Condition>
    <Intervention>Other: Nutrition support</Intervention>
    <Primary_outcome>28-day all cause mortality</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04275414</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia</Public_title>
    <Scientific_title>A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)</Scientific_title>
    <Acronym>BEST-CP</Acronym>
    <Primary_sponsor>Qilu Hospital of Shandong University</Primary_sponsor>
    <Date_registration>14/02/2020</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04275414</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 2020</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Yuguo Chen, Dr;Jiaojiao Pang, Dr;Jiaojiao Pang</Contact_Lastname>
    <Contact_Email>;jiaojiaopang@126.com;jiaojiaopang@126.com</Contact_Email>
    <Contact_Tel>;(086)0531-82166843;(086)0531-82166843</Contact_Tel>
    <Contact_Affiliation>Qilu Hospital of Shandong University;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age 18 to 80.&lt;br&gt;&lt;br&gt;          2. Confirmed COVID-19 diagnosis(including the clinically confirmed cases in Hubei).&lt;br&gt;&lt;br&gt;          3. Accord with any of the following: ? Respiratory distress, RR = 30 breaths/min; ? SpO2&lt;br&gt;             = 93% at rest; ? Partial arterial oxygen pressure (PaO2) / Fraction of inspiration O2&lt;br&gt;             (FiO2) = 300mmHg (1mmHg = 0.133kPa).&lt;br&gt;&lt;br&gt;          4. Chest imaging confirms lung involvement and has inflammatory exudation or pleural&lt;br&gt;             effusion.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Cannot obtain informed consent.&lt;br&gt;&lt;br&gt;          2. Severe hepatic dysfunction (Child Pugh score = C, or AST&gt; 5 times the upper limit);&lt;br&gt;             Severe renal dysfunction (estimated glomerular filtration rate = 30mL / min / 1.73 m2)&lt;br&gt;             or receive continuous renal replacement therapy, hemodialysis, or peritoneal dialysis.&lt;br&gt;&lt;br&gt;          3. Unsatisfactory controlled hypertension (seated systolic blood pressure&gt; 160mmHg, or&lt;br&gt;             diastolic blood pressure&gt; 100mmHg); previous history of hypertension crisis or&lt;br&gt;             hypertensive encephalopathy.&lt;br&gt;&lt;br&gt;          4. Poorly controlled heart diseases, such as NYHA class II and above cardiac&lt;br&gt;             insufficiency, unstable angina pectoris, myocardial infarction within 1 year before&lt;br&gt;             enrollment, supraventricular or ventricular arrhythmia need treatment or intervention.&lt;br&gt;&lt;br&gt;          5. Hereditary bleeding tendency or coagulopathy; received full-dose anticoagulant or&lt;br&gt;             thrombolytic therapy within10 days before enrollment, or have taken non-steroidal&lt;br&gt;             anti-inflammatory drugs with platelet suppression within 10 days before enrollment&lt;br&gt;             (Except those who use small doses of aspirin =325mg / day for preventive use).&lt;br&gt;&lt;br&gt;          6. Thrombosis within 6 months before enrollment. And from those patients, screen who had&lt;br&gt;             arterial / venous thromboembolic events, such as, ischemic stroke, transient ischemic&lt;br&gt;             attack, deep venous thrombosis, pulmonary embolism, etc. within 1 year ahead of&lt;br&gt;             enrollment. Severe vascular disease (including aneurysms or arterial thrombosis&lt;br&gt;             requiring surgery) within 6 months before enrollment.&lt;br&gt;&lt;br&gt;          7. Unhealed wounds, active gastric ulcers or fractures. Gastrointestinal perforation,&lt;br&gt;             gastrointestinal fistula, abdominal abscess, visceral fistula formation within 6&lt;br&gt;             months before enrollment. Major surgery (including preoperative Chest biopsy) or major&lt;br&gt;             trauma (such as a fracture) within 28 days before enrollment. May have surgery during&lt;br&gt;             the trial.&lt;br&gt;&lt;br&gt;          8. Severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous&lt;br&gt;             system bleeding, and nosebleeds within 1 month before enrollment.&lt;br&gt;&lt;br&gt;          9. Malignant tumors within 5 years before enrollment.&lt;br&gt;&lt;br&gt;         10. Allergic to bevacizumab or its components.&lt;br&gt;&lt;br&gt;         11. Untreated active hepatitis or HIV-positive patients.&lt;br&gt;&lt;br&gt;         12. Pregnant and lactating women and those planning to get pregnant.&lt;br&gt;&lt;br&gt;         13. Participated in other clinical trials, not considered suitable for this study by the&lt;br&gt;             researchers.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus Infections</Condition>
    <Intervention>Drug: Bevacizumab Injection</Intervention>
    <Primary_outcome>Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029988</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49218</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-13</Date_enrollement>
    <Target_size>Experimental group:40;Control group:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhao Yan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>doctoryanzhao@whu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13995577963</Contact_Tel>
    <Contact_Affiliation>Zhongnan Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Male and female, 18-70 years old;&lt;br&gt;2) Severe patients (in any case: respiratory distress, RR &gt;= 30 times / min; in resting state, oxygen saturation &lt;= 93%; PaO2 / FiO2 &lt;= 300MMHG);&lt;br&gt;3) Within 12 days after illness onset;&lt;br&gt;4) Agree to sign the informed consent;&lt;br&gt;5) Able to ingest, absorb and tolerate oral medication;&lt;br&gt;6) Agree to collect clinical samples;&lt;br&gt;7) Consent to contraceptive measures for sex within 7 days of the last oral medication.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Cases with severe vomiting and difficulty in taking drugs orally or causing difficulty in taking drugs after oral administration;&lt;br&gt;2) Pregnant and lactating women;&lt;br&gt;3) The subjects received specific antiviral drugs such as lopinavir / lidonavir, ribavirin and monoclonal antibody within one week before admission;&lt;br&gt;4) Cases with no hope of survival, hospice care only, or deep coma and no response to supportive treatment within three hours after admission;&lt;br&gt;5) Cases of deep shock and respiratory failure;&lt;br&gt;6) Severe liver diseases (such as child Pugh score &gt;= C, AST more than 5 times of the upper limit of normal);&lt;br&gt;7) Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;= 30ml / min / 1.73m2) or undergoing continuous renal replacement therapy, hemodialysis, peritoneal dialysis;&lt;br&gt;8) Patients with known allergic reactions or contraindications to chloroquine phosphate;&lt;br&gt;9) The doctor decided that it was not in the best interests of the subjects to participate in the study, or there was any situation in which the agreement could not be followed safely.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>Experimental group:Chloroquine Phosphate;Control group:No;</Intervention>
    <Primary_outcome>Time to Clinical Recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029985</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Study for mental health status and influencing factors of nurses during epidemic prevention of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study on mental health status and influencing factors of nurses during epidemic prevention of Novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Sichuan Academy of Medical Sciences &amp; Sichuan Provincial Peoples Hospital</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49711</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>22</Inclusion_agemin>
    <Inclusion_agemax>55</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Case series:1853;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Caixia Xie</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>32 West Second Section, First Ring Road, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>8999578@qq.com</Contact_Email>
    <Contact_Tel>+86 13699093647</Contact_Tel>
    <Contact_Affiliation>Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) nurses with working years &gt;=1 year;&lt;br&gt;(2) registered nurses who are qualified to practice;&lt;br&gt;(3) nurses who volunteered to participate in this study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) advanced and trainee nurses; &lt;br&gt;(2) nurses during the investigation period due to leave (sickness, affairs, pregnancy, etc.) reasons not post.</Exclusion_Criteria>
    <Condition>NO</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>HSCS;SCSQ;GHQ-12;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04261270</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia</Public_title>
    <Scientific_title>A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tongji Hospital</Primary_sponsor>
    <Date_registration>04/02/2020</Date_registration>
    <Date_registration3>20200204</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04261270</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>55 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 1, 2020</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). </Study_design>
    <Phase>Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Qing Ning, Professor;Qin Ning, professor</Contact_Lastname>
    <Contact_Email>qning@vip.sina.com;qning@vip.sina.com</Contact_Email>
    <Contact_Tel>+8613971521450;</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age:18~55 years old, unlimited gender.&lt;br&gt;&lt;br&gt;          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV and accompanied with clinical&lt;br&gt;             manifestations.&lt;br&gt;&lt;br&gt;          3. Patients with newly diagnosed respiratory discomfort who have been hospitalized (The&lt;br&gt;             proper diagnosis time is less than 7 days).&lt;br&gt;&lt;br&gt;          4. Women who have no planned pregnancy in the next six months,and are willing to take&lt;br&gt;             effective measures to prevent contraception from the first dose of study drug to 30&lt;br&gt;             days after the last dose.&lt;br&gt;&lt;br&gt;          5. Agree not to participate in other clinical studies within 30 days from the first dose&lt;br&gt;             of the study drug to the last dose.&lt;br&gt;&lt;br&gt;          6. Patients who voluntarily sign informed consent forms.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        1.2019-nCoV severe Pneumonia patients.&lt;br&gt;&lt;br&gt;        Meet the definition of severe pneumonia(Comply with any of the followings):&lt;br&gt;&lt;br&gt;          1. Respiratory distress ,RR=30 bpm;&lt;br&gt;&lt;br&gt;          2. In a resting state:SPO2=93%;&lt;br&gt;&lt;br&gt;          3. PaO2/ FiO2=300mmHg.&lt;br&gt;&lt;br&gt;             2.2019-nCoV critical and severe Pneumonia patients.Comply with any of the&lt;br&gt;             followings:Respiratory failure and need mechanical ventilation;Shock;Patients combined&lt;br&gt;             with other organ failure need ICU monitoring and treatment.&lt;br&gt;&lt;br&gt;             3.Severe liver disease(such as:the ChildPugh score=C;AST &gt; 5 times the upper limit).&lt;br&gt;&lt;br&gt;             4.Patients who are allergic to the ingredients of ASC09/ritonavir compound tablets.&lt;br&gt;&lt;br&gt;             5.Patients with definite contraindications in ritonavir tablets.&lt;br&gt;&lt;br&gt;             6.Female subjects were positive for the pregnancy test during the screening period.&lt;br&gt;&lt;br&gt;             7.Researcher judges unsuitable for participation in this clinical trial(such as:during&lt;br&gt;             the study patients may be transferred to hospital for treatment;patients with multiple&lt;br&gt;             underlying diseases, etc)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV Pneumonia</Condition>
    <Intervention>Drug: ASC09F+Oseltamivir;Drug: Ritonavir+Oseltamivir;Drug: Oseltamivir</Intervention>
    <Primary_outcome>Rate of comprehensive adverse outcome</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04285801</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study</Public_title>
    <Scientific_title>Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Chinese University of Hong Kong</Primary_sponsor>
    <Date_registration>24/02/2020</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04285801</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 14, 2020</Date_enrollement>
    <Target_size>8</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>Hong Kong</Countries>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  admission to ICU&lt;br&gt;&lt;br&gt;          -  adult (=18 years old)&lt;br&gt;&lt;br&gt;          -  confirmed case of 2019-nCov infection by 2019-nCov RNA by reverse transcription&lt;br&gt;             polymerase chain reaction , isolation in cell culture of 2019-nCov from a clinical&lt;br&gt;             specimen or serum antibody to 2019-nCov&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        - none&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Primary_outcome>28 day mortality</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04288713</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Eculizumab (Soliris) in Covid-19 Infected Patients</Public_title>
    <Scientific_title>Soliris to Stop Immune Mediated Death In Covid 19 Infected Patients. A Trial of Distal Complement Inhibition.</Scientific_title>
    <Acronym>SOLID-C19</Acronym>
    <Primary_sponsor>Hudson Medical</Primary_sponsor>
    <Date_registration>27/02/2020</Date_registration>
    <Date_registration3>20200227</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04288713</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 2020</Date_enrollement>
    <Target_size />
    <Study_type>Expanded Access</Study_type>
    <Study_design />
    <Phase>Phase 2</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Thomas C Pitts, M.D.</Contact_Lastname>
    <Contact_Email>Drpitts@hudsonmedical.com</Contact_Email>
    <Contact_Tel>6465967386</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  COVID-19 positive patients over the age of 18.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients who are currently intubated.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus</Condition>
    <Intervention>Drug: Eculizumab</Intervention>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04290871</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.</Public_title>
    <Scientific_title>Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.</Scientific_title>
    <Acronym>NOSARSCOVID</Acronym>
    <Primary_sponsor>Xijing Hospital</Primary_sponsor>
    <Date_registration>27/02/2020</Date_registration>
    <Date_registration3>20200227</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04290871</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 1, 2020</Date_enrollement>
    <Target_size>104</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). </Study_design>
    <Phase>Phase 2</Phase>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Chong Lei, MD, PhD;Lorenzo Berra, MD;Lei Chong, MD, PhD</Contact_Lastname>
    <Contact_Email>;;crystalleichong@126.com</Contact_Email>
    <Contact_Tel>;;+86-18629011362</Contact_Tel>
    <Contact_Affiliation>Fourth Military Medical University;Massachusetts General Hospital;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age =18 years&lt;br&gt;&lt;br&gt;          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV&lt;br&gt;&lt;br&gt;          3. PaO2/FiO2 &lt; 300 or SpO2 below 93% breathing ambient air&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Physician makes a decision that trial involvement is not in the patient's best&lt;br&gt;             interest, or any condition that does not allow the protocol to be followed safely&lt;br&gt;&lt;br&gt;          2. Pregnant or positive pregnancy test in a pre-dose examination&lt;br&gt;&lt;br&gt;          3. Use of high flow nasal cannula&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus;SARS (Severe Acute Respiratory Syndrome)</Condition>
    <Intervention>Drug: Nitric Oxide Gas</Intervention>
    <Primary_outcome>SARS-free patients at 14 days</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029974</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Qingdao East Sea Pharmaceutical Co., Ltd.</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49321</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-09</Date_enrollement>
    <Target_size>Experimental group:150;Control group:150;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Dong Liang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1377 Jiao-Zhou-Wan Road West, Yinzhou Street, Huangdao District, Qingdao, Shandong, China</Contact_Address>
    <Contact_Email>dl5506@126.com</Contact_Email>
    <Contact_Tel>+86 18560082787</Contact_Tel>
    <Contact_Affiliation>Qilu Hospital of Shandong University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients or his/her legal representatives agreed to participate the study and signed the informed consent. &lt;br&gt;2. Those diagnosed with mild or moderate novel coronavirus pneumonia (NCP) or those with severe NCP but can take medicines orally or via stomach tube. The confirmed patients were defined as those NCP suspects with one of the following pathogenic evidences:&lt;br&gt;1) The novel coronavirus in respiratory or blood specimens were confirmed by real time RT-PCR.&lt;br&gt;2) The genetic sequence of the virus detected in respiratory or blood specimen are highly homologous with the known coronavirus;&lt;br&gt;3. Adult patient aged&gt;=18 years;&lt;br&gt;4. Those who are able to communicate well with investigators and to complete the study according to the protocol.       </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The serious NCP patients who can neither swallow medicines nor take medicine via stomach tube, and the critical serious NCP patients;&lt;br&gt;2. Those with severe hypo-immunity due to, but not limited to, one of the following reasons:&lt;br&gt;1) HIV/AIDS,  the condition is still unstable in the process of mediation and /or the  last detection value of CD4 plus T lymphocyte is less than 200;&lt;br&gt;2) Those who received organ transplantation and are given systematic immune treatment;&lt;br&gt;3) Long-term systematic administration of corticosteroids is defined as daily intake of over 40 mg of Prednisone or equivalent in 14 days before the first medication;&lt;br&gt;4. Patients who are unable to take medicines orally or via stomach tube;&lt;br&gt;5. Patients who are allergic to the test medicines;&lt;br&gt;6. Those with poor communication skills, understanding, cooperation or compliance and those cannot follow protocol to complete the study;&lt;br&gt;7. Those suffered with serious diseases such as malignancy, mental diseases and so on, or those ineligible to participate the study according to investigators judgement. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:atic treatment medicines;Control group:Symptomatic treatment medicines;</Intervention>
    <Primary_outcome>Time to Clinical recovery;Butyrate in feces;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029955</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging</Public_title>
    <Scientific_title>Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>West China Second University Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-17</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49531</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Target condition:80;Difficult condition:20</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ying-kun Guo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>20 South Renmin Road, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>gykpanda@163.com</Contact_Email>
    <Contact_Tel>+86 18180609256</Contact_Tel>
    <Contact_Affiliation>West China Second University Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was confirmed by 2019-nCoV and the Chinese medicine authority;&lt;br&gt;2. No contraindications for MR examination;&lt;br&gt;3. understand the potential risks / benefits, patients or guardians agree to participate in the study, understand all the study procedures, agree  the plan of follow-up.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with congenital heart disease, primary and other secondary cardiomyopathy, severe arrhythmia, frequent atrial fibrillation, and serious image quality artifacts;&lt;br&gt;2. Contraindications of MRI: there are ferromagnetic metal foreign bodies in the body (such as cardiac pacemaker, nerve stimulator, artificial metal heart valve, aneurysm clip, intraocular metal foreign body, inner ear implant, metal prosthesis, metal prosthesis, metal joint, etc.); see the informed consent of enhanced MRI for details;&lt;br&gt;3. The patients with claustrophobia had recently developed allergic diseases such as measles and allergic dermatitis;&lt;br&gt;4. Contraindications of gadolinium contrast agent: estimated glomerular filtration rate (EGFR) &lt;30 ml/min/1.73 m2; previous adverse reactions or other drug allergy history of gadolinium contrast agent injection.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Clinical outcome, meet the guideline of novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was confirmed by 2019-nCoV.;Index test:First&amp;#32;pass&amp;#32;perfusion&amp;#32;imaging&amp;#32;parameters&amp;#32;(slope,&amp;#32;tip,&amp;#32;PT)&amp;#32;and&amp;#32;delayed&amp;#32;enhancement&amp;#32;ratio&amp;#32;(%);&amp;#32;quantitative&amp;#32;T1&amp;#32;\&amp;#32;T2&amp;#32;values,&amp;#32;ECV&amp;#32;and&amp;#32;pseudocolor&amp;#32;images&amp;#32;were&amp;#32;obtained&amp;#32;by&amp;#32;t1mapping&amp;#32;\&amp;#32;T2&amp;#32;mapping.&amp;#32;Meanwhile,&amp;#32;the&amp;#32;degree&amp;#32;of&amp;#32;myocardial&amp;#32;edema&amp;#32;and&amp;#32;fat&amp;#32;replacement&amp;#32;was&amp;#32;analyzed.&amp;#32;Myocardial&amp;#32;creatine&amp;#32;metabolism&amp;#32;was&amp;#32;analyzed&amp;#32;by&amp;#32;MRS,;</Intervention>
    <Primary_outcome>First pass perfusion i;Delayed enhancement;T1 /T2 mapping;Extracellular volume;MRS;CEST;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029972</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-17</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49664</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Experimental group:20;control:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chen Hong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>chenhong1129@hotmail.com</Contact_Email>
    <Contact_Tel>+86 13296508243</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Aged 18-65 years;&lt;br&gt;(2) Virus nucleic acid test is positive;&lt;br&gt;(3) Lung CT showed multiple patchy, lumpy ground glass opacity(GGO) or consolidation in both lungs.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Positive for other pathogens such as A, B, Mycoplasma, Adenovirus;&lt;br&gt;(2) Respiratory failure occurs, requiring mechanical ventilation;&lt;br&gt;(3) People with metal or pacemaker;&lt;br&gt;(4) active tuberculosis;&lt;br&gt;(5) Massive pulmonary fibrosis;&lt;br&gt;(6) Those with shock;&lt;br&gt;(7) Those who have bleeding tendency or active bleeding in the lungs;&lt;br&gt;(8) Patients with multiple organ failure who need ICU monitoring and treatment;&lt;br&gt;(9) Patients with tumor and severe basic diseases;&lt;br&gt;(10) pregnant or lactating women;&lt;br&gt;(11) Patients with active tuberculosis;&lt;br&gt;(12) Those with other contraindications to ultrashort wave;&lt;br&gt;(13) Patients with severe cognitive impairment who cannot follow the instructions to complete the treatment;&lt;br&gt;(14) Those without signed informed consent;&lt;br&gt;(15) Researchers believe that other reasons are not suitable for clinical trials.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:ultra short wave  Electrotherapy;control:standard medical therapy;</Intervention>
    <Primary_outcome>the rate of Coronary virus nucleic acid negative at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;Symptom recovery at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029954</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial</Public_title>
    <Scientific_title>Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Hubei Hospital of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-17</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49402</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-04-30</Date_enrollement>
    <Target_size>Control group:100;Experimental group 1:100;Experimental group 2:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yang Yi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>4 Garden Hill, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>153267742@qq.com</Contact_Email>
    <Contact_Tel>+86 18971163518</Contact_Tel>
    <Contact_Affiliation>Hubei Hospital of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Diagnosed Novel coronavirus pneumonia patients or clinically diagnosed NCP patients in Hubei Province;&lt;br&gt;2. Aged 18 to 65 years;&lt;br&gt;3. The time interval between symptom onset and randomization was within 7 days (the onset of symptom was mainly determined by the time of fever);&lt;br&gt;4. Sign the written informed consent before the study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infection caused by basic diseases such as primary immunodeficiency disease, congenital respiratory tract malformation, congenital heart disease, gastroesophageal reflux disease and pulmonary dysplasia;	&lt;br&gt;2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory system bacterial infection such as suppurative tonsillitis, acute bronchitis, sinusitis, otitis media or other respiratory diseases affecting the evaluation of clinical trials. Or with Chest CT confirmed the presence of serious interstitial lung disease, bronchiectasis and other basic lung diseases;&lt;br&gt;3. critically ill patients based on the New Protocol for Diagnosis and Treatment of NCP;&lt;br&gt;4. Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 ULN);&lt;br&gt;5. Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;=30ml/min/1.73m2) or continuous renal replacement therapy, hemodialysis or peritoneal dialysis;&lt;br&gt;6. Pregnant or breast-feeding women;&lt;br&gt;7. Patients may be transferred to non-designated hospitals within 72 hours;&lt;br&gt;8. Patients who have participated in other clinical trials in the past 7 days;&lt;br&gt;9. Allergic constitution, such as those who are allergic to two or over twodrugs ,with history of food allergies, or known to be allergic to the ingredients of this drug;&lt;br&gt;10. In the opinion of the investigator, subjects who are not suitable for enrollment or with any factors that affect the outcome of the trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Treated according to the New Protocol for Diagnosis and Treatment of NCP(5th edition), without using traditional Chinese medicine;Experimental group 1:Basic treatment+Low dose of honeysuckle oral liquid 60ml each time, tid;Experimental group 2:Basic treatment + high dose of honeysuckle oral liquid 180 ml each time, tid;</Intervention>
    <Primary_outcome>Recovery time;Pneumonia psi score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029803</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Renmin Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49428</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>60</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>A1:80;A2:80;B1:80;B2:80;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhan Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>doctorzhang2003@163.com</Contact_Email>
    <Contact_Tel>+86 18062567610</Contact_Tel>
    <Contact_Affiliation>Renmin Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. 18 years old &lt;= age &lt;= 60 years old when screening, not limited to men and women;&lt;br&gt;2. Who are in close contact with suspected cases, confirmed cases, and positive test of new coronavirus nucleic acid, and those who have not taken effective protection, that is, close contacts;&lt;br&gt;3. Study subjects are willing to be randomly assigned to any designated treatment group;&lt;br&gt;4. Must agree to not participate in another study of study drugs until day 24 of completion of the study.&lt;br&gt;5. Participants volunteered to participate in this study and signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The physician decides that participating in the trial is not in the best interest of the patient, or does not meet any conditions for safe follow-up in the protocol;&lt;br&gt;2. People with heart disease such as cardiac block;&lt;br&gt;3. People with eye diseases such as retina and cornea;&lt;br&gt;4. Severe liver disease (such as Child Pugh score &gt;= C or AST &gt; 5 times the upper limit);&lt;br&gt;5. Pregnancy or breastfeeding, or a positive pregnancy test during the pre-dose check;&lt;br&gt;6. Patients with known severe renal insufficiency (estimated glomerular filtration rate &lt;= 30mL / min / 1.73m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>A1:Hydroxychloroquine, small dose;A2:Hydroxychloroquine, high dose;B1:Abidol hydrochloride, small dose;B2:Abidol hydrochloride, high dose;</Intervention>
    <Primary_outcome>Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029780</TrialID>
    <Last_Refreshed_on>25 February 2020</Last_Refreshed_on>
    <Public_title>A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49220</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>experimental group:80;control group:80;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xin Zheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>Xin11@hotmail.com</Contact_Email>
    <Contact_Tel>+86 18602724981</Contact_Tel>
    <Contact_Affiliation>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Aged &gt;= 18 years;&lt;br&gt;2) In line with the diagnostic criteria of "new coronavirus pneumonia diagnosis program", the patient was diagnosed as pneumonia infected by the new coronavirus;&lt;br&gt;3) Severe pneumonia index (PSI) class for III ~ IV;&lt;br&gt;4) The course of symptoms should be less than or equal to 8 days;&lt;br&gt;5) Volunteers and comply with the hospital regulations, can cooperate with the completion of the prescribed inspection;&lt;br&gt;6) Voluntary informed consent was signed prior to the trial.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1)One of the following conditions:&lt;br&gt;Respiratory distress, RR &gt;= 30 times/min;&lt;br&gt;At rest, oxygen saturation is less than 93%;&lt;br&gt;Artial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) &lt;= 300mmHg (1mmHg=0.133kPa);&lt;br&gt;Respiratory failure is present and mechanical ventilation is required;&lt;br&gt;Shock;&lt;br&gt;Combined with other organ failure requires intensive care unit;&lt;br&gt;It is expected to be transferred to a non-study hospital within 72 hours.&lt;br&gt;2)Severe influenza and influenza patients with complications (such as secondary bacterial pneumonia, pneumonia caused by other pathogens and other viral pneumonia);Or the patient is hospitalized with severe influenza;&lt;br&gt;3)Patients with other upper respiratory tract infections: asthma requiring daily treatment, any other chronic respiratory diseases, respiratory bacterial infections such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media and other respiratory diseases affecting clinical trial evaluation.Imaging confirmed the existence of severe pulmonary interstitial lesions, bronchiectasis and other basic pulmonary diseases;&lt;br&gt;4)Past or present diseases may affect the outcome of the study, such as unresectable malignant tumors, hematological diseases, active bleeding, malignant fluid, liver and kidney diseases, nervous system diseases, endocrine system diseases, etc.;&lt;br&gt;5)Suffering from diseases that seriously affect the immune system, such as HIV infection, splenectomy, organ transplantation, etc.;&lt;br&gt;6)A woman who is pregnant or breastfeeding;&lt;br&gt;7)Test drug components allergy, or allergic constitution;&lt;br&gt;8)Patients with a history of substance abuse;&lt;br&gt;9)Participants in other clinical trials in the last 3 months;&lt;br&gt;10)The investigator considers it inappropriate to participate in this clinical trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>experimental group:Routine treatment and Shenqi Fuzheng Injection;control group:Routine treatment ;</Intervention>
    <Primary_outcome>Recovery time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04292327</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus</Public_title>
    <Scientific_title>Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus(2019-nCoV)</Scientific_title>
    <Acronym>2019-nCoV</Acronym>
    <Primary_sponsor>Fujian Provincial Hospital</Primary_sponsor>
    <Date_registration>23/02/2020</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04292327</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 1, 2020</Date_enrollement>
    <Target_size>400</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>Phase 2/Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Xiuling Shang</Contact_Lastname>
    <Contact_Email />
    <Contact_Tel />
    <Contact_Affiliation>Fujian Provincial Hospital</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion criteria.&lt;br&gt;&lt;br&gt;          1. 2019-nCov (SARA-Cov-2) nucleic acid positive detected by PCR.&lt;br&gt;&lt;br&gt;          2. Older than 18 years old and younger than 75 years old.&lt;br&gt;&lt;br&gt;          3. Meet the diagnostic criteria of COVID-19 for different types (including ordinary type,&lt;br&gt;             heavy type and critical type)&lt;br&gt;&lt;br&gt;        Exclusion criteria.&lt;br&gt;&lt;br&gt;          1. the age is less than 18 years old;&lt;br&gt;&lt;br&gt;          2. pregnant or lactating women;&lt;br&gt;&lt;br&gt;          3. severe underlying diseases, such as advanced malignant tumor, end-stage lung disease,&lt;br&gt;             etc.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Pneumonia Caused by Human Coronavirus</Condition>
    <Primary_outcome>Mortality;The time interval of Nucleic acid detection become negative</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04295551</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)</Public_title>
    <Scientific_title>Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</Primary_sponsor>
    <Date_registration>03/03/2020</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04295551</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>100 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 14, 2020</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Aged &gt;=18 years;&lt;br&gt;&lt;br&gt;          2. Novel coronavirus pneumonia patients diagnosed by pathogenic testing;&lt;br&gt;&lt;br&gt;          3. The patient himself participated in the study voluntarily, agreed and signed the&lt;br&gt;             informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Meet the diagnostic criteria for severe new-type coronavirus infection pneumonia;&lt;br&gt;&lt;br&gt;          2. Severe primary diseases that affect survival, including: uncontrolled malignant&lt;br&gt;             tumors, hematological diseases, and HIV that have not been metastasized in multiple&lt;br&gt;             places;&lt;br&gt;&lt;br&gt;          3. Obstructive pneumonia, pulmonary interstitial fibrosis, alveolar proteinosis, and&lt;br&gt;             allergic alveolitis caused by lung tumors;&lt;br&gt;&lt;br&gt;          4. Women who are breastfeeding or pregnant;&lt;br&gt;&lt;br&gt;          5. Those who are known to be allergic to the ingredients contained in the research&lt;br&gt;             medication, or patients with allergies;&lt;br&gt;&lt;br&gt;          6. Those who have continued to use immunosuppressive agents or organ transplants in the&lt;br&gt;             past 6 months;&lt;br&gt;&lt;br&gt;          7. Patients who have participated in other drug clinical trials within 3 months before&lt;br&gt;             the screening test;&lt;br&gt;&lt;br&gt;          8. The investigator judges that he or she cannot complete or should not participate in&lt;br&gt;             the study (expected death within 48 hours, and the patient refuses active treatment)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection;Drug: Lopinavir/ritonavir treatment</Intervention>
    <Primary_outcome>Clinical recovery time</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04296643</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Medical Masks vs N95 Respirators for COVID-19</Public_title>
    <Scientific_title>Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>McMaster University</Primary_sponsor>
    <Date_registration>03/03/2020</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04296643</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>April 1, 2020</Date_enrollement>
    <Target_size>576</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor). </Study_design>
    <Phase>N/A</Phase>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Mark B Loeb;Mark Loeb, MD</Contact_Lastname>
    <Contact_Email>;loebm@mcmaster.ca</Contact_Email>
    <Contact_Tel>;9053340010</Contact_Tel>
    <Contact_Affiliation>McMaster University;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Nurses who work &gt; 37 hours per week in medical, emergency, pediatric units&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Nurses with one or more comorbidities&lt;br&gt;&lt;br&gt;          -  Nurses who cannot pass an N95 respirator fit-test&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus;N95;Medical Mask</Condition>
    <Intervention>Device: Medical Mask;Device: N95 respirator</Intervention>
    <Primary_outcome>RT-PCR confirmed COVID-19 infection</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04299152</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2</Public_title>
    <Scientific_title>Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tianhe Stem Cell Biotechnologies Inc.</Primary_sponsor>
    <Date_registration>28/02/2020</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04299152</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>60 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>April 10, 2020</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Care Provider). </Study_design>
    <Phase>Phase 2</Phase>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>YONG ZHAO, MD,PhD;YONG ZHAO, MD,PhD</Contact_Lastname>
    <Contact_Email>;Zhao@TianheCell.com</Contact_Email>
    <Contact_Tel>;2019880290</Contact_Tel>
    <Contact_Affiliation>Tianhe Stem Cell Biotechnologies Inc.;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Adult patients (18 years)&lt;br&gt;&lt;br&gt;          2. Must have a clinical diagnosis of SARS-CoV-2, with at least one of clinical symptoms&lt;br&gt;             (e.g., fever =38C, fatigue, cough) and a positive result by the reverse-transcription&lt;br&gt;             polymerase chain reaction (RT-PCR) testing&lt;br&gt;&lt;br&gt;          3. Patients must not have received any antiviral treatments known to affect SARS-CoV-2&lt;br&gt;&lt;br&gt;          4. Patients must agree that they are not permitted to use any other treatment to affect&lt;br&gt;             SARS-CoV-2 during a period of 6 months after undergoing SCE therapy&lt;br&gt;&lt;br&gt;          5. Adequate venous access for apheresis&lt;br&gt;&lt;br&gt;          6. Ability to provide informed consent&lt;br&gt;&lt;br&gt;          7. For female patients only, willingness to use FDA-recommended birth control&lt;br&gt;             (http://www.fda.gov/downloads/ForConsumers/ByAudience/ForWomen/FreePublications/UCM356&lt;br&gt;             451.pdf) until 6 months post treatment.&lt;br&gt;&lt;br&gt;          8. Must agree to comply with all study requirements and be willing to complete all study&lt;br&gt;             visits&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. AST or ALT 2 &gt; x upper limit of normal.&lt;br&gt;&lt;br&gt;          2. Abnormal bilirubin (total bilirubin &gt; 1.2 mg/dL, direct bilirubin &gt; 0.4 mg/dL)&lt;br&gt;&lt;br&gt;          3. Creatinine &gt; 2.0 mg/dl.&lt;br&gt;&lt;br&gt;          4. Known coronary artery disease or EKG suggestive of coronary artery disease unless&lt;br&gt;             cardiac clearance for apheresis is obtained from a cardiologist.&lt;br&gt;&lt;br&gt;          5. Known active infection such as Hepatitis B, Hepatitis C, or Human Immunodeficiency&lt;br&gt;             Virus (HIV)&lt;br&gt;&lt;br&gt;          6. Pregnancy assessed by a positive serum pregnancy test or breastfeeding mothers&lt;br&gt;&lt;br&gt;          7. Use of immunosuppressive medication within one month of enrollment including but not&lt;br&gt;             limited to cyclosporine, tacrolimus, sirolimus, and chemotherapy.&lt;br&gt;&lt;br&gt;          8. Anticoagulation other than ASA.&lt;br&gt;&lt;br&gt;          9. Hemoglobin &lt; 10 g/dl or platelets &lt; 100 k/ml&lt;br&gt;&lt;br&gt;         10. Is unable or unwilling to provide informed consent&lt;br&gt;&lt;br&gt;         11. Presence of any other physical or psychological medical condition that, in the opinion&lt;br&gt;             of the investigator, would preclude participation&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</Condition>
    <Intervention>Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis</Intervention>
    <Primary_outcome>Determine the number of Covid-19 patients who were unable to complete SCE Therapy</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04272710</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China</Public_title>
    <Scientific_title>Clinical Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China</Scientific_title>
    <Acronym />
    <Primary_sponsor>Chongqing Medical University</Primary_sponsor>
    <Date_registration>12/02/2020</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04272710</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>100 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 25, 2020</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Dongying Zhang, doctor</Contact_Lastname>
    <Contact_Email>zdy.chris@qq.com</Contact_Email>
    <Contact_Tel>+8613608398395</Contact_Tel>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adult aged &gt;=18years old;&lt;br&gt;&lt;br&gt;          -  Diagnosed with 2019-nCoV. Diagnostic criteria including: Laboratory (RT-PCR) confirmed&lt;br&gt;             2019-nCoV infection; CT of the lung conformed to the manifestation of viral pneumonia.&lt;br&gt;&lt;br&gt;          -  Diagnosed with primary hypertension.&lt;br&gt;&lt;br&gt;          -  Criteria for severe or critical ill conditions: Respiratory rate &gt;=30/min; or Rest&lt;br&gt;             SPO2&lt;=93%; or PaO2/FiO2&lt;=300mmHg.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Near-death state (expected survival time less than 24 hours);&lt;br&gt;&lt;br&gt;          -  Malignant tumor;&lt;br&gt;&lt;br&gt;          -  Pregnancy or puerperium women;&lt;br&gt;&lt;br&gt;          -  ACEI contraindication&lt;br&gt;&lt;br&gt;          -  Patients who refused to participant.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV</Condition>
    <Primary_outcome>Death;Mechanical Ventilation;Occupancy rate in the intensive care unit (ICU)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04279899</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>The Investigation of the Neonates With or With Risk of COVID-19</Public_title>
    <Scientific_title>A Multicenter Observational Study of the Perinatal-neonatal Population With or With Risk of COVID-19 in China</Scientific_title>
    <Acronym />
    <Primary_sponsor>Children's Hospital of Fudan University</Primary_sponsor>
    <Date_registration>18/02/2020</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04279899</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>28 Days</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 1, 2020</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The neonates with COVID-19,or neonates born by infected mothers&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The neonates with major anomalies&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Neonatal Infection;Perinatal Problems;Infectious Disease</Condition>
    <Primary_outcome>The death of newborns with COVID-19;The SARS-CoV-2 infection of neonates born to mothers with COVID-19</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030433</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Application of Rehabilitation and Lung Eight-segment Exercise in Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>The Application of Rehabilitation and Lung Eight-segment Exercise in  Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Fujian Medical University</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50273</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>one group:80;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Nijun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>20 Chazhong Road, Taijiang District, Fuzhou, Fujian, China</Contact_Address>
    <Contact_Email>nijun1000@126.com</Contact_Email>
    <Contact_Tel>+86 19890572216</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Fujian Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. aged between 18-70 years old;&lt;br&gt;2. clinical dignosied 2019-nCov pneumonia and clinical recovery,diagnostic criteria according to the   2019-nCov pneumonia-6th edition;&lt;br&gt;3. Cured within one month of discharge;&lt;br&gt;4. consious,emotionormal,able to communicate well with medical staff and finish the exercise;&lt;br&gt;5. Understand and be willing to participate in this clinical trial and provide signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Heart rate: heart rate &lt;40 or &gt;130 times/min;&lt;br&gt;2. New myocardial ischemia or arrhythmia;&lt;br&gt;3. Severe liver and kidney dysfunction or the appearance of new progressive liver and kidney dysfunction;&lt;br&gt;4. Oxygen saturation &lt;=93%;&lt;br&gt;5. Patients with tracheotomy;&lt;br&gt;6. Other complications not suitable for respiratory rehabilitation;&lt;br&gt;7. Can not cooperate with the training of cognitive impairment, consciousness disorder patients</Exclusion_Criteria>
    <Condition>2019-nCov pneumonia</Condition>
    <Intervention>one group:Rehabilitation Lung Health Eight - Stage Exercise ;</Intervention>
    <Primary_outcome>PCL;HRQL;IPAQ;PASE;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04279782</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection</Public_title>
    <Scientific_title>Investigation on Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection in Isolation Unit</Scientific_title>
    <Acronym />
    <Primary_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</Primary_sponsor>
    <Date_registration>15/02/2020</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04279782</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 20, 2020</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>Phase 1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Liang Peng, Doctor;Wenxiong Xu, Doctor;Liang Peng, Doctor</Contact_Lastname>
    <Contact_Email>;xwx1983@163.com;pzp33@hotmail.com</Contact_Email>
    <Contact_Tel>;+8613760783281;+8613533978874</Contact_Tel>
    <Contact_Affiliation>Third Affiliated Hospital of Sun Yat-sen University;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Epidemiological history including resident of Hubei province, or travel history to&lt;br&gt;             Hubei province or exposure to suspected patients in the past two weeks.&lt;br&gt;&lt;br&gt;          2. Symptoms like fever, fatigue, myalgia, headache, cough, sputum production, chest&lt;br&gt;             tightness, dyspnea, etc.&lt;br&gt;&lt;br&gt;          3. White blood cells decreased or were normal, or lymphocytes decreased, and chest CT&lt;br&gt;             images showed typical findings of viral pneumonia.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients can not follow-up;&lt;br&gt;&lt;br&gt;          2. Investigator considering inappropriate.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus</Condition>
    <Intervention>Other: Comprehensive treatment</Intervention>
    <Primary_outcome>Survival rate</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04279795</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations</Public_title>
    <Scientific_title>Study on Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations in Patients</Scientific_title>
    <Acronym />
    <Primary_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</Primary_sponsor>
    <Date_registration>19/02/2020</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04279795</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 20, 2020</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>Phase 1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Liang Peng, Doctor;Wenxiong Xu, Doctor;Liang Peng, Doctor</Contact_Lastname>
    <Contact_Email>;xwx1983@163.com;pzp33@hotmail.com</Contact_Email>
    <Contact_Tel>;+8613760783281;+8613533978874</Contact_Tel>
    <Contact_Affiliation>Third Affiliated Hospital of Sun Yat-sen University;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Epidemiological history including resident of Hubei province, or travel history to&lt;br&gt;             Hubei province or exposure to suspected patients in the past two weeks.&lt;br&gt;&lt;br&gt;          2. Symptoms like fever, fatigue, myalgia, headache, cough, sputum production, chest&lt;br&gt;             tightness, dyspnea, etc.&lt;br&gt;&lt;br&gt;          3. White blood cells decreased or were normal, or lymphocytes decreased, and chest CT&lt;br&gt;             images showed typical findings of viral pneumonia.&lt;br&gt;&lt;br&gt;          4. Detection of 2019 Novel Coronavirus nucleic acid is positive by local Center for&lt;br&gt;             Disease Control and Prevention (CDC).&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients can not follow-up;&lt;br&gt;&lt;br&gt;          2. Investigator considering inappropriate.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus</Condition>
    <Primary_outcome>Positive rate of 2019 Novel Coronavirus RNA</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04280224</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>NK Cells Treatment for Novel Coronavirus Pneumonia</Public_title>
    <Scientific_title>Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus</Scientific_title>
    <Acronym />
    <Primary_sponsor>Xinxiang medical university</Primary_sponsor>
    <Date_registration>13/02/2020</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04280224</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 20, 2020</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>ZHU, Professor;GUO, Professor</Contact_Lastname>
    <Contact_Email>wulingzhu@xxmu.edu.cn;guomh@163.com</Contact_Email>
    <Contact_Tel>00863733029089;00863734402517</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  1. Male or female, aged at 18 years-65 years old&lt;br&gt;&lt;br&gt;          -  2. Pneumonia that is judged by chest radiograph or computed tomography&lt;br&gt;&lt;br&gt;          -  3. Laboratory confirmation of NCP infection by reverse-transcription polymerase chain&lt;br&gt;             reaction(RT-PCR) from any diagnostic sampling source&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  1. Pregnancy or breastfeeding&lt;br&gt;&lt;br&gt;          -  2. Known HIV, HBV or HCV infection&lt;br&gt;&lt;br&gt;          -  3. Patients with malignant tumor, other serious systemic diseases and psychosis&lt;br&gt;&lt;br&gt;          -  4. Patients who are participating in other clinical trials&lt;br&gt;&lt;br&gt;          -  5. Inability to provide informed consent or to comply with test requirements&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia</Condition>
    <Intervention>Biological: NK Cells</Intervention>
    <Primary_outcome>Improvement of clinical symptoms including duration of fever;Improvement of clinical symptoms including respiratory frequency;Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030442</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>the Second Affiliated hospital of Xi'an Jiaotong University</Primary_sponsor>
    <Date_registration>2020-03-02</Date_registration>
    <Date_registration3>20200302</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50380</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-03-05</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Ma Xiaorong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>157 West 5th Road, Xi'an, Shaanxi, China</Contact_Address>
    <Contact_Email>maxr0910@163.com</Contact_Email>
    <Contact_Tel>+86 13992856156</Contact_Tel>
    <Contact_Affiliation>the Second Affiliated hospital of Xi'an Jiaotong University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: severe case of COVID-19</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Allergy to any medicine&lt;br&gt;Pregnancy</Exclusion_Criteria>
    <Condition>Coronavirus Disease 2019</Condition>
    <Intervention>Case series:Combination of Tocilizumab, IVIG and CRRT;</Intervention>
    <Primary_outcome>Inhospital time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030418</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Fujian Medical University</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50341</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Group 1:40;Group 2:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ni Jun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>20 Chazhong Road, Fuzhou, Fujian, China</Contact_Address>
    <Contact_Email>nijun1000@126.com</Contact_Email>
    <Contact_Tel>+86 19890572216</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Fujian Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-80 years;&lt;br&gt;2. Meet the diagnostic criteria of "New Coronavirus Infected Pneumonia Sixth Edition";&lt;br&gt;3. Blood pressure 90-150 / 60-100mmHg, respiratory rate 12-20 beats / min, heart rate 60-100 beats / min;&lt;br&gt;4. Extremity muscle strength examination is more than 5-grade;&lt;br&gt;5. Accept the study with the consent of the patient or family, and sign an informed consent form before the study</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Heart rate: Heart rate &lt;40 or&gt; 130 beats / min;&lt;br&gt;2. New onset of myocardial ischemia or arrhythmia;&lt;br&gt;3. Blood pressure: mean arterial pressure (MAP) &lt;65mmHg or&gt; 110mmHg;&lt;br&gt;4. Body temperature: &gt;=38.5 degree C;&lt;br&gt;5. Blood oxygen saturation &lt;=93%;&lt;br&gt;6. Hemodynamic instability;&lt;br&gt;7. Severe liver and kidney dysfunction or newly emerging progressive liver and kidney dysfunction;&lt;br&gt;8. Tracheal intubation or tracheotomy patients, mechanical ventilation patients;&lt;br&gt;9. There are other complications that are not suitable for respiratory rehabilitation;&lt;br&gt;10. Patients with cognitive impairment or conscious impairment who cannot cooperate with training.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 1:Eight lung exercises for rehabilitation;Group 2:Free activities;</Intervention>
    <Primary_outcome>Post-traumatic stress disorder checklist;Clinical prognostic outcome;Il-6;Health-related quality of life inventory;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030386</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Hu'nan university of chinese medicine</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50323</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>0</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Case series:1000;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiaorong Chang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Hanpu Science and Teaching Road, Yuelu District, Changsha, Hu'nan, China</Contact_Address>
    <Contact_Email>xrchang1956@163.com</Contact_Email>
    <Contact_Tel>+86 0731 88458187</Contact_Tel>
    <Contact_Affiliation>Hu'nan University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Moxibustion intervention study plan for 14 days of NCP close contact with forced home isolation:&lt;br&gt;Participants inclusion criteria:&lt;br&gt;1. Aged 18 to 75 years old;&lt;br&gt;2. Those that meet one or more of the following:&lt;br&gt;(1)In the past 1 month, there is a history of contact with patients with pneumonia diagnosed by new coronavirus;&lt;br&gt;(2) People who have lived or stayed in Wuhan or the affected area in the past month;&lt;br&gt;3. Those who have had close contacts with returnees from Hubei in the past month;&lt;br&gt;4. Persons who live or work in 2 or more confirmed cases of novel coronavirus infection pneumonia;&lt;br&gt;5. Take the same transportation with the newly diagnosed cases of Novel Coronary Pneumonia and have close contact with people, including those who have taken care of the patient on the transportation and the patient's colleagues (family, colleagues, friends, etc.);&lt;br&gt;6. The area is limited to Hunan Province;&lt;br&gt;7. Voluntarily participate in this research and sign the informed consent.&lt;br&gt;Patient who meet the above 4 items can be included in this study.&lt;br&gt;Research Program on Moxibustion Intervention in NCP Home Isolation Population:&lt;br&gt;1. Aged 18 to 75 years old;&lt;br&gt;2. Those that meet one or more of the following:&lt;br&gt;(1) There is no contact history of patients with pneumonia diagnosed with new-type coronavirus in the past month;&lt;br&gt;(2) The corpus callosum is weak, susceptible to wind and cold, and has a history of chronic respiratory diseases;&lt;br&gt;3. The area is limited to Hunan Province;&lt;br&gt;4. Voluntarily participate in this research and sign the informed consent.&lt;br&gt;Patient who meet the above 4 items can be included in this study.&lt;br&gt;Research Program on Moxibustion Intervention in NCP Home Isolation Medical Care Group:&lt;br&gt;1. Aged 18 to 75 years old;&lt;br&gt;2. Those that meet one or more of the following:&lt;br&gt;(1) Occupation is doctor and patient;&lt;br&gt;(2) There is no contact history of patients with pneumonitis diagnosed with new-type coronavirus in the past 1 month;&lt;br&gt;3. The area is limited to Hu'nan Province;&lt;br&gt;4. Voluntarily participate in this research and sign the informed consent.&lt;br&gt;Participants who meet the above 4 items can be included in this study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system;&lt;br&gt;(2) Those with malignant changes in the lungs;&lt;br&gt;(3) Persons with a mental, intellectual or language impairment;&lt;br&gt;(4) pregnant women, lactating women and those who have pregnancy requirements in the last 6 months;&lt;br&gt;(5) Those who are unable to fill in the questionnaire materials using mobile phones, computers, etc.;&lt;br&gt;(6) Those who are unwilling to receive moxibustion, or who are allergic to moxibustion or Wenwen cream;&lt;br&gt;(7) Those who are participating in other clinical trials.&lt;br&gt;Patients who meet any of the above are excluded.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:moxibustion;</Intervention>
    <Primary_outcome>mood assessment;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030424</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Henan Provincial People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50174</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-02</Date_enrollement>
    <Target_size>Case series:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Shao Fengmin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>7 Weiwu Road, Jinshui District, Zhengzhou, He'nan, China</Contact_Address>
    <Contact_Email>guyuesunny@163.com</Contact_Email>
    <Contact_Tel>+86 15037167775</Contact_Tel>
    <Contact_Affiliation>He'nan Provincial People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) aged &gt;=18 years;&lt;br&gt;(2) positive COVID-19 nucleic acid was detected by RT-PCR in sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions, or viral gene sequencing was detected in sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions, which was highly homologous with known COVID-19;&lt;br&gt;(3) Confirmed to be diagnosed as COVID-19, meeting the diagnostic criteria for moderate and severe patients in the diagnosisin line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment plan (trial version 6), and not significantly improved after treatment with the triple antiviral program;&lt;br&gt;(4) Informed consent has been signed.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) known or suspected allergies to the components of azivudine tablets;&lt;br&gt;(2) women who are breast-feeding during pregnancy or have a family plan during the trial period and within 6 months after the end of the trial;&lt;br&gt;(3) participating in other clinical trials or taking experimental drugs within 12 weeks prior to administration&lt;br&gt;(4) severe liver disease (TBIL&gt;=2 times normal upper limit; ALTAST&gt;=5 times normal upper limit);&lt;br&gt;(5) patients with severe renal insufficiency or receiving continuous renal replacement therapy or peritoneal dialysis&lt;br&gt;(6) Other conditions that not appropriate to be enrolled into this study based on investigator's advise.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment;</Intervention>
    <Primary_outcome>Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030391</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients</Public_title>
    <Scientific_title>A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Lishui Central Hospital</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=30796</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chuxiao Shao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>289 Kuocang Road, Liandu District, Lishui, Zhejiang, China </Contact_Address>
    <Contact_Email>scx1818@126.com</Contact_Email>
    <Contact_Tel>+86 0578 2285102</Contact_Tel>
    <Contact_Affiliation>Lishui Central Hospital </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Confirmed cases of novel coronavirus pneumonia</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pneumonia caused by other pathogens; &lt;br&gt;2. Not receiving antiviral treatment.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:NA;</Intervention>
    <Primary_outcome>cure rate;virus negative rate;time of virus negative;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030382</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet</Public_title>
    <Scientific_title>Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Hubei Provincial Hospital of TCM</Primary_sponsor>
    <Date_registration>2020-02-17</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50325</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Case series:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhongyu Zhou</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>4 Huayuan Hill, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>2209447940@qq.com</Contact_Email>
    <Contact_Tel>+86 18672308659</Contact_Tel>
    <Contact_Affiliation>Hubei Provincial Hospital of TCM</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Meet the diagnostic criterias for novel coronavirus pneumonia during the medical observation period, light type (the syndrome of cold and damp stagnating lungs), ordinary type (the syndrome of lung block by cold and damp), and recovery period  (qi deficiency of the spleen and the lung syndrome); &lt;br&gt;2. Aged 18 to 65 years old; 10-day spacer&lt;br&gt;3. Voluntarily received inderect moxibustion for at least 10 days;&lt;br&gt;4. Voluntarily test and abide by the relevant management regulations of the hospital, and be able to cooperate in completing the various inspections.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. If the researcher judges that a previous or current disease may affect the outcome of participating in the trial or study: severe lung disease, diabetes, cardiovascular and cerebrovascular disease, liver and kidney disease, malignant tumor, neuropsychiatric disease and other diseases that seriously affect survival;&lt;br&gt;2. Suffering from diseases that seriously affect the immune system: such as HIV infection, splenectomy, organ transplantation, etc.;&lt;br&gt;3. Pregnant and lactating women;&lt;br&gt;4. Those who are allergic to moxibustion or Chinese medicine, or allergies;&lt;br&gt;5. Hyperthermia, irritability Patients with intense heat;&lt;br&gt;6. local skin damage caused by the application is not suitable;&lt;br&gt;7. those who have participated in other clinical trials within the past 3 months;&lt;br&gt;8. researchers who are not suitable to participate in this clinical trial.</Exclusion_Criteria>
    <Condition>Novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:routine treatment+indirect moxibustion;</Intervention>
    <Primary_outcome>pulmonary iconography;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030334</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)</Public_title>
    <Scientific_title>microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Nanjing Second Hospital</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49491</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-19</Date_enrollement>
    <Target_size>Target condition:25;Difficult condition:25</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yongxiang Yi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Kangfu Road, Tangshan Street, Jiangning District, Nanjing, China </Contact_Address>
    <Contact_Email>ian0126@126.com</Contact_Email>
    <Contact_Tel>+86 13338628626</Contact_Tel>
    <Contact_Affiliation>Nanjing Second Hospital </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Age is not limited; &lt;br&gt;2. Confirmed group:clinical diagnosis is in accordance with the "Notice on issuing a new type of coronavirus pneumonia diagnosis and treatment program (Fifth edition)" on the diagnosis of a new type of coronavirus infection; &lt;br&gt;3. Suspected group: clinical diagnosis is in accordance with the "Notice on issuing a new type of coronavirus pneumonia diagnosis and treatment program (Fifth edition)" on the diagnosis of suspecting a new type of coronavirus infection.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:COVID-19 viral PCR;Index test:MicroRNA;</Intervention>
    <Primary_outcome>SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04257656</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Severe 2019-nCoV Remdesivir RCT</Public_title>
    <Scientific_title>A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe 2019-nCoVRespiratory Disease.</Scientific_title>
    <Acronym />
    <Primary_sponsor>Capital Medical University</Primary_sponsor>
    <Date_registration>31/01/2020</Date_registration>
    <Date_registration3>20200131</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04257656</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 6, 2020</Date_enrollement>
    <Target_size>453</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). </Study_design>
    <Phase>Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Bin Cao, Professor</Contact_Lastname>
    <Contact_Email>caobin@zryhyy.com.cn</Contact_Email>
    <Contact_Tel>+01084206264</Contact_Tel>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age =18 years at time of signing Informed Consent Form&lt;br&gt;&lt;br&gt;          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV.&lt;br&gt;&lt;br&gt;          3. Lung involvement confirmed with chest imaging&lt;br&gt;&lt;br&gt;          4. Hospitalized with a SaO2/SPO2=94% on room air or Pa02/Fi02 ratio &lt;300mgHg&lt;br&gt;&lt;br&gt;          5. =12 days since illness onset&lt;br&gt;&lt;br&gt;          6. Willingness of study participant to accept randomization to any assigned treatment&lt;br&gt;             arm.&lt;br&gt;&lt;br&gt;          7. Must agree not to enroll in another study of an investigational agent prior to&lt;br&gt;             completion of Day 28 of study.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Physician makes a decision that trial involvement is not in patients' best interest,&lt;br&gt;             or any condition that does not allow the protocol to be followed safely.&lt;br&gt;&lt;br&gt;          2. Severe liver disease (e.g. Child Pugh score = C, AST&gt;5 times upper limit)&lt;br&gt;&lt;br&gt;          3. Pregnant or breastfeeding, or positive pregnancy test in a predose examination&lt;br&gt;&lt;br&gt;          4. Patients with known severe renal impairment (estimated glomerular filtration rate =30&lt;br&gt;             mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis,&lt;br&gt;             peritoneal dialysis&lt;br&gt;&lt;br&gt;          5. Will be transferred to another hospital which is not the study site within 72 hours.&lt;br&gt;&lt;br&gt;          6. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or&lt;br&gt;             trial related) within the 30 days prior to the time of the screening evaluation.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCov;Remdesivir</Condition>
    <Intervention>Drug: Remdesivir;Drug: Remdesivir placebo</Intervention>
    <Primary_outcome>Time to Clinical Improvement (TTCI) [Censored at Day 28]</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04275245</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia</Public_title>
    <Scientific_title>Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tang-Du Hospital</Primary_sponsor>
    <Date_registration>06/02/2020</Date_registration>
    <Date_registration3>20200206</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04275245</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 3, 2020</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 1/Phase 2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Jianqi Lian, MD;Sicao Li</Contact_Lastname>
    <Contact_Email>liangjq@fmmu.edu.cn;</Contact_Email>
    <Contact_Tel>+86-13571892829;+86-029-84777631</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Men and women aged 18 to 75 years (inclusive)&lt;br&gt;&lt;br&gt;          -  In line with the new coronavirus infection pneumonia diagnosis and treatment plan&lt;br&gt;             (trial version 4) issued by the Health Commission, patients with new coronavirus (2019&lt;br&gt;             ncov) pneumonia were clinically diagnosed;&lt;br&gt;&lt;br&gt;          -  The subjects must be able to understand the study and willing to participate in the&lt;br&gt;             study, and sign the informed consent (if the subjects with no behavioral ability think&lt;br&gt;             it is in their own interests to participate in the test, they should sign the informed&lt;br&gt;             consent by their legal guardian, or notify the consent by phone (recording) and&lt;br&gt;             explain it in the original medical record and other relevant documents).&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Known or expected to have allergic reactions or a history of allergy to any of the&lt;br&gt;             ingredients treated in this trial;&lt;br&gt;&lt;br&gt;          -  In the judgment of the investigator, there are other reasons that the patient is not&lt;br&gt;             suitable to participate in this study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoVs Infection Pneumonia</Condition>
    <Intervention>Drug: Meplazumab for Injection</Intervention>
    <Primary_outcome>2019 nCoV nucleic acid detection</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04275388</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia</Public_title>
    <Scientific_title>A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia</Scientific_title>
    <Acronym />
    <Primary_sponsor>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</Primary_sponsor>
    <Date_registration>17/02/2020</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04275388</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 14, 2020</Date_enrollement>
    <Target_size>348</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Hongzhou Lu, Master</Contact_Lastname>
    <Contact_Email>lunliweiyuanhui2009@126.com</Contact_Email>
    <Contact_Tel>021-37990333</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Aged between 18 and 70 years, extremes included, male or female&lt;br&gt;&lt;br&gt;          2. Fever (armpit temperature =37.3  C, or mouth temperature =38.0  C, or anal or ear&lt;br&gt;             temperature =38.6  C) =7 days according to the official guideline "Pneumonia&lt;br&gt;             Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)"&lt;br&gt;&lt;br&gt;          3. Laboratory test (RT-PCR) confirms infection 2019-nCoV&lt;br&gt;&lt;br&gt;          4. No previous or experimental treatment for pneumonia associated with a novel&lt;br&gt;             coronavirus infection. Patients who have been treated with proprietary Chinese&lt;br&gt;             medicines or lopinavir / ritonavir tablets for less than 3 days can be enrolled&lt;br&gt;&lt;br&gt;          5. Informed Consent Form (ICF) signed voluntarily&lt;br&gt;&lt;br&gt;          6. Based on the investigator's judgment, the subject / legal guardian is considered&lt;br&gt;             reliable and able to comply with this program, visit plan and medication arrangement&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Suffer from diseases that need to be distinguished from new coronavirus infection&lt;br&gt;             pneumonia, such as tuberculosis, bacterial or viral pneumonia other than new&lt;br&gt;             coronavirus pneumonia, hospital-acquired pneumonia, and other pathogenic&lt;br&gt;             microorganisms pneumonia;&lt;br&gt;&lt;br&gt;          2. Patients with basic diseases such as primary immunodeficiency disease, acquired&lt;br&gt;             immunodeficiency syndrome, congenital respiratory malformations, abnormal lung&lt;br&gt;             development, aspiration pneumonia, lung malignant tumors, etc .;&lt;br&gt;&lt;br&gt;          3. Researchers have judged that previous or current diseases may affect patients'&lt;br&gt;             participation in the trial or influence the outcome of the study, including: malignant&lt;br&gt;             disease, autoimmune disease, liver and kidney disease, blood disease, neurological&lt;br&gt;             disease, and endocrine Disease; currently suffering from diseases that seriously&lt;br&gt;             affect the immune system, such as: human immunodeficiency virus (HIV) infection, or&lt;br&gt;             the blood system, or splenectomy, organ transplantation, etc .;&lt;br&gt;&lt;br&gt;          4. Subjects with: asthma requiring daily treatment, any other chronic respiratory&lt;br&gt;             disease, respiratory bacterial infections such as purulent tonsillitis, acute&lt;br&gt;             tracheobronchitis, sinusitis, otitis media, and other respiratory tracts that affect&lt;br&gt;             clinical trial evaluation Disease: Chest CT confirmed patients with basic lung&lt;br&gt;             diseases such as severe interstitial lung disease and bronchiectasis;&lt;br&gt;&lt;br&gt;          5. Patients diagnosed with severe, critically recurrent coronavirus infection, pneumonia,&lt;br&gt;             or need mechanical ventilation or need systemic antihormonal treatment;&lt;br&gt;&lt;br&gt;          6. Breastfeeding or pregnancy test result is positive during the screening period or&lt;br&gt;             test;&lt;br&gt;&lt;br&gt;          7. The research drug Xiyanping injection or a drug with similar efficacy (see Prohibition&lt;br&gt;             of Medication) has been used for more than 3 days during screening.&lt;br&gt;&lt;br&gt;          8. Allergic constitution (persons who are allergic to more than 2 kinds of substances),&lt;br&gt;             people who are allergic to similar drugs in the past or those who are known to be&lt;br&gt;             allergic to the ingredients and auxiliary materials in the test drugs;&lt;br&gt;&lt;br&gt;          9. Patients who have participated in other clinical trials in the past 3 months;&lt;br&gt;&lt;br&gt;         10. The investigator determines that it is not appropriate to participate in a clinical&lt;br&gt;             trial.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019 Novel Coronavirus Pneumonia</Condition>
    <Intervention>Drug: Xiyanping injection;Drug: Lopinavir / ritonavir, alpha-interferon nebulization</Intervention>
    <Primary_outcome>Clinical recovery time</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04279197</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu</Public_title>
    <Scientific_title>A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV</Scientific_title>
    <Acronym />
    <Primary_sponsor>ShuGuang Hospital</Primary_sponsor>
    <Date_registration>15/02/2020</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04279197</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>65 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 15, 2020</Date_enrollement>
    <Target_size>136</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). </Study_design>
    <Phase>Phase 2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Chenghai Liu, PhD;Chenghai Liu, PhD</Contact_Lastname>
    <Contact_Email>chenghailiu@hotmail.com;</Contact_Email>
    <Contact_Tel>8621-20256521;</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with pulmonary fibrosis after standard treatment of COVID-19&lt;br&gt;&lt;br&gt;          -  Age 18-65&lt;br&gt;&lt;br&gt;          -  2019-nCoV nucleic acid negative in respiratory tract or blood samples were detected by&lt;br&gt;             real-time fluorescence PCR for more than 2 times&lt;br&gt;&lt;br&gt;          -  The patient did not participant in other drug clinical studies within 1 month.&lt;br&gt;&lt;br&gt;          -  The patient or the patient's guardian agrees to participate the trial and sign the&lt;br&gt;             informed Consent Form&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Gestation or lactation period women and women who plan to get pregnant during the&lt;br&gt;             study period&lt;br&gt;&lt;br&gt;          -  Those who are unable to communicate, such as patients in unconsciousness or with&lt;br&gt;             dementia, various mental , etc.&lt;br&gt;&lt;br&gt;          -  Severe background disease like severe cardiac insufficiency (cardiac function grade&lt;br&gt;             IV), severe liver and kidney diseases, bronchial asthma, COPD, neurological diseases,&lt;br&gt;             tumors,etc.&lt;br&gt;&lt;br&gt;          -  Long-term bedridden for various reasons&lt;br&gt;&lt;br&gt;          -  Patient who are allergy to the experimental drug&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Pulmonary Fibrosis Due to 2019-nCoV</Condition>
    <Intervention>Drug: N-acetylcysteine+ Fuzheng Huayu Tablet;Drug: N-acetylcysteine+Placebo</Intervention>
    <Primary_outcome>High-resolution computed tomography (HRCT) score;Lung function including FVC, FVC as a percentage of projected value and DLco</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04299711</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019</Public_title>
    <Scientific_title>Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019: A Longitudinal Study Protocol</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Macau</Primary_sponsor>
    <Date_registration>04/03/2020</Date_registration>
    <Date_registration3>20200304</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04299711</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>10 Years</Inclusion_agemin>
    <Inclusion_agemax>19 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>October 15, 2020</Date_enrollement>
    <Target_size>3428</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. age range: 10-19;&lt;br&gt;&lt;br&gt;          2. full-time students in these targets high or middle schools;&lt;br&gt;&lt;br&gt;          3. nationality: China;&lt;br&gt;&lt;br&gt;          4. exposure context: COVID-19;&lt;br&gt;&lt;br&gt;          5. able to adequately understand the content of consent form and questionnaire;&lt;br&gt;&lt;br&gt;        (d) able to sufficiently state the purpose of the research and acknowledge the potential&lt;br&gt;        risks and benefits based on the questionnaire&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Mental Disorder</Condition>
    <Intervention>Other: Exposed to the novel coronavirus disease 2019</Intervention>
    <Primary_outcome>The prevalence and incidence changes of common mental disorders</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04302519</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells</Public_title>
    <Scientific_title>Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells</Scientific_title>
    <Acronym />
    <Primary_sponsor>CAR-T (Shanghai) Biotechnology Co., Ltd.</Primary_sponsor>
    <Date_registration>27/02/2020</Date_registration>
    <Date_registration3>20200227</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04302519</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 5, 2020</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Early Phase 1</Phase>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Liwei cheng, doctor;Xiaoyang Zhou, doctor</Contact_Lastname>
    <Contact_Email>;xiaoyangzh@hotmail.com</Contact_Email>
    <Contact_Tel>;18986033792</Contact_Tel>
    <Contact_Affiliation>Research office of wuhan renmin university;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  1. Age = 18, age = 75, gender unlimited;&lt;br&gt;&lt;br&gt;          -  2. novel coronavirus diagnosed severe pneumonia and confirmed no effective treatment&lt;br&gt;             plan. (severe patients meet any of the following: (1) respiratory distress, RR &gt; 30&lt;br&gt;             times / minute; (2) resting state, oxygen saturation is less than 93%; (3) arterial&lt;br&gt;             oxygen partial pressure (PaO2) / oxygen inhalation (FiO2) is less than 300 mmHg (1mm&lt;br&gt;             Hg=0.133 kPa).&lt;br&gt;&lt;br&gt;          -  3. Those who voluntarily participate in the clinical study and can cooperate with&lt;br&gt;             researchers to carry out the study, and the patients themselves or their legal&lt;br&gt;             representatives voluntarily sign the informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  1. Patients with autoimmune diseases in the past or screening;&lt;br&gt;&lt;br&gt;          -  2. Those who have serious basic diseases that affect their survival, including:&lt;br&gt;             malignant tumor, hematopathy, malignant fluid, active hemorrhage, severe malnutrition,&lt;br&gt;             etc. which have not been controlled and can not be removed due to multiple metastasis;&lt;br&gt;&lt;br&gt;          -  3. Known or self-reported HIV or syphilis infected persons;&lt;br&gt;&lt;br&gt;          -  4. Have participated in stem cell clinical research;&lt;br&gt;&lt;br&gt;          -  5. Pregnant or lactating women or those who have fertility plans in the past year;&lt;br&gt;&lt;br&gt;          -  6. The estimated life cycle is less than 48 hours;&lt;br&gt;&lt;br&gt;          -  7. Those who participated in other clinical trials within 3 months before screening;&lt;br&gt;&lt;br&gt;          -  8. Other conditions that the researcher thinks are not suitable for participating in&lt;br&gt;             the experiment.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Biological: Dental pulp mesenchymal stem cells</Intervention>
    <Primary_outcome>Disppear time of ground-glass shadow in the lungs</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04304053</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic</Public_title>
    <Scientific_title>Antiviral Treatment of COVID-19 Confirmed Cases and Ring Chloroquine Chemoprevention in Close Contacts: a Cluster Randomized Clinical Trial</Scientific_title>
    <Acronym>CQ4COV19</Acronym>
    <Primary_sponsor>Lihir Medical Centre</Primary_sponsor>
    <Date_registration>05/03/2020</Date_registration>
    <Date_registration3>20200305</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04304053</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 15, 2020</Date_enrollement>
    <Target_size>3040</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). </Study_design>
    <Phase>Phase 3</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>oriol Mitja, PhD</Contact_Lastname>
    <Contact_Email>oriolmitja@hotmail.com</Contact_Email>
    <Contact_Tel>0034 934651072</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria for a case:&lt;br&gt;&lt;br&gt;          1. Patients who meet the requirements of the New Coronavirus Infection Diagnosis (Acute&lt;br&gt;             respiratory infection symptoms or acute cough alone and positive PCR)&lt;br&gt;&lt;br&gt;          2. Aged =18 years male or female;&lt;br&gt;&lt;br&gt;          3. In women of childbearing potential, negative pregnancy test and commitment to use&lt;br&gt;             contraceptive method throughout the study.&lt;br&gt;&lt;br&gt;          4. Willing to take study medication&lt;br&gt;&lt;br&gt;          5. Willing to comply with all study procedures, including repeat nasal swab at day 3&lt;br&gt;&lt;br&gt;          6. Able to provide written, informed consent and/or assent&lt;br&gt;&lt;br&gt;        Exclusion Criteria for a case:&lt;br&gt;&lt;br&gt;          1. Serious condition meeting one of the following: (1) respiratory distress with&lt;br&gt;             respiratory rate &gt;=30 breaths/min; (2) oxygen saturation&lt;=93% on quiet status; (3)&lt;br&gt;             Arterial partial pressure of oxygen (PaO2)/oxygen concentration&lt;=300mmHg;&lt;br&gt;&lt;br&gt;          2. Critically ill patients meeting one of the following: (1) Experience respiratory&lt;br&gt;             failure and need to receive mechanical ventilation; (2) Experience shock; (3)&lt;br&gt;             Complicated with other organs failure and need intensive care and therapy in ICU;&lt;br&gt;&lt;br&gt;          3. With known history of cardiac arrhythmia (or QT prolongation syndrome);&lt;br&gt;&lt;br&gt;          4. Unable to take drugs by mouth;&lt;br&gt;&lt;br&gt;          5. With significantly abnormal liver function (Child Pugh C)&lt;br&gt;&lt;br&gt;          6. Need of dialysis treatment, or GFR=30 mL/min/1.73 m2;&lt;br&gt;&lt;br&gt;          7. Participants with retinal disease, hearing loss;&lt;br&gt;&lt;br&gt;          8. Participants with severe neurological and mental illness;&lt;br&gt;&lt;br&gt;          9. Pregnant or lactating women;&lt;br&gt;&lt;br&gt;         10. Inability to consent and/or comply with study protocol;&lt;br&gt;&lt;br&gt;         11. Individuals with known hypersensitivity to the study drugs.&lt;br&gt;&lt;br&gt;         12. Persons already treated with any of the study drugs during the last 30 days.&lt;br&gt;&lt;br&gt;         13. Any other contraindications as perin the Data Sheet of Rezolsta or Chloroquine.&lt;br&gt;&lt;br&gt;        Inclusion Criteria for a contact:&lt;br&gt;&lt;br&gt;          1. Patients who meet the definition of a contact according to the Catalan Public Health&lt;br&gt;             Department Guidelines&lt;br&gt;&lt;br&gt;          2. Aged =18 years male or female;&lt;br&gt;&lt;br&gt;          3. In women of childbearing potential, negative pregnancy test and commitment to use&lt;br&gt;             contraceptive method throughout the study.&lt;br&gt;&lt;br&gt;          4. Willing to take study medication;&lt;br&gt;&lt;br&gt;          5. Willing to comply with all study procedures;&lt;br&gt;&lt;br&gt;          6. Able to provide oral, informed consent and/or assent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria for a contact:&lt;br&gt;&lt;br&gt;          1. With known history of cardiac arrhythmia (or QT prolongation syndrome);&lt;br&gt;&lt;br&gt;          2. Unable to take drugs by mouth;&lt;br&gt;&lt;br&gt;          3. With significantly abnormal liver function (Child Pugh C)&lt;br&gt;&lt;br&gt;          4. Need of dialysis treatment, or GFR=30 mL/min/1.73 m2;&lt;br&gt;&lt;br&gt;          5. Participants with retinal disease, hearing loss.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Drug: Antiviral treatment and prophylaxis;Other: Standard Public Health measures</Intervention>
    <Primary_outcome>Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04305457</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 Infection</Public_title>
    <Scientific_title>Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19 Infection: a Randomized Clinical Trial</Scientific_title>
    <Acronym>NoCovid</Acronym>
    <Primary_sponsor>Massachusetts General Hospital</Primary_sponsor>
    <Date_registration>09/03/2020</Date_registration>
    <Date_registration3>20200309</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04305457</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 13, 2020</Date_enrollement>
    <Target_size>240</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 2</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Lorenzo Berra</Contact_Lastname>
    <Contact_Email>lberra@mgh.harvard.edu</Contact_Email>
    <Contact_Tel>+16176437733</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Laboratory confirmed COVID19 infection defined with a positive RT-PCR from any&lt;br&gt;             specimen and/or detection of SARS-CoV-2 IgM/IgG antibodies.&lt;br&gt;&lt;br&gt;          2. Hospital admission with at least one of the following:&lt;br&gt;&lt;br&gt;               1. fever = 36.6 C from axillary site; or = 37.2C from oral site; or = 37.6C from&lt;br&gt;                  tympanic or rectal site.&lt;br&gt;&lt;br&gt;               2. Respiratory rate = 24 bpm&lt;br&gt;&lt;br&gt;               3. cough&lt;br&gt;&lt;br&gt;          3. Spontaneous breathing with or without hypoxia of any degree. Gas exchange and&lt;br&gt;             ventilation maybe assisted by any continuous continuous airway pressure (CPAP), or any&lt;br&gt;             system of Non Invasive Ventilation (NIV), with Positive End-Expiratory Pressure (PEEP)&lt;br&gt;             = 10 cmH2O.&lt;br&gt;&lt;br&gt;          4. = 8 days since onset of the symptoms&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Pregnancy&lt;br&gt;&lt;br&gt;          2. Tracheostomy&lt;br&gt;&lt;br&gt;          3. Therapy with high flow nasal cannula&lt;br&gt;&lt;br&gt;          4. Any clinical contro-indication, as judged by the attending physician&lt;br&gt;&lt;br&gt;          5. hospitalized and confirmed diagnosis of COVID-19 for more than 72 hours -&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus Infections;Pneumonia, Viral;Acute Respiratory Distress Syndrome</Condition>
    <Intervention>Drug: Nitric Oxide</Intervention>
    <Primary_outcome>Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030327</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>The Second Affiliated hospital of Anhui Medical University</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50214</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-21</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhenhua Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>678 Furong Road, Jingkai District, Hefei, Anhui, China</Contact_Address>
    <Contact_Email>zzh1974cn@163.com</Contact_Email>
    <Contact_Tel>+86 13215510411</Contact_Tel>
    <Contact_Affiliation>The Second Affiliated hospital of Anhui Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: A total of 200 2019-new coronavirus infections were included, regardless of age or sex.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: none</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Blood Routine;Liver function;Blood electrolyte;Anticoagulation index;Lung CT;Viral RNA;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030325</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang</Public_title>
    <Scientific_title>A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50227</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-28</Date_enrollement>
    <Target_size>Intervention group:500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ming Chen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>136 Jingzhou Street, Xiangcheng, Xiangyang, Hubei, China</Contact_Address>
    <Contact_Email>55815147@qq.com</Contact_Email>
    <Contact_Tel>+86 13797625096</Contact_Tel>
    <Contact_Affiliation>Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Front line medical staff;&lt;br&gt;2. Participate in the prevention and treatment of COVID-19;&lt;br&gt;3. Voluntary to finish psychological survey;&lt;br&gt;4. without psychological history.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. refuse to participate in the questionnaire survey&lt;br&gt;2. with mental disorders</Exclusion_Criteria>
    <Condition>psychological health; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Intervention group:Psychological intervention;</Intervention>
    <Primary_outcome>Psychological questionnaire;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04305574</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Social Media Use During COVID-19</Public_title>
    <Scientific_title>Getting it Right: Towards Responsible Social Media Use During a Pandemic</Scientific_title>
    <Acronym />
    <Primary_sponsor>Jean Liu</Primary_sponsor>
    <Date_registration>08/03/2020</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04305574</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>21 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 9, 2020</Date_enrollement>
    <Target_size>5000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>Singapore</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Jean Liu, PhD;Jean Liu, PhD</Contact_Lastname>
    <Contact_Email>;jeanliu@yale-nus.edu.sg</Contact_Email>
    <Contact_Tel>;66013694</Contact_Tel>
    <Contact_Affiliation>Yale-NUS College;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  At least 21 years&lt;br&gt;&lt;br&gt;          -  Has stayed in Singapore for at least 2 years&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Below 21 years&lt;br&gt;&lt;br&gt;          -  Has stayed in Singapore for less than 2 years&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus;Depression;Anxiety;Stress</Condition>
    <Intervention>Behavioral: Use of social media during COVID-19</Intervention>
    <Primary_outcome>Assessment of COVID-19 situation;Depression, Anxiety and Stress Scale</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030897</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>HwaMei Hospital, University of Chinese Academy of Sciences</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50462</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Control group:10;Experimental group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Honghua Ye</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>41 Xibei Street, Haisu District, Ningbo, Zhejiang, China </Contact_Address>
    <Contact_Email>yehonghua@medmail.com.cn</Contact_Email>
    <Contact_Tel>+86 13505743664</Contact_Tel>
    <Contact_Affiliation>HwaMei Hospital, University of Chinese Academy of Sciences </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission. Criteria for diagnosis (meet all the following criteria): &lt;br&gt;(1) With epidemiological history;&lt;br&gt;(2) Clinical manifestations (meet any 2 of the following): fever, normal or decreased white blood cell count or lymphopenia in the early stage of onset, and Chest radiology in the early stage shows multiple small patchy shadowing and interstitial changes which is especially significant in periphery pulmonary. Furthermore, it develops into bilateral multiple ground-glass opacity and infiltrating shadowing. Pulmonary consolidation occurs in severe cases. Pleural effusion is rare;&lt;br&gt;(3) Confirmed case (suspected case obtained one of the following etiologic evidences): a positive result to real-time reverse-transcriptase PCR for respiratory specimen or blood specimen, or Genetic sequencing result of virus in respiratory or blood specimens are highly homologous to SARS-CoV-2; &lt;br&gt;2. The person is treated with de-isolation and meets hospital discharge criteria according to the 'Diagnosis and treatment of novel coronavirus pneumonia (trial edition 5)'. However, the respiratory nucleic acid turned positive and there were changes in lung imaging;&lt;br&gt;3. Gastrointestinal anatomy and function allowed and use safely, without nausea, vomiting and other gastrointestinal symptoms.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Gestational female patients;&lt;br&gt;2. Patients with other malignant diseases such as malignant tumours, chronic liver or kidney diseases, and reaching the end stage;&lt;br&gt;3. Patients with known psychiatric disorders;&lt;br&gt;4. Patients withdrawing from other clinical trial within 4 weeks.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Routine medicines and food;Experimental group:Taking Newgen beta-gluten probiotic composite powder;</Intervention>
    <Primary_outcome>serum albumin;siderophilin;prealbumin;lung CT scanning result;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04280588</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Fingolimod in COVID-19</Public_title>
    <Scientific_title>Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)</Scientific_title>
    <Acronym />
    <Primary_sponsor>First Affiliated Hospital of Fujian Medical University</Primary_sponsor>
    <Date_registration>20/02/2020</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04280588</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 22, 2020</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Ying Fu;Wan-Jin Chen, MD</Contact_Lastname>
    <Contact_Email>fuying1995@163.com;wanjinchen75@fjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86;+1386061359</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The patients who were diagnosed with the common type of NCP (including severe risk&lt;br&gt;             factors) and severe cases of new coronavirus pneumonia;&lt;br&gt;&lt;br&gt;          -  Aged 18 to 85 years;&lt;br&gt;&lt;br&gt;          -  Patients or authorized family members volunteered to participate in this study and&lt;br&gt;             signed informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with any history of bradyarrhythmia or atrioventricular blocks&lt;br&gt;&lt;br&gt;          -  Patients who are participating in other drug clinical trials;&lt;br&gt;&lt;br&gt;          -  Pregnant or lactating women;&lt;br&gt;&lt;br&gt;          -  ALT / AST&gt; 5 ULN, neutrophils &lt;0.5, platelets less than 50;&lt;br&gt;&lt;br&gt;          -  Definite diagnosis of rheumatic immune-related diseases;&lt;br&gt;&lt;br&gt;          -  Long-term oral anti-rejection or immunomodulatory drugs;&lt;br&gt;&lt;br&gt;          -  Patients with active pulmonary tuberculosis, with definite bacterial and fungal&lt;br&gt;             infections.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus Disease (COVID-19)</Condition>
    <Intervention>Drug: Fingolimod 0.5 mg</Intervention>
    <Primary_outcome>The change of pneumonia severity on X-ray images</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030432</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic</Public_title>
    <Scientific_title>Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Fujian Medical University</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50268</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20</Inclusion_agemin>
    <Inclusion_agemax>45</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-02</Date_enrollement>
    <Target_size>Case series:40;Control group:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>RongJin Lin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>20 Chazhong Road, Taijiang District, Fuzhou, Fujian, China</Contact_Address>
    <Contact_Email>nplrj@126.com</Contact_Email>
    <Contact_Tel>+86 13809508580</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Fujian Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Aged 20-45 years old;&lt;br&gt;(2) Understand and willing to participate in this clinical trial and provide signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with severe cardiovascular disease, lung disease, sleep disorder, psychological disease, musculoskeletal system disease and other sports contraindications.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:rehabilitation and Lung eight-segment exercise;Control group:Keep the initial life style;</Intervention>
    <Primary_outcome>PCL;PSQI;FSI;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030333</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A randomized, open-label controlled trial for the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label study to evaluate the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus infection (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48801</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-04</Date_enrollement>
    <Target_size>Pirfenidone group:147;Control group:145;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Huilan Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>huillanz_76@163.com</Contact_Email>
    <Contact_Tel>+86 15391532171</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. First diagnosis of novel coronavirus infection&lt;br&gt;2. Epidemiological history Travel history or residence history of Wuhan City within two weeks before the onset of illness; or patients who have had fever from Wuhan with respiratory symptoms within 14 days before the onset of illness, or have cluster Onset;&lt;br&gt;3. Clinical manifestations:&lt;br&gt;(1) fever;&lt;br&gt;(2) with the following imaging characteristics of pneumonia; early lesions are limited, showing patchy, subsegmental or segmental ground glass shadows, with or without thickening of lobular septum; progression Increased lesions and expanded scope, involving multiple lung lobes, some lesions consolidation, coexistence of ground glass shadows and consolidation shadows or strip shadows; diffuse lung lesions in severe stages, a few of which show "white lung", mainly consolidation , Combined with ground glass shadow, multiple cord shadow, air bronchus sign. Pleural effusion or lymphadenopathy are rare;&lt;br&gt;(3) The total number of white blood cells is normal or decreased, or the lymphocyte count is decreased in the early stage of onset.&lt;br&gt;On the basis of confirmed cases meeting the criteria for suspected cases, sputum, throat swabs, lower respiratory tract secretions, and other specimens were tested by real-time fluorescent RT-PCR to detect positive nucleic acid of the new coronavirus; or viral gene sequencing was highly similar to known new coronavirus source. Trial diagnosis and treatment plan according to the fourth edition of the new Coronavirus Infected Pneumonia issued by the National Health and Health Commission;&lt;br&gt;Diagnosis criteria for severe pneumonia:&lt;br&gt;One of the following:&lt;br&gt;(1) respiratory distress (&gt;=30 beats / min);&lt;br&gt;(2) In a resting state, SPO2&lt;=93% under inhaled air;&lt;br&gt;(3) PaO2 / FiO2&lt;=300mmHg;&lt;br&gt;Criteria for critical pneumonia:&lt;br&gt;One of the following:&lt;br&gt;(1) Respiratory failure, requiring mechanical ventilation;&lt;br&gt;(2) shock;&lt;br&gt;(3) complicated with other organ failure requires intensive care unit.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. AST and ALT&gt; 1.5 x ULN at visit 1;&lt;br&gt;2. bilirubin&gt; 1.5 x ULN at visit 1;&lt;br&gt;3. At visit 1, calculated by CockcroftGault formula, creatinine clearance &lt;30 mL / min;&lt;br&gt;4. Patients with potential chronic liver disease (Child Pugh A, B or C liver injury);&lt;br&gt;5. Previous treatment with nidanib or pirfenidone;&lt;br&gt;6. One month before the screening visit (Visit 1) or 6 half-lives (whichever is greater) were treated with other research drugs;&lt;br&gt;7. Diagnosis of IPF based on ATS/ERS/JRS/ALAT2011 guidelines (p11-07084);&lt;br&gt;8. Significant pulmonary hypertension (PAH) defined by any of the following criteria:&lt;br&gt;(1) Clinical / echocardiographic evidence of previously significant right heart failure;&lt;br&gt;(2) History including right heart catheterization showing a cardiac index &lt;=2 l / min / m2;&lt;br&gt;(3) Prostaglandin required Parenteral administration of Treprostinil for PAH 9. Other clinically significant pulmonary abnormalities that the investigators believe;&lt;br&gt;10. Major extrapulmonary physiological limitations (eg, chest wall deformity, large pleural effusion);&lt;br&gt;11. Cardiovascular disease, any of the following diseases:&lt;br&gt;(1) Severe hypertension within 6 months of visit 1, uncontrollable after treatment (&gt;=160 / 100 mmHg)&lt;br&gt;(2) Myocardial infarction within 6 months of visit 1, Unstable angina pectoris within 6 months of Visit 1;&lt;br&gt;12. History of severe central nervous system (CNS) events;&lt;br&gt;13. Known allergy to test drug;&lt;br&gt;14. Other diseases that may interfere with the testing process or that the investigator judges may interfere with the trial participation or may put patients at risk when participating in the trial;&lt;br&gt;15. Women who were pregnant, lactating or planning to become pregnant in this trial;&lt;br&gt;16. Patients are unable to understand or follow the trial procedures, including completing the questionnaires themselves without assistance.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Pirfenidone group:Conventional standard treatment + Pirfenidone 400mg three times a day;Control group:Conventional standard treatment;</Intervention>
    <Primary_outcome>K-bld questionnaire survey;Refers to the pulse oxygen;chest CT;blood gas;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030317</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical study for a new type of Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period</Public_title>
    <Scientific_title>A prospective randomized controlled trial for a Self-made Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>West China Hospital of Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50247</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>79</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>The experimental group:150;Control group:150;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hu Bing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China.</Contact_Address>
    <Contact_Email>hubingnj@163.com</Contact_Email>
    <Contact_Tel>+86 18980601278</Contact_Tel>
    <Contact_Affiliation>West China Hospital of Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients undergoing painless gastroscopy in our hospital.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients undergoing general gastroscopy;&lt;br&gt;2. With trachea dysfunction;&lt;br&gt;3. pregnant women, children, age more than 80 years;&lt;br&gt;4. Patients with difficulty in intubation.</Exclusion_Criteria>
    <Condition>Digestive endoscopy gastroscopy; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>The experimental group:Wear a self-made "gastroscope mask" during gastroscopy;Control group:Without self-made "gastroscope mask" during gastroscopy;</Intervention>
    <Primary_outcome>During the operation, the patient's volume of local exhaled air from the mouth and nose, the patient's heart rate, respiratory rate and blood oxygen saturation;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030324</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50231</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-28</Date_enrollement>
    <Target_size>Two groups:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ming Chen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>136 Jingzhou Street, Xiangcheng DIstrict, Xiangyang, Hubei, China</Contact_Address>
    <Contact_Email>55815147@qq.com</Contact_Email>
    <Contact_Tel>+86 13797625096</Contact_Tel>
    <Contact_Affiliation>Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Confirmed or clinically diagnosed cases;&lt;br&gt;2. Aged &gt;= 2 years;&lt;br&gt;3. Volunteers.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. With local skin infection, trauma and other contraindications;&lt;br&gt;2. Patients who refuse massage.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19); children</Condition>
    <Intervention>Two groups:Chinese massage versus control;</Intervention>
    <Primary_outcome>Temperature;Respiratory symptoms;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030293</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical observation and research plan of novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>Clinical observation and research plan of novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Shanghai Public Health Clinical Center</Primary_sponsor>
    <Date_registration>2020-02-27</Date_registration>
    <Date_registration3>20200227</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50195</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax>92</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Case series:300;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Feng Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>2901 Caolang Road, Jinshan District, Shanghai, China</Contact_Address>
    <Contact_Email>dr_lif08@126.com</Contact_Email>
    <Contact_Tel>+86 18121150282</Contact_Tel>
    <Contact_Affiliation>Shanghai Public Health Clinical Center</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. be over 18 years of age;&lt;br&gt;2. 2019-nCoV infected patients confirmed by viral nucleic acid testing;&lt;br&gt;3. Subjects and their families (or guardians) have fully read, understood, and signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Retrospective analysis;</Intervention>
    <Primary_outcome>Clinical indicators;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030315</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of Changchun University of traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50255</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-01</Date_enrollement>
    <Target_size>Case series:120;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang Tan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1478 Gongnong Road, Chaoyang  District, Changchun, Jilin, China </Contact_Address>
    <Contact_Email>Wangtan215@sina.com</Contact_Email>
    <Contact_Tel>+86 13756858523</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of Changchun University of traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Suspected, mild, normal and severe cases diagnosed in accordance with the diagnosis and treatment scheme for pneumonia of novel coronavirus infection (trial version 5);&lt;br&gt;2. Aged &gt;= 18 years;&lt;br&gt;3. Patients who voluntarily participate in the study and sign informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Known to be allergic to the ingredients contained in the research medication, or patients with allergies;&lt;br&gt;(2) Unwilling to cooperate with the information collector;&lt;br&gt;(3) Patients with mental illness, or cognitive impairment;&lt;br&gt;(4) Women who are breastfeeding or pregnant, or who have a positive urine pregnancy test, or who do not agree to contraception within 3 months of participating in the test;&lt;br&gt;(5) Other patients that the investigator considers unsuitable to participate in this study</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series: Prescription based on syndrome differentiation of TCM and Routine treatment of Western Medicine;</Intervention>
    <Primary_outcome>Critically ill patients (%);Mortality Rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030300</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>Umbilical cord mesenchymal stem cells for the treatment of patients at high risk of novel coronavirus pneumonia  (COVID-19): a single-center, prospective, open clinical study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Nanjing Second Hospital</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50022</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Case series:9;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yongxiang Yi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1-1 Zhongfu Road, Gulou District, Nanjingy, Jiangsu, China</Contact_Address>
    <Contact_Email>hcm200702@163.com</Contact_Email>
    <Contact_Tel>+86 13584010516</Contact_Tel>
    <Contact_Affiliation>Nanjing Second Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Upon the judgment of the researcher, the subject or his legal representative can understand and comply with the requirements of the program, and voluntarily sign the informed consent;&lt;br&gt;2. According to the new type of coronavirus pneumonia diagnosis and treatment scheme (trial version 5) diagnostic criteria, accord with standard of new coronavirus pneumonia confirmed cases, clinical diagnostic criteria for classification to heavy (pneumonia severity index (PSI) III - V level, or arterial blood oxygen partial pressure (PaO2 / oxygen concentration (FiO2) (P/F) 300 mmHg) or less;&lt;br&gt;3. Aged 18 to 75 years male or female.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The subject has a history of substance abuse (defined as the use of any illicit drug) or alcohol abuse within the first year of screening;&lt;br&gt;2. The subject suffers from active psychosis, which the researcher believes may interfere with their compliance with the study process;&lt;br&gt;3. Subjects are unable to participate in all study visits or follow study procedures;&lt;br&gt;4. The subject is a staff member of the research center or a member of his or her immediate family or relatives (such as spouse, parents, children, siblings) performing the study or the subject is compelled to agree to participate in the study;&lt;br&gt;5. Female subjects during lactation, or female subjects with positive results of serum pregnancy test during screening, or female subjects with positive results of urine pregnancy test before drug administration;&lt;br&gt;6. Have participated in other clinical research projects;&lt;br&gt;7. Subjects have hypersensitivity reactions or allergic reactions to the stem cell preparation or its components;&lt;br&gt;8. The subject suffers from any unstable or uncontrolled cardiovascular, lung, liver, kidney, gastrointestinal, urogenital, hematology, coagulation, immunology, endocrine/metabolic or other medical conditions that the investigator considers to interfere with the outcome of the study or endanger the subject's safety;&lt;br&gt;9. The subject has a history of malignant tumor;&lt;br&gt;10. Subjects have a history of severe neurological disorders, including stroke, multiple sclerosis, brain tumors, or neurodegenerative diseases.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:mesenchymal stem cells therapy;</Intervention>
    <Primary_outcome>Time to disease recovery;Exacerbation (transfer to RICU) time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030398</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19).</Public_title>
    <Scientific_title>A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50173</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-27</Date_enrollement>
    <Target_size>Experimental group:170;Control group:170;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Dingyu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Yintan Road, Dongxihu District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>1813886398@qq.com</Contact_Email>
    <Contact_Tel>+86 13507117929</Contact_Tel>
    <Contact_Affiliation>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 75 years men and women;&lt;br&gt;2. Inpatients with novel coronavirus(SARS-CoV-2) infection confirmed by PCR;&lt;br&gt;3. Agree and sign the informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Cannot take medicine by mouth;&lt;br&gt;2. Those who are allergic to bismuth potassium citrate capsules or who have taken bismuth preparations within 1 month;&lt;br&gt;3. Critical patients meet one of the following conditions:&lt;br&gt;(1) Respiratory failure occurs and requires mechanical ventilation;&lt;br&gt;(2) Shock occurs;&lt;br&gt;(3) ICU monitoring and treatment is required for other organ failure;&lt;br&gt;4. Patients with long-term hemodialysis and known severe renal impairment (glomerular filtration rate &lt;30ml / min / 1.73m2) or patients receiving continuous renal replacement therapy, hemodialysis or peritoneal dialysis;&lt;br&gt;5. Pregnant woman and lactation period;&lt;br&gt;6. The patient may be transferred to a non-participating hospital within 72 hours;&lt;br&gt;7. Researchers deem unsuitable and cannot implement the protocol.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;Control group:Simulated capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;</Intervention>
    <Primary_outcome>Pharynx swabs, lower respiratory tract samples (sputum/endotracheal aspiration/alveolar lavage), and anal swabs rt-pcr of novel coronavirus nucleic acid negative conversion rate.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030389</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Hubei Provincial Hospital Of TCM</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50278</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-29</Date_enrollement>
    <Target_size>Exposure group:60;Control group:60;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jianzhong Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>4 Garden Hill, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>ljzwd@163.com</Contact_Email>
    <Contact_Tel>+86 13307173928</Contact_Tel>
    <Contact_Affiliation>Hubei Provincial Hospital of TCM</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with Novel coronavirus pneumonia who are mainly admitted to hospitals in Hubei Province and whose temperature is normal for at least 5 days after treatment, whose vital signs are stable (including to be discharged) or who have been discharged, but whose lung damage has not improved.&lt;br&gt;1. Aged &gt;=18 years male and female;&lt;br&gt;2. Clinically diagnosed and confirmed cases;&lt;br&gt;3. Classification: clinically diagnosed cases, confirmed cases of ordinary, severe, critical.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Other pneumonia;&lt;br&gt;2. Known to be allergic to traditional Chinese medicine ingredients, or patients with allergies;&lt;br&gt;3. Women during lactation and pregnancy, or have a positive urine pregnancy test.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Exposure group:Western medicine routine treatment+triple energizer treatment;Control group:Conventional medicine routine treatment;</Intervention>
    <Primary_outcome>Lung CT;TCM symptoms;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030892</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19) Fibrosis: a prospective exploratory experimental medical study</Public_title>
    <Scientific_title>Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis:a prospective exploratory experimental medical study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51118</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-06</Date_enrollement>
    <Target_size>Experimental group:20;Control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qun Luo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>luoqunx@163.com</Contact_Email>
    <Contact_Tel>+86 13710658121</Contact_Tel>
    <Contact_Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients aged from 18 to 80 years;&lt;br&gt;2. conformed to epidemic history;&lt;br&gt;3. fever and respiratory symptoms;&lt;br&gt;4. normal or decreased leukocyte count in peripheral blood; or decreased lymphocyte count;&lt;br&gt;5. conformed to imaging features of COVID-19 pneumonia;&lt;br&gt;6. positive for COVID-19 nucleic acid test or second-generation sequencing of pathogens;&lt;br&gt;7. serum KL- 61500U / ml;&lt;br&gt;8. and conforms to any of the following:&lt;br&gt;(1) respiratory distress, RR &gt;=30 beats / min;&lt;br&gt;(2) oxygen saturation &lt;=93% at rest;&lt;br&gt;(3) partial pressure of arterial oxygen (PaO2) / oxygen concentration (FiO2) &lt;=300mmHg (1mmHg=0.133kPa).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. people who are allergic to pifenidone capsules;&lt;br&gt;2. the researchers judged that the compliance of the subjects was not good;&lt;br&gt;3. those who cannot take drugs through gastrointestinal tract;&lt;br&gt;4. any significant clinical or laboratory abnormalities that may affect the safety assessment, such as: serum creatinine &gt; 2mg/dL or 176.8mmol sputum alt, AST &gt;=2.5 ULN or TBIL &gt;=1.5 ULN;&lt;br&gt;5. patients with severe liver disease;&lt;br&gt;6. pregnant and lactating patients;&lt;br&gt;7. patients with severe nephropathy or requiring dialysis treatment;&lt;br&gt;8. those who need to take fluvoxamine at the same time (a drug for the treatment of depression or obsessive-compulsive disorder).</Exclusion_Criteria>
    <Condition>Fibrosis after Severe Coronavirus Disease 2019 (COVID-19) Pneumonia</Condition>
    <Intervention>Experimental group:Pirfenidone;Control group:Blank;</Intervention>
    <Primary_outcome>HRCT pulmonary fibrosis score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030883</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50960</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>10</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-18</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yang Si-Jin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>182 Chunhui Road, Longmatan District, Luzhou, Sichuan, China</Contact_Address>
    <Contact_Email>lykyk3160823@126.com</Contact_Email>
    <Contact_Tel>+86 15228218357</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Based on the diagnostic criteria of provinces other than hubei province in the latest diagnosis and treatment program of novel coronavirus pneumonia issued by the national health commission, the light, common, severe and critical types of suspected and confirmed cases were determined by combining epidemiological history, clinical manifestations and laboratory examination.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) patients allergic to the prescription of traditional Chinese medicine;&lt;br&gt;(2) infants and young children unable to take traditional Chinese medicine decoction;&lt;br&gt;(3) patients with unconsciousness or loss of consciousness;&lt;br&gt;(4) pregnant and lactating patients, or positive urine pregnancy test;&lt;br&gt;(5) according to the judgment of the doctor in the study, it is not suitable for the patients who take qingfei detoxification mixture.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:qingfei detoxification decoction (mixture);</Intervention>
    <Primary_outcome>temperature;Systemic symptom;Respiratory symptoms;Chest imaging changes;Detection of novel coronavirus nucleic acid two consecutive negative time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030290</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus pneumonia (COVID-19) from two hospitals in China</Public_title>
    <Scientific_title>Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus infection (COVID-19) from two hospitals in China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Xiamen University</Primary_sponsor>
    <Date_registration>2020-02-27</Date_registration>
    <Date_registration3>20200227</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50175</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>60</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-11</Date_enrollement>
    <Target_size>Case series:2000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jiemin Zhu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Room 222, Alice Lee Building, Xiangan Campus, Xiamen University, Fujian, China</Contact_Address>
    <Contact_Email>jieminzhu@xmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 15960212649</Contact_Tel>
    <Contact_Affiliation>Xiamen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The front line nurses who were taking care of the nCoV infected patients in the participating hospitals </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Nurses who were diagnosed with any mental disorders and who were infected by nCoV were excluded from the study. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Quality of Life;Epidemic Prevention Medical Protective Equipment related Skin Lesion and Management Scale;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030259</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial</Public_title>
    <Scientific_title>Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19): a randomized, open and controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Shanghai Changzheng Hospital</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49918</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-22</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Junxue Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>415 Fengyang Road, Huangpu District, Shanghai, China</Contact_Address>
    <Contact_Email>docd1@sina.com</Contact_Email>
    <Contact_Tel>+86 18917387623</Contact_Tel>
    <Contact_Affiliation>Shanghai Changzheng Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 75 years old;&lt;br&gt;2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the current diagnosis and treatment plan for pneumonia with new coronavirus infection;&lt;br&gt;3. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days);&lt;br&gt;4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;&lt;br&gt;5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration;&lt;br&gt;6. Patients who voluntarily sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR &lt;=30 times / min; or SaO2 / SpO2 &lt;=93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt;=300MMHG (1mmhg = 0.133kpa);&lt;br&gt;2. Pneumonia patients with severe new coronavirus infection meet one of the following conditions: respiratory failure and need mechanical ventilation; or shock; or other organ failure combined with ICU monitoring treatment;&lt;br&gt;3.Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 times upper limit);&lt;br&gt;4. Patients with contraindications specified in the instructions of danorevir and ritonavir tablets;&lt;br&gt;5. Patients who have taken or are taking protease inhibitor drugs;&lt;br&gt;6. The pregnancy test of female subjects in the screening period was positive;&lt;br&gt;7. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Danorevir sodium tablets,/ritonavir oral;Control group:Symptomatic treatment;</Intervention>
    <Primary_outcome>Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030283</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Correlation between imaging characteristics and laboratory tests of new coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Correlation between imaging characteristics and laboratory tests of new coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Xianning Central Hospital</Primary_sponsor>
    <Date_registration>2020-02-27</Date_registration>
    <Date_registration3>20200227</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50119</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-27</Date_enrollement>
    <Target_size>case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Kaihu Yu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>228 Jingui Road, Xianning, Hubei, China</Contact_Address>
    <Contact_Email>2066255602@qq.com</Contact_Email>
    <Contact_Tel>+86 13508649926</Contact_Tel>
    <Contact_Affiliation>Xianning Central Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients diagnosed with COVID-19;&lt;br&gt;2. Underwent chest CT scan during the treatment and at least one chest CT scan during follow-up;&lt;br&gt;3. Able to complete the study. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. CT image quality does not meet the analysis criteria;&lt;br&gt;2. Pregnant and lactating women. </Exclusion_Criteria>
    <Condition>Novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>case series:N/A;</Intervention>
    <Primary_outcome>imaging feature;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030265</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Study for continuous renal replacement therapy with adsorption filter in the treatment of the novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical research program of continuous renal replacement therapy with adsorption filter for the treatment of the novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Harbin Medical University</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49691</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>High inflammation oXiris CRRT treatment group:10;High inflammation Conventional treatment group:10;Low inflammation conventional treatment group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Kaijiang Yu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>23 Youzheng Street, Nangang District, Harbin, Heilongjiang, China</Contact_Address>
    <Contact_Email>drkaijiang@163.com</Contact_Email>
    <Contact_Tel>+86 13303608899</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Harbin Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 85 years old;&lt;br&gt;2. It conforms to the diagnostic criteria of severe and critical type in "Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (6th Edition)";&lt;br&gt;3. Sign the informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Serious basic diseases affecting survival, including: uncontrolled malignant tumor with multiple metastases that cannot be removed, hematological diseases, cachexia, active hemorrhage, severe malnutrition, AIDS, etc.;&lt;br&gt;2. Obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis and allergic alveolitis caused by lung tumor;&lt;br&gt;3. Continuous use of immunosuppressive agents or organ transplants in the past 6 months;&lt;br&gt;4. Use in vitro life support (ECMO, ECCO2R);&lt;br&gt;5. Patients are expected to die within 48 hours;&lt;br&gt;6. Patients with acute kidney injury and AKI stage 2 or above;&lt;br&gt;7. Any potential violation of test compliance or any other circumstance affecting safety and effectiveness evaluation that may exist, which the researchers believe is not suitable for patients participating in the study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>High inflammation oXiris CRRT treatment group:oXiris CRRT treatment;High inflammation Conventional treatment group:Conventional treatment;Low inflammation conventional treatment group:Conventional treatment;</Intervention>
    <Primary_outcome>Inflammation factor;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030387</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Tongji Hospital of Tongji University</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50329</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Mild group:100;Serere group:30;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ziqiang Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>389 Xincun Road, Putuo District, Shanghai, China</Contact_Address>
    <Contact_Email>zzq1419@126.com</Contact_Email>
    <Contact_Tel>+86 18721335536</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital of Tongji University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: According to the "Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (Trial Version 6)" issued by the General Office of the State Health Committee of the People's Republic of China, newly diagnosed patients with pneumonia have been diagnosed. Clinical classification: &lt;br&gt;(1) mild: clinical symptoms are mild, and no pneumonia is found on imaging;&lt;br&gt;(2) Common type: with fever, respiratory tract and other symptoms, pneumonia can be seen on imaging;&lt;br&gt;(3) Heavy duty. &lt;br&gt;Comply with any of the following: &lt;br&gt;1. shortness of breath, RR&gt;=30 times/min;&lt;br&gt;2. In the resting state, oxygen saturation &lt;=93%;&lt;br&gt;3. arterial partial pressure of oxygen (PaO2)/ oxygen concentration (FiO2)&lt;=300mmHg(1mmHg=0.133kPa). In areas with high altitude (over 1,000 meters above sea level), PaO2/FiO2 shall be corrected according to the following formula: PaO2/FiO2*[ atmospheric pressure (mmHg)/760]; Pulmonary imaging showed that patients with obvious lesion progress &gt; 50% within 24-48 hours should be managed according to heavy duty;&lt;br&gt;4. Critical type: one of the following conditions is met: &lt;br&gt;(1) Respiratory failure occurs and mechanical ventilation is required;&lt;br&gt;(2) Shock;&lt;br&gt;(3) ICU monitoring and treatment are required for patients with other organ failure. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with serious heart and lung, liver and kidney functions and central nervous system diseases;&lt;br&gt;2. Pregnant or lactating patients;&lt;br&gt;3. Cancer patients.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Mild group:Conventional treatment;Serere group:intensive care;</Intervention>
    <Primary_outcome>Epidemiological and clinical characteristics;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030330</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical research of 6-minute walk training on motor function of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>the effects of 6-minute walk training on walking distance, oxygen saturation, heart rate and global rating of change of normal or critial novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50274</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-28</Date_enrollement>
    <Target_size>Case series:10;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ming Wu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>17 Lujiang Road, Luyang District, Hefei, Anhui, China</Contact_Address>
    <Contact_Email>ahslyywm@163.com</Contact_Email>
    <Contact_Tel>+86 18655106697</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Normal and severe cases diagnosed in accordance with the diagnosis for pneumonia of novel coronavirus infection;&lt;br&gt;2. Viral nucleic acid test is negative or positive after treatment;&lt;br&gt;3. Aged &gt;= 18 years;&lt;br&gt;4. Patients with clear consciousness;&lt;br&gt;5. Patients who voluntarily participate in the study and sign informed consent.  </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pneumonia caused by other reasons;&lt;br&gt;2. Have contraindications that can not participate in sports activities;&lt;br&gt;3. Mental disorders, cognitive impairments etc. can not cooperate with researchers subjectively;&lt;br&gt;4. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease;&lt;br&gt;5. Pregnant or lactating women.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:6-minute walk training;</Intervention>
    <Primary_outcome>walking distance;oxygen saturation;heart rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030865</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection</Public_title>
    <Scientific_title>Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Huazhong university of science and technology</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49933</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Luo Xiaoping</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>xpluo@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 027-83662684</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All patients who meet one or two of the followings will be included in this study(pregnant women and newborns delivered):&lt;br&gt;Epidemiological history: &lt;br&gt;1. travel or residence history of Wuhan or other areas with continuous transmission of local cases within 14 days before the onset of the disease; or contact with local cases from Wuhan or other areas within 14 days before the onset of the disease; or associated with the occurrence of clustering disease;&lt;br&gt;2. Clinical manifestations: fever; or chest CT imaging features: multiple small patches and interstitial changes at the early stage, showing clearly in the lung. In severe cases, lung consolidation and pleural effusion are rare. or In the early stage of infection, the total number of white blood cells was normal or decreased, or the lymphocyte count was decreased. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The family refused</Exclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Maternal and neonatal morbidity;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030858</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital</Public_title>
    <Scientific_title>Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Hubei Cancer Hospital</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51097</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>82</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-06</Date_enrollement>
    <Target_size>Case series:483;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Tiejun Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>116 Zhuodaoquan Road South, Hongshan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>tiejunwanghp@163.com</Contact_Email>
    <Contact_Tel>+86 13277914596</Contact_Tel>
    <Contact_Affiliation>Department of Breast Surgery, Hubei Cancer Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The mild cases were defined as those with mild clinical symptoms and no abnormalities on imaging examination; critical cases were those that met any of the following conditions: &lt;br&gt;1) respiratory failure requiring mechanical ventilation; &lt;br&gt;2) shock;&lt;br&gt;3) combined with another organ failure, the need for intensive care unit (ICU) monitoring and treatment. The process of classified management of mild and severe cases is shown in Figure 1. Among the patients we followed, 62 patients progressed to severe cases; they were transferred to designated hospitals for further treatment. &lt;br&gt;Moreover, the discharge diagnostic criteria were as follows: &lt;br&gt;1) body temperature returned to normal for more than 3 d; &lt;br&gt;2) respiratory symptoms improved significantly; &lt;br&gt;3) significant improvement in lung imaging; &lt;br&gt;4) negative nucleic acid test for nasal and pharyngeal swabs twice.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: All mild patients need to be isolated and treated in mobile cabin hospitals. After admission, patients were given antiviral and symptomatic treatment according to their condition and symptoms, and patients with fever were given antibiotics at the same time. Besides, the patient was instructed to exercise and psychological intervention, all drugs were presented in Supplementary Table S1. During the hospital stay, decide whether you need a chest CT or chest radiograph based on the patient's condition. When the patient has no fever for three days and the respiratory symptoms are relieved, start nucleic acid tests and chest radiographs or CT scans of the lungs. The decision to be discharged based on whether the test results meet discharge criteria. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:none;</Intervention>
    <Primary_outcome>Discharge rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030258</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>The Fourth Affiliated Hospital of Harbin Medical University</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49887</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-21</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Treatment study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wei Yang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Yiyuan Street, Nangang District, Harbin, Heilongjiang, China</Contact_Address>
    <Contact_Email>hydyangwei@tom.com</Contact_Email>
    <Contact_Tel>+86 13845099775</Contact_Tel>
    <Contact_Affiliation>The Fourth Affiliated Hospital of Harbin Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Adults aged &gt;=18 years understand and agree to sign informed consent;&lt;br&gt;(2) a novel coronavirus infection confirmed by laboratory RT-PCR.&lt;br&gt;(3) Hospitalized patients with fever (axillary temperature &gt;=37.0 degree C) or respiratory symptoms;&lt;br&gt;(4) The interval between symptom onset and immediate enrollment is within 14 days;&lt;br&gt;(5) Those who did not participate in other clinical trials within 3 months;&lt;br&gt;(6) No other antiviral drugs were involved in the follow-up study within 14 days.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) novel coronavirus pneumonia is a disease or condition beyond the pneumonia. That is, according to the researchers' judgement, the subjects will be at risk for taking part in the research, or will have an impact on the results of the study and the ability of the subjects to participate in the study;&lt;br&gt;(2) A woman who is pregnant or breastfeeding or who plans to be pregnant during the study period;&lt;br&gt;(3) Combined with heart, liver, kidney, hematopoietic system and other important organs or systems of serious primary diseases;&lt;br&gt;(4) Severe and critical patients: respiratory distress, RR &gt;=30 times / min; in resting state, oxygen saturation &lt;= 93%; arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt; 300MMHG; respiratory failure, mechanical ventilation; shock; other organ failure requiring ICU monitoring and treatment;&lt;br&gt;(5) Patients over 70 years old;&lt;br&gt;(6) Patients with mental disorders and cognitive disorders;&lt;br&gt;(7) Those who have poor compliance, are unwilling to participate in the project or do not sign the informed consent during their stay in the hospital. There are doubts about the validity of informed consent: subjects with mental illness, mental retardation, poor motivation, drug abuse (including drugs and alcohol) or other disease history restricting the validity of informed consent in this study;&lt;br&gt;(8) Patients with glucocorticoid;&lt;br&gt;(9) The researchers think it is not suitable to participate in this study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional drug therapy plus hydrogen inhalation;Control group:Conventional drug therapy;</Intervention>
    <Primary_outcome>temperature;respiratory rate;Blood oxygen saturation;Cough symptom;Lung CT;Fatality rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030257</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>The coagulation function of novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>The coagulation function of novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Puren Hospital of Wuhan City</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50006</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-09</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Jiangping</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Benxi Street, Fouth Jianshe Road, Qinshan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>1078404424@qq.com</Contact_Email>
    <Contact_Tel>+86 18602764053</Contact_Tel>
    <Contact_Affiliation>Puren Hospital of Wuhan City</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: the diagnosed COVID-19 pneumonia inpatients</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: blood disease, hepatosis, maglinant tumor, other diseases affecting coagulation function. and taking anticoagulation drugs.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>INR;PT;TT;APTT;FIB;DD;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030264</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>ICU healthcare personnel burnout investigation during the fight against novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>ICU healthcare personnel burnout investigation during the fight against novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Department of critical care, Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50161</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-28</Date_enrollement>
    <Target_size>Burnout positive group versus burnout negative group:1000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>WANG Jing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>wangjing9279@163.com</Contact_Email>
    <Contact_Tel>+86 18186161668</Contact_Tel>
    <Contact_Affiliation>Department of critical care, Zhongnan Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All ICU staff involved in the fight against the new coronary pneumonia for at least 1 week</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: no</Exclusion_Criteria>
    <Condition>job burnout; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Burnout positive group versus burnout negative group:NO;</Intervention>
    <Primary_outcome>no;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030215</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)</Public_title>
    <Scientific_title>Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Nanchang University, Ten layers pulse Research Institute of traditional Chinese medicine, Nanchang University</Primary_sponsor>
    <Date_registration>2020-02-25</Date_registration>
    <Date_registration3>20200225</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50107</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-26</Date_enrollement>
    <Target_size>Experimental group 1:20;Control group (Mild patients):20;Experimental group 2:20;Control group (general patient):20;Experimental group 3:20;Control group (severe patients):20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Shao Yi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China</Contact_Address>
    <Contact_Email>freebee99@163.com</Contact_Email>
    <Contact_Tel>+86 13576955700</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Nanchang University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) The confirmed patient (or legal guardian) agrees to participate in the study and signs the informed consent form;&lt;br&gt;2) aged 18 to 65 years;&lt;br&gt;3) The time interval between the onset of symptoms and random enrollment is within 8 days (the onset of symptoms is mainly based on the occurrence of fever);&lt;br&gt;4) Real-time fluorescent RT-PCR of respiratory specimens or blood specimens to detect patients with 2019-nCoV nucleic acid positive;&lt;br&gt;5) Patients were diagnosed as type 3 patients with mild, common and severe cases according to the "Diagnosis and Treatment Scheme for 2019-nCoV (Trial Version 6)".</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Any situation where the solution cannot be carried out safely;&lt;br&gt;2) Allergic constitution, allergic to one or more foods or drugs;&lt;br&gt;3) Severe basic diseases affecting survival, including uncontrolled clinically significant heart, lung, kidney, digestive, hematological, neuropsychiatric diseases, immune diseases, metabolic diseases or malignant tumors, severe malnutrition;&lt;br&gt;4) pregnant or lactating women;&lt;br&gt;5) The patient may be transferred to a non-participating hospital within 72 hours;&lt;br&gt;6) Those who have continued to use immunosuppressive agents or organ transplants in the past 6 months;&lt;br&gt;7) Within 15 days before enrollment, during the hospitalization period, any patient who is being treated with antiviral drugs other than this program during treatment;&lt;br&gt;8) People who cannot cooperate with mental state, suffer from mental illness, have no self-control, and cannot express clearly;&lt;br&gt;9) History of HBV, HCV, TPPA, HIV, and pancreatitis before infection;&lt;br&gt;10) Those who are participating in other clinical trials.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group 1:Routine treatment + Kanguan No. 1;Control group (Mild patients):Routine treatment;Experimental group 2:Routine treatment + Kanguan No. 2;Control group (general patient):Routine treatment;Experimental group 3:Routine treatment + Kanguan No. 3;Control group (severe patients):Routine treatment;</Intervention>
    <Primary_outcome>Routine physical examination;Vital signs: breathing, body temperature (armpit temperature);Blood routine;C-reactive protein;Liver and kidney function test;Myocardial enzyme content;ESR;T cell subsets;Cytokine;Liver, gallbladder, thyroid, and lymph node imaging;Chest CT;Infectious disease test;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030328</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50241</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-02</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yun Lin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China  </Contact_Address>
    <Contact_Email>frank0130@126.com</Contact_Email>
    <Contact_Tel>+86 13986268403</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Comply with the diagnostic criteria for general type COVID-19 in the "Diagnosis and Treatment Program for COVID-19"(trial version 6th);&lt;br&gt;(2) Patients =18 years of age with tracheal intubation;&lt;br&gt;(3) Agree to participate in the trial, and the patient, the legal guardian or the person in charge of the medical institution signed the informed consent through paper signature, electronic signature of mobile phone software, or voice authorization. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.Serious basic diseases affecting survival, including: uncontrolled malignant tumor with multiple metastases that cannot be removed, hematological diseases, cachexia, active hemorrhage, severe malnutrition, AIDS, etc.;&lt;br&gt;2.Obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis and allergic alveolitis caused by lung tumor;&lt;br&gt;3.Use in vitro life support (ECMO, ECCO2R);&lt;br&gt;4.Patients with bronchial asthma, peptic ulcer, and patients allergic to acetylcysteine;&lt;br&gt;5.Any potential violation of test compliance or any other circumstance affecting safety and effectiveness evaluation that may exist, which the researchers believe is not suitable for patients participating in the study. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Acetylcysteine inhaled via tracheal tube;Control group:Placebo (saline) inhaled via tracheal tube;</Intervention>
    <Primary_outcome>Lung CT after 3 days;Lung CT after 7 days;Oxygenation parameters: SpO2, Partial arterial oxygen pressure (PaO2), PaO2/FiO2;Hospital stay;Novel coronavirus nucleic acid detection;Recurrence rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030288</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy of Traditional Chinese Medicine in the Treatment of Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial</Public_title>
    <Scientific_title>Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>China Academy of Chinese Medical Sciences</Primary_sponsor>
    <Date_registration>2020-02-27</Date_registration>
    <Date_registration3>20200227</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50202</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-27</Date_enrollement>
    <Target_size>experimental group:102;control group:102;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Huang Luqi; Ruan Lianguo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China</Contact_Address>
    <Contact_Email>huangluqi01@126.com</Contact_Email>
    <Contact_Tel>+86 010-64089801</Contact_Tel>
    <Contact_Affiliation>China Academy of Chinese Medical Sciences</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Comply with the diagnostic criteria for general type COVID-19 in the "Diagnosis and Treatment Program for COVID-19"(trial version 6th);&lt;br&gt;(2) Aged &gt;= 18 years;&lt;br&gt;(3) Agree to participate in the trial, and the patient, the legal guardian or the person in charge of the medical institution signed the informed consent through paper signature, electronic signature of mobile phone software, or voice authorization.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Critical patients;&lt;br&gt;(2) Patients who can not guarantee compliance of using TCM during the treatment period, or patients who are difficult to take medicine by oral or nasal route;&lt;br&gt;(3) Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID-19;&lt;br&gt;(4) Pregnant or parturient women. Patient who have a pregnancy plan or a positive urine pregnancy test;&lt;br&gt;(5) Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, etc., which the researchers consider unsuitable for participation in the trial;&lt;br&gt;(6) Patients who have been allergic or intolerant to taking TCM.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>experimental group:TCM formula and general treatment based on "Diagnosis and Treatment Program for COVID-19" (trial version 6th);control group:general treatment based on "Diagnosis and Treatment Program for COVID-19" (trial version 6th);</Intervention>
    <Primary_outcome>The time to 2019-nCoV RNA negativity in patients;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030856</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>An artificial intelligence assistant system for suspected novel coronavirus pneumonia (COVID-19) based on chest CT</Public_title>
    <Scientific_title>An artificial intelligence assistant system for suspected new coronavirus pneumonia based on chest CT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51091</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20</Inclusion_agemin>
    <Inclusion_agemax>88</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Target condition:600;Difficult condition:100</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Liming Xia</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>Lmxia@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13607176908</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. COVID-19 patients with positive SARS-COV-2 nucleic acid RT-PCR test results;&lt;br&gt;2. Viral pneumonia manifestation on CT.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: CT negative results</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:RT-PCR test results;Index test:Artificial&amp;#32;intelligence&amp;#32;model;</Intervention>
    <Primary_outcome>sensitivity;SPE;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030849</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Investigation on psychological status of novel coronavirus pneumonia (COVID-19) rehabilitation patients in Zhengzhou City and research on coping strategies</Public_title>
    <Scientific_title>Investigation on psychological status of COVID-19 rehabilitation patients in Zhengzhou City and research on coping strategies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Zhengzhou People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51086</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>7</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-16</Date_enrollement>
    <Target_size>Case series:81;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yibin Hao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China</Contact_Address>
    <Contact_Email>haoyibin0506@126.com</Contact_Email>
    <Contact_Tel>+86 15903715671</Contact_Tel>
    <Contact_Affiliation>Zhengzhou people's hospital </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Above 7 years old, understand the purpose and significance of the research, and be able to cooperate with the research;&lt;br&gt;2. Meet the diagnostic criteria of the COVID-19;&lt;br&gt;3. Clear consciousness and stable vital signs;&lt;br&gt;4. Voluntarily participate in this study and sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Too young to understand the research or to cooperate with the research;&lt;br&gt;2. Non-neoplastic coronary pneumonia patients;&lt;br&gt;3. Impaired consciousness, affecting its understanding and expression;&lt;br&gt;4. Those who cannot cooperate with research or cannot express because of malignant basic disease or critical illness of this disease;&lt;br&gt;5. People with a history of mental illness;&lt;br&gt;6. Those who cannot follow up in the field and those who fall off naturally during observation.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Psychological intervention;</Intervention>
    <Primary_outcome>SCL-90 scale;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030198</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical research of pulmonary rehabilitation in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Effect of pulmonary rehabilitation on pulmonary function, exercise capacity, activity of daily living and quality of life in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>West China Hospital of Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-25</Date_registration>
    <Date_registration3>20200225</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50066</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-08-24</Date_enrollement>
    <Target_size>experimental group:30;control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chengqi He</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>hxkfhcq@126.com</Contact_Email>
    <Contact_Tel>+86 18980601618</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients discharged from severe or critical new coronavirus pneumonia;&lt;br&gt;2. Adults over 18 years of age who signed the informed consent;&lt;br&gt;3. Study participants are willing to accept random assignment to any designated treatment group;&lt;br&gt;4. Prior to the completion of this study, participants must agree not to participate in another study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pneumonia caused by other reasons;&lt;br&gt;2. Have contraindications that can not participate in sports activities;&lt;br&gt;3. Mental disorders, cognitive impairments etc. can not cooperate with researchers subjectively.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Health education+ pulmonary rehabilitation;control group:Health educatio;</Intervention>
    <Primary_outcome>pulmonary function;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030196</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Central South Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-25</Date_registration>
    <Date_registration3>20200225</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49883</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Case series:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>2</Phase>
    <Countries>china</Countries>
    <Contact_Firstname>Zhiyong Peng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>Pengzy5@hotmail.com</Contact_Email>
    <Contact_Tel>+86 18672396028</Contact_Tel>
    <Contact_Affiliation>Central South Hospital, Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients volunteered to sign the informed consent;&lt;br&gt;2. Patients who were diagnosed with the common type of NCP and severe cases of new coronavirus pneumonia, Referring to the New Coronavirus Pneumonia Diagnosis and Treatment Plan, with elevation of IL-6, and grade 2-3 CRS.In the case of atypical signs of CRS, he or she should be judged by the investigator;&lt;br&gt;3. Aged &gt;=18 years. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. People with serious or uncontrolled concomitant diseases, including sensory, vascular, heart, liver, kidney, gastric, intestinal, endocrine, etc.;&lt;br&gt;2. Having received Vaccine in the 4 weeks before entry or Planning to receive vaccine during the study;&lt;br&gt;3. Hypersensitivity to tocilizumab;&lt;br&gt;4. Pregnant or positive of the pregnancy test, lactating women;&lt;br&gt;5. Other reasons to exclude from the study. </Exclusion_Criteria>
    <Condition>cytokine release syndrome of new coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:conventional therapy+tocilizumab;</Intervention>
    <Primary_outcome>the relive of CRS;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030226</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>The treatment status and risk factors related to prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a descriptive study</Public_title>
    <Scientific_title>The treatment status and risk factors related to prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a descriptive study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>The Fourth Hospital of Hebei Medical University</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49855</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:40;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhenjie Hu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>12 Jiankang Road, Shi-Jia-Zhuang, Hebei, China</Contact_Address>
    <Contact_Email>syicu@vip.sina.com</Contact_Email>
    <Contact_Tel>+86 13933856908</Contact_Tel>
    <Contact_Affiliation>The Fourth Hospital of Hebei Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All patients with 2019 novel coronavirusinfected pneumonia enrolled in this study were diagnosed according to guidance(trial version 5) of China,and met the standard of Heavy or critically ill.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Pregnancy;Sudden death disease, such as fatal heart disease patients.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Clinical characteristics;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030225</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49945</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-22</Date_enrollement>
    <Target_size>Experimental group:93;Control Group:93;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhou Jia</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>110 Ganhe Road, Hongkou District, Shanghai, China</Contact_Address>
    <Contact_Email>pdzhoujia@163.com</Contact_Email>
    <Contact_Tel>+86 18017306677</Contact_Tel>
    <Contact_Affiliation>Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 80 years;&lt;br&gt;2. Patients with novel coronavirus pneumonia who were diagnosed as general type or severe type according to the western medicine classification general type, severe type and Chinese medicine classification criteria;&lt;br&gt;3. Understand and agree to participate in the study and sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with other serious pulmonary diseases, cardiovascular and cerebrovascular diseases, diabetes mellitus, tumor, hematopoiesis, autoimmune diseases, digestive system diseases, skin diseases, psychosis, etc.;&lt;br&gt;2. Patients who cannot complete the treatment;&lt;br&gt;3. Pregnant or lactating women.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional treatment &amp; Acupuncture;Control Group:Conventional treatment;</Intervention>
    <Primary_outcome>Length of hospital stay;Discharge time of general type;Discharge time of severe type;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030263</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic</Public_title>
    <Scientific_title>Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Beijing Geriatric Hospital</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50140</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Epidemilogical research</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jihui Lyu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>118 Wenquan Road, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>lvjihui@139.com</Contact_Email>
    <Contact_Tel>+86 010 62402842</Contact_Tel>
    <Contact_Affiliation>Beijing Geriatric Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: staff working in hospital during the epidemic of COVID-19</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: anyone who are reluctant or unable to answer the questionnaire</Exclusion_Criteria>
    <Condition>psychological status</Condition>
    <Intervention>Case series:N/A;</Intervention>
    <Primary_outcome>GHQ-20;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030261</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Wuxi Fifth People's Hospital</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49963</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Exocrine group:13;Control group:13;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Meiping Chu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1215 Guangrui Road, Wuxi, Jiangsu, China</Contact_Address>
    <Contact_Email>chump1981@163.com</Contact_Email>
    <Contact_Tel>+86 15052103816</Contact_Tel>
    <Contact_Affiliation>Wuxi Fifth People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients meet the diagnostic criteria "Diagnosis and treatment of novel coronavirus pneumonia (trial version fifth)"for suspected cases outside Hubei Province: combined with the following epidemiological and clinical manifestations: epidemiological history &lt;br&gt;1. Patients with travel or residence history in Wuhan and surrounding areas or other communities with case reports within 14 days before the onset of the disease; &lt;br&gt;2. Patients with a novel coronavirus infection (positive for nucleic acid detection) within 14 days before onset;,&lt;br&gt;3. Patients with fever or respiratory symptoms from Wuhan and surrounding areas or from the community with case report had been contacted within 14 days before the onset of the disease; &lt;br&gt;4.  Clustering disease; clinical manifestations:&lt;br&gt; (1) fever and / or respiratory symptoms;&lt;br&gt; (2) having the above-mentioned imaging characteristics of pneumonia;&lt;br&gt; (3) normal or reduced leukocyte count or lymphocyte count in the early stage of the disease. &lt;br&gt;There is any one in the epidemiological history, and it is consistent with any two in the clinical manifestations. &lt;br&gt;If there is no clear epidemiological history, it is in line with 3 of the clinical manifestations.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Age &lt; 18 or &gt; 65; &lt;br&gt;(2) Patients with severe heart, brain, lung, kidney dysfunction, endocrine disease, hematopoiesis system disease or other serious diseases and psychosis; &lt;br&gt;(3) Pregnant and lactating women.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Exocrine group:Aerosol inhalation of exosomes;Control group:Blank;</Intervention>
    <Primary_outcome>Lung CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030022</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>First Affiliated Hospital of Anhui Medical University</Primary_sponsor>
    <Date_registration>2020-02-20</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49797</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-22</Date_enrollement>
    <Target_size>Experimental group:50;Control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Liangdan Sun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>218 Jixi Road, Hefei, Anhui, China</Contact_Address>
    <Contact_Email>ahmusld@163.com</Contact_Email>
    <Contact_Tel>+86 13856985045</Contact_Tel>
    <Contact_Affiliation>First Affiliated Hospital of Anhui Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Age 18 to 80 years old (including threshold), sex unlimited, inpatient&lt;br&gt;(2) Respiratory specimen were positive for COVID-19 nucleic acid by RT-PCR;&lt;br&gt;(3) Clinical classification is mild or moderate type (with symptoms of fever, respiratory tract, imaging findings of pneumonia);&lt;br&gt;(4) Hospitalization for the following reasons:Fever (axillary temperature &gt;= 36.7 degrees C, or mouth temperature &gt;= 38.0 degrees C, or anal or ear temperature &gt;= 38.6 degrees C) and respiratory frequency &gt; 24 beats/min or cough (Shortness of breath and cough at least one);&lt;br&gt;(5) Informed consent signed.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Patients with known or suspected to be allergic to the components of the test drug; &lt;br&gt;(2) Patients with known hepatitis B, C, AIDS and other viral infections;&lt;br&gt;(3) Patients with severe or severe clinical classification who have experienced complications such as respiratory failure and acute respiratory distress syndrome (ARDS);&lt;br&gt;(4) Patients who have participated or are participating in other drug clinical trials within 2 weeks before screening;&lt;br&gt;(5) Pregnancy: Positive pregnancy test for Female patients;&lt;br&gt;(6) Patients may be transferred to non-participating hospitals within 72 hours; &lt;br&gt;(7) Patients with respiratory infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and lung development;&lt;br&gt;(8) Patients being treated with other Chinese medicine;&lt;br&gt;(9) Believed to be not suitable to participate in clinical trials by investigator.</Exclusion_Criteria>
    <Condition>Novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional therapy and Pediatric Huatanzhike granules;Control group:Conventional therapy;</Intervention>
    <Primary_outcome>COVID-19 nucleic acid detection time from positive to negative (respiratory secretion) or (3,5,7,10 days from positive to negative rate);;Lung CT observation of inflammation absorption;;Proportion of cases with progressive disease;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030013</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.</Public_title>
    <Scientific_title>A study on the efficacy and safety of recombinant human interferon alpha 1b spray in preventing novel coronavirus (COVID-19) infection in highly exposed medical staffs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Chinese PLA General Hospital</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49796</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Experimental group:300;Control group:150;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Feng Cao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>28 Fuxing Road, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>fengcao8828@163.com</Contact_Email>
    <Contact_Tel>+86 13911798280</Contact_Tel>
    <Contact_Affiliation>Chinese PLA General Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 70 years old;&lt;br&gt;2. Non-suspected and non-confirmed cases;&lt;br&gt;3. Front-line medical staffs in designated hospitals during the outbreak of pneumonia caused by COVID-19;&lt;br&gt;4. Participate voluntarily and sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Suspected cases and confirmed cases;&lt;br&gt;2. Patients with severe heart, brain, liver, kidney and other visceral diseases or other serious metabolic disorders and tumors;&lt;br&gt;3. People who could not complete the study for other reasons;&lt;br&gt;4. Pregnant or lactating women. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:recombinant human interferon a1b spray;Control group:Blank;</Intervention>
    <Primary_outcome>Blood routine examination;Chest CT;Arterial Blood Oxygen Saturation;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030833</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical validation and application of high-throughput novel coronavirus (2019-nCoV) screening detection kit</Public_title>
    <Scientific_title>Clinical validation and application of high-throughput novel coronavirus (2019-ncov) screening detection kit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51035</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-03-22</Date_enrollement>
    <Target_size>Target condition:400;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ning Qin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Hankou, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>qning@vip.sina.com</Contact_Email>
    <Contact_Tel>+86 027-83662391</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with novel coronavirus pneumonia and suspending patients</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: none</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:PCR Nucleic acid detection;Index test:high-throughput&amp;#32;novel&amp;#32;coronavirus&amp;#32;(2019-nCoV)&amp;#32;screening&amp;#32;detection&amp;#32;kit;</Intervention>
    <Primary_outcome>RNA of 2019-nCov;SPE, SEN, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030831</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia (COVID-19): a single center and descriptive study in Wuhan</Public_title>
    <Scientific_title>The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia: a single center and descriptive study in Wuhan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51036</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>99</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-01</Date_enrollement>
    <Target_size>Case series:75;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ye Tu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>whtuye@163.com</Contact_Email>
    <Contact_Tel>+86 18986152706</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) patients who were diagnosed to NCP;&lt;br&gt;(2) patients who received with invasive mechanical ventilation</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Aged &lt;18 years;&lt;br&gt;(2) pneumonia patients whose novel coronavirus nucleic acid test were negative ;</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Laboratory inspection index;Imaging examination results(chest CT);performance of intubation;therapeutic schedule;prognosis;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030224</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49968</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-26</Date_enrollement>
    <Target_size>1 the critical group :8;2 the severe group:8;3 the control group of the critical group:8;4 the control group of the severe group:8;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chengyun Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>chengyunliu@hust.edu.cn</Contact_Email>
    <Contact_Tel>+86 18007117616</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Female patients aged &gt;=18 years who were of childbearing years were excluded from pregnancy and agreed to use non-drug contraceptive measures during the study period;&lt;br&gt;2. SARS-CoV-2 nucleic acid test positive;&lt;br&gt;3. Lung CT examination showed evaluable lesions;&lt;br&gt;4. Meet the diagnostic criteria for severe or critical illness in the diagnosis and treatment program for new coronavirus pneumonia (trial version 6);&lt;br&gt;5. Subjects voluntarily participate in the study and sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Allergy to drugs and excipients used in this study;&lt;br&gt;2. Pregnant and lactating women and women of child-bearing years did not agree to use contraception during the experiment;&lt;br&gt;3.Have malignant tumor or hypercoagulant state;&lt;br&gt;4. Suffer from mental illness and can't cooperate well;&lt;br&gt;5. Those who have participated in or are participating in clinical trials of other drugs during the course of the disease;&lt;br&gt;6. Other conditions considered inappropriate for inclusion by the researcher.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>1 the critical group :injecting Mesenchymal stem cells;2 the severe group:injecting Mesenchymal stem cells;3 the control group of the critical group:injecting normal saline;4 the control group of the severe group:injecting normal saline;</Intervention>
    <Primary_outcome>SP02;lesions of lung CT;temperature;Blood routine;Inflammatory biomarkers;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030223</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID19) outbreak: an online survey</Public_title>
    <Scientific_title>Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID19) outbreak: an online survey                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>NA</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50026</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>General population:5000;</Target_size>
    <Study_type>Health services reaserch</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Daisy Dexing Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>4/F, School of Public Health and Primary Care</Contact_Address>
    <Contact_Email>zhangdxdaisy@cuhk.edu.hk</Contact_Email>
    <Contact_Tel>+852 22528451</Contact_Tel>
    <Contact_Affiliation>JC School Of Public Health And Primary Care, The Chinese University Of Hong Kong</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The inclusion criteria are: aged 18 or above; those who can understand Chinese language; be able to give access to the online survey and answer questions. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclusion criterion: those who do not agree to participate. </Exclusion_Criteria>
    <Condition>Biopsychosocial health; novel coronavirus pneumonia (COVID19)</Condition>
    <Intervention>General population:Health Advice based on survey results;</Intervention>
    <Primary_outcome>Quality of life;Socio-demographcis and others;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030254</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A randomized, open-controlled trial for farpiravir tablets in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-controlled trial for farpiravir tablets in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50137</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Experimental group:120;Control group:120;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xinghuan Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>wangxinghuan@whu.edu.cn</Contact_Email>
    <Contact_Tel>+86 027 67813096</Contact_Tel>
    <Contact_Affiliation>Zhongnan Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients aged &gt;=18 years;&lt;br&gt;2. Signed informed consent form in person;&lt;br&gt;3. The diagnosis of novel coronavirus pneumonia was confirmed in hospitalized or hospitalized patients;&lt;br&gt;4. The occurrence of relevant clinical symptoms until the diagnosis is clear within 12 days.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who are allergic to farpiravir or abedore;&lt;br&gt;2. AST was elevated 5 times above the normal upper limit or child-Pugh C level;&lt;br&gt;3. Critically ill patients with a life expectancy of less than 48 hours;&lt;br&gt;4. Contraindications for the use of farpiravir or abedore. Patients who plan or are using drugs that interact with farpiravir or abedore (including: drugs highly dependent on CYP3A clearance and associated with severe and/or life-threatening events with elevated plasma concentrations [narrow treatment index], CYP3A inducers [instructions], and cannot be discontinued or switched to other drugs;&lt;br&gt;5. Women of childbearing age who have positive pregnancy test results;&lt;br&gt;6. HIV-infected people;&lt;br&gt;7. Patients that researchers say are not suitable.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Farpiravir tablets;Control group:Abidole tablets;</Intervention>
    <Primary_outcome>pulse oxygen saturation;Parameters Respiratory support ;Nucleic acid test of novel coronavirus;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030222</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled due to lack of participants                                        Study for the Impact of Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People</Public_title>
    <Scientific_title>Study for the Impact of Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>The Thirteenth People's Hospital of Chongqing</Primary_sponsor>
    <Date_registration>2020-02-25</Date_registration>
    <Date_registration3>20200225</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50048</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>60</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-21</Date_enrollement>
    <Target_size>the elderly population:658;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Bin Zhan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>16 Railway New Village, Jiulongpo Districts, Chongqing, China</Contact_Address>
    <Contact_Email>406302524@qq.com</Contact_Email>
    <Contact_Tel>+86 13678494357</Contact_Tel>
    <Contact_Affiliation>The Thirteenth People's Hospital of Chongqing</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: subjects who are over 60 years old, and willing to participate in the investigation. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who are unable to complete the questionnaire;&lt;br&gt;2. Patients and healthy people who are not willing to participate in the survey. </Exclusion_Criteria>
    <Condition>Geriatrics; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>the elderly population:none;</Intervention>
    <Primary_outcome>health status;Mental health status;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029991</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Nanchang University</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49666</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-18</Date_enrollement>
    <Target_size>Kesuting syrup group:24;Keqing capsule group:24;control group:24;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wei Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>17 Yongwai Main Street, Nanchang, Jiangxi</Contact_Address>
    <Contact_Email>zhangweiliuxin@163.com</Contact_Email>
    <Contact_Tel>+86 0791-88693401</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Nanchang University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients withmild and moderate novel coronavirus pneumonia (COVID-19) diagnosed  refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 5);&lt;br&gt;2. Patient cough score &gt; 1;&lt;br&gt;3. Aged 18- 80 years old; &lt;br&gt;4. The subjects (including male subjects) had no pregnancy, sperm donor, egg donor for nearly half a year, and were willing to take effective contraception from the first dose until three months after the last;&lt;br&gt;5. Subjects are fully aware of the purpose, nature, content, process and possible adverse reactions of the study and voluntarily sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Expected to die within 48 hours;&lt;br&gt;2. Patients with asthma attack, purulent tonsillitis, acute and chronic bronchitis, sinusitis, otitis media, and other respiratory diseases affecting clinical trial evaluation; and chest CT confirmed the existence of severe pulmonary interstitial disease, bronchiectasis, obstructive pulmonary disease With lung disease;&lt;br&gt;3. Patients with respiratory infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and lung development;&lt;br&gt;4. At the discretion of the investigator, previous or present chronic or severe illness may affect participation in the trial or affect the outcome of the study, including but not limited to the gastrointestinal system, cardio-cerebral vascular system, liver, kidney, hematopoietic system, lymph System, endocrine system, immune system, malignant tumor, severe malnutrition, nervous system and endocrine system and other diseases; and currently suffering from human immunodeficiency virus (HIV) infection, splenectomy, organ transplantation and other diseases that seriously affect the immune system By;&lt;br&gt;5. People who cannot co-operate with mental state, suffer from mental illness, cannot control themselves, and cannot express;&lt;br&gt;6. Patients with poorly controlled hypertension: low pressure &gt;=110 mmHg or high pressure &gt;= 180 mmHg;&lt;br&gt;7. Patients with ALT, AST &gt;= 1.5 times the upper limit of normal value, and Scr&gt; upper limit of normal value;&lt;br&gt;8. People with a specific history of allergies (such as asthma, measles, eczema, etc.), or allergies (such as those allergic to two or more drugs, foods such as milk and pollen), or those who are allergic to the components of cough syrup and cough capsule;&lt;br&gt;9. Patients with a history of drug abuse or dependence within 6 months before randomization;&lt;br&gt;10. Those who have used any Chinese and Western medicine for cough and phlegm elimination within 24 hours before random enrollment;&lt;br&gt;11. Female patients during pregnancy and lactation;&lt;br&gt;12. Patients who have participated or are participating in other drug clinical trials within 3 months before screening;&lt;br&gt;13. Researchers consider others unsuitable to participate in this clinical trial.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Kesuting syrup group:conventional therapy and Kesuting syrup, p.o., 20ml, three times a day;Keqing capsule group:conventional therapy and Keqing capsule, p.o., three pills once, three times a day;control group:conventional therapy;</Intervention>
    <Primary_outcome>cough;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029755</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College of HUST</Primary_sponsor>
    <Date_registration>2020-02-12</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49301</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>experimental group:60;control group:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Liu Dong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei</Contact_Address>
    <Contact_Email>ld_2069@163.com</Contact_Email>
    <Contact_Tel>+86 13507183749</Contact_Tel>
    <Contact_Affiliation>Institutional Review Board, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who  were confirmed diagnosis of 2019-ncov virus pneumonia, according to the "pneumonia diagnosis and treatment program for novel coronavirus infection (trial version 5)",including clinical symptoms, pulmonary CT manifestations and positive nucleic acid test;&lt;br&gt;2. Inpatients 18 years old (including 18), regardless of gender;&lt;br&gt;3. Willing to participate in this clinical trial and sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with severe pneumonia requiring mechanical ventilation and severe new coronavirus infection with pneumonia;&lt;br&gt;2. Death is expected within 48 hours;&lt;br&gt;3. There is clear evidence of bacterial infection in respiratory tract infections caused by primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory tract malformation, congenital heart disease, gastroesophageal reflux disease, pulmonary dysplasia and other basic diseases;&lt;br&gt;4 subjects with the following conditions: daily treatment of asthma, any other chronic respiratory diseases, respiratory bacterial infections such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media and other respiratory diseases that affect clinical trial evaluation.Chest CT confirmed the existence of severe pulmonary interstitial lesions, bronchiectasis and other basic pulmonary diseases;&lt;br&gt;5. According to the researcher's judgment, the previous or current diseases may affect the patient's participation in the trial or the outcome of the study, including malignant diseases, autoimmune diseases, severe malnutrition, liver and kidney diseases, blood diseases, nervous system diseases, and endocrine diseases;He is suffering from serious diseases that affect the immune system, such as human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc.&lt;br&gt;Unable to cooperate in mental state, suffering from mental disease, unable to control, unable to express clearly;&lt;br&gt;Allergic constitution (such as allergic to two or more drugs or food) or history of allergy to this product and conventional treatment drugs;&lt;br&gt;8. A history of substance abuse or dependence;&lt;br&gt;9. Pregnant or nursing women;&lt;br&gt;10. Other researchers consider it inappropriate to participate in clinical trials.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:routine treatment, Jinyebaidu granule, po, 1-2 bags once, 3 times a day;;control group:routinel treatment, treatment according to the fifth version  of the diagnosis and treatment protocol, no use of traditional Chinese medicine.;</Intervention>
    <Primary_outcome>Validity observation index;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030816</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Nutritional risk assessment and outcome prediction of critically ill novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>Nutritional risk assessment and outcome prediction of critically ill COVID-19 patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51048</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yi Bian</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>bianyi2526@163.com</Contact_Email>
    <Contact_Tel>+86 15102710366</Contact_Tel>
    <Contact_Affiliation>Eergency / Intensive Care Department of Tongji Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Meets COVID-19 diagnosis criteria from WHO;&lt;br&gt;2) Critically ill COVID-19 patients who admiteed to ICUs;&lt;br&gt;3) length of stay in ICU &gt;=24 hours</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Aged &lt;14 years; &lt;br&gt;2) Pregnant; &lt;br&gt;3) COVID-19 as an complication on other major diseases;&lt;br&gt;4) Insufficient medical information.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:none;</Intervention>
    <Primary_outcome>Mortality of ICU 28-day;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030814</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based analysis of clinical evidence of human-to-human transmission of 2019 novel coronavirus pneumonia (COVID-19) by conjunctival route</Public_title>
    <Scientific_title>Ocular dectection of SARS-CoV-2 in 114 cases of COVID-19 pneumonia in Wuhan, China: an observational study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Tongji hospital, Tongji medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51042</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>10</Inclusion_agemin>
    <Inclusion_agemax>88</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Junming Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>eyedrwjm@163.com</Contact_Email>
    <Contact_Tel>+86 13886169836</Contact_Tel>
    <Contact_Affiliation>Tongji hospital, Tongji medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Subjects must understand the clinical trial requirements and potential risks, with voluntarily participation, and sign the informed consent;&lt;br&gt;(2) Fever and/or respiratory symptoms, normal or reduced total white blood cell count in the early stage of disease, or reduced lymphocyte count;&lt;br&gt;(3) With an epidemiological history and radiological features of viral pneumonia;&lt;br&gt;(4) Respiratory tract specimens were detected positive for sars-cov-2 virus nucleic acid by RT-PCR</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Infection with influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial pneumonovirus, SARS coronavirus and other known viral pneumonia patients;&lt;br&gt;(2) Patients with mycoplasma pneumoniae, chlamydia pneumonia and bacterial pneumonia;&lt;br&gt;(3) Patients with non-infectious diseases, such as vasculitis, dermatomyositis and mechanical pneumonia;&lt;br&gt;(4) Clinical diagnosis of SARS- Cov-2 virus nucleic acid test negative in respiratory tract swab.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:N/A;</Intervention>
    <Primary_outcome>Ocular  Symptoms;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030162</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                     Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Cancelled                         Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Cancelled</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49570</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size />
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Cancelled</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Cancelled</Contact_Address>
    <Contact_Email>wdxjy@whu.edu</Contact_Email>
    <Contact_Tel>123</Contact_Tel>
    <Contact_Affiliation>Cancelled</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Cancelled</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Cancelled</Exclusion_Criteria>
    <Condition>Cancelled</Condition>
    <Intervention />
    <Primary_outcome>Cancelled;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029899</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial</Public_title>
    <Scientific_title>Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Peking University Third Hospital</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49536</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>hydroxychloroquine sulfate:50;phosphate chloroquine:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Shen Ning</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>49 Huayuan Road North, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>shenning1972@126.com</Contact_Email>
    <Contact_Tel>+86 15611908958</Contact_Tel>
    <Contact_Affiliation>Peking University Third Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 years at time of signing Informed Consent Form;&lt;br&gt;2. Patients with confirmed cases meeting the following criteria&lt;br&gt;(1) Epidemiology history;&lt;br&gt;(2) Clinical manifestations (epidemiological history and in accordance with any of the following 2 items; no clear epidemiology history, conforms to  3 items in clinical manifestations):&lt;br&gt;Fever and / or respiratory symptoms;&lt;br&gt;In the early stage of the disease, the total leukocyte count was normal or decreased, or the lymphocyte count decreased;&lt;br&gt;Early chest imaging showed multiple small plaques and interstitial changes, which were evident in the extraneous lung. Further, multiple ground-glass shadows and infiltration shadows were found in both lungs, and lung consolidation and pleural effusion were rare in severe cases;&lt;br&gt;(3) Having one of the following etiological evidence:&lt;br&gt;Respiratory tract, blood or fecal samples RT-PCR confirmed infection with 2019-nCoV;&lt;br&gt;The virus genes of the above samples were sequenced and highly homologous to the 2019-nCoV;&lt;br&gt;3. Patients who meet the following mild and normal criteria;&lt;br&gt;Mild: mild clinical symptoms, no signs of pneumonia on imaging;&lt;br&gt;Normal: fever, respiratory symptoms, imaging manifestations of pneumonia;&lt;br&gt;4. Antimalarial drugs such as chloroquine and hydroxychloroquine were not used within 3 months;&lt;br&gt;5. Agree not to participate in other clinical researchers within 30 days from the first administration of the study drug to the last administration;&lt;br&gt;6. Eligible fertile subjects (male and female) must agree to use effective birth control (hormone or barrier or abstinence) with their partner during the trial period and for at least 3 months after the last dose;&lt;br&gt;7. Patients who agree to participate in this study and are willing to sign the informed consent form voluntarily.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with identified allergies to 4-aminoquinoline and lopinavir/litonavir;&lt;br&gt;2. Patients with server diseases of the blood system;&lt;br&gt;3. Patients with identified severe liver disease, underlying cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation more than 3 times the normal upper limit;&lt;br&gt;4. Patients with alcoholism or are taking hepatotoxic drugs;&lt;br&gt;5. Patients with renal impairment (estimated glomerular filtration rate [eGFR]&lt; 30 mL/min/1.73m2, using the MDRD method);&lt;br&gt;6. Patients with 6-phosphate dehydrogenase deficiency;&lt;br&gt;7. History of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months; New York Heart Association (NYHA) level ?-?;&lt;br&gt;8. QTc &gt;= 480ms;&lt;br&gt;9. Uncorrected patients with hypokalemia or hypokalemia;&lt;br&gt;10. Patients with retinopathy, fundus lesions, macular degeneration;&lt;br&gt;11. Patients with psychiatric disorders;&lt;br&gt;12. Patients with pancreatitis;&lt;br&gt;13. Patients with server auditory damage;&lt;br&gt;14. Pregnant or breastfeeding women or female with positive pregnancy test at child-bearing age;&lt;br&gt;15. Patients with medication that affect drug absorption, metabolism and excretion, that can induce QT interval prolongation, or drugs that can increase adverse reactions, etc.;&lt;br&gt;16. Patients were not eligible for this trial based on Investigator's considerationsPatients with a history of malignant tumor in the last 5 years.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day1-3:500mg,BID Day4-5:250mg,BID;</Intervention>
    <Primary_outcome>Time to Clinical Recovery, TTCR;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030218</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Fifth People's Hospital of Ganzhou</Primary_sponsor>
    <Date_registration>2020-02-25</Date_registration>
    <Date_registration3>20200225</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50115</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-22</Date_enrollement>
    <Target_size>Experimental group of ordinary COVID-19:30;Control group of ordinary COVID-19:30;Experimental group of severe COVID-19:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xie Liangdong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Chizhuling Fifth People's Hospital, Shuixi Town, Ganzhou, Jiangxi, China</Contact_Address>
    <Contact_Email>2590410004@qq.com</Contact_Email>
    <Contact_Tel>+86 13707077997</Contact_Tel>
    <Contact_Affiliation>Fifth People's Hospital of Ganzhou</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Aged &gt;=18 years;&lt;br&gt;(2) Novel coronavirus pneumonia patients diagnosed by pathogenic testing;&lt;br&gt;(3) The patient himself participated in the study voluntarily, agreed and signed the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Meet the diagnostic criteria for severe new-type coronavirus infection pneumonia;&lt;br&gt;(2) Severe primary diseases that affect survival, including: uncontrolled malignant tumors, hematological diseases, and HIV that have not been metastasized in multiple places;&lt;br&gt;(3) Obstructive pneumonia, pulmonary interstitial fibrosis, alveolar proteinosis, and allergic alveolitis caused by lung tumors;&lt;br&gt;(4) Women who are breastfeeding or pregnant;&lt;br&gt;(5) Those who are known to be allergic to the ingredients contained in the research medication, or patients with allergies;&lt;br&gt;(6) Those who have continued to use immunosuppressive agents or organ transplants in the past 6 months;&lt;br&gt;(7) Patients who have participated in other drug clinical trials within 3 months before the screening test;&lt;br&gt;(8) The investigator judges that he or she cannot complete or should not participate in the study (expected death within 48 hours, and the patient refuses active treatment)</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group of ordinary COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;Control group of ordinary COVID-19:Keep ritonavir/ritonavir treatment;Experimental group of severe COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;</Intervention>
    <Primary_outcome>Clinical recovery time;Pneumonia Severity Index (PSI) score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029952</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled due to lack of patient                         Medical records based study for epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Chongqing</Public_title>
    <Scientific_title>Epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Chongqing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Chongqing Three Gorges Central Hospital(Chongqing University Three Gorges Hospital  )</Primary_sponsor>
    <Date_registration>2020-02-17</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49630</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>79</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Case series:0;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Kaihu Xiao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>165 Xincheng Road, Wanzhou District, Chongqing, China</Contact_Address>
    <Contact_Email>xiaokh1@163.com</Contact_Email>
    <Contact_Tel>+86 19923204040</Contact_Tel>
    <Contact_Affiliation>Chongqing Three Gorges Central Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All patients diagnosed with novel coronavirus pneumonia by nucleic acid detection.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: NO.</Exclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Clinical symptoms;Test result;Examination result;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029728</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Tongji Hospital affiliated to Tongji medical college of HUST</Primary_sponsor>
    <Date_registration>2020-02-10</Date_registration>
    <Date_registration3>20200210</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49250</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Case series:500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Liu Dong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>ld_2069@163.com</Contact_Email>
    <Contact_Tel>+86 13507183749</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital affiliated to Tongji Medical College of HUST</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Staff of tongji hospital willing to participate this study;&lt;br&gt;2. Aged &gt;=18 years.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Meets any contraindications of ARB;&lt;br&gt;2. Meets any contraindications of Jinyebaidu Granule;&lt;br&gt;3. Pregnant women, lactating women, severe renal insufficiency.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>The proportion of patients diagnosed with 2019-ncov viral pneumonia;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029496</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection in eliminating novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection in eliminating novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>The First Hospital of Changsha; The Second Xiangya Hospital of Central South University</Primary_sponsor>
    <Date_registration>2020-02-02</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48809</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-29</Date_enrollement>
    <Target_size>Intervention A:30;intervention B:30;intervention C:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Gong Guozhong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>139 Renmin Road, Furong District, Changsha, Hu'nan, China</Contact_Address>
    <Contact_Email>gongguozhong@csu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13873104819</Contact_Tel>
    <Contact_Affiliation>The Second Xiangya Hospital of Cental South University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) aged 18 to 70 years;&lt;br&gt;(2) Light and heavy patients with new coronavirus infection confirmed by etiology.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) any situation in which the program cannot proceed safely;&lt;br&gt;(2) allergic constitution;&lt;br&gt;(3) serious basic diseases affecting survival, including uncontrolled malignant tumors with multiple metastases that cannot be resected, blood diseases, malignant fluid, active bleeding, severe malnutrition, HIV, etc.;&lt;br&gt;The main organ function is abnormal&lt;br&gt;(4) liver function was obviously abnormal: ALT/AST increased by more than 5 times the normal upper limit, increase of total bilirubin more than 2 times of normal upper limit;&lt;br&gt;(5) obstructive pneumonia, severe pulmonary fibrosis, alveolar proteinosis and allergic alveolitis caused by lung tumors;&lt;br&gt;(6) pregnancy: positive pregnancy test for women of child-bearing age;&lt;br&gt;(7) the patient may be transferred to a non-participating hospital within 72h;&lt;br&gt;(8) continuous use of immunosuppressants or organ transplants within the past 6 months;&lt;br&gt;(9) in vitro life support patients (ECMO, ECCO2R, RRT);&lt;br&gt;(10) expected survival no more than 48 hours.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Intervention A:On the basis of routine medical treatment, the patients were given Novaferon Atomization inhalation, 20ug each time, twice a day, 7-14 days.;intervention B:On the basis of routine medical treatment, the patients were given lopinavir / ritonavir tablets (Kaletra) twice a day, twice each time, 7-14 days.;intervention C:On the basis of routine medical treatment, combined with Novafron and Kaletra, the usage and course of treatment are the same as above.;</Intervention>
    <Primary_outcome>Time of new coronavirus nucleic acid turning negative;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030807</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical characteristics and prognosis of cancer patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Screening and Identification of SARS-CoV-2 Infection and Progression in Cancer Patients Based on Bioinformatics Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51019</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>23</Inclusion_agemin>
    <Inclusion_agemax>94</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>non-cancer COVID-19 versus cancer with COVID-19:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhihua Wang, Xianglin Yuan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>zhwang_hust@hotmail.com</Contact_Email>
    <Contact_Tel>+86 13607195518</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology(HUST)</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. tumor group:&lt;br&gt;(1) Aged &gt;=18 years;&lt;br&gt;(2) Diagnosed as a malignant tumor or has a history of malignant tumors before enrollment;&lt;br&gt;(3) The diagnosis and treatment of new coronavirus pneumonia was issued in the seventh edition of the New Coronary Virus Pneumonia Diagnosis and Treatment Plan (trial implementation of the seventh edition) issued by the seventh edition of the National Health Committee in March 2020;&lt;br&gt;(4) Life expectancy is at least 2 years.&lt;br&gt;2. Control group (non-tumor group):&lt;br&gt;(1) Aged &gt;=18 years;&lt;br&gt;(2) no history of malignant tumors;&lt;br&gt;(3) No basic diseases such as diabetes, coronary heart disease, pneumonia, chronic bronchitis;&lt;br&gt;(4) The diagnosis and treatment of new coronavirus pneumonia was issued by the Seventh Edition of the National Health Committee of the People's Republic of China in March 2020 in the "Diagnosis and Treatment of New Coronavirus Pneumonia (Trial Version 7)";&lt;br&gt;(5) Life expectancy is at least 2 years.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Those who do not meet the inclusion criteria of this study;&lt;br&gt;(2) Complicated with severe primary heart, liver, and kidney disease;&lt;br&gt;(3) Patients during perioperative period (within 7 days after operation);&lt;br&gt;(4) Immune dysfunction diseases (such as systemic lupus erythematosus) in the active phase;&lt;br&gt;(5) Those who lack clinical data or cannot obtain accurate data.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>non-cancer COVID-19 versus cancer with COVID-19:none;</Intervention>
    <Primary_outcome>lynphocyte;cytokine;cancer history;order of severity;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030805</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Quantitative CT characteristic estimate the severity of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Quantitative CT characteristic estimate the severity of 2019-nCoV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51026</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Contact_Firstname>Liang Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>wang6@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13971625289</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: This study was a retrospective single-center study, which included patients suspected of novel coronavirus infection and underwent both chest CT imaging and laboratory virus nucleic acid test (RT-PCR assay with throat swab samples) from February 15, 2020 to February 29, 2020.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: There were no hospitalized patients, no CT patients.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Quantitative CT characteristic;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029898</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial</Public_title>
    <Scientific_title>Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Peking University Third Hospital</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49482</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>hydroxychloroquine sulfate:50;phosphate chloroquine:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Shen Ning</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>49 Huayuan Road North, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>shenning1972@126.com</Contact_Email>
    <Contact_Tel>+86 15611908958</Contact_Tel>
    <Contact_Affiliation>Peking University Third Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.  Age 18 to 75 Yearsmale or female subjects&lt;br&gt;2.  Diagnosed with COVID-19,according to "New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (Pilot  Sixth Edition);&lt;br&gt;3.  Sever COVID-19, except shock and ICU care with organ failure;&lt;br&gt;4.  Antimalarial drugs such as chloroquine and hydroxychloroquine sulfate were not used within 3 months.;&lt;br&gt;5.  Agreed not to participate in other clinical trials in the period of 30 days from first dose;&lt;br&gt;6.  Eligible subjects (male and female) agree to use effective birth-control method (hormone or barrier or abstinence) during the trial and at least 3 month after the last dose;&lt;br&gt;7.  Willingness of participant the study with inform consent form</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1 Patients with identified allergies to 4-aminoquinoline and lopinavir/litonavir;&lt;br&gt;2 Patients with server diseases of the blood system;&lt;br&gt;3 Patients with identified severe liver disease, underlying cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation more than 3 times the normal upper limit;&lt;br&gt;4 Patients with alcoholism or are taking hepatotoxic drugs;&lt;br&gt;5 Patients with renal impairment (estimated glomerular filtration rate [eGFR]&lt; 30 mL/min/1.73m2, using the MDRD method);&lt;br&gt;6 Patients with 6-phosphate dehydrogenase deficiency;&lt;br&gt;7 History of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months; New York Heart Association (NYHA) level ?-?;&lt;br&gt;8 QTc=480ms&lt;br&gt;9 uncorrected patients with hypokalemia or hypokalemia&lt;br&gt;10Patients with retinopathy, fundus lesions, macular degeneration;&lt;br&gt;11 Patients with psychiatric disorders;&lt;br&gt;12? Patients with pancreatitis;&lt;br&gt;13? Patients with server auditory damage;&lt;br&gt;14? Pregnant or breastfeeding women or female with positive pregnancy test at child-bearing age;&lt;br&gt;15? Patients with medication that affect drug absorption, metabolism and excretion, that can induce QT interval prolongation, or drugs that can increase adverse reactions, etc.;&lt;br&gt;16? Patients were not eligible for this trial based on Investigator's considerationsPatients with a history of malignant tumor in the last 5 years.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day 1-3:500mg BID; Day 4-5:250mg BID;</Intervention>
    <Primary_outcome>TTCI (Time to Clinical Improvement);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029829</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled due to lack of patient                                 Medical records based study for Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Medical records based study for Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Chongqing Three Gorges Central Hospital</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49520</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Case series:40;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang Hailong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>165 Xincheng Road, Wanzhou, Chongqing, China</Contact_Address>
    <Contact_Email>wangjinlong2007666@163.com</Contact_Email>
    <Contact_Tel>+86 15923859880</Contact_Tel>
    <Contact_Affiliation>Three Gorges Central Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 2020.01.01 Patients who have tested positive for new coronavirus in our hospital </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:No;</Intervention>
    <Primary_outcome>Worsening condition;Death;Heart fatty acid binding protein;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029900</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the Hospital Workers and Nosocomial  Prevention and Control Strategy</Public_title>
    <Scientific_title>Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the Hospital Workers and Nosocomial  Prevention and Control Strategy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Renmin Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49377</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yu Jia</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>99 Zhang-Zhi-Dong Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>yogaqq116@whu.edu.cn</Contact_Email>
    <Contact_Tel>+86 18062586860</Contact_Tel>
    <Contact_Affiliation>Renmin Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Hospital workers with diagnosis of new coronavirus pneumonia in Wuhan;&lt;br&gt;2. Aged &gt;=18 years old.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who are unable to complete the questionnaire;&lt;br&gt;2. Patients  who are not willing to participate in the survey.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>exposed factors;latent period;preventive measures;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029761</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled due to lack of patient                Clinical study on the safety and effectiveness of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Multicenter, randomized, open clinical study of Hydroxychloroquine Sulfate tablets in the treatment of common patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Chongqing Medical University</Primary_sponsor>
    <Date_registration>2020-02-12</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49400</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-13</Date_enrollement>
    <Target_size>Low-dose group:60;Medium-dose group:60;High-dose group:60;control group:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wenxiang Huang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing</Contact_Address>
    <Contact_Email>wenxiang_huang@163.com</Contact_Email>
    <Contact_Tel>+86 13883533808</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Chongqing Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Subjects who meet the following conditions can become subjects of this study:&lt;br&gt;1. Sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian;&lt;br&gt;2. Chinese who are &gt;= 18 years of age;&lt;br&gt;3. It complies with the diagnostic criteria for NCP diagnosis of common patients, that is, the "Pneumonitis Diagnosis and Treatment Scheme for New Coronavirus Infection (Trial Fifth Edition)".&lt;br&gt;Comprehensive analysis based on the following epidemiological history, clinical manifestations and etiological examination:&lt;br&gt;a. Epidemiological history&lt;br&gt;(1)Travel history or residence history of Wuhan and surrounding areas or other communities with case reports within 14 days before the onset of illness;&lt;br&gt;(2)Have a history of contact with a new coronavirus infected person (positive nucleic acid test) within 14 days before the onset of illness;&lt;br&gt;(3)Patients with fever or respiratory symptoms from Wuhan and surrounding areas or from communities with case reports within 14 days before the onset of illness;&lt;br&gt;(4)Aggressive onset;&lt;br&gt;b. clinical manifestations&lt;br&gt;(1)Fever and / or respiratory symptoms;&lt;br&gt;(2)NCP imaging features (early multiple small patchy shadows and interstitial changes, obvious in the extrapulmonary zone. Then developed into multiple lungs with ground glass and infiltrates. In severe cases, pulmonary consolidation and pleural effusion Rare&lt;br&gt;(3)The total number of early white blood cells is normal or decreased, or the lymphocyte count is decreased.&lt;br&gt;c. Real-time fluorescent RT-PCR of respiratory or blood specimens for detection of novel coronavirus nucleic acid;&lt;br&gt;NCP confirmed case criteria:&lt;br&gt;(1)Have any one of the epidemiological history, and meet any two of the clinical manifestations, and at the same time, the pathogenic test is positive;&lt;br&gt;(2)If there is no clear epidemiological history, it meets any three of the clinical manifestations, and at the same time, the pathogenic examination is positive.&lt;br&gt;4. The course of disease is within 10 days after the onset of illness;&lt;br&gt;5. Will take nasopharyngeal or oropharyngeal swabs before administration.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with any of the following were excluded from the study:&lt;br&gt;1. Patients with previous allergy to 4-aminoquinoline compounds;&lt;br&gt;2. Patients with previous severe retinal or visual field related diseases;&lt;br&gt;3. Patients with severe liver dysfunction and patients with renal dysfunction (creatinine clearance rate &lt;= 50 mL / min);&lt;br&gt;4. Patients weighing &lt;35kg;&lt;br&gt;5. Patients exposed to other study drugs within 30 days before administration;&lt;br&gt;6. Being pregnant or breastfeeding. Or have a pregnancy plan (including partner) within one month.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>Low-dose group:Low-dose hydroxychloroquine and conventional therapy;Medium-dose group:Medium-dose hydroxychloroquine and conventional therapy;High-dose group:High-dose hydroxychloroquine and conventional therapy;control group:conventional therapy;</Intervention>
    <Primary_outcome>Negative conversion rate of 2019-nCoV nucleic acid ;Lung inflammation absorption ratio;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030798</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for clinical characteristics of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical characteristics of COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Wuhan 3rd Hospital</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50994</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>30</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang Hua-bing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>273225540@qq.com</Contact_Email>
    <Contact_Tel>+86 15377628125</Contact_Tel>
    <Contact_Affiliation>Wuhan 3rd Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Confirmed case: any one of the epidemiological history, and in line with the two clinical manifestations, with one of the following etiological evidence:&lt;br&gt;(1) epidemiological history:&lt;br&gt;1) travel history or residence history of wuhan and surrounding areas or other communities with reported cases within 14 days before onset;&lt;br&gt;2) within 14 days prior to onset, the patient had been exposed to fever or respiratory symptoms from wuhan city and surrounding areas, or from communities with reported cases;&lt;br&gt;3) cluster disease;&lt;br&gt;4) a history of contact with a new type of coronavirus infection (positive in the detection of pathogen nucleic acid);&lt;br&gt;(2) clinical manifestations:&lt;br&gt;1) fever and/or respiratory symptoms;&lt;br&gt;2) the total number of white blood cells in the early stage of the disease is normal or decreased, or the lymphocyte count is reduced;&lt;br&gt;(3) pathogenic evidence:&lt;br&gt;1) real-time fluorescence rt-pcr detection of positive nucleic acid of novel coronavirus in respiratory tract or blood samples;&lt;br&gt;2) the gene sequencing of the respiratory or blood specimen virus is highly homologous to the known novel coronavirus;&lt;br&gt;2. Suspected cases: any one of them has an epidemiological history and conforms to any three of the clinical manifestations;&lt;br&gt;(1) epidemiological history:&lt;br&gt;1) travel history or residence history of wuhan and surrounding areas or other communities with reported cases within 14 days before onset;&lt;br&gt;2) within 14 days prior to onset, the patient had been exposed to fever or respiratory symptoms from wuhan city and surrounding areas, or from communities with reported cases;&lt;br&gt;3) cluster disease;&lt;br&gt;4) a history of contact with a new type of coronavirus infection (positive in the detection of pathogen nucleic acid).&lt;br&gt;(2) clinical manifestations:&lt;br&gt;1) fever and/or respiratory symptoms;&lt;br&gt;2) imaging features of the above pneumonia;&lt;br&gt;3) the total number of white blood cells in the early stage of the disease was normal or decreased, or the lymphocyte count was decreased.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Missing clinical data.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>blood biochemistry;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030796</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical characteristics and treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical characteristics and treatment of COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>The Second Hospital of Hebei Medical University</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50991</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-29</Date_enrollement>
    <Target_size>Case series:500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Contact_Firstname>Yuan Yadong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>215 Heping Road West, Shijiazhuang, Hebei, China</Contact_Address>
    <Contact_Email>yuanyd1108@163.com</Contact_Email>
    <Contact_Tel>+86 15833119392</Contact_Tel>
    <Contact_Affiliation>The Second Hospital of Hebei Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who meet the diagnostic criteria for confirmed cases of pneumonia in the diagnosis and treatment program for novel coronavirus infection (trial seventh edition) issued by the national health commission on March 3, 2020</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Non-definitively diagnosed cases</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>mortality;effective rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029759</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Retracted due to lack of patient                               A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm</Public_title>
    <Scientific_title>A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The Second Affiliated Hospital of Chongqing Medical University</Primary_sponsor>
    <Date_registration>2020-02-12</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49352</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>control group 1:20;control group 2:20;Experimental group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Peng Hu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>74 Lingjiang Road, Yuzhong District, Chongqing, China</Contact_Address>
    <Contact_Email>hp_cq@163.com</Contact_Email>
    <Contact_Tel>+86 13608338064</Contact_Tel>
    <Contact_Affiliation>The Second Affiliated Hospital of Chongqing Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18- 80 years old; &lt;br&gt;2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 5);&lt;br&gt;3. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days);&lt;br&gt;4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;&lt;br&gt;5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration;&lt;br&gt;6. Patients who voluntarily sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Severe liver disease (such as child Pugh score &gt;= C, AST &gt; 5 times upper limit);&lt;br&gt;2. The patients were allergic to the components in asc09 / ritonavir compound tablets;&lt;br&gt;3. Patients with contraindications specified in the instructions of ritonavir tablets;&lt;br&gt;4. The pregnancy test of female subjects in the screening period was positive;&lt;br&gt;5. Patients have treat with HIV protease inhibitor;&lt;br&gt;6. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia  (COVID-19)</Condition>
    <Intervention>control group 1:Lopinavir / Ritonavir (Kaletra)  and IFN aerosol inhalation;control group 2:Abidol and IFN aerosol inhalation.;Experimental group:ASC09/ Ritonavir (ASC09F)  and IFN aerosol inhalation;</Intervention>
    <Primary_outcome>time to recovery.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029386</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: a randomized controlled trial</Public_title>
    <Scientific_title>A study on treatment strategies of novel coronavirus pnueumonia patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Chongqing Public Health Medical Center</Primary_sponsor>
    <Date_registration>2020-01-29</Date_registration>
    <Date_registration3>20200129</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48777</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-29</Date_enrollement>
    <Target_size>Experimental group:24;Control group:24;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yaokai Chen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>109 Baoyu Road, Shapingba District, Chongqing, China</Contact_Address>
    <Contact_Email>yaokaichen@hotmail.com</Contact_Email>
    <Contact_Tel>+86 13638352995</Contact_Tel>
    <Contact_Affiliation>Chongqing Public Health Medical Center</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Male or female over 18 years of age;&lt;br&gt;2. Novel coronavirus infection is confirmed by pathogenic detection;&lt;br&gt;3. The diagnosis of severe coronavirus pneumonia will have to meet at least one of the following criteria: &lt;br&gt;(1) Respiratory distress, RR&gt;30 times/minute&lt;br&gt;(2) In the state of no oxygen at rest, the patient's SPO2&lt;=93%&lt;br&gt;(3) Oxygenation Index (PaO2/FiO2)&lt;=300 mmHg (1mmHg=0.133kPa);&lt;br&gt;(4) Respiratory failure requiring mechanical ventilation; &lt;br&gt;(5) Sepsis; &lt;br&gt;(6) Other organ failure requiring ICU care.&lt;br&gt;4. Be willing to give the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients are allergic or intolerant to therapeutic drugs;&lt;br&gt;2. Pregnancy or lactating women;&lt;br&gt;3. Researchers believe that patients may have other factors affecting the efficacy or safety evaluation of this study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Methylprednisolone, intravenous injection, 1-2mg/kgd for 3 days.;Control group:Without any glucocorticoid therapy;</Intervention>
    <Primary_outcome>SOFA score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029387</TrialID>
    <Last_Refreshed_on>2 March 2020</Last_Refreshed_on>
    <Public_title>Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia</Public_title>
    <Scientific_title>Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Chongqing Public Health Medical Center</Primary_sponsor>
    <Date_registration>2020-01-29</Date_registration>
    <Date_registration3>20200129</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48782</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-25</Date_enrollement>
    <Target_size>arm A:36;arm B:36;arm C:36;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yaokai Chen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>109 Baoyu Road, Shapingba District, Chongqing, China</Contact_Address>
    <Contact_Email>yaokaichen@hotmail.com</Contact_Email>
    <Contact_Tel>+86 023-65481658</Contact_Tel>
    <Contact_Affiliation>Chongqing Public Health Medical Center</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) 1865 years of age; &lt;br&gt;(2) Diagnosed as mild to moderate COVID-19; &lt;br&gt;(3) Be willing to sign informed consent;&lt;br&gt;(4) The clinical assessment and condition of the subject does not influence the completion of the study. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Patients are diagnosed as a case of severe NCIP;&lt;br&gt;(2) Patients are pregnant or breastfeeding women; &lt;br&gt;(3) Patients have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 5UNL or creatinine clearance &lt;50 ml / min; &lt;br&gt;(4) Patients are allergic or intolerant to the proposed antiviral therapeutic drugs;&lt;br&gt;(5) Patients are HIV-positive; &lt;br&gt;(6) Patients with hemoglobin disease&lt;br&gt;(7) Patients have severe heart disease, brain disease, lung disease, kidney disease, tumor or other severe systemic diseases;&lt;br&gt;(8) Patients are not willing to provide signed informed consent. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>arm A:Ribavirin + Interferon alpha-1b;arm B:lopinavir / ritonavir + interferon alpha-1b;arm C:Ribavirin + LPV/r+Interferon alpha-1b;</Intervention>
    <Primary_outcome>The time to 2019-nCoV RNA negativity in patients;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04276688</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment</Public_title>
    <Scientific_title>An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection</Scientific_title>
    <Acronym />
    <Primary_sponsor>The University of Hong Kong</Primary_sponsor>
    <Date_registration>11/02/2020</Date_registration>
    <Date_registration3>20200211</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04276688</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 10, 2020</Date_enrollement>
    <Target_size>70</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 2</Phase>
    <Countries>Hong Kong</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Ivan FN Hung, MD FRCP;Ivan FN Hung, MD FRCP;Ivan FN Hung, MD FRCP</Contact_Lastname>
    <Contact_Email>;ivanfn@gmail.com;ivanfn@gmail.com</Contact_Email>
    <Contact_Tel>;+862 22554049;852 22554049</Contact_Tel>
    <Contact_Affiliation>The University of Hong Kong;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Recruited subjects include all adult patients =18 years hospitalised for virologically&lt;br&gt;             confirmed 2019-n-CoV infection.&lt;br&gt;&lt;br&gt;          2. NEWS of =1 upon recruitment&lt;br&gt;&lt;br&gt;          3. Auditory temperature =38C with at least one of the following symptoms (cough, sputum&lt;br&gt;             production, sore-throat, nasal discharge, myalgia, headache or fatigue) upon admission&lt;br&gt;&lt;br&gt;          4. Symptom duration =10 days&lt;br&gt;&lt;br&gt;          5. All subjects give written informed consent.&lt;br&gt;&lt;br&gt;          6. Subjects must be available to complete the study and comply with study procedures.&lt;br&gt;             Willingness to allow for serum samples to be stored beyond the study period, for&lt;br&gt;             potential additional future testing to better characterize immune response.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Inability to comprehend and to follow all required study procedures.&lt;br&gt;&lt;br&gt;          2. Allergy or severe reactions to the study drugs&lt;br&gt;&lt;br&gt;          3. Patients with known prolonged QT or PR interval, second- or third-degree heart block,&lt;br&gt;             or ventricular cardiac arrhythmias, including torsade de pointes&lt;br&gt;&lt;br&gt;          4. Patients taking medication that will potentially interact with lopinavir/ ritonavir,&lt;br&gt;             ribavirin or interferon-beta1b&lt;br&gt;&lt;br&gt;          5. Patients with known history of severe depression&lt;br&gt;&lt;br&gt;          6. Pregnant or lactation women&lt;br&gt;&lt;br&gt;          7. Inability to comprehend and to follow all required study procedures&lt;br&gt;&lt;br&gt;          8. Received an experimental agent (vaccine, drug, biologic, device, blood product, or&lt;br&gt;             medication) within 1 month prior to recruitment in this study or expect to receive an&lt;br&gt;             experimental agent during this study. Unwilling to refuse participation in another&lt;br&gt;             clinical study through the end of this study.&lt;br&gt;&lt;br&gt;          9. Have a history of alcohol or drug abuse in the last 5 years.&lt;br&gt;&lt;br&gt;         10. Have any condition that the investigator believes may interfere with successful&lt;br&gt;             completion of the study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Novel Coronavirus Infection</Condition>
    <Intervention>Drug: Lopinavir/ritonavir;Drug: Ribavirin;Drug: Interferon Beta-1B</Intervention>
    <Primary_outcome>Time to negative NPS</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04287686</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19</Public_title>
    <Scientific_title>A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19</Scientific_title>
    <Acronym />
    <Primary_sponsor>The First Affiliated Hospital of Guangzhou Medical University</Primary_sponsor>
    <Date_registration>21/02/2020</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04287686</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 2020</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Yimin Li, PhD, MD;Yimin Li, PhD, MD;Xinyun Yang, MD</Contact_Lastname>
    <Contact_Email>;dryiminli@vip.163.com;gyfygcp@163.com</Contact_Email>
    <Contact_Tel>;+8613533569161;020-83062338</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Guangzhou Medical University;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Laboratory diagnosis:&lt;br&gt;&lt;br&gt;               -  Respiratory specimen is positive for SARS-CoV-2 nucleic acid by RT-PCR; OR,&lt;br&gt;&lt;br&gt;               -  The viral gene sequencing of the respiratory specimen is highly homologous to&lt;br&gt;                  known novel coronavirus.&lt;br&gt;&lt;br&gt;          2. Fever:&lt;br&gt;&lt;br&gt;             Axillary temperature &gt;37.3?&lt;br&gt;&lt;br&gt;          3. Respiratory variables (meets one of the following criteria):&lt;br&gt;&lt;br&gt;               -  Respiratory rate: RR =25 breaths/min&lt;br&gt;&lt;br&gt;               -  Oxygen saturation =93% at rest on room air&lt;br&gt;&lt;br&gt;               -  PaO2/FiO2 =300 mmHg(1 mmHg=0.133 KPa)&lt;br&gt;&lt;br&gt;               -  Pulmonary imaging showed that the lesions progressed more than 50% within 24-48&lt;br&gt;                  hours, and the patients were managed as severe&lt;br&gt;&lt;br&gt;          4. HBsAg negative, or HBV DNA =10^4 copy/ml if HBsAg positive; anti-HCV negative; HIV&lt;br&gt;             negative two weeks prior to signed Informed Consent Form (ICF)&lt;br&gt;&lt;br&gt;          5. Appropriate ethics approval and&lt;br&gt;&lt;br&gt;          6. ICF&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Age &lt;18 years; Age &gt;80 years&lt;br&gt;&lt;br&gt;          -  Pregnant or breast feeding woman or with positive pregnancy test result&lt;br&gt;&lt;br&gt;          -  P/F &lt;100 mmHg&lt;br&gt;&lt;br&gt;          -  Moribund condition (death likely in days) or not expected to survive for &gt;7 days&lt;br&gt;&lt;br&gt;          -  Refusal by attending MD&lt;br&gt;&lt;br&gt;          -  Not hemodynamically stable in the preceding 4 hours (MAP =65 mmHg, or SAP &lt;90 mmHg,&lt;br&gt;             DAP &lt;60 mmHg, vasoactive agents are required)&lt;br&gt;&lt;br&gt;          -  Patient on invasive mechanical ventilation or ECMO&lt;br&gt;&lt;br&gt;          -  Patient in other therapeutic clinical trial within 30 days before ICF&lt;br&gt;&lt;br&gt;          -  Receive any other ACE inhibitors (ACEI), angiotensin-receptor blockers (ARB) treatment&lt;br&gt;             within 7 days before ICF&lt;br&gt;&lt;br&gt;          -  Chronic immunosuppression: current autoimmune diseases or patients who received&lt;br&gt;             immunotherapy within 30 days before ICF&lt;br&gt;&lt;br&gt;          -  Hematologic malignancy (lymphoma, leukemia, multiple myeloma)&lt;br&gt;&lt;br&gt;          -  Other patient characteristics (not thought to be related to underlying COVID-19) that&lt;br&gt;             portend a very poor prognosis (e.g, severe liver failure, and ect)&lt;br&gt;&lt;br&gt;          -  Known allergy to study drug or its ingredients related to renin-angiotensin system&lt;br&gt;             (RAS), or frequent and/or severe allergic reactions with multiple medications&lt;br&gt;&lt;br&gt;          -  Other uncontrolled diseases, as judged by investigators&lt;br&gt;&lt;br&gt;          -  Body weight =85 kg&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)</Intervention>
    <Primary_outcome>Time course of body temperature (fever);Viral load over time</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030552</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-07</Date_registration>
    <Date_registration3>20200307</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49708</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-08</Date_enrollement>
    <Target_size>Case series:70;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Shusheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei.</Contact_Address>
    <Contact_Email>shushengli16@sina.com</Contact_Email>
    <Contact_Tel>+86 13971086498</Contact_Tel>
    <Contact_Affiliation>Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt; 18 years; &lt;br&gt;2. COVID-19 coronavirus nucleic acid positive (including throat swabs, sputum, bronchoalveolar lavage fluid, stool and other specimens); &lt;br&gt;3. Chest imaging has clear viral pneumonia changes; &lt;br&gt;4. Respiratory dysfuntion, which meets the following criteria: &lt;br&gt;(1) Respiratory distress, respiratory rate (RR) is greater than 30 times /min; &lt;br&gt;(2) Finger pulse oxygen saturation &lt;= 93% at resting state;&lt;br&gt;(3) PaO2 / FiO2 &lt;= 300 mmHg (1 mmHg = 0.133 kPa); and &lt;br&gt;(4) Pulmonary imaging showed that the lesions progressed more than 50% within 24-48 hours.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Children and pregnant women; &lt;br&gt;2. Serious cardiopulmonary diseases (chronic obstructive pulmonary disease, acute coronary syndrome, dilated cardiomyopathy, congenital heart disease, chronic pulmonary hypertension, etc.); &lt;br&gt;3. End stage of malignant tumor.</Exclusion_Criteria>
    <Condition>2019 novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:N/A;</Intervention>
    <Primary_outcome>Lung ultrasound index;Right ventricular function ultrasound index;Left ventricular function ultrasound index;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030782</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Cangzhou People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-14</Date_registration>
    <Date_registration3>20200314</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50976</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>2</Inclusion_agemin>
    <Inclusion_agemax>89</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:20;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Case-Control study</Study_design>
    <Phase>N/A</Phase>
    <Contact_Firstname>Lihui Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>13 North Qingchi Avenue, Xinhua District, Cangzhou, Hebei, China</Contact_Address>
    <Contact_Email>849614995@qq.com</Contact_Email>
    <Contact_Tel>+86 13832102657</Contact_Tel>
    <Contact_Affiliation>Cangzhou People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: New Coronavirus Patients Meeting the Criteria for the Diagnosis and Treatment of New Coronavirus Infected Pneumonia (Trial Version 5)</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Pregnant woman</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:none;</Intervention>
    <Primary_outcome>28-day prognosis;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030773</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Huashan Hospital Fudan Universtiy</Primary_sponsor>
    <Date_registration>2020-03-14</Date_registration>
    <Date_registration3>20200314</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50934</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>Case series:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Cohort study</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jing Chen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>12 Wulumuqi Road Middle, Jin'an District, Shanghai, China</Contact_Address>
    <Contact_Email>money_0921@163.com</Contact_Email>
    <Contact_Tel>+86 13816108686</Contact_Tel>
    <Contact_Affiliation>Huashan Hospital Fudan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 80 years;&lt;br&gt;2. Diagnosed as COVID-19 pneumonia (according to the latest diagnostic criteria of The novel coronavirus pneumonia diagnosis and treatment plan formulated by the State Health Protection Committee);&lt;br&gt;3. admitted into ICU;&lt;br&gt;4. Rapid increase of serum IL-6 level.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Renal replacement therapy has been performed;&lt;br&gt;2. Relative / absolute contraindications of blood purification;&lt;br&gt;3. Pregnant women, participating in other clinical trials, etc.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Early initiation of blood purification;</Intervention>
    <Primary_outcome>death;Number of failure organs;Length of hospital stay;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030535</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine</Public_title>
    <Scientific_title>Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Wuhan Red Cross Hospital</Primary_sponsor>
    <Date_registration>2020-03-06</Date_registration>
    <Date_registration3>20200306</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49790</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>experimental group:50;control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xu Zhihua</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Mianyang Central Hospital of Sichuan province</Contact_Address>
    <Contact_Email>1121733818@qq.com</Contact_Email>
    <Contact_Tel>+86 18508160990</Contact_Tel>
    <Contact_Affiliation>Mianyang Central Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 75 years;&lt;br&gt;2. Real-time fluorescence RT-PCR detection of nucleic acid positive of novel coronavirus in respiratory tract specimens or blood preparation;&lt;br&gt;3. Sequencing of virus genes in respiratory tract specimens or blood preparation, highly homologous to known novel coronavirus ;&lt;br&gt;4. The patients are diagnosed with common type of novel coronavirus pneumonia according to the Pneumonia Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6), and have fever and/or respiratory symptoms, and shows pneumonia in the chest CT.&lt;br&gt;5. Can be included in some severe patients, consistent with any of the following:&lt;br&gt;(1) Respiratory distress, RR &gt;= 30 times/min;&lt;br&gt;(2) Under quiescent condition, Oxygen saturation &lt;= 93%;&lt;br&gt;(3) Arterial partial pressure of oxygen(PaO2)/oxygen concentration(FiO2)&lt;= 300mmHg.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Combined with high blood pressure, diabetes, coronary heart disease and other underlying disease; &lt;br&gt;(2) Combined with malignant tumor or a medical history of malignant tumor; &lt;br&gt;(3) Pregnant or lactating women; &lt;br&gt;(4) Suffering from severe mental illness; &lt;br&gt;(5) Medical history of unstable angor pectoris or myocardial?infarction within 6 months, coronary arteriography; it indicates severe stenosis of the main branch of the coronary artery; &lt;br&gt;(6) Medical history of cerebral infarction or cerebral hemorrhage within 6 months; &lt;br&gt;(7) Intolerant or allergic to interferon preparations; &lt;br&gt;(8) The investigator determined that the patients were not eligible for the trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:ebastine 10mg bid, nterferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid;control group:interferon-alpha aerosol inhalation 5million U  bid and Lopinavir 200 mg, 2 capsules at a time, bid;</Intervention>
    <Primary_outcome>Clinical therapeutic course;Pathogenic detectio;Chest CT;Laboratory indicators (blood routine, myocardial enzyme spectrum, inflammatory cytokines, etc.);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030522</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of Chengdu University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-06</Date_registration>
    <Date_registration3>20200306</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=44213</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-09</Date_enrollement>
    <Target_size>experimental group:50;control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chuantao Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>39 Shi-Er-Qiao Road, Chengdu, Sichuan, China </Contact_Address>
    <Contact_Email>1035788783@qq.com</Contact_Email>
    <Contact_Tel>+86 13880336152</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of Chengdu University of Traditional Chinese Medicine </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Laboratory confirmed infection with 2019-nCoV;&lt;br&gt;2. Clinical classification is mild or common;&lt;br&gt;3. Lung involvement confirmed with chest imaging;&lt;br&gt;4. Hospitalised with: Fever: axilla temperature &gt;= 36.7 degrees C, or Oral temperature &gt;= 38.0 degrees C, or rectal temperature &gt;= 38.6 degrees C.And at least one of Respiratory rate &gt; 24/min Or Cough;&lt;br&gt;5. TCM syndrome differentiation is phlegm-heat obstructing the lung syndrome; &lt;br&gt;6. Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study;&lt;br&gt;7. Aged between 18-75 years of signing Informed Consent Form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with serious primary diseases such as severe mental and psychological disorders, heart and brain vessels diseases, liver and kidney diseases, endocrine diseases, hematopoietic system diseases and malignant tumors;&lt;br&gt;2. Patients are known to be allergic to trail drugs or a certain Chinese medicine of this study;&lt;br&gt;3. Women are breastfeeding, pregnant or preparing for pregnancy;&lt;br&gt;4. Patients participating in other clinical studies.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Ma-Xing-Gan-Shi decoction and Conventional Western Medicine Treatment;control group:placebo and Conventional Western Medicine Treatment;</Intervention>
    <Primary_outcome>Time to Clinical Recovery (TTCR);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030764</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Research for the influence of epidemic of novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations</Public_title>
    <Scientific_title>Research for the influence of epidemic of  novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50852</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-07</Date_enrollement>
    <Target_size>4 groups:2800;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xia Hong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Xiyuan Playground, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>970236538@qq.com</Contact_Email>
    <Contact_Tel>+86 13699207252</Contact_Tel>
    <Contact_Affiliation>Xiyuan Hospital of China Academy of Chinese Medical Sciences</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Aged &gt;18 years old; &lt;br&gt;(2) can complete the wechat questionnaire independently.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: People with severe mental disorders</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19); psychosomatic medicine</Condition>
    <Intervention>4 groups:N/A;</Intervention>
    <Primary_outcome>PSQI;PPHQ-9;GAD-7;PTSDChecklist-Civilian Version,PCL-C;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030762</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''</Public_title>
    <Scientific_title>Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50950</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1</Inclusion_agemin>
    <Inclusion_agemax>99</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2019-12-01</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Epidemilogical research</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>GuoLin Song</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>32 Feishan Street, Guiyang, Guizhou, China</Contact_Address>
    <Contact_Email>ant000999@126.com</Contact_Email>
    <Contact_Tel>+86 13985004689</Contact_Tel>
    <Contact_Affiliation>The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Common and severe new coronavirus pneumonia</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Mild and critical new coronavirus pneumonia</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Clinical characteristics according to TCM;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030519</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Study for the clinical characteristics and digestive system damage of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for the clinical characteristics and digestive system damage of novel coronavirus pneumonia COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Guangzhou Eighth People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-05</Date_registration>
    <Date_registration3>20200305</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50604</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-06</Date_enrollement>
    <Target_size>Case series:40;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chuo Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>8 Huaying Road, Baiyun District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>gz8hlc@126.com</Contact_Email>
    <Contact_Tel>+86 15989096626</Contact_Tel>
    <Contact_Affiliation>Guangzhou Eighth People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Pharyngeal swabs and / or anal swab specimens are positive for new coronavirus nucleic acids, or viral gene sequencing is highly homologous to known new coronaviruses;&lt;br&gt;2. Males and females aged 18 to 85 years;&lt;br&gt;3. Participants should fully understand the purpose, nature, methods and possible complications of the trial, volunteer to participate in this study and sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who have contraindications to specimen collection, such as: coagulopathy, rectal tumors, anal canal disease, severe cardiopulmonary dysfunction, etc .;&lt;br&gt;2. Patients with mental illness cannot cooperate with sampling;&lt;br&gt;3. The patient did not agree to participate in the study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>RNA of  Coronavirus;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030503</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Extracorporeal blood purification therapy using Li's Artifical Liver System for patients with severe novel coronavirus pneumonia (COVID19) patient</Public_title>
    <Scientific_title>Effecacy and safty of extracorporeal blood purification therapy for severe patients with novel coronavirus pneumonia (COVID19): a prospective cohort study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Zhejiang University School of Medicine</Primary_sponsor>
    <Date_registration>2020-03-05</Date_registration>
    <Date_registration3>20200305</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49632</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-20</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiaowei XU</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>xxw69@126.com</Contact_Email>
    <Contact_Tel>+86 13605708066</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. aged &gt;=18 years old;&lt;br&gt;2. laboratory conformed SARS-CoV-2 infection;&lt;br&gt;3. critically ill and require intensive care.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. pregnancy;&lt;br&gt;2. blood purification treatment prior to admission;&lt;br&gt;3. patients had other indications for blood purification treatment including hyperkalemia, acute kidney failure, and so on;&lt;br&gt;4. allergic to dimethyl sulfoxide, dextran or Heparin;&lt;br&gt;5. currently active malignant tumor or under Immunosuppressive therapy.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Hemadsorption+conventional treatment;Control group:conventional treatment;</Intervention>
    <Primary_outcome>Mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04252118</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus</Public_title>
    <Scientific_title>Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With 2019 Novel Coronavirus</Scientific_title>
    <Acronym />
    <Primary_sponsor>Beijing 302 Hospital</Primary_sponsor>
    <Date_registration>27/01/2020</Date_registration>
    <Date_registration3>20200127</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04252118</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 27, 2020</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Lei Shi, MD,PhD;Lei Shi, MD, PhD</Contact_Lastname>
    <Contact_Email>shilei302@126.com;shilei302@126.com</Contact_Email>
    <Contact_Tel>86-10-66933333;86-10-66933333</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Male or female, aged at 18 years (including) -70 years old&lt;br&gt;&lt;br&gt;          2. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase&lt;br&gt;             chain reaction (RT-PCR) from any diagnostic sampling source; and&lt;br&gt;&lt;br&gt;          3. Pneumonia that is judged by chest radiograph or computed tomography.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Pregnancy, lactation and those who are not pregnant but do not take effective&lt;br&gt;             contraceptives measures;&lt;br&gt;&lt;br&gt;          2. Patients with malignant tumor, other serious systemic diseases and psychosis;&lt;br&gt;&lt;br&gt;          3. Patients who are participating in other clinical trials;&lt;br&gt;&lt;br&gt;          4. Inability to provide informed consent or to comply with test requirements.&lt;br&gt;&lt;br&gt;          5. Co-Infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory&lt;br&gt;             infection virus.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019 Novel Coronavirus Pneumonia</Condition>
    <Intervention>Biological: MSCs</Intervention>
    <Primary_outcome>Size of lesion area by chest radiograph or CT;Side effects in the MSCs treatment group</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04273763</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Second Affiliated Hospital of Wenzhou Medical University</Primary_sponsor>
    <Date_registration>14/02/2020</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04273763</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 16, 2020</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>XIAN SHEN, phd</Contact_Lastname>
    <Contact_Email />
    <Contact_Tel />
    <Contact_Affiliation>The 2nd Affiliated Hospital of Wenzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Aged between 18 and 80 years (Including 18and 80years, male or female).&lt;br&gt;&lt;br&gt;          -  One of them:&lt;br&gt;&lt;br&gt;               1. Laboratory (RT-PCR) and clinical symptoms confirmed case of novel coronavirus&lt;br&gt;                  pneumonia (COVID-19).&lt;br&gt;&lt;br&gt;               2. Patients diagnosed clinically as suspected cases.&lt;br&gt;&lt;br&gt;          -  Ability to communicate well with researchers and sign the informed consent Form (ICF)&lt;br&gt;             voluntarily.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  ALT=5 times of ULN, level of total bilirubin=3 times of ULN, or Cr=1.5 times of ULN.&lt;br&gt;&lt;br&gt;          -  Patients with serious severe liver disease.&lt;br&gt;&lt;br&gt;          -  Excluded who diagnosed as pneumonia patients with novel coronavirus infection of&lt;br&gt;             severe type and critical type. ?Diagnostic criteria reference the official guideline&lt;br&gt;             "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial&lt;br&gt;             Version 5) "?.&lt;br&gt;&lt;br&gt;          -  Patients with previous history of severe gastrointestinal diseases such as gastric&lt;br&gt;             ulcers and bleeding.&lt;br&gt;&lt;br&gt;          -  Patients with lactose intolerance.&lt;br&gt;&lt;br&gt;          -  Patients who are allergic to the components of this medicine (Major components:&lt;br&gt;             Bromhexine Hydrochloride; excipient: starch, lactose, magnesium stearate).&lt;br&gt;&lt;br&gt;          -  Positive serum pregnancy test result for women with childbearing potential at&lt;br&gt;             screening or lactating women.&lt;br&gt;&lt;br&gt;          -  Other circumstances that the researcher considers inappropriate to participate in this&lt;br&gt;             study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia;2019-nCoV</Condition>
    <Intervention>Drug: Bromhexine Hydrochloride Tablets;Drug: Arbidol Hydrochloride Granules;Drug: Recombinant Human Interferon a2b Spray;Drug: Favipiravir Tablets</Intervention>
    <Primary_outcome>Time to clinical recovery after treatment</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04276987</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia</Public_title>
    <Scientific_title>A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia</Scientific_title>
    <Acronym />
    <Primary_sponsor>Ruijin Hospital</Primary_sponsor>
    <Date_registration>16/02/2020</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04276987</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 15, 2020</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 1</Phase>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Jie-ming Qu, MD.,PhD.;Jie-ming Qu, MD.,PhD.</Contact_Lastname>
    <Contact_Email>;jmqu0906@163.com</Contact_Email>
    <Contact_Tel>;+86-21-64370045</Contact_Tel>
    <Contact_Affiliation>Ruijin Hospital, Medical School of Shanghai Jiaotong University Shanghai, China;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        1.Willingness of study participant to accept this treatment arm, and signed informed&lt;br&gt;        consent; 2.Male or female, aged at 18 years (including) to 75 years old; 3.Patients with&lt;br&gt;        confirmed novel coronavirus pneumonia; 4.Confirmation of SARS-CoV-2 infection by&lt;br&gt;        reverse-transcription polymerase chain reaction (RT-PCR) from respiratory tract or blood&lt;br&gt;        specimens; 5.Diagnostic criteria of "Severe" or " Critical":&lt;br&gt;&lt;br&gt;          1. Severe, comply with any of the following:&lt;br&gt;&lt;br&gt;               1. Respiratory distress, Respiratory rate (RR) = 30 times/min&lt;br&gt;&lt;br&gt;               2. Pulse oxygen saturation (SpO2) at rest = 93%&lt;br&gt;&lt;br&gt;               3. Partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) = 300mmHg&lt;br&gt;&lt;br&gt;          2. Critical, comply with any of the following:&lt;br&gt;&lt;br&gt;               1. Respiratory failure, and requirement for mechanical ventilation&lt;br&gt;&lt;br&gt;               2. Shock&lt;br&gt;&lt;br&gt;               3. Other organ failure and requirement for ICU monitoring&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Allergic or hypersensitive to any of the ingredients;&lt;br&gt;&lt;br&gt;          2. Pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or other&lt;br&gt;             viruses;&lt;br&gt;&lt;br&gt;          3. Obstructive HABP/VABP induced by lung cancer or other known causes;&lt;br&gt;&lt;br&gt;          4. Carcinoid syndrome;&lt;br&gt;&lt;br&gt;          5. History of long-term use of immunosuppressive agents;&lt;br&gt;&lt;br&gt;          6. History of epilepsy and requirement for continuous anticonvulsant treatment or&lt;br&gt;             anticonvulsant treatment received within the last 3 years;&lt;br&gt;&lt;br&gt;          7. History of severe chronic respiratory disease and requirement for long-term oxygen&lt;br&gt;             therapy;&lt;br&gt;&lt;br&gt;          8. Undergoing hemodialysis or peritoneal dialysis;&lt;br&gt;&lt;br&gt;          9. Estimated or actual rate of creatinine clearance &lt; 15 ml/min;&lt;br&gt;&lt;br&gt;         10. History of moderate and severe liver disease (Child-Pugh score &gt;12);&lt;br&gt;&lt;br&gt;         11. Expectation of receiving any of following medications during the study:&lt;br&gt;&lt;br&gt;               1. Receiving continuous valproic acid or sodium valproate within the first 2 weeks&lt;br&gt;                  prior to screening&lt;br&gt;&lt;br&gt;               2. Receiving 5-transtryptamine reuptake inhibitors, tricyclic antidepressants, 5-HT1&lt;br&gt;                  receptor agonists or monoamine oxidase inhibitors within the first 2 weeks prior&lt;br&gt;                  to screening&lt;br&gt;&lt;br&gt;         12. Incapable of understanding study protocol;&lt;br&gt;&lt;br&gt;         13. History of deep venous thrombosis or pulmonary embolism within the last 3 years;&lt;br&gt;&lt;br&gt;         14. Undergoing ECMO or high-frequency oscillatory ventilation support;&lt;br&gt;&lt;br&gt;         15. HIV, hepatitis virus, or syphilis infection;&lt;br&gt;&lt;br&gt;         16. Period of pregnancy or lactation, or planned pregnancy within 6 months;&lt;br&gt;&lt;br&gt;         17. Any condition of unsuitable for the study determined by investigators.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus</Condition>
    <Intervention>Biological: MSCs-derived exosomes</Intervention>
    <Primary_outcome>Adverse reaction (AE) and severe adverse reaction (SAE);Time to clinical improvement (TTIC)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030760</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China</Public_title>
    <Scientific_title>Clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Zhejiang Hospital</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50955</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>74</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-13</Date_enrollement>
    <Target_size>two groups:74;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Case-Control study</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hong Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1229 Gudun Road, Xihu District, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>hongwang71@yahoo.com</Contact_Email>
    <Contact_Tel>+86 0571 87377780</Contact_Tel>
    <Contact_Affiliation>Zhejiang Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: According to the sixth edition of the Chinese New Coronary Virus Pneumonia Diagnosis and Treatment Guidelines, patients with suspected novel coronavirus pneumonia were included in the study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Not eligible for novel coronavirus pneumonia</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>two groups:no intervention;</Intervention>
    <Primary_outcome>the clinical, laboratory and the radiologic characteristics;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030755</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for characteristics, prognosis of ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area</Public_title>
    <Scientific_title>Characteristics, prognosis of  ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area: a dual-center, retrospective, cohort study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50945</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>65</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-15</Date_enrollement>
    <Target_size>Case series:400;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Cuntai Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>ctzhang0425@163.com</Contact_Email>
    <Contact_Tel>+86 15927668408</Contact_Tel>
    <Contact_Affiliation>Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. confirmed with COVID-19;&lt;br&gt;2 olderer than 65 years;&lt;br&gt;3. meet the critically ill criteria according to Chinese management guideline for COVID-19 (version 7).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. declared clinical death or discharged after admission within 24 hour;&lt;br&gt;2. important data missing.</Exclusion_Criteria>
    <Condition>Novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:no;</Intervention>
    <Primary_outcome>Critical illness ratio;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030487</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of HeNan University of CM</Primary_sponsor>
    <Date_registration>2020-03-04</Date_registration>
    <Date_registration3>20200304</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50507</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-04</Date_enrollement>
    <Target_size>Azvudine Plus Symptomatic treatment:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Suyun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>19 Renmin Road, Zhengzhou, He'nan, China</Contact_Address>
    <Contact_Email>38797527@qq.com</Contact_Email>
    <Contact_Tel>13938415502</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of HeNan University of CM</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) aged &gt;=18 years; &lt;br&gt;(2) positive COVID-19 nucleic acid was detected by RT-PCR in sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions, or viral gene sequencing was detected in sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions, which was highly homologous with known COVID-19; &lt;br&gt;(3) Confirmed to be diagnosed as COVID-19, meeting the diagnostic criteria for moderate and severe patients in the diagnosisin line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment plan (trial version 6), and not significantly improved after treatment with the triple antiviral program; &lt;br&gt;(4) Informed consent has been signed. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) known or suspected allergies to the components of azivudine tablets;&lt;br&gt;(2) women who are breast-feeding during pregnancy or have a family plan during the trial period and within 6 months after the end of the trial;&lt;br&gt;(3) participating in other clinical trials or taking experimental drugs within 12 weeks prior to administration;&lt;br&gt;(4) severe liver disease (TBIL&gt;=2 times normal upper limit; ALTAST&gt;=5 times normal upper limit);&lt;br&gt;(5) patients with severe renal insufficiency or receiving continuous renal replacement therapy or peritoneal dialysis &lt;br&gt;(6) Other conditions that not appropriate to be enrolled into this study based on investigator's advise. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Azvudine Plus Symptomatic treatment:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment&amp;#32;</Intervention>
    <Primary_outcome>Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030485</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A medical records based retrospective Cohort study</Public_title>
    <Scientific_title>Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A case records based retrospective Cohort study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50459</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-03</Date_enrollement>
    <Target_size>Group 2:50;Group 1:40;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Shusheng Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>shushengli16@sina.com</Contact_Email>
    <Contact_Tel>+86 13971086498</Contact_Tel>
    <Contact_Affiliation>Eergency / Intensive Care Department of Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Meets 2019 novel coronavirus pneumonia diagnosis criteria;&lt;br&gt;2. Under non-invasive ventilation, finger oxygen saturation&lt;90%.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Age &lt;14 years;&lt;br&gt;2. Pregnant;&lt;br&gt;3. Patient is irritable during NIV treatment, and still cannot tolerate NIV after adequate health education and nursing guidance;&lt;br&gt;4. Intubation-mechanical ventilation without previous NIV treatment;&lt;br&gt;5. Patient or legal representative refuses to participate in this clinical study;&lt;br&gt;6. Patient or legal representative refuses intubation and/or mechanical ventilation.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 2:conservation mechanical ventilation group;Group 1:aggressive mechanical ventilation;</Intervention>
    <Primary_outcome>28-day mortality;ICU 14-day mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030593</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study</Public_title>
    <Scientific_title>Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital, College of Medicine of Zhejiang University</Primary_sponsor>
    <Date_registration>2020-03-08</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50228</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-10</Date_enrollement>
    <Target_size>Case series:150;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiaoyang Lu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>luxiaoyang@zju.edu.cn</Contact_Email>
    <Contact_Tel>+86 13605715886</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital, College of Medicine of Zhejiang University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Aged &gt;=18 years;&lt;br&gt;(2) novel coronavirus pneumonia novel coronavirus pneumonia diagnosis and treatment plan (trial version sixth) is diagnosed as new type coronavirus pneumonia common, heavy and critical patients;&lt;br&gt;(3) Patients who used antiviral drugs such as lopinavir / ritonavir, abidol, darunavir / corbistadine and fabiravir for more than 72 hours.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Patients allergic to antiviral drugs;&lt;br&gt;(2) Pregnant or lactating women;&lt;br&gt;(3) Patients whose GPT or total bilirubin is higher than the upper limit of normal value before antiviral drug use.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:None;</Intervention>
    <Primary_outcome>ALT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030559</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for the safety of artificial liver cluster nursing in critically ill patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Retrospective study to assess the safety of in vitro blood purification treatment in critically ill patients with novel coronavirus pneumonia COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Zhejiang University School of Medicine</Primary_sponsor>
    <Date_registration>2020-03-07</Date_registration>
    <Date_registration3>20200307</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50583</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-07</Date_enrollement>
    <Target_size>Case series:12;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Huafen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>zhanghuafen@zju.edu.cn</Contact_Email>
    <Contact_Tel>+86 13757120681</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Critically ill patients with SARS-CoV-2 infection who had perform blood purificationtherapy using artificial liver suppoer system and underwent clustering nusing progremm </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Patient or family member does not agree to sign informed consent;&lt;br&gt;2) Patients with previous or existing history of DVT;&lt;br&gt;3) The investigator believes that the patient has other conditions that are not suitable for enrollment;</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:clustering nusing progremm;</Intervention>
    <Primary_outcome>Unplanned shutdowns;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030753</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Shandong Provincial Chest hospital</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50901</web_address>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fenglin Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>12 Lieshishan Road East, Licheng District, Jinan, Shandong, China</Contact_Address>
    <Contact_Email>xkyylfl@163.com</Contact_Email>
    <Contact_Tel>+86 13953116564</Contact_Tel>
    <Contact_Affiliation>Shandong Provincial Chest hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;&lt;br&gt;2. ARDS patients according to the Berlin definition;&lt;br&gt;3. Patients in ICU met the VAP criteria and were not associated with other site infection.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. With other parts of the infection occurred within 7 days after discontinuation of antibiotic therapy, including urinary tract infections, bloodstream infections, biliary tract infections, central nervous system infections, and so on;&lt;br&gt;2. The drainage tube of important organs can not be extracted within 14 days;&lt;br&gt;3. Patients or relatives request to suspend the trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>case series:no;</Intervention>
    <Primary_outcome>ICU hospitalization days;The recurrence rate of infection;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030744</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Shandong Provincial Chest Hospital</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50910</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>ECMO group:10;the conventional treatment group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fenglin Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China</Contact_Address>
    <Contact_Email>xkyylfl@163.com</Contact_Email>
    <Contact_Tel>+86 13953116564</Contact_Tel>
    <Contact_Affiliation>Shandong Provincial Chest Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;&lt;br&gt;2. Severe ARDS patients according to the Berlin definition.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Aged&lt;14 years;&lt;br&gt;2. Accompanied by other serious organ dysfunction (including severe liver and kidney dysfunction, upper gastrointestinal bleeding, DIC, etc.).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>ECMO group:ECMO therapy;the conventional treatment group:no;</Intervention>
    <Primary_outcome>Inpatient mortality;ICU hospital stay;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030472</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Shenyang Sixth People's Hospita</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49753</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-25</Date_enrollement>
    <Target_size>Experimental group:10;Control group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ye Gu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>85 Heping Street South, Heping District, Shenyang, Liaoning, China</Contact_Address>
    <Contact_Email>sylykjk@163.com</Contact_Email>
    <Contact_Tel>+86 18502468189</Contact_Tel>
    <Contact_Affiliation>Shenyang Sixth People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-75 years old;&lt;br&gt;2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection;&lt;br&gt;3. patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 10 days);&lt;br&gt;4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;&lt;br&gt;5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration;&lt;br&gt;6. Patients who voluntarily sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR 30 times / min; or SaO2 / SpO2 &lt;93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt;300MMHG (1mmhg = 0.133kpa);&lt;br&gt;2. Pneumonia patients with severe new coronavirus infection meet one of the following conditions: respiratory failure and need mechanical ventilation; or shock; or other organ failure combined with ICU monitoring treatment;&lt;br&gt;3. Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 times upper limit);&lt;br&gt;4. Patients with contraindications specified in the instructions of ritonavir tablets;&lt;br&gt;5. The patient who previous or ongoing use of protease inhibitors;&lt;br&gt;6. The pregnancy test of female subjects in the screening period was positive;&lt;br&gt;7. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).? </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Ganovo/ ritonavir oral+conventional treatment;Control group:Conventional treatment;</Intervention>
    <Primary_outcome>Rate of composite advers outcomes: SPO2, PaO2/FiO2 and respiratory rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030471</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Maoming People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-02</Date_registration>
    <Date_registration3>20200302</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50421</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-02</Date_enrollement>
    <Target_size>Lipoic acid group:197;Blank control group:197;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chen Chunbo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>101 Weimin Road, Maoming, Guangdong, China</Contact_Address>
    <Contact_Email>gghicu@163.com</Contact_Email>
    <Contact_Tel>+86 13922745788</Contact_Tel>
    <Contact_Affiliation>Maoming People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Patients aged from 18 to 75 years old;&lt;br&gt;(2) Mild patients with confirmed COVID-19 according to the diagnostic criteria of "novel coronavirus Infection Diagnosis and Treatment Plan (Trial 6th Edition)" issued by the National Health and Safety Commission;&lt;br&gt;(3) Patients and their families voluntarily participated in the study and signed an informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Female patients during pregnancy or lactation;&lt;br&gt;(2) Patients allergic to lipoic acid or similar drugs (B vitamins), previously intolerant to the recommended dose of lipoic acid;&lt;br&gt;(3) Patients who are taking part in clinical trials of other drugs;&lt;br&gt;(4) Patients are taking other foods or drugs with antioxidant effect, such as vitamin C, vitamin E, etc.&lt;br&gt;(5) Patients with other serious diseases that may threaten life, such as cancer.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Lipoic acid group:Routine Therapy and administration of Lipoic acid injection;Blank control group:Routine Therapy and administration of placebo;</Intervention>
    <Primary_outcome>Progression rate from mild to critical/severe;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030557</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19)</Public_title>
    <Scientific_title>A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>The Third Affiliated Hospital of the Second Military Medical University</Primary_sponsor>
    <Date_registration>2020-03-07</Date_registration>
    <Date_registration3>20200307</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50667</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-10</Date_enrollement>
    <Target_size>Case series:1030;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang Hongyang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>225 Changhai Road, Yangpu District, Shanghai, China</Contact_Address>
    <Contact_Email>hywangk@vip.sina.com</Contact_Email>
    <Contact_Tel>+86 13801955367</Contact_Tel>
    <Contact_Affiliation>The Third Affiliated Hospital of the Second Military Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: COVID-19 patients were diagnosed and cured as convalescent patients with disappearance of clinical symptoms and convalescent patients who met the discharge criteria after imaging examination and viral nucleic acid test.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) &lt; 18 years old or &gt;=80 years old; &lt;br&gt;2) pregnant and lactating women; &lt;br&gt;3) patients with mental illness.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>viral load;virus genotyping;Classification of lymphocytes;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030543</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Central Theater General Hospital of PLA</Primary_sponsor>
    <Date_registration>2020-03-06</Date_registration>
    <Date_registration3>20200306</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50541</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>Case series:35;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chen Xiao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>627 Wuluo Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>cxfn817@163.com</Contact_Email>
    <Contact_Tel>+86 13986156712</Contact_Tel>
    <Contact_Affiliation>Central Theater General Hospital of PLA</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All enrolled patients with confirmed NCIP according to both clinical way ( include  symptoms,blood routine test and chest computed tomography) and labotatory way (the revere-transcriptase-polymerase-chain-rection (RT-PCR) reaction from throat swab sample) .The patients signed consent was obtained for each sample collection.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The patients disagreed for sample collection will be excluded.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:reverse transcription polymerase chain reaction;</Intervention>
    <Primary_outcome>A cycle threshold value (Ct-value);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030739</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS</Public_title>
    <Scientific_title>Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Shandong Provincial Chest hospital</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50896</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Case study</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fenglin Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China</Contact_Address>
    <Contact_Email>xkyylfl@163.com</Contact_Email>
    <Contact_Tel>+86 13953116564</Contact_Tel>
    <Contact_Affiliation>Shandong Provincial Chest hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who were diagnosed as COVID-19 by nucleic acid test and were in accordance with the clinical classification of severe or critically illness. (refer to the clinical classification criteria in the pneumonia diagnosis and treatment program of novel coronavirus infection, General Office of the National Health Commission (trial version 7)).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: no</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>case series:no;</Intervention>
    <Primary_outcome>Tempreture;cough;dyspnea;Blood Routine;Aterial Blood Gas;Chest CT Scan;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030721</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of Guangdong Medical University</Primary_sponsor>
    <Date_registration>2020-03-12</Date_registration>
    <Date_registration3>20200312</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50759</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-16</Date_enrollement>
    <Target_size>Target condition:50;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Huanqin Han</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>57 South Renmin Road, Zhanjiang, Guangdong, China</Contact_Address>
    <Contact_Email>huanqinhan@126.com</Contact_Email>
    <Contact_Tel>+86 13828291023</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of Guangdong Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 15-79 years;&lt;br&gt;2. Patients with COVID-19 confirmed by testing for novel coronavirus of the respiratory tract;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The patient has a history of alcohol or narcotic drug abuse, or a history of mental illness (such as schizophrenia, obsessive-compulsive disorder, depression), antagonistic personality, bad motivation, doubt, or other emotional or intellectual problems that may affect participation in this study The status of informed effectiveness;&lt;br&gt;2. Patients cannot cooperate with the relevant examinations of this project and do not agree with the informed consent form&lt;br&gt;3. The required information is incomplete;&lt;br&gt;4. pregnancy;&lt;br&gt;5. There are contraindications for sputum induction. Those who induce sputum by atomization may cause diseases, including:&lt;br&gt;(1) Severe chest and lung diseases: such as acute asthma, acute exacerbation of COPD, pneumothorax, massive pleural effusion, acute or chronic respiratory failure;&lt;br&gt;(2) a large amount of pericardial effusion;&lt;br&gt;(3) cardiac function level III or above.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Patients with mild or light COVID-19 confirmed by testing for novel coronavirus of the respiratory tract;Index test:1.&amp;#32;throat&amp;#32;swab&lt;br&gt;2.&amp;#32;induced&amp;#32;sputum;</Intervention>
    <Primary_outcome>detection of SARS-CoV-2 RNA;SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030469</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Shanghai University of TCM</Primary_sponsor>
    <Date_registration>2020-03-02</Date_registration>
    <Date_registration3>20200302</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50082</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-27</Date_enrollement>
    <Target_size>Control group:48;Experimental group:48;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiuming Song</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>528 Zhanghen Road, Pudong New Area District, Shanghai, China</Contact_Address>
    <Contact_Email>Xiumingsong@sina.com</Contact_Email>
    <Contact_Tel>+86 13817525012</Contact_Tel>
    <Contact_Affiliation>Shuguang Hospital Affiliated to Shanghai University of T.C.M.</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Real-time fluorescent RT-PCR detection of new coronavirus nucleic acid positive, or viral gene sequencing is highly homologous with known new coronavirus;&lt;br&gt;2. Confirmed as a novel coronavirus pneumonia common and severe patients, meets the diagnostic criteria of the "novel coronavirus pneumonia diagnosis and treatment plan (trial implementation of the sixth edition)"&lt;br&gt;3. aged 18 to 65 years;&lt;br&gt;4. Learn about the significance of the study before the trial also the possible inconveniences and potential risk.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with mild and critical novel coronavirus pneumonia;&lt;br&gt;2. Acute respiratory disease caused by non- novel coronavirus pneumonia;&lt;br&gt;3. Patients with diabetes and hypertension accompanied by severe primary immunodeficiency disease acquired immunodeficiency syndrome congenital respiratory malformation congenital heart disease pulmonary dysplasia and other diseases;&lt;br&gt;4. Patients with obvious abnormal heart, liver and kidney disease or serious other system diseases such as digestive system urogenital system blood system hemorrhagic disease central nervous system psychiatric diseases in acute stage, and endocrine and metabolic diseases;&lt;br&gt;5. People who are known to be allergic to the ingredients in the research drug, or patients with allergies; &lt;br&gt;6. Women who are breastfeeding, pregnant, or have a positive urine pregnancy test;&lt;br&gt;7. Patients who are participating in other clinical trials or patients who have participated in other drug clinical trials within 1 month;&lt;br&gt;8. Researchers find the patient inappropriate to be involved in the trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN;</Intervention>
    <Primary_outcome>fever clearance time;Effective rate of TCM symptoms;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030468</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Study for the key technique of integrative therapy of Novel Coronavirus Pneumonia (COVID-19): the TCM symptoms and treatment regulation</Public_title>
    <Scientific_title>Key techniques of combination therapy of Novel Coronavirus Pneumonia (COVID-19) - Study on TCM symptoms and treatment law                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of Shandong University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-02</Date_registration>
    <Date_registration3>20200302</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50390</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-28</Date_enrollement>
    <Target_size>PRE-GROUP1:400;PRE-GROUP2:400;TRE-GROUP1:100;TRE-GROUP2:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Wei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>42 Wenhua Road West, Lixia District, Ji'nan, Shandong, China</Contact_Address>
    <Contact_Email>zhagnweijinan@126.com</Contact_Email>
    <Contact_Tel>+86 13505319899</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of Shandong University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Criteria for inclusion of confirmed patients:&lt;br&gt;(1) Comply with the diagnostic criteria of "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Pneumonia (COVID-19) (Trial Version 5)";&lt;br&gt;(2) Above 2 years old;&lt;br&gt;2. Inclusion criteria for close contacts:&lt;br&gt;One of the following contact situations after the onset of the case, but did not take effective protection:&lt;br&gt;(1) People who live, study, work or have close contact with the case, such as working close to the case or sharing the same classroom or living in the same house as the case;&lt;br&gt;(2) Medical staff, family members, or other people who have close contact with the case, such as direct treatment and care of the case, visiting or staying in the closed environment where the case is located, and the case is the same as other cases in the ward. Patients and their caregivers;&lt;br&gt;(3) People who are in the same transportation as the case and have close contact with them, including those who have taken care of the patient on the transportation, and the patient's colleagues (family, colleagues, friends, etc.) are found to be likely to be near Distance from other passengers and flight attendants who are in contact with the patient;&lt;br&gt;(4) On-site investigators evaluate that they are qualified to meet other contacts with close contacts.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Patients during pregnancy;&lt;br&gt;(2) Complicated liver, kidney, and metabolic diseases;&lt;br&gt;(3) Have other serious primary cardiovascular disease, kidney disease, liver disease, hematological changes, or serious diseases that affect its quality of life, such as malignant tumors, AIDS, etc.;&lt;br&gt;(4) Have or suspect a history of alcohol, drug abuse, etc.;&lt;br&gt;(5) People with mental illness or manic disorder, or unwilling to accept research measures, or unwilling to cooperate with others;&lt;br&gt;(6) Those who have participated in other clinical studies and influenced the results of this survey.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>PRE-GROUP1:Taking Chinese medicine preventive decoction;PRE-GROUP2:General prevention methods;TRE-GROUP1:TCM syndrome differentiation treatment+ Western medicine treatment;TRE-GROUP2:Western medicine treatment;</Intervention>
    <Primary_outcome>disease incidence;Duration of PCR normalization;Distribution pattern of TCM syndromes;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04280913</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Outcomes of Patients With COVID19</Public_title>
    <Scientific_title>Clinical Outcomes of Hospitalized Patients With Coronavirus Disease 2019</Scientific_title>
    <Acronym />
    <Primary_sponsor>Guangzhou Institute of Respiratory Disease</Primary_sponsor>
    <Date_registration>20/02/2020</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04280913</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 22, 2020</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Luqian Zhou, MD;Luqian Zhou, MD;Luqian Zhou, MD</Contact_Lastname>
    <Contact_Email>;zhlx09@163.com;zhlx09@163.com</Contact_Email>
    <Contact_Tel>;15622236759;+8615622236759</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Guangzhou Medical University;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Hospitalized patients with COVID19&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Suspected patients with COVID19, not confirmed by the laboratory&lt;br&gt;&lt;br&gt;          -  Patients who are refused to receive medical treatments&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus Disease 2019</Condition>
    <Intervention>Other: retrospective analysis</Intervention>
    <Primary_outcome>Time to negative conversion of severe acute respiratory syndrome coronavirus 2</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04281693</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A New Screening Strategy for 2019 Novel Coronavirus Infection</Public_title>
    <Scientific_title>Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection</Scientific_title>
    <Acronym />
    <Primary_sponsor>Affiliated Hospital to Academy of Military Medical Sciences</Primary_sponsor>
    <Date_registration>20/02/2020</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04281693</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 2020</Date_enrollement>
    <Target_size>230</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention model: Single Group Assignment. Primary purpose: Screening. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Yan Liu;Xiaotian Sun;Yan Liu, Ph.D.</Contact_Lastname>
    <Contact_Email>;xiaotian-sun@hotmail.com;13911798288@163.com</Contact_Email>
    <Contact_Tel>;+86-01066823480;010-66947473</Contact_Tel>
    <Contact_Affiliation>The Fifth Medical Center of Chinese PLA General Hospital;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Who agree to participate in the study and sign written informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Confirmed NCIP patients&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Novel Coronavirus Infection Pneumonia</Condition>
    <Intervention>Diagnostic Test: Standard screening strategy;Diagnostic Test: New screening strategy</Intervention>
    <Primary_outcome>Screening accuracy</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04282902</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection</Public_title>
    <Scientific_title>A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection</Scientific_title>
    <Acronym />
    <Primary_sponsor>Huilan Zhang</Primary_sponsor>
    <Date_registration>10/02/2020</Date_registration>
    <Date_registration3>20200210</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04282902</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 4, 2020</Date_enrollement>
    <Target_size>294</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Huilan Zhang, PD;Huilan Zhang, PD</Contact_Lastname>
    <Contact_Email>huilanz_76@163.com;</Contact_Email>
    <Contact_Tel>15391532171;</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        (1) Age = 18 years. (2) Clinically diagnosed patients with new type of coronavirus&lt;br&gt;        pneumonia include: on the basis of meeting the criteria for suspected cases, one of the&lt;br&gt;        following pathogenic evidence: ? real-time fluorescent RT-PCR of respiratory specimens or&lt;br&gt;        blood specimens for detection of new coronavirus nucleic acid; Respiratory or blood&lt;br&gt;        specimens are genetically sequenced and highly homologous to known new coronaviruses. (3)&lt;br&gt;        The time interval between the suspected neocoronary pneumonia pneumonia case and the random&lt;br&gt;        enrollment is determined within 4 days to 7 days according to the history symptoms and&lt;br&gt;        chest CT imaging. Cough, diarrhea, or other related symptoms can be used. The imaging&lt;br&gt;        changes are mainly based on chest CT.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        (1) AST and ALT&gt; 1.5 x ULN at visit 1; (2) bilirubin&gt; 1.5 x ULN at visit 1; (3) creatinine&lt;br&gt;        clearance rate calculated by Cockcroft-Gault formula at visit 1 &lt;30 mL / min; (4) patients&lt;br&gt;        with potential chronic liver disease (Child Pugh A, B or C liver injury; (5) previous&lt;br&gt;        treatment with nidanib or pirfenidone; (6) screening visits (interviews 1) Received other&lt;br&gt;        research drug treatment within 1 month or 6 half-lives (whichever is greater); (7) IPF&lt;br&gt;        diagnosis based on ATS / ERS / JRS / ALAT 2011 guidelines (P11-07084); (8 ) Significant&lt;br&gt;        pulmonary hypertension (PAH) defined by any of the following standards: ? Clinical /&lt;br&gt;        echocardiographic evidence of previously significant right heart failure; ? Medical history&lt;br&gt;        including right heart catheter showing a cardiac index = 2l / min / m2; ? Prostaglandol /&lt;br&gt;        qu Parenteral administration of prostacyclin in the treatment of PAH; (9) other clinically&lt;br&gt;        significant lung abnormalities considered by the investigator; (10) major extrapulmonary&lt;br&gt;        physiological limitations (such as chest wall deformity, large amount of pleural effusion);&lt;br&gt;        (11) Cardiovascular diseases, any of the following diseases: ? Severe hypertension within 6&lt;br&gt;        months of Visit 1, uncontrollable after treatment (=160 / 100 mmHg); ? myocardial&lt;br&gt;        infarction within 6 months of visit 1; ? unstable angina within 6 months of visit 1; (12)&lt;br&gt;        history of severe central nervous system (CNS) events; (13) known trials Drug allergies;&lt;br&gt;        (14) Other diseases that may interfere with the testing process or as judged by the&lt;br&gt;        investigator may interfere with the trial participation or may put the patient at risk when&lt;br&gt;        participating in the trial; (15) Women who are pregnant, breastfeeding, or planning&lt;br&gt;        pregnancy in this trial (16) Patients are unable to understand or follow the trial&lt;br&gt;        procedures, including completing the questionnaires themselves without assistance.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia;Pneumonia;Pirfenidone</Condition>
    <Intervention>Drug: pirfenidone</Intervention>
    <Primary_outcome>K-BILD;blood gas;Finger pulse oxygen;chest CT</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04284046</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>CT Scores Predict Mortality in 2019-nCoV Pneumonia</Public_title>
    <Scientific_title>CT Scores Predict Mortality in 2019-nCoV Pneumonia</Scientific_title>
    <Acronym />
    <Primary_sponsor>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</Primary_sponsor>
    <Date_registration>22/02/2020</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04284046</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 31, 2020</Date_enrollement>
    <Target_size>39</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  all patients suspected of 2019 novel coronavirus infection.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patients' data are not available.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>CT Scores Predict Mortality in 2019-nCoV Pneumonia</Condition>
    <Intervention>Other: CT score</Intervention>
    <Primary_outcome>7-day mortality</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030719</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan</Public_title>
    <Scientific_title>A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Wuhan Hospital of Integrated Traditional Chinese and Western Medicine</Primary_sponsor>
    <Date_registration>2020-03-11</Date_registration>
    <Date_registration3>20200311</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50867</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Integrated traditional Chinese and western medicine group:771;Western medicine group:300;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Cohort study</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wei Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>784404524@qq.com</Contact_Email>
    <Contact_Tel>+86 18995598097</Contact_Tel>
    <Contact_Affiliation>Wuhan Hospital of Integrated Traditional Chinese and Western Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Comply with the diagnostic criteria for patients with new pneumonia virus in the The Pneumonitis Diagnosis and Treatment Program for Corona Virus Disease 2019(Sixth Edition); &lt;br&gt;(2) Complete clinical data of patients.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Patients who were eventually diagnosed with other bacterial or viral infections; &lt;br&gt;(2) Patients whose data could not be obtained for special reasons.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Integrated traditional Chinese and western medicine group:Traditional Chinese medicine and routine treatment of western medicine;Western medicine group:Routine treatment of western medicine;</Intervention>
    <Primary_outcome>Mortality rate;Common-severe conversion rate;Length of hospital stay.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030703</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Xiangya Hospital of Central South University</Primary_sponsor>
    <Date_registration>2020-03-10</Date_registration>
    <Date_registration3>20200310</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50251</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-10</Date_enrollement>
    <Target_size>experimental group:20;control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Pinhua Pan, Yehong Kuang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>87 Xiangya Road, Kaifu District, Changsha, Hu'nan, China</Contact_Address>
    <Contact_Email>pinhuapan668@126.com</Contact_Email>
    <Contact_Tel>+86 13574171102</Contact_Tel>
    <Contact_Affiliation>Xiangya Hospital of Central South University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 75 years old;&lt;br&gt;2. The diagnosis of new-type coronavirus pneumonia was confirmed by RT-PCR or gene sequencing according to the "Diagnosis and Treatment Scheme for Pneumonia of New Coronavirus Infection (Trial Version 6 and Updated)", and the clinical type was general (including severe high-risk factors) and severe;&lt;br&gt; Note: Patients with common new type of coronavirus pneumonia (including severe high-risk factors): patients with common type with multiple lung multiple lesions, or pulmonary imaging shows that the lesion progresses significantly within 50% within 24 to 48 hours;&lt;br&gt;3. IL-6 is elevated (Roche chemiluminescence detection is recommended);&lt;br&gt;4. The patient voluntarily signed the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Critical new pneumonia infection that meets one of the following conditions: respiratory failure occurs and requires mechanical ventilation; shock; combined organ failure requires ICU monitoring and treatment&lt;br&gt;2. Known allergies to Ixekizumab or antiviral drugs;&lt;br&gt;3. ALT / AST&gt; 5 times ULN, neutrophils &lt;0.5x10^9/L, Platelets less than 50x10^9/L;&lt;br&gt;4. Patients with impaired renal function: serum creatinine &gt;=2 mg/dl (176 umol/l);&lt;br&gt;5. Combined with severe underlying diseases, the expected life cycle is less than 3 months;&lt;br&gt;6. Active hepatitis, patients with definite severe bacterial and fungal infections, tuberculosis infection, and HIV infection;&lt;br&gt;7. Clear diagnosis of malignant tumors such as lymphoproliferative diseases;&lt;br&gt;8. Known active Crohn's disease;&lt;br&gt;9. Pregnant or lactating women;&lt;br&gt;10. Participated in other interventional clinical trials in the past 3 months;&lt;br&gt;11. Other conditions that the researcher considers unsuitable.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Ixekizumab and antiviral therapy;control group:antiviral therapy;</Intervention>
    <Primary_outcome>Lung CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030541</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country</Public_title>
    <Scientific_title>Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Xiamen Medical College,Shijiazhuang Medical College</Primary_sponsor>
    <Date_registration>2020-03-06</Date_registration>
    <Date_registration3>20200306</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50623</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax>30</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-06</Date_enrollement>
    <Target_size>Medical students group; Non-medical students group:1300;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ye Wan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1999 Guankou Middle Road, Jimei District, Xiamen, Fujian, China</Contact_Address>
    <Contact_Email>417433835@qq.com</Contact_Email>
    <Contact_Tel>+86 13806086169</Contact_Tel>
    <Contact_Affiliation>Xiamen Medical College</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Full-time college and graduate students are willing to participate in the research.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: On-the-job college students and graduate students.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Medical students group; Non-medical students group:None;</Intervention>
    <Primary_outcome>PSS-14;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030539</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Study for clinical oral characteristics of patients with novel coronavirus pneumonia (COVID-19) and Effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus</Public_title>
    <Scientific_title>Study for the effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus of the patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Guangzhou Eighth People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-06</Date_registration>
    <Date_registration3>20200306</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50660</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-06</Date_enrollement>
    <Target_size>control group:20;Experimental group (mild and normal type in patients with new coronavirus pneumonia):20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Case-Control study</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fan Zhong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>8 Huaying Road, Baiyun District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>gz8hzf@126.com</Contact_Email>
    <Contact_Tel>+86 18122317900</Contact_Tel>
    <Contact_Affiliation>Guangzhou Eighth People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Pharyngeal swabs are used to detect the positive nucleic acid of the novel coronavirus, or the virus gene sequencing is highly homologous with the known novel coronavirus;&lt;br&gt;2. Ages between 18 to 85 years male or female;&lt;br&gt;3. Subjects should fully understand the purpose, nature, methods and reactions of the experiment, voluntarily participate in the study and sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with mental illness who cannot cooperate with the sampling;&lt;br&gt;2. Patients judged by the researchers as unsuitable for the study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>control group:None;Experimental group (mild and normal type in patients with new coronavirus pneumonia):3% hydrogen peroxide gargle;</Intervention>
    <Primary_outcome>novel coronavirus nucleic acid;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030453</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19)</Public_title>
    <Scientific_title>Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Wenzhou Medical University</Primary_sponsor>
    <Date_registration>2020-03-02</Date_registration>
    <Date_registration3>20200302</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50381</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-02</Date_enrollement>
    <Target_size>ACEIs/ARBs:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yanling Shi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.Zhejiang, China</Contact_Address>
    <Contact_Email>akidney_doctor@hotmail.com</Contact_Email>
    <Contact_Tel>+86 0577 55579261</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Wenzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: confirmed cases of novel coronavirus(COVID-19) by real time fluorescent RT-PCR in Wenzhou City from January 2020</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria:  infection caused by other pathogens</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>ACEIs/ARBs:NA;</Intervention>
    <Primary_outcome>ratio of severe cases;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030312</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled, due to modify the protocol                                          A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment&amp;</Public_title>
    <Scientific_title>A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>First people's hospital of Jiangxi district,Wuhan</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50258</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-29</Date_enrollement>
    <Target_size>Case series:24;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Bende Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Culture Avenue, Jiangxia District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>liubende99@outlook.com</Contact_Email>
    <Contact_Tel>+86 13907191851</Contact_Tel>
    <Contact_Affiliation>First People's Hospital of Jiangxi District</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 70 years old;&lt;br&gt;2. Patients with pneumonia infected by new coronavirus: confirmed cases in compliance with the Diagnosis and Treatment Plan for Pneumonia Infected by New Coronavirus (Sixth Edition);&lt;br&gt;3. Confirmed cases who can be transfused into anti-SARS-CoV-2 virus inactivated plasma after fully assessing patients condition;&lt;br&gt;4. Cases who score 3 or 4 according to 6-grade scale;&lt;br&gt;5. The subjects and/or their legal guardians voluntarily participated in the study and voluntarily signed an informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The clinical classification of patients with severe novel coronavirus infection is to meet any of the following:&lt;br&gt;1) Respiratory failure occurs and requires mechanical ventilation;&lt;br&gt;2) Shock occurs;&lt;br&gt;3) Combined failure of other organs requires ICU monitoring and treatment;&lt;br&gt;2. Those who are allergic to blood products or plasma components and auxiliary materials (sodium citrate);&lt;br&gt;3. There is multiple organ failure, and the estimated survival time is less than 3 days;&lt;br&gt;4. Those who tested positive for HIV antibodies before enrollment;&lt;br&gt;5. Women who are pregnant or breastfeeding or have a birth plan within the past year;&lt;br&gt;6. Participants in other clinical trials within 3 months before screening;&lt;br&gt;7.Poor adherence or other conditions that the investigator believes are not suitable for inclusion (such as poor physical condition).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Anti-SARS-CoV-2 virus inactivated plasma;</Intervention>
    <Primary_outcome>Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04285190</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19</Public_title>
    <Scientific_title>A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tasly Pharmaceuticals, Inc.</Primary_sponsor>
    <Date_registration>19/02/2020</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04285190</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>85 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 26, 2020</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Shuiping Zhou, PhD;Yi He, PhD</Contact_Lastname>
    <Contact_Email>;heyi@tasly.com</Contact_Email>
    <Contact_Tel>;86-022-86343860</Contact_Tel>
    <Contact_Affiliation>Tasly Pharmaceutical Group Co., Ltd.;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Adult male or female patients aged 18-85 years old;&lt;br&gt;&lt;br&gt;          2. The newly diagnosed COVID-19 patients who meet the diagnostic criteria set forth in&lt;br&gt;             the "Guidance of Diagnosis and Treatment for Patients with Coronavirus Disease 2019&lt;br&gt;             (COVID-19) (Procedural Version 5 Amendment)", issued by the National Health Commission&lt;br&gt;             of the People's Republic of China on 8 February 2020;&lt;br&gt;&lt;br&gt;          3. Patients whose blood oxygen saturation is not less than 90%.&lt;br&gt;&lt;br&gt;          4. Patients who agree to participate in the study and voluntarily comply with the&lt;br&gt;             relevant requirements of the study.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients with other diseases that may affect, in the opinion of study researchers, the&lt;br&gt;             implementation of the study or the observation of the efficacy data;&lt;br&gt;&lt;br&gt;          2. Patients with severe Coronavirus Disease 2019 (COVID-19), that is based on "Guidance&lt;br&gt;             of Diagnosis and Treatment for Patients with Coronavirus Disease 2019 (COVID-19)&lt;br&gt;             (Procedural Version 5 Amendment)" with respect to the criteria for clinical severity&lt;br&gt;             classification;&lt;br&gt;&lt;br&gt;          3. Female patients with known pregnancy and in lactation at screening;&lt;br&gt;&lt;br&gt;          4. Patients with previous allergies to T89 or Radix Salvia Miltiorrhizae, Radix&lt;br&gt;             Notoginseng and Borneol;&lt;br&gt;&lt;br&gt;          5. Any other condition that, in the opinion of the investigator, may affect the conduct&lt;br&gt;             of the study, reduce compliance or increase the risk of patients.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus Disease 2019;Novel Coronavirus Pneumonia</Condition>
    <Intervention>Drug: T89</Intervention>
    <Primary_outcome>The time to oxygen saturation recovery to normal level (=97%);The proportion of patients with normal level of oxygen saturation(=97%)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030627</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases</Public_title>
    <Scientific_title>Study on the application of convalescent plasma therapy in severe COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Zhengzhou University</Primary_sponsor>
    <Date_registration>2020-03-08</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50727</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Experimental group:15;Control group:15;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Guojun Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Jianshe Road East, Zhengzhou, He'nan, China</Contact_Address>
    <Contact_Email>zlgj-001@126.com</Contact_Email>
    <Contact_Tel>+86 13673665268</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Zhengzhou University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who were diagnosed as COVID-19 by nucleic acid test and were in accordance with the clinical classification of severe or critically illness. (refer to the clinical classification criteria in the pneumonia diagnosis and treatment program of novel coronavirus infection, General Office of the National Health Commission (trial version 4)).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with hypersensitivity to plasma products; patients with severe transfusion reactions in the past; patients with acute pulmonary edema, congestive heart failure, pulmonary embolism, malignant hypertension, polycythemia vera, extreme renal failure and other diseases.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Convalescent plasma therapy + routine treatment;Control group:routine treatment;</Intervention>
    <Primary_outcome>Tempreture;Virus nucleic acid detection;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030518</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial</Public_title>
    <Scientific_title>Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>The Second Affiliated Hospital of Wenzhou Medical University</Primary_sponsor>
    <Date_registration>2020-03-05</Date_registration>
    <Date_registration3>20200305</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50586</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-29</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yuanrong Dai</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>109 Xueyuan Road West, Lucheng District, Wenzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>13968888872@163.com</Contact_Email>
    <Contact_Tel>+86 13857715778</Contact_Tel>
    <Contact_Affiliation>the Second Affiliated Hospital of Wenzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Aged 18 years or older, male or female;&lt;br&gt;(2) Real-time fluorescent RT-PCR of pharyngeal swab samples was positive for novel coronavirus nucleic acid;&lt;br&gt;(3) Clinical classification is common or severe;&lt;br&gt;(4) Signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Known or suspected allergy to the components of zedoary turmeric oil injection, or allergic constitution;&lt;br&gt;(2) Mild and severe patients.&lt;br&gt;(3) Combined with severe liver disease (such as Child-Pugh score &gt;=C, TBIL &gt;=2 times the upper limit of normal, ALT/AST &gt;=5 times the upper limit of normal);&lt;br&gt;(4) Combined with severe renal insufficiency (eGFR &lt;=30 mL/min/1.73 m2) or undergoing continuous renal replacement therapy, hemodialysis, peritoneal dialysis;&lt;br&gt;(5) Pregnant and lactating women or have fertility plans during the trial and within 6 months after the end of the trial;&lt;br&gt;(6) Participated in other clinical trials within 3 months before enrollment;&lt;br&gt;(7) According to the investigator's judgment, there are other conditions that are not suitable for participating in this trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Intravenous drip, 0.2 g (4 vials) once daily for adults; slow drip after dilution with 250 ml of 5% Glucose Injection or 0.9% Sodium Chloride Injection, not less than 120 minutes or 30-40 drops/minute. Continuous administration for 7 days, observation until 21 days or discharge;Control group:Conventional treatment, no control drug;</Intervention>
    <Primary_outcome>Real-time fluorescent RT-PCR detection of pharyngeal swab were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested after the end of medication) and the negative conversion time(measured every other day after the start of medication, determined according to clinical needs);Time to clinical improvement;Change in size of lesion area by chest CT;Time to fever subsidence, defined as the time at which a subject with fever at enrollment has returned to normal temperature for at least 72 hours;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030491</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for Comparing Differences of Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients between Sichuan Province and Wuhan City</Public_title>
    <Scientific_title>Comparative Study for Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients in Sichuan Province and Wuhan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>West China Hospital of Sichuan University</Primary_sponsor>
    <Date_registration>2020-03-04</Date_registration>
    <Date_registration3>20200304</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50552</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-03</Date_enrollement>
    <Target_size>Patients in Wuhan versus Sichuan:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Cross-sectional</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Kang Yan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>Kangyan@scu.edu.cn</Contact_Email>
    <Contact_Tel>+86 18980601566</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients diagnosed with new coronavirus pneumonia</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: None</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Patients in Wuhan versus Sichuan:none;</Intervention>
    <Primary_outcome>length of stay;length of stay in ICU;Hospital costs;Hospital costs;Antibiotic use;Organ function support measures;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030687</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Novel coronavirus pneumonia (COVID-19) associated kidney injury in children</Public_title>
    <Scientific_title>COVID-19 infection associated kidney injury in children                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Department of Nephrology, Wuhan children's Hospital</Primary_sponsor>
    <Date_registration>2020-03-09</Date_registration>
    <Date_registration3>20200309</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50572</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>18</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Infection without renal injury group:30;Infection with proteinuria group:30;Infection with hematuria group:30;Infection with impaired renal function group:30;</Target_size>
    <Study_type>Basic Science</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang Xiaowen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>100 Hongkong Road, Jiang'an District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>b5477@163.com</Contact_Email>
    <Contact_Tel>+86 15907190882</Contact_Tel>
    <Contact_Affiliation>Department of Nephrology, Wuhan Children's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. COVID-19 infection;&lt;br&gt;2. Children with kidney injury: Hematuria, Proteinuria, renal dysfunction.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Exclusion of COVID-19 infection in children;&lt;br&gt;2. Dead children;&lt;br&gt;3. Sign to reject this project.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19); Kidney disease in children</Condition>
    <Intervention>Infection without renal injury group:none;Infection with proteinuria group:Bailing Capsule;Infection with hematuria group:Bailing Capsule;Infection with impaired renal function group:Bailing Capsule, Renal replacement therapy;</Intervention>
    <Primary_outcome>temperature;heart rate;respiratory rate;blood pressure;Urine volume;blood routine;C-reactive protein;erythrocyte sedimentation rat;pulmonary CT;liver function;coagulation function;renal function;immunoglobulin;complement;T cell subsets;electrolytes;Urine analysis;microalbuminuria;COVID-19 nucleic acid;COVID-19 antibody;renal ultrasound;24-hour urine protein;Tc-DTPA renal dynamic imaging;eGFR;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030545</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial</Public_title>
    <Scientific_title>Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Hubei Hospital of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-06</Date_registration>
    <Date_registration3>20200306</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50126</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-04</Date_enrollement>
    <Target_size>Control group:100;Experimental group 1:100;Experimental group 2:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China?</Countries>
    <Contact_Firstname>Yang Yi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>4 Garden Hill, Wuchang District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>153267742@qq.com</Contact_Email>
    <Contact_Tel>+86 18971163518</Contact_Tel>
    <Contact_Affiliation>Hubei Hospital of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Diagnosed Novel coronavirus pneumonia patients or clinically diagnosed NCP patients in Hubei Province;&lt;br&gt;2. Aged 18 to 65 years;&lt;br&gt;3. The time interval between symptom onset and randomization was within 7 days (the onset of symptom was mainly determined by the time of fever);&lt;br&gt;4. Sign the written informed consent before the study. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infection caused by basic diseases such as primary immunodeficiency disease, congenital respiratory tract malformation, congenital heart disease, gastroesophageal reflux disease and pulmonary dysplasia;&lt;br&gt;2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory system bacterial infection such as suppurative tonsillitis, acute bronchitis, sinusitis, otitis media or other respiratory diseases affecting the evaluation of clinical trials. Or with Chest CT confirmed the presence of serious interstitial lung disease, bronchiectasis and other basic lung diseases;&lt;br&gt;3. critically ill patients based on the New Protocol for Diagnosis and Treatment of NCP;&lt;br&gt;4. Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 ULN);&lt;br&gt;5. Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;=30ml/min/1.73m2) or continuous renal replacement therapy, hemodialysis or peritoneal dialysis;&lt;br&gt;6. Pregnant or breast-feeding women;&lt;br&gt;7. Patients may be transferred to non-designated hospitals within 72 hours;&lt;br&gt;8. Patients who have participated in other clinical trials in the past 7 days;&lt;br&gt;9. Allergic constitution, such as those who are allergic to two or over twodrugs, with history of food allergies, or known to be allergic to the ingredients of this drug;&lt;br&gt;10. In the opinion of the investigator, subjects who are not suitable for enrollment or with any factors that affect the outcome of the trial. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Basic treatment refers to the treatment according to the diagnosis and treatment plan of the health care Commission (Sixth Edition). (after three days of medication, if the symptoms cannot be controlled in time and effectively, the patients can be sent out of the group immediately to receive the treatment&amp;#;Experimental group 1:Basic treatment + honeysuckle oral liquid at a low dose of 60ml / time, three times a day;Experimental group 2:Basic treatment + honeysuckle oral liquid high dose group, honeysuckle oral liquid120ml / time, three times a day.;</Intervention>
    <Primary_outcome>Recovery time;Pneumonia psi score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030304</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>The Third Affiliated Hospital of Sun Yat-sen University</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49653</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20</Inclusion_agemin>
    <Inclusion_agemax>55</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-10</Date_enrollement>
    <Target_size>Case series:300;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Pang Yong-li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>pangi88@126.com</Contact_Email>
    <Contact_Tel>+86 15626235237</Contact_Tel>
    <Contact_Affiliation>The Third Affiliated Hospital of Sun Yat-sen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) registered nurse;&lt;br&gt;(2) to combat the new coronavirus pneumonia of the first line of nurses (infection department, fever clinic, emergency);&lt;br&gt;(3) volunteer to participate in this study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: suspected or diagnosed isolation of nurses</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Mental status;Social support;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030256</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China</Public_title>
    <Scientific_title>Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Daping Hospital,Army Medical University</Primary_sponsor>
    <Date_registration>2020-02-26</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50078</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:1000;</Target_size>
    <Study_type>Epidemilogical research</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Cao Guoqiang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>10 Changjiang Branch Road, Yuzhong District, Chongqing, China</Contact_Address>
    <Contact_Email>cgq1963@163.com</Contact_Email>
    <Contact_Tel>+86 023 68757780</Contact_Tel>
    <Contact_Affiliation>Daping Hospital, Army Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients admitted to the hospital</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: NO</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Epidemiological and clinical characteristics;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030579</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Shandong Provincial Hospital</Primary_sponsor>
    <Date_registration>2020-03-08</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50692</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jiang Shujuan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>, Jinan, Shandong,Shandong,PR China</Contact_Address>
    <Contact_Email>docjiangshujuan@163.com</Contact_Email>
    <Contact_Tel>+86 15168887199</Contact_Tel>
    <Contact_Affiliation>Department of Respiratory Medicine, Shandong Provincial Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who were diagnosed with novel coronavirus pneumonia by the nucleic acid test;&lt;br&gt;2. Patients who agreed to enrollment.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>clinic outcome;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030578</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Shandong Provincial Hospital</Primary_sponsor>
    <Date_registration>2020-03-08</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50690</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-07</Date_enrollement>
    <Target_size>Experimental group:20;Control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Liu Yi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>324 Jing-Wu-Wei-Qi Road, Huaiyin District, Ji'nan, Shandong, China </Contact_Address>
    <Contact_Email>15168888626@163.com</Contact_Email>
    <Contact_Tel>+86 18660117915</Contact_Tel>
    <Contact_Affiliation>Shandong Provincial Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with new type of coronavirus pneumonia admitted to the designated hospital of Jinan City have the same diagnostic criteria as "Pneumonitis diagnosis and treatment plan for new type of coronavirus infection (latest version)&lt;br&gt;during 2020.02-2020.05</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Chronic obstructive pulmonary disease; &lt;br&gt;(2) Cardiorenal insufficiency; &lt;br&gt;(3) Pregnant women</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Lung rehabilitation training+Conventional treatment;Control group:Conventional treatment;</Intervention>
    <Primary_outcome>Pulmonary function;6 minutes walking distance;The Short Form -36 Healthy Survey;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030466</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled due to lack of patients                                       Investigation on Mental Health Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Investigation on Mental Health Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Yongchuan Hospital,Chongqing Medical University</Primary_sponsor>
    <Date_registration>2020-03-02</Date_registration>
    <Date_registration3>20200302</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50387</web_address>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>55</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-26</Date_enrollement>
    <Target_size>Case series:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Song Ying</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>439 Xuanhua Road, Yongchuan District, Chongqing, China</Contact_Address>
    <Contact_Email>164738059@qq.com</Contact_Email>
    <Contact_Tel>+86 13668077090</Contact_Tel>
    <Contact_Affiliation>Yongchuan Hospital, Chongqing Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All patients meet the diagnostic criteria for neo-coronary pneumonia (New Coronavirus Infected Pneumonia Diagnosis and Treatment Program, Fifth Edition)</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: People with a history of mental illness or a genetic history of familial psychosis, people with previous mental disorders, sequelae of traumatic brain injury, patients with drug and alcohol abuse, or people with other mental illnesses.</Exclusion_Criteria>
    <Condition>Mental health; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Psychological counseling;</Intervention>
    <Primary_outcome>Comprehensive psychological assessment;Mental toughness;Solution;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030388</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Jingzhou First People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50306</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-18</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>xiao wei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>8 Hangkong Road, Shashi District, Jingzhou, Hubei, China</Contact_Address>
    <Contact_Email>99xw@sina.com</Contact_Email>
    <Contact_Tel>+86 071 68494565</Contact_Tel>
    <Contact_Affiliation>Jingzhou First People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. The patient signs the written informed consent;&lt;br&gt;2. Aged 18-80 years;&lt;br&gt;3. the novel coronavirus novel coronavirus infection diagnostic criteria for pneumonia, namely, the new coronavirus pneumonia diagnosis and treatment plan (trial version sixth). It conforms to any of the following:&lt;br&gt;1) in case of shortness of breath, RR &gt;=30 times / min;&lt;br&gt;2) in case of resting state, oxygen saturation &lt;=93%;&lt;br&gt;3) in case of arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt;=300MMHG (1mmhg = 0.133kpa). PaO2 / FiO2 should be corrected according to the following formula in high altitude (over 1000m above sea level): PaO2 / FiO2 * [atmospheric pressure (mmHg) / 760]; pulmonary imaging showed that in 24-48 hours, patients with obvious progress of lesions &gt; 50% should be treated as severe management;&lt;br&gt;4. The course of disease is within 14 days after onset.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Those who are allergic to Xuebijing injection and its components;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. Serious basic diseases affecting survival, including: malignant tumor, hematopathy, HIV, etc;&lt;br&gt;4. Expected death within 48 hours;&lt;br&gt;5. Patients who are participating in other clinical trials;&lt;br&gt;6. The researchers think other reasons are not suitable for clinical trials</Exclusion_Criteria>
    <Condition>Novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:On the basis of routine treatment, add 100ml of normal saline and 50ml of Xuebijing injection twice a day;;Control group:conventional therapy;</Intervention>
    <Primary_outcome>The percentage of patients who convert to moderate one;The rate of shock;Endotracheal intubation ratio;Time spent on the ventilator;mortality;Time of virus nucleic acid test turning negative;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030489</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases</Public_title>
    <Scientific_title>Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-04</Date_registration>
    <Date_registration3>20200304</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50490</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>COVID-2019 patients in Tongji Hospital:250;COVID-2019 patients in Mobile field hospital:250;Medical staff in Tongji Hospital:250;Control:250;</Target_size>
    <Study_type>Epidemilogical research</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xufang Sun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>s_1862777@163.com</Contact_Email>
    <Contact_Tel>+86 18627770651</Contact_Tel>
    <Contact_Affiliation>Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. COVID-19 suspected or confirmed patients: meet the following suspected or confirmed case diagnostic criteria; aged between 18 and 70 years old;&lt;br&gt;1.1 Diagnostic criteria for suspected cases;&lt;br&gt;1.1.1 History of Epidemiology:&lt;br&gt;(1) travel history or residence history within 14 days before the morbidity in Wuhan and its surrounding areas, or in other communities with reported cases;&lt;br&gt;(2) History of contact with new coronavirus infection (positive nucleic acid test) within 14 days before morbidity;&lt;br&gt;(3) Patients with fever or respiratory symptoms from Wuhan and its surrounding areas, or from communities with reported cases, had been contacted within 14 days before the morbidity;&lt;br&gt;(4) Clustered morbidity (2 or more cases of fever and/or respiratory symptoms in a small area such as home, office, school class, etc. Within 2 weeks);&lt;br&gt;1.1.2 Clinical manifestations:&lt;br&gt;(1) Fever and/or respiratory symptoms;&lt;br&gt;(2) Having the above novel coronavirus pneumonia imaging features;&lt;br&gt;(3) In the early stage of morbidity, the total number of white blood cells is normal or reduced, or the number of lymphocytes is normal or reduced;&lt;br&gt;1.1.3 Have any of the epidemiological history, and meet any 2 of the clinical signs. If there was no clear epidemiological history, it was in accordance with the 3 items in the clinical signs;&lt;br&gt;1.2 Diagnostic criteria for confirmed case&lt;br&gt;Suspected cases also have one of the following etiological or serological evidence:&lt;br&gt;(1) Detection of High Homology of Novel Coronavirus by Real-time Fluorescence RT-PCR; &lt;br&gt;(2) Sequencing of the viral genome, which is highly homologous to known novel coronaviruses;&lt;br&gt;(3) Serum specific IgM antibody and IgG antibody of new type coronavirus were positive; the specific IgG antibody of new type coronavirus in serum changed from negative to positive or increased by 4 times or more in recovery stage than in acute stage;&lt;br&gt;2. non-COVID healthy residents: Wuhan residents; non-COVID-2019 patients;&lt;br&gt;3. medical staff: age 18-70 years old and in-service hospital staff.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. COVID-19 suspected or confirmed patients:&lt;br&gt;(1) Those who refuse to cooperate;&lt;br&gt;(2) Pregnant women;&lt;br&gt;(3)Patients with mental disorders and cognitive dysfunction.&lt;br&gt;2. non-COVID healthy residents:&lt;br&gt;(1) Those who refuse to cooperate;&lt;br&gt;(2) Patients with mental disorders and cognitive dysfunction.&lt;br&gt;3. medical staff:&lt;br&gt;(1) Those who refuse to cooperate;&lt;br&gt;(2) non-working staff;&lt;br&gt;(3) Patients with mental disorders and cognitive dysfunction.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>COVID-2019 patients in Tongji Hospital:none;COVID-2019 patients in Mobile field hospital:none;Medical staff in Tongji Hospital:none;Control:none;</Intervention>
    <Primary_outcome>Nuclei acid test of SARS-CoV-2 of conjunctival swab;Nuclei acid test of SARS-CoV-2 of throat swab;Nuclei acid test of SARS-CoV-2 of peripheral blood sample;Eye symptoms;Clinical symptoms;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030484</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Hubei Shiyan Taihe hospital</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50263</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-02</Date_enrollement>
    <Target_size>treatment group1:30;treatment group 2:30;control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jie Luo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>32 Renmin Road South, Shiyan, Hubei, China</Contact_Address>
    <Contact_Email>182190248@qq.com</Contact_Email>
    <Contact_Tel>+86 0719 8801713</Contact_Tel>
    <Contact_Affiliation>Shiyan Taihe hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) The novel coronavirus was detected at the age of 18~70 years when signing the informed consent; (2) the nucleic acid test of the pharyngeal test, sputum, lower respiratory tract secretions, blood and so on (RT-PCR detection of the new coronavirus nucleic acid positive) and the sequencing of the virus gene, which were highly homologous with the known new coronavirus, and confirmed that the 2019-nCoV was detected. Chest X * ray and CT imaging confirmed pneumonia (manifested as pulmonary infiltration, single lung or multiple lung lesions, mainly located in the lung field and subpleural area of the Chinese and foreign countries. Lesions were presented as "mosaic" sign caused by small patch glass, consolidation and coexistence of small nodules, ground glass shadow and air retention). Lung imaging showed significant progress in 24-48 hours. The patients had no improvement or progressive aggravation after standard anti bacteria treatment; ? had fever, fatigue, cough, shortness of breath and other symptoms, because of fever (body temperature = 37.3 ?), respiratory rate &gt; 30 times / min, SpO2 = 93% (quiet, resting state), oxygenation index = 300; ? The total number of leukocytes in the early stage of onset was normal / decreased, or lymphocyte count decreased. C reactive protein and ESR increased, PCT was normal. (6) epidemiological history (two weeks before onset, Hubei or other higher incidence rate of travel history, or contact with persons from above regions, or the removal of other suspected and confirmed cases), the time from onset to less than 14 days. The subjects are willing to be randomly assigned to any designated treatment group; ? on the basis of current routine treatment, the patients are still in progress, fully informed and signed with the patients and their families; ? they must agree not to participate in another study of the drug under study before the 28th day after the completion of the study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: ? Doctors decided that it was not in the best interests of the subjects to participate in the study, or there was any situation that could not follow the agreement safely; ? there was a history of pulmonary embolism; ? there were patients with human immunodeficiency virus (HIV) infection; ? there were severe organ failure; such as severe liver disease (such as child Pugh score = grade C, AST more than 5 times of the upper limit of normal; or severe renal insufficiency (estimated glomerular filtration rate = 30ml / min / 1.73m2) or patients undergoing continuous renal replacement therapy, hemodialysis, peritoneal dialysis; severe shock or other situations that clinicians think are not suitable for use. (Note: due to the newly discovered disease, clinicians can't give up the hope of treatment at will based on the principle of rescuing the dead and supporting the wounded) ? pregnant and lactating women, or positive pregnancy test before medication; ? human immunodeficiency virus (HIV) infected patients; ? Patients with malignant tumors, except those with cervical carcinoma in situ, skin non metastatic squamous or basal cell carcinoma who have been treated completely; ? any experimental treatment for lung injured cells or stem cells within 28 days before screening and evaluation.</Exclusion_Criteria>
    <Condition>Lung injury</Condition>
    <Intervention>treatment group1:HUMSCs: intravenous infusion, 5  10E7 cells / time, once / week, twice / course;treatment group 2:HUMSCs: intravenous infusion, 5  107 cells / time, 1 time / week, 2 times / course, a total of 2 courses;            Exosomes: intravenous administration, 180mg / time, 1 time / day, 7 days / course, 2 courses in total;control group:The control group was given the same amount of placebo (stem cell solvent);</Intervention>
    <Primary_outcome>PaO2 / FiO2 or respiratory rate (without oxygen);Frequency of respiratory exacerbation;Observe physical signs and symptoms and record clinical recovery time;The number and range of lesions indicated by CT and X-ray of lung;Time for cough to become mild or absent;Time for dyspnea to become mild or no dyspnea;Frequency of oxygen inhalation or noninvasive ventilation, frequency of mechanical ventilation;Inflammatory cytokines (CRP / PCT / SAA, etc.);Frequency of serious adverse events;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029550</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Hospital of Chengdu University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-04</Date_registration>
    <Date_registration3>20200204</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48775</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-29</Date_enrollement>
    <Target_size>Experimental group 1 (mild):150;Experimental group 1 (moderate):150;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xie Chunguang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>xcg718@aliyun.com</Contact_Email>
    <Contact_Tel>+86 18980880132</Contact_Tel>
    <Contact_Affiliation>Hospital of Chengdu University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Conform to the western medicine influenza diagnostic criteria&lt;br&gt;2. Conform to the diagnostic criteria of TCM wind-heat clip dampness syndrome&lt;br&gt;3. Over 18 years old</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>influenza</Condition>
    <Intervention>Experimental group 1 (mild):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g,  tid,with warm water;Experimental group 1 (moderate):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, q4hwith warm water;</Intervention>
    <Primary_outcome>CRP;ESR;PCT;Tn;Mb;D-Dimer;blood routine examination;chest CT;creatase;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029549</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Hospital of Chengdu University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-04</Date_registration>
    <Date_registration3>20200204</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49014</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>Experimental group:200;Control group:200;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xie Chunguang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>xcg718@aliyun.com</Contact_Email>
    <Contact_Tel>+86 18980880132</Contact_Tel>
    <Contact_Affiliation>Hospital of Chengdu University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with suspected and confirmed diagnosis of 2019-nCoV Pneumonia Version 4.0 (published at 2020.01.27) of the National Health Commission</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclude patients with severe and critical 2019-nCoV pneumonia</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Western medicine routine treatment combined with traditional Chinese medicine treatment;Control group:Western medicine routine treatment;</Intervention>
    <Primary_outcome>Severe conversion rate;Oxygenation index;2019-nCoV nucleic acid test;Chest CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030564</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)</Public_title>
    <Scientific_title>Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-07</Date_registration>
    <Date_registration3>20200307</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50653</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>18</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-15</Date_enrollement>
    <Target_size>monitor cases, suspected cases and diagnosed cases:120;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yan Hao; Xiaoping Luo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>haoyaner@163.com</Contact_Email>
    <Contact_Tel>+86 13971679960</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: This study intends to select surveillance cases, suspected cases and diagnosed cases of COVID-19 for children aged 0-18 who were admitted to the department of Pediatrics in Tongji Hospital from December 2019 to June 2020.&lt;br&gt;1. Epidemiological classification: all children are divided into three levels: high, medium and low risk according to their epidemiological history:&lt;br&gt;(1) high risk: participant was close to suspected or confirmed case of COVID-19 within 14 days before the onset of illness;&lt;br&gt;(2) intermediate risk: cluster of COVID-19 cases in the place of residence or the community;&lt;br&gt;(3) low risk: The residence or community has no cluster cases or not from epidemic area;&lt;br&gt;2. Surveillance cases: high-risk children who do not show symptoms are surveillance cases, and intermediate or low risk children who have any of the following symptoms are surveillance cases:&lt;br&gt;(1) Fever;&lt;br&gt;(2) Respiratory symptoms or weakness, nausea, vomiting, abdominal discomfort and diarrhea.&lt;br&gt;3. Suspected cases: Newborns born to pregnant women diagnosed with COVID-19 are suspected cases. High-risk children and surveillance cases at intermediate and low risk are suspected cases after excluding influenza (standardized administration of oseltamivir phosphate for 2 days) and other common respiratory pathogen infections who meet any two of the following three conditions are suspected cases:&lt;br&gt;(1) persistent Fever, obvious respiratory symptoms, shortness of breath or decreased pulse oxygen saturation, or gastrointestinal manifestations such as nausea, vomiting, abdominal discomfort and diarrhea;&lt;br&gt;(2) Laboratory tests: normal or decreased white blood cells, decreased lymphocyte count, normal or slightly elevated CRP;&lt;br&gt;(3) pulmonary imaging with signs of COVID-19.&lt;br&gt;4. Confirmed cases: meeting the criteria for suspected cases, positive result on COVID-19 nucleic acid test with samples of respiratory swabs or secretions, blood, feces and urine ; highly homologous viral gene sequencing with known COVID-19.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Exclude influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, boca virus, and other known viral respiratory infections;&lt;br&gt;(2) Exclude pneumonia caused by atypical microorganisms such as  Mycoplasma pneumoniae, Legionella, fungal pneumonia, and tuberculosis;&lt;br&gt;(3) Exclude children with basic diseases who have invasive fungal infections;&lt;br&gt;(4) Exclude children with no clear infectious etiology who have non-infectious diseases such as vasculitis, dermatomyositis, idiopathic interstitial lung disease, and organizing pneumonia;&lt;br&gt;(5) Exclude If the guardian of the child does not agree to sign the informed consent form or collect information.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>monitor cases, suspected cases and diagnosed cases:Provide psychological intervention for children with severe stress response;</Intervention>
    <Primary_outcome>Child Stress Disorders Checklist evaluation;Achenbach children's behavior checklist evaluation;children's severe emotional disorder and psychological crisis during inpatient treatment;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030544</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-06</Date_registration>
    <Date_registration3>20200306</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50134</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Case series:1500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Minghao Fang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>Fangmh@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 15071157405</Contact_Tel>
    <Contact_Affiliation>Emergency / Intensive Care Department of Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Have any of the following epidemiological history: &lt;br&gt;(1) travel history or residence history of Wuhan and surrounding areas, or other communities with case reports within 14 days before the onset of illness; &lt;br&gt;(2) close contact with febrile patients from Wuhan and surrounding areas, or other communities with case reports within 14 days before the onset of illness; &lt;br&gt;(3) Aggressive onset; &lt;br&gt;(4) History of close contact with novel coronavirus infections. People with a novel coronavirus infection are those who test positive for a nucleic acid.&lt;br&gt;2. Have any two of the following clinical manifestations: &lt;br&gt;(1) fever and / or respiratory symptoms; &lt;br&gt;(2) have the above-mentioned imaging characteristics of pneumonia; &lt;br&gt;(3) the total number of white blood cells is normal or decreased in the early stage of onset, or the lymphocyte count is decreased.&lt;br&gt;3. Evidence of any of the following pathogens: &lt;br&gt;(1) Real-time fluorescent RT-PCR of respiratory specimens or blood specimens to detect novel coronavirus nucleic acid is positive; &lt;br&gt;(2) The sequence of genes in the respiratory tract or blood specimens is homologous to known novel coronavirus.&lt;br&gt;Meet the above three cases as confirmed cases and be included in the study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) &lt;14 years of age;&lt;br&gt;2) pregnant women;&lt;br&gt;3) ICU hospital stay &lt;24 hours;&lt;br&gt;4) The necessary clinical information is incomplete.</Exclusion_Criteria>
    <Condition>2019 novel coronavirus pneumonia(COVID-19)</Condition>
    <Intervention>Case series:no;</Intervention>
    <Primary_outcome>in-ICU mortality;mortality of 28 days;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030114</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia(COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Peking University People's Hospital</Primary_sponsor>
    <Date_registration>2020-02-23</Date_registration>
    <Date_registration3>20200223</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49987</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Target condition:150;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhu Fengxue</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>11 Xizhimen Street South, Xicheng District, Beijing, China</Contact_Address>
    <Contact_Email>fxzhu72@163.com</Contact_Email>
    <Contact_Tel>+86 13911005275</Contact_Tel>
    <Contact_Affiliation>Peking University People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with severe cases of newly diagnosed novel coronavirus pneumonia, aged over 18 years old, meeting the diagnostic criteria for confirmed cases and patients with severe and critical types in the sixth edition of the diagnosis and treatment program for novel coronavirus pneumonia.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with severe hemodynamic instability, unfavorable to change body position; Patients with severe deformity of the thorax or massive subcutaneous emphysema that cannot be examined by lung ultrasound; Patients who did not check all 10 points of the BLUE-plus regimen.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia</Condition>
    <Intervention>Gold Standard:Chest CT examination;Index test:Lung&amp;#32;ultrasound&amp;#32;examination;</Intervention>
    <Primary_outcome>Lung ultrasound;Chest computed tomography (CT);Respiratory and oxygenation indicators;Prognostic indicators (length of stay, mortality);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030082</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator             Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Nanchang University</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49915</web_address>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-23</Date_enrollement>
    <Target_size>experimental group:20;control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hong tao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China</Contact_Address>
    <Contact_Email>ht2000@vip.sina.com</Contact_Email>
    <Contact_Tel>+86 13803535961</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Nanchang University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with mild/common novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent form</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The investigator considers that the subject has other conditions that make him/her unsuitable to participate in the clinical trial or other special circumstances.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:dihydroartemisinin piperaquine tablets combined with antiviral treatment.;control group:antiviral treatment was selected as: a-interferon and Ardibdol;</Intervention>
    <Primary_outcome>The time when the nucleic acid of the novel coronavirus turns negative;Conversion to heavy/critical type;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030482</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A Multicenter, Long- term Follow-up and Registration Study for Myocardial Injury and Prognosis of Novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>SARS-CoV-2 Infection on Myocardial Injury and Prognosis: a Multicenter, Long- term Follow-up and Registration Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Peking University First Hospital</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50353</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-06</Date_enrollement>
    <Target_size>Case series:8000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yong Huo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>No.8 Xishiku Street, West city District, Peking</Contact_Address>
    <Contact_Email>drhuoyong@163.com</Contact_Email>
    <Contact_Tel>+86 13901333060</Contact_Tel>
    <Contact_Affiliation>Peking University First Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) All confirmed and diagnosed SARS-CoV-2 infection patients (including the clinical diagnosis case of the New Coronavirus Pneumonia HUBEI) (Fifth Edition)&lt;br&gt;(2) Voluntarily agree to enter the trial and sign the written informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients not suitable for study judged by researchers.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:NA;</Intervention>
    <Primary_outcome>Cardiac injury;Death in hospital and/or Endotracheal Intubation Deaths during hospitalization;Admitted to the ICU;Composite end points of cardiovascular events( nonfatal heart failure, nonfatal myocardial infarction, nonfatal stroke or cardiovascular death);Stroke;Heart failure;Myocardial infarction;Other cardiovascular health related endpoints;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030475</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>The Effect and Safety of cytokine removal therapy in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) adult patients: a Prospective Open-label Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50452</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-04</Date_enrollement>
    <Target_size>Case series:19;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xuemei Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Shuai-Fu-Yuan, Dongcheng District, Beijing, China</Contact_Address>
    <Contact_Email>lixmpumch@126.com</Contact_Email>
    <Contact_Tel>+86 13911467356</Contact_Tel>
    <Contact_Affiliation>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Written informed consent from patients or representative;&lt;br&gt;2. Aged over 18&lt;br&gt;3. Fullfill the diagnostic criteria of critically ill 2019-nCoV Respiratory Disease;&lt;br&gt;2019-nCoV diagnosis confirmed by the combination of epidemiology, clinical manifestation and virus PCR results of respiratory specimen;&lt;br&gt;Critically ill patients should include one of the followings at least:&lt;br&gt;1) respritary failure, mechanical ventilation required;&lt;br&gt;2) shock;&lt;br&gt;3) complicated with other organ failures, require ICU admission.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Respiratory failure explained with other lung conditions, including influenza virus, bacterial infection, fungi infection, non-infectious causes;&lt;br&gt;2. Comorbidities including lupus, vasculitis, APS et al.;&lt;br&gt;3. Concurrent use of anti-IL6 receptor antibody;&lt;br&gt;4. Malignancy;&lt;br&gt;5. Pregnancy;&lt;br&gt;6. there is potential of transfer to other hospital during the trial;&lt;br&gt;7. Other potential conditions determined by the investigators.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:cytokine removal therapy with Cytosorb;</Intervention>
    <Primary_outcome>28 day mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029479</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population</Public_title>
    <Scientific_title>Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Hospital of Chengdu University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-02</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48773</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-30</Date_enrollement>
    <Target_size>Experimental group:10000;blank cntrol group:10000;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Cluster randomization</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Tang Jianyuan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>tangjianyuan163@163.com</Contact_Email>
    <Contact_Tel>+86 13910768464</Contact_Tel>
    <Contact_Affiliation>Hospital of Chengdu University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. No physical discomfort;&lt;br&gt;2. Aged 16 years old and above;&lt;br&gt;3. Take the medicine recommended by this research voluntarily.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: If one of the following situations occurs, it is not recommended to take the traditional Chinese medicine preparation recommended by this plan:&lt;br&gt;(1) Has fever, cough, fatigue, stuffy nose, runny nose, dry throat, thirst, poor stool or diarrhea, little sputum or sputum, chest tightness, abdominal distension, constipation and other discomfort symptoms;&lt;br&gt;(2) Patients with severe primary diseases of the cardiovascular, cerebrovascular, lung, kidney and hematopoietic system;&lt;br&gt;(3) pregnant or lactating women;&lt;br&gt;(4) History of allergy to prescription drugs.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:1. Jinhao Artemisia Antipyretic Granules 8g / time, bid, take it with warm water after meals; 2. Huoxiangzhengqi oral liquid 10ml / time, bid, orally after meals.;blank cntrol group:non-intervention;</Intervention>
    <Primary_outcome>Inccidence of 2019-nCoV pneumonia;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04252274</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV</Public_title>
    <Scientific_title>Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV</Scientific_title>
    <Acronym>DACO-nCoV</Acronym>
    <Primary_sponsor>Shanghai Public Health Clinical Center</Primary_sponsor>
    <Date_registration>29/01/2020</Date_registration>
    <Date_registration3>20200129</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04252274</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>January 30, 2020</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Hongzhou Lu, Ph.D</Contact_Lastname>
    <Contact_Email>luhongzhou@fudan.edu.cn</Contact_Email>
    <Contact_Tel>+86-021-37990333</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The participants were diagnosed as pneumonia caused by 2019-nCoV, according to the&lt;br&gt;             notice on printing and distributing the diagnosis and treatment plan of pneumonia with&lt;br&gt;             new coronavirus infection (trial version 4 or update version) made by National Health&lt;br&gt;             Commission of the People's Republic of China.&lt;br&gt;&lt;br&gt;          -  Written the informed consent&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Hypersensitivity to darunavir, colibrestat, or any excipients&lt;br&gt;&lt;br&gt;          -  Patients with severe liver injury (Child-Pugh Class C)&lt;br&gt;&lt;br&gt;          -  Concomitant medications that are highly dependent on CYP3A clearance, and the elevated&lt;br&gt;             plasma concentrations are associated with serious or life-threatening events.&lt;br&gt;&lt;br&gt;          -  Subjects were considered to be unable to complete the study, or not suitable for the&lt;br&gt;             study by researchers&lt;br&gt;&lt;br&gt;        Exit criteria:&lt;br&gt;&lt;br&gt;          -  Subjects asked to withdraw the study&lt;br&gt;&lt;br&gt;          -  Subject will benefit if withdraw according to researchers' suggestions&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Pneumonia, Pneumocystis;Coronavirus</Condition>
    <Intervention>Drug: Darunavir and Cobicistat</Intervention>
    <Primary_outcome>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030494</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Early risk stratification of the Novel coronavirus infected diseases (COVID-19): a multicenter retrospective study  (ERS-COVID-19 study)</Public_title>
    <Scientific_title>Early risk stratification of the coronavirus disease 2019 (COVID-19): a multicenter retrospective study  (ERS-COVID-19 study)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-03-05</Date_registration>
    <Date_registration3>20200305</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50077</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Novel coronavirus pneumonia:600;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Rui Zeng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan</Contact_Address>
    <Contact_Email>dongze.li@ymail.com</Contact_Email>
    <Contact_Tel>+86 028-85423248</Contact_Tel>
    <Contact_Affiliation>Department of emergency Medicine, West China Hospital, Sichuan University </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;18 years old;&lt;br&gt;2. patients diagnosed COVID-19.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients without complete clinical data;&lt;br&gt;2. Give up treatment and discharge patients automatically.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Novel coronavirus pneumonia:none;</Intervention>
    <Primary_outcome>In-hospital mortality;Hospital mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030493</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected disases (COVID-19)</Public_title>
    <Scientific_title>Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected disases (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Renmin Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-03-04</Date_registration>
    <Date_registration3>20200304</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50547</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-04</Date_enrollement>
    <Target_size>cross-sectional study:1300;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhongyuan Xia</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>238 Jiefang Road, 99 Zhangzhidong Raod, Wuchang, Hubei, China  </Contact_Address>
    <Contact_Email>wenqin-1987@163.com</Contact_Email>
    <Contact_Tel>+86 13808628560</Contact_Tel>
    <Contact_Affiliation>Renmin Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Chinese residents who experienced the noval coronavirus;&lt;br&gt;(2) People aged between 18 and 65 years old;&lt;br&gt;(3) People have electronic social software such as WeChat, QQ and Email.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1)People who complicated with mental illness&lt;br&gt;(2) people who can't use smart phones&lt;br&gt;(3)people who can't recognize or clearly read Chinese characters&lt;br&gt;(4)people who can't understand Chinese characters</Exclusion_Criteria>
    <Condition>sleep disorders</Condition>
    <Intervention>cross-sectional study:no;</Intervention>
    <Primary_outcome>Pittsburgh sleep quality index;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030464</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>The Third Xiangya Hospital, Central South University</Primary_sponsor>
    <Date_registration>2020-03-02</Date_registration>
    <Date_registration3>20200302</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50382</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-03</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Epidemilogical research</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Contact_Firstname>Chengxian Guo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>138 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China</Contact_Address>
    <Contact_Email>gchxyy@163.com</Contact_Email>
    <Contact_Tel>+86 0731-88618338</Contact_Tel>
    <Contact_Affiliation>The Third Xiangya Hospital, Central South University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Novel Coronavirus Pneumonia (COVID-19) patients</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: NO</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Clinical characteristics;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030163</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A Medical Based Retrospective Real World Study for Assessment of Effectiveness of Comprehensive Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>The Real World Study to Evaluate the Added Treatment Effectiveness of Comprehensive Traditional Chinese Medicine for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Tranditional Medicine</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50031</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-25</Date_enrollement>
    <Target_size>Case series:256;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Bin Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>110 Ganhe Road, Hongkou District, Shanghai, China</Contact_Address>
    <Contact_Email>18930568129@163.com</Contact_Email>
    <Contact_Tel>+86 18930568129</Contact_Tel>
    <Contact_Affiliation>Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Tranditional Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Observational study, no inclusion criteria</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Observational study, no exclusion criteria</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:NA;</Intervention>
    <Primary_outcome>cure rate;duration of hospitalization;days of treatment;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029984</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator              Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Guangzhou reborn health management consultation co., LTD</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49712</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Wei Wei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China </Contact_Address>
    <Contact_Email>wwei@chinacord.org</Contact_Email>
    <Contact_Tel>+86 13729856651</Contact_Tel>
    <Contact_Affiliation>Guangzhou reborn health management consultation co., LTD</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with confirmed novel coronavirus-infected pneumonia; &lt;br&gt;2. Voluntarily sign written informed consent.  </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Routine treatment +biological preparation of human placenta;Control group:conventional therapy;</Intervention>
    <Primary_outcome>IFN-gama;TNF-alpha;Blood routine index;Time and rate of coronavirus become negative;immunoglobulin;Exacerbation (transfer to RICU) time;Clearance rate and time of main symptoms (fever, fatigue, cough);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029957</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                         An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The Second Affiliated Hospital Of Xi'an Jiaotong University</Primary_sponsor>
    <Date_registration>2020-02-17</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49633</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-24</Date_enrollement>
    <Target_size>Case series:66;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Gao Dengfeng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>157 Xiwu Road, Xi'an, Shaanxi, China</Contact_Address>
    <Contact_Email>gaomedic@163.com</Contact_Email>
    <Contact_Tel>+86 15091544672</Contact_Tel>
    <Contact_Affiliation>The Second Affiliated Hospital of Xi'an Jiaotong University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged&gt;=18 years old;&lt;br&gt;2. Diagnosed as severe and critical patients with novel coronavirus pneumonia;&lt;br&gt;3. Being treated in the ICU.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Allergic to vitamin C;&lt;br&gt;2. Cardiogenic dyspnea;&lt;br&gt;3. Life expectancy&lt;24h;&lt;br&gt;4. Pregnant and/or lactating female;&lt;br&gt;5. There is a state of tracheotomy or home oxygen therapy in the past;&lt;br&gt;6. Previously complicated with interstitial lung disease, malignant tumors,diffuse alveolar hemorrhage, diabetic ketoacidosis, or an active kidney stone;&lt;br&gt;7. Participating in other clinical trials;&lt;br&gt;8. Researchers believe patients are not suitable for clinical trials for other reasons.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:high-dose Vitamin C+Standard treatment;</Intervention>
    <Primary_outcome>Ventilation-free days;mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030480</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Department of Respiratory and Critical Care Medicine, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50470</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>110</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-03</Date_enrollement>
    <Target_size>Interferon Therapy Group:164;Control group:164;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Huilan Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>huilanz_76@163.com</Contact_Email>
    <Contact_Tel>+86 15391532171</Contact_Tel>
    <Contact_Affiliation>Department of Respiratory and Critical Care Medicine, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 years;&lt;br&gt;2. Clinically diagnosed patients with COVID-19, including: on the basis of meeting the criteria for suspected cases, one of the following etiology evidence:&lt;br&gt;(1) real-time fluorescent RT-PCR detection of SARS-Cov-2 nucleic acid samples in respiratory or blood samples;&lt;br&gt;(2) Sequencing of viral genes in respiratory specimens or blood specimens, highly homologous to known SARS-Cov-2;&lt;br&gt;3. The interval between the onset of symptoms and random enrollment is within 7 days. The onset of symptoms is mainly based on fever. Cough, diarrhea or other related symptoms can be used for the evidence of onset symptoms if without fever.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Any situation where the programme cannot be carried out safely;&lt;br&gt;2. Patients who have used interferon or remedesivir;&lt;br&gt;3. No clinical manifestations and chest imaging findings;&lt;br&gt;4. Known allergy or hypersensitivity to interferon (including asthma);&lt;br&gt;5. Disabled in patients with uncontrolled autoimmune diseases;&lt;br&gt;6. Patients with severe heart disease, decompensated liver disease, renal insufficiency (CrCL &lt;50ml / min), and those with abnormal bone marrow function are prohibited;&lt;br&gt;7. Epilepsy and impaired central nervous system function;&lt;br&gt;8. Pregnancy: Positive pregnancy test for women of childbearing age;&lt;br&gt;9. Breastfeeding women have not stopped breastfeeding;&lt;br&gt;10. The patient may be transferred to a non-participating hospital within 72 hours.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Interferon Therapy Group:Standard treatment + cerrokin (recombinant human interferon alpha 1beta) 10UG BID is administered by nebulization for 10 days.;Control group:Standard treatment + blank;</Intervention>
    <Primary_outcome>Incidence of side effects;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030479</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50450</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-26</Date_enrollement>
    <Target_size>Control group:50;Experimental group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhijun Fang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>100 Cross Street, Hongshan Road, Nanjing, Jiangsu, China</Contact_Address>
    <Contact_Email>fangzjnj@hotmail.com</Contact_Email>
    <Contact_Tel>+86 13372018676</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Confirmed or clinically diagnosed patients with the novel coronavirus disease;&lt;br&gt;2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung;&lt;br&gt;3) Inpatients aged 18 to 75 years male or female;&lt;br&gt;4) Volunteer to receive treatment under their own scheme and sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Patients with mild, severe or critical novel coronavirus disease;&lt;br&gt;2) According to the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, severe malnutrition, liver and kidney disease, blood disease, nervous system Diseases and endocrine diseases; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;&lt;br&gt;3) Those who are allergic to the research drug and its main ingredients;&lt;br&gt;4) pregnant or lactating women;&lt;br&gt;5) Those who have difficulty taking medicine orally.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:Refer to the National Health Office Medical Letter (2020) 77 document "Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)" general treatment plan.;Experimental group:Refer to the National Health Office Medical Letter (2020) 77 document "Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)" general treatment plan. Based on the general treatment plan of western medicine + Yiqi Huashi Jiedu Fang (same as above), decoction of decoction machine, 300mL;</Intervention>
    <Primary_outcome>lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029993</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A pilot study for Integrated Chinese and Western Medicine in the treatment of non-critical novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multicenter, randomized, open-label, parallel controlled trial for the safety and efficacy of Integrated Chinese and Western Medicine in treatment of non-critical novel coronavirus pneumonia (COVID-19): pilot study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Guangzhou Medical University</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49435</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>group A:20;control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ye Feng/ Yang Zifeng/ Xu Xuyan/ Zhu Jun/ Jiang Lihong/ Zhang Yunhui/ Yuan Bing/ Chen Shi/ Fan Jie</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>yefeng@gird.cn</Contact_Email>
    <Contact_Tel>+86 13710494278; +86 13622273918</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Guangzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged&gt;= 18, male or female;&lt;br&gt;2. Fever, axillary temperature &gt; 37.3 degrees;&lt;br&gt;3. Consistent with the clinical diagnosis of COVID-19 mild, normal, severe case;&lt;br&gt;4. Patients who sign informed consent form freely and voluntarily.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Critical case with the following situation:&lt;br&gt; i. Patients with respiratory failure and needing mechanical ventilation;&lt;br&gt; ii. Patients with shock;&lt;br&gt; iii. Patients with other organ failures and needing ICU monitoring and treatment;&lt;br&gt;2. Patients who have other respiratory tract infection;&lt;br&gt;3. Patients used Liu Shen Capsule  within 1 month before screening;&lt;br&gt;4. Allergic constitution patients, who are allergic to the drugs used in this research;&lt;br&gt;5. Lactating or pregnant females, or urine pregnancy test was positive or did not agree to use contraception 3 months after the trial;&lt;br&gt;6. Immunodeficiency (such as a malignant tumor, solid organ or bone marrow transplant, aids, using immunosuppressive drugs within 3 months before screening);&lt;br&gt;7. Severe liver insufficiency (ALT or AST &gt; 5ULN, or ALT or AST &gt; 3ULN with BIL &gt; 3ULN); Severe renal insufficiency (Ccr &lt; 50ml/min, estimated by Scr);&lt;br&gt;8. Patients who do-not-resuscitate;&lt;br&gt;9. The researchers consider the patients are not suitable.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>group A:Arbidol Hydrochloride Tablets, Liushen Capsule, standard therapy;control group:standard therapy;</Intervention>
    <Primary_outcome>Main symptom relief time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029638</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of 2019 Novel Coronavirus (2019-nCoV) Infected Pneumonia</Public_title>
    <Scientific_title>A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-02-08</Date_registration>
    <Date_registration3>20200208</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49224</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-03</Date_enrollement>
    <Target_size>Treatment group:50;Control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lunxu Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>No.37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, 610041, P.R China</Contact_Address>
    <Contact_Email>lunxu_liu@aliyun.com</Contact_Email>
    <Contact_Tel>+86 18980601525</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Aged 18 to 75 years old;&lt;br&gt;(2) Real-time fluorescent RT-PCR for respiratory or blood specimens to detect novel coronavirus nucleic acid positive;&lt;br&gt;(3) The sequence of virus genes in respiratory or blood samples was highly homologous with the known novel coronavirus;&lt;br&gt;(4) According to the "Pneumonitis Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Fifth Edition)", the common patients diagnosed with novel coronavirus pneumonia that have fever, respiratory symptoms, and imaging shows pneumonia.&lt;br&gt;(5) Some severe patients could be included. Accord with any of the following: ? Respiratory distress, RR = 30 times / minute; ? In resting state, means oxygen saturation = 93%; ? Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) = 300mmHg.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Combining basic diseases such as hypertension, diabetes, and coronary heart disease,which were judged unsuitable for inclusion in the trial by researchers.&lt;br&gt;(2) Malignant tumor or with a history of malignant tumor;&lt;br&gt;(3) pregnant or lactating women;&lt;br&gt;(4) suffer from severe mental illness;&lt;br&gt;(5) History of unstable angina pectoris or myocardial infarction within 6 months; coronary angiography suggested severe stenosis of the main branches of the coronary arteries;&lt;br&gt;(6) History of cerebral infarction or cerebral hemorrhage within 6 months;&lt;br&gt;(7) People who are intolerant or allergic to interferon preparations;&lt;br&gt;(8)Other patients  were judged unsuitable for inclusion in the trial by researchers.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Treatment group:nebulization of recombinant super-compound interferon (rSIFN-co);Control group:nebulization of  interferon a;</Intervention>
    <Primary_outcome>Clinical symptoms;Blood routine;Biochemical and myocardial enzymes;C-reactive protein;Erythrocyte sedimentation rate;Inflammatory cytokines;Chest CT;Etiology Inspection;Vital signs;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029817</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                    Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Guangzhou reborn health management consultation co., LTD</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49384</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>High dose group:20;Conventional dose group:20;Preventive dose group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Chao Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China </Contact_Address>
    <Contact_Email>164972769@qq.com</Contact_Email>
    <Contact_Tel>+86 15018720816</Contact_Tel>
    <Contact_Affiliation>Guangzhou reborn health management consultation co., LTD</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;&lt;br&gt;2. Voluntarily sign written informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (NCP)</Condition>
    <Intervention>High dose group:High-dose NK cells (&gt;5x10^9)and mesenchymal stem cells(&gt;5x10^9),Intravenous infusion once every two days for a total of five times;Conventional dose group:Conventional dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every two days for a total of three times;Preventive dose group:Preventive dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every week for a total of one time;</Intervention>
    <Primary_outcome>Time to disease recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029812</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator               Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Guangzhou reborn health management consultation co., LTD</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49374</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Chao Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>164972769@qq.com</Contact_Email>
    <Contact_Tel>+86 15018720816</Contact_Tel>
    <Contact_Affiliation>Guangzhou reborn health management consultation co., LTD </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;&lt;br&gt;2. Voluntarily sign written informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional treatment followed by Intravenous infusion of  Umbilical Cord Blood Mononuclear Cells preparations;Control group:Conventional treatment;</Intervention>
    <Primary_outcome>Time to disease recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04254874</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia</Public_title>
    <Scientific_title>An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tongji Hospital</Primary_sponsor>
    <Date_registration>02/02/2020</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04254874</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 1, 2020</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). </Study_design>
    <Phase>Phase 4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Qing Ning, Professor;Qin Ning, professor</Contact_Lastname>
    <Contact_Email>qning@vip.sina.com;qning@vip.sina.com</Contact_Email>
    <Contact_Tel>+8613971521450;</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        1)2019-nCoV nucleic acid test was positive. 2)CT of the lung conformed to the manifestation&lt;br&gt;        of viral pneumonia.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients who meet any of the contraindications in the experimental drug labeling&lt;br&gt;&lt;br&gt;          2. Patients who do not want to participate in this clinical study&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV</Condition>
    <Intervention>Drug: Abidol hydrochloride;Drug: Abidol Hydrochloride combined with Interferon atomization</Intervention>
    <Primary_outcome>Rate of disease remission;Time for lung recovery</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04278963</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19</Public_title>
    <Scientific_title>Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19</Scientific_title>
    <Acronym />
    <Primary_sponsor>China Academy of Chinese Medical Sciences</Primary_sponsor>
    <Date_registration>19/02/2020</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04278963</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 27, 2020</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). </Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Wei Zhang;Jiang-Rong Huang, M.D.;Xiao-Dong Li, M.D.</Contact_Lastname>
    <Contact_Email>;;</Contact_Email>
    <Contact_Tel>;;</Contact_Tel>
    <Contact_Affiliation>Jingzhou Hospital of Traditional Chinese Medicine;Yangtze University Health Science Center;Hubei Hospital of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age =18 years at time of signing Informed Consent Form.&lt;br&gt;&lt;br&gt;          2. Laboratory (RT-PCR) confirmed infection with CoVID-19.&lt;br&gt;&lt;br&gt;          3. Hospitalised with Fever(=36.7? -axilla or oral temperature = 38.0 ? or =38.6C&lt;br&gt;             tympanic or rectal) and cough;&lt;br&gt;&lt;br&gt;          4. No difficulty swallowing oral medications.&lt;br&gt;&lt;br&gt;          5. Must agree not to enroll in another study of an investigational agent prior to&lt;br&gt;             completion of Day 28 of study.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Allergies, known to be allergic to research drugs or drug excipients;&lt;br&gt;&lt;br&gt;          2. Patient weight is less than 40 kg;&lt;br&gt;&lt;br&gt;          3. Respiratory distress-RR=30 / min on room air,or SPO2= 93%, or PaO2/FiO2 =300mmHg&lt;br&gt;             (1mmHg = 0.133kPa)&lt;br&gt;&lt;br&gt;          4. Shock;&lt;br&gt;&lt;br&gt;          5. The clinician judges that ICU monitoring treatment is needed;&lt;br&gt;&lt;br&gt;          6. Patients who have participated in other clinical trials within 1 month;&lt;br&gt;&lt;br&gt;          7. Known patients with impaired renal function (estimated creatinine clearance &lt;60 mL /&lt;br&gt;             min (male: Cr (ml / min) = (140-age)  body weight (kg) / 72  blood creatinine&lt;br&gt;             concentration (mg / dl); female: Cr (ml / min) = (140-age)  weight (kg) / 85  blood&lt;br&gt;             creatinine concentration (mg / dl));&lt;br&gt;&lt;br&gt;          8. During the screening or within 24 hours before screening, patients were found to have&lt;br&gt;             any of the following laboratory parameter abnormalities (based on local laboratory&lt;br&gt;             reference range):-ALT or AST level&gt; 5 times the upper limit of normal range (ULN)&lt;br&gt;             or-ALT or AST &gt; 3 times ULN and total bilirubin levels&gt; 2 times ULN;&lt;br&gt;&lt;br&gt;          9. Being pregnant or breastfeeding, or having a positive pregnancy test at the time of&lt;br&gt;             pre-dose inspection, or planning to become pregnant within 3 months of study&lt;br&gt;             treatment.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>CoVID-19;Chinese Medicine</Condition>
    <Intervention>Drug: YinHu QingWen Decoction;Drug: YinHu QingWen Decoction (low dose);Other: Chinese medicine treatment;Other: standard western medicine treatment</Intervention>
    <Primary_outcome>Mean clinical recovery time (hours)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04280705</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Adaptive COVID-19 Treatment Trial</Public_title>
    <Scientific_title>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</Primary_sponsor>
    <Date_registration>20/02/2020</Date_registration>
    <Date_registration3>20200220</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04280705</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>99 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 21, 2020</Date_enrollement>
    <Target_size>394</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). </Study_design>
    <Phase>Phase 2</Phase>
    <Countries>United States;Korea, Republic of;United States</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>John Herbert Beigel</Contact_Lastname>
    <Contact_Email>jbeigel@niaid.nih.gov</Contact_Email>
    <Contact_Tel>13014519881</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Subject (or legally authorized representative) provides written informed consent prior&lt;br&gt;             to initiation of any study procedures.&lt;br&gt;&lt;br&gt;          2. Understands and agrees to comply with planned study procedures.&lt;br&gt;&lt;br&gt;          3. Agrees to the collection of oropharyngeal (OP) swabs and venous blood per protocol.&lt;br&gt;&lt;br&gt;          4. Male or non-pregnant female adult &gt;/=18 years of age at time of enrollment.&lt;br&gt;&lt;br&gt;          5. Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by&lt;br&gt;             polymerase chain reaction (PCR), or other commercial or public health assay in any&lt;br&gt;             specimen &lt; 72 hours prior to randomization.&lt;br&gt;&lt;br&gt;          6. Illness of any duration, and at least one of the following:&lt;br&gt;&lt;br&gt;               -  Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR&lt;br&gt;&lt;br&gt;               -  Clinical assessment (evidence of rales/crackles on exam) AND SpO2 &lt;/= 94% on room&lt;br&gt;                  air, OR&lt;br&gt;&lt;br&gt;               -  Requiring mechanical ventilation and/or supplemental oxygen.&lt;br&gt;&lt;br&gt;          7. Women of childbearing potential must agree to use at least one primary form of&lt;br&gt;             contraception for the duration of the study (acceptable methods will be determined by&lt;br&gt;             the site).&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Alanine transaminase/aspartate transaminase (ALT/AST) &gt; 5 times the upper limit of&lt;br&gt;             normal.&lt;br&gt;&lt;br&gt;          2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated glomerular&lt;br&gt;             filtration rate (eGFR) &lt; 30)&lt;br&gt;&lt;br&gt;          3. Pregnancy or breast feeding.&lt;br&gt;&lt;br&gt;          4. Anticipated transfer to another hospital which is not a study site within 72 hours.&lt;br&gt;&lt;br&gt;          5. Allergy to any study medication.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Corona Virus Infection</Condition>
    <Intervention>Other: Placebo;Drug: Remdesivir</Intervention>
    <Primary_outcome>Percentage of subjects reporting each severity rating on the 7-point ordinal scale</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030477</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>oXiris Membrane in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>The Effect and Safety of oXiris Membrane Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19): a Single Center Prospective Open-label Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50458</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-04</Date_enrollement>
    <Target_size>Case series:19;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xuemei Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Shuai-Fu-Yuan,  Dongdan, Dongcheng District, Beijing, China</Contact_Address>
    <Contact_Email>lixmpumch@126.com</Contact_Email>
    <Contact_Tel>+86 13911467356</Contact_Tel>
    <Contact_Affiliation>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Written informed consent from patients or representative;&lt;br&gt;2. Aged over 18 years;&lt;br&gt;3. Fullfill the diagnostic criteria of critically ill 2019-nCoV Respiratory Disease;&lt;br&gt;2019-nCoV diagnosis confirmed by the combination of epidemiology, clinical manifestation and virus PCR results of respiratory specimen;&lt;br&gt;Critically ill patients should include one of the followings at least:&lt;br&gt;1) respritary failure, mechanical ventilation required;&lt;br&gt;2) shock;&lt;br&gt;3) complicated with other organ failures, require ICU admission.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Respiratory failure explained with other lung conditions, including influenza virus, bacterial infection, fungi infection, non-infectious causes;&lt;br&gt;2. Comorbidities including lupus, vasculitis, APS et al.&lt;br&gt;3. Concurrent use of anti-IL6 receptor antibody;&lt;br&gt;4. Malignancy;&lt;br&gt;5. Pregnancy;&lt;br&gt;6. Potential tranfer to other hospital during the trial;&lt;br&gt;7. Other potential conditions determined by the investigators.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:oXiris membrane;</Intervention>
    <Primary_outcome>28 day mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030436</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Application of flash glucose monitoring to evaluate the effect of blood glucose changes on prognosis in patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Application of flash glucose monitoring to evaluate the effect of hyperglycemia and glycemic variability on prognosis in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Shanghai Sixth People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50297</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-06</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>ZHOU JIAN</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>600 Yishan Road, Xuhui District, Shanghai, China </Contact_Address>
    <Contact_Email>zhoujian@sjtu.edu.cn</Contact_Email>
    <Contact_Tel>+86 18930172033</Contact_Tel>
    <Contact_Affiliation>Shanghai Sixth People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. patient with novel coronavirus pneumonia (including nucleic acid positive case or clinically diagnosed case);&lt;br&gt;2. patients with type 2 diabetes;&lt;br&gt;3. Aged between 18-80 years old;&lt;br&gt;4. With effective flash glucose monitoring data.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.diabetic ketoacidosis, hyperosmolar hyperglycemic status, or severe recurrent hypoglycemia occurred within 3 months;&lt;br&gt;2.previous history of cardiovascular disease, malignant tumor, mental illness or severe liver and kidney dysfunction.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>time in range;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029579</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>The investigation of cytokine expression profile of novel coronavirus pneumonia (COVID-19) and its clinical significance</Public_title>
    <Scientific_title>The investigation of cytokine expression profile of novel coronavirus pneumonia (COVID-19) and its clinical significance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-05</Date_registration>
    <Date_registration3>20200205</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49045</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-31</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jianfeng Zhou</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>zhougene@medmail.com.cn</Contact_Email>
    <Contact_Tel>+86 027-83665506</Contact_Tel>
    <Contact_Affiliation>Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.No age restriction.&lt;br&gt;2. Clinically confirmed 2019-nCoV infected patients.&lt;br&gt;3. Patients with willingness and ability to sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients without any clinical and chest radiographic findings.&lt;br&gt;2. Patients not providing written informed consent.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Cytokines;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029433</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Hebei Yiling Hospital?Renmin Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-01</Date_registration>
    <Date_registration3>20200201</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48898</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Routine treatment + Lianhua Qingwen Capsules/granules:120;Conventional treatment:120;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhong Nanshan/Zhang Boli/Li Lanjuan/Duan Zhongping/Li Xingwang/Liu Qingquan/Song Yuanlin/Jia Zhenhua</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>385 North Xinshi Road, Qiaoxi District, Shijiazhuang, Hebei, China</Contact_Address>
    <Contact_Email>jiactm@163.com</Contact_Email>
    <Contact_Tel>+86 0311-83855881</Contact_Tel>
    <Contact_Affiliation>Shijiazhuang Yiling Pharmaceutical Co., Ltd.</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Those who meet the diagnostic criteria for suspected cases in the diagnosis and treatment scheme;&lt;br&gt;2. Over 18 years old (including 18 years old), male or female;&lt;br&gt;3. At the time of enrollment, the patient had any of the main symptoms (fever, cough, fatigue);&lt;br&gt;4. Voluntarily sign a written informed consent before the study begins.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Respiratory tract infection caused by primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory tract malformation, congenital heart disease, gastroesophageal reflux disease, abnormal lung development and other basic diseases, with clear evidence of bacterial infection;&lt;br&gt;2. Subjects with the following conditions: daily treatment of asthma, any other chronic respiratory diseases, respiratory bacterial infections such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media and other respiratory diseases that affect clinical trial evaluation.Chest CT confirmed the existence of severe pulmonary interstitial lesions, bronchiectasis and other basic pulmonary diseases;&lt;br&gt;3. Severe pneumonia requiring mechanical ventilation;&lt;br&gt;4. In the judgment of the investigator, the previous or current diseases may affect the patient's participation in the trial or the outcome of the study, including malignant diseases, autoimmune diseases, liver and kidney diseases, blood diseases, nervous system diseases, and endocrine diseases;The patient is suffering from serious diseases that affect the immune system, such as human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc.;&lt;br&gt;5. Pregnant or lactating women;&lt;br&gt;6. Patients who participated in other clinical trials within the last 3 months;&lt;br&gt;7. Allergic constitution, such as a history of allergy to two or more drugs or food, or a known allergy to the ingredients of the drug;&lt;br&gt;8. The investigator considers that there are any factors that are inappropriate for inclusion or affect the evaluation of the efficacy.</Exclusion_Criteria>
    <Condition>suspected novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan;</Intervention>
    <Primary_outcome>Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029958</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for the clinical characteristics of anesthesia novel coronavirus pneumonia (COVID-19) patients during perioperative period and assessment of infection and mental health of Anesthesiology Department</Public_title>
    <Scientific_title>A medical records based study for the clinical characteristics of anesthesia novel coronavirus pneumonia (COVID-19) patients during perioperative period and assessment of infection and mental health of Anesthesiology Department                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Department of Anesthesiology, Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-02-17</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49635</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>99</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>patient group:200;Health care team:60;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zongze Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>zhangzz@whu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13971687403</Contact_Tel>
    <Contact_Affiliation>Zhongnan Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Confirmed and suspected patients undergoing new crown anesthesia;&lt;br&gt;2. Medical staff of anesthesiology department contacted with patients suspected of new crown in operating room;&lt;br&gt;3. Voluntary participation in the test and signing of informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. General anesthesia surgery patients;&lt;br&gt;2. Medical staff with contact history outside the operating room.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>patient group:Under surgical and anesthesia;Health care team:Anesthesiologists for NCP patients;</Intervention>
    <Primary_outcome>CT image of lung;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029757</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial</Public_title>
    <Scientific_title>Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>China-Japan friendship hospital</Primary_sponsor>
    <Date_registration>2020-02-12</Date_registration>
    <Date_registration3>20200212</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49081</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>-</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>Experimental group:100;Control group:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Cao Bin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Cherry Blossom Garden East Street, Chaoyang District, Beijing </Contact_Address>
    <Contact_Email>caobin_ben@163.com</Contact_Email>
    <Contact_Tel>13911318339</Contact_Tel>
    <Contact_Affiliation>China-Japan friendship hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. The patient signed an informed consent form to participate in the study of convalescent plasma therapy;&lt;br&gt;2.The age of the patient is 18 or more than18 years old;&lt;br&gt;3. COVID-19 patients diagnosed by PCR;&lt;br&gt;4. Nucleic acid positive within 72 hours before blood transfusion;&lt;br&gt;5. Pneumonia confirmed by imaging;&lt;br&gt;6. The clinical symptoms reach the standard of severe or critical.&lt;br&gt;Severe patients meet any of the following:&lt;br&gt;a) respiratory distress, RR = 30 beats / min;&lt;br&gt;b) in resting state, oxygen saturation = 93%;&lt;br&gt;c) partial pressure of oxygen in arterial blood (PaO2) / oxygen concentration (FiO2) &lt;br&gt;= 300mmHg (1mmHg=0.133kPa)&lt;br&gt;Critically ill patients meet any of the following:&lt;br&gt;a) respiratory failure and need mechanical ventilation;&lt;br&gt;b) shock;&lt;br&gt;c) patients with other organ failure need ICU monitoring treatment.&lt;br&gt;7. Accept random grouping into any group;&lt;br&gt;8. The patient was hospitalized before the end of the clinical study.&lt;br&gt;9. Willing to participate in all necessary research directions and be able to participate in follow-up;&lt;br&gt;10. During the period of participating in this study, they will no longer participate in clinical trials such as other antiviral drugs.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.The doctor believes that the patient is not suitable to participate in this trial, including those who may not cooperate, do not comply with the requirements of the procedure, or participate in this trial may put the patient in an unsafe situation.&lt;br&gt;2.Pregnant or lactation periods women;&lt;br&gt;3.Immunoglobulin allergy;&lt;br&gt;4.Immunoglobulin A deficiency;&lt;br&gt;5.There are diseases that may increase the risk of thrombosis, such as cold globulinemia, severe refractory hypertriglyceridemia, clinically defined monoclonal gamma globulinemia, etc.&lt;br&gt;6.High titer of anti-novel coronavirus antibody RBDIgG (higher than 1) could be detected.&lt;br&gt;7.Received any experimental treatment for novel coronavirus infection within 30 days before screening;&lt;br&gt;8.The researchers judged that the patients had the following life-threatening conditions, including, but not limited to, Phammer F &lt; 100mmHg, near-death state or expected survival time less than 24 hours, severe septic shock or disseminated intravascular coagulation ((DIC)), etc&lt;br&gt;9.Severe congestive heart failure, or other relative contraindications for plasma transfusion determined by researchers.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional treatment and convalescent plasma therapy;Control group:Conventional treatment;</Intervention>
    <Primary_outcome>the number of days between randomised grouping and clinical improvement;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04292899</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19)</Public_title>
    <Scientific_title>A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe COVID-19</Scientific_title>
    <Acronym />
    <Primary_sponsor>Gilead Sciences</Primary_sponsor>
    <Date_registration>28/02/2020</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04292899</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 6, 2020</Date_enrollement>
    <Target_size>400</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 3</Phase>
    <Countries>United States;Korea, Republic of;United States</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Gilead Study Director;Gilead Clinical Study Information Center</Contact_Lastname>
    <Contact_Email>;GileadClinicalTrials@gilead.com</Contact_Email>
    <Contact_Tel>;1-833-445-3230 (GILEAD-0)</Contact_Tel>
    <Contact_Affiliation>Gilead Sciences;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Key Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Willing and able to provide written informed consent prior to performing study&lt;br&gt;             procedures&lt;br&gt;&lt;br&gt;          -  Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by&lt;br&gt;             polymerase chain reaction (PCR) test = 4 days before randomization&lt;br&gt;&lt;br&gt;          -  Currently hospitalized with fever defined as temperature = 36.6 C armpit, = 37.2 C&lt;br&gt;             oral, or = 37.8 C rectal&lt;br&gt;&lt;br&gt;          -  Peripheral capillary oxygen saturation (SpO2) = 94% on room air at screening&lt;br&gt;&lt;br&gt;          -  Radiographic evidence of pulmonary infiltrates&lt;br&gt;&lt;br&gt;        Key Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Participation in any other clinical trial of an experimental treatment for COVID-19&lt;br&gt;&lt;br&gt;          -  Concurrent treatment with other agents with actual or possible direct acting antiviral&lt;br&gt;             activity against SARS-CoV-2 is prohibited &lt; 24 hours prior to study drug dosing&lt;br&gt;&lt;br&gt;          -  Evidence of multiorgan failure&lt;br&gt;&lt;br&gt;          -  Requiring mechanical ventilation at screening&lt;br&gt;&lt;br&gt;          -  Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 X upper limit&lt;br&gt;             of normal (ULN)&lt;br&gt;&lt;br&gt;          -  Creatinine clearance &lt; 50 mL/min&lt;br&gt;&lt;br&gt;        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Drug: Remdesivir;Drug: Standard of Care</Intervention>
    <Primary_outcome>Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04302688</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Accurate Classification System for Patients With COVID-19 Pneumonitis</Public_title>
    <Scientific_title>Accurate Classification System for Patients With COVID-19 Based on Prognostic Nomogram</Scientific_title>
    <Acronym />
    <Primary_sponsor>Renmin Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>07/03/2020</Date_registration>
    <Date_registration3>20200307</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04302688</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>December 10, 2019</Date_enrollement>
    <Target_size>669</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Qiong Gong, MD.</Contact_Lastname>
    <Contact_Email />
    <Contact_Tel />
    <Contact_Affiliation>Renmin Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients with novel coronavirus pneumonia should be examined and diagnosed by CT and&lt;br&gt;             swab test of viral nucleic acid.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients who should have died during the course of the disease, but the cause of death&lt;br&gt;             was unrelated to viral pneumonia.&lt;br&gt;&lt;br&gt;          -  Suspected patient review refers to the negative nucleic acid test.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Pneumonitis</Condition>
    <Primary_outcome>survival status</Primary_outcome>
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04306393</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Nitric Oxide Gas Inhalation for SARS-CoV-2</Public_title>
    <Scientific_title>Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by 2019-nCoV</Scientific_title>
    <Acronym>NOSARSCoV2</Acronym>
    <Primary_sponsor>Massachusetts General Hospital</Primary_sponsor>
    <Date_registration>10/03/2020</Date_registration>
    <Date_registration3>20200310</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04306393</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>99 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 10, 2020</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). </Study_design>
    <Phase>Phase 2</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Lorenzo Berra, MD</Contact_Lastname>
    <Contact_Email>lberra@mgh.harvard.edu</Contact_Email>
    <Contact_Tel>+16176437733</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  &gt;/= 18 years old&lt;br&gt;&lt;br&gt;          -  ICU admission&lt;br&gt;&lt;br&gt;          -  Intubation and mechanical ventilation&lt;br&gt;&lt;br&gt;          -  Positivity of 2019-nCoV rt-PCR&lt;br&gt;&lt;br&gt;          -  PaO2/FiO2 ratio &lt; 300 mmHg&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  patients intubated for 72 hours or more from initiation of the treatment gas&lt;br&gt;&lt;br&gt;          -  physician being contrary to the involvement as participating in the trial is not in&lt;br&gt;             the patient's best interest, or any condition that does not allow the protocol to be&lt;br&gt;             followed safely&lt;br&gt;&lt;br&gt;          -  pregnancy&lt;br&gt;      </Inclusion_Criteria>
    <Condition>SARS (Severe Acute Respiratory Syndrome);Coronavirus</Condition>
    <Intervention>Drug: Nitric Oxide Gas</Intervention>
    <Primary_outcome>Change of arterial oxygenation at 48 hours from enrollment</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04307459</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Acute Respiratory Failure and SARS-CoV-2 Infection in Real Life</Public_title>
    <Scientific_title>Acute Respiratory Failure and CPAP Therapy in Patients With SARS-CoV-2 Infection: a Real Life Evaluation</Scientific_title>
    <Acronym />
    <Primary_sponsor>University of Milan</Primary_sponsor>
    <Date_registration>10/03/2020</Date_registration>
    <Date_registration3>20200310</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04307459</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 19, 2020</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>Italy</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Pierachille Santus, MD, PhD;Pierachille Santus, MD, PhD</Contact_Lastname>
    <Contact_Email>pierachille.santus@unimi.it;pierachille.santus@unimi.it</Contact_Email>
    <Contact_Tel>+390239042801;0239042801</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Patients that can give written or oral informed consent&lt;br&gt;&lt;br&gt;          -  patients with microbiological diagnosis (i.e. rhinopharingeal swab) of SARS-CoV2&lt;br&gt;             infection&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  severe cognitive impairment&lt;br&gt;&lt;br&gt;          -  absolute controindication to non invasive ventilation or cpap therapy&lt;br&gt;&lt;br&gt;          -  rhinopharingeal swab negative for SARS-CoV2&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus Infections;Respiratory Failure;Ventilator Lung</Condition>
    <Intervention>Other: standard operating procedures</Intervention>
    <Primary_outcome>Real life data of COVID19 infection</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029308</TrialID>
    <Last_Refreshed_on>9 March 2020</Last_Refreshed_on>
    <Public_title>A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with 2019-nCoV infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)</Primary_sponsor>
    <Date_registration>2020-01-23</Date_registration>
    <Date_registration3>20200123</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=48684</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-10</Date_enrollement>
    <Target_size>intervention group:80;Control group:80;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Dingyu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Yintan Road, Dongxihu District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>1813886398@qq.com</Contact_Email>
    <Contact_Tel>13507117929</Contact_Tel>
    <Contact_Affiliation>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Adult aged &gt;=18years old;&lt;br&gt;2. Patients infected with new coronavirus confirmed by PCR&lt;br&gt;3. In the state of no oxygen at rest, the patient's SPO2&lt;=94% or the oxygenation index is less than 300mmHg.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Any situation that makes the programme cannot proceed safely;&lt;br&gt;2. Known allergy or hypersensitivity reaction to lopinavir / ritonavir;&lt;br&gt;3. Increase in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is more than 5 times the upper limit of normal;&lt;br&gt;4. Use of medications that are contraindicated with lopinavir / ritonavir and that cannot be replaced or stopped during the study period, such as CYP3A inhibitors;&lt;br&gt;5. Pregnancy: positive pregnancy test for women of childbearing age;&lt;br&gt;6. Known HIV infection, because of concerns about the development of resistance to lopinavir/rionavir if used without combination with other anti-HIV drugs;&lt;br&gt;7. Patient likely to be transferred to a non-participating hospital within 72 hours;&lt;br&gt;8. Researchers consider unsuitable.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>intervention group:Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and  50 mg of ritonavir), twice a day, 2 tablets at a time;Control group:Conventional standardized treatment;</Intervention>
    <Primary_outcome>Clinical improvement time of 28 days after randomization;The 7-point scale;7 points: death;6 points: admission to ECMO and / or mechanical ventilation;5 points: Hospitalized for non-invasive ventilation and / or high-flow oxygen therapy;4 points: hospitalization for oxygen therapy;3 points: Hospitalization does not require oxygen therapy;2 points: discharged but not restored to normal functional status;1 point: discharged to normal function;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04263402</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia</Public_title>
    <Scientific_title>An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tongji Hospital</Primary_sponsor>
    <Date_registration>02/02/2020</Date_registration>
    <Date_registration3>20200202</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04263402</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 1, 2020</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). </Study_design>
    <Phase>Phase 4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Qing Ning, Professor;Qin Ning, professor</Contact_Lastname>
    <Contact_Email>qning@vip.sina.com;qning@vip.sina.com</Contact_Email>
    <Contact_Tel>+8613971521450;</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        1.Meet the definition of severe pneumonia(Comply with any of the followings):&lt;br&gt;&lt;br&gt;          1. Shortness of breath,RR=30 bpm;&lt;br&gt;&lt;br&gt;          2. In a resting state:SPO2=93%;&lt;br&gt;&lt;br&gt;          3. PaO2/FiO2=300mmHg.&lt;br&gt;&lt;br&gt;        2.2019-nCoV nucleic acid test was positive.&lt;br&gt;&lt;br&gt;        3.CT of the lung conformed to the manifestation of viral pneumonia.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. dying state (i.e. survival time is less than 24 hours);&lt;br&gt;&lt;br&gt;          2. progressive malignant tumor with life expectancy less than 6 months;&lt;br&gt;&lt;br&gt;          3. immunosuppressive status(patients using immunosuppressants or chemotherapeutic drugs)&lt;br&gt;&lt;br&gt;          4. underlying diseases requiring long-term glucocorticoid treatment in the past 6 months&lt;br&gt;             or short-term glucocorticoid therapy in the past 4 weeks;&lt;br&gt;&lt;br&gt;          5. pregnancy&lt;br&gt;&lt;br&gt;          6. patients with glucocorticoid taboos&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV Severe Pneumonia</Condition>
    <Intervention>Drug: Methylprednisolone;Drug: Methylprednisolone</Intervention>
    <Primary_outcome>Rate of disease remission;Rate and time of entering the critical stage</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04307693</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</Public_title>
    <Scientific_title>Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Asan Medical Center</Primary_sponsor>
    <Date_registration>10/03/2020</Date_registration>
    <Date_registration3>20200310</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04307693</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16 Years</Inclusion_agemin>
    <Inclusion_agemax>99 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 11, 2020</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 2</Phase>
    <Countries>Korea, Republic of</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Sung-Han Kim, MD.PhD</Contact_Lastname>
    <Contact_Email>shkimmd@amc.seoul.kr</Contact_Email>
    <Contact_Tel>82-2-3010-3114</Contact_Tel>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  confirmed mild COVID-19 (NEWS scoring system 0-4)&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  unable to take oral medication&lt;br&gt;&lt;br&gt;          -  pregnancy or breast feeding&lt;br&gt;&lt;br&gt;          -  immunocompromised patients&lt;br&gt;&lt;br&gt;          -  creatinine clearance (CCL) &lt; 30 mL/min&lt;br&gt;&lt;br&gt;          -  aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 5 times Upper limit of&lt;br&gt;             normal (ULN)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine sulfate</Intervention>
    <Primary_outcome>Viral load</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030896</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Application and Theoretical Discussion of Fu-Zheng Qing-Fei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Application and Theoretical Discussion of Fuzheng Qingfei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Zhengzhou People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51028</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-06</Date_enrollement>
    <Target_size>Case series:24;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang Dazhong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China</Contact_Address>
    <Contact_Email>13803818341@163.com</Contact_Email>
    <Contact_Tel>+86 13803818341</Contact_Tel>
    <Contact_Affiliation>Zhengzhou People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Pneumonitis patients infected with new coronavirus;&lt;br&gt;2. Meet the standard of TCM syndrome differentiation;&lt;br&gt;3. Sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Complicated active tuberculosis, malignant arrhythmia, acute myocardial infarction, stroke, etc.&lt;br&gt;2. pregnant and lactating women;&lt;br&gt;3. Combining severe cognitive and mental disorders;&lt;br&gt;4. Clinical researchers who are participating in other interventions within 1 month before being selected;&lt;br&gt;5. Those who are known to be allergic to treatment drugs;&lt;br&gt;6. Those who are critically ill.&lt;br&gt;7. The researcher thinks that others are not suitable for enrollment.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:traditional Chinese medicine and Western medicine treatment;</Intervention>
    <Primary_outcome>Improvement of symptoms;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030895</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Retrospective and Prospective Study for Nosocomial infection in Stomatology Department under the Background of novel coronavirus pneumonia (COVID-19) epidemic period</Public_title>
    <Scientific_title>Retrospective and Prospective Study on Nosocomial infection in Stomatology Department under the Background of COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51034</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-03-14</Date_enrollement>
    <Target_size>Case series:1000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jingzhi Ma</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>majingzhi2002@163.com</Contact_Email>
    <Contact_Tel>+86 13871257728</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients of stomatology department in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 4 to January 23, 2020.&lt;br&gt;1. The visiting data of patients could be backtracked;&lt;br&gt;2. The patients could be connected;&lt;br&gt;3. The patients or the guardians could understand the content of investigation;&lt;br&gt;4. The patients or the guardians signed informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The patients refused to cooperate in investigation;&lt;br&gt;2. The patients were out of contact;&lt;br&gt;3. The patients was unable to receive the investigation or could not understand the content of investigation;&lt;br&gt;4. The patients was under 18 years old and without the help from guardians;&lt;br&gt;5. The patients hided the truth on purpose.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>nosocomial infection ratio of SARS-Cov-2;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030894</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial</Public_title>
    <Scientific_title>Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Peking University First Hospital</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51126</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Group 1:90;Group 2:30;Group 3:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Guiqiang Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>8 Xishiku Street, Xicheng District, Beijing, China</Contact_Address>
    <Contact_Email>john131212@126.com</Contact_Email>
    <Contact_Tel>+86 13911405123</Contact_Tel>
    <Contact_Affiliation>Peking University First Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Male and female aged 18-65 years;&lt;br&gt;2. Clinically diagnosed with Corona Virus Disease 2019;&lt;br&gt;3. Increased interleukin-6;&lt;br&gt;4. Sign the informed consent;&lt;br&gt;5. Subjects who can take medicine orally;&lt;br&gt;6. Agree to collect clinical samples;&lt;br&gt;7. Female subjects of childbearing age are not pregnant and agree to take effective contraception within 7 days of the last oral medication to ensure that they are not pregnant within 3-6 months;&lt;br&gt;8. Male patients agree to effective contraception within 7 days of last oral medication.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Cases of severe vomiting that make it difficult to take the drug orally;&lt;br&gt;2. Allergic to Favipiravir or tocilizumab;&lt;br&gt;3. Pregnant and lactating women;&lt;br&gt;4. Subjects received specific antiviral drugs such as lopinavir / ritonavir, ribavirin, arbidol, chloroquine phosphate, hydroxychloroquine, and monoclonal antibodies within one week before admission;&lt;br&gt;5. Cases of respiratory failure and requiring mechanical ventilation;&lt;br&gt;6. Cases of shock;&lt;br&gt;7. Combined organ failure requires ICU monitoring and treatment;&lt;br&gt;8. Predicted clinically that there is no hope of survival, or cases of deep coma that do not respond to supportive treatment measures within three hours of admission;&lt;br&gt;9. Alanine aminotransferase / Aspartate aminotransferase&gt; 5 times of upper limit of normal;&lt;br&gt;10. Neutrophils &lt;0.5  10^9 / L, platelets less than 50 x 10^9/L;&lt;br&gt;11. Clear diagnosis of rheumatoid immunity, malignant tumors and other related diseases&lt;br&gt;12. Long-term oral anti-rejection drugs or immunomodulatory drugs;&lt;br&gt;13. Allergic reactions to tocilizumab or any excipients;&lt;br&gt;14. Patients with active hepatitis, tuberculosis, and definite bacterial and fungal infections;&lt;br&gt;15. Organ transplant patients;&lt;br&gt;16. Patients with mental disorders.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 1:Favipiravir Combined With Tocilizumab;Group 2:Favipiravir;Group 3:Tocilizumab;</Intervention>
    <Primary_outcome>Clinical cure rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04061382</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Sero-epidemiological Survey of England in 2019/2020</Public_title>
    <Scientific_title>Serum Testing of Representative Youngsters: Sero- Epidemiological Survey of England in 2019/2020</Scientific_title>
    <Acronym>STORY</Acronym>
    <Primary_sponsor>University of Oxford</Primary_sponsor>
    <Date_registration>30/07/2019</Date_registration>
    <Date_registration3>20190730</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04061382</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>24 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>October 15, 2019</Date_enrollement>
    <Target_size>2300</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>United Kingdom</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Matthew Snape, Professor;Iason Vichos;Iason Vichos</Contact_Lastname>
    <Contact_Email>;iason.vichos@paediatrics.ox.ac.uk;iason.vichos@paediatrics.ox.ac.uk</Contact_Email>
    <Contact_Tel>;01865611400;01865 611 400</Contact_Tel>
    <Contact_Affiliation>University of Oxford;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Parents/legal guardians or adult participant* is willing and able to give informed&lt;br&gt;             consent for participation in the study.&lt;br&gt;&lt;br&gt;          -  Male or Female, aged 0 - 24 years inclusive.&lt;br&gt;&lt;br&gt;          -  Parents/legal guardians or adult participants are willing to allow their General&lt;br&gt;             Practitioner or relevant NHS databases to be contacted for a full immunisation history&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  If participants do not live in the postcode districts selected by PHE&lt;br&gt;&lt;br&gt;          -  Medically diagnosed bleeding disorder&lt;br&gt;&lt;br&gt;          -  Medically diagnosed platelet disorder&lt;br&gt;&lt;br&gt;          -  Anticoagulation medication&lt;br&gt;&lt;br&gt;          -  Pregnancy&lt;br&gt;&lt;br&gt;          -  If another member of their household is participating who is within 5 years of age of&lt;br&gt;             the potential participants age&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Serogroup C Meningococcal Meningitis;Diphtheria;COVID-19</Condition>
    <Intervention>Procedure: venepuncture</Intervention>
    <Primary_outcome>Feasibility of developing a UK based sero-epidemiological programme in 0-24 year olds;Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds;Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04261517</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )</Public_title>
    <Scientific_title>Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )</Scientific_title>
    <Acronym />
    <Primary_sponsor>Shanghai Public Health Clinical Center</Primary_sponsor>
    <Date_registration>06/02/2020</Date_registration>
    <Date_registration3>20200206</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04261517</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 6, 2020</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Hongzhou Lu, Ph.D;Hongzhou Lu, PI</Contact_Lastname>
    <Contact_Email>luhongzhou@fudan.edu.cn;luhongzhou@fudan.edu.cn</Contact_Email>
    <Contact_Tel>+86-021-37990333;+86-021-37990333</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The participants were diagnosed as pneumonia caused by 2019-nCoV, according to the&lt;br&gt;             notice on printing and distributing the diagnosis and treatment plan of pneumonia with&lt;br&gt;             new coronavirus infection (trial version 4 or update version) made by National Health&lt;br&gt;             Commission of the People's Republic of China;&lt;br&gt;&lt;br&gt;          -  Participants aged over 18;&lt;br&gt;&lt;br&gt;          -  Written the informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Hypersensitivity to chloroquine or hydroxychloroquine;&lt;br&gt;&lt;br&gt;          -  Women during pregnancy;&lt;br&gt;&lt;br&gt;          -  Severe heart, lung, kidney, brain, blood diseases or other important systemic&lt;br&gt;             diseases;&lt;br&gt;&lt;br&gt;          -  Participants with retinal disease, hearing loss;&lt;br&gt;&lt;br&gt;          -  Participants with severe neurological and mental illness;&lt;br&gt;&lt;br&gt;          -  Subjects were considered to be unable to complete the study, or not suitable for the&lt;br&gt;             study by researchers.&lt;br&gt;&lt;br&gt;        Exit criteria:&lt;br&gt;&lt;br&gt;          -  Subjects asked to withdraw the study&lt;br&gt;&lt;br&gt;          -  Subject will benefit if withdraw according to researchers' suggestions&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Pneumonia, Pneumocystis;Coronavirus</Condition>
    <Intervention>Drug: Hydroxychloroquine</Intervention>
    <Primary_outcome>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5;The mortality rate of subjects at weeks 2;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04264533</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia</Public_title>
    <Scientific_title>Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>ZhiYong Peng</Primary_sponsor>
    <Date_registration>04/02/2020</Date_registration>
    <Date_registration3>20200204</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04264533</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 14, 2020</Date_enrollement>
    <Target_size>140</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). </Study_design>
    <Phase>Phase 2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Zhiyong Peng, professor;Zhiyong Peng, professor;Zhiyong Peng, professor</Contact_Lastname>
    <Contact_Email>;pengzy5@hotmail.com;</Contact_Email>
    <Contact_Tel>;+8618672396028;</Contact_Tel>
    <Contact_Affiliation>Wuhan University;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. = 18 years old;&lt;br&gt;&lt;br&gt;          2. Diagnosed as serious or critical SARI (according to the 4th version of Diagnosis and&lt;br&gt;             Clinical management of 2019-nCoV infected pneumonia);&lt;br&gt;&lt;br&gt;          3. Being treated in the ICU.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Allergic to vitamin C;&lt;br&gt;&lt;br&gt;          2. Dyspnea due to cardiogenic pulmonary edema;&lt;br&gt;&lt;br&gt;          3. Pregnant or breastfeeding;&lt;br&gt;&lt;br&gt;          4. Expected life is less than 24 hours;&lt;br&gt;&lt;br&gt;          5. There is a state of tracheotomy or home oxygen therapy in the past;&lt;br&gt;&lt;br&gt;          6. Previously complicated with end-stage lung disease, end-stage malignancy,&lt;br&gt;             glucose-6-phosphate dehydrogenase deficiency, diabetic ketoacidosis, and active kidney&lt;br&gt;             stone disease;&lt;br&gt;&lt;br&gt;          7. The patient participates in another clinical trial at the same time.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Vitamin C;Pneumonia, Viral;Pneumonia, Ventilator-Associated</Condition>
    <Intervention>Drug: VC;Drug: Sterile Water for Injection</Intervention>
    <Primary_outcome>Ventilation-free days</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04283396</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for Novel Coronavirus Pneumonia (NCP)</Public_title>
    <Scientific_title>Study for Clinical Epidemiology and Methods of Diagnosis and Treatment of Novel Coronavirus Pneumonia (NCP)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Wuhan Union Hospital, China</Primary_sponsor>
    <Date_registration>13/02/2020</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04283396</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 21, 2020</Date_enrollement>
    <Target_size>2000</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Yang Jin;Yang Jin</Contact_Lastname>
    <Contact_Email>whunjy@126.com;whuhjy@126.com</Contact_Email>
    <Contact_Tel>13554361146;13554361146</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  1?Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer&lt;br&gt;             to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial&lt;br&gt;             Version 5)"; 2?Patients who voluntarily signed informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Physician judged the patient was not suitable for this clinical trial.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia</Condition>
    <Intervention>Combination Product: systemic treatment</Intervention>
    <Primary_outcome>recovery</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04276896</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Immunity and Safety of Covid-19 Synthetic Minigene Vaccine</Public_title>
    <Scientific_title>Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus</Scientific_title>
    <Acronym />
    <Primary_sponsor>Shenzhen Geno-Immune Medical Institute</Primary_sponsor>
    <Date_registration>17/02/2020</Date_registration>
    <Date_registration3>20200217</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04276896</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>6 Months</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 24, 2020</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 1/Phase 2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Lung-Ji Chang, PhD;Lung-Ji Chang, PhD;Lung-Ji Chang, PhD</Contact_Lastname>
    <Contact_Email>;c@szgimi.org;c@szgimi.org</Contact_Email>
    <Contact_Tel>;+86(755)8672 5195;86-755-86725195</Contact_Tel>
    <Contact_Affiliation>Shenzhen Geno-Immune Medical Institute;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Laboratory (RT-PCR) confirmed Covid-19 infection in throat swab and/or sputum and/or&lt;br&gt;             lower respiratory tract samples;&lt;br&gt;&lt;br&gt;          -  The interval between the onset of symptoms and randomized is within 7 days. The onset&lt;br&gt;             of symptoms is mainly based on fever. If there is no fever, cough or other related&lt;br&gt;             symptoms can be used;&lt;br&gt;&lt;br&gt;          -  White blood cells = 3,500 / l, lymphocytes = 750 / l;&lt;br&gt;&lt;br&gt;          -  Human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV)&lt;br&gt;             or tuberculosis (TB) test is negative;&lt;br&gt;&lt;br&gt;          -  Sign the Informed Consent Form on a voluntary basis;&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subject infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV&lt;br&gt;             antibody positive), or HTLV (HTLV antibody positive).&lt;br&gt;&lt;br&gt;          -  Subject is albumin-intolerant.&lt;br&gt;&lt;br&gt;          -  Subject with life expectancy less than 4 weeks.&lt;br&gt;&lt;br&gt;          -  Subject participated in other investigational somatic cell therapies within past 30&lt;br&gt;             days.&lt;br&gt;&lt;br&gt;          -  Subject with positive pregnancy test result.&lt;br&gt;&lt;br&gt;          -  Researchers consider unsuitable.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Pathogen Infection Covid-19 Infection</Condition>
    <Intervention>Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs</Intervention>
    <Primary_outcome>Clinical improvement based on the 7-point scale;Lower Murray lung injury score</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04290780</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus</Public_title>
    <Scientific_title>Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus</Scientific_title>
    <Acronym>NOSO-COR</Acronym>
    <Primary_sponsor>Hospices Civils de Lyon</Primary_sponsor>
    <Date_registration>27/02/2020</Date_registration>
    <Date_registration3>20200227</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04290780</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 9, 2020</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>France</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Philippe VANHEMS, MD, PhD;Philippe VANHEMS, MD, PhD</Contact_Lastname>
    <Contact_Email>;philippe.vanhems@chu-lyon.fr</Contact_Email>
    <Contact_Tel>;04 72 11 07 20</Contact_Tel>
    <Contact_Affiliation>Service Hygine, Epidmiologie et Prvention;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        1 ) Any adult or child or member of the nursing staff from the study participant hospital&lt;br&gt;        who presents an infectious syndrome including the following definition :&lt;br&gt;&lt;br&gt;        2) Suspect Case:&lt;br&gt;&lt;br&gt;        Fever above 37.8  C if no antipyretics are taken; And or Cough or pharyngeal pain or other&lt;br&gt;        symptom suggestive of respiratory infection. AND at least 1 of the following&lt;br&gt;        characteristics:&lt;br&gt;&lt;br&gt;          -  return from a trip to China, or to a country in which the increase in the incidence of&lt;br&gt;             infections in SARS-CoV-2 has been proven;&lt;br&gt;&lt;br&gt;          -  close contact (sharing the same place of family, professional life, same plane, etc.)&lt;br&gt;             with a person defined as a suspected or confirmed case;&lt;br&gt;&lt;br&gt;          -  Occurring in an establishment having received at least one case of suspected or&lt;br&gt;             confirmed infection at SARS-CoV-2.&lt;br&gt;&lt;br&gt;        Or 3) Confirmed Case: The same clinical definitions, in addition to a positive RT-PCR-type&lt;br&gt;        virological diagnostic result specific to SARS-CoV-2&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Anyone who does not meet the above definition.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Infection Viral</Condition>
    <Intervention>Other: nosocomial infection/hospital acquired infection</Intervention>
    <Primary_outcome>nosocomial infection</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04290858</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection</Public_title>
    <Scientific_title>Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial</Scientific_title>
    <Acronym>NoCovid</Acronym>
    <Primary_sponsor>Xijing Hospital</Primary_sponsor>
    <Date_registration>27/02/2020</Date_registration>
    <Date_registration3>20200227</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04290858</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 1, 2020</Date_enrollement>
    <Target_size>240</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 2</Phase>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Lei Chong, MD, PhD;Lorenzo Berra, MD;Lei Chong, MD, PhD</Contact_Lastname>
    <Contact_Email>;;cryststalleichong@126.com</Contact_Email>
    <Contact_Tel>;;+86 8629011362</Contact_Tel>
    <Contact_Affiliation>Xijing Hospital;Massachusetts General Hospital;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Laboratory confirmed COVID19 infection defined with a positive RT-PCR from any&lt;br&gt;             specimen.&lt;br&gt;&lt;br&gt;          2. Hospital admission with at least one of the following:&lt;br&gt;&lt;br&gt;               -  fever = 36.6 C from axillary site; or = 37.2C from oral site; or = 37.6C from&lt;br&gt;                  tympanic or rectal site.&lt;br&gt;&lt;br&gt;               -  Respiratory rate = 24 bpm&lt;br&gt;&lt;br&gt;               -  cough&lt;br&gt;&lt;br&gt;          3. Spontaneous breathing with or without hypoxia of any degree. Gas exchange and&lt;br&gt;             ventilation maybe assisted by any continuous continuous airway pressure (CPAP), or any&lt;br&gt;             system of Non Invasive Ventilation (NIV), with Positive End-Expiratory Pressure (PEEP)&lt;br&gt;             = 10 cmH2O.&lt;br&gt;&lt;br&gt;          4. = 8 days since onset of the symptoms&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Pregnancy, or positive pregnancy test in a predose examination&lt;br&gt;&lt;br&gt;          2. Open tracheostomy&lt;br&gt;&lt;br&gt;          3. Therapy with high flow nasal cannula&lt;br&gt;&lt;br&gt;          4. Clinical controindication, as deemed by the attending physician&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus Infections;Pneumonia, Viral;Dyspnea</Condition>
    <Intervention>Drug: Nitric Oxide</Intervention>
    <Primary_outcome>Reduction in the incidence of intubation and mechanical ventilation</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04292730</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</Public_title>
    <Scientific_title>A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment</Scientific_title>
    <Acronym />
    <Primary_sponsor>Gilead Sciences</Primary_sponsor>
    <Date_registration>28/02/2020</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04292730</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 2020</Date_enrollement>
    <Target_size>600</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 3</Phase>
    <Countries>United States;Korea, Republic of;United States</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Gilead Study Director;Gilead Clinical Study Information Center</Contact_Lastname>
    <Contact_Email>;GileadClinicalTrials@gilead.com</Contact_Email>
    <Contact_Tel>;1-833-445-3230 (GILEAD-0)</Contact_Tel>
    <Contact_Affiliation>Gilead Sciences;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Key Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Willing and able to provide written informed consent prior to performing study&lt;br&gt;             procedures&lt;br&gt;&lt;br&gt;          -  Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by&lt;br&gt;             polymerase chain reaction (PCR) test = 4 days before randomization&lt;br&gt;&lt;br&gt;          -  Currently hospitalized with fever defined as temperature = 36.6 C armpit, = 37.2 C&lt;br&gt;             oral, or = 37.8 C rectal&lt;br&gt;&lt;br&gt;          -  Peripheral capillary oxygen saturation (SpO2) &gt; 94% on room air at screening&lt;br&gt;&lt;br&gt;          -  Radiographic evidence of pulmonary infiltrates&lt;br&gt;&lt;br&gt;        Key Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Participation in any other clinical trial of an experimental treatment for COVID-19&lt;br&gt;&lt;br&gt;          -  Concurrent treatment with other agents with actual or possible direct acting antiviral&lt;br&gt;             activity against SARS-CoV-2 is prohibited &lt; 24 hours prior to study drug dosing&lt;br&gt;&lt;br&gt;          -  Requiring mechanical ventilation at screening&lt;br&gt;&lt;br&gt;          -  Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 X upper limit&lt;br&gt;             of normal (ULN)&lt;br&gt;&lt;br&gt;          -  Creatinine clearance &lt; 50 mL/min&lt;br&gt;&lt;br&gt;        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Drug: Remdesivir;Drug: Standard of Care</Intervention>
    <Primary_outcome>Proportion of Participants Discharged by Day 14</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030893</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for effects of crisis intervention based on positive psychology for medical staffs working in the novel coronavirus pneumonia (COVID-19) field</Public_title>
    <Scientific_title>Study of effects of crisis intervention on medical staff based on positive psychology                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Zhengzhou People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51073</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-19</Date_enrollement>
    <Target_size>Observation group:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang He</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China</Contact_Address>
    <Contact_Email>WH9400@163.com</Contact_Email>
    <Contact_Tel>+86 15937129400</Contact_Tel>
    <Contact_Affiliation>Zhengzhou People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Positive Screening for the SCL-90; Voluntary participation in this research</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: no</Exclusion_Criteria>
    <Condition>psychological well-being; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Observation group:Positive Psychological Guidance Group Counseling;</Intervention>
    <Primary_outcome>Symptom Checklist 90;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030863</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19): An Multicenter Cohort Study</Public_title>
    <Scientific_title>Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19)9: An Multicenter Cohort Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Jinling Hospital, Medical School of Nanjing University</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50767</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-22</Date_enrollement>
    <Target_size>Case series:5000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lu Guangming</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>305 East Zhongshan Road, Nanjing, Jiangsu, China</Contact_Address>
    <Contact_Email>cjr.luguangming@vip.163.com</Contact_Email>
    <Contact_Tel>+86 13951608346</Contact_Tel>
    <Contact_Affiliation>Jinling Hospital, Medical School of Nanjing University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Suspected COVID-19 patients with chest CT scannings(including follow-up scanning);&lt;br&gt;2. Patients confirmed with etiological detection and clinical following data.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. CT imaging data with poor quality;&lt;br&gt;2. Incomplete etiological or clinical data.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:None;</Intervention>
    <Primary_outcome>chest CT images;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030862</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Correlation analysis of blood eosinophil cell levels and clinical type category of novel coronavirus pneumonia (COVID-19): a medical records based retrospective study</Public_title>
    <Scientific_title>Correlation analysis of blood eosinophil cell levels and clinical novel coronavirus pneumonia type: a single-center, retrospective study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51107</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>99</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-24</Date_enrollement>
    <Target_size>Ordinary COVID-19 patients:100;Heavy COVID-19 patients:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Feng Gao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>13971587381@163.com</Contact_Email>
    <Contact_Tel>+86 13971587381</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: COVID-19 nucleic acid testing positive non-critically ill hospitalized patients.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) before the application or hospital admission corticosteroids; &lt;br&gt;(2) malignancies;&lt;br&gt;(3) the presence of severely impaired immune function, immunodeficiency diseases; &lt;br&gt;(4) 7 days before admission row major surgery or severe trauma; &lt;br&gt;(5) with asthma; &lt;br&gt;(6) COVID-19 undiagnosed patients.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Ordinary COVID-19 patients:Nil;Heavy COVID-19 patients:Nil;</Intervention>
    <Primary_outcome>Laboratory inspection index;Oxygen therapy case;Film degree exam;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030861</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling</Public_title>
    <Scientific_title>Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of the Guangzhou Medical University</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51103</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2019-02-27</Date_enrollement>
    <Target_size>Case series:90;</Target_size>
    <Study_type>Health services reaserch</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Shiyue Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>lishiyue@188.com</Contact_Email>
    <Contact_Tel>+86 13902233925</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of the Guangzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Stage I and ii healthy subjects&lt;br&gt;Stage 3:&lt;br&gt;1. Clinical manifestations:&lt;br&gt;(1) Fever;&lt;br&gt;(2) normal or decreased white blood cells;&lt;br&gt;(3) CT pulmonary exudation; Or a suspected patient with an epidemiological history;&lt;br&gt;2. Isolation ward: patients with novel coronavirus (mild, common).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Stage 1 and stage 2: subjects who cannot cooperate; Patients with fever, cough and expectoration in recent 2 weeks; Patients with underlying diseases.&lt;br&gt;Stage 3:&lt;br&gt;1. Patients who cannot cooperate with the throat swab examination;&lt;br&gt;2. Three patients who are not consistent with clinical manifestations at the same time and not suspected of novel coronavirus;&lt;br&gt;3. Patients considered inappropriate by the researcher;&lt;br&gt;4. Patients with severe or unstable vital signs with novel coronavirus.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030860</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid of novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>Investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51102</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-03-16</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Sheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>aloof3737@126.com</Contact_Email>
    <Contact_Tel>+86 18971201115</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with confirmed COVID-19</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: N/A</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:N/A;</Intervention>
    <Primary_outcome>RT-PCR test for SARS-CoV-2;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030812</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Shanghai Ninth People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50947</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-31</Date_enrollement>
    <Target_size>Case series:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Cohort study</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xu Jie</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>280 Mohe Road, Baoshan District, Shanghai, China</Contact_Address>
    <Contact_Email>dr.xu@aliyun.com</Contact_Email>
    <Contact_Tel>+86 13501722091</Contact_Tel>
    <Contact_Affiliation>Shanghai Ninth People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 years Chinese people;&lt;br&gt;2. Clinical diagnosis of 2019 - nCoV suspected cases: clinical diagnosis of 2019 - nCoV suspected cases: according to the national health committee office of the general office of the state administration of traditional Chinese medicine on February 3, 2020 promulgated the new coronavirus infection pneumonia diagnosis and treatment scheme (trial version 5) notice, will be suspected cases are defined as any article 1 has a history of epidemiology, conform to the clinical manifestation of 2:1) history of epidemiology: in 14 days before the onset of Wuhan city and surrounding areas, or other cases reported history of history of travel or live in the community; In the 14 days before onset, the patient had been exposed to fever or respiratory symptoms from wuhan city and surrounding areas or from the case reporting community.Cluster disease; With the new coronavirus infection has a history of contact, the new coronavirus infection refers to the pathogen nucleic acid test positive.(2) clinical manifestations: fever and/or respiratory symptoms;The imaging features of pneumonia were as follows: multiple small patches and stromal changes were observed in the early stage, and the lung exhalation was obvious. Then, multiple ground glass and infiltrating shadows were found in both lungs.&lt;br&gt;3. In severe cases, lung consolidation could occur, and pleural effusion was rare.The total number of white blood cells in the early stage of the disease is normal or decreased, or the lymphocyte count is reduced.The clinical diagnosis was confirmed as 2019-ncov cases: based on the suspected cases, sputum, pharyngeal swab, secretions of the lower respiratory tract and other specimens were tested for positive nucleic acid of the novel coronavirus by real-time fluorescence rt-pcr. Or virus gene sequencing, and known new coronavirus highly homologous.Mild cases or severe cases were included in the study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Unsigned or unwilling to sign informed consent</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:none;</Intervention>
    <Primary_outcome>Single cell sequencing;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04283461</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection</Public_title>
    <Scientific_title>Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults</Scientific_title>
    <Acronym />
    <Primary_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</Primary_sponsor>
    <Date_registration>21/02/2020</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04283461</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>55 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 3, 2020</Date_enrollement>
    <Target_size>45</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label). </Study_design>
    <Phase>Phase 1</Phase>
    <Countries>United States</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Lisa A. Jackson</Contact_Lastname>
    <Contact_Email>lisa.a.jackson@kp.org</Contact_Email>
    <Contact_Tel>12064425216</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;        A subject must meet all of the following criteria to be eligible to participate in this&lt;br&gt;        study:&lt;br&gt;&lt;br&gt;          1. Provides written informed consent prior to initiation of any study procedures.&lt;br&gt;&lt;br&gt;          2. Be able to understand and agrees to comply with planned study procedures and be&lt;br&gt;             available for all study visits.&lt;br&gt;&lt;br&gt;          3. Agrees to the collection of venous blood per protocol.&lt;br&gt;&lt;br&gt;          4. Male or non-pregnant female, 18 to 55 years of age, inclusive, at time of enrollment.&lt;br&gt;&lt;br&gt;          5. Body Mass Index 18-35 kg/m^2, inclusive, at screening.&lt;br&gt;&lt;br&gt;          6. Women of childbearing potential* must agree to use or have practiced true abstinence**&lt;br&gt;             or use at least one acceptable primary form of contraception.***, **** Note: These&lt;br&gt;             criteria are applicable to females in a heterosexual relationship and child-bearing&lt;br&gt;             potential (i.e., the criteria do not apply to subjects in a same sex relationship).&lt;br&gt;&lt;br&gt;             *Not of childbearing potential - post-menopausal females (defined as having a history&lt;br&gt;             of amenorrhea for at least one year) or a documented status as being surgically&lt;br&gt;             sterile (hysterectomy, bilateral oophorectomy, tubal ligation/salpingectomy, or&lt;br&gt;             Essure(R) placement).&lt;br&gt;&lt;br&gt;             **True abstinence is 100% of time no sexual intercourse (male's penis enters the&lt;br&gt;             female's vagina). (Periodic abstinence [e.g., calendar, ovulation, symptothermal,&lt;br&gt;             post-ovulation methods] and withdrawal are not acceptable methods of contraception).&lt;br&gt;&lt;br&gt;             ***Acceptable forms of primary contraception include monogamous relationship with a&lt;br&gt;             vasectomized partner who has been vasectomized for 180 days or more prior to the&lt;br&gt;             subject's first vaccination, intrauterine devices, birth control pills, and&lt;br&gt;             injectable/implantable/insertable hormonal birth control products.&lt;br&gt;&lt;br&gt;             ****Must use at least one acceptable primary form of contraception for at least 30&lt;br&gt;             days prior to the first vaccination and at least one acceptable primary form of&lt;br&gt;             contraception for 60 days after the last vaccination.&lt;br&gt;&lt;br&gt;          7. Women of childbearing potential must have a negative urine or serum pregnancy test&lt;br&gt;             within 24 hours prior to each vaccination.&lt;br&gt;&lt;br&gt;          8. Male subjects of childbearing potential*: use of condoms to ensure effective&lt;br&gt;             contraception with a female partner from first vaccination until 3 months after the&lt;br&gt;             last vaccination.&lt;br&gt;&lt;br&gt;             *Biological males who are post-pubertal and considered fertile until permanently&lt;br&gt;             sterile by bilateral orchiectomy or vasectomy.&lt;br&gt;&lt;br&gt;          9. Male subjects agree to refrain from sperm donation from the time of first vaccination&lt;br&gt;             until 3 months after the last vaccination.&lt;br&gt;&lt;br&gt;         10. Oral temperature is less than 100.0 degrees Fahrenheit (37.8 degrees Celsius).&lt;br&gt;&lt;br&gt;         11. Pulse no greater than 100 beats per minute.&lt;br&gt;&lt;br&gt;         12. Systolic blood pressure (BP) is 85 to 150 mmHg, inclusive.&lt;br&gt;&lt;br&gt;         13. Clinical screening laboratory evaluations (white blood cell (WBC), hemoglobin (Hgb),&lt;br&gt;             platelets (PLTs), alanine transaminase (ALT), aspartate transaminase (AST), creatinine&lt;br&gt;             (Cr), alkaline phosphatase (ALP), total bilirubin (T. Bili), Lipase, prothrombin time&lt;br&gt;             (PT), and partial thromboplastin time (PTT)) are within acceptable normal reference&lt;br&gt;             ranges at the clinical laboratory being used.&lt;br&gt;&lt;br&gt;         14. Must agree to have samples stored for secondary research.&lt;br&gt;&lt;br&gt;         15. Agrees to adhere to Lifestyle Considerations throughout study duration.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;        A subject who meets any of the following criteria will be excluded from participation in&lt;br&gt;        this study:&lt;br&gt;&lt;br&gt;          1. Positive pregnancy test either at screening or just prior to each vaccine&lt;br&gt;             administration.&lt;br&gt;&lt;br&gt;          2. Female subject who is breastfeeding or plans to breastfeed from the time of the first&lt;br&gt;             vaccination through 60 days after the last vaccination.&lt;br&gt;&lt;br&gt;          3. Has any medical disease or condition that, in the opinion of the site PI or&lt;br&gt;             appropriate sub-investigator, precludes study participation.*&lt;br&gt;&lt;br&gt;             *Including acute, subacute, intermittent or chronic medical disease or condition that&lt;br&gt;             would place the subject at an unacceptable risk of injury, render the subject unable&lt;br&gt;             to meet the requirements of the protocol, or may interfere with the evaluation of&lt;br&gt;             responses or the subject's successful completion of this trial.&lt;br&gt;&lt;br&gt;          4. Presence of self-reported or medically documented significant medical or psychiatric&lt;br&gt;             condition(s).*&lt;br&gt;&lt;br&gt;             *Significant medical or psychiatric conditions include but are not limited to:&lt;br&gt;             Respiratory disease (e.g., chronic obstructive pulmonary disease [COPD], asthma)&lt;br&gt;             requiring daily medications currently or any treatment of respiratory disease&lt;br&gt;             exacerbations (e.g., asthma exacerbation) in the last 5 years. Asthma medications:&lt;br&gt;             inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and&lt;br&gt;             short acting beta agonists, theophylline, ipratropium, biologics.&lt;br&gt;&lt;br&gt;             Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy,&lt;br&gt;             ischemic heart disease) or history of myocarditis or pericarditis as an adult.&lt;br&gt;&lt;br&gt;             Neurological or neurodevelopmental conditions (e.g., migraines, epilepsy, stroke,&lt;br&gt;             seizures in the last 3 years, encephalopathy, focal neurologic deficits,&lt;br&gt;             Guillain-Barr syndrome, encephalomyelitis or transverse myelitis).&lt;br&gt;&lt;br&gt;             Ongoing malignancy or recent diagnosis of malignancy in the last five years excluding&lt;br&gt;             basal cell and squamous cell carcinoma of the skin, which are allowed.&lt;br&gt;&lt;br&gt;             An autoimmune disease, including hypothyroidism without a defined non-autoimmune&lt;br&gt;             cause, localized or history of psoriasis.&lt;br&gt;&lt;br&gt;             An immunodeficiency of any cause.&lt;br&gt;&lt;br&gt;          5. Has an acute illness*, as determined by the site PI or appropriate sub-investigator,&lt;br&gt;             with or without fever [oral temperature &gt;38.0 degrees Celsius (100.4 degrees&lt;br&gt;             Fahrenheit)] within 72 hours prior to each vaccination.&lt;br&gt;&lt;br&gt;             *An acute illness which is nearly resolved with only minor residual symptoms remaining&lt;br&gt;             is allowable if, in the opinion of the site PI or appropriate sub-investigator, the&lt;br&gt;             residual symptoms will not interfere with the ability to assess safety parameters as&lt;br&gt;             required by the protocol.&lt;br&gt;&lt;br&gt;          6. Has a positive test result for hepatitis B surface antigen, hepatitis C virus&lt;br&gt;             antibody, or HIV types 1 or 2 antibodies at screening.&lt;br&gt;&lt;br&gt;          7. Has participated in another investigational study involving any investigational&lt;br&gt;             product* within 60 days, or 5 half-lives, whichever is longer, before the first&lt;br&gt;             vaccine administration.&lt;br&gt;&lt;br&gt;             *study drug, biologic or device&lt;br&gt;&lt;br&gt;          8. Currently enrolled in or plans to participate in another clinical trial with an&lt;br&gt;             investigational agent* that will be received during the study-reporting period.**&lt;br&gt;&lt;br&gt;             *Including</Inclusion_Criteria>
    <Condition>Corona Virus Infection</Condition>
    <Intervention>Biological: mRNA-1273</Intervention>
    <Primary_outcome>Frequency of solicited local reactogenicity adverse events (AEs);Frequency of any medically-attended adverse events (MAAEs);Frequency of any new-onset chronic medical conditions (NOCMCs);Frequency of any serious adverse events (SAEs);Frequency of any unsolicited adverse events (AEs);Frequency of solicited systemic reactogenicity adverse events (AEs);Grade of any unsolicited adverse events (AEs);Grade of solicited local reactogenicity adverse events (AEs);Grade of solicited systemic reactogenicity adverse events (AEs)</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04288102</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)</Public_title>
    <Scientific_title>Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Mesenchymal Stem Cell(MSC) for the Treatment of Severe Corona Virus Disease 2019(COVID-19)</Scientific_title>
    <Acronym />
    <Primary_sponsor>Beijing 302 Hospital</Primary_sponsor>
    <Date_registration>24/02/2020</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04288102</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>70 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 5, 2020</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). </Study_design>
    <Phase>Phase 1/Phase 2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Fu-Sheng Wang, MD, PhD;Lei Shi, MD,PhD;Lei Shi, MD, PhD</Contact_Lastname>
    <Contact_Email>;shilei302@126.com;shilei302@126.com</Contact_Email>
    <Contact_Tel>;86-10-66933333;</Contact_Tel>
    <Contact_Affiliation>The fifth medical center of PLA general hospital;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Male or female, aged at 18 years (including) -70 years old&lt;br&gt;&lt;br&gt;          2. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase&lt;br&gt;             chain reaction (RT-PCR) from any diagnostic sampling source&lt;br&gt;&lt;br&gt;          3. Pneumonia that is judged by chest radiograph or computed tomography&lt;br&gt;&lt;br&gt;          4. In accordance with any one of the following : 1)dyspnea (RR = 30 times / min),&lt;br&gt;             2)finger oxygen saturation = 93% in resting state, 3)arterial oxygen partial pressure&lt;br&gt;             (PaO2) / oxygen absorption concentration (FiO2) = 300MMHG, 4)pulmonary imaging shows&lt;br&gt;             that the focus progress &gt; 50% in 24-48 hours&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Pregnancy, lactation and those who are not pregnant but do not take effective&lt;br&gt;             contraceptives measures;&lt;br&gt;&lt;br&gt;          2. Patients with malignant tumor, other serious systemic diseases and psychosis;&lt;br&gt;&lt;br&gt;          3. Patients who are participating in other clinical trials;&lt;br&gt;&lt;br&gt;          4. Inability to provide informed consent or to comply with test requirements.&lt;br&gt;&lt;br&gt;          5. Co-Infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory&lt;br&gt;             infection virus.&lt;br&gt;&lt;br&gt;          6. Invasive ventilation&lt;br&gt;&lt;br&gt;          7. Shock&lt;br&gt;&lt;br&gt;          8. combined with other organ failure( need organ support)&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Corona Virus Disease 2019(COVID-19)</Condition>
    <Intervention>Biological: MSCs;Biological: Saline containing 1% Human serum albumin(solution of MSC)</Intervention>
    <Primary_outcome>Improvement time of clinical critical treatment index within 28 days;Side effects in the MSCs treatment group</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04291053</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19</Public_title>
    <Scientific_title>The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tongji Hospital</Primary_sponsor>
    <Date_registration>27/02/2020</Date_registration>
    <Date_registration3>20200227</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04291053</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 1, 2020</Date_enrollement>
    <Target_size>550</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 2/Phase 3</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Lin Chen</Contact_Lastname>
    <Contact_Email>chenlin_tj@126.com</Contact_Email>
    <Contact_Tel>+8613517260864</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Aged between 18 and 75 years, extremes included, male or female&lt;br&gt;&lt;br&gt;          2. Patients diagnosed with mild or common type COVID-19, according to the official&lt;br&gt;             guideline "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection&lt;br&gt;             (Trial Version 6)"&lt;br&gt;&lt;br&gt;          3. patients can generally tolerable for treatment recommended by the official guideline&lt;br&gt;             "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial&lt;br&gt;             Version 6)"&lt;br&gt;&lt;br&gt;          4. Patients have not been accompanied by serious physical diseases of heart, lung, brain,&lt;br&gt;             etc., EOCG:0-1&lt;br&gt;&lt;br&gt;          5. Ability to understand and the willingness to sign a written informed consent document.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Female subjects who are pregnant or breastfeeding.&lt;br&gt;&lt;br&gt;          2. patients who are allergic to this medicine&lt;br&gt;&lt;br&gt;          3. patients meet the contraindications of Huaier granule&lt;br&gt;&lt;br&gt;          4. Patients with diabetes&lt;br&gt;&lt;br&gt;          5. Patients have any condition that in the judgement of the Investigators would make the&lt;br&gt;             subject inappropriate for entry into this study.&lt;br&gt;&lt;br&gt;          6. patients can't take drugs orally&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Drug: Huaier Granule</Intervention>
    <Primary_outcome>Mortality rate</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04291729</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection</Public_title>
    <Scientific_title>An Open and Controlled Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of Novel Coronavirus(2019-nCoV) Infection</Scientific_title>
    <Acronym />
    <Primary_sponsor>The Ninth Hospital of Nanchang</Primary_sponsor>
    <Date_registration>27/02/2020</Date_registration>
    <Date_registration3>20200227</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04291729</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 17, 2020</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Yahong Chen, MD;Hongyi Chen, MD;Hongyi Chen, MD</Contact_Lastname>
    <Contact_Email>;Chenhongyi8660@163.com;Chenhongyi8660@163.com</Contact_Email>
    <Contact_Tel>;8613807088660;8613807088660</Contact_Tel>
    <Contact_Affiliation>Ascletis Pharmaceuticals Co., Ltd.;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Aged 18-75 years old;&lt;br&gt;&lt;br&gt;          -  Pneumonia patients with new coronavirus infection were confirmed to be positive by&lt;br&gt;             RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and&lt;br&gt;             treatment plan for pneumonia with new coronavirus infection (Current Trial Version);&lt;br&gt;&lt;br&gt;          -  Patients with newly diagnosed respiratory system discomfort who have been hospitalized&lt;br&gt;             (the diagnosis time of respiratory system discomfort shall not exceed 7 days);&lt;br&gt;&lt;br&gt;          -  Women and their partners who have no planned pregnancy for nearly half a year and are&lt;br&gt;             willing to take effective contraceptive measures within 30 days from the first&lt;br&gt;             administration of the study drug to the last administration;&lt;br&gt;&lt;br&gt;          -  Agree not to participate in other clinical research within 30 days from the first&lt;br&gt;             administration of the study drug to the last administration;&lt;br&gt;&lt;br&gt;          -  Patients who voluntarily sign informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The pneumonia patients with severe new coronavirus infection met one of the following&lt;br&gt;             conditions: respiratory distress, RR &gt;= 30 times / min; or SaO2 / SpO2 &lt;93% in resting&lt;br&gt;             state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2)&lt;br&gt;             &lt;300MMHG (1mmhg = 0.133kpa);&lt;br&gt;&lt;br&gt;          -  Pneumonia patients with severe new coronavirus infection meet one of the following&lt;br&gt;             conditions: respiratory failure and need mechanical ventilation; or shock; or other&lt;br&gt;             organ failure combined with ICU monitoring treatment;&lt;br&gt;&lt;br&gt;          -  Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 times upper limit);&lt;br&gt;&lt;br&gt;          -  Patients with contraindications specified in the instructions of ritonavir tablets;&lt;br&gt;&lt;br&gt;          -  The pregnancy test of female subjects in the screening period was positive;&lt;br&gt;&lt;br&gt;          -  The researchers judged that it was not suitable to participate in this clinical trial&lt;br&gt;             (for example, patients who may be transferred to another hospital during the study&lt;br&gt;             period; patients with multiple basic diseases, etc.).&lt;br&gt;      </Inclusion_Criteria>
    <Condition>2019-nCoV Pneumonia</Condition>
    <Intervention>Drug: Ganovo+ritonavir+/-Interferon atomization;Drug: Long acting interferon;Drug: Recombinant cytokine gene-derived protein;Drug: Lopinavir+ritonavir;Drug: Chinese medicines +interferon atomization</Intervention>
    <Primary_outcome>Rate of composite adverse outcomes</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04292964</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Prognostic Factors of Patients With COVID-19</Public_title>
    <Scientific_title>Prognostic Factors of Patients With COVID-19</Scientific_title>
    <Acronym />
    <Primary_sponsor>Chongqing Medical University</Primary_sponsor>
    <Date_registration>01/03/2020</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04292964</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 1, 2020</Date_enrollement>
    <Target_size>98</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Dongying Zhang, doctor</Contact_Lastname>
    <Contact_Email>zdy.chris@qq.com</Contact_Email>
    <Contact_Tel>+8613608398395</Contact_Tel>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Adult aged &gt;=18years old;&lt;br&gt;&lt;br&gt;          -  Diagnosed with CONVID19. Diagnostic criteria including: Laboratory (RT-PCR) confirmed&lt;br&gt;             SARS-Cov-2 infection; CT of the lung conformed to the manifestation of viral&lt;br&gt;             pneumonia.&lt;br&gt;&lt;br&gt;          -  Criteria for severe or critical ill conditions: Respiratory rate &gt;=30/min; or Rest&lt;br&gt;             SPO2&lt;=93%; or PaO2/FiO2&lt;=300mmHg.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Near-death state (expected survival time less than 24 hours);&lt;br&gt;&lt;br&gt;          -  Malignant tumor;&lt;br&gt;&lt;br&gt;          -  Pregnancy or puerperium women;&lt;br&gt;&lt;br&gt;          -  Patients who refused to participant.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>SARS-CoV-2;Outcome, Fatal</Condition>
    <Primary_outcome>all-cause mortality</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04298814</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia</Public_title>
    <Scientific_title>Analysis of Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tongji Hospital</Primary_sponsor>
    <Date_registration>26/02/2020</Date_registration>
    <Date_registration3>20200226</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04298814</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>90 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 7, 2020</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Wuhan residents;&lt;br&gt;&lt;br&gt;          -  novel coronavirus pneumonia was found to be characterized by fever and cough.&lt;br&gt;             Laboratory tests revealed leukocyte or lymphocyte decrease, chest CT examination&lt;br&gt;             showed viral pneumonia changes, and was diagnosed as COVID-19 pneumonia according to&lt;br&gt;             the national health and Health Committee's new coronavirus pneumonia diagnosis and&lt;br&gt;             treatment plan (trial version fifth Revision).&lt;br&gt;&lt;br&gt;          -  Severe and critical patients with covid-19 pneumonia in urgent need of tracheal&lt;br&gt;             intubation;&lt;br&gt;&lt;br&gt;          -  Sign informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Suspected patients with covid-19 pneumonia;&lt;br&gt;&lt;br&gt;          -  Patients who need emergency endotracheal intubation due to other causes of respiratory&lt;br&gt;             failure;&lt;br&gt;&lt;br&gt;          -  The family refused to sign the informed consent.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19;Endotracheal Intubation</Condition>
    <Intervention>Other: severe covid-19 pneumonia with ET</Intervention>
    <Primary_outcome>Success rate of intubation;Infection rate of Anesthesiologist</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04299724</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Safety and Immunity of Covid-19 aAPC Vaccine</Public_title>
    <Scientific_title>Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine</Scientific_title>
    <Acronym />
    <Primary_sponsor>Shenzhen Geno-Immune Medical Institute</Primary_sponsor>
    <Date_registration>05/03/2020</Date_registration>
    <Date_registration3>20200305</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04299724</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>6 Months</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 15, 2020</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Lung-Ji Chang;Lung-Ji Chang;Lung-Ji Chang</Contact_Lastname>
    <Contact_Email>;c@szgimi.org;c@szgimi.org</Contact_Email>
    <Contact_Tel>;+86(755)8672 5195;86-755-86725195</Contact_Tel>
    <Contact_Affiliation>Shenzhen Geno-Immune Medical Institute;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Healthy and Covid-19-positive volunteers&lt;br&gt;&lt;br&gt;          -  The interval between the onset of symptoms and randomized is within 7 days in Covid-19&lt;br&gt;             patients. The onset of symptoms is mainly based on fever. If there is no fever, cough&lt;br&gt;             or other related symptoms can be used;&lt;br&gt;&lt;br&gt;          -  White blood cells = 3,500/l, lymphocytes = 750/l;&lt;br&gt;&lt;br&gt;          -  Human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV)&lt;br&gt;             or tuberculosis (TB) test negative;&lt;br&gt;&lt;br&gt;          -  Sign the Informed Consent voluntarily;&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Subject with active HCV, HBV or HIV infection.&lt;br&gt;&lt;br&gt;          -  Subject is albumin-intolerant.&lt;br&gt;&lt;br&gt;          -  Subject with life expectancy less than 4 weeks.&lt;br&gt;&lt;br&gt;          -  Subject participated in other investigational vaccine therapies within the past 60&lt;br&gt;             days.&lt;br&gt;&lt;br&gt;          -  Subject with positive pregnancy test result.&lt;br&gt;&lt;br&gt;          -  Researchers consider unsuitable.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Treat and Prevent Covid-19 Infection</Condition>
    <Intervention>Biological: Pathogen-specific aAPC</Intervention>
    <Primary_outcome>Frequency of vaccine events;Frequency of serious vaccine events;Proportion of subjects with positive T cell response</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04303299</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial</Public_title>
    <Scientific_title>A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Chloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Chloroquine in Mild COVID19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Chloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Chloroquine in Moderate to Critically Ill COVID19</Scientific_title>
    <Acronym>THDMS-COVID19</Acronym>
    <Primary_sponsor>Rajavithi Hospital</Primary_sponsor>
    <Date_registration>24/02/2020</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04303299</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16 Years</Inclusion_agemin>
    <Inclusion_agemax>100 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 15, 2020</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 3</Phase>
    <Countries>Thailand</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Subsai Kongsaengdao, M.D.</Contact_Lastname>
    <Contact_Email>skhongsa@gmail.com</Contact_Email>
    <Contact_Tel>66818180890</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The subject has to grant permission to enter into the study by signing and dating the&lt;br&gt;             informed consent form before completing any study-related procedure such as any&lt;br&gt;             assessment or evaluation not related to the normal medical care of the subject.&lt;br&gt;&lt;br&gt;          -  Able to give written inform consent and retained one copy of the consent form&lt;br&gt;&lt;br&gt;          -  Male or female subject, aged between 16 - 100 years old.&lt;br&gt;&lt;br&gt;          -  Subject diagnosed to be COVID19&lt;br&gt;&lt;br&gt;          -  Female subject in good health and sexually active was instructed by the investigator&lt;br&gt;             to avoid pregnancy during the study and to use condom or other contraceptive measure&lt;br&gt;             if necessary. The subject was required to have a negative urine pregnancy test before&lt;br&gt;             being eligible for the study. (At each of the subsequent visit, a urine pregnancy test&lt;br&gt;             was performed).&lt;br&gt;&lt;br&gt;          -  Subject judged to be reliable for compliance for taking medication and capable of&lt;br&gt;             recording the effects of the medication and motivated in receiving benefits from the&lt;br&gt;             treatment.and compliance to quarantine procedure 7-14 days after treatment&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The subject was pregnant or lactating.&lt;br&gt;&lt;br&gt;          -  The subject was a female at risk of pregnancy during the study and not taking adequate&lt;br&gt;             precautions against pregnancy.&lt;br&gt;&lt;br&gt;          -  The subject had a known hypersensitivity to any of the test materials or related&lt;br&gt;             compounds.&lt;br&gt;&lt;br&gt;          -  The subject was unable or unwilling to comply fully with the protocol.&lt;br&gt;&lt;br&gt;          -  Treatment with investigational drug (s) within 6 months before the screening visit.&lt;br&gt;&lt;br&gt;          -  The subject had previously entered in this study.&lt;br&gt;&lt;br&gt;          -  Patient who planned to schedule elective surgery during the study&lt;br&gt;&lt;br&gt;          -  The used of other antiviral agents&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus Infections;COVID19</Condition>
    <Intervention>Drug: Oral</Intervention>
    <Primary_outcome>SARS-CoV-2 eradication time</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030810</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine</Public_title>
    <Scientific_title>Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50986</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-23</Date_enrollement>
    <Target_size>Experimental group:50;control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Cross-sectional</Study_design>
    <Phase>1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Xugui</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>279 Luoyu Road, Hongshan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>spine672@163.com</Contact_Email>
    <Contact_Tel>+86 13807172756</Contact_Tel>
    <Contact_Affiliation>Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) mild / general patients who meet the diagnostic criteria of the Protocol;&lt;br&gt;(2) Aged &gt;=18 years;&lt;br&gt;(3) Obtain patients' informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Patients who cannot guarantee medication compliance during treatment, and patients who have difficulty in oral administration;&lt;br&gt;(2) Patients more than 7 days after diagnosis;&lt;br&gt;(3) Patients with severe primary respiratory diseases, or patients with other pathogenic microbial pneumonia that needs to be identified with NCP; &lt;br&gt;(4) pregnant women, those with positive urine pregnancy tests;&lt;br&gt;(5) Combined with other systemic malignant diseases such as malignant tumors and mental diseases;&lt;br&gt;(6) Patients with other serious diseases such as uremia and severe heart failure;&lt;br&gt;(7) Those who are allergic to the test drugs or who are intolerant to taking the drugs;&lt;br&gt;(8) Patients that the investigator considers unsuitable to participate in the study.</Exclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Experimental group:oral medicine(trditional medicine);control group:oral medicine( anti virious);</Intervention>
    <Primary_outcome>Average discharge time;WBC;ALT, AST, gama-GT, BUN, Cr, CK-MB;turn serious/crisis ratio;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030809</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for clinical outcomes and follow-up of novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>Clinical outcomes and follow-up study of COVID-19 patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51015</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>13</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-22</Date_enrollement>
    <Target_size>Case series:1000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xu Shuyun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>sxu@hust.edu.cn</Contact_Email>
    <Contact_Tel>+86 13517248539</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: According to the clinical diagnostic criteria of the fifth edition "diagnosis and treatment of pneumonia with novel coronavirus infection", COVID 19 pneumonia was clinically diagnosed.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Discharge cases that cannot be contacted by WeChat or telephone;&lt;br&gt;2. Discharge cases with language and other barriers, inability to communicate effectively, or failure to receive follow-up for various reasons.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Clinical outcomes after discharge;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04292340</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19</Public_title>
    <Scientific_title>The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study</Scientific_title>
    <Acronym />
    <Primary_sponsor>Shanghai Public Health Clinical Center</Primary_sponsor>
    <Date_registration>25/02/2020</Date_registration>
    <Date_registration3>20200225</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04292340</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 1, 2020</Date_enrollement>
    <Target_size>15</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>Phase 2/Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Hongzhou Lu, Ph.D;Hongzhou Lu, Ph.D;Jun Chen</Contact_Lastname>
    <Contact_Email>;luhongzhou@fudan.edu.cn;</Contact_Email>
    <Contact_Tel>;+86-021-37990333;008602137990333</Contact_Tel>
    <Contact_Affiliation>Shanghai Public Health Clinical Center;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  The participants were diagnosed as COVID-19;&lt;br&gt;&lt;br&gt;          -  Participants received anti-SARS-CoV-2 inactivated convalescent plasma&lt;br&gt;&lt;br&gt;          -  Written the informed consent.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Participants lacked detailed medical history&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus</Condition>
    <Primary_outcome>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7;Numbers of participants with different Clinical outcomes</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04293692</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus</Public_title>
    <Scientific_title>Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus</Scientific_title>
    <Acronym />
    <Primary_sponsor>Puren Hospital Affiliated to Wuhan University of Science and Technology</Primary_sponsor>
    <Date_registration>24/02/2020</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04293692</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 24, 2020</Date_enrollement>
    <Target_size>48</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). </Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Yan Liu, MD;Yan Liu, MD</Contact_Lastname>
    <Contact_Email>447822853@qq.com;447822853@qq.com</Contact_Email>
    <Contact_Tel>+8613387517458;+8613387517458</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Male or female, 18 years old = age = 75years old;&lt;br&gt;&lt;br&gt;          2. CT image is characteristic of 2019 novel coronavirus pneumonia;&lt;br&gt;&lt;br&gt;          3. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase&lt;br&gt;             chain reaction (RT-PCR);&lt;br&gt;&lt;br&gt;          4. In compliance with the 2019-nCoV pneumonia diagnosis standard (according to the novel&lt;br&gt;             coronavirus infection pneumonia diagnosis and treatment program (Trial Implementation&lt;br&gt;             Version 6) issued by the National Health and Medical Commission, and WHO 2019 new&lt;br&gt;             coronavirus guidelines standards): (A) increased breathing rate (=30 beats / min),&lt;br&gt;             difficulty breathing, cyanosis of the lips; (B) in resting state, means oxygen&lt;br&gt;             saturation =93%; (C) partial pressure of arterial oxygen (PaO2) / Fraction of inspired&lt;br&gt;             oxygen (FiO2) =300 mmHg (1mmHg = 0.133kPa);&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients with severe allergies or allergies to stem cells;&lt;br&gt;&lt;br&gt;          2. Patients with serious basic diseases that affect survival, including: blood diseases,&lt;br&gt;             cachexia, active bleeding, severe malnutrition, etc.;&lt;br&gt;&lt;br&gt;          3. Patients with pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis,&lt;br&gt;             alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or&lt;br&gt;             bacterial pneumonia;&lt;br&gt;&lt;br&gt;          4. Continuous use of immunosuppressive agents or organ transplants in the past 6 months;&lt;br&gt;&lt;br&gt;          5. In vitro life support (ECMO, ECCO2R, RRT);&lt;br&gt;&lt;br&gt;          6. Expected deaths within 48 hours, uncontrolled infections;&lt;br&gt;&lt;br&gt;          7. Patients with malignant blood-borne diseases such as HIV or syphilis;&lt;br&gt;&lt;br&gt;          8. Patient with pregnancy, are planning to become pregnant or breastfeeding;&lt;br&gt;&lt;br&gt;          9. Patients with poor compliance and unable to complete the full study;&lt;br&gt;&lt;br&gt;         10. The investigator determines that there may be increased risk of the subject or other&lt;br&gt;             conditions that interfere with the clinical trial and the judgment of the results&lt;br&gt;             (such as excessive stress, sensitivity or cognitive impairment, etc.);&lt;br&gt;&lt;br&gt;         11. There are other situations that the researchers think are not suitable to participate&lt;br&gt;             in this clinical study&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Biological: UC-MSCs;Other: Placebo</Intervention>
    <Primary_outcome>Size of lesion area by chest imaging;Blood oxygen saturation</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04293887</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy and Safety of IFN-a2 in the Treatment of Novel Coronavirus Patients</Public_title>
    <Scientific_title>Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon a1 in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tongji Hospital</Primary_sponsor>
    <Date_registration>15/02/2020</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04293887</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 1, 2020</Date_enrollement>
    <Target_size>328</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Early Phase 1</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Jianping Zhao, Ph.D.</Contact_Lastname>
    <Contact_Email>Zhaojp88@126.com</Contact_Email>
    <Contact_Tel>13507138234</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age = 18 years;&lt;br&gt;&lt;br&gt;          2. Clinically diagnosed patients with new type of coronavirus pneumonia, including: in&lt;br&gt;             accordance with the criteria for suspected cases, have one of the following etiology&lt;br&gt;             evidence:&lt;br&gt;&lt;br&gt;             ? Real-time fluorescence RT-PCR of respiratory specimens or blood specimens for&lt;br&gt;             detection of new coronavirus nucleic acid;&lt;br&gt;&lt;br&gt;             ? Sequencing of viral genes in respiratory specimens or blood specimens, highly&lt;br&gt;             homologous to known new coronavirus&lt;br&gt;&lt;br&gt;          3. The time interval between the onset of symptoms and random enrollment is within 7&lt;br&gt;             days. The onset of symptoms is mainly based on fever. If there is no fever, cough,&lt;br&gt;             diarrhea or other related symptoms can be used.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Any situation where the programme cannot be carried out safely;&lt;br&gt;&lt;br&gt;          2. Patients who have used interferon or remedesivir;&lt;br&gt;&lt;br&gt;          3. No clinical manifestations and chest imaging findings&lt;br&gt;&lt;br&gt;          4. Known allergy or hypersensitivity to interferon (including asthma);&lt;br&gt;&lt;br&gt;          5. Disabled in patients with uncontrolled autoimmune diseases;&lt;br&gt;&lt;br&gt;          6. Patients with severe heart disease, decompensated liver disease, renal insufficiency&lt;br&gt;             (CrCL &lt;50ml / min), and those with abnormal bone marrow function are prohibited;&lt;br&gt;&lt;br&gt;          7. Epilepsy and impaired central nervous system function;&lt;br&gt;&lt;br&gt;          8. Pregnancy: Positive pregnancy test for women of childbearing age;&lt;br&gt;&lt;br&gt;          9. Breastfeeding women have not stopped breastfeeding;&lt;br&gt;&lt;br&gt;         10. The patient may be transferred to a non-participating hospital within 72 hours.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19;Recombinant Human Interferon a1</Condition>
    <Intervention>Drug: Recombinant human interferon a1</Intervention>
    <Primary_outcome>The incidence of side effects;The incidence of side effects;The incidence of side effects</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04302766</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Expanded Access Remdesivir (RDV; GS-5734)</Public_title>
    <Scientific_title>Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734)</Scientific_title>
    <Acronym />
    <Primary_sponsor>U.S. Army Medical Research and Development Command</Primary_sponsor>
    <Date_registration>02/03/2020</Date_registration>
    <Date_registration3>20200302</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04302766</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 2, 2020</Date_enrollement>
    <Target_size />
    <Study_type>Expanded Access</Study_type>
    <Study_design />
    <Phase>N/A</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Sandi K Parriott</Contact_Lastname>
    <Contact_Email>sandi.k.parriott.mil@mail.mil</Contact_Email>
    <Contact_Tel>301-619-6824</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  DoD-affiliated personnel (including active and reserve component service members, US&lt;br&gt;             civilian employees, contractors, other US personnel, and dependents of any age, as&lt;br&gt;             well as allied military forces and local nationals) who have been granted access to&lt;br&gt;             the medical facility&lt;br&gt;&lt;br&gt;          -  Have a COVID-19 diagnosis&lt;br&gt;&lt;br&gt;          -  Available for clinical follow-up for duration of the treatment and follow-up period&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;         Unable or unwilling to meet the requirements of the protocol&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Coronavirus Disease 2019</Condition>
    <Intervention>Drug: Remdesivir</Intervention>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030795</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A multicenter retrospective study of rheumatic  patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multicenter retrospective study of rheumatic  patients with COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50982</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>12</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-20</Date_enrollement>
    <Target_size>Case series:90;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lingli Dong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>tjhdongll@163.com</Contact_Email>
    <Contact_Tel>+86 18672912727</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients must meet all of the following inclusion criteria before they can join this study: &lt;br&gt;1. Patients admitted to hospital from December 2019 to March 2020;&lt;br&gt;2. Patients identified as any rheumatic disease according to the latest international diagnostic standards for the respective disease;&lt;br&gt;3. COVID-19 patients have been diagnosed according to the Chinese New Coronavirus Pneumonia Diagnosis and Treatment Program (trial version 7).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients who meet any of the following criteria are not eligible for this study: &lt;br&gt;1. The clinical data are insufficient and the required clinical data cannot be collected;&lt;br&gt;2. The age of the patient is below 12 years old.</Exclusion_Criteria>
    <Condition>Rheumatic disease; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Clinical features;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030778</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for epidemic and clinical features of novel coronavirus pneumonia (COVID-19) in Ningbo First Hospital</Public_title>
    <Scientific_title>Epidemiologic and Clinical features of COVID-19 in Ningbo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Ningbo First Hospital</Primary_sponsor>
    <Date_registration>2020-03-14</Date_registration>
    <Date_registration3>20200314</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50987</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-20</Date_enrollement>
    <Target_size>Case series:40;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qian Guoqing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>59 Liuting  Street, Ningbo, Zhejiang, China</Contact_Address>
    <Contact_Email>guoqing.qian@foxmail.com</Contact_Email>
    <Contact_Tel>+86 15888193663</Contact_Tel>
    <Contact_Affiliation>Ningbo First Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All confirmed COVID-19 followed  by  the guidance of NHC.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: None.</Exclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Case series:No;</Intervention>
    <Primary_outcome>Epidemiological features;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04303507</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting</Public_title>
    <Scientific_title>Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)</Scientific_title>
    <Acronym>COPCOV</Acronym>
    <Primary_sponsor>University of Oxford</Primary_sponsor>
    <Date_registration>06/03/2020</Date_registration>
    <Date_registration3>20200306</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04303507</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>May 2020</Date_enrollement>
    <Target_size>10000</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator). </Study_design>
    <Phase>N/A</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>William Schilling, MD</Contact_Lastname>
    <Contact_Email>William@tropmedres.ac</Contact_Email>
    <Contact_Tel>+66 2 203-6333</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Participant is willing and able to give informed consent for participation in the&lt;br&gt;             study and agrees with the study and its conduct&lt;br&gt;&lt;br&gt;          -  Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential&lt;br&gt;             antivirals&lt;br&gt;&lt;br&gt;          -  Adults = 16 years&lt;br&gt;&lt;br&gt;          -  Not previously diagnosed with COVID-19&lt;br&gt;&lt;br&gt;          -  Participant works in healthcare facility or other well characterised high-risk&lt;br&gt;             environment, OR is an inpatient or relative of a patient in a participating hospital&lt;br&gt;             and likely exposed to COVID-19 infection or another high-risk group&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Hypersensitivity reaction to chloroquine, hydroxychloroquine or 4-aminoquinolines&lt;br&gt;&lt;br&gt;          -  Contraindication to taking chloroquine as prophylaxis e.g. known epileptic, creatinine&lt;br&gt;             clearance &lt; 10 ml/min&lt;br&gt;&lt;br&gt;          -  Already taking chloroquine, hydroxychloroquine or 4-aminoquinolines&lt;br&gt;&lt;br&gt;          -  Known retinal disease&lt;br&gt;&lt;br&gt;          -  Inability to be followed up for the trial period&lt;br&gt;&lt;br&gt;          -  Taking a concomitant medication (Abiraterone acetate, Agalsidase, Amodiaquine,&lt;br&gt;             Conivaptan, Dabrafenib, Dacomitinib, Dapsone (Systemic), Enzalutamide, Fusidic Acid&lt;br&gt;             (Systemic), Idelalisib, Lanthanum, Lumefantrine, Mefloquine, MiFEPRIStone, Mitotane,&lt;br&gt;             Pimozide, QT-prolonging Agents, Stiripentol) which cannot be safely stopped&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID19;Coronavirus;Acute Respiratory Illnesses</Condition>
    <Intervention>Drug: Chloroquine;Drug: Placebo</Intervention>
    <Primary_outcome>Number of symptomatic COVID-19 infections</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04305106</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia-RCT</Public_title>
    <Scientific_title>The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia--a Multi-Centered Randomized ControlledClinical Trial</Scientific_title>
    <Acronym />
    <Primary_sponsor>Qilu Hospital of Shandong University</Primary_sponsor>
    <Date_registration>09/03/2020</Date_registration>
    <Date_registration3>20200309</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04305106</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 12, 2020</Date_enrollement>
    <Target_size>118</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). </Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Jiaojiao Pang, PHD</Contact_Lastname>
    <Contact_Email>sddxlcyjzx@163.com</Contact_Email>
    <Contact_Tel>+86 18560089129</Contact_Tel>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Age: 18-80 years old, male and female;&lt;br&gt;&lt;br&gt;          2. Covid-19 confirmed cases;&lt;br&gt;&lt;br&gt;          3. Comply with any of the following:&lt;br&gt;&lt;br&gt;               -  Dyspnea, RR = 30 times / min;&lt;br&gt;&lt;br&gt;                    -  In resting state, transcutaneous oxygen saturation = 93%;&lt;br&gt;&lt;br&gt;                         -  Oxygenation index (PaO2 / FiO2) &lt; 300MMHG;&lt;br&gt;&lt;br&gt;          4. Pulmonary imaging showed diffuse exudative lesions.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Unable to obtain informed consent;&lt;br&gt;&lt;br&gt;          2. Patients with severe liver dysfunction (Child Pugh score = C, or AST &gt; 5 times of the&lt;br&gt;             upper limit), severe renal dysfunction (estimated glomerular filtration rate = 30ml /&lt;br&gt;             min / 1.73 m2), or continuous renal replacement therapy, hemodialysis, peritoneal&lt;br&gt;             dialysis;&lt;br&gt;&lt;br&gt;          3. Patients with hypertension and unsatisfactory control of antihypertensive drugs&lt;br&gt;             (sitting systolic blood pressure &gt; 160mmHg, or diastolic blood pressure &gt; 100mmHg) had&lt;br&gt;             a history of hypertension crisis or hypertensive encephalopathy;&lt;br&gt;&lt;br&gt;          4. Patients with heart disease or clinical symptoms that can not be well controlled, such&lt;br&gt;             as NYHA class II or above of cardiac insufficiency, unstable angina, myocardial&lt;br&gt;             infarction within one year, supraventricular or ventricular arrhythmias need treatment&lt;br&gt;             or intervention;&lt;br&gt;&lt;br&gt;          5. Those with known hereditary bleeding tendency or coagulation dysfunction, those who&lt;br&gt;             had received full dose anticoagulant or thrombolytic therapy in the first 10 days of&lt;br&gt;             the group, or those who had taken nonsteroidal anti-inflammatory drugs with platelet&lt;br&gt;             inhibition in the first 10 days of the group (except those who had preventive use of&lt;br&gt;             low-dose aspirin = 325mg / day);&lt;br&gt;&lt;br&gt;          6. In the first 6 months of the group, the patients who had thrombosis, such as ischemic&lt;br&gt;             stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism and other&lt;br&gt;             thrombotic diseases, and in the first 6 months of the group, the patients who had&lt;br&gt;             serious angiopathy (including aneurysms or arterial thrombosis requiring surgical&lt;br&gt;             treatment) were screened;&lt;br&gt;&lt;br&gt;          7. Patients with unhealed wounds, active gastric ulcer or fracture; patients with&lt;br&gt;             gastrointestinal perforation, gastrointestinal fistula, abdominal abscess and internal&lt;br&gt;             fistula in the first 6 months of the group; patients with major surgical history&lt;br&gt;             (including thoracotomy biopsy), major trauma (such as fracture) or possible surgery in&lt;br&gt;             the course of participating in the trial within 28 days before the group;&lt;br&gt;&lt;br&gt;          8. There were hemoptysis, gastrointestinal bleeding, central nervous system bleeding,&lt;br&gt;             nose bleeding and other serious and active bleeding patients within one month before&lt;br&gt;             admission;&lt;br&gt;&lt;br&gt;          9. There were malignant tumors in the past 5 years;&lt;br&gt;&lt;br&gt;         10. Those allergic to bevacizumab and its components;&lt;br&gt;&lt;br&gt;         11. Untreated active hepatitis patients and HIV positive patients;&lt;br&gt;&lt;br&gt;         12. Pregnant women, lactating women and planned pregnant women;&lt;br&gt;&lt;br&gt;         13. Have participated in other clinical trials or the researchers think it is not suitable&lt;br&gt;             to participate in this study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19 Pneumonia</Condition>
    <Intervention>Drug: Bevacizumab</Intervention>
    <Primary_outcome>Proportion of patients whose oxygenation index increased by 100mmhg on the 7th day after admission</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04308187</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Influence of the COvid-19 Epidemic on STRESS</Public_title>
    <Scientific_title>The COVISTRESS Study: Influence of the COvid-19 Epidemic on STRESS</Scientific_title>
    <Acronym>COVISTRESS</Acronym>
    <Primary_sponsor>University Hospital, Clermont-Ferrand</Primary_sponsor>
    <Date_registration>12/03/2020</Date_registration>
    <Date_registration3>20200312</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04308187</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>N/A</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 11, 2020</Date_enrollement>
    <Target_size>50000</Target_size>
    <Study_type>Observational [Patient Registry]</Study_type>
    <Study_design />
    <Phase>Phase 2</Phase>
    <Countries>France</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>Frderic DUTHEIL;Lise Laclautre;Lise Laclautre</Contact_Lastname>
    <Contact_Email>;promo_interne_drci@chu-clermontferrand.fr;</Contact_Email>
    <Contact_Tel>;0473754963;0473754963</Contact_Tel>
    <Contact_Affiliation>University Hospital, Clermont-Ferrand;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Anyone volunteer to participate&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Anyone non-voluntary to participate&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Stress, Psychological</Condition>
    <Primary_outcome>Stress</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030898</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The affiliated Hospital to Changchun University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50780</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-27</Date_enrollement>
    <Target_size>Population under risk:1000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang Tan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1478 Gongnong Road, Changchun, Jilin, China</Contact_Address>
    <Contact_Email>Wangtan215@sina.com</Contact_Email>
    <Contact_Tel>+86 13756858523</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of Changchun University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Vulnerable and high risk groups such as health care workers and non health care workers in health care settings. 2019-ncov.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. A pregnant or lactating woman; &lt;br&gt;2. With other major diseases, such as serious heart, lung, liver, kidney damage or psychiatric patients. Participants should not take part in the study under any of the above circumstances. The Research Hospital and the applicant unit will not bear the responsibility if they intentionally conceal the medical history and medication history.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Population under risk:Chushifangyi prescription;</Intervention>
    <Primary_outcome>Confirmed 2019-ncov pneumonia;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030866</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical COVID-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>The First Hospital of Changsha</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50299</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>MSC group:30;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xie yuanlin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>311 Yingpan Road, Kaifu District, Changsha, Hu'nan, China</Contact_Address>
    <Contact_Email>1286779459@qq.com</Contact_Email>
    <Contact_Tel>+86 13975137399</Contact_Tel>
    <Contact_Affiliation>The First Hospital of Changsha</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients diagnosed as severe or critical COVID-19; or patients who have turned negative for viral nucleic acid detection but still have the following severe or critical manifestations:&lt;br&gt;According to the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 6)" promulgated by the National Health Commission, any of the following is confirmed to be diagnosed as severe COVID-19: &lt;br&gt;1) shortness of breath, RR &gt;=30 times / minute; &lt;br&gt;2) in a resting state , Oxygen saturation&lt;=93%; &lt;br&gt;3) arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) &lt;=300mmHg (1mmHg = 0.133kPa). &lt;br&gt;The diagnosis of critical COVID-19 is consistent with any of the following: &lt;br&gt;1) respiratory failure occurs and requires mechanical ventilation; &lt;br&gt;2) shock occurs; &lt;br&gt;3) combined organ failure requires ICU monitoring and treatment;&lt;br&gt;2. Informed consent, voluntary participation and signing of informed consent by patients (or entrusted agents).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Past medical history of pulmonary embolism;&lt;br&gt;(2) Patients infected with human immunodeficiency virus (HIV);&lt;br&gt;(3) Patients with malignant tumors: Patients with cervical carcinoma in situ, skin non metastatic squamous or basal cell carcinoma after complete treatment are excluded;&lt;br&gt;(4) pregnant and lactating women;&lt;br&gt;(5) Other situations that the clinician considers unsuitable.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>MSC group:Intravenous infusion of MSC based on conventional treatments;</Intervention>
    <Primary_outcome>Oxygenation index (arterial oxygen partial pressure (PaO2) / oxygen concentration (FiO2));Conversion rate from serious to critical patients;Conversion rate and conversion time from critical to serious patients;Mortality in serious and critical patients;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030864</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study for TCM Decoction in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Xiangyang 1st people's Hospital</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50662</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhu Bo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>3 Yunxing Road, Fancheng District, Xiangyang, Hubei, China</Contact_Address>
    <Contact_Email>274770142@qq.com</Contact_Email>
    <Contact_Tel>+86 13995789500</Contact_Tel>
    <Contact_Affiliation>Xiangyang 1st People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. novel coronavirus pneumonia diagnostic criteria;&lt;br&gt;2. age unlimited, male and female unlimited.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. not qualified for novel coronavirus pneumonia diagnostic criteria;&lt;br&gt;2. Pregnant or lactating women who are allergic to the drug;&lt;br&gt;3. Patients with severe primary diseases and psychosis, such as cardiovascular, liver, kidney and hematopoietic system;&lt;br&gt;4. There are factors influencing the observation of curative effect;&lt;br&gt;5. Those who do not meet the inclusion criteria, fail to use the medicine according to the regulations, fail to determine the curative effect or incomplete data, which affect the judgment of curative effect or safety.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Western medicine plus Qingfei Paidu decoction;</Intervention>
    <Primary_outcome>2019-ncov-RNA;Chest CT;Routine blood test;Blood biochemistry;TCM symptom;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030759</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Wenzhou Medical University</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49284</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>control group:14;experimental group:56;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jing-Guo Cheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Wenzhou Medical University, Chashan Higher Education Park, Wenzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>wzwsjcjg@126.com</Contact_Email>
    <Contact_Tel>+86 13857797188</Contact_Tel>
    <Contact_Affiliation>WenZhou Medical University </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Patients with Novel coronavirus pneumonia diagnosed according to &lt;diagnosis and treatment scheme for pneumonia of new coronavirus infection (trial version 5)&gt;;&lt;br&gt;(2) Inpatients aged &gt;18 years old;&lt;br&gt;(3) Patients Know the informed consent, voluntary participate in this clinical trial and sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Death is expected within 48 hours;&lt;br&gt;(2) Basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation , congenital heart disease, gastroesophageal reflux disease, congenital pulmonary airway malformation and more with  the exact evidence of bacterial infection;&lt;br&gt;(3)  Patients with the following conditions: Daily treatment of asthma, chronic respiratory disease, bacterial infections of the respiratory system such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media, etc that affect clinical trial evaluation. Chest CT confirmed the existence of severe pulmonary interstitial lesions, bronchiectasis and other basic pulmonary diseases;&lt;br&gt;(4) As judged by the researcher, past or present diseases may affect the participation of patients in the research outcome, including malignant diseases, autoimmune diseases, severe malnutrition, liver and kidney diseases, hematological diseases, nervous system diseases, endocrine diseases and serious diseases affecting the immune system such as human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc.&lt;br&gt;(5) Mental state unable to cooperation: suffering from mental illness, unabling to control or  express clearly;&lt;br&gt;(6) Allergic constitution (such as allergic to two or more drugs or food) or history of alleric to this product and conventional treatment drugs;&lt;br&gt;(7) History of substance abuse or dependence;&lt;br&gt;(8) Pregnant or nursing women;&lt;br&gt;(9) Participants in clinical trials of other drugs in the past 3 months;&lt;br&gt;(10) Researchers believe that patients are not suitable for any other situation in this study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>control group:Routine supportive treatment;experimental group:TCM decoction intervention + routine supportive treatment;</Intervention>
    <Primary_outcome>The time for the positive nucleic acid of the novel coronavirus to turn negative;Incidence of deterioration;The defervescence time;Chest CT;Primary symptom remission rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030758</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for sedation and Analgesia Usage in critically ill patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Sedation and Analgesia Usage in critically ill patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50590</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-10</Date_enrollement>
    <Target_size>NIV group:150;MV group:50;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhigang He</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>1097685807@qq.com</Contact_Email>
    <Contact_Tel>+86 18827001384</Contact_Tel>
    <Contact_Affiliation>Eergency / Intensive Care Department of Tongji Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) The diagnosis meets the diagnostic criteria for new coronavirus pneumonia;&lt;br&gt;2) Patients receiving NIV or MV treatment.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Age &lt; 14 years;&lt;br&gt;2) Pregnant women;&lt;br&gt;3) Incomplete information of necessary clinical data.</Exclusion_Criteria>
    <Condition>Novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>NIV group:no;MV group:no;</Intervention>
    <Primary_outcome>Dose of analgesic and sedative drugs;28-day mortality rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04304313</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A Pilot Study of Sildenafil in COVID-19</Public_title>
    <Scientific_title>A Pilot Study of Sildenafi in the Treatment of COVID-19</Scientific_title>
    <Acronym />
    <Primary_sponsor>Tongji Hospital</Primary_sponsor>
    <Date_registration>14/02/2020</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04304313</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>N/A</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 9, 2020</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). </Study_design>
    <Phase>Phase 3</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; </Contact_Firstname>
    <Contact_Lastname>Qing Ning, Professor;Qin Ning, professor</Contact_Lastname>
    <Contact_Email>qning@vip.sina.com;qning@vip.sina.com</Contact_Email>
    <Contact_Tel>+8613971521450;</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Patients diagnosed as COVID-19:&lt;br&gt;&lt;br&gt;               1. mild patient: fever,respiratory and other symptoms, the manifestation of&lt;br&gt;                  pneumonia can be seen on imaging.&lt;br&gt;&lt;br&gt;               2. severe patients: meet the definition of severe pneumonia(comply with any of the&lt;br&gt;                  followings): Shortness of breath,RR=30 bpm;In a resting&lt;br&gt;                  state:SPO2=93%;PaO2/FiO2=300mmHg.&lt;br&gt;&lt;br&gt;          2. Age=18 years old,unlimited gender.&lt;br&gt;&lt;br&gt;          3. Patients who cannot stop the following drugs during the trial:erythromycin or strong&lt;br&gt;             inhibitors of CYP3A4 (such as saquinavir,ketoconazole,itraconazole),nonspecific&lt;br&gt;             inhibitors of CYP (such as cimetidine),HIV protease inhibitors (such as ritonavir).&lt;br&gt;&lt;br&gt;          4. Willing to participate in this study,signed Informed Consent and willing to&lt;br&gt;             participate in regular follow-up during the study.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Suffer from severe cognitive impairment or mental illness.&lt;br&gt;&lt;br&gt;          2. Pregnant and lactating women.&lt;br&gt;&lt;br&gt;          3. Patients taking nitric oxide drugs and nitrates in any dosage form.&lt;br&gt;&lt;br&gt;          4. Patients with malignant tumors;AMI, stroke or life-threatening arrhythmias within 6&lt;br&gt;             months;hereditary pigmented retinitis;heart failure or unstable angina pectoris of&lt;br&gt;             coronary heart disease;patients with severe hypotension and hypertension.&lt;br&gt;&lt;br&gt;          5. Patients who are allergic to the study drug or the researcher believes it is not&lt;br&gt;             appropriate.&lt;br&gt;&lt;br&gt;          6. Participate in other clinical studies at the same time.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Drug: Sildenafil citrate tablets</Intervention>
    <Primary_outcome>Rate of disease remission;Rate of entering the critical stage;Time of entering the critical stage</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04306055</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Blood Donor Recruitment During Epidemic of COVID-19</Public_title>
    <Scientific_title>Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China</Scientific_title>
    <Acronym />
    <Primary_sponsor>Guangzhou Blood Center</Primary_sponsor>
    <Date_registration>08/03/2020</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04306055</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>60 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 12, 2020</Date_enrollement>
    <Target_size>1500</Target_size>
    <Study_type>Interventional</Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: None (Open Label). </Study_design>
    <Phase>N/A</Phase>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Blood donors whose last donation were between 1 Jan to 31 March, 2019.&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Blood donors whose blood test results were positive.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Blood Donation</Condition>
    <Intervention>Other: Questionnaire with precaution information;Other: Experimental: Questionnaire without precaution information</Intervention>
    <Primary_outcome>Differences of attitude about blood donation towards different questionnaires</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04306497</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.</Public_title>
    <Scientific_title>Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19 in Jiangsu Province</Scientific_title>
    <Acronym>CTOROTSADTOC</Acronym>
    <Primary_sponsor>Jiangsu Famous Medical Technology Co., Ltd.</Primary_sponsor>
    <Date_registration>01/03/2020</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04306497</web_address>
    <Recruitment_Status>Not recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>75 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>March 2, 2020</Date_enrollement>
    <Target_size>340</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>Phase 4</Phase>
    <Contact_Firstname xml:space="preserve"> </Contact_Firstname>
    <Contact_Lastname>Haibo Cheng, phD</Contact_Lastname>
    <Contact_Email>363994906@qq.com</Contact_Email>
    <Contact_Tel>13815857118</Contact_Tel>
    <Contact_Affiliation />
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          -  It conforms to the diagnostic criteria of confirmed cases of COVID-19;&lt;br&gt;&lt;br&gt;          -  Age from 18-75, regardless gender.&lt;br&gt;&lt;br&gt;          -  The patient informed consent and sign the informed consent form (if the subject has no&lt;br&gt;             capacity, limited capacity and limited expression of personal will, he or she should&lt;br&gt;             obtain the consent of his guardian and sign the informed consent at the same time).&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          -  Women during pregnancy or lactation;&lt;br&gt;&lt;br&gt;          -  Allergic constitution, such as those who have a history of allergy to two or more&lt;br&gt;             drugs or food, or who are known to be allergic to drug ingredients observed in this&lt;br&gt;             study.&lt;br&gt;&lt;br&gt;          -  Severe complications such as multiple organ failure and shock occurred.&lt;br&gt;&lt;br&gt;          -  Complicated with severe primary diseases such as heart, brain, liver, kidney and so&lt;br&gt;             on.&lt;br&gt;&lt;br&gt;          -  Patients have mental illness.&lt;br&gt;&lt;br&gt;          -  Patients who participated in or is currently participating in other clinical trials&lt;br&gt;             within the first month of this study.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>Drug: TCM prescriptions</Intervention>
    <Primary_outcome>The relief / disappearance rate of main symptoms;Chest CT absorption</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>NCT04306705</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19</Public_title>
    <Scientific_title>A Retrospective Study of Evaluating Safety and Efficacy of Tocilizumab Compared to Continuous Renal Replacement Therapy in Controlling CRS Triggered by COVID-19</Scientific_title>
    <Acronym>TACOS</Acronym>
    <Primary_sponsor>Tongji Hospital</Primary_sponsor>
    <Date_registration>08/03/2020</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ClinicalTrials.gov</Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04306705</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18 Years</Inclusion_agemin>
    <Inclusion_agemax>80 Years</Inclusion_agemax>
    <Inclusion_gender>All</Inclusion_gender>
    <Date_enrollement>February 20, 2020</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Observational</Study_type>
    <Study_design />
    <Phase>Phase 4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname> ; ; </Contact_Firstname>
    <Contact_Lastname>AIHUA DU, M.D;YIKAI YU, M.D;AIHUA DU, M.D</Contact_Lastname>
    <Contact_Email>;yuyikai@163.com;</Contact_Email>
    <Contact_Tel>;+1 (484) 995-5917;+86 2783662886</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital;</Contact_Affiliation>
    <Inclusion_Criteria>&lt;br&gt;        Inclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Agrees to the collection of oropharyngeal or anal swabs and venous blood per protocol.&lt;br&gt;&lt;br&gt;          2. Male or non-pregnant female adult =18 years of age at time of enrollment.&lt;br&gt;&lt;br&gt;          3. Has laboratory-confirmed novel coronavirus infection as determined by polymerase chain&lt;br&gt;             reaction (PCR), or other commercial or public health assay in oropharyngeal or anal&lt;br&gt;             specimen within 72 hours prior to hospitalization.&lt;br&gt;&lt;br&gt;          4. Illness of any duration, and at least one of the following:&lt;br&gt;&lt;br&gt;               1. Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR&lt;br&gt;&lt;br&gt;               2. Clinical assessment (evidence of rales/crackles on physical examination) AND SpO2&lt;br&gt;                  =93% on room air, OR&lt;br&gt;&lt;br&gt;               3. Requiring mechanical ventilation and/or supplemental oxygen, OR&lt;br&gt;&lt;br&gt;               4. Sustained fever in the past 24 hours and unresponsive to NSAID or steroid&lt;br&gt;&lt;br&gt;          5. Serum IL-6 =3 times the upper limit of normal&lt;br&gt;&lt;br&gt;        Exclusion Criteria:&lt;br&gt;&lt;br&gt;          1. Alanine transaminase/aspartate transaminase (ALT/AST) &gt; 5 times the upper limit of&lt;br&gt;             normal.&lt;br&gt;&lt;br&gt;          2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated glomerular&lt;br&gt;             filtration rate (eGFR) &lt; 30 ml /min/1.73 m^2)&lt;br&gt;&lt;br&gt;          3. Hemoglobin&lt;80 g/L&lt;br&gt;&lt;br&gt;          4. Leukocytes&lt;2.010^9&lt;br&gt;&lt;br&gt;          5. Platelets&lt;5010^9&lt;br&gt;&lt;br&gt;          6. Pregnancy or breast feeding.&lt;br&gt;&lt;br&gt;          7. Anticipated transfer to another hospital which is not a study site within 72 hours.&lt;br&gt;&lt;br&gt;          8. Expected life span does not exceed 7 days.&lt;br&gt;&lt;br&gt;          9. Allergy to any study medication.&lt;br&gt;      </Inclusion_Criteria>
    <Condition>Covid-19;SARS;Cytokine Storm;Cytokine Release Syndrome;Tocilizumab</Condition>
    <Intervention>Drug: Tocilizumab;Other: Standard of care;Procedure: Continuous renal replacement therapy</Intervention>
    <Primary_outcome>Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14</Primary_outcome>
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030757</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of investigator-initiated clinical trial and the resilience of medical service providers</Public_title>
    <Scientific_title>Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of investigator-initiated clinical trial and the resilience of medical service providers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Clinical Research Institute, Shenzhen-Peking University-The Hong Kong University of Science &amp; Technology Medical Center</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50648</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-13</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Yue</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1120 Lianhua Road, Futian District, Shenzhen, Guangdong, China</Contact_Address>
    <Contact_Email>zyzy1933@163.com</Contact_Email>
    <Contact_Tel>+86 18823361933</Contact_Tel>
    <Contact_Affiliation>Clinical Research Institute, Shenzhen-Peking University-The Hong Kong University of Science &amp; Technology Medical Center</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Currently participating in or responsible for an investigator-initiated clinical trial;&lt;br&gt;(2) Voluntarily participate in this study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: none</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19); mental health status</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Psychological assessment;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030756</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Shenzhen Hospital of Southern Medical University</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50705</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>20</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Case series:60;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qingyou Zheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1333 Xinhu Road, Bao'an District, Shenzhen, Guangdong, China</Contact_Address>
    <Contact_Email>zhengqingyou@163.com</Contact_Email>
    <Contact_Tel>+86 18601085226</Contact_Tel>
    <Contact_Affiliation>Shenzhen Hospital of Southern Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: we collected 30 mild and common type patients who have positive SARS-CoV-2 of throat swab and 30 suspected patients who have negative nucleic acid but have some symptoms (fever, cough, etc) as controls </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: severe patients and juveniles</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>SARS-CoV-2;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030859</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical based analysis for influencing factors of death of novel coronavirus pneumonia (COVID-19) patients in Wuhan third hospital</Public_title>
    <Scientific_title>Analysis of influencing factors of death of COVID-19 patients in wuhan third hospital                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Wuhan Third Hospital</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51025</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Group 1:700;Group 2:605;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>Chian</Countries>
    <Contact_Firstname>Guoqin Sun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>707986890@qq.com</Contact_Email>
    <Contact_Tel>+86 18971163158</Contact_Tel>
    <Contact_Affiliation>Wuhan Third Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Comply with the diagnostic criteria for patients with new pneumonia virus in the Pneumonitis Diagnosis and Treatment Program for Corona Virus Disease 2019(7th Edition);&lt;br&gt;(2) Complete clinical data of patients. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Patients who were eventually diagnosed with other bacterial or viral infections;&lt;br&gt;(2) Patients whose data could not be obtained for special reasons. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 1:Traditional Chinese medicine and routine treatment of western medicine;Group 2:Routine treatment of western medicine;</Intervention>
    <Primary_outcome>Mortality rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030857</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51040</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Case series:30;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Shusheng Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>Shushengli16@sina.com</Contact_Email>
    <Contact_Tel>+86 13971086498</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Critical patients with COVID-19 confirmed by etiology test;&lt;br&gt;2. airway intubation with mechanical ventilation is used;&lt;br&gt;3. voluntarily joined this study with informed consents.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnant women;&lt;br&gt;2. Combined with severe basal diseases such as malignant tumor, cirrhosis and HIV;&lt;br&gt;3. Patients with lung tumor, interstitial fibrosis, alveolar proteinosis, and allergic alveolitis.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:The use of fiberoptic bronchoscopy;</Intervention>
    <Primary_outcome>cytology;proteomics;chest X-ray;Oxygenation index;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030902</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Analysis for the mental health status of residents in Jingzhou during the outbreak of the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors</Public_title>
    <Scientific_title>Analysis for the mental health status of residents in Jingzhou during the outbreak of the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Jingzhou Mental Health Center</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51130</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Case series:1000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Deng Xiaopeng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>47 Taqiao Road North, Shashi District, Jingzhou, Hubei, China</Contact_Address>
    <Contact_Email>49637569@qq.com</Contact_Email>
    <Contact_Tel>+86 13872250922</Contact_Tel>
    <Contact_Affiliation>Jingzhou Mental Health Center</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. including confirmed, suspected patients, isolated observers, ordinary residents and frontline staff;&lt;br&gt;2. residence in Jingzhou for more than 14 days during the outbreak;&lt;br&gt;3. Aged 16-65 years;&lt;br&gt;4. self-volunteered.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: To rule out anyone not living in Jingzhou during the outbreak.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:None;</Intervention>
    <Primary_outcome>mental health status and influence factors;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030901</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Retrospective analysis of epidemiology and transmission dynamics of patients confirmed with Coronavirus Disease (COVID-19) in Hong Kong</Public_title>
    <Scientific_title>Retrospective analysis of epidemiology and transmission dynamics of patients confirmed with Coronavirus Disease (COVID-19) in Hong Kong                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>The Chinese University of Hong Kong</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51064</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-09</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Prof. Christopher CK Lai</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Department of Microbiology Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin , NT, Hong Kong SAR</Contact_Address>
    <Contact_Email>chris.kclai@cuhk.edu.hk</Contact_Email>
    <Contact_Tel>+852 3505 3333</Contact_Tel>
    <Contact_Affiliation>The Chinese University of Hong Kong</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All patients with laboratory confirmed diagnosis of COVID-19 and are listed in the Centre for Health Protection (CHP) database will be included in the study.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Not applicable</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Not applicable;</Intervention>
    <Primary_outcome>Transmission dynamics of COVID-19 in Hong Kong;Characteristics of super-spreading events;Effectiveness of public health measures;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030855</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe new coronavirus pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Department of Critical Care Medicine, the Third Affiliated Hospital of Zunyi Medical University</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51090</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>1</Phase>
    <Contact_Firstname>Wen Jianli</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>98 Fenghuang Road, Huichuan District, Zunyiy, Guizhou, China</Contact_Address>
    <Contact_Email>zywenjianli@163.com</Contact_Email>
    <Contact_Tel>+86 15186660001</Contact_Tel>
    <Contact_Affiliation>The Third Affiliated Hospital of Zunyi Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 years;&lt;br&gt;2. Endotracheal intubation patients with positive nucleic acid test of novel coronavirus;&lt;br&gt;3. Patients with off-line extubation.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Family members refuse to extubate;</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:external diaphragmatic pacing;</Intervention>
    <Primary_outcome>Length of stay in ICU;Diaphragm movement;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030850</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for the physical and mental health status of medical workers under the novel coronavirus pneumonia (COVID-19) epidemic</Public_title>
    <Scientific_title>Study for the physical and mental health status of medical workers under the situation of COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51056</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>??</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-15</Date_enrollement>
    <Target_size>Observation group:113;Control group:113;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fengbin Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China </Contact_Address>
    <Contact_Email>liufb163@163.com</Contact_Email>
    <Contact_Tel>+86 020-36591782</Contact_Tel>
    <Contact_Affiliation> the First Affiliated Hospital, Guangzhou University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-65 years, gender without limitation;&lt;br&gt;2. Meical workers normal working during the period of COVID-19;&lt;br&gt;3. Auqired the informed consent and willing to be a volunteer.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Medical worker who is diagnosed with COVID-19,suspected to COVID-19 or segregated due to COVID-19;&lt;br&gt;2. Occupation is not medical wokers such as manager,secretary or support staff who is work in medical institution;&lt;br&gt;3. Medical worker who is suffering from mental and psychological illness;&lt;br&gt;4. Medical worker who visit doctor due to discomfort dring the past 14 days;&lt;br&gt;5. Medical worker refuse to be investigated.</Exclusion_Criteria>
    <Condition>Somatopsychic illness; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Observation group:Medical workers in Hubei province;Control group:Non-Hubei medical staffNon-Hubei medical staff;</Intervention>
    <Primary_outcome>Chinese health status scale;Self-rating Anxiety Scale;Self-rating Depression Scale;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030742</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19): a dual-center, retrospective, cohort study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50857</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-15</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hongyu Gao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>hygao@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13886188018</Contact_Tel>
    <Contact_Affiliation>Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. confirmed with COVID-19;&lt;br&gt;2. ICU admission;&lt;br&gt;3. meet the critically ill criteria  according to Chinese management guideline for COVID-19 (version 7)</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. younger than 18 years old;&lt;br&gt;2. do not fulfill the criteria of critical cases;&lt;br&gt;3. declared clinical death or discharged after ICU admission within 24 hour;&lt;br&gt;4. important data missing.</Exclusion_Criteria>
    <Condition>Novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:no;</Intervention>
    <Primary_outcome>in-ICU mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030741</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with  Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with  Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Shandong Provincial Chest hospital</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50907</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>transnasal high-flow oxygen therapy:50;noninvasive mechanical ventilation:30;invasive mechanical ventilation:20;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fenglin Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China</Contact_Address>
    <Contact_Email>xkyylfl@163.com</Contact_Email>
    <Contact_Tel>+86 13953116564</Contact_Tel>
    <Contact_Affiliation>Shandong Provincial Chest Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;&lt;br&gt;2. aged 14 years or more;&lt;br&gt;3. diagnosis of  ARDS according to Berlin definition.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Hemodynamic instability: Cardiac pacemaker inserted in the last 2 days or life-threatening arrhythmias or circulatory disorders (use of large doses of vasoactive drugs);&lt;br&gt;2. Intracranial pressure &gt;30 mm Hg or cerebral perfusion pressure &lt;60 mmHg;&lt;br&gt;3. Massive hemoptysis requiring an immediate surgical or interventional radiology procedure;&lt;br&gt;4. Tracheal surgery or sternotomy during the previous 15 days;&lt;br&gt;5. Serious facial trauma or facial surgery;&lt;br&gt;6. Deep venous thrombosis treated for less than 2 days;&lt;br&gt;7. Anterior chest wall placed closed thoracic drainage device;&lt;br&gt;8. Open wound of abdominal cavity;&lt;br&gt;9. Unstable spine;&lt;br&gt;10. femur or pelvic fractures;&lt;br&gt;11. Pregnant women;&lt;br&gt;12. Use of extracorporeal membrane oxygenation (ECMO) before inclusion;&lt;br&gt;13. Chronic respiratory failure requiring oxygen therapy or non-invasive ventilation(NIV);&lt;br&gt;14. Previous inclusion in the present study;&lt;br&gt;15. Opposition from next of kin.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>transnasal high-flow oxygen therapy:prone position ventilation;noninvasive mechanical ventilation:prone position ventilation ;invasive mechanical ventilation:prone position ventilation;</Intervention>
    <Primary_outcome>PaO2;PaCO2;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030854</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A clinical multicenter study for the occurrence, development and prognosis of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A clinical multicenter study on the occurrence, development and prognosis of 2019 ncov infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Li Lanjuan</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51083</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-22</Date_enrollement>
    <Target_size>The triple combination antiviral therapy:196;The dual combination antiviral therapy:41;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Cohort study</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Lanjuan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>ljli@zju.edu.cn</Contact_Email>
    <Contact_Tel>+86 13906514210</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital, College of Medicine,Zhejiang University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria:  From January 22 to February 16, 2020,Patients diagnosed with new coronavirus infection in 15 medical institutions in Zhejiang Province.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with negative detection of new coronavirus nucleic acid</Exclusion_Criteria>
    <Condition>COVID-19</Condition>
    <Intervention>The triple combination antiviral therapy:abidor,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b);The dual combination antiviral therapy:,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b);</Intervention>
    <Primary_outcome>white blood cell;lymphocyte;creatinine;CRP;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030853</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Evaluation of the protective effect of dexmedetomidine on patients with severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Evaluation of the protective effect of dexmedetomidine on patients with severe new coronavirus pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Department of critical care medicine, the third affiliated hospital of zunyi medical university</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51081</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:200;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Wen Jianli</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>98 Fenghuang Road, Huichuan District, Zunyiy, Guizhou, China</Contact_Address>
    <Contact_Email>zywenjianli@163.com</Contact_Email>
    <Contact_Tel>+86 15186660001</Contact_Tel>
    <Contact_Affiliation>The Third Affiliated Hospital of Zunyi Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged &gt;=18 years old;&lt;br&gt;2. Symptoms of novel coronavirus infection;&lt;br&gt;3. Positive nucleic acid test of novel coronavirus.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnancy;&lt;br&gt;2. Patients with advanced malignant tumor;&lt;br&gt;3. Suspected cases.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:dexmedetomidine;</Intervention>
    <Primary_outcome>CK-MB;CTnI;neuron-specific enolase,NSE;BUN;scr.;lactic acid;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030841</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Exploratory study for Immunoglobulin From Cured COVID-19 Patients in the Treatment of Acute Severe novel coronavirus pneuvirus (COVID-19)</Public_title>
    <Scientific_title>Treatment of Acute Severe COVID-19 With Immunoglobulin From Cured COVID-19 Patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Union hospital of Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51072</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Experimental group:5;Control group:5;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiang Cheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>nathancx@hust.edu.cn</Contact_Email>
    <Contact_Tel>+86 15972061080</Contact_Tel>
    <Contact_Affiliation>Union hospital of Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Volunteers who have understood and signed the informed consent;&lt;br&gt;2. Aged &gt;=18 years;&lt;br&gt;3. Patients diagnosed with acute severe 2019-nCoV pneumonia:&lt;br&gt;(1) Laboratory (RT-PCR) confirmed infection with 2019-nCoV.&lt;br&gt;(2) Lung involvement confirmed with pulmonary CT scan;&lt;br&gt;(3) At least one of the following conditions should be met: respiratory distress, RR &gt;=30 times/min; oxygen saturation &lt;=93% in resting state; PaO2/FiO2 &lt;=300mmHg; respiratory failure and mechanical ventilation are required; shock occurs; ICU monitoring and treatment is required in combination with other organ failure.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Viral pneumonia with other viruses besides 2019-nCoV;&lt;br&gt;2. Patients are not suitable for immunoglobulin therapy;&lt;br&gt;3. Participation in other studies;&lt;br&gt;4. Other circumstances in which the investigator determined that the patient is not suitable for the clinical trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Immunoglobulin of cured patients;Control group:gama-Globulin;</Intervention>
    <Primary_outcome>Time to Clinical Improvement (TTCI);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030839</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Preliminary screening of novel coronavirus pneumonia (COVID-19) by special laboratory examination and CT imaging before surgery</Public_title>
    <Scientific_title>Preliminary screening of Coronavirus Disease (COVID-19) by special laboratory examination and CT imaging before surgery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Tongren Hospital, Shanghai Jiao Tong University School of Medicine</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50904</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>12</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Screening</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Peng Sun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1111 Xianxia Road, Changning District, Shangha</Contact_Address>
    <Contact_Email>SP2082@shtrhospital.com</Contact_Email>
    <Contact_Tel>+86 18121225835</Contact_Tel>
    <Contact_Affiliation>Tongren Hospital, Shanghai Jiao Tong University School of Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Surgical admission patients requires emergency or scheduled surgery.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The patients were diagnosed with Coronavirus Disease (COVID-19) before surgery.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Laboratory examination and pulmonary CT;</Intervention>
    <Primary_outcome>SAA;Detection of respiratory pathogen serotype;Lymphocyte subgroup detection;IgM and IgG detection;Pulmonary CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030740</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19).</Public_title>
    <Scientific_title>Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Shandong Provincial Chest hospital</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50900</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fenglin Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China</Contact_Address>
    <Contact_Email>xkyylfl@163.com</Contact_Email>
    <Contact_Tel>+86 13953116564</Contact_Tel>
    <Contact_Affiliation>Shandong Provincial Chest Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;&lt;br&gt;2. ARDS patients are defined According to the Berlin definition.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Aged&lt;14 years; &lt;br&gt;2. Pneumothorax; &lt;br&gt;3. Severe asthma or COPD.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>case series:no;</Intervention>
    <Primary_outcome>mortality;ICU hospital stay;mechanical ventilation time;mortality of 28 days;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030708</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cross sectional study of dialysis treatment and mental status under the outbreak of novel coronavirus pneumonia (COVID-2019) in China</Public_title>
    <Scientific_title>Cross sectional study of dialysis treatment and mental status under the outbreak of COVID-2019 in China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-03-11</Date_registration>
    <Date_registration3>20200311</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50083</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>24</Inclusion_agemin>
    <Inclusion_agemax>89</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-10</Date_enrollement>
    <Target_size>Case series:1000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hui Zhong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China</Contact_Address>
    <Contact_Email>zhonghui39@126.com</Contact_Email>
    <Contact_Tel>+86 18980601215</Contact_Tel>
    <Contact_Affiliation>West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Hemodialysis and peritoneal dialysis patients</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who are not willing to fill in the scale;&lt;br&gt;2. Patients without the ability to fill in the scale  autonomously.</Exclusion_Criteria>
    <Condition>End-stage renal disease; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:filling in the  scale;</Intervention>
    <Primary_outcome>Levels of anxiety, stress and depression;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030832</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study on the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51044</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-16</Date_enrollement>
    <Target_size>Group 1:200;Group 2:200;Group 3:200;Group 4:200;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Yuan Yang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>yuanyang70@hotmail.com</Contact_Email>
    <Contact_Tel>+86 13995561816</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology(HUST)</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Intervention group:&lt;br&gt;(1) Aged 18 to 50 years;&lt;br&gt;(2) Diagnosed as a depression or anxiety by Diagnostic and Statistical Manual of Mental Disorders (DSM-5); the score of HAMD-17&gt;17,or HAMA&gt;7;&lt;br&gt;2. Non-intervention group:&lt;br&gt;(1) Aged 18 to 50 years;&lt;br&gt;(2) Diagnosed as a depression or anxiety by Diagnostic and Statistical Manual of Mental Disorders (DSM-5); the score of HAMD-17&gt;17,or HAMA&gt;7.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) other psychiatric disorders;&lt;br&gt;(2) complicating with sever medical disorder on nervous, cardiovascular, respiratory system;&lt;br&gt;(3) taking antidepressants, psychoactive drugs, steroids, drugs that affect heart rate and blood pressure;&lt;br&gt;(4) be in the Lactation or pregnancy.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 1:mindfulness therapy;Group 2:cognitive behavioral therapy;Group 3:exercise therapy;Group 4:Without treatment, online assessment per two weeks;</Intervention>
    <Primary_outcome>PHQ-9;GAD-7;PHQ-15;PSS-14;ISI;SHARPS;ACTH;cortisol;24-hour ECG;Magnetic resonance spectroscopy;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030830</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Development and application of novel coronavirus pneumonia (COVID-19) intelligent image classification system based on deep learning</Public_title>
    <Scientific_title>Development and application of COVID-19 intelligent image classification system based on deep learning                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Hwa Mei Hospital, University of Chinese Academy of Sciences</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51009</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-01</Date_enrollement>
    <Target_size>Case series:150;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jingfeng Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Room 711, Building 4, 41 Xibei Street, Haishu Distruct, Ningbo, Zhejiang, China</Contact_Address>
    <Contact_Email>jingfengzhang73@163.com</Contact_Email>
    <Contact_Tel>+86 15706855886</Contact_Tel>
    <Contact_Affiliation>Hwa Mei Hospital, University of Chinese Academy of Sciences</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All patients hospitalized for novel coronavirus pneumonia in Hwa Mei Hospital, University of Chinese Academy Sciences from January 2020 were enrolled. The subjects were included the confirmed cases following the latest guideline of diagnostic and treatment Covid-19 issued by China Health Committee, and suspected patients admitting in isolation and observation ward during the same study period.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Confirmed cases who had the organ transplantation were excluded following the latest guideline of diagnostic and treatment Covid-19 issued by China Health Committee.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Abnormalities on chest CT;Exposure to source of transmission within past 14 days;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030707</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau</Public_title>
    <Scientific_title>Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Ganzi Hospital of West China Hospital, Sichuan University</Primary_sponsor>
    <Date_registration>2020-03-11</Date_registration>
    <Date_registration3>20200311</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50160</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-20</Date_enrollement>
    <Target_size>Case series:78;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Lijia Demi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>94 West Street, Kangding, Ganzi Prefecture, Sichuan, China</Contact_Address>
    <Contact_Email>27216302@qq.com</Contact_Email>
    <Contact_Tel>+86 17723451376</Contact_Tel>
    <Contact_Affiliation>Ganzi Hospital of West China Hospital, Sichuan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients diagnosed with NCIP in Tibetan Plateau were included in the study</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients in non plateau areas</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Blood oxygen saturation;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030706</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                       Application of cas13a-mediated RNA detection in the assay of novel coronavirus nucleic acid (COVID-19)</Public_title>
    <Scientific_title>Application of cas13a-mediated RNA detection in the detection of novel coronavirus nucleic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of Zunyi Medical University</Primary_sponsor>
    <Date_registration>2020-03-11</Date_registration>
    <Date_registration3>20200311</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50001</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-09</Date_enrollement>
    <Target_size>Target condition:300;Difficult condition:200</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Guangtao huang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>149 Dalian Road, Zunyi, Guizhou, China</Contact_Address>
    <Contact_Email>haitao3140@sina.com</Contact_Email>
    <Contact_Tel>+86 18085287828</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of Zunyi Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Pneumonia cases with suspected SARS-CoV-2 have either of the following epidemiological histories consistent with the following two clinical manifestations:&lt;br&gt;A comprehensive analysis was conducted based on the following epidemiological history and clinical manifestations&lt;br&gt;1. Epidemiological history&lt;br&gt;(1) Travel history or residence history of wuhan and surrounding areas or other communities shall provide case reports before the onset of the disease;&lt;br&gt;(2) Cases have been reported in patients with fever or respiratory symptoms in community residents of wuhan and surrounding areas;&lt;br&gt;(3) Aggressive attack;&lt;br&gt;(4) History of exposure to new coronavirus infections people with new coronavirus infections are those who have tested positive for nucleic acid;&lt;br&gt;2. Clinical manifestations&lt;br&gt;(1) Fever and/or respiratory symptoms;&lt;br&gt;(2) Pneumonia with the above imaging features;&lt;br&gt;(3) The total number of white blood cells was normal or decreased or the number of lymphocytes decreased at the initial stage of the disease. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Suspected patients unable to collect nasopharyngeal swabs;&lt;br&gt;2. Pneumonia caused by other pathogens.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR&amp;#32;product&amp;#32;of&amp;#32;SARS-CoV-2.;</Intervention>
    <Primary_outcome>Sensitivity, specificity and accuracy;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030806</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Wuhan Third Hospital</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51029</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>experimental group:20;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>JIAN PENG</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>216 Guanshan Avenue, Hongshan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>137585260@qq.com</Contact_Email>
    <Contact_Tel>+86 13907105212</Contact_Tel>
    <Contact_Affiliation>Wuhan third hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The confirmed patients with common type of new coronavirus pneumonia were selected, and the diagnostic criteria were shown in [diagnosis and treatment scheme 5.0 for pneumonia caused by new coronavirus infection].</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Aged &gt; 75 years old and &lt; 18 years old;&lt;br&gt;2. Patients who are contraindicated or allergic to this study drug (lung-clearing and detoxification decoction and ulinastatin for injection);&lt;br&gt;3. Patients with previous tumor, severe liver disease, pulmonary fibrosis, tuberculosis, autoimmune diseases, and treatment with glucocorticoids and immunosuppressive agents;&lt;br&gt;4. The diagnostic criteria for severe patients with novel coronavirus pneumonia were [novel coronavirus infection pneumonia treatment scheme 5.0].</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Oral Chinese medicine "qingfei detoxification soup" + intravenous injection of ulinastatin 200000 U Bid.;</Intervention>
    <Primary_outcome>blood RT;ABG;blood clotting function;liver and kidney function;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030804</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial</Public_title>
    <Scientific_title>Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Maoming People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51018</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Exocarpium Citri Grandis Group:64;Placebo Group:64;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hu Linhui</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>101 Weimin Road, Maoming, Guangdong, China</Contact_Address>
    <Contact_Email>hulinhui@live.cn</Contact_Email>
    <Contact_Tel>+86 13580013426</Contact_Tel>
    <Contact_Affiliation>Maoming People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) aged between 18 and 75 years old;&lt;br&gt;(2) Common type patients with confirmed COVID-19 according to the diagnostic criteria of "novel coronavirus Infection Diagnosis and Treatment Plan (Trial 6th Edition)" issued by the National Health and Safety Commission;&lt;br&gt;(3) Patients and their families voluntarily participated in the study and signed an informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Female patients during pregnancy or lactation;&lt;br&gt;(2) Patients with allergy to Exocarpium Citri Grandis preparation, patients with intolerance to the recommended dose of Exocarpium Citri Grandis were previously applied;&lt;br&gt;(3) Patients who are taking part in clinical trials of other drugs;&lt;br&gt;(4) Patients are taking other foods or drugs with antitussive and antiasthmatic effects.&lt;br&gt;(5) There are other serious diseases that may threaten life, such as cancer.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Exocarpium Citri Grandis Group:Oral Administration of Exocarpium Citri Grandis Phlegm Cough Solution;Placebo Group:Oral Administration of Placebo;</Intervention>
    <Primary_outcome>Cough Score;Expectoration score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030690</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for immune cell subsets in convalescent patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study on immune cell subsets in convalescent patients with SARS-CoV-2 infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>The Third Affiliated Hospital of the Second Military Medical University</Primary_sponsor>
    <Date_registration>2020-03-10</Date_registration>
    <Date_registration3>20200310</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50261</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Two groups:30;</Target_size>
    <Study_type>Basic Science</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wang Hongyang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>225 Changhai Road, Yangpu District, Shanghai, China</Contact_Address>
    <Contact_Email>hywangk@vip.sina.com</Contact_Email>
    <Contact_Tel>+86 13801955367</Contact_Tel>
    <Contact_Affiliation>The Third Affiliated Hospital of the Second Military Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: COVID-19 confirmed that the clinical symptoms of patients disappeared, after imaging examination, virus nucleic acid test, in line with the discharge criteria of convalescent patients.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) &lt; 18 years old or = 80 years old; &lt;br&gt;2) pregnant and lactating women; &lt;br&gt;3) patients with severe primary diseases such as cardiovascular, liver, kidney and hematopoietic system.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Two groups:Nil;</Intervention>
    <Primary_outcome>Lymphocyte grouping;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030580</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Efficacy and safety of tozumab combined with adamumab(Qletli) in severe and critical patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Tozumab combined with adamumab(Qletli) in the treatment of severe and critically ill patients with novel coronavirus pneumonia (COVID-19):A prospective, single-center, randomized, parallel controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Shanghai General Hospital</Primary_sponsor>
    <Date_registration>2020-03-08</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50693</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>experimental group:30;control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Min Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>NO.85 Wujin Road, Hongkou District, Shanghai, China</Contact_Address>
    <Contact_Email>maggie_zhangmin@163.com</Contact_Email>
    <Contact_Tel>+86 18121288279</Contact_Tel>
    <Contact_Affiliation>Shanghai General Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) aged 18-80 years old;&lt;br&gt;(2) severe (including critical risk factors) and critical patients with confirmed novel coronavirus pneumonia;&lt;br&gt;(3) blood CRP and ESR were more than twice higher than normal or TNFa and Il-6 were higher than normal;&lt;br&gt;(4) sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) pregnant or breast-feeding women;&lt;br&gt;(2) ALT/AST &gt; 5 times ULN, neutrophils &lt; 0.5x10^9/L, platelets less than 50x10^9/L;&lt;br&gt;(3) definite diagnosis of rheumatoid immunity, malignant tumor and other related diseases;&lt;br&gt;(4) patients with long-term oral immunoregulatory drugs or who had used large doses of glucocorticoids within 14 days;&lt;br&gt;(5) allergic reactions to adamumab or tozumab;&lt;br&gt;(6) active hepatitis, tuberculosis, associated with specific severe bacterial and fungal infections, organ transplantation or mental disorders;&lt;br&gt;(7) received Il-6 monoclonal antibody or TNFa monoclonal antibody within 14 days.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Based on the standard treatment recommended in the guidelines, a combination of tozumab and adamumab was used;control group:Follow the guidelines for standard treatment;</Intervention>
    <Primary_outcome>chest computerized tomography;Nucleic acid detection of novel coronavirus;TNF-alpha;IL-6;IL-10;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030799</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50995</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-20</Date_enrollement>
    <Target_size>Target condition:1000;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>TAO WANG</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>wt7636@126.com</Contact_Email>
    <Contact_Tel>+86 13971477320</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who were confirmed diagnosis of COVID-19 pneumonia, according to the "pneumonia diagnosis and treatment program for novel coronavirus infection (trial version seven)", including clinical symptoms, pulmonary CT manifestations and positive nucleic acid test;&lt;br&gt;2. Patients who admitted to the designated hospitals. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Previous medication information was not recorded;&lt;br&gt;2. The patients' medical records  were incomplete after admission.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Clinical outcome;Index test:artificial&amp;#32;intelligence&amp;#32;prediction&amp;#32;model;</Intervention>
    <Primary_outcome>cure rate;propotion of progression;SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030797</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Shanghai Fifth People's Hospital, Fudan University</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50988</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-07</Date_enrollement>
    <Target_size>Case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yingjia Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>801 Heqing Road, Shanghai, China</Contact_Address>
    <Contact_Email>xuyingjia@5thhospital.com</Contact_Email>
    <Contact_Tel>+86 18017321696</Contact_Tel>
    <Contact_Affiliation>Shanghai Fifth People's Hospital, Fudan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 80 yrs;&lt;br&gt;2. Diagnosed as COVID-19 pneumonia(according to the latest diagnostic criteria of The novel coronavirus pneumonia diagnosis and treatment plan formulated by the State Health Protection Committee) </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with mental abnormality or unwilling to participate in this study;&lt;br&gt;2. Patients participating in other clinical trials.</Exclusion_Criteria>
    <Condition>Corona Virus Disease 2019(COVID-19)</Condition>
    <Intervention>Case series:Noninvasive hemodynamic monitoring;</Intervention>
    <Primary_outcome>all-cause death;fatal arrhythmias;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030558</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator             Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital</Public_title>
    <Scientific_title>Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Guangzhou Panyu Central Hospital</Primary_sponsor>
    <Date_registration>2020-03-07</Date_registration>
    <Date_registration3>20200307</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50678</web_address>
    <other_records>No</other_records>
    <Inclusion_agemin>1</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-07</Date_enrollement>
    <Target_size>1:132;2:132;</Target_size>
    <Study_type>Epidemilogical research</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hanwei Chen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>8 Fuyu Road East, Qiaonan Street, Panyu District ,Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>docterwei@sina.com</Contact_Email>
    <Contact_Tel>+86 18922238906</Contact_Tel>
    <Contact_Affiliation>Guangzhou Panyu central hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Epidemiological history:&lt;br&gt;1. History of residence or travel in Hubei province within 14 day before the onset of illness;&lt;br&gt;2. Exposure history to resident or traveler in Hubei province within 14 days before the onset of illness.&lt;br&gt;Suspected features:&lt;br&gt;1. fever;&lt;br&gt;2. Lymphopenia;&lt;br&gt;3. typical CT pneumonia features.&lt;br&gt;Inclusion criteria for cases admitted to the hospital: &lt;br&gt;all patients with fever, outpatient, emergency and in-patient.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Persons who do not meet the inclusion criteria</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>1:Throat swab virus nucleic acid test combined with low-dose chest CT;2:Throat swab virus nucleic acid test combined with low-dose chest CT;</Intervention>
    <Primary_outcome>CT image features;Fever;Throat swab virus nucleic acid tes;lymphocyte;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030329</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                          Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>The Second Affiliated Hospital of Xi'an Medical University</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49779</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-05</Date_enrollement>
    <Target_size>Control group:30;CIK group:30;NK group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Gao Jun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>167 Fangdong Street, Baqiao District, Xi'an, Shaanxi, China</Contact_Address>
    <Contact_Email>13816012151@163.com</Contact_Email>
    <Contact_Tel>+86 13816012151</Contact_Tel>
    <Contact_Affiliation>The Second Affiliated Hospital of Xi'an Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. New-type coronavirus infection is diagnosed as mild or common (diagnosed according to the "Notice on the Issuance of a New Coronavirus-Infected Pneumonia Diagnosis and Treatment Plan (Trial Implementation of the Sixth Edition)") or patients with poor immune function (cured discharged patients but peripheral hemolymph Cell count and classification are abnormal).&lt;br&gt;2. Aged 18-65 years;&lt;br&gt;3. Sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Doctors and researchers consider that the patient inappropriate to enroll in the study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Control group:conventional therapy;CIK group:Umbilical cord blood CIK cells (1.610E8/kg) were injected twice every other day.;NK group:Umbilical cord blood NK cells (1.610E8/kg) were injected twice every other day.;</Intervention>
    <Primary_outcome>Status of immune function;The time of nucleic acid turns to negative;Length of stay in-hospital;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030779</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A clinical trial for Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, open-label, controlled trial for the efficacy and safety of  Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Shanghai Changzheng Hospital</Primary_sponsor>
    <Date_registration>2020-03-14</Date_registration>
    <Date_registration3>20200314</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50973</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-16</Date_enrollement>
    <Target_size>Experimental group:50;Control group:50;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhaofen Lin,Wansheng Chen,Weifen Xie</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>415 Fengyang Road, Huangpu District, Shanghai, China</Contact_Address>
    <Contact_Email>linzhaofen@sina.com</Contact_Email>
    <Contact_Tel>+86 13601605100, 13301833859, 13701682806</Contact_Tel>
    <Contact_Affiliation>Shanghai Changzheng Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged between 18 and 75 years;&lt;br&gt;2. In accordance with NCP criteria for severe and critical illness. Combined with the following epidemiological history, clinical manifestations, and pathogenic examinations to make a comprehensive judgment;&lt;br&gt;3. Will not participate in other drug clinical trials since the first day of Ulinastatin Injection admission;&lt;br&gt;4. Will sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. With contraindications of Ulinastatin Injection;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. Patients taking other urinary trypsin inhibitors;&lt;br&gt;4. Not suitable to participate in the clinical trial by investigator's judgement.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional treatent and Ulinastatin;Control group:Conventional treatent ;</Intervention>
    <Primary_outcome>blood gas;SOFA score;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030763</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A Medical Records Based analysis for Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Analysis of Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Shandong Provincial Chest hospital</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50921</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>case series:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fenglin Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China</Contact_Address>
    <Contact_Email>xkyylfl@163.com</Contact_Email>
    <Contact_Tel>+86 13953116564</Contact_Tel>
    <Contact_Affiliation>Shandong Provincial Chest Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;&lt;br&gt;2. ARDS patients according to the Berlin definition.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Age&lt;14 years;&lt;br&gt;2. Accompanied by other serious organ dysfunction (including severe liver and kidney dysfunction, upper gastrointestinal bleeding, DIC, etc.).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>case series:no;</Intervention>
    <Primary_outcome>Pulmonary function;Cardiac function;neural function;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030852</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Factors associated with death in patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Factors associated with death patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Beijing An Zhen Hospital, Capital Medical University</Primary_sponsor>
    <Date_registration>2020-03-16</Date_registration>
    <Date_registration3>20200316</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51077</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-27</Date_enrollement>
    <Target_size>Case series:150;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jiang Xie</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>2 Anzhen Road, Chaoyang District, Beijing, China</Contact_Address>
    <Contact_Email>frank782008@aliyun.com</Contact_Email>
    <Contact_Tel>+86 13161985564</Contact_Tel>
    <Contact_Affiliation>Beijing Anzhen Hospital, Capital Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. positiveness of nucleic acid of COVID-19 in a in throat swab nucleic acid positive;&lt;br&gt;2. newly-onset pneumonia in a CT scan;&lt;br&gt;3. typical symptoms of pneumonia, i.e., fever, cough, dyspnea, etc.;&lt;br&gt;4. live in Wuhan in the past one month.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: mild COVID-19 infection without intrapulmonary lesions</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Death;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030838</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Development of warning system with clinical differential diagnosis and prediction for severe type of novel coronavirus pneumonia (COVID-19) patients based on artificial intelligence and CT images</Public_title>
    <Scientific_title>Development of warning system with clinical differential diagnosis and prediction for severe type of SARS-Cov-2 patients based on artificial intelligence and CT images                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51071</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-20</Date_enrollement>
    <Target_size>Target condition:1000;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xu Haibo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>xuhaibo1120@hotmail.com</Contact_Email>
    <Contact_Tel>+86 13545009416</Contact_Tel>
    <Contact_Affiliation>Wuhan University Central South Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Patients diagnosed with COVID-19 infection; the diagnostic criteria are as follows: SARS-COV-2 nucleic acid RT-PCR test results of respiratory specimens are positive;&lt;br&gt;(2) There are CT image examination data and manifestations of viral pneumonia;&lt;br&gt;(3) There are clinical laboratory examination data and follow-up data.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) CT result is negative;&lt;br&gt;(2) Incomplete clinical data.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:RT-PCR test results;Index test:Typing&amp;#32;and&amp;#32;prediction&amp;#32;accuracy&amp;#32;of&amp;#32;artificial&amp;#32;intelligence&amp;#32;models;</Intervention>
    <Primary_outcome>Precision;SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030306</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                               Mechanism of novel coronavirus pneumonia (COVID-19) virus with silent latent immune system induced by envelope protein and vaccine development</Public_title>
    <Scientific_title>Novel coronavirus pneumonia (COVID-19) in asymptomatic patients: a single center, prospective, open clinical study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Luohu hospital group medical center of Shenzhen University</Primary_sponsor>
    <Date_registration>2020-02-28</Date_registration>
    <Date_registration3>20200228</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50222</web_address>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>60</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-19</Date_enrollement>
    <Target_size>Case series:15;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Bi Xiaohui</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>33 Zhongyuan Road, Buji Town, Longgang District, Shenzhen, Guangdong, China  </Contact_Address>
    <Contact_Email>524712958@qq.com</Contact_Email>
    <Contact_Tel>+86 15618795225</Contact_Tel>
    <Contact_Affiliation>Luohu hospital group medical center of Shenzhen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Upon the judgment of the researcher, the subject or his legal representative can understand and comply with the requirements of the program, and voluntarily sign the informed consent;&lt;br&gt;2. According to the new type of coronavirus pneumonia diagnosis and treatment scheme (trial version 5) diagnostic criteria, accord with standard of new coronavirus pneumonia confirmed cases, clinical diagnostic criteria for classification to heavy (pneumonia severity index (PSI) III - V level, or arterial blood oxygen partial pressure (PaO2 / oxygen concentration (FiO2) (P/F) 300 mmHg) or less;&lt;br&gt;3. Aged 18 to 75 years male or female. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The subject has a history of substance abuse (defined as the use of any illicit drug) or alcohol abuse within the first year of screening;&lt;br&gt;2. The subject suffers from active psychosis, which the researcher believes may interfere with their compliance with the study process;&lt;br&gt;3. Subjects are unable to participate in all study visits or follow study procedures;&lt;br&gt;4. The subject is a staff member of the research center or a member of his or her immediate family or relatives (such as spouse, parents, children, siblings) performing the study or the subject is compelled to agree to participate in the study;&lt;br&gt;5. Female subjects during lactation, or female subjects with positive results of serum pregnancy test during screening, or female subjects with positive results of urine pregnancy test before drug administration;&lt;br&gt;6. Have participated in other clinical research projects;&lt;br&gt;7. Subjects have hypersensitivity reactions or allergic reactions to the stem cell preparation or its components;&lt;br&gt;8. The subject suffers from any unstable or uncontrolled cardiovascular, lung, liver, kidney, gastrointestinal, urogenital, hematology, coagulation, immunology, endocrine/metabolic or other medical conditions that the investigator considers to interfere with the outcome of the study or endanger the subject's safety;&lt;br&gt;9. The subject has a history of malignant tumor;&lt;br&gt;10. Subjects have a history of severe neurological disorders, including stroke, multiple sclerosis, brain tumors, or neurodegenerative diseases. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:no;</Intervention>
    <Primary_outcome>Time to disease recovery;Time and rate of coronavirus become negative;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030221</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator               Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Guangzhou Panyu Central Hospital</Primary_sponsor>
    <Date_registration>2020-02-25</Date_registration>
    <Date_registration3>20200225</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50071</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>60</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-31</Date_enrollement>
    <Target_size>Case series:960;</Target_size>
    <Study_type>Health services reaserch</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Zhu Haibing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>8 East Fuyu Road, South Bridge Street, Panyu District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>zhb-ck@163.com</Contact_Email>
    <Contact_Tel>+86 13826041759</Contact_Tel>
    <Contact_Affiliation>Central Hospital of Panyu District, Guangzhou City</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All staff, excluding the internship and probationer, who aged from 18y to 60y and volunteered for this survey, were included in this survey.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Employees who go out for further study or leave, people with previous mental disorders, and sufferers who recently undergo a major injury to work or family life, were excluded in this survey.</Exclusion_Criteria>
    <Condition>Sleep; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>sleep status and related factors of insomnia;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030761</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study</Public_title>
    <Scientific_title>Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50956</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-05-31</Date_enrollement>
    <Target_size>Case series:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qin Wang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1630 Dongfang Road, Pudong District, Shanghai, China</Contact_Address>
    <Contact_Email>qinwang_1975@126.com</Contact_Email>
    <Contact_Tel>+86 13621964604</Contact_Tel>
    <Contact_Affiliation>Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who agree to join the study and signed the informed consent;&lt;br&gt;2. Aged &gt;16 years old;&lt;br&gt;3. Patients with CRP more than twice the upper limit of laboratory test;&lt;br&gt;4. The severe or critial patients with COVID-19 according to the sixth edition of guideline for diagnosis and treatment of COVID-19 from national health council;&lt;br&gt;5. With renal injury: &lt;br&gt;(1) CKD 5 stage;&lt;br&gt;(2) Acute kidney injury: increase in SCr by &gt;26.5umol/L within 48 hours; or increase in SCr to &gt;1.5 times baseline; or urine volume &lt;0.5ml/Kg/h for 6 hours.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who are unable to establish proper vascular access;&lt;br&gt;2. Patients with hemodynamic instability;&lt;br&gt;3. With severe coagulation dysfunction;&lt;br&gt;4. With active bleeding, especially intracranial hemorrhage;&lt;br&gt;5. Pregnant patients;&lt;br&gt;6. Patients not suitable for this study judged by researchers.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:CRRT;</Intervention>
    <Primary_outcome>CRP;IL-6;TNF-alpha;IL-8;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030754</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Medical records based study for the accuracy of SARS-CoV-2 IgM antibody screening for diagnosis of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Accuracy analysis of SARS-CoV-2 IgM antibody screening for diagnosis of COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>The Third Affiliated Hospital of Sun Yat-sen University</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50824</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-11</Date_enrollement>
    <Target_size>Target condition:30;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhanlian Huang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>zhanlianh@163.com</Contact_Email>
    <Contact_Tel>+86 13580584031</Contact_Tel>
    <Contact_Affiliation>The Third Affiliated Hospital of Sun Yat-sen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: patients with positive SARS-CoV-2 IgM antibody </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: recently diagnosed as a confirmed COVID-19 case </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:2019 nCOV detection;Index test:SARS-CoV-2 IgM;</Intervention>
    <Primary_outcome>false positive rate of SARS-CoV-2 IgM antibody;SEN, SPE, ACC, AUC of ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030187</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Jingzhou First People's Hospital</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50057</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-25</Date_enrollement>
    <Target_size>Experimental group:30;control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wei Xiao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>8 Hangkong Road, Shashi District, Jingzhou, Hubei, China</Contact_Address>
    <Contact_Email>99xw@sina.com</Contact_Email>
    <Contact_Tel>+86 18972161798</Contact_Tel>
    <Contact_Affiliation>Jingzhou First People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Sign the written informed consent;&lt;br&gt;2. Aged 18-80 years old;&lt;br&gt;3. Meet the diagnostic criteria for novel coronavirus infection(trial version sixth), confirmed by combining with the epidemiological history, clinical manifestations and etiology examination;&lt;br&gt;4. Course of disease within 14 days after onset.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who are participating in clinical trials of other drugs;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. ALT / AST &gt; 2-fold ULN;&lt;br&gt;4. Expected survival time &lt; 1 week;&lt;br&gt;5. With serious liver disease;&lt;br&gt;6. Patients taking orally anti-tumor drugs or immunomodulatory drugs for a long time;&lt;br&gt;7. Patients who are participating in other clinical trials;&lt;br&gt;8. The researchers think that other reasons are not suitable for clinical trials.</Exclusion_Criteria>
    <Condition>Novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Lopinavir and Ritonavir Tablets;control group:Routine symptomatic support treatment;</Intervention>
    <Primary_outcome>Endotracheal intubation rate;mortality;Ratio of virus nucleic acid detection to negative;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029895</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by investigator                Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Guangzhou Eighth People's Hospital</Primary_sponsor>
    <Date_registration>2020-02-16</Date_registration>
    <Date_registration3>20200216</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49569</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-16</Date_enrollement>
    <Target_size>Case series:160;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>1-2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Weiping Cai</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>627 Dongfeng Road East, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>gz8hcwp@126.com</Contact_Email>
    <Contact_Tel>+86 020-83710825</Contact_Tel>
    <Contact_Affiliation>Guangzhou Eighth People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1)Aged &gt;=18 years old, gender unlimited, inpatient;&lt;br&gt;(2) Novel coronavirus nucleic acid positive in pharyngeal swab specimen by real-time fluorescent RT-PCR;&lt;br&gt;(3) Clinical classification is ordinary or severe patients;&lt;br&gt;(4) Informed consent has been signed.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Known or suspected to be allergic to the components of GD31;&lt;br&gt;(2) Mild or critical patients in clinical classification;&lt;br&gt;(3) Severe liver diseases (such as child Pugh score &gt;=C, TBIL &gt;=2 ULN, AST &gt;=5 ULN), or HBsAg positive&lt;br&gt;(4) Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;=30ml/min/1.73m2) or undergoing continuous renal replacement therapy, hemodialysis and peritoneal dialysis;&lt;br&gt;(5) Pregnant or lactating women or women with birth plan during or within 6 months after the trial;&lt;br&gt;(6) According to the judgment of the researcher, there are other situation of the patient that are not suitable for attending the trial;&lt;br&gt;(7) Patients who had received chloroquine treatment within 4 weeks.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Routine treatment+GD31, GD31: D1: 200mg QD, dissolved in 100ml of saline, intravenous drip, about 60 minutes; D2 ~ 10: 100mg QD, dissolved in 100ml of saline, intravenous drip, 30 minutes.;</Intervention>
    <Primary_outcome>The negative conversion rate and negative conversion time of novel coronavirus nucleic acid;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030752</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based analysis for risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Analysis of risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Shandong Provincial Chest hospital</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50925</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>case series:500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Fenglin Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China</Contact_Address>
    <Contact_Email>xkyylfl@163.com</Contact_Email>
    <Contact_Tel>+86 13953116564</Contact_Tel>
    <Contact_Affiliation>Shandong Provincial Chest hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients who were diagnosed as COVID-19 by nucleic acid test</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: no</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>case series:Nil;</Intervention>
    <Primary_outcome>Outcome;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030747</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A prospective cohort  study for comprehensive treatment of Chinese medicine in the treatment of convalescent patients of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A prospective cohort  study on recovering patients with novel coronavirus pneumonia (COVID-19) by comprehensive treatment of Chinese medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Hubei Provincial Hospital of TCM</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50000</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-22</Date_enrollement>
    <Target_size>Control group :750;Comprehensive treatment group:750;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Xiaodong</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>856 Luoyu Road, Hongshan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>lixiaodong555@126.com</Contact_Email>
    <Contact_Tel>+86 13908658127</Contact_Tel>
    <Contact_Affiliation>Hubei Provincial Hospital of TCM</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) Corresponding to diagnosis standards of convalescence of COVID-19 mentioned above;&lt;br&gt;(2) Imaging manifestations Fibrous cable-like shadow (patchy) ground glass changes in the lungs,honeycomb sign,reticular changes, increased bronchovascular shadows, pleural effusion,nodular change, any one or more of the above;&lt;br&gt;(3) Aged 18-65 years;&lt;br&gt;(4) Signing of informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. With other serious primary pulmonary diseases (such as active pulmonary tuberculosis, pneumothorax, pleural effusion, pulmonary embolism and neuromuscular diseases affecting respiratory and motor function);&lt;br&gt;2. Severe primary diseases, belong to heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract, may affect the patients' participation in the study or the outcome of the study;&lt;br&gt;3. A family history of mental illness or a history of mental illness;&lt;br&gt;4. Allergic constitution or known drug allergy;&lt;br&gt;5. Pregnant or lactating women and those with recent pregnancy plans;&lt;br&gt;6. Bedridden for various reasons.</Exclusion_Criteria>
    <Condition>Novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Control group :Health education and   symptomatic treatment;Comprehensive treatment group:Health education+Comprehensive TCM treatment;</Intervention>
    <Primary_outcome>CT Scan-Chest;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030836</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy</Public_title>
    <Scientific_title>Novel covid-19 pneumonia combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51054</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Group 2:150;Group 1:150;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Bangjiang Fang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>725 Wanping Road South, Xuhui District, Shanghai, China</Contact_Address>
    <Contact_Email>fangbji@163.com</Contact_Email>
    <Contact_Tel>+86 18917763257</Contact_Tel>
    <Contact_Affiliation>Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. patients with novel coronavirus pneumonia confirmed by pathogenic detection;&lt;br&gt;2. Fever, respiratory tract and other symptoms, the change of pneumonia can be seen in imaging;&lt;br&gt;3. Aged 18 to 80 years;&lt;br&gt;4. Signed informed consent. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Ordinary covid-19 pneumonia is not in conformity with the standard diagnostic criteria.            &lt;br&gt;2) Patients with allergy to traditional Chinese medicine and allergic constitution;           &lt;br&gt;3) Patients with malignant tumor, cirrhosis, chronic renal failure (uremic stage), blood system disease, HIV and other serious basic diseases;            &lt;br&gt;4) Long term use of hormone, immunosuppressant and other drugs to treat patients;            &lt;br&gt;5) Suffering from serious mental illness or being unable to cooperate with the trial;            &lt;br&gt;6) Pregnant and lactating women.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 2:Truncated Torsion' Formula and Routine treatment of Western Medicine;Group 1:Routine treatment of Western Medicine;</Intervention>
    <Primary_outcome>14 day outcome of the subjects, including: recovery, improvement, turning critical, death. ;Lung CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030835</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>the First Affiliated Hospital of Xinxiang Medical University</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51050</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>16</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-14</Date_enrollement>
    <Target_size>High dose group:10;Low dose group:10;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Single arm</Study_design>
    <Phase>New Treatment Measure Clinical Study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Dou Qifeng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>88 Jiankang Road, Weihui, Xinxiang, He'nan, China</Contact_Address>
    <Contact_Email>douqifeng@126.com</Contact_Email>
    <Contact_Tel>+86 13503735556</Contact_Tel>
    <Contact_Affiliation>the First Affiliated Hospital of Xinxiang Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Male or female patients aged 16-75 years;&lt;br&gt;2. Willing to sign informed consent;&lt;br&gt;3. novel coronavirus novel coronavirus is highly novel correlate with the novel coronavirus, based on the standard of suspected cases of new coronavirus infection, real-time fluorescence RT-PCR detection of new coronavirus nucleic acid positive, and sequencing of the virus gene;&lt;br&gt;4. novel coronavirus pneumonia novel coronavirus infection was diagnosed according to the new coronavirus pneumonia diagnosis and treatment plan (trial version sixth). Severe pneumonia is defined by compliance with any of the following:&lt;br&gt;(1) Dyspnea, RR &gt;=30 times / min;&lt;br&gt;(2) At rest, the oxygen saturation &lt;=93%;&lt;br&gt;(3) PaO2 / FiO2 &lt;=300MMHG (lmmhg = o.133kpa). Pa02 / fi02 should be corrected according to the formula: PaO2 / FiO2 x[atmospheric pressure (mmHg) / 760] The pulmonary imaging showed that the lesions progressed more than 50% within 24-48 hours, and the patients were managed as severe. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pregnant or lactating women;&lt;br&gt;2. Patients with malignant tumor, other serious systemic diseases and psychosis;&lt;br&gt;3. Patients who have recently or are participating in other clinical trials;&lt;br&gt;4. There was evidence of drug addiction within one year before the trial;&lt;br&gt;5. Inability or unwillingness to provide informed consent or comply with test requirements;&lt;br&gt;6. Combined with HIV, tuberculosis, influenza virus, adenovirus and other respiratory tract infection virus infection;&lt;br&gt;7. Other conditions judged by the researcher as unsuitable for participating in the clinical study. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>High dose group:routine treatment + MSc (2 x10^6 / kg / time);Low dose group:routine treatment + MSc (1x10^6 / kg / time);</Intervention>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030722</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Shanghai First People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-12</Date_registration>
    <Date_registration3>20200312</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50338</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-09</Date_enrollement>
    <Target_size>Case series:30;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhi Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>100 Haining Road, Hongkou District, Shanghai, China</Contact_Address>
    <Contact_Email>16683890@qq.com</Contact_Email>
    <Contact_Tel>+86 13621759762</Contact_Tel>
    <Contact_Affiliation>Shanghai First People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. over 18 years old;&lt;br&gt;2. Patients diagnosed with Covid-19 pneumonia (those who meet the clinical diagnosis above the common type or have a positive nucleic acid test);&lt;br&gt;3. Have 64-row high-resolution CT examination of the chest within 24 hours;&lt;br&gt;4. There is no clear history of other cardiopulmonary diseases (such as with COPD, massive pleural effusion, tuberculosis, pulmonary hypertension, severe heart failure, pulmonary heart disease, etc.);&lt;br&gt;5. Able to cooperate with lung auscultation and agree to participate in the examination;&lt;br&gt;6. Be able to sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Investigator believes that subjects should not be included (patients are severely uncooperative);&lt;br&gt;2. Not suitable for inclusion in subjects (clinically considered fully healthy patients or light);&lt;br&gt;3. Patients who cannot auscultate clearly with non-invasive or invasive ventilation (patients who can still auscultate are not excluded);&lt;br&gt;4. Pregnant women and children.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>ascultation;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030720</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management</Public_title>
    <Scientific_title>Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Hubei Provincial Hospital of TCM</Primary_sponsor>
    <Date_registration>2020-03-11</Date_registration>
    <Date_registration3>20200311</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50793</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Group 2:60;Group 1:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiaodong Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>856 Luoyu Road, Hongshan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>lixiaodong555@126.com</Contact_Email>
    <Contact_Tel>+86 13908658127</Contact_Tel>
    <Contact_Affiliation>Hubei Provincial Hospital of TCM</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Conforming to the Chinese and Western Medicine Diagnostic Standards of patients with novel coronavirus pneumonia (COVID-19) in recovery period;&lt;br&gt;2. Aged between 18 and 65 years old;&lt;br&gt;3. Signing the generalized informed consent form (The intervention objects is incorporated in the clinical study as desired).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with severe primary diseases such as heart, kidney, lung, endocrine, blood, metabolism, and gastrointestinal tract, etc., may affect participation in the trial or may affect the outcome of the study by the judgment of the researcher;&lt;br&gt;2. Patients who have a family history of mental illness or have had a mental illness; &lt;br&gt;3. Patients who are allergic constitution or allergy to multiple drug; &lt;br&gt;4. Pregnant or lactating women.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 2:Western medicine conventional treatment;Group 1:TCM treatment;</Intervention>
    <Primary_outcome>Medical imaging improvement rate in patients during recovery period;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030834</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Epidemiological Characteristics and Antibody Levels of novel coronavirus pneumonia (COVID-19) of Pediatric Medical Staff working in Quarantine Area</Public_title>
    <Scientific_title>Epidemiological Characteristics and Antibody Levels of COVID-19 Infection of Pediatric Medical Staff working in Quarantine Area                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51047</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-16</Date_enrollement>
    <Target_size>Case series:500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Yan Hao, Xiaoping Luo</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou DIstrict, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>haoyaner@163.com</Contact_Email>
    <Contact_Tel>+86 13971679960</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: This study intends to recruit all doctors, nurses, and care workers who have been in clinical work for more than half a month from January to March 2020 in pediatric fever clinic, pediatric buffer clinic, pediatric emergency department, PICU, NICU, neonatal specialty, pediatric infectious and digestive disorders specialty, pediatric kidney and vascular disease specialty, pediatric hematology specialty, children's genetic endocrinology and respiratory specialty, and children's health care specialty.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Exclude medical staff who are not in clinical work due to sick leave;&lt;br&gt;2. Exclude medical staff who worked in the clinical setting for less than half a month recently.&lt;br&gt;3. Exclude if the medical staff and family members do not agree to complete the informed consent form or do not agree to provide relevant information.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Epidemiological characteristics;SARS-CoV-2 IgM, IgG antibody titer test result;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030819</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Retrospective analysis of digestive system symptoms in 600 cases of novel coronavirus pneumonia (COVID-19) in Guanggu district, Wuhan</Public_title>
    <Scientific_title>Retrospective analysis of digestive system symptoms in 600 cases of 2019-ncov pneumonia in Guanggu district, Wuhan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Wuhan Third Hospital</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51039</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>1</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Case series:600;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xia Tian</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>hcwy100@163.com</Contact_Email>
    <Contact_Tel>+86 13871480868</Contact_Tel>
    <Contact_Affiliation>Wuhan Third Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Novel coronavirus pneumonia patients</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>Liver function;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029837</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator          A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumon (COVID-19)ia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Jingzhou Central Hospital</Primary_sponsor>
    <Date_registration>2020-02-15</Date_registration>
    <Date_registration3>20200215</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49495</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Phosphoric chloroquine:80;Placebo:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jinghua Mao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>60 Jingjing Road, Jingzhou District, Jingzhou, Hubei, China</Contact_Address>
    <Contact_Email>hbjzyyywlc@163.com</Contact_Email>
    <Contact_Tel>+86 071 68497225</Contact_Tel>
    <Contact_Affiliation>Jingzhou Central Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Subjects who meet the all of the following criterion to be elegiable for this study:&lt;br&gt;1. Meet the requirements of the "New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)";&lt;br&gt;2. Aged 18 to 65 years male or female; &lt;br&gt;3. The interval from the onset of symptoms to enrollment is within 7days: onset of symptoms is defined as onset of at least one systematic symtom(such as fever(temperature&gt;=37.3 degree C) or shivering,headache,hypodynamia,muscle pain or joint pain) or respiratory symptom(such as cough,pharyngodynia,nasal obstruction,rhinorrhea);&lt;br&gt;4. Agree to participate in this study and write informed content.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Serious/critically ill patients with novel coronavirus(COVID-19) pneumonia or patients that clinician consider that he/she shall be treated in ICU;&lt;br&gt;2. With pneumonia infected by other virus;&lt;br&gt;3. With one of following abnormal laboratory parameters( judged per local Laboratory reference range):&lt;br&gt;-ALT or AST&gt;5 ULN or;&lt;br&gt;-ALT or AST &gt;3 ULN, and total bilirubin&gt;2 ULN;&lt;br&gt;4. Previous or current disease, judged by investigator, may affect his/her participation in this study or outcome of the study, including but not limited to malignant tumor,autoimmune disease,liver and kidney disease, cardiovascular disease(including but not limited to &lt;br&gt;5. definate history of cadiac diease and arrhythmia and QT prolongation),neurological disease psychiatric disease,active bleeding,serious malnutrition and endocrine disease; currently complicated with serious respiratory disease or that seriously affect immune system, such as HIV,blood system disease, or splenectomy, organ transplantion etc.;&lt;br&gt;6. Need to receive digitalis for original disease;&lt;br&gt;7. May be transfered to non-study hospital;&lt;br&gt;8. Allergy to study drug phosphoric chloroquine;&lt;br&gt;9. With history of grug abuse and drug dependency;&lt;br&gt;10. Pregant or lactating women;or planing to be pregnant within 3 months after study;&lt;br&gt;11. One that the investigator consider not applicable for this study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);</Intervention>
    <Primary_outcome>Time of conversion to be negative of novel coronavirus  nucleic acid;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029826</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator            A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Jingzhou Central Hospital</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49481</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-17</Date_enrollement>
    <Target_size>Phosphoric chloroquine:30;Placebo:15;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jinghua Mao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>60 Jingjing Road, Jingzhou District, Jingzhou, Hubei, China</Contact_Address>
    <Contact_Email>hbjzyyywlc@163.com</Contact_Email>
    <Contact_Tel>+86 071 68497225</Contact_Tel>
    <Contact_Affiliation>Jingzhou Central Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients who meet the requirements of the New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);&lt;br&gt;2. Aged 18-75 years male or female;&lt;br&gt;3. Serious patient meet one of the following:&lt;br&gt;(1) respiratory distress wiht respiratory rate &gt;=30 breaths/min;&lt;br&gt;(2) oxygen saturation&lt;=93% on quiet status;&lt;br&gt;(3) Arterial partial pressure of oxygen(PaO2)/oxygen concentration&lt;=300mmHg;&lt;br&gt;4. critically ill patients meet one of the following:&lt;br&gt;(1) Experience respiratory failure and need to receive mechanical ventilation;&lt;br&gt;(2) Experience shock;&lt;br&gt;(3) Complicated with other organs failure and need intensive care and therapy in ICU;&lt;br&gt;5. Agree to particapate this study and write the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: If subject meet one of the following exclusion critera, he/she cannot be enrolled in this study:&lt;br&gt;1. Be dysphagia and cannot receive drud by oral administration;&lt;br&gt;2. Complicated with pneumonia infected by other virus;&lt;br&gt;3. Allergy to or intolerance to study drug phosphoric chloroquine;&lt;br&gt;4. With significantly abnormal liver function( judged per local Laboratory reference range):&lt;br&gt;-ALT/AST&gt;5 times ULN or;&lt;br&gt;-ALT/AST&gt;3 times ULN, and total bilirubin&gt;2 times ULN or;&lt;br&gt;-need dDialysis treatment, or GFR=30 mL/min/1.73 m2.&lt;br&gt;5. With definate history of cadiac diease and arrhythmia and QT prolong;&lt;br&gt;6. Need to receive digitalis for original diease;&lt;br&gt;7. With history of grug abuse and drug dependency;&lt;br&gt;8. Pregant or lactating women;&lt;br&gt;9. One that the investigator consider not applicable for this study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by "New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)";Placebo:2 tablets placebo BID;</Intervention>
    <Primary_outcome>Mortality rate;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030818</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for the value of Lymphocyte subsets in the diagnose and treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>The value of Lymphocyte subsets in Coronavirus Disease 2019                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Department of Critical Care Medicine, The First Affiliated Hospital, Henan Traditional Chinese Medicine University</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51037</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>86</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-31</Date_enrollement>
    <Target_size>	 Case series:10;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhengrong Mao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>19 Renmin Road, Jinshui District, Zhengzhou, He'nan, China</Contact_Address>
    <Contact_Email>maozhengrong1971@163.com</Contact_Email>
    <Contact_Tel>+86 18695808321</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital, He'nan Traditional Chinese Medicine University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Acorrding to  Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected Jan 11, 2020.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: none</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>	 Case series:none;</Intervention>
    <Primary_outcome>ymphocyte subsets;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030817</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound</Public_title>
    <Scientific_title>Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50631</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-28</Date_enrollement>
    <Target_size>Light group:200;Common group:200;Severe group:200;Critical group:200;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Mingxing Xie</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Wuhan, Hubei, China </Contact_Address>
    <Contact_Email>xiemx@hust.edu.cn</Contact_Email>
    <Contact_Tel>+86 13607108938</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Diagnosis confirmed Novel Coronavirus Pneumonia (COVID-19)  </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: no exclusion critereia</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Light group:N/A;Common group:N/A;Severe group:N/A;Critical group:N/A;</Intervention>
    <Primary_outcome>Two-dimensional ultrasound;M mode echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029820</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by investigator                                      A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Wuhan Asia General Hospital</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49492</web_address>
    <other_records>No</other_records>
    <Inclusion_agemin>1</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:410;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Huang Keqiang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>300 Taizihu north Road, Wuhan Economic and Technological Development Zone, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>hkq123123@163.com</Contact_Email>
    <Contact_Tel>+86 15287110369</Contact_Tel>
    <Contact_Affiliation>Wuhan Asia General Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 2020.01.01 Patients who have tested positive for new coronavirus in our hospital</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 2020.01.01 Patients who have tested negative for new coronavirus in our hospital</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>DEATH;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030704</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>The First People's Hospital of Jiangxia District, Wuhan</Primary_sponsor>
    <Date_registration>2020-03-10</Date_registration>
    <Date_registration3>20200310</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50778</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>7</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Experimental group:25;control group:25;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Cross-over</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Hu Xingxing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>100 Shizi Street, Hongshan Road, Qixia District, Nanjing, Jiangsu, China</Contact_Address>
    <Contact_Email>huxingxing82@163.com</Contact_Email>
    <Contact_Tel>+86 17327006987</Contact_Tel>
    <Contact_Affiliation>Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Novel coronavirus pneumonia is diagnosed in the fifth edition of the national health and Health Committee;&lt;br&gt;2. Respiratory rate in calm state &gt;=30 times / min;OR Finger pulse oxygen saturation under rest and non oxygen absorption state &lt;=93%; OR PO2/FiO2)&lt;=300mmHg; OR PO2&lt;60mmHg.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Aged &lt; 7-year-old;&lt;br&gt;2. previous arrhythmia;&lt;br&gt;3. previous chronic respiratory failure caused by other diseases, such as heart failure, thoracic deformity, structural lung disease, etc.;&lt;br&gt;4. hemodynamic instability;&lt;br&gt;5. severe immune deficiency or recent use of immunosuppressive agents;&lt;br&gt;6. allergic patients;&lt;br&gt;7. estimated survival time less than 3 days;&lt;br&gt;8. dropout on the halfway as well as lose of follow-up.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Bufonis venenum injection;control group:NS;</Intervention>
    <Primary_outcome>PO2/FiO2;ROX INDEX;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030702</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Plasma of the convalescent in the treatment of novel coronavirus pneumonia (COVID-19) common patient: a prospective clinical trial</Public_title>
    <Scientific_title>Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>China-Japan friendship hospital</Primary_sponsor>
    <Date_registration>2020-03-10</Date_registration>
    <Date_registration3>20200310</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50537</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>-</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-15</Date_enrollement>
    <Target_size>eperimental group:25;control group:25;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Cao Bin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>2 Yinghua Street East, Chaoyang District, Beijing, China</Contact_Address>
    <Contact_Email>caobin_ben@163.com</Contact_Email>
    <Contact_Tel>+86 13911318339</Contact_Tel>
    <Contact_Affiliation>China-Japan Friendship Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. The patient signed an informed consent form to participate in the study of convalescent plasma therapy;&lt;br&gt;2. patient aged &gt;=18 years old;&lt;br&gt;3. COVID-19 patients diagnosed by PCR;&lt;br&gt;4. Nucleic acid positive within 72 hours before blood transfusion;&lt;br&gt;5. Pneumonia confirmed by imaging; &lt;br&gt;6. Hospitalization for the following reason:&lt;br&gt;Fever: axillary temperature&gt;=36.7 degree C, or oral temperature&gt;=38.0 degree C, or anal or ear temperature=38.6 ?&lt;br&gt;And respiratory rate&gt; 24 beats / min or cough (at least one of the two);&lt;br&gt;7. There are severe clinical warning indicators: such as a progressive decrease in peripheral blood lymphocytes, a progressive increase in peripheral blood inflammatory factors, a progressive increase in lactic acid, and rapid progress of lung lesions in the short term, et al.&lt;br&gt;8. Accept random grouping into any group;&lt;br&gt;9. The patient was hospitalized before the end of the clinical study.&lt;br&gt;10. Willing to participate in all necessary research directions and be able to participate in follow-up;&lt;br&gt;11. During the period of participating in this study, they will no longer participate in clinical trials such as other antiviral drugs.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The doctor believes that the patient is not suitable to participate in this trial, including those who may not cooperate, do not comply with the requirements of the procedure, or participate in this trial may put the patient in an unsafe situation.&lt;br&gt;2. Pregnant or lactation periods women;&lt;br&gt;3. Immunoglobulin allergy;&lt;br&gt;4. Immunoglobulin A deficiency;&lt;br&gt;5. The clinical symptoms are mild or reach the standard of severe or critical.&lt;br&gt;Mild symptoms:&lt;br&gt;Clinical symptoms are mild and no pneumonia on imaging.&lt;br&gt;Severe patients meet any of the following:&lt;br&gt;1) respiratory distress, RR &gt;=30 beats / min;&lt;br&gt;2) in resting state, oxygen saturation &lt;=93%;&lt;br&gt;3) partial pressure of oxygen in arterial blood (PaO2) / oxygen concentration (FiO2) &lt;br&gt;&lt;=300mmHg (1mmHg=0.133kPa)&lt;br&gt;Critically ill patients meet any of the following:&lt;br&gt;1) respiratory failure and need mechanical ventilation;&lt;br&gt;2) shock;&lt;br&gt;3) patients with other organ failure need ICU monitoring treatment.&lt;br&gt;6. There are diseases that may increase the risk of thrombosis, such as cold globulinemia, severe refractory hypertriglyceridemia, clinically defined monoclonal gamma globulinemia, etc.&lt;br&gt;7. High titer of anti-novel coronavirus antibody RBDIgG (higher than 1) could be detected.&lt;br&gt;8. Received any experimental treatment for novel coronavirus infection within 30 days before screening;&lt;br&gt;9. The researchers judged that the patients had the following life-threatening conditions, including, but not limited to, Phammer F &lt; 100mmHg, near-death state or expected survival time less than 24 hours, severe septic shock or disseminated intravascular coagulation ((DIC)), etc.,&lt;br&gt;10. Severe congestive heart failure, or other relative contraindications for plasma transfusion determined by researchers.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>eperimental group:Conventional treatment and convalescent plasma therapy;control group:conventional treatment;</Intervention>
    <Primary_outcome>Time to clinical recovery after randomization;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030697</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A multi-center, open-label observation study for psychological status and intervention efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia (COVID-19) designated hospitals</Public_title>
    <Scientific_title>A multi-center, open-label observation study for psychological status and intervention efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia (COVID-19) designated hospitals                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Ningbo First Hospital, Ningbo Hospital of Zhejiang University</Primary_sponsor>
    <Date_registration>2020-03-10</Date_registration>
    <Date_registration3>20200310</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50781</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>96</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-10</Date_enrollement>
    <Target_size>Case series:1500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhongze Lou</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>59 Liuting Street, Haishu, Ningbo, Zhejiang, China </Contact_Address>
    <Contact_Email>lorenzo_87@163.com</Contact_Email>
    <Contact_Tel>+86 0574-87085111</Contact_Tel>
    <Contact_Affiliation>Ningbo First Hospital, Ningbo Hospital of Zhejiang University </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Medical staff of designated hospitals for new crown pneumonia in Ningbo area;&lt;br&gt;2. Patients with new-coronary pneumonia infection, suspected cases, patients in fever observation ward, forced isolation and home isolation in Ningbo area;&lt;br&gt;3. Medical staff and staff entering isolation ward and fever observation ward;&lt;br&gt;4. Medical staff and staff who went to Wuhan to participate in the aid of Hubei to fight the epidemic;&lt;br&gt;5. Family members of medical staff involved in fighting the epidemic;&lt;br&gt;6. Ordinary people participating in this survey.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Those who have not completed effective psychological consultation and assessment;&lt;br&gt;2. Researchers who are unwilling to participate in this survey;&lt;br&gt;3. The investigator is unwilling to continue during the evaluation process.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)N; psychosomatic medicine</Condition>
    <Intervention>Case series:NA;</Intervention>
    <Primary_outcome>SDS;SAS;PSQI;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030686</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>The effects of prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak</Public_title>
    <Scientific_title>The effects of  prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Peking University Third Hospital</Primary_sponsor>
    <Date_registration>2020-03-09</Date_registration>
    <Date_registration3>20200309</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50714</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-03</Date_enrollement>
    <Target_size>tumor patients group:300;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Baoshan Cao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>49 North Garden Road, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>caobaoshan0711@aliyun.com</Contact_Email>
    <Contact_Tel>+86 15611963362</Contact_Tel>
    <Contact_Affiliation>Peking University Third Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. patients diagnosed as malignant tumor by pathology or cytology inpatient or outpatient in general hospital during the outbreak of 2019-nCOV;&lt;br&gt;2. aged 18 or above;&lt;br&gt;3. informed consent and ability to cooperate with research. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: anyone who is  reluctant or unable to answer the questionnaire </Exclusion_Criteria>
    <Condition>malignant  tumor</Condition>
    <Intervention>tumor patients group:no;</Intervention>
    <Primary_outcome>impact on the treatment of tumor patients;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030803</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Collection and analysis of clinical data in severe and critically ill patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical characteristics of severe or critically ill patients infected with 2019-nCoV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51007</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-31</Date_enrollement>
    <Target_size>severe patients:400;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Contact_Firstname>Xin Li</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>314440820@qq.com</Contact_Email>
    <Contact_Tel>+86 13797062903</Contact_Tel>
    <Contact_Affiliation>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The patients who had been confirmed with SARS-CoV-2 infection by a nucleic acid-positive test and identified as severe or critical according to the diagnosis and treatment protocol for novel coronavirus pneumonia , were enrolled in this study</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients who are younger than 18 years , who have severe liver or kidney dysfunction,or patients with other condition evaluated by doctors were excluded from this study.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>severe patients:none;</Intervention>
    <Primary_outcome>age;sex;comorbidities;chest-CT examination;standard blood counts;albumin;pre-albumin;hemoglobin;alanine transaminase;aspartate transaminase;creatinine;glucose;lipids;procalcitonin;C-reactive protein;coagulation function;nutritional risk screening;body weight;body height;prognosis;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030802</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A retrospective study of clinical drug therapy in patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A retrospective study of clinical drug therapy in patients with COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji medical college of HUST</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=51004</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-27</Date_enrollement>
    <Target_size>Case series:2000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Case study</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>LIU DONG</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>ld_2069@163.com</Contact_Email>
    <Contact_Tel>+86 13507183749</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College of HUST</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Those who meet the diagnosis of COVID-19;&lt;br&gt;2. In-patients admitted in designated hospitals.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Incomplete medical records, especially medication information,which may affect the evaluation&lt;br&gt;2. Those which the researchers deemed inappropriate</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>time  and rate of cure; proportion and time of patients who progressed to severe disease;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030679</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children</Public_title>
    <Scientific_title>Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</Primary_sponsor>
    <Date_registration>2020-03-09</Date_registration>
    <Date_registration3>20200309</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50730</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>18</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-28</Date_enrollement>
    <Target_size>case series:500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Liu Zhisheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>100 Hongkong Road, Jiang'an District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>liuzsc@126.com</Contact_Email>
    <Contact_Tel>+86 027-82433145</Contact_Tel>
    <Contact_Affiliation>Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Children aged 0-18 years and met the guideline for the diagnosis and treatment of COVID-19;&lt;br&gt;2. Agreed to participant in the study;&lt;br&gt;3. Can cooperate with the later on follow-up.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: no exclusion criteria </Exclusion_Criteria>
    <Condition>Novel Coronavirus (COVID-19) Infected Diseases</Condition>
    <Intervention>case series:N/A;</Intervention>
    <Primary_outcome>Clinical characteristics;Clinical outcomes;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030606</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-08</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50713</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>ND</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-09</Date_enrollement>
    <Target_size>Chinese medicine treatment cohort:40;Integrated Chinese and western medicine treatment cohort:40;Western medicine treatment cohort:40;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Miao Qing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Xiyuan Playground, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>miaoqing55@sina.com</Contact_Email>
    <Contact_Tel>+86 13910812309</Contact_Tel>
    <Contact_Affiliation>Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Compliance with NCP diagnostic criteria; &lt;br&gt;2. Aged &gt;=18 years. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Cases of patients with tumor or mental disorder or immunosuppressive disease; &lt;br&gt;2. A case of a pregnant or lactating woman; &lt;br&gt;3. Incomplete case. </Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia</Condition>
    <Intervention>Chinese medicine treatment cohort:traditional Chinese medicine;Integrated Chinese and western medicine treatment cohort:Chinese medicine and western medicine;Western medicine treatment cohort:western medicine;</Intervention>
    <Primary_outcome>Imaging;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030801</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Analysis of risk factors affecting prognosis of elderly patients infected with novel coronavirus pneumonia (COVID-19): a single-center retrospective observational study</Public_title>
    <Scientific_title>Analysis of risk factors affecting prognosis of elderly patients infected with COVID-19 pneumonia: a single-center retrospective observational study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>The Third Hospital of Wuhan</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50998</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>65</Inclusion_agemin>
    <Inclusion_agemax>100</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-23</Date_enrollement>
    <Target_size>discharge group:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Case study</Study_design>
    <Phase>1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Peng Jian</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>241 Peng-Liu-Yang Road, Wuchang, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>541163409@qq.com</Contact_Email>
    <Contact_Tel>+86 18627151212</Contact_Tel>
    <Contact_Affiliation>The Third Hospital of Wuhan</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Aged &gt;=65 years patient with novel coronavirus pneumonia COVID-19</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Transfers to Huoshen shan or Leishen shan hospital;&lt;br&gt;2. Patient with only one laboratory test.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>discharge group:no;</Intervention>
    <Primary_outcome>discharg time;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030800</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia (COVID-19) and their diagnostic and prognostic value</Public_title>
    <Scientific_title>Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia and their diagnostic and prognostic value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>The Third Affiliated Hospital of Zunyi Medical University</Primary_sponsor>
    <Date_registration>2020-03-15</Date_registration>
    <Date_registration3>20200315</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50997</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>0</Inclusion_agemin>
    <Inclusion_agemax>86</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Target condition:22;Difficult condition:57</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Wu Kaifeng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>98 Fenghuang Road, Huichuan District, Zunyi, Guizhou, China</Contact_Address>
    <Contact_Email>kiphoonwu@126.com</Contact_Email>
    <Contact_Tel>+86 13788989286</Contact_Tel>
    <Contact_Affiliation>The Third Affiliated Hospital of Zunyi Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Refer to the national health commission document "diagnosis and treatment plan of new coronavirus pneumonia (trial seven edition)".</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: none</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Epidemiological history + CT + clinical manifestations + sars-cov-2 nucleic acid positive;Index test:Elisa&amp;#32;analysis&amp;#32;of&amp;#32;validation&amp;#32;factors,&amp;#32;inflammatory&amp;#32;factors,&amp;#32;adhesion&amp;#32;factors;</Intervention>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030597</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>China Academy of Chinese Medical Science</Primary_sponsor>
    <Date_registration>2020-03-08</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50702</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>ND</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-09</Date_enrollement>
    <Target_size>Case series:150;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Miao Qing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Xiyuan Playground, Haidian District, Beijing, China</Contact_Address>
    <Contact_Email>miaoqing55@sina.com</Contact_Email>
    <Contact_Tel>+86 13910812309</Contact_Tel>
    <Contact_Affiliation>Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Compliance with NCP diagnostic criteria;&lt;br&gt;2. Aged &gt;=18 years.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Cases of patients with tumor or mental disorder or immunosuppressive disease;&lt;br&gt;2. A case of a pregnant or lactating woman;&lt;br&gt;3. Incomplete case.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:N/A;</Intervention>
    <Primary_outcome>Disease Severity;Imaging;Syndrome Features of TCM;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030528</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>The Second Clinical College of Guangzhou University of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-06</Date_registration>
    <Date_registration3>20200306</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50641</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-03-06</Date_enrollement>
    <Target_size>Group 1:30;Group 2:30;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Non randomized control</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Meizhen Lin</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>lmzmay@163.com</Contact_Email>
    <Contact_Tel>+86 18922108136</Contact_Tel>
    <Contact_Affiliation>The Second Clinical College of Guangzhou University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Refer to the National Health and Health Commission's "Diagnosis and Treatment Plan for New Coronavirus Infected Pneumonia (Trial Version 5)" (hereinafter referred to as "Diagnosis and Treatment Plan") to confirm the diagnosis of adult patients with new coronavirus infection.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Participants in other clinical trials within 4 weeks before the start of this study</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group 1:Baduanjin;Group 2:Auricular acupressure;</Intervention>
    <Primary_outcome>GAD-7;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030784</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A study for clinical characteristics of novel coronavirus pneumonia (COVID-19) patients follow-up in Guangxi</Public_title>
    <Scientific_title>A study for clinical characteristics of novel coronavirus pneumonia (COVID-19) patients follow-up in Guangxi                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>The People's Hospital of Guangxi Zhuang Autonomous Region</Primary_sponsor>
    <Date_registration>2020-03-14</Date_registration>
    <Date_registration3>20200314</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50307</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-17</Date_enrollement>
    <Target_size>Case series:150;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Guo Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>6 Taoyuan Road, Nanning, Guangxi Zhuang Autonomous Region, China</Contact_Address>
    <Contact_Email>zhangguogx@hotmail.com</Contact_Email>
    <Contact_Tel>+86 13978839646</Contact_Tel>
    <Contact_Affiliation>The People's Hospital of Guangxi Zhuang Autonomous Region</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Inclusion criteria Patients confirmed to be infected with 2019-nCoV. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who refused to participate in the project;&lt;br&gt;2. Patients developed symptoms caused by other pathogens rather than the 2019-nCoV, and there was no evidence show that patients were infected with 2019-nCoV. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:No;</Intervention>
    <Primary_outcome>Epidemiological characteristics;clinical features;Treatment outcome;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030768</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for the Psychological Status of Medical Staff of Otolaryngology Head and Neck Surgery in Hubei Province under the Epidemic of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Risk Factors for Anxiety of Otolaryngology Workers in Hubei Province Fighting Against novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-03-14</Date_registration>
    <Date_registration3>20200314</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50968</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:450;</Target_size>
    <Study_type>Epidemilogical research</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xiong Chen</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuchang District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>zn_chenxiong@126.com</Contact_Email>
    <Contact_Tel>+86 13995599373</Contact_Tel>
    <Contact_Affiliation>Zhongnan Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: otolaryngology healthcare workers in Hubei Province</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: People with anxiety or depression prior to the COVID-19 outbreak.</Exclusion_Criteria>
    <Condition>Anxiety; Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:no;</Intervention>
    <Primary_outcome>anxiety;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030509</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator           Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>The First Hospital of Harbin Medical University</Primary_sponsor>
    <Date_registration>2020-03-05</Date_registration>
    <Date_registration3>20200305</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49956</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>80</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-13</Date_enrollement>
    <Target_size>experimental group:20;control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Kaijiang Yu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>23 Youzheng Street, Harbin, Heilongjiang, China</Contact_Address>
    <Contact_Email>drkaijiang@163.com</Contact_Email>
    <Contact_Tel>+86 0451-53602290</Contact_Tel>
    <Contact_Affiliation>The First Hospital of Harbin Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Male or female aged 18-80 years old;&lt;br&gt;2. Patients with confirmed novel coronavirus-infected pneumonia;&lt;br&gt;3. Diagnosed as moderate cases of COVID-19 with fever and respiratory symptoms and image showing pneumonia;&lt;br&gt;4. Voluntarily sign written informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Sever cases with shock, acute respiratory distress syndrome;&lt;br&gt;2. Multiple organ failure;&lt;br&gt;3. Pregnant or lactating women;&lt;br&gt;4. Cases with malignant disease, autoimmune disease or sever diseases of immune immune system, such as: HIV infection;&lt;br&gt;5. Major organ transplantation;&lt;br&gt;6. Other conditions that are not suitable for enrollment.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Intravenous infusion of NK cells on day 0,3 and 6 , 1*1071*108/kg body weight of NK cells each day.;control group:Sodium Potassium Magnesium Calcium and Glucose Injection.;</Intervention>
    <Primary_outcome>Time and rate of novel coronavirus become negative.;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030476</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50455</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-03</Date_enrollement>
    <Target_size>1:100;2:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jia Lijun</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>725 Wanping Road South, Xuhui District, Shanghai, China</Contact_Address>
    <Contact_Email>ljjia@shutcm.edu.cn</Contact_Email>
    <Contact_Tel>+86 13585779708</Contact_Tel>
    <Contact_Affiliation>Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) diagnosed as a mild and common type of the new coronavirus pneumonia, meeting the diagnostic criteria of the new coronavirus pneumonia diagnosis plan (trial version 6), both male and female;&lt;br&gt;(2) aged 14 to 70 years old;&lt;br&gt;(3) body temperature &gt; 37.3 degree C; &lt;br&gt;(4) understand the nature, significance, possible benefits, inconvenience and potential dangers of the test in detail before the test;&lt;br&gt;(5) understand the study procedure and voluntarily sign the written informed consent (signed by both the patient and the legal guardian for the minor patient).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) patients with severe heart, liver, kidney and other complications or other serious primary disease or mental illness;&lt;br&gt;(2) patients whose survival time is not expected to exceed 48 hours from screening;&lt;br&gt;(3) endotracheal intubation and mechanical ventilation had been performed during screening;&lt;br&gt;(4) any influence on inclusion judged by the researcher.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>1:meditation+Standard treatment of traditional Chinese and Western Medicine;2:Standard treatment of traditional Chinese and Western Medicine;</Intervention>
    <Primary_outcome>Self-rating depression scale;self-rating anxiety scale;Athens Insomnia Scale;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030751</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of Inner Mongolia University for the Nationalities</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50941</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-01-25</Date_enrollement>
    <Target_size>Case series:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Burenbatu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1742 Huolinhe Street, Keerqin District, Tongliao, Inner Mongolia Autonomous Region, China</Contact_Address>
    <Contact_Email>nmbrbt8989@163.com</Contact_Email>
    <Contact_Tel>+86 18804758989</Contact_Tel>
    <Contact_Affiliation>Affilated Hospital of Inner Mongolia University for the Nationalities</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) novel coronavirus pneumonia novel coronavirus pneumonia is diagnosed according to the new pneumonia diagnosis and treatment plan (trial version fifth);&lt;br&gt;(2) According to the diagnostic standard of "lung invasion" in Mongolian medicine "myxosis", the patients were diagnosed as Mongolian medicine "myxosis" acute fever;&lt;br&gt;(3) RT-PCR was used to detect the new coronavirus in respiratory or blood samples;&lt;br&gt;(4) Aged 18 to 70 years old;&lt;br&gt;(5) subjects' informed consent and signing informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Other viral pneumonia (influenza virus parainfluenza virus adenovirus respiratory syncytial virus rhinovirus human metapneumovirus SARS Coronavirus) was excluded;&lt;br&gt;(2) Serious mental illness or history of depression;&lt;br&gt;(3) Suspected allergy to any of the following substances or contraindications for the application of any of the following substances include the active ingredients of the test drug and emergency medicine and other ingredients contained in the test drug or emergency medicine;&lt;br&gt;(4) Pregnant and lactating women who plan to be pregnant or cannot use reliable contraceptive measures;&lt;br&gt;(5) Any concomitant disease that may interfere with the procedure or evaluation of the trial or other conditions that the investigator considers unsuitable for inclusion in the trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Traditional Mongolian Medicine;</Intervention>
    <Primary_outcome>nucleic acids probing;blood routine;blood biochemistry;Urine Routine;Blood Gas Analysis;CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030750</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia</Public_title>
    <Scientific_title>A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Shenzhen Third People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-13</Date_registration>
    <Date_registration3>20200313</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50928</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>25</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>common type :30;Latent period group:30;Normal control group:30;Blank vaccine control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>1-2</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhenlin Zhao</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Floor 10, Building 10, Biomedical Innovation Industrial Park, 14 Jinhui Road, Kengzi street, Pingshan District, Shenzhen, Guangdong, China</Contact_Address>
    <Contact_Email>zhaozl2006@163.com</Contact_Email>
    <Contact_Tel>+86 13828895409</Contact_Tel>
    <Contact_Affiliation>Shenzhen Ruipuxun Academy for Stem Cell &amp; Regenerative Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Confirmed cases: positive nucleic acid test;&lt;br&gt;2. Aged 25-65 years old;&lt;br&gt;3. Asexual difference;&lt;br&gt;4. Clinical stage (light, common type);&lt;br&gt;5. Immunology standard: peripheral blood lymphocyte was higher than the lower limit of normal;&lt;br&gt;6. No complications of multiple organ failure.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. There were symptoms but negative nucleic acid test;&lt;br&gt;2. Patients with malignant tumor;&lt;br&gt;3. Pregnant women;&lt;br&gt;4. HIV positive;&lt;br&gt;5. Critical stage (ARDS with multiple organ failure);&lt;br&gt;6. The peripheral blood lymphocyte was lower than the lower limit of normal.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>common type :Immunotherapy with recombinant chimeric DC vaccine;Latent period group:Immunotherapy with recombinant chimeric DC vaccine;Normal control group:Immunotherapy with recombinant chimeric DC vaccine;Blank vaccine control group:0.9%NS;</Intervention>
    <Primary_outcome>Shorten the duration of the disease;Antipyretic rate;Severe rate;Time of virus nucleic acid turning negative;Negative rate of viral nucleic acid;Time for improvement of lung image;PCT;CRP;IL-17;WBC;Lymphocyte subtype analysis;Blood gas analysis;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030417</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                               Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Harbin infectious diseases hospital</Primary_sponsor>
    <Date_registration>2020-03-01</Date_registration>
    <Date_registration3>20200301</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50279</web_address>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>Experimental group:15;control group:15;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jing Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>Room 319, life medicine venture building, Limin biomedical R &amp; D center, East Shenyang Street and South Zhuhai Road, Harbin, Heilongjiang, China</Contact_Address>
    <Contact_Email>18604501911@163.com</Contact_Email>
    <Contact_Tel>+86 18604501911</Contact_Tel>
    <Contact_Affiliation>Harbin Peiyou Jiandi Biotechnology Co., Ltd</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 65 years old, both male and female;&lt;br&gt;2. The eligible subjects (male and female) with fertility must agree to take effective contraceptive measures from the beginning of self-sufficiency with their partners to 6 months after drug withdrawal;&lt;br&gt;3. Novel coronavirus pneumonia diagnosis novel coronavirus pneumonia novel coronavirus pneumonia diagnosis and treatment plan (latest edition) is confirmed;&lt;br&gt;4. Drugs without chloroquine and its derivatives within three months;&lt;br&gt;5. Sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with allergic history to 4-aminoquinoline (such as chloroquine, hydroxychloroquine, piperaquine, aminophenquine, etc.) and similar drugs (such as primaquine, etc.) were identified;&lt;br&gt;2. Patients with blood system diseases;&lt;br&gt;3. Patients with hearing impairment;&lt;br&gt;4. Patients with known severe liver disease, basic disease of liver cirrhosis or ALT / AST increased more than 2 times of the upper limit of normal;&lt;br&gt;5. Patients who drink alcohol or are taking hepatotoxic drugs;&lt;br&gt;6. Patients with known impairment of renal function (estimated glomerular filtration rate [EGFR] &lt; 30ml / min / 1.73m2, estimated by MDRD method);&lt;br&gt;7. Patients with known 6-phosphate dehydrogenase deficiency;&lt;br&gt;8. In the past 6 months, there were history of acute myocardial infarction, unstable angina, serious arrhythmia (multiple frequent ventricular premature, ventricular tachycardia, ventricular fibrillation), NYHA class III-IV;&lt;br&gt;9.QTc&gt;=450ms;&lt;br&gt;10. Patients with uncorrected hypokalemia and hypomagnesemia;&lt;br&gt;11. Patients with known retinopathy, fundus disease and macular disease;&lt;br&gt;12. Patients known to have mental illness;&lt;br&gt;13. Patients with pancreatitis;&lt;br&gt;14. Female patients in pregnancy, childbearing age with positive pregnancy test or lactation;&lt;br&gt;15. Taking drugs that affect drug absorption, metabolism and excretion, can prolong QTc interval, can affect drug efficacy or increase adverse reactions;&lt;br&gt;16. Patients with a history of malignancy in the last 5 years;&lt;br&gt;17. Patients with skin diseases (including skin rash, dermatitis, psoriasis);&lt;br&gt;18. The novel coronavirus pneumonia diagnosis and treatment scheme (latest edition) has been adopted in the standard treatment of 2 and 2 or more antiviral drugs;&lt;br&gt;19. The researchers judged that it was not suitable to participate in this clinical trial.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Combined standard therapy of chloroquine phosphate aerosol inhalation solution;control group:Water for injection atomization inhalation combined with standard therapy;</Intervention>
    <Primary_outcome>Temperature returns to normal for more than 3 days;Respiratory symptoms improved significantly;Pulmonary imaging showed that acute exudative lesions were significantly improved;Negative for two consecutive tests of respiratory pathogenic nucleic acid (sampling interval at least 1 day);</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030381</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by investigator           A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient</Public_title>
    <Scientific_title>A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>First people's hospital of Jiangxi district,Wuhan</Primary_sponsor>
    <Date_registration>2020-02-29</Date_registration>
    <Date_registration3>20200229</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50290</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-29</Date_enrollement>
    <Target_size>Experimental group:20;Control group:20;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Bende Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Wenhua Avenue, Jiangxia District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>liubende99@outlook.com</Contact_Email>
    <Contact_Tel>+86 13907191851</Contact_Tel>
    <Contact_Affiliation>First people's hospital of Jiangxi district, Wuhan</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18 to 70 years old;&lt;br&gt;2. Patients with pneumonia infected by new coronavirus: confirmed cases in compliance with the Diagnosis and Treatment Plan for Pneumonia Infected by New Coronavirus (Sixth Edition);&lt;br&gt;3. Confirmed cases who can be transfused into anti-SARS-CoV-2 virus inactivated plasma after fully assessing patients condition; &lt;br&gt;4. Cases who score 3 or 4 according to 6-grade scale;&lt;br&gt;5. The subjects and/or their legal guardians voluntarily participated in the study and voluntarily signed an informed consent form.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The clinical classification of patients with severe novel coronavirus infection is to meet any of the following:&lt;br&gt;1) Respiratory failure occurs and requires mechanical ventilation;&lt;br&gt;2) Shock occurs;&lt;br&gt;3) Combined failure of other organs requires ICU monitoring and treatment;&lt;br&gt;2. Those who are allergic to blood products or plasma components and auxiliary materials (sodium citrate);&lt;br&gt;3. There is multiple organ failure, and the estimated survival time is less than 3 days;&lt;br&gt;4. Those who tested positive for HIV antibodies before enrollment;&lt;br&gt;5. Women who are pregnant or breastfeeding or have a birth plan within the past year;&lt;br&gt;6. Participants in other clinical trials within 3 months before screening;&lt;br&gt;7.Poor adherence or other conditions that the investigator believes are not suitable for inclusion (such as poor physical condition).</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional treatment and anti-SARS-CoV-2 virus inactivated plasma;Control group:Conventional treatment and Ordinary plasma;</Intervention>
    <Primary_outcome>Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030718</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study of Chloroquine Phosphate in the Treatment of 2019-nCoV Infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Zhongnan Hospital of Wuhan University</Primary_sponsor>
    <Date_registration>2020-03-11</Date_registration>
    <Date_registration3>20200311</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50843</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-12</Date_enrollement>
    <Target_size>Experimental group:40;Control group:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhao Yan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>169 Donghu Road, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>doctoryanzhao@whu.edu.cn</Contact_Email>
    <Contact_Tel>+86 13995577963</Contact_Tel>
    <Contact_Affiliation>Zhongnan Hospital of Wuhan University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Male and female, older than 18 years; &lt;br&gt;2. Patients with confirmed COVID19;&lt;br&gt;3. Need to continue the antivirus therapy;&lt;br&gt;4. Agree to sign the informed consent;&lt;br&gt;5. Able to ingest, absorb and tolerate oral medication;&lt;br&gt;6. Agree to collect clinical samples;&lt;br&gt;7. Consent to contraceptive measures for sex within 7 days of the last oral medication. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Cases with severe vomiting and difficulty in taking drugs orally or causing difficulty in taking drugs after oral administration;&lt;br&gt;2. Pregnant and lactating women;&lt;br&gt;3. The subjects participated other clinical trials within 30 days before admission;&lt;br&gt;4. Cases with no hope of survival, hospice care only, or deep coma and no response to supportive treatment within three hours after admission;&lt;br&gt;5. Cases of deep shock and respiratory failure;&lt;br&gt;6. Severe liver diseases (such as child Pugh score &gt;= C, AST more than 5 times of the upper limit of normal);&lt;br&gt;7. Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;= 30ml / min / 1.73m2) or undergoing continuous renal replacement therapy, hemodialysis, peritoneal dialysis;&lt;br&gt;8. Patients with known allergic reactions or contraindications to chloroquine phosphate;&lt;br&gt;9. The doctor decided that it was not in the best interests of the subjects to participate in the study, or there was any situation in which the agreement could not be followed safely. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:chloroquine phosphate ;Control group:none;</Intervention>
    <Primary_outcome>Time to Clinical Recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030717</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based study for risk assessment and treatment timing of invasive fungal infection in novel coronavirus pneumonia (COVID-19) critical patients</Public_title>
    <Scientific_title>Risk assessment and treatment timing of invasive fungal infection in critically ill covid-19 patients: medical records based study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</Primary_sponsor>
    <Date_registration>2020-03-11</Date_registration>
    <Date_registration3>20200311</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50860</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>14</Inclusion_agemin>
    <Inclusion_agemax>90</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-04-01</Date_enrollement>
    <Target_size>Exposed group:130;Control group:130;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Minghao Fang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Road, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>fangmh@tjh.tjmu.edu.cn</Contact_Email>
    <Contact_Tel>+86 15071157405</Contact_Tel>
    <Contact_Affiliation>Department of Emergency, Tongji Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. confirmed critically ill covid-19;&lt;br&gt;2. grouping criteria: meet the clinical risk factor combination criteria for invasive candidiasis in critically ill patients proposed by ostrosky-zeichner et al in 2009:&lt;br&gt;(1) the length of stay in ICU exceeds 4 days;&lt;br&gt;(2) in line with two of the following three conditions: broad-spectrum antibiotics; Central venous catheterization; Mechanical ventilation;&lt;br&gt;(3) meeting one of the following six criteria: total parenteral nutrition (day 1 to day 3); Dialysis (1-3 days); Major surgery or pancreatitis or immunosuppression or glucocorticoids (within 7 days).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. If the patient received any antifungal treatment (excluding fluconazole or up to 7 days of selective digestion purification therapy) within 14 days prior to randomization, or if there was evidence of IFI; &lt;br&gt;2. aged &lt; 14 years;&lt;br&gt;3. pregnant or lactating women;&lt;br&gt;4. allergy or hypersensitivity to any research drug or excipient;&lt;br&gt;5. participate in another clinical study or treat with an experimental drug 28 days prior to registration or use an accompanying drug therapy that the investigator considers likely to interfere with the study target.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Exposed group:Prophylactic antifungal therapy;Control group:Diagnostic antifungal therapy;</Intervention>
    <Primary_outcome>14-days mortality;28-days mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030135</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                  A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients</Public_title>
    <Scientific_title>A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>The Second Affiliated Hospital Of Xi'an Jiaotong University</Primary_sponsor>
    <Date_registration>2020-02-24</Date_registration>
    <Date_registration3>20200224</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50002</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-25</Date_enrollement>
    <Target_size>Experimental group:26;Control group:13;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Gao Dengfeng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>157 Xiwu Road, Xi'an, Shaanxi, China </Contact_Address>
    <Contact_Email>gaomedic@163.com</Contact_Email>
    <Contact_Tel>+86 15091544672</Contact_Tel>
    <Contact_Affiliation>The Second Affiliated Hospital of Xi'an Jiaotong University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged&gt;=18 years old;&lt;br&gt;2. Diagnosed as severe and critical patients with novel coronavirus pneumonia;&lt;br&gt;3. Being treated in the ICU. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Allergic to vitamin C; &lt;br&gt;2. Cardiogenic dyspnea; &lt;br&gt;3. Life expectancy&lt;24h; &lt;br&gt;4. Pregnant and/or lactating female; &lt;br&gt;5. There is a state of tracheotomy or home oxygen therapy in the past; &lt;br&gt;6. Previously complicated with interstitial lung disease, malignant tumors,diffuse alveolar hemorrhage, diabetic ketoacidosis, or an active kidney stone; &lt;br&gt;7. Participating in other clinical trials; &lt;br&gt;8. Researchers believe patients are not suitable for clinical trials for other reasons. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:High-dose Vitamin C;Control group:Routine treatment;</Intervention>
    <Primary_outcome>Ventilation-free days;mortality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030085</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator               Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients</Public_title>
    <Scientific_title>Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49948</web_address>
    <other_records>No</other_records>
    <Inclusion_agemin>12</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-22</Date_enrollement>
    <Target_size>Target condition:400;Difficult condition:100</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zairong Wei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>149 Dalian Road, Huichuan District, Zunyi, Guizhou, China</Contact_Address>
    <Contact_Email>188116999@qq.com</Contact_Email>
    <Contact_Tel>+86 15208660008</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of Zunyi Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Common inpatient, volunteer and fever patient;&lt;br&gt;2. Patients who are older than 12 years, gender unlimited;&lt;br&gt;3. Consenting or the guardian of a minor is willing to participate in this trial and will sign the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: With acute cardio-cerebrovascular liver and kidney function damage, or combined with other important organ injury;</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Nucleic acid detection method of COVID-19;Index test:IgM/IgG&amp;#32;detection&amp;#32;method&amp;#32;of&amp;#32;COVID-19;</Intervention>
    <Primary_outcome>Positive/Negtive;False positive of rate  ;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030716</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Shedding of SARS-CoV-2 in human semen and evaluation of reproductive health of novel coronavirus pneumonia (COVID-19) male patients</Public_title>
    <Scientific_title>Shedding of SARS-CoV-2 in human semen and reproductive health evaluation of ever infected males                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Tongji Medical College, HUST</Primary_sponsor>
    <Date_registration>2020-03-11</Date_registration>
    <Date_registration3>20200311</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50850</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>22</Inclusion_agemin>
    <Inclusion_agemax>55</Inclusion_agemax>
    <Inclusion_gender>Male</Inclusion_gender>
    <Date_enrollement>2020-03-05</Date_enrollement>
    <Target_size>in hospital:50;Recovered:100;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>HONGGANG LI</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>13 Hangkong Road, Qiaokou District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>lhgyx@hotmail.com</Contact_Email>
    <Contact_Tel>+86 13871402927</Contact_Tel>
    <Contact_Affiliation>Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Men with diagnosed COVID-19, aged 22-55 years old. 50 inpatients and 100 males after recovery. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Severe patients</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>in hospital:Virus detection in semen;Recovered:Hormones and sperm quality;</Intervention>
    <Primary_outcome>SARS-CoV-2 virus;sex hormones;sperm quality;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030701</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A randomized, parallel controlled open-label trial for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in the treatment of adult patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A randomized, parallel controlled open-label trial to evaluate the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in adult hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>The Third People's Hospital of Shenzhen</Primary_sponsor>
    <Date_registration>2020-03-10</Date_registration>
    <Date_registration3>20200310</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50795</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-10</Date_enrollement>
    <Target_size>experimental group:30;control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Cai Qingxian</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>29 Bulan Road, Longgang District, Shenzhen, Guangdong, China</Contact_Address>
    <Contact_Email>41180423@qq.com</Contact_Email>
    <Contact_Tel>+86 13760857996</Contact_Tel>
    <Contact_Affiliation>The Third People's Hospital of Shenzhen</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Those who agree to take part in the test and sign the informed consent form voluntarily;&lt;br&gt;2. Adult aged &gt;=18years old, male or female;&lt;br&gt;3. The inpatients with mild or common type of COVID-19 confirmed according to the diagnostic criteria "COVID-19 diagnosis and treatment plan -  Sixth trial edition" issued by the National Health Commission.&lt;br&gt;4. Respiratory Specimens (including but not limited to sputum, nasopharyngeal swab and secretion of lower respiratory tracts) were positive for 2019-ncov nucleic acid by real-time fluorescent RT-PCR; or respiratory specimens were genetically sequenced and highly homologous to known 2019-ncov.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Participation in the study is not in accordance with the rights and interests of the patient based on PIs judgement, or any other circumstances that investigators consider inappropriate for participation;&lt;br&gt;2. Low body weight patients (females&lt;45kg, males&lt;57kg);&lt;br&gt;3. With bleeding or bleeding associated with severe coagulation disorders (except for disseminated intravascular coagulation unrelated to heparin therapy), with a history of severe type II heparin-induced thrombocytopenia, whether or not caused by unfractionated heparin or low-molecular-weight heparin (significantly reduced by platelet count previously), active peptic ulcer or organ damage with bleeding tendency, clinically significant active bleeding , cerebral hemorrhage;&lt;br&gt;4. Have any situation that treatment with low molecular heparin is required;&lt;br&gt;5. Females who are pregnant or likely to be pregnant, or who are lactating and unable to stop breastfeeding, or who have positive pregnancy tests during screening;&lt;br&gt;6. Males or females who have a birth plan or are unwilling to take reliable contraceptive measures for contraception within 90 days from signing the informed consent to the last dose;&lt;br&gt;7. With severe liver disease: patient with basic diseases of liver cirrhosis , or alanine aminotransferase (ALT) / aspartate aminotransferase (AST) increased more than 5 times of the normal upper limit;&lt;br&gt;8. Patients known to have severe renal impairment [creatinine clearance (CcCl) &lt; 30 ml/min], or to receive continuous renal replacement therapy, hemodialysis or peritoneal dialysis;&lt;br&gt;9. At rest without oxygen inhalation, SPO2 &lt;=93%, or PaO2/ FiO2 &lt;=300 mmHg;&lt;br&gt;10. Patients allergic to enoxaparin, heparin or its derivatives, including other low-molecular-weight heparins.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;</Intervention>
    <Primary_outcome>Time to Virus Eradication;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029976</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>The effect of Gymnastic Qigong Yangfeifang on functional recovery and quality of life in patients with mild novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Novel coronavirus pneumonia (COVID-19) emergency research project tackled by Shanghai University of Traditional Chinese Medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Shanghai University of Traditional Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-02-18</Date_registration>
    <Date_registration3>20200218</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49631</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>25</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-18</Date_enrollement>
    <Target_size>experimental group:40;control group:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Shan Chunlei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1200 Cailun Road, Pudong New District, Shanghai, China </Contact_Address>
    <Contact_Email>shanclhappy@163.com</Contact_Email>
    <Contact_Tel>+86 18616974986</Contact_Tel>
    <Contact_Affiliation>Shanghai University of Traditional Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: A novel coronavirus pneumonia is 25-65 years old. It has no gender limitation. It has clinical symptoms such as cough, chest tightness and fatigue. Physical energy can withstand indoor standing for 20 minutes or 2 times a day.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: He has been suffering from respiratory system disease, unstable condition, risk of falling, severe other organ disease or mental disease, cognitive or language communication disorders.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia</Condition>
    <Intervention>experimental group:Fitness Qigong Yangfei prescription;control group:general advice and related psychological comfort.;</Intervention>
    <Primary_outcome>Oxygen Inhalation Frequency;Oxygen Intake Time;cough;Degree of expiratory dyspnoea;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029818</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator            Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Guangzhou reborn health management consultation co., LTD</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49382</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Experimental group :30;Control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Chao Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China </Contact_Address>
    <Contact_Email>164972769@qq.com</Contact_Email>
    <Contact_Tel>+86 15018720816</Contact_Tel>
    <Contact_Affiliation>Guangzhou reborn health management consultation co., LTD </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;&lt;br&gt;2. Voluntarily sign written informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (NCP)</Condition>
    <Intervention>Experimental group :Conventional treatment followed by Intravenous infusion of Umbilical Cord Blood Plasma preparations;Control group:Conventional treatment ;</Intervention>
    <Primary_outcome>Time to disease recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030700</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in treatment of novel coronavirus pneumonia (COVID-19) adult common patients</Public_title>
    <Scientific_title>An evaluative clinical study: efficacy and safety of of Prolongin (Enoxaparin Sodium Injection) in treatment of hospitalized adult patients with common novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-03-10</Date_registration>
    <Date_registration3>20200310</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50786</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-09</Date_enrollement>
    <Target_size>experimental group:30;control group:30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zhang Yu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>whxhzy@163.com</Contact_Email>
    <Contact_Tel>+86 13971292838</Contact_Tel>
    <Contact_Affiliation>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Those who agree to take part in the test and sign the informed consent form voluntarily;&lt;br&gt;2. Adults aged &gt;=18years old, male or female;&lt;br&gt;3. The inpatients with mild or common type of COVID-19 confirmed according to the diagnostic criteria "COVID-19 diagnosis and treatment plan -  Sixth trial edition" issued by the National Health Commission.&lt;br&gt;4. Respiratory Specimens (including but not limited to sputum, nasopharyngeal swab and secretion of lower respiratory tracts) are positive for 2019-nCoV nucleic acid by real-time fluorescent RT-PCR; or respiratory specimens are genetically sequenced and highly homologous to known 2019-nCoV.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Participation in the study is not in accordance with the rights and interests of the patient based on PIs judgement, or any other circumstances that investigators consider inappropriate for participation;&lt;br&gt;2. With bleeding or bleeding associated with severe coagulation disorders (except for disseminated intravascular coagulation unrelated to heparin therapy), with a history of severe type II heparin-induced thrombocytopenia, whether or not caused by unfractionated heparin or low-molecular-weight heparin (significantly reduced by platelet count previously), active peptic ulcer or organ damage with bleeding tendency, clinically significant active bleeding , cerebral hemorrhage;&lt;br&gt;3. Have any situation that treatment with low molecular heparin is required;&lt;br&gt;4. Females who are pregnant or likely to be pregnant, or who are lactating and unable to stop breastfeeding, or who have positive pregnancy tests during screening;&lt;br&gt;5. Males or females who have a birth plan or are unwilling to take reliable contraceptive measures for contraception within 90 days from signing the informed consent to the last dose;&lt;br&gt;6. With severe liver disease: patient with basic diseases of liver cirrhosis , or alanine aminotransferase (ALT) / aspartate aminotransferase (AST) increased more than 5 times of the normal upper limit;&lt;br&gt;7. Patients known to have severe renal impairment [creatinine clearance (CcCl) &lt; 30 ml / min], or to receive continuous renal replacement therapy, hemodialysis or peritoneal dialysis;&lt;br&gt;8. At rest without oxygen inhalation, SPO2 &lt;=93%, or PaO2/ FiO2 &lt;=300 mmHg; &lt;br&gt;9. Patients allergic to enoxaparin, heparin or its derivatives, including other low-molecular-weight heparins.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;</Intervention>
    <Primary_outcome>Time to Virus Eradication;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030683</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>The prediction value of prognosis of novel coronavirus pneumonia (COVID-19) in elderly patients by modified early warning score (MEWS): a medical records based retrospective observational study</Public_title>
    <Scientific_title>The prediction value of prognosis of COVID-19 in elderly patients by modified early warning score (MEWS): a retrospective observational study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>The Sixth Affiliated Hospital of Sun Yat-sen University</Primary_sponsor>
    <Date_registration>2020-03-09</Date_registration>
    <Date_registration3>20200309</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50633</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>60</Inclusion_agemin>
    <Inclusion_agemax>110</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-09</Date_enrollement>
    <Target_size>Target condition:234;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Chen Lei</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>26 Yuancun Erheng Road, Tianhe District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>chenlei0nan@163.com</Contact_Email>
    <Contact_Tel>+86 13570236595</Contact_Tel>
    <Contact_Affiliation>The Sixth Affiliated Hospital of Sun Yat-sen University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. From January 1, 2020 to March 31, 2020, the elderly patients who aged 60 or over were clinically diagnosed as new coronavirus pneumonia by the Guangdong medical team of Hankou hospital, Wuhan city, Hubei province;&lt;br&gt;2. From January 1, 2020 to March 31, 2019, the elderly patients who aged 60 years or above were diagnosed with new coronavirus pneumonia by the Guangdong medical team of hankou hospital, Wuhan city, Hubei province (See schedule 1 of the study protocol for details).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Pneumonia caused by other etiology; &lt;br&gt;2. Patients with incomplete data.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:Clinical outcomes;Index test:MEWS&amp;#32;and&amp;#32;other&amp;#32;scores;</Intervention>
    <Primary_outcome>In-hospital mortality;ACC, SEN, SPE, ROC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029816</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                      Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Clinical Study of  Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Guangzhou reborn health management consultation co., LTD</Primary_sponsor>
    <Date_registration>2020-02-14</Date_registration>
    <Date_registration3>20200214</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49389</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Experimental group:30;Control group :30;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Contact_Firstname>Chao Xu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>85 Kefeng Road, Hi-Tech Development District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>164972769@qq.com</Contact_Email>
    <Contact_Tel>+86 15018720816</Contact_Tel>
    <Contact_Affiliation>Guangzhou reborn health management consultation co., LTD </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;&lt;br&gt;2. Voluntarily sign written informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;&lt;br&gt;2. Pregnant or lactating women;&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Experimental group:Conventional treatment followed by Intravenous infusion of Cord Blood Mesenchymal Stem Cells preparations ;Control group :Conventional treatment ;</Intervention>
    <Primary_outcome>Time to disease recovery;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029770</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-13</Date_registration>
    <Date_registration3>20200213</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49412</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-13</Date_enrollement>
    <Target_size>Case series:500;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jin Yang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>whuhjy@sina.com</Contact_Email>
    <Contact_Tel>+86 13554361146</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)"</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Physician judged the patient was not suitable for this clinical trial.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Case series:NA;</Intervention>
    <Primary_outcome>Patients general information: epidemiological indicators such as age, gender, address, telephone, exposure history, past medical history, and BMI;Clinical symptoms;Patients' signs;blood routine examination;Urine routine test;stool routine examination;Blood biochemistry;myocardial enzyme spectrum;full set of coagulation;blood gas analysis;cytokine profile;T lymphocyte subsets;ESR;CRP;PCT;complete set of self-immunity test;Etiology related inspections;Chest X-ray;lung CT;Patients' treatment history;Patients' Prognosis;the cause of death;Others;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030681</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of Novel Coronavirus Pneumonia (COVID-19) and other infectious viruses in the operating Room</Public_title>
    <Scientific_title>An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of SARS-CoV-2 and other infectious viruses in the operating Room                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Liaocheng People's Hospital</Primary_sponsor>
    <Date_registration>2020-03-09</Date_registration>
    <Date_registration3>20200309</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50763</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>2</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-16</Date_enrollement>
    <Target_size>Group A:60;Group B:60;Group C:60;Group D:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Zunyuan Liu</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>67 Dongchang Road West, Liaocheng, Shandong, China</Contact_Address>
    <Contact_Email>ly29.love@163.com</Contact_Email>
    <Contact_Tel>+86 18263511977</Contact_Tel>
    <Contact_Affiliation>Liaocheng People's Hospital</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Aged 2-65 years, with a BMI of 18-28, who underwent otolaryngological surgery. The patients were ASA grade I-III.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with difficult airways;Patients who need to remain tracheal intubation to return to the ward after surgery;After signing the informed consent, those who were conscious and awake during the perioperative period refused to continue to participate in the test.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Group A:Sevoflurane anesthesia maintenance, common extubation;Group B:Sevoflurane anesthesia was maintained, and the extubation strategy of "circulatory induced respiration" was adopted after the operation.;Group C:Propofol anesthesia maintenance, common extubation;Group D:Propofol anesthesia was maintained, and the extubation strategy of "circulatory induced respiration" was adopted after the operation.;</Intervention>
    <Primary_outcome>cough;agitation;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030619</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A medical records based real world study for the characteristics and correlation mechanism of traditional Chinese medicine combined with western medicine in the treatment of patients with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Analysis of the characteristics of traditional Chinese medicine combined with western medicine and its correlation mechanism based on real-world patients with  novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Bengbu Medical College</Primary_sponsor>
    <Date_registration>2020-03-08</Date_registration>
    <Date_registration3>20200308</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50656</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-01</Date_enrollement>
    <Target_size>Case series:160;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>Retrospective study</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qingping Shi</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>287 Changhuai Road, Longzihu District, Bengbu, Anhui, China</Contact_Address>
    <Contact_Email>sir_shi@126.com</Contact_Email>
    <Contact_Tel>+86 13855288331</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Bengbu Medical College</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients were diagnosed with a new type of coronavirus pneumonia when they were discharged or admitted to the hospital. The diagnostic criteria were based on the New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial) (First to Sixth Edition).</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) Those who were not treated with drugs during hospitalization;&lt;br&gt;(2) Patients with active tuberculosis;&lt;br&gt;(3) Organ transplant patients;&lt;br&gt;(4) Patients with mental disorders.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Case series:Nil;</Intervention>
    <Primary_outcome>treatment effect;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030483</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator         A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>The first affiliated hospital of guangzhou university of Chinese medicine</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50495</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-03-01</Date_enrollement>
    <Target_size>treatment group :16;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>1</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>He jing</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>sakeonel@126.com</Contact_Email>
    <Contact_Tel>+86 13760661654</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Guangzhou University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (1) age: 18-75 years old (including threshold), regardless of gender;&lt;br&gt;(2) compliance with the pneumonia diagnosis and treatment protocol for novel coronavirus infection - the diagnostic criteria for the trial version 6 (the latest version, which is currently updated to version 6).&lt;br&gt;(3) the sixth version of the reference treatment scheme meets the common type standard;&lt;br&gt;(4) no participation in traditional health exercise (ba duan jin, tai chi, wu qin xi or other fitness qigong) within 7 days;&lt;br&gt;(5) steady gait and clear consciousness;&lt;br&gt;(6) patients who agreed to participate in this study and voluntarily signed the informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: (1) asthma requiring daily treatment, any other chronic respiratory disease&lt;br&gt;(2) patients with severe mental illness and severe neurosis.?&lt;br&gt;(3) the risk stratification of exercise rehabilitation was assessed as high-risk patients or those who were restricted from activities for other reasons;&lt;br&gt;(4) patients with severe renal insufficiency and liver insufficiency;&lt;br&gt;(5) patients with severe copd, cor pulmonale or respiratory failure;&lt;br&gt;(6) severe hematopoietic system, tumor and other serious primary diseases;&lt;br&gt;(7) those who practice traditional Chinese medicine skills (ba duan jin, tai chi, wu qin xi or other fitness qigong) within 14 days.&lt;br&gt;There are speech, cognitive impairment and other effects of communicators.&lt;br&gt;(8) the sixth trial version of the reference diagnosis and treatment scheme is for patients with severe or critical criteria;</Exclusion_Criteria>
    <Condition>novel common type of coronavirus pneumonia</Condition>
    <Intervention>treatment group :Ba duanjin;</Intervention>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030478</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                                    Study for the Effectiveness and Safety of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)</Public_title>
    <Scientific_title>Positively Controlled Clinical Study of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine</Primary_sponsor>
    <Date_registration>2020-03-03</Date_registration>
    <Date_registration3>20200303</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=50460</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>75</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-26</Date_enrollement>
    <Target_size>Positive drug control group:60;Compound Yuxingcao Mixture Group:60;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>0</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Haibin Ni</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>100 Cross Street, Hongshan Road, Nanjing, Jiangsu, China</Contact_Address>
    <Contact_Email>nhb_2002@126.com</Contact_Email>
    <Contact_Tel>+86 15312019183</Contact_Tel>
    <Contact_Affiliation>Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Confirmed or clinically diagnosed patients with the novel coronavirus disease;&lt;br&gt;2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung;&lt;br&gt;3) Inpatients aged 18 to 75 years male or female;&lt;br&gt;4) Volunteer to receive treatment under their own scheme and sign informed consent.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Patients with mild, severe or critical novel coronavirus disease;&lt;br&gt;2) According to the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, severe malnutrition, liver and kidney disease, blood disease, nervous system Diseases and endocrine diseases; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;&lt;br&gt;3) Those who are allergic to the research drug and its main ingredients;&lt;br&gt;4) pregnant or lactating women;&lt;br&gt;5) Those who have difficulty taking medicine orally.</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Positive drug control group:Refer to the National Health Office Medical Letter (2020) 77 document "Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)" general treatment plan. Based on the general treatment plan of Western medicine + Lianhua Qingwen Capsule (0.35 g per capsule) orally, 4 capsules each time;Compound Yuxingcao Mixture Group:Refer to the National Health Office Medical Letter (2020) 77 document "Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)" general treatment plan. Based on the general treatment plan of western medicine + compound Yuxingcao mixture orally, 30mL each time, 3 times a day.;</Intervention>
    <Primary_outcome>lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030055</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)</Public_title>
    <Scientific_title>Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Guangzhou Medical University</Primary_sponsor>
    <Date_registration>2020-02-22</Date_registration>
    <Date_registration3>20200222</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49864</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>70</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-10</Date_enrollement>
    <Target_size>Routine treatment group:230;Dipyridamole treatment group:230;</Target_size>
    <Study_type>Prognosis study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Qingling Zhang</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China</Contact_Address>
    <Contact_Email>zqling68@hotmail.com</Contact_Email>
    <Contact_Tel>+86 13609068871</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Guangzhou Medical University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Suspected cases of neo-coronary pneumonia (outside Hubei province), clinically diagnosed cases (in Hubei province), and light / general confirmed cases, severe/critical confirmed cases, aged 18-70 years, each center enrolls cases in a competitive manner.&lt;br&gt;The diagnostic criteria for the new coronavirus pneumonia conform to the diagnostic criteria issued by the National Health and Medical Commission for the diagnosis and treatment of pneumonia in the new coronavirus infection (trial version 5):&lt;br&gt;(1) Suspected cases.&lt;br&gt;Comprehensively analyze combinations of the following epidemiological history and clinical presentations:&lt;br&gt;1.1.1.Epidemiological history&lt;br&gt;(1) Within 14 days prior to onset, had history of travel or residence in Wuhan or surrounding regions, or other communities reporting cases;&lt;br&gt;(2) Within 14 days prior to symptom onset, having had contact with patients infected with 2019-nCoV (positive nucleic acid test).&lt;br&gt;(3) Within 14 days prior to onset, had contact with patients who had a fever or respiratory tract symptoms that had come from Wuhan, its surrounding regions, or other communities reporting cases.&lt;br&gt;(4) Clustered onset (Within a span of 2 weeks, 2 or more cases with fever and/or respiratory symptoms appear in a small area, such as a family, an office, or a school class)&lt;br&gt;2. Clinical presentations&lt;br&gt;(1) Fever and/or respiratory tract symptoms;&lt;br&gt;(2) Having the imaging features of novel coronavirus pneumonia discussed above;&lt;br&gt;(3) During the early stages of the disease, white blood cell count is normal or reduced, while the lymphocyte count is normal or reduced.&lt;br&gt;Where there are any of the epidemiologic history items, and any 2 of the clinical presentions are met.&lt;br&gt;Where there is no clear epidemiological history, and at least 3 of the clinical presentations are met.&lt;br&gt;(2) Confirmed cases.&lt;br&gt;A 2019-nCoV diagnosis is confirmed if the suspected cases also have one of the following etiological or serological evidence.&lt;br&gt;1.1.Positive result in real-time fluorescence RT-PCR detection of novel coronavirus nucleic acid;&lt;br&gt;2.The sequence of the virus is highly homologues to that of 2019-nCoV.&lt;br&gt;3.Specific IgM and IgG antibodies against 2019-nCoV test positive in the serum; IgG antibodies specific to 2019-nCoV test positive after previous negative results, or increased by more than 4 times in the recovery phase compared to the acute phase.&lt;br&gt;VI. Clinical classifications&lt;br&gt;(1) Mild form.&lt;br&gt;Clinical symptoms are minor, imaging does not show signs of lung inflammation.&lt;br&gt;(2) Regular form.&lt;br&gt;Has fever and respiratory tract symptoms, imaging shows visible lung inflammation.&lt;br&gt;(3) Severe form.&lt;br&gt;Adults who meet any one of the following:&lt;br&gt;1.1.Shortness of breath, RR &gt; 30 breaths/minute; 2. Oxygen saturation &lt; 93% at rest&lt;br&gt;2.Arterial oxygen partial pressure (PaO2)/ fraction of inspired oxygen (FiO2) &lt; 300mmHg (1mmHg=0.133kPa).&lt;br&gt;For high altitude (altitude over 1000 meters) regions, (PaO2/FiO2) should be corrected according to the following formula: PaO2/FiO2 x [ atmospheric pressure (mmHg)/760]&lt;br&gt;The patient should be managed as a severe case if lung imaging shows a substantial progression of lesions (greater than 50%) within 24-48 hours.&lt;br&gt;Children who meet any one of the following:&lt;br&gt;1. Show shortness of breath (&lt; 2 months old, RR&gt; 60 times/min; 2~12 months old, RR&gt;50 times/min; 1~5 years old, RR&gt;40 times/min; 55 years old, RR&gt;0 times/min), except the effects of fever and crying;&lt;br&gt;2. Oxygen saturation &lt; 92% at rest.&lt;br&gt;3. Laboured breathing (wheezing, flaring o</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients with presence, coagulopathy or hypotension;&lt;br&gt;2. Pregnant and lactating women;&lt;br&gt;3. People with allergies or allergies to Xuebijing Injection and its components;&lt;br&gt;4. Severe basic diseases that affect survival, including: uncontrolled malignant tumors that have metastasized and cannot be removed, blood diseases, cachexia, active bleeding, severe malnutrition, HIV, etc.;&lt;br&gt;5. Pulmonary tumors caused by obstructive pneumonia, severe interstitial fibrosis, alveolar proteinosis, allergic alveolitis;&lt;br&gt;6. Continued use of immunosuppressive agents or organ transplants in the last 6 months;&lt;br&gt;7. Extracorporeal life support (ECMO, ECCO2R, RRT);&lt;br&gt;8. Expected deaths within 48 hours;&lt;br&gt;9. Clinicians judge inappropriate.</Exclusion_Criteria>
    <Condition>2019-nCoV pneumonia</Condition>
    <Intervention>Routine treatment group:Conventional treatment of 2019-nCoV pneumonia;Dipyridamole treatment group:Conventional treatment of 2019-nCoV pneumonia and Dipyridamole;</Intervention>
    <Primary_outcome>Complete Blood Count;CRP;blood coagulation;D-dimer;Virological examination of pharyngeal swab;Pulmonary imaging;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030031</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Cancelled by the investigator                              A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COV</Public_title>
    <Scientific_title>A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)</Primary_sponsor>
    <Date_registration>2020-02-21</Date_registration>
    <Date_registration3>20200221</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49806</web_address>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-20</Date_enrollement>
    <Target_size>Phosphoric chloroquine:80;Placebo:40;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Ying Deng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>22 Second Shuguang Road, Qingcheng District, Qingyuan, Guangdong, China</Contact_Address>
    <Contact_Email>surewin001@126.com</Contact_Email>
    <Contact_Tel>+86 13500296796</Contact_Tel>
    <Contact_Affiliation>The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Meet the requirements of the "New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)";&lt;br&gt;2. Aged 18 to 65 years male or female; &lt;br&gt;3. The interval from the onset of symptoms to enrollment is within 7days: onset of symptoms is defined as onset of at least one systematic symtom(such as fever(temperature&gt;=37.3 degree C) or shivering,headache,hypodynamia,muscle pain or joint pain) or respiratory symptom(such as cough,pharyngodynia,nasal obstruction,rhinorrhea);&lt;br&gt;4. Agree to participate in this study and write informed content. </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Serious/critically ill patients with novel coronavirus(COVID-19) pneumonia or patients that clinician consider that he/she shall be treated in ICU;&lt;br&gt;2. With pneumonia infected by other virus;&lt;br&gt;3. With one of following abnormal laboratory parameters( judged per local Laboratory reference range):&lt;br&gt;-ALT or AST&gt;5 ULN or;&lt;br&gt;-ALT or AST &gt;3 ULN, and total bilirubin&gt;2 ULN;&lt;br&gt;4. Previous or current disease, judged by investigator, may affect his/her participation in this study or outcome of the study, including but not limited to malignant tumor, autoimmune disease, liver and kidney disease, cardiovascular disease (including but not limited to definate history of cadiac diease and arrhythmia and QT prolongation), neurological disease psychiatric disease, active bleeding,serious malnutrition and endocrine disease; currently complicated with serious respiratory disease or that seriously affect immune system, such as HIV, blood system disease, or splenectomy, organ transplantion etc.;&lt;br&gt;5. Need to receive digitalis for original disease;&lt;br&gt;6. May be transfered to non-study hospital;&lt;br&gt;7.Those who had taken phosphoric chloroquine or hydroxychloroquine within one week before participating in the study&lt;br&gt;8. Allergy to study drug phosphoric chloroquine or hydroxychloroquine;&lt;br&gt;9. With history of grug abuse and drug dependency;&lt;br&gt;10. Pregant or lactating women;or planing to be pregnant within 3 months after study;&lt;br&gt;11. One that the investigator consider not applicable for this study. </Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);</Intervention>
    <Primary_outcome>Time of conversion to be negative of novel coronavirus nucleic acid;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>No</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000030005</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test</Public_title>
    <Scientific_title>Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-19</Date_registration>
    <Date_registration3>20200219</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49669</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>85</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-21</Date_enrollement>
    <Target_size>Target condition:200;Difficult condition:0</Target_size>
    <Study_type>Diagnostic test</Study_type>
    <Study_design>Sequential</Study_design>
    <Phase>N/A</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Jingzhi Ma</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1095 Jiefang Avenue, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>majingzhi2002@163.com</Contact_Email>
    <Contact_Tel>+86 13871257728</Contact_Tel>
    <Contact_Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Confirmed or suspected case of COVID-19 in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.&lt;br&gt;1. Aged between 18-85 years old;&lt;br&gt;2. Patients with newly diagnosed and suspected COVID-19;&lt;br&gt;3. Willing and able to sign informed consent;&lt;br&gt;4. Before having breakfast in the morning.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients without any clinical or chest imaging manifestations;&lt;br&gt;2. Those with severe nasal diseases affecting the sampling;&lt;br&gt;3. Inability to understand or follow research protocols for severe mental illness;&lt;br&gt;4. Invasive ventilation with endotracheal intubation;&lt;br&gt;5. Patients with frequent vomiting;</Exclusion_Criteria>
    <Condition>Novel Coronavirus Pneumonia (COVID-19)</Condition>
    <Intervention>Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: 1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-Cov-2; 2. Gene sequencing of respiratory or blood samples is highly homologous with SARS-Cov-2. ;Index test:SARS-Cov-2&amp;#32;nucleic&amp;#32;acid&amp;#32;test:&amp;#32;1.morning&amp;#32;sputum&amp;#32;samples;&amp;#32;2.&amp;#32;oropharyngeal&amp;#32;samples&amp;#32;;</Intervention>
    <Primary_outcome>detection of SARS-Cov-2 nucleic acid;SEN, ACC;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029592</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff</Public_title>
    <Scientific_title>Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Primary_sponsor>
    <Date_registration>2020-02-05</Date_registration>
    <Date_registration3>20200205</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49069</web_address>
    <Recruitment_Status>Not Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin>18</Inclusion_agemin>
    <Inclusion_agemax>65</Inclusion_agemax>
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-07</Date_enrollement>
    <Target_size>Two cohorts:1000;</Target_size>
    <Study_type>Observational study</Study_type>
    <Study_design>Factorial</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Xin Zheng</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China</Contact_Address>
    <Contact_Email>xin11@hotmail.com</Contact_Email>
    <Contact_Tel>+86 027 85726732</Contact_Tel>
    <Contact_Affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: High-risk population including medical staff on duty during the outbreak of 2019-nCoV pneumonia.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. People with high-risk exposure who are unwilling to participate in this survey;&lt;br&gt;2. People with high-risk exposure who want to withdraw from the research during the study.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Two cohorts:Arbidol cohort versus without Arbidol cohort;</Intervention>
    <Primary_outcome>2019-nCoV RNA;2019-nCoV antibody;Chest CT;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
  <Trial>
    <TrialID>ChiCTR2000029573</TrialID>
    <Last_Refreshed_on>16 March 2020</Last_Refreshed_on>
    <Public_title>A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection</Public_title>
    <Scientific_title>A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>The First Affiliated Hospital of Medical College of Zhejiang University</Primary_sponsor>
    <Date_registration>2020-02-05</Date_registration>
    <Date_registration3>20200205</Date_registration3>
    <Export_date>3/18/2020 6:53:35 PM</Export_date>
    <Source_Register>ChiCTR</Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=49065</web_address>
    <Recruitment_Status>Recruiting</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>Both</Inclusion_gender>
    <Date_enrollement>2020-02-06</Date_enrollement>
    <Target_size>Group A:100;Group B:100;Group C:100;Group D:100;Group E:100;Group F:100;</Target_size>
    <Study_type>Interventional study</Study_type>
    <Study_design>Parallel</Study_design>
    <Phase>4</Phase>
    <Countries>China</Countries>
    <Contact_Firstname>Li Lanjuan</Contact_Firstname>
    <Contact_Lastname />
    <Contact_Address>79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China</Contact_Address>
    <Contact_Email>ljli@zju.edu.cn</Contact_Email>
    <Contact_Tel>+86 13906514210</Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital of Medical College of Zhejiang University</Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. the diagnosed patient (or legal guardian) agrees to participate in the study and signs the informed consent;&lt;br&gt;2. aged 18 to 65 years;&lt;br&gt;3. the time interval between symptom onset and random enrollment was less than 10 days (the onset of symptoms was mainly determined by the onset of fever);&lt;br&gt;4. real-time fluorescence RT-PCR of respiratory or blood samples was used to detect positive patients with new coronavirus nucleic acid;&lt;br&gt;5. according to the "pneumonia diagnosis and treatment scheme for new coronavirus infection (trial version 5)" for light, common and severe cases.</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. any situation where the program cannot proceed safely;&lt;br&gt;2. allergic constitution, allergic to one or more food or drugs;&lt;br&gt;3. accompanied by serious basic diseases that affect survival, including uncontrolled and clinically significant heart, lung, kidney, digestion, blood diseases, neuropsychiatric diseases, immune diseases, metabolic diseases or malignant tumors, severe malnutrition, etc.;&lt;br&gt;4. pregnant or nursing women;&lt;br&gt;5. the patient may be transferred to a non-participating hospital within 72h;&lt;br&gt;6. continuous use of immunosuppressants or organ transplants within the past 6 months;&lt;br&gt;7. critically ill patients according to the "pneumonia diagnosis and treatment program for new coronavirus infection (trial version 5)";&lt;br&gt;8. patients who were treated with antiviral drugs listed in any of the protocols under study during hospitalization prior to enrollment;&lt;br&gt;9. those who are unable to cooperate in their mental state, suffer from mental disease, have no self-control and cannot express clearly;&lt;br&gt;10. had a history of HBV, HCV, TPPA, HIV and pancreatitis before infection;&lt;br&gt;11. participants in other clinical trials.</Exclusion_Criteria>
    <Condition>novel coronavirus pneumonia (COVID-19)</Condition>
    <Intervention>Group A:Arbidol Tablets 200mg/ time, p.o.tid.;Group B:Novaferon  injection 20g/ time, atomized inhalation, tid.Arbidol Tablets 200mg/ time, p.o.tid.;Group C:Lopinavir/litonavir 500mg/100mg/ time, p.o.tid.;Group D:Arbidol Tablets 200mg/ time, p.o.tid.;Group E:Novaferon injection 20g/ time, atomized inhalation, tid.Lopinavir/litonavir 500mg/100mg/ time, p.o.tid.;Group F:Novaferon injection 20g/ time, atomized inhalation, tid.Arbidol Tablets 200mg/ time, p.o.tid.;</Intervention>
    <Primary_outcome>2019-nCoV nucleic acid test confirmed negative;</Primary_outcome>
    <results_url_link />
    <Retrospective_flag>Yes</Retrospective_flag>
    <Bridging_flag_truefalse>False</Bridging_flag_truefalse>
    <Bridged_type xml:space="preserve">          </Bridged_type>
  </Trial>
</Trials_downloaded_from_ICTRP>